Word	Tag	Begin-End
Extensive	O	0-9
modulation	O	10-20
of	O	21-23
a	O	24-25
set	O	26-29
of	O	30-32
microRNAs	O	33-42
in	O	43-45
primary	O	46-53
glioblastoma	O	54-66
.	O	66-67

MicroRNAs	O	68-77
(	O	78-79
miRNAs	O	79-85
)	O	85-86
are	O	87-90
short	O	91-96
non	O	97-100
-	O	100-101
coding	O	101-107
RNA	O	108-111
molecules	O	112-121
playing	O	122-129
regulatory	O	130-140
roles	O	141-146
in	O	147-149
animals	O	150-157
and	O	158-161
plants	O	162-168
by	O	169-171
repressing	O	172-182
translation	O	183-194
or	O	195-197
cleaving	O	198-206
RNA	O	207-210
transcripts	O	211-222
.	O	222-223

The	O	224-227
specific	O	228-236
modulation	O	237-247
of	O	248-250
several	O	251-258
microRNAs	O	259-268
has	O	269-272
been	O	273-277
recently	O	278-286
associated	O	287-297
to	O	298-300
some	O	301-305
forms	O	306-311
of	O	312-314
human	O	315-320
cancer	O	321-327
,	O	327-328
suggesting	O	329-339
that	O	340-344
these	O	345-350
short	O	351-356
molecules	O	357-366
may	O	367-370
represent	O	371-380
a	O	381-382
new	O	383-386
class	O	387-392
of	O	393-395
genes	O	396-401
involved	O	402-410
in	O	411-413
oncogenesis	O	414-425
.	O	425-426

In	O	427-429
our	O	430-433
study	O	434-439
,	O	439-440
we	O	441-443
examined	O	444-452
by	O	453-455
microarray	O	456-466
the	O	467-470
global	O	471-477
expression	O	478-488
levels	O	489-495
of	O	496-498
245	O	499-502
microRNAs	O	503-512
in	O	513-515
glioblastoma	O	516-528
multiforme	O	529-539
,	O	539-540
the	O	541-544
most	O	545-549
frequent	O	550-558
and	O	559-562
malignant	O	563-572
of	O	573-575
primary	O	576-583
brain	O	584-589
tumors	O	590-596
.	O	596-597

The	O	598-601
analysis	O	602-610
of	O	611-613
both	O	614-618
glioblastoma	O	619-631
tissues	O	632-639
and	O	640-643
glioblastoma	O	644-656
cell	O	657-661
lines	O	662-667
allowed	O	668-675
us	O	676-678
to	O	679-681
identify	O	682-690
a	O	691-692
group	O	693-698
of	O	699-701
microRNAs	O	702-711
whose	O	712-717
expression	O	718-728
is	O	729-731
significantly	O	732-745
altered	O	746-753
in	O	754-756
this	O	757-761
tumor	O	762-767
.	O	767-768

The	O	769-772
most	O	773-777
interesting	O	778-789
results	O	790-797
came	O	798-802
from	O	803-807
miR	B	808-811
-	I	811-812
221	I	812-815
,	O	815-816
strongly	O	817-825
up	O	826-828
-	O	828-829
regulated	O	829-838
in	O	839-841
glioblastoma	O	842-854
and	O	855-858
from	O	859-863
a	O	864-865
set	O	866-869
of	O	870-872
brain	O	873-878
-	O	878-879
enriched	O	879-887
miRNAs	O	888-894
,	O	894-895
miR	B	896-899
-	I	899-900
128	I	900-903
,	O	903-904
miR	B	905-908
-	I	908-909
181a	I	909-913
,	O	913-914
miR	B	915-918
-	I	918-919
181b	I	919-923
,	O	923-924
and	O	925-928
miR	B	929-932
-	I	932-933
181c	I	933-937
,	O	937-938
which	O	939-944
are	O	945-948
down	O	949-953
-	O	953-954
regulated	O	954-963
in	O	964-966
glioblastoma	O	967-979
.	O	979-980

Overgrowth	O	0-10
caused	O	11-17
by	O	18-20
misexpression	O	21-34
of	O	35-37
a	O	38-39
microRNA	O	40-48
with	O	49-53
dispensable	O	54-65
wild	O	66-70
-	O	70-71
type	O	71-75
function	O	76-84
.	O	84-85

MicroRNAs	O	86-95
(	O	96-97
miRNAs	O	97-103
)	O	103-104
represent	O	105-114
an	O	115-117
abundant	O	118-126
class	O	127-132
of	O	133-135
non	O	136-139
-	O	139-140
coding	O	140-146
RNAs	O	147-151
that	O	152-156
negatively	O	157-167
regulate	O	168-176
gene	O	177-181
expression	O	182-192
,	O	192-193
primarily	O	194-203
at	O	204-206
the	O	207-210
post	O	211-215
-	O	215-216
transcriptional	O	216-231
level	O	232-237
.	O	237-238

miRNA	O	239-244
genes	O	245-250
are	O	251-254
frequently	O	255-265
located	O	266-273
in	O	274-276
proximity	O	277-286
to	O	287-289
fragile	O	290-297
chromosomal	O	298-309
sites	O	310-315
associated	O	316-326
with	O	327-331
cancers	O	332-339
and	O	340-343
amplification	O	344-357
of	O	358-360
a	O	361-362
miRNA	O	363-368
cluster	O	369-376
has	O	377-380
been	O	381-385
correlated	O	386-396
with	O	397-401
the	O	402-405
etiology	O	406-414
of	O	415-417
lymphomas	O	418-427
and	O	428-431
solid	O	432-437
tumors	O	438-444
.	O	444-445

The	O	446-449
oncogenic	O	450-459
potential	O	460-469
of	O	470-472
a	O	473-474
miRNA	O	475-480
polycistron	O	481-492
has	O	493-496
recently	O	497-505
been	O	506-510
demonstrated	O	511-523
in	O	524-526
vivo	O	527-531
.	O	531-532

Here	O	533-537
,	O	537-538
we	O	539-541
show	O	542-546
that	O	547-551
misexpression	O	552-565
of	O	566-568
the	O	569-572
Drosophila	O	573-583
miRNA	O	584-589
mirvana	O	590-597
/	O	597-598
mir	B	598-601
-	I	601-602
278	I	602-605
in	O	606-608
the	O	609-612
developing	O	613-623
eye	O	624-627
causes	O	628-634
massive	O	635-642
overgrowth	O	643-653
,	O	653-654
in	O	655-657
part	O	658-662
due	O	663-666
to	O	667-669
inhibition	O	670-680
of	O	681-683
apoptosis	O	684-693
.	O	693-694

A	O	695-696
single	O	697-703
base	O	704-708
substitution	O	709-721
affecting	O	722-731
the	O	732-735
mature	O	736-742
miRNA	O	743-748
blocks	O	749-755
the	O	756-759
gain	O	760-764
-	O	764-765
of	O	765-767
-	O	767-768
function	O	768-776
phenotype	O	777-786
but	O	787-790
is	O	791-793
not	O	794-797
associated	O	798-808
with	O	809-813
a	O	814-815
detectable	O	816-826
reduction	O	827-836
-	O	836-837
of	O	837-839
-	O	839-840
function	O	840-848
phenotype	O	849-858
when	O	859-863
homozygous	O	864-874
.	O	874-875

This	O	876-880
result	O	881-887
demonstrates	O	888-900
that	O	901-905
misexpressed	O	906-918
miRNAs	O	919-925
may	O	926-929
acquire	O	930-937
novel	O	938-943
functions	O	944-953
that	O	954-958
cause	O	959-964
unscheduled	O	965-976
proliferation	O	977-990
in	O	991-993
vivo	O	994-998
and	O	999-1002
thus	O	1003-1007
exemplifies	O	1008-1019
the	O	1020-1023
potential	O	1024-1033
of	O	1034-1036
miRNAs	O	1037-1043
to	O	1044-1046
promote	O	1047-1054
tumor	O	1055-1060
formation	O	1061-1070
.	O	1070-1071

Specific	O	0-8
activation	O	9-19
of	O	20-22
microRNA	B	23-31
-	I	31-32
127	I	32-35
with	O	36-40
downregulation	O	41-55
of	O	56-58
the	O	59-62
proto	O	63-68
-	O	68-69
oncogene	O	69-77
BCL6	O	78-82
by	O	83-85
chromatin	O	86-95
-	O	95-96
modifying	O	96-105
drugs	O	106-111
in	O	112-114
human	O	115-120
cancer	O	121-127
cells	O	128-133
.	O	133-134

Expression	O	135-145
profiling	O	146-155
of	O	156-158
T24	O	159-162
cells	O	163-168
revealed	O	169-177
that	O	178-182
17	O	183-185
out	O	186-189
of	O	190-192
313	O	193-196
human	O	197-202
miRNAs	O	203-209
were	O	210-214
upregulated	O	215-226
more	O	227-231
than	O	232-236
3	O	237-238
-	O	238-239
fold	O	239-243
by	O	244-246
simultaneous	O	247-259
treatment	O	260-269
with	O	270-274
the	O	275-278
chromatin	O	279-288
-	O	288-289
modifying	O	289-298
drugs	O	299-304
5	O	305-306
-	O	306-307
aza	O	307-310
-	O	310-311
2	O	311-312
'	O	312-313
-	O	313-314
deoxycytidine	O	314-327
and	O	328-331
4	O	332-333
-	O	333-334
phenylbutyric	O	334-347
acid	O	348-352
.	O	352-353

One	O	354-357
of	O	358-360
these	O	361-366
,	O	366-367
miR	B	368-371
-	I	371-372
127	I	372-375
,	O	375-376
is	O	377-379
embedded	O	380-388
in	O	389-391
a	O	392-393
CpG	O	394-397
island	O	398-404
and	O	405-408
is	O	409-411
highly	O	412-418
induced	O	419-426
from	O	427-431
its	O	432-435
own	O	436-439
promoter	O	440-448
after	O	449-454
treatment	O	455-464
.	O	464-465

miR	B	466-469
-	I	469-470
127	I	470-473
is	O	474-476
usually	O	477-484
expressed	O	485-494
as	O	495-497
part	O	498-502
of	O	503-505
a	O	506-507
miRNA	O	508-513
cluster	O	514-521
in	O	522-524
normal	O	525-531
cells	O	532-537
but	O	538-541
not	O	542-545
in	O	546-548
cancer	O	549-555
cells	O	556-561
,	O	561-562
suggesting	O	563-573
that	O	574-578
it	O	579-581
is	O	582-584
subject	O	585-592
to	O	593-595
epigenetic	O	596-606
silencing	O	607-616
.	O	616-617

In	O	618-620
addition	O	621-629
,	O	629-630
the	O	631-634
proto	O	635-640
-	O	640-641
oncogene	O	641-649
BCL6	O	650-654
,	O	654-655
a	O	656-657
potential	O	658-667
target	O	668-674
of	O	675-677
miR	B	678-681
-	I	681-682
127	I	682-685
,	O	685-686
was	O	687-690
translationally	O	691-706
downregulated	O	707-720
after	O	721-726
treatment	O	727-736
.	O	736-737

These	O	738-743
results	O	744-751
suggest	O	752-759
that	O	760-764
DNA	O	765-768
demethylation	O	769-782
and	O	783-786
histone	O	787-794
deacetylase	O	795-806
inhibition	O	807-817
can	O	818-821
activate	O	822-830
expression	O	831-841
of	O	842-844
miRNAs	O	845-851
that	O	852-856
may	O	857-860
act	O	861-864
as	O	865-867
tumor	O	868-873
suppressors	O	874-885
.	O	885-886

MicroRNAs	O	0-9
:	O	9-10
small	O	11-16
but	O	17-20
potent	O	21-27
oncogenes	O	28-37
or	O	38-40
tumor	O	41-46
suppressors	O	47-58
.	O	58-59

MicroRNAs	O	60-69
(	O	70-71
miRNAs	O	71-77
)	O	77-78
are	O	79-82
small	O	83-88
,	O	88-89
non	O	90-93
-	O	93-94
coding	O	94-100
RNAs	O	101-105
that	O	106-110
modulate	O	111-119
the	O	120-123
expression	O	124-134
of	O	135-137
target	O	138-144
mRNA	O	145-149
.	O	149-150

Many	O	151-155
miRNAs	O	156-162
are	O	163-166
known	O	167-172
to	O	173-175
be	O	176-178
up	O	179-181
-	O	181-182
or	O	183-185
downregulated	O	186-199
in	O	200-202
a	O	203-204
variety	O	205-212
of	O	213-215
cancers	O	216-223
,	O	223-224
suggesting	O	225-235
a	O	236-237
role	O	238-242
for	O	243-246
miRNAs	O	247-253
in	O	254-256
tumorigenesis	O	257-270
.	O	270-271

The	O	272-275
correlation	O	276-287
between	O	288-295
the	O	296-299
expression	O	300-310
of	O	311-313
miRNAs	O	314-320
and	O	321-324
their	O	325-330
effects	O	331-338
on	O	339-341
target	O	342-348
oncogenes	O	349-358
,	O	358-359
on	O	360-362
tumorigenesis	O	363-376
and	O	377-380
on	O	381-383
the	O	384-387
proliferation	O	388-401
of	O	402-404
cancer	O	405-411
cells	O	412-417
is	O	418-420
beginning	O	421-430
to	O	431-433
gain	O	434-438
experimental	O	439-451
evidence	O	452-460
.	O	460-461

For	O	462-465
example	O	466-473
,	O	473-474
the	O	475-478
miRNA	O	479-484
(	B	485-486
miR	I	486-489
)	I	489-490
-	I	490-491
17	I	491-493
-	I	493-494
92	I	494-496
cluster	O	497-504
has	O	505-508
been	O	509-513
characterized	O	514-527
as	O	528-530
an	O	531-533
oncogene	O	534-542
,	O	542-543
while	O	544-549
let	B	550-553
-	I	553-554
7	I	554-555
represses	O	556-565
Ras	O	566-569
and	O	570-573
miR	B	574-577
-	I	577-578
15a	I	578-581
/	O	581-582
-	B	582-583
16	I	583-585
-	I	585-586
1	I	586-587
represses	O	588-597
Bcl	O	598-601
-	O	601-602
2	O	602-603
,	O	603-604
thereby	O	605-612
acting	O	613-619
as	O	620-622
tumor	O	623-628
suppressors	O	629-640
.	O	640-641

Thus	O	642-646
,	O	646-647
an	O	648-650
oncogenic	O	651-660
or	O	661-663
tumor	O	664-669
suppressive	O	670-681
miRNA	O	682-687
may	O	688-691
have	O	692-696
potential	O	697-706
as	O	707-709
a	O	710-711
therapeutic	O	712-723
target	O	724-730
to	O	731-733
control	O	734-741
cancers	O	742-749
.	O	749-750

This	O	751-755
review	O	756-762
will	O	763-767
discuss	O	768-775
the	O	776-779
relationship	O	780-792
between	O	793-800
miRNAs	O	801-807
and	O	808-811
tumorigenesis	O	812-825
,	O	825-826
and	O	827-830
the	O	831-834
potential	O	835-844
for	O	845-848
modulating	O	849-859
miRNAs	O	860-866
for	O	867-870
the	O	871-874
treatment	O	875-884
of	O	885-887
cancer	O	888-894
.	O	894-895

Potential	O	0-9
mRNA	O	10-14
degradation	O	15-26
targets	O	27-34
of	O	35-37
hsa	B	38-41
-	I	41-42
miR	I	42-45
-	I	45-46
200c	I	46-50
,	O	50-51
identified	O	52-62
using	O	63-68
informatics	O	69-80
and	O	81-84
qRT	O	85-88
-	O	88-89
PCR	O	89-92
.	O	92-93

Using	O	94-99
an	O	100-102
anchored	O	103-111
oligo	O	112-117
(	O	117-118
dT	O	118-120
)	O	120-121
based	O	122-127
RT	O	128-130
-	O	130-131
PCR	O	131-134
approach	O	135-143
we	O	144-146
quantified	O	147-157
endogenous	O	158-168
expression	O	169-179
of	O	180-182
ten	O	183-186
microRNAs	O	187-196
in	O	197-199
six	O	200-203
cell	O	204-208
lines	O	209-214
.	O	214-215

This	O	216-220
identified	O	221-231
a	O	232-233
miRNA	O	234-239
,	O	239-240
miR	B	241-244
-	I	244-245
200c	I	245-249
,	O	249-250
with	O	251-255
variable	O	256-264
expression	O	265-275
,	O	275-276
ranging	O	277-284
from	O	285-289
undetectable	O	290-302
in	O	303-305
MDA	O	306-309
-	O	309-310
MB	O	310-312
-	O	312-313
231	O	313-316
and	O	317-320
HT1080	O	321-327
to	O	328-330
highly	O	331-337
expressed	O	338-347
in	O	348-350
MCF7	O	351-355
.	O	355-356

The	O	357-360
variable	O	361-369
expression	O	370-380
provided	O	381-389
a	O	390-391
model	O	392-397
system	O	398-404
to	O	405-407
investigate	O	408-419
endogenous	O	420-430
interactions	O	431-443
between	O	444-451
miRNAs	O	452-458
and	O	459-462
their	O	463-468
computationally	O	469-484
predicted	O	485-494
targets	O	495-502
.	O	502-503

As	O	504-506
the	O	507-510
expression	O	511-521
level	O	522-527
of	O	528-530
the	O	531-534
predicted	O	535-544
mRNA	O	545-549
targets	O	550-557
and	O	558-561
miR	B	562-565
-	I	565-566
200c	I	566-570
in	O	571-573
these	O	574-579
lines	O	580-585
should	O	586-592
have	O	593-597
an	O	598-600
inverse	O	601-608
relationship	O	609-621
if	O	622-624
cleavage	O	625-633
or	O	634-636
degradation	O	637-648
results	O	649-656
from	O	657-661
the	O	662-665
interaction	O	666-677
.	O	677-678

To	O	679-681
select	O	682-688
targets	O	689-696
for	O	697-700
analysis	O	701-709
we	O	710-712
used	O	713-717
Affymetrix	O	718-728
expression	O	729-739
data	O	740-744
and	O	745-748
computational	O	749-762
prediction	O	763-773
programs	O	774-782
.	O	782-783

Affymetrix	O	784-794
data	O	795-799
indicated	O	800-809
approximately	O	810-823
3500	O	824-828
candidate	O	829-838
mRNAs	O	839-844
,	O	844-845
absent	O	846-852
in	O	853-855
MCF7	O	856-860
and	O	861-864
present	O	865-872
in	O	873-875
MDA	O	876-879
-	O	879-880
MB	O	880-882
-	O	882-883
231	O	883-886
or	O	887-889
HT1080	O	890-896
.	O	896-897

These	O	898-903
targets	O	904-911
were	O	912-916
cross	O	917-922
-	O	922-923
referenced	O	923-933
against	O	934-941
approximately	O	942-955
600	O	956-959
computationally	O	960-975
predicted	O	976-985
miR	B	986-989
-	I	989-990
200c	I	990-994
targets	O	995-1002
,	O	1002-1003
identifying	O	1004-1015
twenty	O	1016-1022
potential	O	1023-1032
mRNAs	O	1033-1038
.	O	1038-1039

Expression	O	1040-1050
analysis	O	1051-1059
by	O	1060-1062
qRT	O	1063-1066
-	O	1066-1067
PCR	O	1067-1070
of	O	1071-1073
these	O	1074-1079
targets	O	1080-1087
and	O	1088-1091
an	O	1092-1094
additional	O	1095-1105
ten	O	1106-1109
mRNAs	O	1110-1115
(	O	1116-1117
selected	O	1117-1125
using	O	1126-1131
the	O	1132-1135
prediction	O	1136-1146
program	O	1147-1154
ranking	O	1155-1162
alone	O	1163-1168
)	O	1168-1169
revealed	O	1170-1178
four	O	1179-1183
mRNAs	O	1184-1189
,	O	1189-1190
BIN1	O	1191-1195
,	O	1195-1196
TCF8	O	1197-1201
,	O	1201-1202
RND3	O	1203-1207
and	O	1208-1211
LHFP	O	1212-1216
with	O	1217-1221
an	O	1222-1224
inverse	O	1225-1232
relationship	O	1233-1245
to	O	1246-1248
miR	B	1249-1252
-	I	1252-1253
200c	I	1253-1257
.	O	1257-1258

Of	O	1259-1261
the	O	1262-1265
remainder	O	1266-1275
,	O	1275-1276
the	O	1277-1280
majority	O	1281-1289
did	O	1290-1293
not	O	1294-1297
appear	O	1298-1304
to	O	1305-1307
be	O	1308-1310
degraded	O	1311-1319
(	O	1320-1321
and	O	1321-1324
may	O	1325-1328
be	O	1329-1331
translational	O	1332-1345
targets	O	1346-1353
)	O	1353-1354
or	O	1355-1357
were	O	1358-1362
undetectable	O	1363-1375
in	O	1376-1378
the	O	1379-1382
cell	O	1383-1387
lines	O	1388-1393
examined	O	1394-1402
.	O	1402-1403

Finally	O	1404-1411
,	O	1411-1412
inhibition	O	1413-1423
of	O	1424-1426
miR	B	1427-1430
-	I	1430-1431
200c	I	1431-1435
using	O	1436-1441
an	O	1442-1444
anti	O	1445-1449
-	O	1449-1450
miRNA	O	1450-1455
2	O	1456-1457
'	O	1457-1458
-	O	1458-1459
0	O	1459-1460
-	O	1460-1461
Methyl	O	1461-1467
oligonucleotide	O	1468-1483
(	O	1484-1485
AMO	O	1485-1488
)	O	1488-1489
resulted	O	1490-1498
in	O	1499-1501
an	O	1502-1504
increase	O	1505-1513
in	O	1514-1516
expression	O	1517-1527
of	O	1528-1530
one	O	1531-1534
of	O	1535-1537
the	O	1538-1541
targets	O	1542-1549
,	O	1549-1550
the	O	1551-1554
transcription	O	1555-1568
factor	O	1569-1575
TCF8	O	1576-1580
.	O	1580-1581

These	O	1582-1587
results	O	1588-1595
indicate	O	1596-1604
that	O	1605-1609
a	O	1610-1611
single	O	1612-1618
miRNA	O	1619-1624
could	O	1625-1630
directly	O	1631-1639
affect	O	1640-1646
the	O	1647-1650
mRNA	O	1651-1655
levels	O	1656-1662
of	O	1663-1665
an	O	1666-1668
important	O	1669-1678
transcription	O	1679-1692
factor	O	1693-1699
,	O	1699-1700
albeit	O	1701-1707
in	O	1708-1710
a	O	1711-1712
manner	O	1713-1719
specific	O	1720-1728
to	O	1729-1731
cell	O	1732-1736
lines	O	1737-1742
.	O	1742-1743

Further	O	1744-1751
investigation	O	1752-1765
is	O	1766-1768
required	O	1769-1777
to	O	1778-1780
confirm	O	1781-1788
this	O	1789-1793
in	O	1794-1796
vivo	O	1797-1801
and	O	1802-1805
determine	O	1806-1815
any	O	1816-1819
translational	O	1820-1833
effects	O	1834-1841
.	O	1841-1842

RNAi	O	0-4
,	O	4-5
microRNAs	O	6-15
,	O	15-16
and	O	17-20
human	O	21-26
disease	O	27-34
.	O	34-35

MicroRNAs	O	36-45
(	O	46-47
miRNAs	O	47-53
)	O	53-54
are	O	55-58
short	O	59-64
,	O	64-65
noncoding	O	66-75
RNAs	O	76-80
that	O	81-85
posttranscriptionally	O	86-107
regulate	O	108-116
gene	O	117-121
expression	O	122-132
.	O	132-133

Over	O	134-138
300	O	139-142
miRNA	O	143-148
genes	O	149-154
have	O	155-159
been	O	160-164
identified	O	165-175
in	O	176-178
the	O	179-182
human	O	183-188
genome	O	189-195
.	O	195-196

We	O	197-199
have	O	200-204
undertaken	O	205-215
the	O	216-219
study	O	220-225
of	O	226-228
miRNA	O	229-234
function	O	235-243
in	O	244-246
mammals	O	247-254
.	O	254-255

Using	O	256-261
a	O	262-263
custom	O	264-270
microarray	O	271-281
platform	O	282-290
,	O	290-291
we	O	292-294
investigated	O	295-307
miRNA	O	308-313
expression	O	314-324
patterns	O	325-333
in	O	334-336
mammalian	O	337-346
development	O	347-358
and	O	359-362
in	O	363-365
cancer	O	366-372
.	O	372-373

We	O	374-376
found	O	377-382
that	O	383-387
many	O	388-392
miRNAs	O	393-399
are	O	400-403
downregulated	O	404-417
in	O	418-420
cancer	O	421-427
.	O	427-428

On	O	429-431
the	O	432-435
other	O	436-441
hand	O	442-446
,	O	446-447
several	O	448-455
miRNA	O	456-461
genes	O	462-467
are	O	468-471
overexpressed	O	472-485
in	O	486-488
tumor	O	489-494
cell	O	495-499
lines	O	500-505
and	O	506-509
primary	O	510-517
tumors	O	518-524
.	O	524-525

Seven	O	526-531
of	O	532-534
these	O	535-540
cancer	O	541-547
-	O	547-548
associated	O	548-558
miRNAs	O	559-565
are	O	566-569
clustered	O	570-579
in	O	580-582
a	O	583-584
single	O	585-591
primary	O	592-599
transcript	O	600-610
termed	O	611-617
chr13orf	O	618-626
25	O	627-629
or	O	630-632
OncomiR	O	633-640
-	O	640-641
1	O	641-642
.	O	642-643

This	O	644-648
cluster	O	649-656
is	O	657-659
located	O	660-667
in	O	668-670
a	O	671-672
region	O	673-679
amplified	O	680-689
in	O	690-692
lymphoma	O	693-701
and	O	702-705
several	O	706-713
solid	O	714-719
malignancies	O	720-732
.	O	732-733

Ectopic	O	734-741
expression	O	742-752
of	O	753-755
these	O	756-761
miRNAs	O	762-768
in	O	769-771
a	O	772-773
mouse	O	774-779
model	O	780-785
of	O	786-788
lymphoma	O	789-797
accelerated	O	798-809
disease	O	810-817
progression	O	818-829
.	O	829-830

In	O	831-833
addition	O	834-842
,	O	842-843
the	O	844-847
lymphomas	O	848-857
had	O	858-861
reduced	O	862-869
apoptosis	O	870-879
and	O	880-883
were	O	884-888
more	O	889-893
disseminated	O	894-906
into	O	907-911
secondary	O	912-921
regions	O	922-929
.	O	929-930

This	O	931-935
work	O	936-940
establishes	O	941-952
noncoding	O	953-962
RNAs	O	963-967
,	O	967-968
and	O	969-972
specifically	O	973-985
miRNAs	O	986-992
,	O	992-993
as	O	994-996
oncogenes	O	997-1006
in	O	1007-1009
human	O	1010-1015
cancers	O	1016-1023
.	O	1023-1024

Positive	O	0-8
and	O	9-12
negative	O	13-21
modulation	O	22-32
of	O	33-35
viral	O	36-41
and	O	42-45
cellular	O	46-54
mRNAs	O	55-60
by	O	61-63
liver	O	64-69
-	O	69-70
specific	O	70-78
microRNA	O	79-87
miR	B	88-91
-	I	91-92
122	I	92-95
.	O	95-96

microRNAs	O	97-106
(	O	107-108
miRNAs	O	108-114
)	O	114-115
are	O	116-119
small	O	120-125
RNAs	O	126-130
that	O	131-135
in	O	136-138
general	O	139-146
down	O	147-151
-	O	151-152
regulate	O	152-160
the	O	161-164
intracellular	O	165-178
abundance	O	179-188
and	O	189-192
translation	O	193-204
of	O	205-207
target	O	208-214
mRNAs	O	215-220
.	O	220-221

We	O	222-224
noted	O	225-230
that	O	231-235
sequestration	O	236-249
of	O	250-252
liver	O	253-258
-	O	258-259
specific	O	259-267
miR	B	268-271
-	I	271-272
122	I	272-275
by	O	276-278
modified	O	279-287
antisense	O	288-297
oligonucleotides	O	298-314
resulted	O	315-323
in	O	324-326
a	O	327-328
dramatic	O	329-337
loss	O	338-342
of	O	343-345
hepatitis	O	346-355
C	O	356-357
virus	O	358-363
(	O	364-365
HCV	O	365-368
)	O	368-369
RNA	O	370-373
in	O	374-376
cultured	O	377-385
human	O	386-391
liver	O	392-397
cells	O	398-403
.	O	403-404

A	O	405-406
binding	O	407-414
site	O	415-419
for	O	420-423
miR	B	424-427
-	I	427-428
122	I	428-431
was	O	432-435
predicted	O	436-445
to	O	446-448
reside	O	449-455
close	O	456-461
to	O	462-464
the	O	465-468
5	O	469-470
'	O	470-471
end	O	472-475
of	O	476-478
the	O	479-482
viral	O	483-488
genome	O	489-495
,	O	495-496
and	O	497-500
its	O	501-504
functionality	O	505-518
was	O	519-522
tested	O	523-529
by	O	530-532
mutational	O	533-543
analyses	O	544-552
of	O	553-555
the	O	556-559
miRNA	O	560-565
-	O	565-566
binding	O	566-573
site	O	574-578
in	O	579-581
viral	O	582-587
RNA	O	588-591
,	O	591-592
resulting	O	593-602
in	O	603-605
reduced	O	606-613
intracellular	O	614-627
viral	O	628-633
RNA	O	634-637
abundance	O	638-647
.	O	647-648

Importantly	O	649-660
,	O	660-661
ectopic	O	662-669
expression	O	670-680
of	O	681-683
miR	B	684-687
-	I	687-688
122	I	688-691
molecules	O	692-701
that	O	702-706
contained	O	707-716
compensatory	O	717-729
mutations	O	730-739
restored	O	740-748
viral	O	749-754
RNA	O	755-758
abundance	O	759-768
,	O	768-769
revealing	O	770-779
a	O	780-781
genetic	O	782-789
interaction	O	790-801
between	O	802-809
miR	B	810-813
-	I	813-814
122	I	814-817
and	O	818-821
the	O	822-825
viral	O	826-831
RNA	O	832-835
genome	O	836-842
.	O	842-843

Studies	O	844-851
with	O	852-856
replication	O	857-868
-	O	868-869
defective	O	869-878
viral	O	879-884
RNAs	O	885-889
demonstrated	O	890-902
that	O	903-907
miR	B	908-911
-	I	911-912
122	I	912-915
affected	O	916-924
mRNA	O	925-929
abundance	O	930-939
by	O	940-942
positively	O	943-953
modulating	O	954-964
RNA	O	965-968
replication	O	969-980
.	O	980-981

In	O	982-984
contrast	O	985-993
,	O	993-994
interaction	O	995-1006
of	O	1007-1009
miR	B	1010-1013
-	I	1013-1014
122	I	1014-1017
with	O	1018-1022
the	O	1023-1026
3	O	1027-1028
'	O	1028-1029
-	O	1029-1030
noncoding	O	1030-1039
region	O	1040-1046
(	O	1047-1048
3	O	1048-1049
'	O	1049-1050
NCR	O	1050-1053
)	O	1053-1054
of	O	1055-1057
the	O	1058-1061
cellular	O	1062-1070
mRNA	O	1071-1075
encoding	O	1076-1084
the	O	1085-1088
cationic	O	1089-1097
amino	O	1098-1103
acid	O	1104-1108
transporter	O	1109-1120
CAT	O	1121-1124
-	O	1124-1125
1	O	1125-1126
resulted	O	1127-1135
in	O	1136-1138
the	O	1139-1142
down	O	1143-1147
-	O	1147-1148
regulation	O	1148-1158
of	O	1159-1161
CAT	O	1162-1165
-	O	1165-1166
1	O	1166-1167
protein	O	1168-1175
abundance	O	1176-1185
.	O	1185-1186

These	O	1187-1192
findings	O	1193-1201
provide	O	1202-1209
evidence	O	1210-1218
that	O	1219-1223
a	O	1224-1225
specific	O	1226-1234
miRNA	O	1235-1240
can	O	1241-1244
regulate	O	1245-1253
distinct	O	1254-1262
target	O	1263-1269
mRNAs	O	1270-1275
in	O	1276-1278
both	O	1279-1283
a	O	1284-1285
positive	O	1286-1294
and	O	1295-1298
negative	O	1299-1307
fashion	O	1308-1315
.	O	1315-1316

The	O	1317-1320
positive	O	1321-1329
role	O	1330-1334
of	O	1335-1337
miR	B	1338-1341
-	I	1341-1342
122	I	1342-1345
in	O	1346-1348
viral	O	1349-1354
replication	O	1355-1366
suggests	O	1367-1375
that	O	1376-1380
this	O	1381-1385
miRNA	O	1386-1391
could	O	1392-1397
be	O	1398-1400
targeted	O	1401-1409
for	O	1410-1413
antiviral	O	1414-1423
therapy	O	1424-1431
.	O	1431-1432

Widespread	O	0-10
deregulation	O	11-23
of	O	24-26
microRNA	O	27-35
expression	O	36-46
in	O	47-49
human	O	50-55
prostate	O	56-64
cancer	O	65-71
.	O	71-72

MicroRNAs	O	73-82
(	O	83-84
miRNAs	O	84-90
)	O	90-91
are	O	92-95
small	O	96-101
regulatory	O	102-112
RNAs	O	113-117
that	O	118-122
can	O	123-126
regulate	O	127-135
gene	O	136-140
expression	O	141-151
by	O	152-154
binding	O	155-162
to	O	163-165
mRNA	O	166-170
sequences	O	171-180
and	O	181-184
repressing	O	185-195
target	O	196-202
-	O	202-203
gene	O	203-207
expression	O	208-218
post	O	219-223
-	O	223-224
transcriptionally	O	224-241
,	O	241-242
either	O	243-249
by	O	250-252
inhibiting	O	253-263
translation	O	264-275
or	O	276-278
promoting	O	279-288
RNA	O	289-292
degradation	O	293-304
.	O	304-305

We	O	306-308
have	O	309-313
analysed	O	314-322
expression	O	323-333
of	O	334-336
328	O	337-340
known	O	341-346
and	O	347-350
152	O	351-354
novel	O	355-360
human	O	361-366
miRNAs	O	367-373
in	O	374-376
10	O	377-379
benign	O	380-386
peripheral	O	387-397
zone	O	398-402
tissues	O	403-410
and	O	411-414
16	O	415-417
prostate	O	418-426
cancer	O	427-433
tissues	O	434-441
using	O	442-447
microarrays	O	448-459
and	O	460-463
found	O	464-469
widespread	O	470-480
,	O	480-481
but	O	482-485
not	O	486-489
universal	O	490-499
,	O	499-500
downregulation	O	501-515
of	O	516-518
miRNAs	O	519-525
in	O	526-528
clinically	O	529-539
localized	O	540-549
prostate	O	550-558
cancer	O	559-565
relative	O	566-574
to	O	575-577
benign	O	578-584
peripheral	O	585-595
zone	O	596-600
tissue	O	601-607
.	O	607-608

These	O	609-614
findings	O	615-623
have	O	624-628
been	O	629-633
verified	O	634-642
by	O	643-645
real	O	646-650
-	O	650-651
time	O	651-655
RT	O	656-658
-	O	658-659
PCR	O	659-662
assays	O	663-669
on	O	670-672
select	O	673-679
miRNAs	O	680-686
,	O	686-687
including	O	688-697
miR	B	698-701
-	I	701-702
125b	I	702-706
,	O	706-707
miR	B	708-711
-	I	711-712
145	I	712-715
and	O	716-719
let	B	720-723
-	I	723-724
7c	I	724-726
.	O	726-727

The	O	728-731
downregulated	O	732-745
miRNAs	O	746-752
include	O	753-760
several	O	761-768
with	O	769-773
proven	O	774-780
target	O	781-787
mRNAs	O	788-793
whose	O	794-799
proteins	O	800-808
have	O	809-813
been	O	814-818
previously	O	819-829
shown	O	830-835
to	O	836-838
be	O	839-841
increased	O	842-851
in	O	852-854
prostate	O	855-863
cancer	O	864-870
by	O	871-873
immunohistochemistry	O	874-894
,	O	894-895
including	O	896-905
RAS	O	906-909
,	O	909-910
E2F3	O	911-915
,	O	915-916
BCL	O	917-920
-	O	920-921
2	O	921-922
and	O	923-926
MCL	O	927-930
-	O	930-931
1	O	931-932
.	O	932-933

Using	O	934-939
a	O	940-941
bioinformatics	O	942-956
approach	O	957-965
,	O	965-966
we	O	967-969
have	O	970-974
identified	O	975-985
additional	O	986-996
potential	O	997-1006
mRNA	O	1007-1011
targets	O	1012-1019
of	O	1020-1022
one	O	1023-1026
of	O	1027-1029
the	O	1030-1033
miRNAs	O	1034-1040
,	O	1040-1041
(	O	1042-1043
miR	B	1043-1046
-	I	1046-1047
125b	I	1047-1051
)	O	1051-1052
that	O	1053-1057
are	O	1058-1061
upregulated	O	1062-1073
in	O	1074-1076
prostate	O	1077-1085
cancer	O	1086-1092
and	O	1093-1096
confirmed	O	1097-1106
increased	O	1107-1116
expression	O	1117-1127
of	O	1128-1130
one	O	1131-1134
of	O	1135-1137
these	O	1138-1143
targets	O	1144-1151
,	O	1151-1152
EIF4EBP1	O	1153-1161
,	O	1161-1162
in	O	1163-1165
prostate	O	1166-1174
cancer	O	1175-1181
tissues	O	1182-1189
.	O	1189-1190

Our	O	1191-1194
findings	O	1195-1203
indicate	O	1204-1212
that	O	1213-1217
changes	O	1218-1225
in	O	1226-1228
miRNA	O	1229-1234
expression	O	1235-1245
may	O	1246-1249
have	O	1250-1254
an	O	1255-1257
important	O	1258-1267
role	O	1268-1272
in	O	1273-1275
the	O	1276-1279
biology	O	1280-1287
of	O	1288-1290
human	O	1291-1296
prostate	O	1297-1305
cancer	O	1306-1312
.	O	1312-1313

Functional	O	0-10
screening	O	11-20
identifies	O	21-31
miR	B	32-35
-	I	35-36
315	I	36-39
as	O	40-42
a	O	43-44
potent	O	45-51
activator	O	52-61
of	O	62-64
Wingless	O	65-73
signaling	O	74-83
.	O	83-84

The	O	85-88
existence	O	89-98
of	O	99-101
vast	O	102-106
regulatory	O	107-117
networks	O	118-126
mediated	O	127-135
by	O	136-138
microRNAs	O	139-148
(	O	149-150
miRNAs	O	150-156
)	O	156-157
suggests	O	158-166
broad	O	167-172
potential	O	173-182
for	O	183-186
miRNA	O	187-192
dysfunction	O	193-204
to	O	205-207
contribute	O	208-218
to	O	219-221
disease	O	222-229
.	O	229-230

However	O	231-238
,	O	238-239
relatively	O	240-250
few	O	251-254
miRNA	O	255-260
-	O	260-261
target	O	261-267
interactions	O	268-280
are	O	281-284
likely	O	285-291
to	O	292-294
make	O	295-299
detectable	O	300-310
contributions	O	311-324
to	O	325-327
phenotype	O	328-337
,	O	337-338
and	O	339-342
effective	O	343-352
strategies	O	353-363
to	O	364-366
identify	O	367-375
these	O	376-381
few	O	382-385
interactions	O	386-398
are	O	399-402
currently	O	403-412
wanting	O	413-420
.	O	420-421

We	O	422-424
hypothesized	O	425-437
that	O	438-442
signaling	O	443-452
cascades	O	453-461
represent	O	462-471
critical	O	472-480
points	O	481-487
of	O	488-490
susceptibility	O	491-505
to	O	506-508
miRNA	O	509-514
dysfunction	O	515-526
,	O	526-527
and	O	528-531
we	O	532-534
developed	O	535-544
a	O	545-546
strategy	O	547-555
to	O	556-558
test	O	559-563
this	O	564-568
theory	O	569-575
by	O	576-578
using	O	579-584
quantitative	O	585-597
cell	O	598-602
-	O	602-603
based	O	603-608
screens	O	609-616
.	O	616-617

Here	O	618-622
we	O	623-625
report	O	626-632
a	O	633-634
screen	O	635-641
for	O	642-645
miRNAs	O	646-652
that	O	653-657
affect	O	658-664
the	O	665-668
Wingless	O	669-677
(	O	678-679
Wg	O	679-681
)	O	681-682
pathway	O	683-690
,	O	690-691
a	O	692-693
conserved	O	694-703
pathway	O	704-711
that	O	712-716
regulates	O	717-726
growth	O	727-733
and	O	734-737
tissue	O	738-744
specification	O	745-758
.	O	758-759

This	O	760-764
process	O	765-772
identified	O	773-783
ectopic	O	784-791
miR	B	792-795
-	I	795-796
315	I	796-799
as	O	800-802
a	O	803-804
potent	O	805-811
and	O	812-815
specific	O	816-824
activator	O	825-834
of	O	835-837
Wg	O	838-840
signaling	O	841-850
,	O	850-851
an	O	852-854
activity	O	855-863
that	O	864-868
we	O	869-871
corroborated	O	872-884
in	O	885-887
transgenic	O	888-898
animals	O	899-906
.	O	906-907

This	O	908-912
miR	B	913-916
-	I	916-917
315	I	917-920
activity	O	921-929
was	O	930-933
mediated	O	934-942
by	O	943-945
direct	O	946-952
inhibition	O	953-963
of	O	964-966
Axin	O	967-971
and	O	972-975
Notum	O	976-981
,	O	981-982
which	O	983-988
encode	O	989-995
essential	O	996-1005
,	O	1005-1006
negatively	O	1007-1017
acting	O	1018-1024
components	O	1025-1035
of	O	1036-1038
the	O	1039-1042
Wg	O	1043-1045
pathway	O	1046-1053
.	O	1053-1054

Genetic	O	1055-1062
interaction	O	1063-1074
tests	O	1075-1080
substantiated	O	1081-1094
both	O	1095-1099
of	O	1100-1102
these	O	1103-1108
genes	O	1109-1114
as	O	1115-1117
key	O	1118-1121
functional	O	1122-1132
targets	O	1133-1140
of	O	1141-1143
miR	B	1144-1147
-	I	1147-1148
315	I	1148-1151
.	O	1151-1152

The	O	1153-1156
ability	O	1157-1164
of	O	1165-1167
ectopic	O	1168-1175
miR	B	1176-1179
-	I	1179-1180
315	I	1180-1183
to	O	1184-1186
activate	O	1187-1195
Wg	O	1196-1198
signaling	O	1199-1208
was	O	1209-1212
not	O	1213-1216
a	O	1217-1218
trivial	O	1219-1226
consequence	O	1227-1238
of	O	1239-1241
predicted	O	1242-1251
miRNA	O	1252-1257
-	O	1257-1258
target	O	1258-1264
relationships	O	1265-1278
because	O	1279-1286
other	O	1287-1292
miRNAs	O	1293-1299
with	O	1300-1304
conserved	O	1305-1314
sites	O	1315-1320
in	O	1321-1323
the	O	1324-1327
Axin	O	1328-1332
3	O	1333-1334
'	O	1334-1335
UTR	O	1336-1339
neither	O	1340-1347
activated	O	1348-1357
Wg	O	1358-1360
outputs	O	1361-1368
nor	O	1369-1372
inhibited	O	1373-1382
an	O	1383-1385
Axin	O	1386-1390
sensor	O	1391-1397
.	O	1397-1398

In	O	1399-1401
summary	O	1402-1409
,	O	1409-1410
activity	O	1411-1419
-	O	1419-1420
based	O	1420-1425
screening	O	1426-1435
can	O	1436-1439
selectively	O	1440-1451
identify	O	1452-1460
miRNAs	O	1461-1467
whose	O	1468-1473
deregulation	O	1474-1486
can	O	1487-1490
lead	O	1491-1495
to	O	1496-1498
interpretable	O	1499-1512
phenotypic	O	1513-1523
consequences	O	1524-1536
.	O	1536-1537

[	O	0-1
MicroRNAs	O	1-10
can	O	11-14
be	O	15-17
expressed	O	18-27
in	O	28-30
cardiomyocyte	O	31-44
-	O	44-45
like	O	45-49
cells	O	50-55
differentiated	O	56-70
from	O	71-75
human	O	76-81
mesenchymal	O	82-93
stem	O	94-98
cells	O	99-104
]	O	104-105
.	O	105-106

OBJECTIVE	O	107-116
:	O	116-117
To	O	118-120
investigate	O	121-132
the	O	133-136
expression	O	137-147
of	O	148-150
representative	O	151-165
heart	O	166-171
-	O	171-172
specific	O	172-180
primary	O	181-188
microRNAs	O	189-198
(	O	199-200
pri	O	200-203
-	O	203-204
miRNAs	O	204-210
)	O	210-211
in	O	212-214
the	O	215-218
cardiomyocyte	O	219-232
-	O	232-233
like	O	233-237
cells	O	238-243
differentiated	O	244-258
from	O	259-263
human	O	264-269
mesenchymal	O	270-281
stem	O	282-286
cells	O	287-292
(	O	293-294
hMSCs	O	294-299
)	O	299-300
.	O	300-301

METHODS	O	302-309
:	O	309-310
The	O	311-314
phenotype	O	315-324
of	O	325-327
hMSCs	O	328-333
isolated	O	334-342
was	O	343-346
identified	O	347-357
by	O	358-360
flow	O	361-365
cytometry	O	366-375
using	O	376-381
monoclonal	O	382-392
antibodies	O	393-403
against	O	404-411
FITC	O	412-416
-	O	416-417
conjugated	O	417-427
CD29	O	428-432
,	O	432-433
CD34	O	434-438
,	O	438-439
and	O	440-443
CD11b	O	444-449
.	O	449-450

The	O	451-454
third	O	455-460
-	O	460-461
passage	O	461-468
hMSCs	O	469-474
were	O	475-479
induced	O	480-487
to	O	488-490
differentiate	O	491-504
into	O	505-509
cardiomyocyte	O	510-523
-	O	523-524
like	O	524-528
cells	O	529-534
by	O	535-537
5	O	538-539
-	O	539-540
azacytidine	O	540-551
and	O	552-555
indirect	O	556-564
coculture	O	565-574
with	O	575-579
neonatal	O	580-588
rat	O	589-592
myocytes	O	593-601
,	O	601-602
respectively	O	603-615
.	O	615-616

Immunocytochemical	O	617-635
analysis	O	636-644
was	O	645-648
performed	O	649-658
to	O	659-661
detect	O	662-668
the	O	669-672
expression	O	673-683
of	O	684-686
the	O	687-690
cardiac	O	691-698
-	O	698-699
specific	O	699-707
proteins	O	708-716
,	O	716-717
namely	O	718-724
cardiac	O	725-732
troponin	O	733-741
I	O	742-743
(	O	744-745
cTnI	O	745-749
)	O	749-750
and	O	751-754
sarcomeric	O	755-765
alpha	O	766-771
-	O	771-772
actinin	O	772-779
,	O	779-780
in	O	781-783
the	O	784-787
cardiomyocyte	O	788-801
-	O	801-802
like	O	802-806
cells	O	807-812
differentiated	O	813-827
from	O	828-832
hMSCs	O	833-838
.	O	838-839

RT	O	840-842
-	O	842-843
PCR	O	843-846
and	O	847-850
DNA	O	851-854
sequencing	O	855-865
were	O	866-870
used	O	871-875
to	O	876-878
identify	O	879-887
the	O	888-891
expression	O	892-902
of	O	903-905
the	O	906-909
5	O	910-911
representative	O	912-926
heart	O	927-932
-	O	932-933
specific	O	933-941
pri	O	942-945
-	O	945-946
miRNAs	O	946-952
.	O	952-953

RESULTS	O	954-961
:	O	961-962
High	O	963-967
hMSC	O	968-972
marker	O	973-979
CD29	O	980-984
expression	O	985-995
rate	O	996-1000
(	O	1001-1002
98	O	1002-1004
.	O	1004-1005
87	O	1005-1007
%	O	1007-1008
)	O	1008-1009
and	O	1010-1013
low	O	1014-1017
hematopoietic	O	1018-1031
cell	O	1032-1036
markers	O	1037-1044
CD34	O	1045-1049
(	O	1050-1051
5	O	1051-1052
%	O	1052-1053
)	O	1053-1054
and	O	1055-1058
CD11b	O	1059-1064
(	O	1065-1066
0	O	1066-1067
.	O	1067-1068
4	O	1068-1069
%	O	1069-1070
)	O	1070-1071
expression	O	1072-1082
rates	O	1083-1088
were	O	1089-1093
identified	O	1094-1104
in	O	1105-1107
the	O	1108-1111
hMSCs	O	1112-1117
isolated	O	1118-1126
.	O	1126-1127

cTnI	O	1128-1132
and	O	1133-1136
sarcomeric	O	1137-1147
alpha	O	1148-1153
-	O	1153-1154
actinin	O	1154-1161
expression	O	1162-1172
occurred	O	1173-1181
in	O	1182-1184
the	O	1185-1188
hMSCs	O	1189-1194
following	O	1195-1204
induction	O	1205-1214
with	O	1215-1219
the	O	1220-1223
2	O	1224-1225
differentiation	O	1226-1241
-	O	1241-1242
inducing	O	1242-1250
methods	O	1251-1258
.	O	1258-1259

miRNA	B	1260-1265
-	I	1265-1266
143	I	1266-1269
and	O	1270-1273
-	B	1274-1275
181	I	1275-1278
expressions	O	1279-1290
were	O	1291-1295
induced	O	1296-1303
in	O	1304-1306
the	O	1307-1310
hMSCs	O	1311-1316
by	O	1317-1319
5	O	1320-1321
-	O	1321-1322
azacytidine	O	1322-1333
and	O	1334-1337
miRNA	B	1338-1343
-	I	1343-1344
143	I	1344-1347
,	O	1347-1348
-	B	1349-1350
181	I	1350-1353
,	O	1353-1354
-	B	1355-1356
206	I	1356-1359
,	O	1359-1360
and	O	1361-1364
-	B	1365-1366
208	I	1366-1369
expressions	O	1370-1381
were	O	1382-1386
induced	O	1387-1394
by	O	1395-1397
indirect	O	1398-1406
coculture	O	1407-1416
with	O	1417-1421
neonatal	O	1422-1430
rat	O	1431-1434
myocytes	O	1435-1443
,	O	1443-1444
but	O	1445-1448
pri	B	1449-1452
-	I	1452-1453
miRNA	I	1453-1458
-	I	1458-1459
1	I	1459-1460
-	I	1460-1461
2	I	1461-1462
expression	O	1463-1473
failed	O	1474-1480
to	O	1481-1483
be	O	1484-1486
induced	O	1487-1494
by	O	1495-1497
these	O	1498-1503
two	O	1504-1507
induction	O	1508-1517
methods	O	1518-1525
.	O	1525-1526

CONCLUSION	O	1527-1537
:	O	1537-1538
Expressions	O	1539-1550
of	O	1551-1553
the	O	1554-1557
representative	O	1558-1572
heart	O	1573-1578
-	O	1578-1579
specific	O	1579-1587
pri	O	1588-1591
-	O	1591-1592
miRNAs	O	1592-1598
in	O	1599-1601
different	O	1602-1611
patterns	O	1612-1620
can	O	1621-1624
be	O	1625-1627
induced	O	1628-1635
in	O	1636-1638
cardiomyocyte	O	1639-1652
-	O	1652-1653
like	O	1653-1657
cells	O	1658-1663
differentiated	O	1664-1678
from	O	1679-1683
hMSCs	O	1684-1689
by	O	1690-1692
5	O	1693-1694
-	O	1694-1695
azacytidine	O	1695-1706
and	O	1707-1710
indirect	O	1711-1719
coculture	O	1720-1729
with	O	1730-1734
neonatal	O	1735-1743
rat	O	1744-1747
myocytes	O	1748-1756
.	O	1756-1757

Detailed	O	0-8
characterization	O	9-25
of	O	26-28
a	O	29-30
homozygously	O	31-43
deleted	O	44-51
region	O	52-58
corresponding	O	59-72
to	O	73-75
a	O	76-77
candidate	O	78-87
tumor	O	88-93
suppressor	O	94-104
locus	O	105-110
at	O	111-113
21q11	O	114-119
-	O	119-120
21	O	120-122
in	O	123-125
human	O	126-131
lung	O	132-136
cancer	O	137-143
.	O	143-144

The	O	145-148
frequent	O	149-157
presence	O	158-166
of	O	167-169
loss	O	170-174
of	O	175-177
heterozygosity	O	178-192
(	O	193-194
LOH	O	194-197
)	O	197-198
at	O	199-201
21q21	O	202-207
in	O	208-210
lung	O	211-215
cancer	O	216-222
suggests	O	223-231
the	O	232-235
existence	O	236-245
of	O	246-248
putative	O	249-257
tumor	O	258-263
suppressor	O	264-274
genes	O	275-280
in	O	281-283
this	O	284-288
genomic	O	289-296
region	O	297-303
.	O	303-304

Furthermore	O	305-316
,	O	316-317
the	O	318-321
identification	O	322-336
of	O	337-339
a	O	340-341
homozygous	O	342-352
deletion	O	353-361
in	O	362-364
this	O	365-369
region	O	370-376
has	O	377-380
lent	O	381-385
further	O	386-393
support	O	394-401
for	O	402-405
its	O	406-409
potential	O	410-419
involvement	O	420-431
in	O	432-434
pathogenesis	O	435-447
.	O	447-448

In	O	449-451
the	O	452-455
present	O	456-463
study	O	464-469
,	O	469-470
extensive	O	471-480
screening	O	481-490
of	O	491-493
a	O	494-495
large	O	496-501
panel	O	502-507
of	O	508-510
lung	O	511-515
cancer	O	516-522
cell	O	523-527
lines	O	528-533
resulted	O	534-542
in	O	543-545
the	O	546-549
identification	O	550-564
of	O	565-567
a	O	568-569
homozygous	O	570-580
deletion	O	581-589
at	O	590-592
21q21	O	593-598
.	O	598-599
1	O	599-600
in	O	601-603
the	O	604-607
large	O	608-613
cell	O	614-618
lung	O	619-623
carcinoma	O	624-633
cell	O	634-638
line	O	639-643
Calu	O	644-648
-	O	648-649
6	O	649-650
.	O	650-651

Subsequent	O	652-662
detailed	O	663-671
characterization	O	672-688
allowed	O	689-696
us	O	697-699
to	O	700-702
narrow	O	703-709
down	O	710-714
the	O	715-718
extent	O	719-725
of	O	726-728
the	O	729-732
shortest	O	733-741
region	O	742-748
of	O	749-751
overlap	O	752-759
of	O	760-762
homozygous	O	763-773
deletions	O	774-783
at	O	784-786
21q21	O	787-792
.	O	792-793
1	O	793-794
to	O	795-797
3	O	798-799
.	O	799-800
4	O	800-801
Mbp	O	802-805
.	O	805-806

Together	O	807-815
with	O	816-820
existing	O	821-829
information	O	830-841
showing	O	842-849
a	O	850-851
relationship	O	852-864
with	O	865-869
the	O	870-873
shortest	O	874-882
region	O	883-889
of	O	890-892
overlap	O	893-900
and	O	901-904
LOH	O	905-908
in	O	909-911
lung	O	912-916
cancer	O	917-923
,	O	923-924
the	O	925-928
overlapping	O	929-940
1	O	941-942
.	O	942-943
8	O	943-944
-	O	944-945
Mbp	O	945-948
region	O	949-955
was	O	956-959
suggested	O	960-969
to	O	970-972
be	O	973-975
a	O	976-977
prime	O	978-983
candidate	O	984-993
for	O	994-997
a	O	998-999
genomic	O	1000-1007
region	O	1008-1014
that	O	1015-1019
may	O	1020-1023
harbor	O	1024-1030
putative	O	1031-1039
tumor	O	1040-1045
suppressor	O	1046-1056
genes	O	1057-1062
.	O	1062-1063

We	O	1064-1066
found	O	1067-1072
frequent	O	1073-1081
downregulation	O	1082-1096
of	O	1097-1099
two	O	1100-1103
coding	O	1104-1110
genes	O	1111-1116
,	O	1116-1117
SAMSN1	O	1118-1124
and	O	1125-1128
USP25	O	1129-1134
,	O	1134-1135
as	O	1136-1138
well	O	1139-1143
as	O	1144-1146
of	O	1147-1149
three	O	1150-1155
miRNA	O	1156-1161
genes	O	1162-1167
,	O	1167-1168
miR	B	1169-1172
-	I	1172-1173
99a	I	1173-1176
,	O	1176-1177
let	B	1178-1181
-	I	1181-1182
7c	I	1182-1184
,	O	1184-1185
and	O	1186-1189
miR	B	1190-1193
-	I	1193-1194
125b	I	1194-1198
-	I	1198-1199
2	I	1199-1200
,	O	1200-1201
which	O	1202-1207
reside	O	1208-1214
in	O	1215-1217
the	O	1218-1221
commonly	O	1222-1230
deleted	O	1231-1238
region	O	1239-1245
in	O	1246-1248
human	O	1249-1254
lung	O	1255-1259
cancer	O	1260-1266
.	O	1266-1267

In	O	1268-1270
addition	O	1271-1279
,	O	1279-1280
initial	O	1281-1288
attempts	O	1289-1297
were	O	1298-1302
made	O	1303-1307
to	O	1308-1310
investigate	O	1311-1322
their	O	1323-1328
potential	O	1329-1338
alterations	O	1339-1350
and	O	1351-1354
functional	O	1355-1365
involvements	O	1366-1378
in	O	1379-1381
the	O	1382-1385
development	O	1386-1397
of	O	1398-1400
lung	O	1401-1405
cancer	O	1406-1412
.	O	1412-1413

Linking	O	0-7
miRNA	O	8-13
regulation	O	14-24
to	O	25-27
BCR	O	28-31
-	O	31-32
ABL	O	32-35
expression	O	36-46
:	O	46-47
the	O	48-51
next	O	52-56
dimension	O	57-66
.	O	66-67

The	O	68-71
introduction	O	72-84
of	O	85-87
tyrosine	O	88-96
kinase	O	97-103
inhibitors	O	104-114
in	O	115-117
the	O	118-121
treatment	O	122-131
of	O	132-134
BCR	O	135-138
-	O	138-139
ABL1	O	139-143
-	O	143-144
rearranged	O	144-154
malignancies	O	155-167
has	O	168-171
revolutionized	O	172-186
therapy	O	187-194
,	O	194-195
but	O	196-199
the	O	200-203
prognosis	O	204-213
for	O	214-217
acute	O	218-223
leukemias	O	224-233
remains	O	234-241
suboptimal	O	242-252
.	O	252-253

In	O	254-256
this	O	257-261
issue	O	262-267
of	O	268-270
Cancer	O	271-277
Cell	O	278-282
,	O	282-283
Bueno	O	284-289
et	O	290-292
al	O	293-295
.	O	295-296

(	O	297-298
2008	O	298-302
)	O	302-303
add	O	304-307
a	O	308-309
new	O	310-313
dimension	O	314-323
to	O	324-326
the	O	327-330
regulation	O	331-341
of	O	342-344
ABL1	O	345-349
expression	O	350-360
.	O	360-361

The	O	362-365
authors	O	366-373
demonstrate	O	374-385
that	O	386-390
ABL1	O	391-395
is	O	396-398
a	O	399-400
direct	O	401-407
target	O	408-414
of	O	415-417
miR	B	418-421
-	I	421-422
203	I	422-425
,	O	425-426
miR	B	427-430
-	I	430-431
203	I	431-434
is	O	435-437
silenced	O	438-446
by	O	447-449
genetic	O	450-457
and	O	458-461
epigenetic	O	462-472
mechanisms	O	473-483
in	O	484-486
hematopoietic	O	487-500
malignancies	O	501-513
expressing	O	514-524
either	O	525-531
ABL1	O	532-536
or	O	537-539
BCR	O	540-543
-	O	543-544
ABL1	O	544-548
,	O	548-549
and	O	550-553
restoration	O	554-565
of	O	566-568
miR	B	569-572
-	I	572-573
203	I	573-576
expression	O	577-587
reduces	O	588-595
ABL1	O	596-600
and	O	601-604
BCR	O	605-608
-	O	608-609
ABL1	O	609-613
levels	O	614-620
and	O	621-624
inhibits	O	625-633
cell	O	634-638
proliferation	O	639-652
.	O	652-653

These	O	654-659
findings	O	660-668
may	O	669-672
have	O	673-677
broad	O	678-683
implications	O	684-696
for	O	697-700
mechanisms	O	701-711
underlying	O	712-722
malignant	O	723-732
transformation	O	733-747
in	O	748-750
hematopoietic	O	751-764
and	O	765-768
other	O	769-774
malignancies	O	775-787
.	O	787-788

Mir	B	0-3
-	I	3-4
302	I	4-7
reprograms	O	8-18
human	O	19-24
skin	O	25-29
cancer	O	30-36
cells	O	37-42
into	O	43-47
a	O	48-49
pluripotent	O	50-61
ES	O	62-64
-	O	64-65
cell	O	65-69
-	O	69-70
like	O	70-74
state	O	75-80
.	O	80-81

Renewal	O	82-89
of	O	90-92
stem	O	93-97
cells	O	98-103
differs	O	104-111
from	O	112-116
cancer	O	117-123
cell	O	124-128
growth	O	129-135
in	O	136-138
self	O	139-143
-	O	143-144
controlled	O	144-154
cell	O	155-159
division	O	160-168
.	O	168-169

The	O	170-173
mir	B	174-177
-	I	177-178
302	I	178-181
microRNA	O	182-190
(	O	191-192
miRNA	O	192-197
)	O	197-198
family	O	199-205
(	O	206-207
mir	B	207-210
-	I	210-211
302s	I	211-215
)	O	215-216
is	O	217-219
expressed	O	220-229
most	O	230-234
abundantly	O	235-245
in	O	246-248
slow	O	249-253
-	O	253-254
growing	O	254-261
human	O	262-267
embryonic	O	268-277
stem	O	278-282
(	O	283-284
ES	O	284-286
)	O	286-287
cells	O	288-293
,	O	293-294
and	O	295-298
quickly	O	299-306
decreases	O	307-316
after	O	317-322
cell	O	323-327
differentiation	O	328-343
and	O	344-347
proliferation	O	348-361
.	O	361-362

Therefore	O	363-372
,	O	372-373
mir	B	374-377
-	I	377-378
302s	I	378-382
was	O	383-386
investigated	O	387-399
as	O	400-402
one	O	403-406
of	O	407-409
the	O	410-413
key	O	414-417
factors	O	418-425
essential	O	426-435
for	O	436-439
maintenance	O	440-451
of	O	452-454
ES	O	455-457
cell	O	458-462
renewal	O	463-470
and	O	471-474
pluripotency	O	475-487
in	O	488-490
this	O	491-495
study	O	496-501
.	O	501-502

The	O	503-506
Pol	O	507-510
-	O	510-511
II	O	511-513
-	O	513-514
based	O	514-519
intronic	O	520-528
miRNA	O	529-534
expression	O	535-545
system	O	546-552
was	O	553-556
used	O	557-561
to	O	562-564
transgenically	O	565-579
transfect	O	580-589
the	O	590-593
mir	B	594-597
-	I	597-598
302s	I	598-602
into	O	603-607
several	O	608-615
human	O	616-621
cancer	O	622-628
cell	O	629-633
lines	O	634-639
.	O	639-640

The	O	641-644
mir	B	645-648
-	I	648-649
302	I	649-652
-	O	652-653
transfected	O	653-664
cells	O	665-670
,	O	670-671
namely	O	672-678
,	O	678-679
miRNA	O	680-685
-	O	685-686
induced	O	686-693
pluripotent	O	694-705
stem	O	706-710
(	O	711-712
mirPS	O	712-717
)	O	717-718
cells	O	719-724
,	O	724-725
not	O	726-729
only	O	730-734
expressed	O	735-744
many	O	745-749
key	O	750-753
ES	O	754-756
cell	O	757-761
markers	O	762-769
,	O	769-770
such	O	771-775
as	O	776-778
Oct3	O	779-783
/	O	783-784
4	O	784-785
,	O	785-786
SSEA	O	787-791
-	O	791-792
3	O	792-793
,	O	793-794
SSEA	O	795-799
-	O	799-800
4	O	800-801
,	O	802-803
Sox2	O	803-807
,	O	807-808
and	O	809-812
Nanog	O	813-818
,	O	818-819
but	O	820-823
also	O	824-828
had	O	829-832
a	O	833-834
highly	O	835-841
demethylated	O	842-854
genome	O	855-861
similar	O	862-869
to	O	870-872
a	O	873-874
reprogrammed	O	875-887
zygotic	O	888-895
genome	O	896-902
.	O	902-903

Microarray	O	904-914
analyses	O	915-923
further	O	924-931
revealed	O	932-940
that	O	941-945
genome	O	946-952
-	O	952-953
wide	O	953-957
gene	O	958-962
expression	O	963-973
patterns	O	974-982
between	O	983-990
the	O	991-994
mirPS	O	995-1000
and	O	1001-1004
human	O	1005-1010
ES	O	1011-1013
H1	O	1014-1016
and	O	1017-1020
H9	O	1021-1023
cells	O	1024-1029
shared	O	1030-1036
over	O	1037-1041
86	O	1042-1044
%	O	1044-1045
similarity	O	1046-1056
.	O	1056-1057

Using	O	1058-1063
molecular	O	1064-1073
guidance	O	1074-1082
in	O	1083-1085
vitro	O	1086-1091
,	O	1091-1092
these	O	1093-1098
mirPS	O	1099-1104
cells	O	1105-1110
could	O	1111-1116
differentiate	O	1117-1130
into	O	1131-1135
distinct	O	1136-1144
tissue	O	1145-1151
cell	O	1152-1156
types	O	1157-1162
,	O	1162-1163
such	O	1164-1168
as	O	1169-1171
neuron	O	1172-1178
-	O	1178-1179
,	O	1179-1180
chondrocyte	O	1181-1192
-	O	1192-1193
,	O	1193-1194
fibroblast	O	1195-1205
-	O	1205-1206
,	O	1206-1207
and	O	1208-1211
spermatogonia	O	1212-1225
-	O	1225-1226
like	O	1226-1230
primordial	O	1231-1241
cells	O	1242-1247
.	O	1247-1248

Based	O	1249-1254
on	O	1255-1257
these	O	1258-1263
findings	O	1264-1272
,	O	1272-1273
we	O	1274-1276
conclude	O	1277-1285
that	O	1286-1290
mir	B	1291-1294
-	I	1294-1295
302s	I	1295-1299
not	O	1300-1303
only	O	1304-1308
function	O	1309-1317
to	O	1318-1320
reprogram	O	1321-1330
cancer	O	1331-1337
cells	O	1338-1343
into	O	1344-1348
an	O	1349-1351
ES	O	1352-1354
-	O	1354-1355
like	O	1355-1359
pluripotent	O	1360-1371
state	O	1372-1377
but	O	1378-1381
also	O	1382-1386
to	O	1387-1389
maintain	O	1390-1398
this	O	1399-1403
state	O	1404-1409
under	O	1410-1415
a	O	1416-1417
feeder	O	1418-1424
-	O	1424-1425
free	O	1425-1429
cultural	O	1430-1438
condition	O	1439-1448
,	O	1448-1449
which	O	1450-1455
may	O	1456-1459
offer	O	1460-1465
a	O	1466-1467
great	O	1468-1473
opportunity	O	1474-1485
for	O	1486-1489
therapeutic	O	1490-1501
intervention	O	1502-1514
.	O	1514-1515

MicroRNA	O	0-8
-	O	8-9
mediated	O	9-17
up	O	18-20
-	O	20-21
regulation	O	21-31
of	O	32-34
an	O	35-37
alternatively	O	38-51
polyadenylated	O	52-66
variant	O	67-74
of	O	75-77
the	O	78-81
mouse	O	82-87
cytoplasmic	O	88-99
{	O	100-101
beta	O	101-105
}	O	105-106
-	O	106-107
actin	O	107-112
gene	O	113-117
.	O	117-118

Actin	O	119-124
is	O	125-127
a	O	128-129
major	O	130-135
cytoskeletal	O	136-148
protein	O	149-156
in	O	157-159
eukaryotes	O	160-170
.	O	170-171

Recent	O	172-178
studies	O	179-186
suggest	O	187-194
more	O	195-199
diverse	O	200-207
functional	O	208-218
roles	O	219-224
for	O	225-228
this	O	229-233
protein	O	234-241
.	O	241-242

Actin	O	243-248
mRNA	O	249-253
is	O	254-256
known	O	257-262
to	O	263-265
be	O	266-268
localized	O	269-278
to	O	279-281
neuronal	O	282-290
synapses	O	291-299
and	O	300-303
undergoes	O	304-313
rapid	O	314-319
deadenylation	O	320-333
during	O	334-340
early	O	341-346
developmental	O	347-360
stages	O	361-367
.	O	367-368

However	O	369-376
,	O	376-377
its	O	378-381
3	O	382-383
'	O	383-384
-	O	384-385
untranslated	O	385-397
region	O	398-404
(	O	405-406
UTR	O	406-409
)	O	409-410
is	O	411-413
not	O	414-417
characterized	O	418-431
and	O	432-435
there	O	436-441
are	O	442-445
no	O	446-448
experimentally	O	449-463
determined	O	464-474
polyadenylation	O	475-490
(	O	491-492
polyA	O	492-497
)	O	497-498
sites	O	499-504
in	O	505-507
actin	O	508-513
mRNA	O	514-518
.	O	518-519

We	O	520-522
have	O	523-527
found	O	528-533
that	O	534-538
the	O	539-542
cytoplasmic	O	543-554
beta	O	555-559
-	O	559-560
actin	O	560-565
(	O	566-567
Actb	O	567-571
)	O	571-572
gene	O	573-577
generates	O	578-587
two	O	588-591
alternative	O	592-603
transcripts	O	604-615
terminated	O	616-626
at	O	627-629
tandem	O	630-636
polyA	O	637-642
sites	O	643-648
.	O	648-649

We	O	650-652
used	O	653-657
3	O	658-659
'	O	659-660
-	O	660-661
RACE	O	661-665
,	O	665-666
EST	O	667-670
end	O	671-674
analysis	O	675-683
and	O	684-687
in	O	688-690
situ	O	691-695
hybridization	O	696-709
to	O	710-712
unambiguously	O	713-726
establish	O	727-736
the	O	737-740
existence	O	741-750
of	O	751-753
two	O	754-757
3	O	758-759
'	O	759-760
-	O	760-761
UTRs	O	761-765
of	O	766-768
varying	O	769-776
length	O	777-783
in	O	784-786
Actb	O	787-791
transcript	O	792-802
in	O	803-805
mouse	O	806-811
neuronal	O	812-820
cells	O	821-826
.	O	826-827

Further	O	828-835
analyses	O	836-844
showed	O	845-851
that	O	852-856
these	O	857-862
two	O	863-866
tandem	O	867-873
polyA	O	874-879
sites	O	880-885
are	O	886-889
used	O	890-894
in	O	895-897
a	O	898-899
tissue	O	900-906
-	O	906-907
specific	O	907-915
manner	O	916-922
.	O	922-923

Although	O	924-932
the	O	933-936
longer	O	937-943
3	O	944-945
'	O	945-946
-	O	946-947
UTR	O	947-950
was	O	951-954
expressed	O	955-964
at	O	965-967
a	O	968-969
relatively	O	970-980
lower	O	981-986
level	O	987-992
,	O	992-993
it	O	994-996
conferred	O	997-1006
higher	O	1007-1013
translational	O	1014-1027
efficiency	O	1028-1038
to	O	1039-1041
the	O	1042-1045
transcript	O	1046-1056
.	O	1056-1057

The	O	1058-1061
longer	O	1062-1068
transcript	O	1069-1079
harbours	O	1080-1088
a	O	1089-1090
conserved	O	1091-1100
mmu	B	1101-1104
-	I	1104-1105
miR	I	1105-1108
-	I	1108-1109
34a	I	1109-1112
/	O	1112-1113
34b	B	1113-1116
-	I	1116-1117
5p	I	1117-1119
target	O	1120-1126
site	O	1127-1131
.	O	1131-1132

Sequence	O	1133-1141
-	O	1141-1142
specific	O	1142-1150
anti	O	1151-1155
-	O	1155-1156
miRNA	O	1156-1161
molecule	O	1162-1170
,	O	1170-1171
mutations	O	1172-1181
of	O	1182-1184
the	O	1185-1188
miRNA	O	1189-1194
target	O	1195-1201
region	O	1202-1208
in	O	1209-1211
the	O	1212-1215
3	O	1216-1217
'	O	1217-1218
-	O	1218-1219
UTR	O	1219-1222
resulted	O	1223-1231
in	O	1232-1234
reduced	O	1235-1242
expression	O	1243-1253
.	O	1253-1254

The	O	1255-1258
expression	O	1259-1269
was	O	1270-1273
restored	O	1274-1282
by	O	1283-1285
a	O	1286-1287
mutant	O	1288-1294
miRNA	O	1295-1300
complementary	O	1301-1314
to	O	1315-1317
the	O	1318-1321
mutated	O	1322-1329
target	O	1330-1336
region	O	1337-1343
implying	O	1344-1352
that	O	1353-1357
miR	B	1358-1361
-	I	1361-1362
34	I	1362-1364
binding	O	1365-1372
to	O	1373-1375
Actb	O	1376-1380
3	O	1381-1382
'	O	1382-1383
-	O	1383-1384
UTR	O	1384-1387
up	O	1388-1390
-	O	1390-1391
regulates	O	1391-1400
target	O	1401-1407
gene	O	1408-1412
expression	O	1413-1423
.	O	1423-1424

Heterogeneity	O	1425-1438
of	O	1439-1441
the	O	1442-1445
Actb	O	1446-1450
3	O	1451-1452
'	O	1452-1453
-	O	1453-1454
UTR	O	1454-1457
could	O	1458-1463
shed	O	1464-1468
light	O	1469-1474
on	O	1475-1477
the	O	1478-1481
mechanism	O	1482-1491
of	O	1492-1494
miRNA	O	1495-1500
-	O	1500-1501
mediated	O	1501-1509
regulation	O	1510-1520
of	O	1521-1523
messages	O	1524-1532
in	O	1533-1535
neuronal	O	1536-1544
cells	O	1545-1550
.	O	1550-1551

microRNAs	O	0-9
and	O	10-13
their	O	14-19
potential	O	20-29
target	O	30-36
genes	O	37-42
in	O	43-45
leukemia	O	46-54
pathogenesis	O	55-67
.	O	67-68

Leukemia	O	69-77
is	O	78-80
the	O	81-84
most	O	85-89
common	O	90-96
hematological	O	97-110
malignancy	O	111-121
,	O	121-122
characterized	O	123-136
by	O	137-139
distorted	O	140-149
proliferation	O	150-163
and	O	164-167
development	O	168-179
of	O	180-182
leukocytes	O	183-193
and	O	194-197
their	O	198-203
precursors	O	204-214
in	O	215-217
the	O	218-221
blood	O	222-227
and	O	228-231
bone	O	232-236
marrow	O	237-243
.	O	243-244

Although	O	245-253
impressive	O	254-264
biologic	O	265-273
advance	O	274-281
has	O	282-285
increased	O	286-295
understanding	O	296-309
of	O	310-312
leukemogenesis	O	313-327
,	O	327-328
we	O	329-331
know	O	332-336
little	O	337-343
regarding	O	344-353
the	O	354-357
pathogenic	O	358-368
events	O	369-375
leading	O	376-383
to	O	384-386
the	O	387-390
initiation	O	391-401
and	O	402-405
progression	O	406-417
of	O	418-420
this	O	421-425
disease	O	426-433
.	O	433-434

microRNAs	O	435-444
(	O	445-446
miRNAs	O	446-452
)	O	452-453
are	O	454-457
now	O	458-461
recognized	O	462-472
as	O	473-475
a	O	476-477
class	O	478-483
of	O	484-486
small	O	487-492
,	O	492-493
non	O	494-497
-	O	497-498
protein	O	498-505
-	O	505-506
coding	O	506-512
RNA	O	513-516
molecules	O	517-526
that	O	527-531
can	O	532-535
regulate	O	536-544
the	O	545-548
expression	O	549-559
of	O	560-562
many	O	563-567
genes	O	568-573
.	O	573-574

The	O	575-578
evolutionarily	O	579-593
conserved	O	594-603
small	O	604-609
molecules	O	610-619
play	O	620-624
important	O	625-634
roles	O	635-640
in	O	641-643
cellular	O	644-652
development	O	653-664
and	O	665-668
function	O	669-677
,	O	677-678
through	O	679-686
mediation	O	687-696
of	O	697-699
target	O	700-706
gene	O	707-711
repression	O	712-722
.	O	722-723

There	O	724-729
is	O	730-732
significant	O	733-744
evidence	O	745-753
showing	O	754-761
that	O	762-766
miRNAs	O	767-773
play	O	774-778
an	O	779-781
important	O	782-791
role	O	792-796
in	O	797-799
disease	O	800-807
,	O	807-808
especially	O	809-819
in	O	820-822
oncogenesis	O	823-834
.	O	834-835

Aberrant	O	836-844
expression	O	845-855
of	O	856-858
miRNAs	O	859-865
appears	O	866-873
to	O	874-876
be	O	877-879
a	O	880-881
common	O	882-888
feature	O	889-896
of	O	897-899
haematological	O	900-914
malignancies	O	915-927
.	O	927-928

Since	O	929-934
the	O	935-938
discovery	O	939-948
of	O	949-951
miR	B	952-955
-	I	955-956
15	I	956-958
and	O	959-962
miR	B	963-966
-	I	966-967
16	I	967-969
in	O	970-972
CLL	O	973-976
,	O	976-977
much	O	978-982
effect	O	983-989
has	O	990-993
been	O	994-998
done	O	999-1003
to	O	1004-1006
investigate	O	1007-1018
the	O	1019-1022
small	O	1023-1028
molecule	O	1029-1037
in	O	1038-1040
leukemia	O	1041-1049
.	O	1049-1050

Several	O	1051-1058
research	O	1059-1067
groups	O	1068-1074
have	O	1075-1079
shown	O	1080-1085
differences	O	1086-1097
in	O	1098-1100
miRNA	O	1101-1106
expression	O	1107-1117
between	O	1118-1125
normal	O	1126-1132
and	O	1133-1136
malignant	O	1137-1146
cells	O	1147-1152
in	O	1153-1155
leukemia	O	1156-1164
.	O	1164-1165

So	O	1166-1168
miRNAs	O	1169-1175
may	O	1176-1179
be	O	1180-1182
involved	O	1183-1191
in	O	1192-1194
leukemia	O	1195-1203
pathogenesis	O	1204-1216
.	O	1216-1217

Despite	O	1218-1225
the	O	1226-1229
recognition	O	1230-1241
of	O	1242-1244
their	O	1245-1250
synthesis	O	1251-1260
,	O	1260-1261
we	O	1262-1264
know	O	1265-1269
little	O	1270-1276
about	O	1277-1282
their	O	1283-1288
exact	O	1289-1294
molecular	O	1295-1304
function	O	1305-1313
and	O	1314-1317
the	O	1318-1321
identifications	O	1322-1337
of	O	1338-1340
their	O	1341-1346
target	O	1347-1353
genes	O	1354-1359
.	O	1359-1360

Some	O	1361-1365
targets	O	1366-1373
of	O	1374-1376
miRNAs	O	1377-1383
are	O	1384-1387
antiapoptotic	O	1388-1401
genes	O	1402-1407
such	O	1408-1412
as	O	1413-1415
Bcl2	O	1416-1420
and	O	1421-1424
Tcl1	O	1425-1429
.	O	1429-1430

MiRNAs	O	1431-1437
to	O	1438-1440
these	O	1441-1446
genes	O	1447-1452
are	O	1453-1456
natural	O	1457-1464
antagonists	O	1465-1476
and	O	1477-1480
may	O	1481-1484
be	O	1485-1487
also	O	1488-1492
applied	O	1493-1500
in	O	1501-1503
leukemia	O	1504-1512
therapy	O	1513-1520
.	O	1520-1521

This	O	1522-1526
article	O	1527-1534
reviews	O	1535-1542
the	O	1543-1546
common	O	1547-1553
science	O	1554-1561
supporting	O	1562-1572
miRNAs	O	1573-1579
and	O	1580-1583
their	O	1584-1589
potential	O	1590-1599
target	O	1600-1606
genes	O	1607-1612
in	O	1613-1615
leukemia	O	1616-1624
pathogenesis	O	1625-1637
.	O	1637-1638

microRNA	O	0-8
expression	O	9-19
profile	O	20-27
in	O	28-30
undifferentiated	O	31-47
gastric	O	48-55
cancer	O	56-62
.	O	62-63

Prognosis	O	64-73
of	O	74-76
patients	O	77-85
with	O	86-90
undifferentiated	O	91-107
gastric	O	108-115
cancer	O	116-122
is	O	123-125
generally	O	126-135
poor	O	136-140
.	O	140-141

The	O	142-145
expression	O	146-156
of	O	157-159
various	O	160-167
microRNAs	O	168-177
(	O	178-179
miRNAs	O	179-185
)	O	185-186
has	O	187-190
not	O	191-194
been	O	195-199
comprehensively	O	200-215
investigated	O	216-228
in	O	229-231
undifferentiated	O	232-248
gastric	O	249-256
cancer	O	257-263
.	O	263-264

Total	O	265-270
RNA	O	271-274
was	O	275-278
extracted	O	279-288
from	O	289-293
the	O	294-297
specimens	O	298-307
of	O	308-310
42	O	311-313
undifferentiated	O	314-330
gastric	O	331-338
cancer	O	339-345
tissues	O	346-353
and	O	354-357
paired	O	358-364
normal	O	365-371
gastric	O	372-379
tissue	O	380-386
.	O	386-387

Quantitative	O	388-400
reverse	O	401-408
transcriptase	O	409-422
-	O	422-423
polymerase	O	423-433
chain	O	434-439
reaction	O	440-448
(	O	449-450
qRT	O	450-453
-	O	453-454
PCR	O	454-457
)	O	457-458
was	O	459-462
performed	O	463-472
for	O	473-476
a	O	477-478
set	O	479-482
of	O	483-485
72	O	486-488
miRNAs	O	489-495
.	O	495-496

The	O	497-500
expression	O	501-511
of	O	512-514
each	O	515-519
miRNA	O	520-525
relative	O	526-534
to	O	535-537
the	O	538-541
internal	O	542-550
control	O	551-558
RNA	O	559-562
was	O	563-566
determined	O	567-577
using	O	578-583
the	O	584-587
2	O	588-589
-	O	589-590
DeltaCt	O	590-597
method	O	598-604
.	O	604-605

The	O	606-609
expression	O	610-620
levels	O	621-627
of	O	628-630
3	O	631-632
miRNAs	O	633-639
(	O	640-641
mir	B	641-644
-	I	644-645
34b	I	645-648
,	O	648-649
mir	B	650-653
-	I	653-654
34c	I	654-657
and	O	658-661
mir	B	662-665
-	I	665-666
128a	I	666-670
)	O	670-671
were	O	672-676
significantly	O	677-690
upregulated	O	691-702
and	O	703-706
those	O	707-712
of	O	713-715
3	O	716-717
miRNAs	O	718-724
(	O	725-726
mir	B	726-729
-	I	729-730
128b	I	730-734
,	O	734-735
mir	B	736-739
-	I	739-740
129	I	740-743
and	O	744-747
mir	B	748-751
-	I	751-752
148	I	752-755
)	O	755-756
were	O	757-761
downregulated	O	762-775
in	O	776-778
undifferentiated	O	779-795
gastric	O	796-803
cancer	O	804-810
tissue	O	811-817
when	O	818-822
compared	O	823-831
with	O	832-836
those	O	837-842
of	O	843-845
the	O	846-849
paired	O	850-856
normal	O	857-863
tissues	O	864-871
.	O	871-872

The	O	873-876
probability	O	877-888
of	O	889-891
survival	O	892-900
was	O	901-904
significantly	O	905-918
lower	O	919-924
in	O	925-927
patients	O	928-936
with	O	937-941
high	O	942-946
expression	O	947-957
levels	O	958-964
of	O	965-967
mir	B	968-971
-	I	971-972
20b	I	972-975
or	O	976-978
150	B	979-982
.	O	982-983

There	O	984-989
was	O	990-993
a	O	994-995
correlation	O	996-1007
between	O	1008-1015
mir	B	1016-1019
-	I	1019-1020
27a	I	1020-1023
and	O	1024-1027
lymph	O	1028-1033
node	O	1034-1038
metastasis	O	1039-1049
.	O	1049-1050

Our	O	1051-1054
investigation	O	1055-1068
provides	O	1069-1077
a	O	1078-1079
list	O	1080-1084
of	O	1085-1087
candidate	O	1088-1097
miRNAs	O	1098-1104
that	O	1105-1109
may	O	1110-1113
be	O	1114-1116
associated	O	1117-1127
with	O	1128-1132
the	O	1133-1136
prognosis	O	1137-1146
in	O	1147-1149
undifferentiated	O	1150-1166
gastric	O	1167-1174
cancer	O	1175-1181
patients	O	1182-1190
.	O	1190-1191

Further	O	1192-1199
study	O	1200-1205
is	O	1206-1208
warranted	O	1209-1218
to	O	1219-1221
identify	O	1222-1230
the	O	1231-1234
target	O	1235-1241
genes	O	1242-1247
of	O	1248-1250
these	O	1251-1256
miRNAs	O	1257-1263
and	O	1264-1267
their	O	1268-1273
function	O	1274-1282
.	O	1282-1283

Molecular	O	0-9
assays	O	10-16
for	O	17-20
the	O	21-24
detection	O	25-34
of	O	35-37
microRNAs	O	38-47
in	O	48-50
prostate	O	51-59
cancer	O	60-66
.	O	66-67

BACKGROUND	O	68-78
:	O	78-79
MicroRNAs	O	80-89
(	O	90-91
miRNAs	O	91-97
)	O	97-98
are	O	99-102
small	O	103-108
non	O	109-112
-	O	112-113
coding	O	113-119
RNAs	O	120-124
(	O	125-126
about	O	126-131
21	O	132-134
to	O	135-137
24	O	138-140
nucleotides	O	141-152
in	O	153-155
length	O	156-162
)	O	162-163
that	O	164-168
effectively	O	169-180
reduce	O	181-187
the	O	188-191
translation	O	192-203
of	O	204-206
their	O	207-212
target	O	213-219
mRNAs	O	220-225
.	O	225-226

Several	O	227-234
studies	O	235-242
have	O	243-247
shown	O	248-253
miRNAs	O	254-260
to	O	261-263
be	O	264-266
differentially	O	267-281
expressed	O	282-291
in	O	292-294
prostate	O	295-303
cancer	O	304-310
,	O	310-311
many	O	312-316
of	O	317-319
which	O	320-325
are	O	326-329
found	O	330-335
in	O	336-338
fragile	O	339-346
regions	O	347-354
of	O	355-357
chromosomes	O	358-369
.	O	369-370

Expression	O	371-381
profiles	O	382-390
of	O	391-393
miRNAs	O	394-400
can	O	401-404
provide	O	405-412
information	O	413-424
to	O	425-427
separate	O	428-436
malignancies	O	437-449
based	O	450-455
upon	O	456-460
stage	O	461-466
,	O	466-467
progression	O	468-479
and	O	480-483
prognosis	O	484-493
.	O	493-494

Here	O	495-499
we	O	500-502
describe	O	503-511
research	O	512-520
prototype	O	521-530
assays	O	531-537
that	O	538-542
detect	O	543-549
a	O	550-551
number	O	552-558
of	O	559-561
miRNA	O	562-567
sequences	O	568-577
with	O	578-582
high	O	583-587
analytical	O	588-598
sensitivity	O	599-610
and	O	611-614
specificity	O	615-626
,	O	626-627
including	O	628-637
miR	B	638-641
-	I	641-642
21	I	642-644
,	O	644-645
miR	B	646-649
-	I	649-650
182	I	650-653
,	O	653-654
miR	B	655-658
-	I	658-659
221	I	659-662
and	O	663-666
miR	B	667-670
-	I	670-671
222	I	671-674
,	O	674-675
which	O	676-681
were	O	682-686
identified	O	687-697
through	O	698-705
expression	O	706-716
profiling	O	717-726
experiments	O	727-738
with	O	739-743
prostate	O	744-752
cancer	O	753-759
specimens	O	760-769
.	O	769-770

The	O	771-774
miRNAs	O	775-781
were	O	782-786
isolated	O	787-795
,	O	795-796
amplified	O	797-806
and	O	807-810
quantified	O	811-821
using	O	822-827
magnetic	O	828-836
bead	O	837-841
-	O	841-842
based	O	842-847
target	O	848-854
capture	O	855-862
and	O	863-866
a	O	867-868
modified	O	869-877
form	O	878-882
of	O	883-885
Transcription	O	886-899
-	O	899-900
Mediated	O	900-908
Amplification	O	909-922
(	O	923-924
TMA	O	924-927
)	O	927-928
.	O	928-929

RESULTS	O	930-937
:	O	937-938
Analytical	O	939-949
sensitivity	O	950-961
and	O	962-965
specificity	O	966-977
were	O	978-982
demonstrated	O	983-995
in	O	996-998
model	O	999-1004
system	O	1005-1011
experiments	O	1012-1023
using	O	1024-1029
synthetic	O	1030-1039
mature	O	1040-1046
microRNAs	O	1047-1056
or	O	1057-1059
in	O	1060-1062
vitro	O	1063-1068
miRNA	O	1069-1074
hairpin	O	1075-1082
precursor	O	1083-1092
transcripts	O	1093-1104
.	O	1104-1105

Research	O	1106-1114
prototype	O	1115-1124
assays	O	1125-1131
for	O	1132-1135
miR	B	1136-1139
-	I	1139-1140
21	I	1140-1142
,	O	1142-1143
miR	B	1144-1147
-	I	1147-1148
182	I	1148-1151
,	O	1151-1152
miR	B	1153-1156
-	I	1156-1157
221	I	1157-1160
and	O	1161-1164
miR	B	1165-1168
-	I	1168-1169
222	I	1169-1172
provided	O	1173-1181
analytical	O	1182-1192
sensitivities	O	1193-1206
ranging	O	1207-1214
from	O	1215-1219
50	O	1220-1222
to	O	1223-1225
500	O	1226-1229
copies	O	1230-1236
of	O	1237-1239
target	O	1240-1246
per	O	1247-1250
reaction	O	1251-1259
in	O	1260-1262
sample	O	1263-1269
transport	O	1270-1279
medium	O	1280-1286
.	O	1286-1287

Specific	O	1288-1296
capture	O	1297-1304
and	O	1305-1308
detection	O	1309-1318
of	O	1319-1321
mature	O	1322-1328
miR	B	1329-1332
-	I	1332-1333
221	I	1333-1336
from	O	1337-1341
complex	O	1342-1349
samples	O	1350-1357
was	O	1358-1361
demonstrated	O	1362-1374
in	O	1375-1377
total	O	1378-1383
RNA	O	1384-1387
isolated	O	1388-1396
from	O	1397-1401
human	O	1402-1407
prostate	O	1408-1416
cancer	O	1417-1423
cell	O	1424-1428
lines	O	1429-1434
and	O	1435-1438
xenografts	O	1439-1449
.	O	1449-1450

CONCLUSION	O	1451-1461
:	O	1461-1462
Research	O	1463-1471
prototype	O	1472-1481
real	O	1482-1486
-	O	1486-1487
time	O	1487-1491
TMA	O	1492-1495
assays	O	1496-1502
for	O	1503-1506
microRNAs	O	1507-1516
provide	O	1517-1524
accurate	O	1525-1533
and	O	1534-1537
reproducible	O	1538-1550
quantitation	O	1551-1563
using	O	1564-1569
10	O	1570-1572
nanograms	O	1573-1582
of	O	1583-1585
input	O	1586-1591
total	O	1592-1597
RNA	O	1598-1601
.	O	1601-1602

These	O	1603-1608
assays	O	1609-1615
can	O	1616-1619
also	O	1620-1624
be	O	1625-1627
used	O	1628-1632
directly	O	1633-1641
with	O	1642-1646
tissue	O	1647-1653
specimens	O	1654-1663
,	O	1663-1664
without	O	1665-1672
the	O	1673-1676
need	O	1677-1681
for	O	1682-1685
a	O	1686-1687
preanalytic	O	1688-1699
RNA	O	1700-1703
isolation	O	1704-1713
step	O	1714-1718
,	O	1718-1719
and	O	1720-1723
thus	O	1724-1728
provide	O	1729-1736
a	O	1737-1738
high	O	1739-1743
-	O	1743-1744
throughput	O	1744-1754
method	O	1755-1761
of	O	1762-1764
microRNA	O	1765-1773
profiling	O	1774-1783
in	O	1784-1786
clinical	O	1787-1795
specimens	O	1796-1805
.	O	1805-1806

Lack	O	0-4
of	O	5-7
correlation	O	8-19
between	O	20-27
BRAF	O	28-32
V600E	O	33-38
mutational	O	39-49
status	O	50-56
and	O	57-60
the	O	61-64
expression	O	65-75
profile	O	76-83
of	O	84-86
a	O	87-88
distinct	O	89-97
set	O	98-101
of	O	102-104
miRNAs	O	105-111
in	O	112-114
papillary	O	115-124
thyroid	O	125-132
carcinoma	O	133-142
.	O	142-143

Recent	O	144-150
studies	O	151-158
demonstrated	O	159-171
a	O	172-173
significant	O	174-185
upregulation	O	186-198
of	O	199-201
distinct	O	202-210
microRNAs	O	211-220
(	O	221-222
miRNAs	O	222-228
)	O	228-229
,	O	229-230
small	O	231-236
endogenous	O	237-247
RNAs	O	248-252
that	O	253-257
regulate	O	258-266
gene	O	267-271
expression	O	272-282
,	O	282-283
in	O	284-286
papillary	O	287-296
thyroid	O	297-304
carcinoma	O	305-314
(	O	315-316
PTC	O	316-319
)	O	319-320
.	O	320-321

In	O	322-324
the	O	325-328
pathogenesis	O	329-341
of	O	342-344
PTC	O	345-348
the	O	349-352
T1799A	O	353-359
(	O	360-361
V600E	O	361-366
)	O	366-367
BRAF	O	368-372
mutation	O	373-381
is	O	382-384
the	O	385-388
most	O	389-393
common	O	394-400
genetic	O	401-408
alteration	O	409-419
leading	O	420-427
to	O	428-430
a	O	431-432
constitutive	O	433-445
activation	O	446-456
of	O	457-459
the	O	460-463
MAPK	O	464-468
pathway	O	469-476
.	O	476-477

The	O	478-481
aim	O	482-485
of	O	486-488
the	O	489-492
present	O	493-500
study	O	501-506
was	O	507-510
to	O	511-513
elucidate	O	514-523
a	O	524-525
possible	O	526-534
correlation	O	535-546
between	O	547-554
BRAF	O	555-559
mutational	O	560-570
status	O	571-577
and	O	578-581
a	O	582-583
distinct	O	584-592
miRNA	O	593-598
expression	O	599-609
profile	O	610-617
.	O	617-618

In	O	619-621
a	O	622-623
series	O	624-630
of	O	631-633
221	O	634-637
PTC	O	638-641
we	O	642-644
determined	O	645-655
the	O	656-659
BRAF	O	660-664
V600E	O	665-670
mutational	O	671-681
status	O	682-688
using	O	689-694
DNA	O	695-698
-	O	698-699
sequencing	O	699-709
and	O	710-713
correlated	O	714-724
the	O	725-728
occurrence	O	729-739
of	O	740-742
the	O	743-746
mutation	O	747-755
with	O	756-760
a	O	761-762
variety	O	763-770
of	O	771-773
clinicopathologcial	O	774-793
data	O	794-798
.	O	798-799

The	O	800-803
miRNA	O	804-809
expression	O	810-820
profile	O	821-828
of	O	829-831
five	O	832-836
selected	O	837-845
subtypes	O	846-854
(	O	855-856
miRNA	B	856-861
-	I	861-862
146b	I	862-866
,	O	866-867
-	B	868-869
181b	I	869-873
,	O	873-874
-	B	875-876
21	I	876-878
,	O	878-879
-	B	880-881
221	I	881-884
,	O	884-885
-	B	886-887
222	I	887-890
)	O	890-891
in	O	892-894
two	O	895-898
matched	O	899-906
cohorts	O	907-914
of	O	915-917
BRAF	O	918-922
positive	O	923-931
(	O	932-933
n	O	933-934
=	O	934-935
28	O	935-937
)	O	937-938
and	O	939-942
wildtype	O	943-951
cases	O	952-957
(	O	958-959
n	O	959-960
=	O	960-961
26	O	961-963
)	O	963-964
was	O	965-968
examined	O	969-977
by	O	978-980
RT	O	981-983
-	O	983-984
PCR	O	984-987
TaqMan	O	988-994
miRNA	O	995-1000
assay	O	1001-1006
.	O	1006-1007

The	O	1008-1011
BRAF	O	1012-1016
V600E	O	1017-1022
mutation	O	1023-1031
was	O	1032-1035
significantly	O	1036-1049
found	O	1050-1055
in	O	1056-1058
PTCs	O	1059-1063
with	O	1064-1068
extrathyroidal	O	1069-1083
extension	O	1084-1093
(	O	1094-1095
p	O	1095-1096
<	O	1097-1098
0	O	1098-1099
.	O	1099-1100
001	O	1100-1103
)	O	1103-1104
.	O	1104-1105

Among	O	1106-1111
them	O	1112-1116
,	O	1116-1117
V600E	O	1118-1123
was	O	1124-1127
even	O	1128-1132
significantly	O	1133-1146
associated	O	1147-1157
with	O	1158-1162
smaller	O	1163-1170
tumour	O	1171-1177
size	O	1178-1182
of	O	1183-1185
1	O	1186-1187
cm	O	1188-1190
or	O	1191-1193
less	O	1194-1198
(	O	1199-1200
microcarcinomas	O	1200-1215
;	O	1215-1216
p	O	1217-1218
<	O	1218-1219
0	O	1219-1220
.	O	1220-1221
003	O	1221-1224
)	O	1224-1225
and	O	1226-1229
the	O	1230-1233
follicular	O	1234-1244
(	O	1245-1246
p	O	1246-1247
=	O	1247-1248
0	O	1248-1249
.	O	1249-1250
017	O	1250-1253
)	O	1253-1254
and	O	1255-1258
tall	O	1259-1263
cell	O	1264-1268
variant	O	1269-1276
(	O	1277-1278
p	O	1278-1279
=	O	1279-1280
0	O	1280-1281
.	O	1281-1282
015	O	1282-1285
)	O	1285-1286
.	O	1286-1287

By	O	1288-1290
calculating	O	1291-1302
relative	O	1303-1311
changes	O	1312-1319
in	O	1320-1322
miRNA	O	1323-1328
gene	O	1329-1333
expression	O	1334-1344
no	O	1345-1347
differences	O	1348-1359
in	O	1360-1362
fold	O	1363-1367
changes	O	1368-1375
could	O	1376-1381
be	O	1382-1384
detected	O	1385-1393
between	O	1394-1401
BRAF	O	1402-1406
positive	O	1407-1415
and	O	1416-1419
wildtype	O	1420-1428
PTC	O	1429-1432
suggesting	O	1433-1443
that	O	1444-1448
BRAF	O	1449-1453
has	O	1454-1457
no	O	1458-1460
regulatory	O	1461-1471
influence	O	1472-1481
on	O	1482-1484
the	O	1485-1488
expression	O	1489-1499
of	O	1500-1502
the	O	1503-1506
five	O	1507-1511
examined	O	1512-1520
miRNAs	O	1521-1527
.	O	1527-1528

However	O	1529-1536
,	O	1536-1537
our	O	1538-1541
study	O	1542-1547
confirmed	O	1548-1557
the	O	1558-1561
diagnostic	O	1562-1572
utility	O	1573-1580
of	O	1581-1583
this	O	1584-1588
distinct	O	1589-1597
set	O	1598-1601
of	O	1602-1604
miRNAs	O	1605-1611
to	O	1612-1614
detect	O	1615-1621
PTC	O	1622-1625
by	O	1626-1628
significant	O	1629-1640
fold	O	1641-1645
changes	O	1646-1653
in	O	1654-1656
at	O	1657-1659
least	O	1660-1665
3	O	1666-1667
miRNAs	O	1668-1674
(	O	1675-1676
miRNA	B	1676-1681
-	I	1681-1682
146b	I	1682-1686
,	O	1686-1687
-	B	1688-1689
221	I	1689-1692
,	O	1692-1693
-	B	1694-1695
222	I	1695-1698
)	O	1698-1699
irrespective	O	1700-1712
of	O	1713-1715
its	O	1716-1719
histological	O	1720-1732
variant	O	1733-1740
.	O	1740-1741

Genomic	O	0-7
profiling	O	8-17
of	O	18-20
microRNAs	O	21-30
in	O	31-33
bladder	O	34-41
cancer	O	42-48
:	O	48-49
miR	B	50-53
-	I	53-54
129	I	54-57
is	O	58-60
associated	O	61-71
with	O	72-76
poor	O	77-81
outcome	O	82-89
and	O	90-93
promotes	O	94-102
cell	O	103-107
death	O	108-113
in	O	114-116
vitro	O	117-122
.	O	122-123

microRNAs	O	124-133
(	O	134-135
miRNA	O	135-140
)	O	140-141
are	O	142-145
involved	O	146-154
in	O	155-157
cancer	O	158-164
development	O	165-176
and	O	177-180
progression	O	181-192
,	O	192-193
acting	O	194-200
as	O	201-203
tumor	O	204-209
suppressors	O	210-221
or	O	222-224
oncogenes	O	225-234
.	O	234-235

Here	O	236-240
,	O	240-241
we	O	242-244
profiled	O	245-253
the	O	254-257
expression	O	258-268
of	O	269-271
290	O	272-275
unique	O	276-282
human	O	283-288
miRNAs	O	289-295
in	O	296-298
11	O	299-301
normal	O	302-308
and	O	309-312
106	O	313-316
bladder	O	317-324
tumor	O	325-330
samples	O	331-338
using	O	339-344
spotted	O	345-352
locked	O	353-359
nucleic	O	360-367
acid	O	368-372
-	O	372-373
based	O	373-378
oligonucleotide	O	379-394
microarrays	O	395-406
.	O	406-407

We	O	408-410
identified	O	411-421
several	O	422-429
differentially	O	430-444
expressed	O	445-454
miRNAs	O	455-461
between	O	462-469
normal	O	470-476
urothelium	O	477-487
and	O	488-491
cancer	O	492-498
and	O	499-502
between	O	503-510
the	O	511-514
different	O	515-524
disease	O	525-532
stages	O	533-539
.	O	539-540

miR	B	541-544
-	I	544-545
145	I	545-548
was	O	549-552
found	O	553-558
to	O	559-561
be	O	562-564
the	O	565-568
most	O	569-573
down	O	574-578
-	O	578-579
regulated	O	579-588
in	O	589-591
cancer	O	592-598
compared	O	599-607
with	O	608-612
normal	O	613-619
,	O	619-620
and	O	621-624
miR	B	625-628
-	I	628-629
21	I	629-631
was	O	632-635
the	O	636-639
most	O	640-644
up	O	645-647
-	O	647-648
regulated	O	648-657
in	O	658-660
cancer	O	661-667
.	O	667-668

Furthermore	O	669-680
,	O	680-681
we	O	682-684
identified	O	685-695
miRNAs	O	696-702
that	O	703-707
significantly	O	708-721
correlated	O	722-732
to	O	733-735
the	O	736-739
presence	O	740-748
of	O	749-751
concomitant	O	752-763
carcinoma	O	764-773
in	O	774-776
situ	O	777-781
.	O	781-782

We	O	783-785
identified	O	786-796
several	O	797-804
miRNAs	O	805-811
with	O	812-816
prognostic	O	817-827
potential	O	828-837
for	O	838-841
predicting	O	842-852
disease	O	853-860
progression	O	861-872
(	O	873-874
e	O	874-875
.	O	875-876
g	O	876-877
.	O	877-878
,	O	878-879
miR	B	880-883
-	I	883-884
129	I	884-887
,	O	887-888
miR	B	889-892
-	I	892-893
133b	I	893-897
,	O	897-898
and	O	899-902
miR	B	903-906
-	I	906-907
518c	I	907-911
*	I	911-912
)	O	912-913
.	O	913-914

We	O	915-917
localized	O	918-927
the	O	928-931
expression	O	932-942
of	O	943-945
miR	B	946-949
-	I	949-950
145	I	950-953
,	O	953-954
miR	B	955-958
-	I	958-959
21	I	959-961
,	O	961-962
and	O	963-966
miR	B	967-970
-	I	970-971
129	I	971-974
to	O	975-977
urothelium	O	978-988
by	O	989-991
in	O	992-994
situ	O	995-999
hybridization	O	1000-1013
.	O	1013-1014

We	O	1015-1017
then	O	1018-1022
focused	O	1023-1030
on	O	1031-1033
miR	B	1034-1037
-	I	1037-1038
129	I	1038-1041
that	O	1042-1046
exerted	O	1047-1054
significant	O	1055-1066
growth	O	1067-1073
inhibition	O	1074-1084
and	O	1085-1088
induced	O	1089-1096
cell	O	1097-1101
death	O	1102-1107
upon	O	1108-1112
transfection	O	1113-1125
with	O	1126-1130
a	O	1131-1132
miR	B	1133-1136
-	I	1136-1137
129	I	1137-1140
precursor	O	1141-1150
in	O	1151-1153
bladder	O	1154-1161
carcinoma	O	1162-1171
cell	O	1172-1176
lines	O	1177-1182
T24	O	1183-1186
and	O	1187-1190
SW780	O	1191-1196
cells	O	1197-1202
.	O	1202-1203

Microarray	O	1204-1214
analysis	O	1215-1223
of	O	1224-1226
T24	O	1227-1230
cells	O	1231-1236
after	O	1237-1242
transfection	O	1243-1255
showed	O	1256-1262
significant	O	1263-1274
miR	B	1275-1278
-	I	1278-1279
129	I	1279-1282
target	O	1283-1289
down	O	1290-1294
-	O	1294-1295
regulation	O	1295-1305
(	O	1306-1307
P	O	1307-1308
=	O	1309-1310
0	O	1311-1312
.	O	1312-1313
0002	O	1313-1317
)	O	1317-1318
and	O	1319-1322
pathway	O	1323-1330
analysis	O	1331-1339
indicated	O	1340-1349
that	O	1350-1354
targets	O	1355-1362
were	O	1363-1367
involved	O	1368-1376
in	O	1377-1379
cell	O	1380-1384
death	O	1385-1390
processes	O	1391-1400
.	O	1400-1401

By	O	1402-1404
analyzing	O	1405-1414
gene	O	1415-1419
expression	O	1420-1430
data	O	1431-1435
from	O	1436-1440
clinical	O	1441-1449
tumor	O	1450-1455
samples	O	1456-1463
,	O	1463-1464
we	O	1465-1467
identified	O	1468-1478
significant	O	1479-1490
expression	O	1491-1501
changes	O	1502-1509
of	O	1510-1512
target	O	1513-1519
mRNA	O	1520-1524
molecules	O	1525-1534
related	O	1535-1542
to	O	1543-1545
the	O	1546-1549
miRNA	O	1550-1555
expression	O	1556-1566
.	O	1566-1567

Using	O	1568-1573
luciferase	O	1574-1584
assays	O	1585-1591
,	O	1591-1592
we	O	1593-1595
documented	O	1596-1606
a	O	1607-1608
direct	O	1609-1615
link	O	1616-1620
between	O	1621-1628
miR	B	1629-1632
-	I	1632-1633
129	I	1633-1636
and	O	1637-1640
the	O	1641-1644
two	O	1645-1648
putative	O	1649-1657
targets	O	1658-1665
GALNT1	O	1666-1672
and	O	1673-1676
SOX4	O	1677-1681
.	O	1681-1682

The	O	1683-1686
findings	O	1687-1695
reported	O	1696-1704
here	O	1705-1709
indicate	O	1710-1718
that	O	1719-1723
several	O	1724-1731
miRNAs	O	1732-1738
are	O	1739-1742
differentially	O	1743-1757
regulated	O	1758-1767
in	O	1768-1770
bladder	O	1771-1778
cancer	O	1779-1785
and	O	1786-1789
may	O	1790-1793
form	O	1794-1798
a	O	1799-1800
basis	O	1801-1806
for	O	1807-1810
clinical	O	1811-1819
development	O	1820-1831
of	O	1832-1834
new	O	1835-1838
biomarkers	O	1839-1849
for	O	1850-1853
bladder	O	1854-1861
cancer	O	1862-1868
.	O	1868-1869

MicroRNA	B	0-8
-	I	8-9
222	I	9-12
regulates	O	13-22
cell	O	23-27
invasion	O	28-36
by	O	37-39
targeting	O	40-49
matrix	O	50-56
metalloproteinase	O	57-74
1	O	75-76
(	O	77-78
MMP1	O	78-82
)	O	82-83
and	O	84-87
manganese	O	88-97
superoxide	O	98-108
dismutase	O	109-118
2	O	119-120
(	O	121-122
SOD2	O	122-126
)	O	126-127
in	O	128-130
tongue	O	131-137
squamous	O	138-146
cell	O	147-151
carcinoma	O	152-161
cell	O	162-166
lines	O	167-172
.	O	172-173

MicroRNA	O	174-182
deregulation	O	183-195
is	O	196-198
involved	O	199-207
in	O	208-210
tumor	O	211-216
initiation	O	217-227
and	O	228-231
progression	O	232-243
.	O	243-244

The	O	245-248
aim	O	249-252
of	O	253-255
this	O	256-260
study	O	261-266
was	O	267-270
to	O	271-273
identify	O	274-282
and	O	283-286
validate	O	287-295
the	O	296-299
microRNA	O	300-308
candidates	O	309-319
that	O	320-324
contribute	O	325-335
to	O	336-338
the	O	339-342
metastasis	O	343-353
of	O	354-356
oral	O	357-361
tongue	O	362-368
squamous	O	369-377
cell	O	378-382
carcinoma	O	383-392
(	O	393-394
OTSCC	O	394-399
)	O	399-400
.	O	400-401

Using	O	402-407
microarrays	O	408-419
,	O	419-420
a	O	421-422
panel	O	423-428
of	O	429-431
differentially	O	432-446
expressed	O	447-456
microRNAs	O	457-466
was	O	467-470
identified	O	471-481
in	O	482-484
paired	O	485-491
OTSCC	O	492-497
cell	O	498-502
lines	O	503-508
with	O	509-513
different	O	514-523
metastatic	O	524-534
potential	O	535-544
.	O	544-545

Selected	O	546-554
microRNA	O	555-563
candidates	O	564-574
(	O	575-576
including	O	576-585
hsa	B	586-589
-	I	589-590
miR	I	590-593
-	I	593-594
222	I	594-597
)	O	597-598
were	O	599-603
further	O	604-611
validated	O	612-621
using	O	622-627
quantitative	O	628-640
PCR	O	641-644
approach	O	645-653
.	O	653-654

Functional	O	655-665
analysis	O	666-674
indicated	O	675-684
that	O	685-689
hsa	B	690-693
-	I	693-694
miR	I	694-697
-	I	697-698
222	I	698-701
inhibits	O	702-710
OTSCC	O	711-716
cell	O	717-721
invasion	O	722-730
.	O	730-731

Ectopic	O	732-739
transfection	O	740-752
of	O	753-755
hsa	B	756-759
-	I	759-760
miR	I	760-763
-	I	763-764
222	I	764-767
reduced	O	768-775
the	O	776-779
expression	O	780-790
of	O	791-793
MMP1	O	794-798
and	O	799-802
SOD2	O	803-807
in	O	808-810
OTSCC	O	811-816
cell	O	817-821
lines	O	822-827
.	O	827-828

Direct	O	829-835
targeting	O	836-845
of	O	846-848
hsa	B	849-852
-	I	852-853
miR	I	853-856
-	I	856-857
222	I	857-860
to	O	861-863
specific	O	864-872
sequences	O	873-882
located	O	883-890
in	O	891-893
the	O	894-897
3	O	898-899
'	O	899-900
-	O	900-901
untranslated	O	901-913
regions	O	914-921
of	O	922-924
both	O	925-929
MMP1	O	930-934
and	O	935-938
SOD2	O	939-943
mRNAs	O	944-949
were	O	950-954
confirmed	O	955-964
using	O	965-970
luciferase	O	971-981
reporter	O	982-990
gene	O	991-995
assays	O	996-1002
.	O	1002-1003

Furthermore	O	1004-1015
,	O	1015-1016
SOD2	O	1017-1021
knockdown	O	1022-1031
by	O	1032-1034
siRNA	O	1035-1040
led	O	1041-1044
to	O	1045-1047
the	O	1048-1051
downregulation	O	1052-1066
of	O	1067-1069
MMP1	O	1070-1074
expression	O	1075-1085
.	O	1085-1086

Taken	O	1087-1092
together	O	1093-1101
,	O	1101-1102
these	O	1103-1108
results	O	1109-1116
suggested	O	1117-1126
that	O	1127-1131
hsa	B	1132-1135
-	I	1135-1136
miR	I	1136-1139
-	I	1139-1140
222	I	1140-1143
regulates	O	1144-1153
the	O	1154-1157
MMP1	O	1158-1162
expression	O	1163-1173
through	O	1174-1181
both	O	1182-1186
direct	O	1187-1193
cis	O	1194-1197
-	O	1197-1198
regulatory	O	1198-1208
mechanism	O	1209-1218
(	O	1219-1220
targeting	O	1220-1229
MMP1	O	1230-1234
mRNA	O	1235-1239
)	O	1239-1240
and	O	1241-1244
indirect	O	1245-1253
trans	O	1254-1259
-	O	1259-1260
regulatory	O	1260-1270
mechanism	O	1271-1280
(	O	1281-1282
indirect	O	1282-1290
controlling	O	1291-1302
of	O	1303-1305
MMP1	O	1306-1310
gene	O	1311-1315
expression	O	1316-1326
by	O	1327-1329
targeting	O	1330-1339
SOD2	O	1340-1344
)	O	1344-1345
.	O	1345-1346

Our	O	1347-1350
results	O	1351-1358
indicate	O	1359-1367
that	O	1368-1372
hsa	B	1373-1376
-	I	1376-1377
miR	I	1377-1380
-	I	1380-1381
222	I	1381-1384
plays	O	1385-1390
an	O	1391-1393
important	O	1394-1403
role	O	1404-1408
in	O	1409-1411
OTSCC	O	1412-1417
invasion	O	1418-1426
,	O	1426-1427
and	O	1428-1431
may	O	1432-1435
serve	O	1436-1441
as	O	1442-1444
a	O	1445-1446
novel	O	1447-1452
therapeutic	O	1453-1464
target	O	1465-1471
for	O	1472-1475
OTSCC	O	1476-1481
patients	O	1482-1490
at	O	1491-1493
risk	O	1494-1498
of	O	1499-1501
metastatic	O	1502-1512
disease	O	1513-1520
.	O	1520-1521

A	O	0-1
miR	B	2-5
-	I	5-6
200	I	6-9
microRNA	O	10-18
cluster	O	19-26
as	O	27-29
prognostic	O	30-40
marker	O	41-47
in	O	48-50
advanced	O	51-59
ovarian	O	60-67
cancer	O	68-74
.	O	74-75

OBJECTIVE	O	76-85
:	O	85-86
Ovarian	O	87-94
cancer	O	95-101
is	O	102-104
one	O	105-108
of	O	109-111
the	O	112-115
most	O	116-120
deadly	O	121-127
human	O	128-133
cancers	O	134-141
,	O	141-142
resulting	O	143-152
in	O	153-155
over	O	156-160
15	O	161-163
,	O	163-164
000	O	164-167
deaths	O	168-174
in	O	175-177
the	O	178-181
US	O	182-184
each	O	185-189
year	O	190-194
.	O	194-195

A	O	196-197
reliable	O	198-206
method	O	207-213
that	O	214-218
could	O	219-224
predict	O	225-232
disease	O	233-240
outcome	O	241-248
would	O	249-254
improve	O	255-262
care	O	263-267
of	O	268-270
patients	O	271-279
with	O	280-284
this	O	285-289
disease	O	290-297
.	O	297-298

The	O	299-302
main	O	303-307
aim	O	308-311
of	O	312-314
this	O	315-319
study	O	320-325
is	O	326-328
to	O	329-331
identify	O	332-340
novel	O	341-346
prognostic	O	347-357
biomarkers	O	358-368
for	O	369-372
advanced	O	373-381
ovarian	O	382-389
cancer	O	390-396
.	O	396-397

METHODS	O	398-405
:	O	405-406
We	O	407-409
hypothesized	O	410-422
that	O	423-427
microRNAs	O	428-437
(	O	438-439
miRNAs	O	439-445
)	O	445-446
may	O	447-450
predict	O	451-458
outcome	O	459-466
and	O	467-470
have	O	471-475
examined	O	476-484
the	O	485-488
prognostic	O	489-499
value	O	500-505
of	O	506-508
these	O	509-514
small	O	515-520
RNA	O	521-524
molecules	O	525-534
on	O	535-537
disease	O	538-545
outcome	O	546-553
prediction	O	554-564
.	O	564-565

miRNAs	O	566-572
are	O	573-576
a	O	577-578
newly	O	579-584
identified	O	585-595
family	O	596-602
of	O	603-605
non	O	606-609
-	O	609-610
coding	O	610-616
RNA	O	617-620
genes	O	621-626
,	O	626-627
and	O	628-631
recent	O	632-638
studies	O	639-646
have	O	647-651
shown	O	652-657
that	O	658-662
miRNAs	O	663-669
are	O	670-673
extensively	O	674-685
involved	O	686-694
in	O	695-697
the	O	698-701
tumor	O	702-707
development	O	708-719
process	O	720-727
.	O	727-728

We	O	729-731
have	O	732-736
profiled	O	737-745
the	O	746-749
expression	O	750-760
of	O	761-763
miRNAs	O	764-770
in	O	771-773
advanced	O	774-782
ovarian	O	783-790
cancer	O	791-797
using	O	798-803
a	O	804-805
novel	O	806-811
PCR	O	812-815
-	O	815-816
based	O	816-821
platform	O	822-830
and	O	831-834
correlated	O	835-845
miRNA	O	846-851
expression	O	852-862
profiles	O	863-871
with	O	872-876
disease	O	877-884
outcome	O	885-892
.	O	892-893

RESULTS	O	894-901
:	O	901-902
By	O	903-905
performing	O	906-916
miRNA	O	917-922
expression	O	923-933
profiling	O	934-943
analysis	O	944-952
of	O	953-955
55	O	956-958
advanced	O	959-967
ovarian	O	968-975
tumors	O	976-982
,	O	982-983
we	O	984-986
have	O	987-991
shown	O	992-997
that	O	998-1002
three	O	1003-1008
miR	B	1009-1012
-	I	1012-1013
200	I	1013-1016
miRNAs	O	1017-1023
(	O	1024-1025
miR	B	1025-1028
-	I	1028-1029
200a	I	1029-1033
,	O	1033-1034
miR	B	1035-1038
-	I	1038-1039
200b	I	1039-1043
and	O	1044-1047
miR	B	1048-1051
-	I	1051-1052
429	I	1052-1055
)	O	1055-1056
in	O	1057-1059
the	O	1060-1063
miR	B	1064-1067
-	I	1067-1068
200b	I	1068-1072
-	I	1072-1073
429	I	1073-1076
cluster	O	1077-1084
are	O	1085-1088
significantly	O	1089-1102
associated	O	1103-1113
with	O	1114-1118
cancer	O	1119-1125
recurrence	O	1126-1136
and	O	1137-1140
overall	O	1141-1148
survival	O	1149-1157
.	O	1157-1158

Further	O	1159-1166
target	O	1167-1173
analysis	O	1174-1182
indicates	O	1183-1192
that	O	1193-1197
these	O	1198-1203
miR	B	1204-1207
-	I	1207-1208
200	I	1208-1211
miRNAs	O	1212-1218
target	O	1219-1225
multiple	O	1226-1234
genes	O	1235-1240
that	O	1241-1245
are	O	1246-1249
involved	O	1250-1258
in	O	1259-1261
cancer	O	1262-1268
development	O	1269-1280
.	O	1280-1281

In	O	1282-1284
addition	O	1285-1293
,	O	1293-1294
we	O	1295-1297
have	O	1298-1302
also	O	1303-1307
shown	O	1308-1313
that	O	1314-1318
overexpression	O	1319-1333
of	O	1334-1336
this	O	1337-1341
miR	B	1342-1345
-	I	1345-1346
200	I	1346-1349
cluster	O	1350-1357
inhibits	O	1358-1366
ovarian	O	1367-1374
cancer	O	1375-1381
cell	O	1382-1386
migration	O	1387-1396
.	O	1396-1397

CONCLUSIONS	O	1398-1409
:	O	1409-1410
miR	B	1411-1414
-	I	1414-1415
200b	I	1415-1419
-	I	1419-1420
429	I	1420-1423
may	O	1424-1427
be	O	1428-1430
used	O	1431-1435
as	O	1436-1438
a	O	1439-1440
prognostic	O	1441-1451
marker	O	1452-1458
for	O	1459-1462
ovarian	O	1463-1470
cancer	O	1471-1477
outcome	O	1478-1485
,	O	1485-1486
and	O	1487-1490
low	O	1491-1494
-	O	1494-1495
level	O	1495-1500
expression	O	1501-1511
of	O	1512-1514
miR	B	1515-1518
-	I	1518-1519
200	I	1519-1522
miRNAs	O	1523-1529
in	O	1530-1532
this	O	1533-1537
cluster	O	1538-1545
predicts	O	1546-1554
poor	O	1555-1559
survival	O	1560-1568
.	O	1568-1569

In	O	1570-1572
addition	O	1573-1581
,	O	1581-1582
our	O	1583-1586
study	O	1587-1592
suggests	O	1593-1601
that	O	1602-1606
miR	B	1607-1610
-	I	1610-1611
200	I	1611-1614
miRNAs	O	1615-1621
could	O	1622-1627
play	O	1628-1632
an	O	1633-1635
important	O	1636-1645
regulatory	O	1646-1656
role	O	1657-1661
in	O	1662-1664
ovarian	O	1665-1672
cancer	O	1673-1679
.	O	1679-1680

IkappaBzeta	O	0-11
expression	O	12-22
is	O	23-25
regulated	O	26-35
by	O	36-38
miR	B	39-42
-	I	42-43
124a	I	43-47
.	O	47-48

IkappaBzeta	O	49-60
belongs	O	61-68
to	O	69-71
the	O	72-75
nuclear	O	76-83
members	O	84-91
of	O	92-94
the	O	95-98
IkappaB	O	99-106
protein	O	107-114
family	O	115-121
.	O	121-122

Its	O	123-126
function	O	127-135
in	O	136-138
regulating	O	139-149
the	O	150-153
activity	O	154-162
of	O	163-165
the	O	166-169
transcription	O	170-183
factor	O	184-190
NFkappaB	O	191-199
is	O	200-202
poorly	O	203-209
understood	O	210-220
.	O	220-221

Here	O	222-226
,	O	226-227
we	O	228-230
demonstrate	O	231-242
that	O	243-247
human	O	248-253
IkappaBzeta	O	254-265
is	O	266-268
posttranscriptionally	O	269-290
regulated	O	291-300
by	O	301-303
microRNA	O	304-312
(	B	313-314
miR	I	314-317
)	I	317-318
-	I	318-319
124a	I	319-323
.	O	323-324

In	O	325-327
HepG2	O	328-333
cells	O	334-339
miR	B	340-343
-	I	343-344
124a	I	344-348
was	O	349-352
not	O	353-356
endogenously	O	357-369
expressed	O	370-379
,	O	379-380
but	O	381-384
upon	O	385-389
enforced	O	390-398
expression	O	399-409
dramatically	O	410-422
inhibited	O	423-432
the	O	433-436
interleukin	O	437-448
-	O	448-449
1beta	O	449-454
-	O	454-455
induced	O	455-462
protein	O	463-470
expression	O	471-481
of	O	482-484
IkappaBzeta	O	485-496
.	O	496-497

The	O	498-501
predicted	O	502-511
binding	O	512-519
site	O	520-524
for	O	525-528
miR	B	529-532
-	I	532-533
124a	I	533-537
in	O	538-540
the	O	541-544
3	O	545-546
'	O	546-547
UTR	O	547-550
of	O	551-553
the	O	554-557
IkappaBzeta	O	558-569
mRNA	O	570-574
revealed	O	575-583
an	O	584-586
imperfect	O	587-596
match	O	597-602
resulting	O	603-612
in	O	613-615
miR	B	616-619
-	I	619-620
124a	I	620-624
-	O	624-625
mediated	O	625-633
suppression	O	634-645
of	O	646-648
IkappaBzeta	O	649-660
expression	O	661-671
through	O	672-679
translational	O	680-693
repression	O	694-704
.	O	704-705

Reporter	O	706-714
gene	O	715-719
analyses	O	720-728
revealed	O	729-737
that	O	738-742
miR	B	743-746
-	I	746-747
124a	I	747-751
targets	O	752-759
IkappaBzeta	O	760-771
mRNA	O	772-776
through	O	777-784
base	O	785-789
pairing	O	790-797
to	O	798-800
the	O	801-804
partially	O	805-814
complementary	O	815-828
sequence	O	829-837
in	O	838-840
the	O	841-844
3	O	845-846
'	O	846-847
UTR	O	847-850
that	O	851-855
was	O	856-859
predicted	O	860-869
as	O	870-872
a	O	873-874
binding	O	875-882
site	O	883-887
by	O	888-890
in	O	891-893
silico	O	894-900
analysis	O	901-909
.	O	909-910

Furthermore	O	911-922
,	O	922-923
we	O	924-926
demonstrate	O	927-938
that	O	939-943
the	O	944-947
7mer	O	948-952
seed	O	953-957
match	O	958-963
is	O	964-966
sufficient	O	967-977
for	O	978-981
recognition	O	982-993
of	O	994-996
the	O	997-1000
IkappaBzeta	O	1001-1012
mRNA	O	1013-1017
.	O	1017-1018

Together	O	1019-1027
,	O	1027-1028
our	O	1029-1032
data	O	1033-1037
identify	O	1038-1046
IkappaBzeta	O	1047-1058
as	O	1059-1061
a	O	1062-1063
target	O	1064-1070
of	O	1071-1073
miR	B	1074-1077
-	I	1077-1078
124a	I	1078-1082
that	O	1083-1087
might	O	1088-1093
be	O	1094-1096
involved	O	1097-1105
in	O	1106-1108
the	O	1109-1112
fine	O	1113-1117
-	O	1117-1118
tuning	O	1118-1124
of	O	1125-1127
NF	O	1128-1130
-	O	1130-1131
kappaB	O	1131-1137
-	O	1137-1138
mediated	O	1138-1146
gene	O	1147-1151
expression	O	1152-1162
.	O	1162-1163

Regulation	O	0-10
of	O	11-13
autophagy	O	14-23
by	O	24-26
a	O	27-28
beclin	O	29-35
1	O	36-37
-	O	37-38
targeted	O	38-46
microRNA	O	47-55
,	O	55-56
miR	B	57-60
-	I	60-61
30a	I	61-64
,	O	64-65
in	O	66-68
cancer	O	69-75
cells	O	76-81
.	O	81-82

beclin	O	83-89
1	O	90-91
,	O	91-92
the	O	93-96
mammalian	O	97-106
homologue	O	107-116
of	O	117-119
the	O	120-123
yeast	O	124-129
Atg6	O	130-134
,	O	134-135
is	O	136-138
a	O	139-140
key	O	141-144
autophagy	O	145-154
-	O	154-155
promoting	O	155-164
gene	O	165-169
that	O	170-174
plays	O	175-180
a	O	181-182
critical	O	183-191
role	O	192-196
in	O	197-199
the	O	200-203
regulation	O	204-214
of	O	215-217
cell	O	218-222
death	O	223-228
and	O	229-232
survival	O	233-241
of	O	242-244
various	O	245-252
types	O	253-258
of	O	259-261
cells	O	262-267
.	O	267-268

However	O	269-276
,	O	276-277
recent	O	278-284
studies	O	285-292
have	O	293-297
observed	O	298-306
that	O	307-311
the	O	312-315
expression	O	316-326
of	O	327-329
beclin	O	330-336
1	O	337-338
is	O	339-341
altered	O	342-349
in	O	350-352
certain	O	353-360
diseases	O	361-369
including	O	370-379
cancers	O	380-387
.	O	387-388

The	O	389-392
causes	O	393-399
underlying	O	400-410
the	O	411-414
aberrant	O	415-423
expression	O	424-434
of	O	435-437
beclin	O	438-444
1	O	445-446
remain	O	447-453
largely	O	454-461
unknown	O	462-469
.	O	469-470

We	O	471-473
report	O	474-480
here	O	481-485
that	O	486-490
microRNAs	O	491-500
(	O	501-502
miRNAs	O	502-508
)	O	508-509
,	O	509-510
a	O	511-512
class	O	513-518
of	O	519-521
endogenous	O	522-532
,	O	532-533
22	O	534-536
-	O	536-537
24	O	537-539
nucleotide	O	540-550
noncoding	O	551-560
RNA	O	561-564
molecules	O	565-574
able	O	575-579
to	O	580-582
affect	O	583-589
stability	O	590-599
and	O	600-603
translation	O	604-615
of	O	616-618
mRNA	O	619-623
,	O	623-624
may	O	625-628
represent	O	629-638
a	O	639-640
previously	O	641-651
unrecognized	O	652-664
mechanism	O	665-674
for	O	675-678
regulating	O	679-689
beclin	O	690-696
1	O	697-698
expression	O	699-709
and	O	710-713
autophagy	O	714-723
.	O	723-724

We	O	725-727
demonstrated	O	728-740
that	O	741-745
beclin	O	746-752
1	O	753-754
is	O	755-757
a	O	758-759
potential	O	760-769
target	O	770-776
for	O	777-780
miRNA	O	781-786
miR	B	787-790
-	I	790-791
30a	I	791-794
,	O	794-795
and	O	796-799
this	O	800-804
miRNA	O	805-810
could	O	811-816
negatively	O	817-827
regulate	O	828-836
beclin	O	837-843
1	O	844-845
expression	O	846-856
resulting	O	857-866
in	O	867-869
decreased	O	870-879
autophagic	O	880-890
activity	O	891-899
.	O	899-900

Treatment	O	901-910
of	O	911-913
tumor	O	914-919
cells	O	920-925
with	O	926-930
the	O	931-934
miR	B	935-938
-	I	938-939
30a	I	939-942
mimic	O	943-948
decreased	O	949-958
,	O	958-959
and	O	960-963
with	O	964-968
the	O	969-972
antagomir	O	973-982
increased	O	983-992
,	O	992-993
the	O	994-997
expression	O	998-1008
of	O	1009-1011
beclin	O	1012-1018
1	O	1019-1020
mRNA	O	1021-1025
and	O	1026-1029
protein	O	1030-1037
.	O	1037-1038

Dual	O	1039-1043
luciferase	O	1044-1054
reporter	O	1055-1063
assay	O	1064-1069
confirmed	O	1070-1079
that	O	1080-1084
the	O	1085-1088
miR	B	1089-1092
-	I	1092-1093
30a	I	1093-1096
binding	O	1097-1104
sequences	O	1105-1114
in	O	1115-1117
the	O	1118-1121
3	O	1122-1123
'	O	1123-1124
-	O	1124-1125
UTR	O	1125-1128
of	O	1129-1131
beclin	O	1132-1138
1	O	1139-1140
contribute	O	1141-1151
to	O	1152-1154
the	O	1155-1158
modulation	O	1159-1169
of	O	1170-1172
beclin	O	1173-1179
1	O	1180-1181
expression	O	1182-1192
by	O	1193-1195
miR	B	1196-1199
-	I	1199-1200
30a	I	1200-1203
.	O	1203-1204

Furthermore	O	1205-1216
,	O	1216-1217
inhibition	O	1218-1228
of	O	1229-1231
beclin	O	1232-1238
1	O	1239-1240
expression	O	1241-1251
by	O	1252-1254
the	O	1255-1258
miR	B	1259-1262
-	I	1262-1263
30a	I	1263-1266
mimic	O	1267-1272
blunted	O	1273-1280
activation	O	1281-1291
of	O	1292-1294
autophagy	O	1295-1304
induced	O	1305-1312
by	O	1313-1315
rapamycin	O	1316-1325
.	O	1325-1326

Our	O	1327-1330
study	O	1331-1336
of	O	1337-1339
the	O	1340-1343
role	O	1344-1348
of	O	1349-1351
miR	B	1352-1355
-	I	1355-1356
30a	I	1356-1359
in	O	1360-1362
regulating	O	1363-1373
beclin	O	1374-1380
1	O	1381-1382
expression	O	1383-1393
and	O	1394-1397
autophagy	O	1398-1407
reveals	O	1408-1415
a	O	1416-1417
novel	O	1418-1423
function	O	1424-1432
for	O	1433-1436
miRNA	O	1437-1442
in	O	1443-1445
a	O	1446-1447
critical	O	1448-1456
cellular	O	1457-1465
event	O	1466-1471
with	O	1472-1476
significant	O	1477-1488
impacts	O	1489-1496
in	O	1497-1499
cancer	O	1500-1506
development	O	1507-1518
,	O	1518-1519
progression	O	1520-1531
and	O	1532-1535
treatment	O	1536-1545
,	O	1545-1546
and	O	1547-1550
in	O	1551-1553
other	O	1554-1559
diseases	O	1560-1568
.	O	1568-1569

MicroRNA	B	0-8
-	I	8-9
138	I	9-12
suppresses	O	13-23
invasion	O	24-32
and	O	33-36
promotes	O	37-45
apoptosis	O	46-55
in	O	56-58
head	O	59-63
and	O	64-67
neck	O	68-72
squamous	O	73-81
cell	O	82-86
carcinoma	O	87-96
cell	O	97-101
lines	O	102-107
.	O	107-108

Metastasis	O	109-119
is	O	120-122
a	O	123-124
critical	O	125-133
event	O	134-139
in	O	140-142
the	O	143-146
progression	O	147-158
of	O	159-161
head	O	162-166
and	O	167-170
neck	O	171-175
squamous	O	176-184
cell	O	185-189
carcinoma	O	190-199
(	O	200-201
HNSCC	O	201-206
)	O	206-207
.	O	207-208

To	O	209-211
identify	O	212-220
microRNAs	O	221-230
associated	O	231-241
with	O	242-246
HNSCC	O	247-252
metastasis	O	253-263
,	O	263-264
six	O	265-268
paired	O	269-275
HNSCC	O	276-281
cell	O	282-286
lines	O	287-292
with	O	293-297
different	O	298-307
metastatic	O	308-318
potential	O	319-328
were	O	329-333
examined	O	334-342
.	O	342-343

Using	O	344-349
microarrays	O	350-361
,	O	361-362
a	O	363-364
panel	O	365-370
of	O	371-373
differentially	O	374-388
expressed	O	389-398
microRNAs	O	399-408
was	O	409-412
identified	O	413-423
,	O	423-424
including	O	425-434
reduction	O	435-444
of	O	445-447
miR	B	448-451
-	I	451-452
138	I	452-455
in	O	456-458
highly	O	459-465
metastatic	O	466-476
cells	O	477-482
.	O	482-483

Ectopic	O	484-491
transfection	O	492-504
of	O	505-507
miR	B	508-511
-	I	511-512
138	I	512-515
suppressed	O	516-526
cell	O	527-531
invasion	O	532-540
and	O	541-544
led	O	545-548
to	O	549-551
cell	O	552-556
cycle	O	557-562
arrest	O	563-569
and	O	570-573
apoptosis	O	574-583
.	O	583-584

Knockdown	O	585-594
of	O	595-597
miR	B	598-601
-	I	601-602
138	I	602-605
enhanced	O	606-614
cell	O	615-619
invasion	O	620-628
and	O	629-632
suppressed	O	633-643
apoptosis	O	644-653
.	O	653-654

Thus	O	655-659
,	O	659-660
our	O	661-664
results	O	665-672
suggested	O	673-682
miR	B	683-686
-	I	686-687
138	I	687-690
acts	O	691-695
as	O	696-698
a	O	699-700
tumor	O	701-706
suppresser	O	707-717
and	O	718-721
may	O	722-725
serve	O	726-731
as	O	732-734
a	O	735-736
therapeutic	O	737-748
target	O	749-755
for	O	756-759
HNSCC	O	760-765
patients	O	766-774
at	O	775-777
risk	O	778-782
of	O	783-785
metastasis	O	786-796
.	O	796-797

FACS	O	0-4
-	O	4-5
assisted	O	5-13
microarray	O	14-24
profiling	O	25-34
implicates	O	35-45
novel	O	46-51
genes	O	52-57
and	O	58-61
pathways	O	62-70
in	O	71-73
zebrafish	O	74-83
gastrointestinal	O	84-100
tract	O	101-106
development	O	107-118
.	O	118-119

BACKGROUND	O	120-130
&	O	131-132
AIMS	O	133-137
:	O	137-138
The	O	139-142
zebrafish	O	143-152
Danio	O	153-158
rerio	O	159-164
is	O	165-167
an	O	168-170
excellent	O	171-180
model	O	181-186
system	O	187-193
for	O	194-197
mammalian	O	198-207
gastrointestinal	O	208-224
development	O	225-236
.	O	236-237

To	O	238-240
identify	O	241-249
differentially	O	250-264
regulated	O	265-274
genes	O	275-280
important	O	281-290
in	O	291-293
gastrointestinal	O	294-310
organogenesis	O	311-324
,	O	324-325
we	O	326-328
profiled	O	329-337
the	O	338-341
transcriptome	O	342-355
of	O	356-358
the	O	359-362
zebrafish	O	363-372
developing	O	373-383
gastrointestinal	O	384-400
tract	O	401-406
.	O	406-407

METHODS	O	408-415
:	O	415-416
Embryos	O	417-424
from	O	425-429
a	O	430-431
transgenic	O	432-442
zebrafish	O	443-452
line	O	453-457
expressing	O	458-468
green	O	469-474
fluorescent	O	475-486
protein	O	487-494
(	O	495-496
GFP	O	496-499
)	O	499-500
in	O	501-503
the	O	504-507
developing	O	508-518
intestine	O	519-528
,	O	528-529
liver	O	530-535
,	O	535-536
and	O	537-540
pancreas	O	541-549
were	O	550-554
dissociated	O	555-566
at	O	567-569
4	O	570-571
developmental	O	572-585
time	O	586-590
points	O	591-597
,	O	597-598
their	O	599-604
cells	O	605-610
sorted	O	611-617
based	O	618-623
on	O	624-626
GFP	O	627-630
expression	O	631-641
with	O	642-646
fluorescence	O	647-659
-	O	659-660
activated	O	660-669
cell	O	670-674
sorting	O	675-682
(	O	683-684
FACS	O	684-688
)	O	688-689
,	O	689-690
and	O	691-694
analyzed	O	695-703
with	O	704-708
microarrays	O	709-720
.	O	720-721

To	O	722-724
improve	O	725-732
our	O	733-736
analysis	O	737-745
,	O	745-746
we	O	747-749
annotated	O	750-759
the	O	760-763
Affymetrix	O	764-774
Zebrafish	O	775-784
GeneChip	O	785-793
with	O	794-798
human	O	799-804
orthologs	O	805-814
.	O	814-815

RESULTS	O	816-823
:	O	823-824
Transcriptional	O	825-840
profiling	O	841-850
showed	O	851-857
significant	O	858-869
differences	O	870-881
between	O	882-889
GFP	O	890-893
(	O	893-894
+	O	894-895
)	O	895-896
and	O	897-900
GFP	O	901-904
(	O	904-905
-	O	905-906
)	O	906-907
cells	O	908-913
.	O	913-914

Up	O	915-917
-	O	917-918
regulated	O	918-927
genes	O	928-933
and	O	934-937
pathways	O	938-946
were	O	947-951
consistent	O	952-962
with	O	963-967
mammalian	O	968-977
gastrointestinal	O	978-994
development	O	995-1006
,	O	1006-1007
such	O	1008-1012
as	O	1013-1015
hepatic	O	1016-1023
nuclear	O	1024-1031
factor	O	1032-1038
gene	O	1039-1043
networks	O	1044-1052
and	O	1053-1056
cancer	O	1057-1063
.	O	1063-1064

We	O	1065-1067
implicate	O	1068-1077
the	O	1078-1081
phosphatidylinositol	O	1082-1102
3	O	1103-1104
kinase	O	1105-1111
(	O	1112-1113
PI3K	O	1113-1117
)	O	1117-1118
pathway	O	1119-1126
and	O	1127-1130
show	O	1131-1135
that	O	1136-1140
inhibition	O	1141-1151
with	O	1152-1156
LY294002	O	1157-1165
causes	O	1166-1172
gastrointestinal	O	1173-1189
defects	O	1190-1197
in	O	1198-1200
zebrafish	O	1201-1210
.	O	1210-1211

We	O	1212-1214
identified	O	1215-1225
novel	O	1226-1231
genes	O	1232-1237
,	O	1237-1238
such	O	1239-1243
as	O	1244-1246
the	O	1247-1250
microRNAs	O	1251-1260
miR	B	1261-1264
-	I	1264-1265
217	I	1265-1268
and	O	1269-1272
miR	B	1273-1276
-	I	1276-1277
122	I	1277-1280
,	O	1280-1281
the	O	1282-1285
tight	O	1286-1291
junction	O	1292-1300
protein	O	1301-1308
claudin	O	1309-1316
c	O	1317-1318
,	O	1318-1319
the	O	1320-1323
gene	O	1324-1328
fam136a	O	1329-1336
,	O	1336-1337
and	O	1338-1341
a	O	1342-1343
zebrafish	O	1344-1353
tetraspanin	O	1354-1365
.	O	1365-1366

Novel	O	1367-1372
pathways	O	1373-1381
include	O	1382-1389
genes	O	1390-1395
containing	O	1396-1406
a	O	1407-1408
putative	O	1409-1417
transcription	O	1418-1431
factor	O	1432-1438
binding	O	1439-1446
sequence	O	1447-1455
,	O	1455-1456
GGAANCGGAANY	O	1457-1469
,	O	1469-1470
and	O	1471-1474
a	O	1475-1476
nucleolar	O	1477-1486
gene	O	1487-1491
network	O	1492-1499
.	O	1499-1500

The	O	1501-1504
zebrafish	O	1505-1514
microarrays	O	1515-1526
also	O	1527-1531
identify	O	1532-1540
a	O	1541-1542
set	O	1543-1546
of	O	1547-1549
32	O	1550-1552
genes	O	1553-1558
that	O	1559-1563
may	O	1564-1567
mediate	O	1568-1575
the	O	1576-1579
effects	O	1580-1587
of	O	1588-1590
gain	O	1591-1595
of	O	1596-1598
chromosome	O	1599-1609
arm	O	1610-1613
8q	O	1614-1616
in	O	1617-1619
human	O	1620-1625
colon	O	1626-1631
,	O	1631-1632
liver	O	1633-1638
,	O	1638-1639
and	O	1640-1643
pancreatic	O	1644-1654
cancers	O	1655-1662
.	O	1662-1663

CONCLUSIONS	O	1664-1675
:	O	1675-1676
We	O	1677-1679
successfully	O	1680-1692
combine	O	1693-1700
FACS	O	1701-1705
and	O	1706-1709
microarray	O	1710-1720
profiling	O	1721-1730
to	O	1731-1733
follow	O	1734-1740
organogenesis	O	1741-1754
throughout	O	1755-1765
development	O	1766-1777
.	O	1777-1778

These	O	1779-1784
experiments	O	1785-1796
identify	O	1797-1805
novel	O	1806-1811
genes	O	1812-1817
and	O	1818-1821
pathways	O	1822-1830
that	O	1831-1835
probably	O	1836-1844
play	O	1845-1849
a	O	1850-1851
role	O	1852-1856
in	O	1857-1859
mammalian	O	1860-1869
gastrointestinal	O	1870-1886
development	O	1887-1898
and	O	1899-1902
are	O	1903-1906
potential	O	1907-1916
targets	O	1917-1924
for	O	1925-1928
therapeutic	O	1929-1940
intervention	O	1941-1953
in	O	1954-1956
the	O	1957-1960
management	O	1961-1971
of	O	1972-1974
gastrointestinal	O	1975-1991
disease	O	1992-1999
and	O	2000-2003
cancer	O	2004-2010
.	O	2010-2011

MicroRNA	B	0-8
-	I	8-9
1	I	9-10
downregulation	O	11-25
by	O	26-28
propranolol	O	29-40
in	O	41-43
a	O	44-45
rat	O	46-49
model	O	50-55
of	O	56-58
myocardial	O	59-69
infarction	O	70-80
:	O	80-81
a	O	82-83
new	O	84-87
mechanism	O	88-97
for	O	98-101
ischaemic	O	102-111
cardioprotection	O	112-128
.	O	128-129

AIMS	O	130-134
:	O	134-135
The	O	136-139
present	O	140-147
study	O	148-153
was	O	154-157
designed	O	158-166
to	O	167-169
investigate	O	170-181
whether	O	182-189
the	O	190-193
beneficial	O	194-204
effects	O	205-212
of	O	213-215
beta	O	216-220
-	O	220-221
blocker	O	221-228
propranolol	O	229-240
are	O	241-244
related	O	245-252
to	O	253-255
regulation	O	256-266
of	O	267-269
microRNA	O	270-278
miR	B	279-282
-	I	282-283
1	I	283-284
.	O	284-285

METHODS	O	286-293
AND	O	294-297
RESULTS	O	298-305
:	O	305-306
We	O	307-309
demonstrated	O	310-322
that	O	323-327
propranolol	O	328-339
reduced	O	340-347
the	O	348-351
incidence	O	352-361
of	O	362-364
arrhythmias	O	365-376
in	O	377-379
a	O	380-381
rat	O	382-385
model	O	386-391
of	O	392-394
myocardial	O	395-405
infarction	O	406-416
by	O	417-419
coronary	O	420-428
artery	O	429-435
occlusion	O	436-445
.	O	445-446

Overexpression	O	447-461
of	O	462-464
miR	B	465-468
-	I	468-469
1	I	469-470
was	O	471-474
observed	O	475-483
in	O	484-486
ischaemic	O	487-496
myocardium	O	497-507
and	O	508-511
strikingly	O	512-522
,	O	522-523
administration	O	524-538
of	O	539-541
propranolol	O	542-553
reversed	O	554-562
the	O	563-566
up	O	567-569
-	O	569-570
regulation	O	570-580
of	O	581-583
miR	B	584-587
-	I	587-588
1	I	588-589
nearly	O	590-596
back	O	597-601
to	O	602-604
the	O	605-608
control	O	609-616
level	O	617-622
.	O	622-623

In	O	624-626
agreement	O	627-636
with	O	637-641
its	O	642-645
miR	B	646-649
-	I	649-650
1	I	650-651
-	O	651-652
reducing	O	652-660
effect	O	661-667
,	O	667-668
propranolol	O	669-680
relieved	O	681-689
myocardial	O	690-700
injuries	O	701-709
during	O	710-716
ischaemia	O	717-726
,	O	726-727
restored	O	728-736
the	O	737-740
membrane	O	741-749
depolarization	O	750-764
and	O	765-768
cardiac	O	769-776
conduction	O	777-787
slowing	O	788-795
,	O	795-796
by	O	797-799
rescuing	O	800-808
the	O	809-812
expression	O	813-823
of	O	824-826
inward	O	827-833
rectifying	O	834-844
K	O	845-846
(	O	846-847
+	O	847-848
)	O	848-849
channel	O	850-857
subunit	O	858-865
Kir2	O	866-870
.	O	870-871
1	O	871-872
and	O	873-876
gap	O	877-880
junction	O	881-889
channel	O	890-897
connexin	O	898-906
43	O	907-909
.	O	909-910

Our	O	911-914
results	O	915-922
further	O	923-930
revealed	O	931-939
that	O	940-944
the	O	945-948
beta	O	949-953
-	O	953-954
adrenoceptor	O	954-966
-	O	966-967
cAMP	O	967-971
-	O	971-972
Protein	O	972-979
Kinase	O	980-986
A	O	987-988
(	O	989-990
PKA	O	990-993
)	O	993-994
signalling	O	995-1005
pathway	O	1006-1013
contributed	O	1014-1025
to	O	1026-1028
the	O	1029-1032
expression	O	1033-1043
of	O	1044-1046
miR	B	1047-1050
-	I	1050-1051
1	I	1051-1052
,	O	1052-1053
and	O	1054-1057
serum	O	1058-1063
response	O	1064-1072
factor	O	1073-1079
(	O	1080-1081
SRF	O	1081-1084
)	O	1084-1085
,	O	1085-1086
which	O	1087-1092
is	O	1093-1095
known	O	1096-1101
as	O	1102-1104
one	O	1105-1108
of	O	1109-1111
the	O	1112-1115
transcriptional	O	1116-1131
enhancers	O	1132-1141
of	O	1142-1144
miR	B	1145-1148
-	I	1148-1149
1	I	1149-1150
,	O	1150-1151
was	O	1152-1155
up	O	1156-1158
-	O	1158-1159
regulated	O	1159-1168
in	O	1169-1171
ischaemic	O	1172-1181
myocardium	O	1182-1192
.	O	1192-1193

Moreover	O	1194-1202
,	O	1202-1203
propranolol	O	1204-1215
inhibited	O	1216-1225
the	O	1226-1229
beta	O	1230-1234
-	O	1234-1235
adrenoceptor	O	1235-1247
-	O	1247-1248
cAMP	O	1248-1252
-	O	1252-1253
PKA	O	1253-1256
signalling	O	1257-1267
pathway	O	1268-1275
and	O	1276-1279
suppressed	O	1280-1290
SRF	O	1291-1294
expression	O	1295-1305
.	O	1305-1306

CONCLUSION	O	1307-1317
:	O	1317-1318
We	O	1319-1321
conclude	O	1322-1330
that	O	1331-1335
the	O	1336-1339
beta	O	1340-1344
-	O	1344-1345
adrenergic	O	1345-1355
pathway	O	1356-1363
can	O	1364-1367
stimulate	O	1368-1377
expression	O	1378-1388
of	O	1389-1391
arrhythmogenic	O	1392-1406
miR	B	1407-1410
-	I	1410-1411
1	I	1411-1412
,	O	1412-1413
contributing	O	1414-1426
to	O	1427-1429
ischaemic	O	1430-1439
arrhythmogenesis	O	1440-1456
,	O	1456-1457
and	O	1458-1461
beta	O	1462-1466
-	O	1466-1467
blockers	O	1467-1475
produce	O	1476-1483
their	O	1484-1489
beneficial	O	1490-1500
effects	O	1501-1508
partially	O	1509-1518
by	O	1519-1521
down	O	1522-1526
-	O	1526-1527
regulating	O	1527-1537
miR	B	1538-1541
-	I	1541-1542
1	I	1542-1543
,	O	1543-1544
which	O	1545-1550
might	O	1551-1556
be	O	1557-1559
a	O	1560-1561
novel	O	1562-1567
strategy	O	1568-1576
for	O	1577-1580
ischaemic	O	1581-1590
cardioprotection	O	1591-1607
.	O	1607-1608

miR	B	0-3
-	I	3-4
200	I	4-7
expression	O	8-18
regulates	O	19-28
epithelial	O	29-39
-	O	39-40
to	O	40-42
-	O	42-43
mesenchymal	O	43-54
transition	O	55-65
in	O	66-68
bladder	O	69-76
cancer	O	77-83
cells	O	84-89
and	O	90-93
reverses	O	94-102
resistance	O	103-113
to	O	114-116
epidermal	O	117-126
growth	O	127-133
factor	O	134-140
receptor	O	141-149
therapy	O	150-157
.	O	157-158

PURPOSE	O	159-166
:	O	166-167
The	O	168-171
epithelial	O	172-182
-	O	182-183
to	O	183-185
-	O	185-186
mesenchymal	O	186-197
transition	O	198-208
(	O	209-210
EMT	O	210-213
)	O	213-214
is	O	215-217
a	O	218-219
cell	O	220-224
development	O	225-236
-	O	236-237
regulated	O	237-246
process	O	247-254
in	O	255-257
which	O	258-263
noncoding	O	264-273
RNAs	O	274-278
act	O	279-282
as	O	283-285
crucial	O	286-293
modulators	O	294-304
.	O	304-305

Recent	O	306-312
studies	O	313-320
have	O	321-325
implied	O	326-333
that	O	334-338
EMT	O	339-342
may	O	343-346
contribute	O	347-357
to	O	358-360
resistance	O	361-371
to	O	372-374
epidermal	O	375-384
growth	O	385-391
factor	O	392-398
receptor	O	399-407
(	O	408-409
EGFR	O	409-413
)	O	413-414
-	O	414-415
directed	O	415-423
therapy	O	424-431
.	O	431-432

The	O	433-436
aims	O	437-441
of	O	442-444
this	O	445-449
study	O	450-455
were	O	456-460
to	O	461-463
determine	O	464-473
the	O	474-477
potential	O	478-487
role	O	488-492
of	O	493-495
microRNAs	O	496-505
(	O	506-507
miRNA	O	507-512
)	O	512-513
in	O	514-516
controlling	O	517-528
EMT	O	529-532
and	O	533-536
the	O	537-540
role	O	541-545
of	O	546-548
EMT	O	549-552
in	O	553-555
inducing	O	556-564
the	O	565-568
sensitivity	O	569-580
of	O	581-583
human	O	584-589
bladder	O	590-597
cancer	O	598-604
cells	O	605-610
to	O	611-613
the	O	614-617
inhibitory	O	618-628
effects	O	629-636
of	O	637-639
the	O	640-643
anti	O	644-648
-	O	648-649
EGFR	O	649-653
therapy	O	654-661
.	O	661-662

EXPERIMENTAL	O	663-675
DESIGN	O	676-682
:	O	682-683
miRNA	O	684-689
array	O	690-695
screening	O	696-705
and	O	706-709
real	O	710-714
-	O	714-715
time	O	715-719
reverse	O	720-727
transcription	O	728-741
-	O	741-742
PCR	O	742-745
were	O	746-750
used	O	751-755
to	O	756-758
identify	O	759-767
and	O	768-771
validate	O	772-780
the	O	781-784
differential	O	785-797
expression	O	798-808
of	O	809-811
miRNAs	O	812-818
involved	O	819-827
in	O	828-830
EMT	O	831-834
in	O	835-837
nine	O	838-842
bladder	O	843-850
cancer	O	851-857
cell	O	858-862
lines	O	863-868
.	O	868-869

A	O	870-871
list	O	872-876
of	O	877-879
potential	O	880-889
miR	B	890-893
-	I	893-894
200	I	894-897
direct	O	898-904
targets	O	905-912
was	O	913-916
identified	O	917-927
through	O	928-935
the	O	936-939
TargetScan	O	940-950
database	O	951-959
.	O	959-960

The	O	961-964
precursor	O	965-974
of	O	975-977
miR	B	978-981
-	I	981-982
200b	I	982-986
and	O	987-990
miR	B	991-994
-	I	994-995
200c	I	995-999
was	O	1000-1003
expressed	O	1004-1013
in	O	1014-1016
UMUC3	O	1017-1022
and	O	1023-1026
T24	O	1027-1030
cells	O	1031-1036
using	O	1037-1042
a	O	1043-1044
retrovirus	O	1045-1055
or	O	1056-1058
a	O	1059-1060
lentivirus	O	1061-1071
construct	O	1072-1081
,	O	1081-1082
respectively	O	1083-1095
.	O	1095-1096

Protein	O	1097-1104
expression	O	1105-1115
and	O	1116-1119
signaling	O	1120-1129
pathway	O	1130-1137
modulation	O	1138-1148
,	O	1148-1149
as	O	1150-1152
well	O	1153-1157
as	O	1158-1160
intracellular	O	1161-1174
distribution	O	1175-1187
of	O	1188-1190
EGFR	O	1191-1195
and	O	1196-1199
ERRFI	O	1200-1205
-	O	1205-1206
1	O	1206-1207
,	O	1207-1208
were	O	1209-1213
validated	O	1214-1223
through	O	1224-1231
Western	O	1232-1239
blot	O	1240-1244
analysis	O	1245-1253
and	O	1254-1257
confocal	O	1258-1266
microscopy	O	1267-1277
,	O	1277-1278
whereas	O	1279-1286
ERRFI	O	1287-1292
-	O	1292-1293
1	O	1293-1294
direct	O	1295-1301
target	O	1302-1308
of	O	1309-1311
miR	B	1312-1315
-	I	1315-1316
200	I	1316-1319
members	O	1320-1327
was	O	1328-1331
validated	O	1332-1341
by	O	1342-1344
using	O	1345-1350
the	O	1351-1354
wild	O	1355-1359
-	O	1359-1360
type	O	1360-1364
and	O	1365-1368
mutant	O	1369-1375
3	O	1376-1377
'	O	1377-1378
-	O	1378-1379
untranslated	O	1379-1391
region	O	1392-1398
/	O	1398-1399
ERRFI	O	1399-1404
-	O	1404-1405
1	O	1405-1406
/	O	1406-1407
luciferse	O	1407-1416
reporters	O	1417-1426
.	O	1426-1427

RESULTS	O	1428-1435
:	O	1435-1436
We	O	1437-1439
identified	O	1440-1450
a	O	1451-1452
tight	O	1453-1458
association	O	1459-1470
between	O	1471-1478
the	O	1479-1482
expression	O	1483-1493
of	O	1494-1496
miRNAs	O	1497-1503
of	O	1504-1506
the	O	1507-1510
miR	B	1511-1514
-	I	1514-1515
200	I	1515-1518
family	O	1519-1525
,	O	1525-1526
epithelial	O	1527-1537
phenotype	O	1538-1547
,	O	1547-1548
and	O	1549-1552
sensitivity	O	1553-1564
to	O	1565-1567
EGFR	O	1568-1572
inhibitors	O	1573-1583
-	O	1583-1584
induced	O	1584-1591
growth	O	1592-1598
inhibition	O	1599-1609
in	O	1610-1612
bladder	O	1613-1620
carcinoma	O	1621-1630
cell	O	1631-1635
lines	O	1636-1641
.	O	1641-1642

Stable	O	1643-1649
expression	O	1650-1660
of	O	1661-1663
miR	B	1664-1667
-	I	1667-1668
200	I	1668-1671
in	O	1672-1674
mesenchymal	O	1675-1686
UMUC3	O	1687-1692
cells	O	1693-1698
increased	O	1699-1708
E	O	1709-1710
-	O	1710-1711
cadherin	O	1711-1719
levels	O	1720-1726
,	O	1726-1727
decreased	O	1728-1737
expression	O	1738-1748
of	O	1749-1751
ZEB1	O	1752-1756
,	O	1756-1757
ZEB2	O	1758-1762
,	O	1762-1763
ERRFI	O	1764-1769
-	O	1769-1770
1	O	1770-1771
,	O	1771-1772
and	O	1773-1776
cell	O	1777-1781
migration	O	1782-1791
,	O	1791-1792
and	O	1793-1796
increased	O	1797-1806
sensitivity	O	1807-1818
to	O	1819-1821
EGFR	O	1822-1826
-	O	1826-1827
blocking	O	1827-1835
agents	O	1836-1842
.	O	1842-1843

The	O	1844-1847
changes	O	1848-1855
in	O	1856-1858
EGFR	O	1859-1863
sensitivity	O	1864-1875
by	O	1876-1878
silencing	O	1879-1888
or	O	1889-1891
forced	O	1892-1898
expression	O	1899-1909
of	O	1910-1912
ERRFI	O	1913-1918
-	O	1918-1919
1	O	1919-1920
or	O	1921-1923
by	O	1924-1926
miR	B	1927-1930
-	I	1930-1931
200	I	1931-1934
expression	O	1935-1945
have	O	1946-1950
also	O	1951-1955
been	O	1956-1960
validated	O	1961-1970
in	O	1971-1973
additional	O	1974-1984
cell	O	1985-1989
lines	O	1990-1995
,	O	1995-1996
UMUC5	O	1997-2002
and	O	2003-2006
T24	O	2007-2010
.	O	2010-2011

Finally	O	2012-2019
,	O	2019-2020
luciferase	O	2021-2031
assays	O	2032-2038
using	O	2039-2044
3	O	2045-2046
'	O	2046-2047
-	O	2047-2048
untranslated	O	2048-2060
region	O	2061-2067
/	O	2067-2068
ERRFI	O	2068-2073
-	O	2073-2074
1	O	2074-2075
/	O	2075-2076
luciferase	O	2076-2086
and	O	2087-2090
miR	B	2091-2094
-	I	2094-2095
200	I	2095-2098
cotransfections	O	2099-2114
showed	O	2115-2121
that	O	2122-2126
the	O	2127-2130
direct	O	2131-2137
down	O	2138-2142
-	O	2142-2143
regulation	O	2143-2153
of	O	2154-2156
ERRFI	O	2157-2162
-	O	2162-2163
1	O	2163-2164
was	O	2165-2168
miR	B	2169-2172
-	I	2172-2173
200	I	2173-2176
-	O	2176-2177
dependent	O	2177-2186
because	O	2187-2194
mutations	O	2195-2204
in	O	2205-2207
the	O	2208-2211
two	O	2212-2215
putative	O	2216-2224
miR	B	2225-2228
-	I	2228-2229
200	I	2229-2232
-	O	2232-2233
binding	O	2233-2240
sites	O	2241-2246
have	O	2247-2251
rescued	O	2252-2259
the	O	2260-2263
inhibitory	O	2264-2274
effect	O	2275-2281
.	O	2281-2282

CONCLUSIONS	O	2283-2294
:	O	2294-2295
Members	O	2296-2303
of	O	2304-2306
the	O	2307-2310
miR	B	2311-2314
-	I	2314-2315
200	I	2315-2318
family	O	2319-2325
appear	O	2326-2332
to	O	2333-2335
control	O	2336-2343
the	O	2344-2347
EMT	O	2348-2351
process	O	2352-2359
and	O	2360-2363
sensitivity	O	2364-2375
to	O	2376-2378
EGFR	O	2379-2383
therapy	O	2384-2391
in	O	2392-2394
bladder	O	2395-2402
cancer	O	2403-2409
cells	O	2410-2415
and	O	2416-2419
the	O	2420-2423
expression	O	2424-2434
of	O	2435-2437
miR	B	2438-2441
-	I	2441-2442
200	I	2442-2445
is	O	2446-2448
sufficient	O	2449-2459
to	O	2460-2462
restore	O	2463-2470
EGFR	O	2471-2475
dependency	O	2476-2486
at	O	2487-2489
least	O	2490-2495
in	O	2496-2498
some	O	2499-2503
of	O	2504-2506
the	O	2507-2510
mesenchymal	O	2511-2522
bladder	O	2523-2530
cancer	O	2531-2537
cells	O	2538-2543
.	O	2543-2544

The	O	2545-2548
targets	O	2549-2556
of	O	2557-2559
miR	B	2560-2563
-	I	2563-2564
200	I	2564-2567
include	O	2568-2575
ERRFI	O	2576-2581
-	O	2581-2582
1	O	2582-2583
,	O	2583-2584
which	O	2585-2590
is	O	2591-2593
a	O	2594-2595
novel	O	2596-2601
regulator	O	2602-2611
of	O	2612-2614
EGFR	O	2615-2619
-	O	2619-2620
independent	O	2620-2631
growth	O	2632-2638
.	O	2638-2639

Characterization	O	0-16
of	O	17-19
small	O	20-25
RNAs	O	26-30
in	O	31-33
Aplysia	O	34-41
reveals	O	42-49
a	O	50-51
role	O	52-56
for	O	57-60
miR	B	61-64
-	I	64-65
124	I	65-68
in	O	69-71
constraining	O	72-84
synaptic	O	85-93
plasticity	O	94-104
through	O	105-112
CREB	O	113-117
.	O	117-118

Memory	O	119-125
storage	O	126-133
and	O	134-137
memory	O	138-144
-	O	144-145
related	O	145-152
synaptic	O	153-161
plasticity	O	162-172
rely	O	173-177
on	O	178-180
precise	O	181-188
spatiotemporal	O	189-203
regulation	O	204-214
of	O	215-217
gene	O	218-222
expression	O	223-233
.	O	233-234

To	O	235-237
explore	O	238-245
the	O	246-249
role	O	250-254
of	O	255-257
small	O	258-263
regulatory	O	264-274
RNAs	O	275-279
in	O	280-282
learning	O	283-291
-	O	291-292
related	O	292-299
synaptic	O	300-308
plasticity	O	309-319
,	O	319-320
we	O	321-323
carried	O	324-331
out	O	332-335
massive	O	336-343
parallel	O	344-352
sequencing	O	353-363
to	O	364-366
profile	O	367-374
the	O	375-378
small	O	379-384
RNAs	O	385-389
of	O	390-392
Aplysia	O	393-400
californica	O	401-412
.	O	412-413

We	O	414-416
identified	O	417-427
170	O	428-431
distinct	O	432-440
miRNAs	O	441-447
,	O	447-448
13	O	449-451
of	O	452-454
which	O	455-460
were	O	461-465
novel	O	466-471
and	O	472-475
specific	O	476-484
to	O	485-487
Aplysia	O	488-495
.	O	495-496

Nine	O	497-501
miRNAs	O	502-508
were	O	509-513
brain	O	514-519
enriched	O	520-528
,	O	528-529
and	O	530-533
several	O	534-541
of	O	542-544
these	O	545-550
were	O	551-555
rapidly	O	556-563
downregulated	O	564-577
by	O	578-580
transient	O	581-590
exposure	O	591-599
to	O	600-602
serotonin	O	603-612
,	O	612-613
a	O	614-615
modulatory	O	616-626
neurotransmitter	O	627-643
released	O	644-652
during	O	653-659
learning	O	660-668
.	O	668-669

Further	O	670-677
characterization	O	678-694
of	O	695-697
the	O	698-701
brain	O	702-707
-	O	707-708
enriched	O	708-716
miRNAs	O	717-723
revealed	O	724-732
that	O	733-737
miR	B	738-741
-	I	741-742
124	I	742-745
,	O	745-746
the	O	747-750
most	O	751-755
abundant	O	756-764
and	O	765-768
well	O	769-773
-	O	773-774
conserved	O	774-783
brain	O	784-789
-	O	789-790
specific	O	790-798
miRNA	O	799-804
,	O	804-805
was	O	806-809
exclusively	O	810-821
present	O	822-829
presynaptically	O	830-845
in	O	846-848
a	O	849-850
sensory	O	851-858
-	O	858-859
motor	O	859-864
synapse	O	865-872
where	O	873-878
it	O	879-881
constrains	O	882-892
serotonin	O	893-902
-	O	902-903
induced	O	903-910
synaptic	O	911-919
facilitation	O	920-932
through	O	933-940
regulation	O	941-951
of	O	952-954
the	O	955-958
transcriptional	O	959-974
factor	O	975-981
CREB	O	982-986
.	O	986-987

We	O	988-990
therefore	O	991-1000
present	O	1001-1008
direct	O	1009-1015
evidence	O	1016-1024
that	O	1025-1029
a	O	1030-1031
modulatory	O	1032-1042
neurotransmitter	O	1043-1059
important	O	1060-1069
for	O	1070-1073
learning	O	1074-1082
can	O	1083-1086
regulate	O	1087-1095
the	O	1096-1099
levels	O	1100-1106
of	O	1107-1109
small	O	1110-1115
RNAs	O	1116-1120
and	O	1121-1124
present	O	1125-1132
a	O	1133-1134
role	O	1135-1139
for	O	1140-1143
miR	B	1144-1147
-	I	1147-1148
124	I	1148-1151
in	O	1152-1154
long	O	1155-1159
-	O	1159-1160
term	O	1160-1164
plasticity	O	1165-1175
of	O	1176-1178
synapses	O	1179-1187
in	O	1188-1190
the	O	1191-1194
mature	O	1195-1201
nervous	O	1202-1209
system	O	1210-1216
.	O	1216-1217

Loss	O	0-4
of	O	5-7
heterozygosity	O	8-22
at	O	23-25
2q37	O	26-30
in	O	31-33
sporadic	O	34-42
Wilms	O	43-48
'	O	48-49
tumor	O	50-55
:	O	55-56
putative	O	57-65
role	O	66-70
for	O	71-74
miR	B	75-78
-	I	78-79
562	I	79-82
.	O	82-83

PURPOSE	O	84-91
:	O	91-92
Wilms	O	93-98
'	O	98-99
tumor	O	100-105
is	O	106-108
a	O	109-110
childhood	O	111-120
cancer	O	121-127
of	O	128-130
the	O	131-134
kidney	O	135-141
with	O	142-146
an	O	147-149
incidence	O	150-159
of	O	160-162
approximately	O	163-176
1	O	177-178
in	O	179-181
10	O	182-184
,	O	184-185
000	O	185-188
.	O	188-189

Cooccurrence	O	190-202
of	O	203-205
Wilms	O	206-211
'	O	211-212
tumor	O	213-218
with	O	219-223
2q37	O	224-228
deletion	O	229-237
syndrome	O	238-246
,	O	246-247
an	O	248-250
uncommon	O	251-259
constitutional	O	260-274
chromosome	O	275-285
abnormality	O	286-297
,	O	297-298
has	O	299-302
been	O	303-307
reported	O	308-316
previously	O	317-327
in	O	328-330
three	O	331-336
children	O	337-345
.	O	345-346

Given	O	347-352
these	O	353-358
are	O	359-362
independently	O	363-376
rare	O	377-381
clinical	O	382-390
entities	O	391-399
,	O	399-400
we	O	401-403
hypothesized	O	404-416
that	O	417-421
2q37	O	422-426
harbors	O	427-434
a	O	435-436
tumor	O	437-442
suppressor	O	443-453
gene	O	454-458
important	O	459-468
in	O	469-471
Wilms	O	472-477
'	O	477-478
tumor	O	479-484
pathogenesis	O	485-497
.	O	497-498

EXPERIMENTAL	O	499-511
DESIGN	O	512-518
:	O	518-519
To	O	520-522
test	O	523-527
this	O	528-532
,	O	532-533
we	O	534-536
performed	O	537-546
loss	O	547-551
of	O	552-554
heterozygosity	O	555-569
analysis	O	570-578
in	O	579-581
a	O	582-583
panel	O	584-589
of	O	590-592
226	O	593-596
sporadic	O	597-605
Wilms	O	606-611
'	O	611-612
tumor	O	613-618
samples	O	619-626
and	O	627-630
mutation	O	631-639
analysis	O	640-648
of	O	649-651
candidate	O	652-661
genes	O	662-667
.	O	667-668

RESULTS	O	669-676
:	O	676-677
Loss	O	678-682
of	O	683-685
heterozygosity	O	686-700
was	O	701-704
present	O	705-712
in	O	713-715
at	O	716-718
least	O	719-724
4	O	725-726
%	O	726-727
of	O	728-730
cases	O	731-736
.	O	736-737

Two	O	738-741
tumors	O	742-748
harbored	O	749-757
homozygous	O	758-768
deletions	O	769-778
at	O	779-781
2q37	O	782-786
.	O	786-787
1	O	787-788
,	O	788-789
supporting	O	790-800
the	O	801-804
presence	O	805-813
of	O	814-816
a	O	817-818
tumor	O	819-824
suppressor	O	825-835
gene	O	836-840
that	O	841-845
follows	O	846-853
a	O	854-855
classic	O	856-863
two	O	864-867
-	O	867-868
hit	O	868-871
model	O	872-877
.	O	877-878

However	O	879-886
,	O	886-887
no	O	888-890
other	O	891-896
evidence	O	897-905
of	O	906-908
second	O	909-915
mutations	O	916-925
was	O	926-929
found	O	930-935
,	O	935-936
suggesting	O	937-947
that	O	948-952
heterozygous	O	953-965
deletion	O	966-974
alone	O	975-980
may	O	981-984
be	O	985-987
sufficient	O	988-998
to	O	999-1001
promote	O	1002-1009
tumorigenesis	O	1010-1023
in	O	1024-1026
concert	O	1027-1034
with	O	1035-1039
other	O	1040-1045
genomic	O	1046-1053
abnormalities	O	1054-1067
.	O	1067-1068

We	O	1069-1071
show	O	1072-1076
that	O	1077-1081
miR	B	1082-1085
-	I	1085-1086
562	I	1086-1089
,	O	1089-1090
a	O	1091-1092
microRNA	O	1093-1101
within	O	1102-1108
the	O	1109-1112
candidate	O	1113-1122
region	O	1123-1129
,	O	1129-1130
is	O	1131-1133
expressed	O	1134-1143
only	O	1144-1148
in	O	1149-1151
kidney	O	1152-1158
and	O	1159-1162
colon	O	1163-1168
and	O	1169-1172
regulates	O	1173-1182
EYA1	O	1183-1187
,	O	1187-1188
a	O	1189-1190
critical	O	1191-1199
gene	O	1200-1204
for	O	1205-1208
renal	O	1209-1214
development	O	1215-1226
.	O	1226-1227

miR	B	1228-1231
-	I	1231-1232
562	I	1232-1235
expression	O	1236-1246
is	O	1247-1249
reduced	O	1250-1257
in	O	1258-1260
Wilms	O	1261-1266
'	O	1266-1267
tumor	O	1268-1273
and	O	1274-1277
may	O	1278-1281
contribute	O	1282-1292
to	O	1293-1295
tumorigenesis	O	1296-1309
by	O	1310-1312
deregulating	O	1313-1325
EYA1	O	1326-1330
.	O	1330-1331

Two	O	1332-1335
other	O	1336-1341
candidate	O	1342-1351
regions	O	1352-1359
were	O	1360-1364
localized	O	1365-1374
at	O	1375-1377
2q37	O	1378-1382
.	O	1382-1383
3	O	1383-1384
and	O	1385-1388
2qter	O	1389-1394
,	O	1394-1395
but	O	1396-1399
available	O	1400-1409
data	O	1410-1414
from	O	1415-1419
patients	O	1420-1428
with	O	1429-1433
constitutional	O	1434-1448
deletions	O	1449-1458
suggest	O	1459-1466
that	O	1467-1471
these	O	1472-1477
probably	O	1478-1486
do	O	1487-1489
not	O	1490-1493
confer	O	1494-1500
a	O	1501-1502
high	O	1503-1507
risk	O	1508-1512
for	O	1513-1516
Wilms	O	1517-1522
'	O	1522-1523
tumor	O	1524-1529
.	O	1529-1530

CONCLUSIONS	O	1531-1542
:	O	1542-1543
Our	O	1544-1547
data	O	1548-1552
support	O	1553-1560
the	O	1561-1564
presence	O	1565-1573
of	O	1574-1576
a	O	1577-1578
tumor	O	1579-1584
suppressor	O	1585-1595
gene	O	1596-1600
at	O	1601-1603
2q37	O	1604-1608
.	O	1608-1609
1	O	1609-1610
and	O	1611-1614
suggest	O	1615-1622
that	O	1623-1627
,	O	1627-1628
in	O	1629-1631
individuals	O	1632-1643
with	O	1644-1648
constitutional	O	1649-1663
2q37	O	1664-1668
deletions	O	1669-1678
,	O	1678-1679
any	O	1680-1683
increased	O	1684-1693
risk	O	1694-1698
for	O	1699-1702
developing	O	1703-1713
Wilms	O	1714-1719
'	O	1719-1720
tumor	O	1721-1726
likely	O	1727-1733
correlates	O	1734-1744
with	O	1745-1749
deletions	O	1750-1759
encompassing	O	1760-1772
2q37	O	1773-1777
.	O	1777-1778
1	O	1778-1779
.	O	1779-1780

miR	B	0-3
-	I	3-4
155	I	4-7
:	O	7-8
on	O	9-11
the	O	12-15
crosstalk	O	16-25
between	O	26-33
inflammation	O	34-46
and	O	47-50
cancer	O	51-57
.	O	57-58

MicroRNAs	O	59-68
are	O	69-72
short	O	73-78
non	O	79-82
-	O	82-83
coding	O	83-89
RNAs	O	90-94
that	O	95-99
posttranscriptionally	O	100-121
modulate	O	122-130
the	O	131-134
expression	O	135-145
of	O	146-148
multiple	O	149-157
target	O	158-164
genes	O	165-170
and	O	171-174
are	O	175-178
thus	O	179-183
implicated	O	184-194
in	O	195-197
a	O	198-199
wide	O	200-204
array	O	205-210
of	O	211-213
cellular	O	214-222
and	O	223-226
developmental	O	227-240
processes	O	241-250
.	O	250-251

miR	B	252-255
-	I	255-256
155	I	256-259
is	O	260-262
processed	O	263-272
from	O	273-277
BIC	O	278-281
,	O	281-282
a	O	283-284
non	O	285-288
-	O	288-289
coding	O	289-295
transcript	O	296-306
highly	O	307-313
expressed	O	314-323
in	O	324-326
both	O	327-331
activated	O	332-341
B	O	342-343
and	O	344-347
T	O	348-349
cells	O	350-355
and	O	356-359
in	O	360-362
monocytes	O	363-372
/	O	372-373
macrophages	O	373-384
.	O	384-385

miR	B	386-389
-	I	389-390
155	I	390-393
levels	O	394-400
change	O	401-407
dynamically	O	408-419
during	O	420-426
both	O	427-431
hematopoietic	O	432-445
lineage	O	446-453
differentiation	O	454-469
and	O	470-473
the	O	474-477
course	O	478-484
of	O	485-487
the	O	488-491
immune	O	492-498
response	O	499-507
.	O	507-508

Different	O	509-518
mouse	O	519-524
models	O	525-531
developed	O	532-541
recently	O	542-550
indicate	O	551-559
that	O	560-564
miR	B	565-568
-	I	568-569
155	I	569-572
plays	O	573-578
a	O	579-580
critical	O	581-589
role	O	590-594
during	O	595-601
hematopoiesis	O	602-615
and	O	616-619
regulates	O	620-629
lymphocyte	O	630-640
homeostasis	O	641-652
and	O	653-656
tolerance	O	657-666
.	O	666-667

A	O	668-669
moderate	O	670-678
increase	O	679-687
of	O	688-690
miR	B	691-694
-	I	694-695
155	I	695-698
levels	O	699-705
is	O	706-708
observed	O	709-717
in	O	718-720
many	O	721-725
types	O	726-731
of	O	732-734
malignancies	O	735-747
of	O	748-750
B	O	751-752
cell	O	753-757
or	O	758-760
myeloid	O	761-768
origin	O	769-775
,	O	775-776
and	O	777-780
transgenic	O	781-791
over	O	792-796
-	O	796-797
expression	O	797-807
of	O	808-810
miR	B	811-814
-	I	814-815
155	I	815-818
in	O	819-821
mice	O	822-826
results	O	827-834
in	O	835-837
cancer	O	838-844
.	O	844-845

While	O	846-851
the	O	852-855
high	O	856-860
levels	O	861-867
of	O	868-870
miR	B	871-874
-	I	874-875
155	I	875-878
reached	O	879-886
transiently	O	887-898
during	O	899-905
the	O	906-909
course	O	910-916
of	O	917-919
the	O	920-923
immune	O	924-930
response	O	931-939
remain	O	940-946
unharmful	O	947-956
for	O	957-960
the	O	961-964
organism	O	965-973
,	O	973-974
the	O	975-978
reason	O	979-985
why	O	986-989
a	O	990-991
moderate	O	992-1000
up	O	1001-1003
-	O	1003-1004
regulation	O	1004-1014
of	O	1015-1017
miR	B	1018-1021
-	I	1021-1022
155	I	1022-1025
can	O	1026-1029
lead	O	1030-1034
to	O	1035-1037
cancer	O	1038-1044
remains	O	1045-1052
obscure	O	1053-1060
.	O	1060-1061

As	O	1062-1064
prolonged	O	1065-1074
exposure	O	1075-1083
to	O	1084-1086
inflammation	O	1087-1099
can	O	1100-1103
lead	O	1104-1108
to	O	1109-1111
cancer	O	1112-1118
,	O	1118-1119
the	O	1120-1123
permanent	O	1124-1133
up	O	1134-1136
-	O	1136-1137
regulation	O	1137-1147
of	O	1148-1150
miR	B	1151-1154
-	I	1154-1155
155	I	1155-1158
might	O	1159-1164
be	O	1165-1167
a	O	1168-1169
link	O	1170-1174
between	O	1175-1182
the	O	1183-1186
two	O	1187-1190
.	O	1190-1191

Therefore	O	1192-1201
,	O	1201-1202
designing	O	1203-1212
miR	B	1213-1216
-	I	1216-1217
155	I	1217-1220
based	O	1221-1226
therapies	O	1227-1236
will	O	1237-1241
require	O	1242-1249
a	O	1250-1251
better	O	1252-1258
understanding	O	1259-1272
of	O	1273-1275
the	O	1276-1279
molecular	O	1280-1289
basis	O	1290-1295
of	O	1296-1298
its	O	1299-1302
action	O	1303-1309
as	O	1310-1312
well	O	1313-1317
as	O	1318-1320
of	O	1321-1323
how	O	1324-1327
miR	B	1328-1331
-	I	1331-1332
155	I	1332-1335
levels	O	1336-1342
are	O	1343-1346
regulated	O	1347-1356
in	O	1357-1359
a	O	1360-1361
cell	O	1362-1366
-	O	1366-1367
specific	O	1367-1375
manner	O	1376-1382
.	O	1382-1383

Reduced	O	0-7
microRNA	B	8-16
-	I	16-17
218	I	17-20
expression	O	21-31
is	O	32-34
associated	O	35-45
with	O	46-50
high	O	51-55
nuclear	O	56-63
factor	O	64-70
kappa	O	71-76
B	O	77-78
activation	O	79-89
in	O	90-92
gastric	O	93-100
cancer	O	101-107
.	O	107-108

BACKGROUND	O	109-119
:	O	119-120
Poor	O	121-125
expression	O	126-136
of	O	137-139
microRNAs	O	140-149
(	O	150-151
miRs	O	151-155
)	O	155-156
reportedly	O	157-167
plays	O	168-173
an	O	174-176
important	O	177-186
role	O	187-191
in	O	192-194
gastric	O	195-202
carcinogenesis	O	203-217
.	O	217-218

Large	O	219-224
-	O	224-225
scale	O	225-230
microarray	O	231-241
assays	O	242-248
have	O	249-253
indicated	O	254-263
that	O	264-268
there	O	269-274
is	O	275-277
significant	O	278-289
down	O	290-294
-	O	294-295
regulation	O	295-305
of	O	306-308
miR	B	309-312
-	I	312-313
218	I	313-316
in	O	317-319
gastric	O	320-327
cancer	O	328-334
.	O	334-335

miR	B	336-339
-	I	339-340
218	I	340-343
also	O	344-348
was	O	349-352
decreased	O	353-362
specifically	O	363-375
in	O	376-378
human	O	379-384
papillomavirus	O	385-399
-	O	399-400
positive	O	400-408
cell	O	409-413
lines	O	414-419
,	O	419-420
cervical	O	421-429
lesions	O	430-437
,	O	437-438
and	O	439-442
cervical	O	443-451
cancer	O	452-458
tissues	O	459-466
and	O	467-470
in	O	471-473
bronchial	O	474-483
airway	O	484-490
epithelium	O	491-501
in	O	502-504
smokers	O	505-512
.	O	512-513

However	O	514-521
,	O	521-522
its	O	523-526
role	O	527-531
in	O	532-534
carcinogenesis	O	535-549
remains	O	550-557
unclear	O	558-565
,	O	565-566
especially	O	567-577
in	O	578-580
Helicobacter	O	581-593
pylori	O	594-600
(	O	601-602
H	O	602-603
.	O	603-604
pylori	O	605-611
)	O	611-612
-	O	612-613
associated	O	613-623
gastric	O	624-631
cancer	O	632-638
.	O	638-639

METHODS	O	640-647
:	O	647-648
miR	B	649-652
-	I	652-653
218	I	653-656
levels	O	657-663
were	O	664-668
evaluated	O	669-678
in	O	679-681
20	O	682-684
noncardia	O	685-694
gastric	O	695-702
cancer	O	703-709
tissues	O	710-717
,	O	717-718
in	O	719-721
10	O	722-724
H	O	725-726
.	O	726-727
pylori	O	728-734
-	O	734-735
infected	O	735-743
and	O	744-747
8	O	748-749
uninfected	O	750-760
normal	O	761-767
gastric	O	768-775
biopsies	O	776-784
,	O	784-785
and	O	786-789
in	O	790-792
the	O	793-796
human	O	797-802
gastric	O	803-810
epithelial	O	811-821
cancer	O	822-828
cell	O	829-833
line	O	834-838
AGS	O	839-842
using	O	843-848
TaqMan	O	849-855
quantitative	O	856-868
real	O	869-873
-	O	873-874
time	O	874-878
polymerase	O	879-889
chain	O	890-895
reaction	O	896-904
analysis	O	905-913
.	O	913-914

Pre	O	915-918
-	O	918-919
miR	B	919-922
-	I	922-923
218	I	923-926
and	O	927-930
anti	O	931-935
-	O	935-936
miR	B	936-939
-	I	939-940
218	I	940-943
inhibitors	O	944-954
were	O	955-959
used	O	960-964
to	O	965-967
examine	O	968-975
the	O	976-979
effects	O	980-987
of	O	988-990
miR	B	991-994
-	I	994-995
218	I	995-998
expression	O	999-1009
on	O	1010-1012
cell	O	1013-1017
proliferation	O	1018-1031
and	O	1032-1035
apoptosis	O	1036-1045
.	O	1045-1046

A	O	1047-1048
luciferase	O	1049-1059
reporter	O	1060-1068
assay	O	1069-1074
was	O	1075-1078
used	O	1079-1083
to	O	1084-1086
examine	O	1087-1094
the	O	1095-1098
potential	O	1099-1108
target	O	1109-1115
genes	O	1116-1121
and	O	1122-1125
related	O	1126-1133
pathways	O	1134-1142
.	O	1142-1143

RESULTS	O	1144-1151
:	O	1151-1152
miR	B	1153-1156
-	I	1156-1157
218	I	1157-1160
expression	O	1161-1171
was	O	1172-1175
reduced	O	1176-1183
significantly	O	1184-1197
in	O	1198-1200
gastric	O	1201-1208
cancer	O	1209-1215
tissues	O	1216-1223
,	O	1223-1224
in	O	1225-1227
H	O	1228-1229
.	O	1229-1230
pylori	O	1231-1237
-	O	1237-1238
infected	O	1238-1246
gastric	O	1247-1254
mucosa	O	1255-1261
,	O	1261-1262
and	O	1263-1266
in	O	1267-1269
H	O	1270-1271
.	O	1271-1272
pylori	O	1273-1279
-	O	1279-1280
infected	O	1280-1288
AGS	O	1289-1292
cells	O	1293-1298
.	O	1298-1299

Overexpression	O	1300-1314
of	O	1315-1317
miR	B	1318-1321
-	I	1321-1322
218	I	1322-1325
inhibited	O	1326-1335
cell	O	1336-1340
proliferation	O	1341-1354
and	O	1355-1358
increased	O	1359-1368
apoptosis	O	1369-1378
in	O	1379-1381
vitro	O	1382-1387
.	O	1387-1388

Epidermal	O	1389-1398
growth	O	1399-1405
factor	O	1406-1412
receptor	O	1413-1421
-	O	1421-1422
coamplified	O	1422-1433
and	O	1434-1437
overexpressed	O	1438-1451
protein	O	1452-1459
(	O	1460-1461
ECOP	O	1461-1465
)	O	1465-1466
,	O	1466-1467
which	O	1468-1473
regulates	O	1474-1483
nuclear	O	1484-1491
factor	O	1492-1498
kappa	O	1499-1504
B	O	1505-1506
(	O	1507-1508
NF	O	1508-1510
-	O	1510-1511
kappaB	O	1511-1517
)	O	1517-1518
transcriptional	O	1519-1534
activity	O	1535-1543
and	O	1544-1547
is	O	1548-1550
associated	O	1551-1561
with	O	1562-1566
apoptotic	O	1567-1576
response	O	1577-1585
,	O	1585-1586
was	O	1587-1590
a	O	1591-1592
direct	O	1593-1599
target	O	1600-1606
of	O	1607-1609
miR	B	1610-1613
-	I	1613-1614
218	I	1614-1617
.	O	1617-1618

Overexpression	O	1619-1633
of	O	1634-1636
miR	B	1637-1640
-	I	1640-1641
218	I	1641-1644
also	O	1645-1649
inhibited	O	1650-1659
NF	O	1660-1662
-	O	1662-1663
kappaB	O	1663-1669
transcriptional	O	1670-1685
activation	O	1686-1696
and	O	1697-1700
transcription	O	1701-1714
of	O	1715-1717
cyclooxygenase	O	1718-1732
-	O	1733-1734
2	O	1734-1735
,	O	1735-1736
a	O	1737-1738
proliferative	O	1739-1752
gene	O	1753-1757
regulated	O	1758-1767
by	O	1768-1770
NF	O	1771-1773
-	O	1773-1774
kappaB	O	1774-1780
.	O	1780-1781

CONCLUSIONS	O	1782-1793
:	O	1793-1794
H	O	1795-1796
.	O	1796-1797
pylori	O	1798-1804
infection	O	1805-1814
resulted	O	1815-1823
in	O	1824-1826
a	O	1827-1828
decrease	O	1829-1837
in	O	1838-1840
miR	B	1841-1844
-	I	1844-1845
218	I	1845-1848
expression	O	1849-1859
.	O	1859-1860

The	O	1861-1864
down	O	1865-1869
-	O	1869-1870
regulation	O	1870-1880
of	O	1881-1883
miR	B	1884-1887
-	I	1887-1888
218	I	1888-1891
has	O	1892-1895
the	O	1896-1899
potential	O	1900-1909
to	O	1910-1912
increase	O	1913-1921
carcinogenesis	O	1922-1936
by	O	1937-1939
losing	O	1940-1946
control	O	1947-1954
of	O	1955-1957
its	O	1958-1961
targets	O	1962-1969
,	O	1969-1970
and	O	1971-1974
it	O	1975-1977
may	O	1978-1981
be	O	1982-1984
correlated	O	1985-1995
with	O	1996-2000
the	O	2001-2004
high	O	2005-2009
transcriptional	O	2010-2025
activity	O	2026-2034
of	O	2035-2037
NF	O	2038-2040
-	O	2040-2041
kappaB	O	2041-2047
that	O	2048-2052
results	O	2053-2060
from	O	2061-2065
H	O	2066-2067
.	O	2067-2068
pylori	O	2069-2075
infection	O	2076-2085
.	O	2085-2086

A	O	0-1
genetic	O	2-9
variant	O	10-17
in	O	18-20
the	O	21-24
pre	O	25-28
-	O	28-29
miR	B	29-32
-	I	32-33
27a	I	33-36
oncogene	O	37-45
is	O	46-48
associated	O	49-59
with	O	60-64
a	O	65-66
reduced	O	67-74
familial	O	75-83
breast	O	84-90
cancer	O	91-97
risk	O	98-102
.	O	102-103

MicroRNAs	O	104-113
(	O	114-115
miRNAs	O	115-121
)	O	121-122
regulate	O	123-131
pathways	O	132-140
involved	O	141-149
in	O	150-152
cell	O	153-157
differentiation	O	158-173
,	O	173-174
proliferation	O	175-188
,	O	188-189
development	O	190-201
,	O	201-202
and	O	203-206
apoptosis	O	207-216
by	O	217-219
degradation	O	220-231
of	O	232-234
target	O	235-241
mRNAs	O	242-247
and	O	248-251
/	O	251-252
or	O	252-254
repression	O	255-265
of	O	266-268
their	O	269-274
translation	O	275-286
.	O	286-287

Although	O	288-296
the	O	297-300
single	O	301-307
nucleotide	O	308-318
polymorphisms	O	319-332
(	O	333-334
SNPs	O	334-338
)	O	338-339
in	O	340-342
miRNAs	O	343-349
target	O	350-356
sites	O	357-362
have	O	363-367
been	O	368-372
studied	O	373-380
,	O	380-381
the	O	382-385
effects	O	386-393
of	O	394-396
SNPs	O	397-401
in	O	402-404
miRNAs	O	405-411
are	O	412-415
largely	O	416-423
unknown	O	424-431
.	O	431-432

In	O	433-435
our	O	436-439
study	O	440-445
,	O	445-446
we	O	447-449
first	O	450-455
systematically	O	456-470
sequenced	O	471-480
miRNA	O	481-486
genes	O	487-492
reported	O	493-501
to	O	502-504
be	O	505-507
involved	O	508-516
in	O	517-519
breast	O	520-526
cancer	O	527-533
to	O	534-536
identify	O	537-545
/	O	545-546
verify	O	546-552
SNPs	O	553-557
.	O	557-558

We	O	559-561
analyzed	O	562-570
four	O	571-575
SNPs	O	576-580
,	O	580-581
one	O	582-585
located	O	586-593
in	O	594-596
the	O	597-600
pre	O	601-604
-	O	604-605
miRNA	O	605-610
and	O	611-614
the	O	615-618
other	O	619-624
three	O	625-630
located	O	631-638
in	O	639-641
miRNA	O	642-647
flanking	O	648-656
regions	O	657-664
,	O	664-665
for	O	666-669
a	O	670-671
putative	O	672-680
association	O	681-692
with	O	693-697
breast	O	698-704
cancer	O	705-711
risk	O	712-716
.	O	716-717

The	O	718-721
SNP	O	722-725
rs895819	O	726-734
,	O	734-735
located	O	736-743
in	O	744-746
the	O	747-750
terminal	O	751-759
loop	O	760-764
of	O	765-767
pre	O	768-771
-	O	771-772
miRNA	B	772-777
-	I	777-778
27a	I	778-781
,	O	781-782
showed	O	783-789
a	O	790-791
protective	O	792-802
effect	O	803-809
.	O	809-810

In	O	811-813
a	O	814-815
large	O	816-821
familial	O	822-830
breast	O	831-837
cancer	O	838-844
study	O	845-850
cohort	O	851-857
,	O	857-858
the	O	859-862
rare	O	863-867
[	O	868-869
G	O	869-870
]	O	870-871
allele	O	872-878
of	O	879-881
rs895819	O	882-890
was	O	891-894
found	O	895-900
to	O	901-903
be	O	904-906
less	O	907-911
frequent	O	912-920
in	O	921-923
the	O	924-927
cases	O	928-933
than	O	934-938
in	O	939-941
the	O	942-945
controls	O	946-954
,	O	954-955
indicating	O	956-966
a	O	967-968
reduced	O	969-976
familial	O	977-985
breast	O	986-992
cancer	O	993-999
risk	O	1000-1004
(	O	1005-1006
[	O	1006-1007
G	O	1007-1008
]	O	1008-1009
vs	O	1010-1012
.	O	1012-1013
[	O	1014-1015
A	O	1015-1016
]	O	1016-1017
:	O	1017-1018
OR	O	1019-1021
=	O	1022-1023
0	O	1024-1025
.	O	1025-1026
88	O	1026-1028
,	O	1028-1029
95	O	1030-1032
%	O	1032-1033
CI	O	1034-1036
0	O	1037-1038
.	O	1038-1039
78	O	1039-1041
-	O	1041-1042
0	O	1042-1043
.	O	1043-1044
99	O	1044-1046
,	O	1046-1047
P	O	1048-1049
=	O	1050-1051
0	O	1052-1053
.	O	1053-1054
0287	O	1054-1058
)	O	1058-1059
.	O	1059-1060

Furthermore	O	1061-1072
,	O	1072-1073
age	O	1074-1077
stratification	O	1078-1092
revealed	O	1093-1101
that	O	1102-1106
the	O	1107-1110
protective	O	1111-1121
effect	O	1122-1128
was	O	1129-1132
mainly	O	1133-1139
observed	O	1140-1148
in	O	1149-1151
the	O	1152-1155
age	O	1156-1159
group	O	1160-1165
<	O	1166-1167
50	O	1168-1170
years	O	1171-1176
of	O	1177-1179
age	O	1180-1183
(	O	1184-1185
[	O	1185-1186
G	O	1186-1187
]	O	1187-1188
vs	O	1189-1191
.	O	1191-1192
[	O	1193-1194
A	O	1194-1195
]	O	1195-1196
:	O	1196-1197
OR	O	1198-1200
=	O	1201-1202
0	O	1203-1204
.	O	1204-1205
83	O	1205-1207
,	O	1207-1208
95	O	1209-1211
%	O	1211-1212
CI	O	1213-1215
0	O	1216-1217
.	O	1217-1218
70	O	1218-1220
-	O	1220-1221
0	O	1221-1222
.	O	1222-1223
98	O	1223-1225
,	O	1225-1226
P	O	1227-1228
=	O	1229-1230
0	O	1231-1232
.	O	1232-1233
0314	O	1233-1237
)	O	1237-1238
,	O	1238-1239
whereas	O	1240-1247
no	O	1248-1250
significant	O	1251-1262
effect	O	1263-1269
was	O	1270-1273
observed	O	1274-1282
in	O	1283-1285
the	O	1286-1289
age	O	1290-1293
group	O	1294-1299
>	O	1300-1301
or	O	1301-1303
=	O	1303-1304
50	O	1305-1307
years	O	1308-1313
of	O	1314-1316
age	O	1317-1320
,	O	1320-1321
indicating	O	1322-1332
a	O	1333-1334
possible	O	1335-1343
hormone	O	1344-1351
-	O	1351-1352
related	O	1352-1359
effect	O	1360-1366
.	O	1366-1367

It	O	1368-1370
has	O	1371-1374
been	O	1375-1379
shown	O	1380-1385
that	O	1386-1390
artificial	O	1391-1401
mutations	O	1402-1411
in	O	1412-1414
the	O	1415-1418
terminal	O	1419-1427
loop	O	1428-1432
of	O	1433-1435
miR	B	1436-1439
-	I	1439-1440
27a	I	1440-1443
can	O	1444-1447
block	O	1448-1453
the	O	1454-1457
maturation	O	1458-1468
process	O	1469-1476
of	O	1477-1479
the	O	1480-1483
miRNA	O	1484-1489
.	O	1489-1490

We	O	1491-1493
hypothesize	O	1494-1505
that	O	1506-1510
the	O	1511-1514
G	O	1515-1516
-	O	1516-1517
variant	O	1517-1524
of	O	1525-1527
rs895819	O	1528-1536
might	O	1537-1542
impair	O	1543-1549
the	O	1550-1553
maturation	O	1554-1564
of	O	1565-1567
the	O	1568-1571
oncogenic	O	1572-1581
miR	B	1582-1585
-	I	1585-1586
27a	I	1586-1589
and	O	1590-1593
thus	O	1594-1598
,	O	1598-1599
is	O	1600-1602
associated	O	1603-1613
with	O	1614-1618
familial	O	1619-1627
breast	O	1628-1634
cancer	O	1635-1641
risk	O	1642-1646
.	O	1646-1647

microRNA	B	0-8
-	I	8-9
342	I	9-12
,	O	12-13
microRNA	B	14-22
-	I	22-23
191	I	23-26
and	O	27-30
microRNA	B	31-39
-	I	39-40
510	I	40-43
are	O	44-47
differentially	O	48-62
expressed	O	63-72
in	O	73-75
T	O	76-77
regulatory	O	78-88
cells	O	89-94
of	O	95-97
type	O	98-102
1	O	103-104
diabetic	O	105-113
patients	O	114-122
.	O	122-123

Regulatory	O	124-134
T	O	135-136
cells	O	137-142
(	O	143-144
Tregs	O	144-149
)	O	149-150
are	O	151-154
critical	O	155-163
regulators	O	164-174
of	O	175-177
autoimmune	O	178-188
diseases	O	189-197
,	O	197-198
including	O	199-208
type	O	209-213
1	O	214-215
diabetes	O	216-224
mellitus	O	225-233
.	O	233-234

It	O	235-237
is	O	238-240
hypothesised	O	241-253
that	O	254-258
Tregs	O	259-264
'	O	264-265
function	O	266-274
can	O	275-278
be	O	279-281
influenced	O	282-292
by	O	293-295
changes	O	296-303
in	O	304-306
the	O	307-310
expression	O	311-321
of	O	322-324
specific	O	325-333
microRNAs	O	334-343
(	O	344-345
miRNAs	O	345-351
)	O	351-352
.	O	352-353

Thus	O	354-358
,	O	358-359
we	O	360-362
performed	O	363-372
miRNAs	O	373-379
profiling	O	380-389
in	O	390-392
a	O	393-394
population	O	395-405
of	O	406-408
Tregs	O	409-414
separated	O	415-424
from	O	425-429
peripheral	O	430-440
blood	O	441-446
of	O	447-449
five	O	450-454
type	O	455-459
1	O	460-461
diabetic	O	462-470
patients	O	471-479
and	O	480-483
six	O	484-487
healthy	O	488-495
donors	O	496-502
.	O	502-503

For	O	504-507
more	O	508-512
detailed	O	513-521
molecular	O	522-531
characterisation	O	532-548
of	O	549-551
Tregs	O	552-557
,	O	557-558
we	O	559-561
additionally	O	562-574
compared	O	575-583
miRNAs	O	584-590
expression	O	591-601
profiles	O	602-610
of	O	611-613
Tregs	O	614-619
and	O	620-623
conventional	O	624-636
T	O	637-638
cells	O	639-644
.	O	644-645

Tregs	O	646-651
were	O	652-656
isolated	O	657-665
according	O	666-675
to	O	676-678
CD3	O	679-682
+	O	682-683
,	O	683-684
CD4	O	685-688
+	O	688-689
,	O	689-690
CD25	O	691-695
(	O	695-696
hi	O	696-698
)	O	698-699
+	O	699-700
and	O	701-704
CD127	O	705-710
-	O	710-711
by	O	712-714
flow	O	715-719
cytometry	O	720-729
,	O	729-730
and	O	731-734
miRNA	O	735-740
expression	O	741-751
profiling	O	752-761
was	O	762-765
performed	O	766-775
using	O	776-781
TaqMan	O	782-788
Array	O	789-794
Human	O	795-800
MicroRNA	O	801-809
Panel	O	810-815
-	O	815-816
1	O	816-817
(	O	818-819
384	O	819-822
-	O	822-823
well	O	823-827
low	O	828-831
density	O	832-839
array	O	840-845
)	O	845-846
.	O	846-847

In	O	848-850
Tregs	O	851-856
of	O	857-859
diabetic	O	860-868
patients	O	869-877
we	O	878-880
found	O	881-886
significantly	O	887-900
increased	O	901-910
expression	O	911-921
of	O	922-924
miRNA	B	925-930
-	I	930-931
510	I	931-934
(	O	935-936
p	O	936-937
=	O	937-938
0	O	938-939
.	O	939-940
05	O	940-942
)	O	942-943
and	O	944-947
decreased	O	948-957
expression	O	958-968
of	O	969-971
both	O	972-976
miRNA	B	977-982
-	I	982-983
342	I	983-986
(	O	987-988
p	O	988-989
<	O	989-990
0	O	990-991
.	O	991-992
0001	O	992-996
)	O	996-997
and	O	998-1001
miRNA	B	1002-1007
-	I	1007-1008
191	I	1008-1011
(	O	1012-1013
p	O	1013-1014
=	O	1014-1015
0	O	1015-1016
.	O	1016-1017
0079	O	1017-1021
)	O	1021-1022
.	O	1022-1023

When	O	1024-1028
comparing	O	1029-1038
Tregs	O	1039-1044
and	O	1045-1048
T	O	1049-1050
cells	O	1051-1056
,	O	1056-1057
we	O	1058-1060
revealed	O	1061-1069
that	O	1070-1074
Tregs	O	1075-1080
had	O	1081-1084
significant	O	1085-1096
higher	O	1097-1103
expression	O	1104-1114
of	O	1115-1117
miRNA	B	1118-1123
-	I	1123-1124
146a	I	1124-1128
and	O	1129-1132
lower	O	1133-1138
expression	O	1139-1149
of	O	1150-1152
eight	O	1153-1158
specific	O	1159-1167
miRNAs	O	1168-1174
(	O	1175-1176
20b	B	1176-1179
,	O	1179-1180
31	B	1181-1183
,	O	1183-1184
99a	B	1185-1188
,	O	1188-1189
100	B	1190-1193
,	O	1193-1194
125b	B	1195-1199
,	O	1199-1200
151	B	1201-1204
,	O	1204-1205
335	B	1206-1209
,	O	1209-1210
and	O	1211-1214
365	B	1215-1218
)	O	1218-1219
.	O	1219-1220

To	O	1221-1223
our	O	1224-1227
knowledge	O	1228-1237
,	O	1237-1238
this	O	1239-1243
is	O	1244-1246
the	O	1247-1250
first	O	1251-1256
study	O	1257-1262
demonstrating	O	1263-1276
changes	O	1277-1284
in	O	1285-1287
miRNA	O	1288-1293
expression	O	1294-1304
profiles	O	1305-1313
occurring	O	1314-1323
in	O	1324-1326
Tregs	O	1327-1332
of	O	1333-1335
T1D	O	1336-1339
patients	O	1340-1348
and	O	1349-1352
a	O	1353-1354
miRNAs	O	1355-1361
signature	O	1362-1371
of	O	1372-1374
adult	O	1375-1380
Tregs	O	1381-1386
.	O	1386-1387

MicroRNAs	O	0-9
:	O	9-10
potential	O	11-20
regulators	O	21-31
involved	O	32-40
in	O	41-43
human	O	44-49
anencephaly	O	50-61
.	O	61-62

MicroRNAs	O	63-72
(	O	73-74
miRNAs	O	74-80
)	O	80-81
are	O	82-85
posttranscriptional	O	86-105
regulators	O	106-116
of	O	117-119
messenger	O	120-129
RNA	O	130-133
activity	O	134-142
.	O	142-143

Neural	O	144-150
tube	O	151-155
defects	O	156-163
(	O	164-165
NTDs	O	165-169
)	O	169-170
are	O	171-174
severe	O	175-181
congenital	O	182-192
anomalies	O	193-202
that	O	203-207
substantially	O	208-221
impact	O	222-228
an	O	229-231
infant	O	232-238
'	O	238-239
s	O	239-240
morbidity	O	241-250
and	O	251-254
mortality	O	255-264
.	O	264-265

The	O	266-269
miRNAs	O	270-276
are	O	277-280
known	O	281-286
to	O	287-289
be	O	290-292
dynamically	O	293-304
regulated	O	305-314
during	O	315-321
neurodevelopment	O	322-338
;	O	338-339
their	O	340-345
role	O	346-350
in	O	351-353
human	O	354-359
NTDs	O	360-364
,	O	364-365
however	O	366-373
,	O	373-374
is	O	375-377
still	O	378-383
unknown	O	384-391
.	O	391-392

In	O	393-395
this	O	396-400
study	O	401-406
,	O	406-407
we	O	408-410
show	O	411-415
the	O	416-419
presence	O	420-428
of	O	429-431
a	O	432-433
specific	O	434-442
miRNA	O	443-448
expression	O	449-459
profile	O	460-467
from	O	468-472
tissues	O	473-480
of	O	481-483
fetuses	O	484-491
with	O	492-496
anencephaly	O	497-508
,	O	508-509
one	O	510-513
of	O	514-516
the	O	517-520
most	O	521-525
severe	O	526-532
forms	O	533-538
of	O	539-541
NTDs	O	542-546
.	O	546-547

Furthermore	O	548-559
,	O	559-560
we	O	561-563
map	O	564-567
the	O	568-571
target	O	572-578
genes	O	579-584
of	O	585-587
these	O	588-593
miRNAs	O	594-600
in	O	601-603
the	O	604-607
human	O	608-613
genome	O	614-620
.	O	620-621

In	O	622-624
comparison	O	625-635
to	O	636-638
healthy	O	639-646
human	O	647-652
fetal	O	653-658
brain	O	659-664
tissues	O	665-672
,	O	672-673
tissues	O	674-681
from	O	682-686
fetuses	O	687-694
with	O	695-699
anencephaly	O	700-711
exhibited	O	712-721
97	O	722-724
down	O	725-729
-	O	729-730
regulated	O	730-739
and	O	740-743
116	O	744-747
up	O	748-750
-	O	750-751
regulated	O	751-760
miRNAs	O	761-767
.	O	767-768

The	O	769-772
microarray	O	773-783
findings	O	784-792
were	O	793-797
extended	O	798-806
using	O	807-812
real	O	813-817
-	O	817-818
time	O	818-822
qRT	O	823-826
-	O	826-827
PCR	O	827-830
for	O	831-834
nine	O	835-839
miRNAs	O	840-846
.	O	846-847

Specifically	O	848-860
,	O	860-861
of	O	862-864
these	O	865-870
validated	O	871-880
miRNAs	O	881-887
,	O	887-888
miR	B	889-892
-	I	892-893
126	I	893-896
,	O	896-897
miR	B	898-901
-	I	901-902
198	I	902-905
,	O	905-906
and	O	907-910
miR	B	911-914
-	I	914-915
451	I	915-918
were	O	919-923
up	O	924-926
-	O	926-927
regulated	O	927-936
,	O	936-937
while	O	938-943
miR	B	944-947
-	I	947-948
9	I	948-949
,	O	949-950
miR	B	951-954
-	I	954-955
212	I	955-958
,	O	958-959
miR	B	960-963
-	I	963-964
124	I	964-967
,	O	967-968
miR	B	969-972
-	I	972-973
138	I	973-976
,	O	976-977
and	O	978-981
miR	B	982-985
-	I	985-986
103	I	986-989
/	O	989-990
107	O	990-993
were	O	994-998
down	O	999-1003
-	O	1003-1004
regulated	O	1004-1013
in	O	1014-1016
the	O	1017-1020
tissues	O	1021-1028
of	O	1029-1031
fetuses	O	1032-1039
with	O	1040-1044
anencephaly	O	1045-1056
.	O	1056-1057

A	O	1058-1059
bioinformatic	O	1060-1073
analysis	O	1074-1082
showed	O	1083-1089
881	O	1090-1093
potential	O	1094-1103
target	O	1104-1110
genes	O	1111-1116
that	O	1117-1121
are	O	1122-1125
regulated	O	1126-1135
by	O	1136-1138
the	O	1139-1142
validated	O	1143-1152
miRNAs	O	1153-1159
.	O	1159-1160

Seventy	O	1161-1168
-	O	1168-1169
nine	O	1169-1173
of	O	1174-1176
these	O	1177-1182
potential	O	1183-1192
genes	O	1193-1198
are	O	1199-1202
involved	O	1203-1211
in	O	1212-1214
a	O	1215-1216
protein	O	1217-1224
interaction	O	1225-1236
network	O	1237-1244
.	O	1244-1245

There	O	1246-1251
were	O	1252-1256
6	O	1257-1258
co	O	1259-1261
-	O	1261-1262
occurrence	O	1262-1272
annotations	O	1273-1284
within	O	1285-1291
the	O	1292-1295
GOSlim	O	1296-1302
process	O	1303-1310
and	O	1311-1314
7	O	1315-1316
co	O	1317-1319
-	O	1319-1320
occurrence	O	1320-1330
annotations	O	1331-1342
within	O	1343-1349
the	O	1350-1353
GOSlim	O	1354-1360
function	O	1361-1369
found	O	1370-1375
by	O	1376-1378
GeneCodis	O	1379-1388
2	O	1389-1390
.	O	1390-1391
0	O	1391-1392
.	O	1392-1393

Our	O	1394-1397
results	O	1398-1405
suggest	O	1406-1413
that	O	1414-1418
miRNA	O	1419-1424
dysregulation	O	1425-1438
is	O	1439-1441
possibly	O	1442-1450
involved	O	1451-1459
in	O	1460-1462
the	O	1463-1466
pathogenesis	O	1467-1479
of	O	1480-1482
anencephaly	O	1483-1494
.	O	1494-1495

Acute	O	0-5
liver	O	6-11
injury	O	12-18
upregulates	O	19-30
microRNA	B	31-39
-	I	39-40
491	I	40-43
-	I	43-44
5p	I	44-46
in	O	47-49
mice	O	50-54
,	O	54-55
and	O	56-59
its	O	60-63
overexpression	O	64-78
sensitizes	O	79-89
Hep	O	90-93
G2	O	94-96
cells	O	97-102
for	O	103-106
tumour	O	107-113
necrosis	O	114-122
factor	O	123-129
-	O	129-130
alpha	O	130-135
-	O	135-136
induced	O	136-143
apoptosis	O	144-153
.	O	153-154

BACKGROUND	O	155-165
:	O	165-166
MicroRNAs	O	167-176
(	O	177-178
miRNAs	O	178-184
)	O	184-185
have	O	186-190
emerged	O	191-198
as	O	199-201
novel	O	202-207
genetic	O	208-215
regulators	O	216-226
of	O	227-229
cell	O	230-234
functions	O	235-244
such	O	245-249
as	O	250-252
proliferation	O	253-266
,	O	266-267
apoptosis	O	268-277
and	O	278-281
cancer	O	282-288
.	O	288-289

AIMS	O	290-294
:	O	294-295
The	O	296-299
aim	O	300-303
of	O	304-306
this	O	307-311
study	O	312-317
was	O	318-321
to	O	322-324
evaluate	O	325-333
the	O	334-337
role	O	338-342
of	O	343-345
a	O	346-347
specific	O	348-356
miRNA	O	357-362
in	O	363-365
modulating	O	366-376
hepatic	O	377-384
cell	O	385-389
functions	O	390-399
.	O	399-400

METHODS	O	401-408
:	O	408-409
C57Bl	O	410-415
/	O	415-416
6	O	416-417
mice	O	418-422
were	O	423-427
administered	O	428-440
anti	O	441-445
-	O	445-446
fas	O	446-449
receptor	O	450-458
antibodies	O	459-469
to	O	470-472
induce	O	473-479
liver	O	480-485
cell	O	486-490
apoptosis	O	491-500
.	O	500-501

miRNAs	O	502-508
were	O	509-513
purified	O	514-522
from	O	523-527
the	O	528-531
liver	O	532-537
tissue	O	538-544
and	O	545-548
evaluated	O	549-558
using	O	559-564
an	O	565-567
miRNA	O	568-573
microarray	O	574-584
.	O	584-585

The	O	586-589
role	O	590-594
of	O	595-597
miRNA	B	598-603
-	I	603-604
491	I	604-607
_	I	607-608
5p	I	608-610
,	O	610-611
which	O	612-617
was	O	618-621
overexpressed	O	622-635
in	O	636-638
the	O	639-642
model	O	643-648
,	O	648-649
in	O	650-652
modulating	O	653-663
hepatic	O	664-671
cell	O	672-676
functions	O	677-686
was	O	687-690
evaluated	O	691-700
.	O	700-701

miRNA	B	702-707
-	I	707-708
491	I	708-711
_	I	711-712
5p	I	712-714
was	O	715-718
overexpressed	O	719-732
in	O	733-735
Hep	O	736-739
G2	O	740-742
cells	O	743-748
,	O	748-749
followed	O	750-758
by	O	759-761
the	O	762-765
addition	O	766-774
of	O	775-777
tumour	O	778-784
necrosis	O	785-793
factor	O	794-800
(	O	801-802
TNF	O	802-805
)	O	805-806
-	O	806-807
alpha	O	807-812
,	O	812-813
and	O	814-817
induction	O	818-827
of	O	828-830
apoptosis	O	831-840
as	O	841-843
well	O	844-848
as	O	849-851
genes	O	852-857
involved	O	858-866
in	O	867-869
apoptosis	O	870-879
pathways	O	880-888
were	O	889-893
evaluated	O	894-903
.	O	903-904

The	O	905-908
effect	O	909-915
of	O	916-918
miRNA	B	919-924
-	I	924-925
491	I	925-928
_	I	928-929
5p	I	929-931
target	O	932-938
genes	O	939-944
on	O	945-947
apoptosis	O	948-957
was	O	958-961
also	O	962-966
analysed	O	967-975
by	O	976-978
inhibiting	O	979-989
their	O	990-995
expression	O	996-1006
by	O	1007-1009
siRNA	O	1010-1015
-	O	1015-1016
induced	O	1016-1023
gene	O	1024-1028
silencing	O	1029-1038
.	O	1038-1039

RESULTS	O	1040-1047
:	O	1047-1048
Upregulation	O	1049-1061
of	O	1062-1064
miRNA	B	1065-1070
-	I	1070-1071
491	I	1071-1074
_	I	1074-1075
5p	I	1075-1077
was	O	1078-1081
found	O	1082-1087
in	O	1088-1090
a	O	1091-1092
high	O	1093-1097
-	O	1097-1098
dose	O	1098-1102
anti	O	1103-1107
-	O	1107-1108
fas	O	1108-1111
receptor	O	1112-1120
antibody	O	1121-1129
group	O	1130-1135
.	O	1135-1136

Overexpression	O	1137-1151
of	O	1152-1154
microRNA	B	1155-1163
-	I	1163-1164
491	I	1164-1167
_	I	1167-1168
5p	I	1168-1170
sensitized	O	1171-1181
Hep	O	1182-1185
G2	O	1186-1188
cells	O	1189-1194
for	O	1195-1198
TNF	O	1199-1202
-	O	1202-1203
alpha	O	1203-1208
-	O	1208-1209
induced	O	1209-1216
apoptosis	O	1217-1226
,	O	1226-1227
and	O	1228-1231
also	O	1232-1236
caused	O	1237-1243
an	O	1244-1246
inhibition	O	1247-1257
of	O	1258-1260
alpha	O	1261-1266
-	O	1266-1267
fetoprotein	O	1267-1278
,	O	1278-1279
(	O	1280-1281
AFP	O	1281-1284
)	O	1284-1285
,	O	1285-1286
heat	O	1287-1291
shock	O	1292-1297
protein	O	1298-1305
-	O	1305-1306
90	O	1306-1308
(	O	1309-1310
hsp	O	1310-1313
-	O	1313-1314
90	O	1314-1316
)	O	1316-1317
and	O	1318-1321
nuclear	O	1322-1329
factor	O	1330-1336
-	O	1336-1337
kappaB	O	1337-1343
(	O	1344-1345
NF	O	1345-1347
-	O	1347-1348
kappaB	O	1348-1354
)	O	1354-1355
.	O	1355-1356

Overexpression	O	1357-1371
of	O	1372-1374
miRNA	B	1375-1380
-	I	1380-1381
491	I	1381-1384
_	I	1384-1385
5p	I	1385-1387
or	O	1388-1390
inhibition	O	1391-1401
of	O	1402-1404
AFP	O	1405-1408
and	O	1409-1412
hsp	O	1413-1416
-	O	1416-1417
90	O	1417-1419
resulted	O	1420-1428
in	O	1429-1431
an	O	1432-1434
increased	O	1435-1444
apoptosis	O	1445-1454
in	O	1455-1457
TNF	O	1458-1461
-	O	1461-1462
alpha	O	1462-1467
-	O	1467-1468
treated	O	1468-1475
Hep	O	1476-1479
G2	O	1480-1482
cells	O	1483-1488
.	O	1488-1489

CONCLUSIONS	O	1490-1501
:	O	1501-1502
One	O	1503-1506
of	O	1507-1509
the	O	1510-1513
miRNAs	O	1514-1520
that	O	1521-1525
is	O	1526-1528
associated	O	1529-1539
with	O	1540-1544
the	O	1545-1548
acute	O	1549-1554
liver	O	1555-1560
injury	O	1561-1567
mouse	O	1568-1573
model	O	1574-1579
,	O	1579-1580
miRNA	B	1581-1586
-	I	1586-1587
491	I	1587-1590
_	I	1590-1591
5p	I	1591-1593
,	O	1593-1594
sensitizes	O	1595-1605
Hep	O	1606-1609
G2	O	1610-1612
cells	O	1613-1618
for	O	1619-1622
TNF	O	1623-1626
-	O	1626-1627
alpha	O	1627-1632
-	O	1632-1633
induced	O	1633-1640
apoptosis	O	1641-1650
,	O	1650-1651
at	O	1652-1654
least	O	1655-1660
in	O	1661-1663
part	O	1664-1668
,	O	1668-1669
by	O	1670-1672
inhibiting	O	1673-1683
AFP	O	1684-1687
,	O	1687-1688
hsp	O	1689-1692
-	O	1692-1693
90	O	1693-1695
and	O	1696-1699
NF	O	1700-1702
-	O	1702-1703
kappaB	O	1703-1709
.	O	1709-1710

Accurate	O	0-8
classification	O	9-23
of	O	24-26
non	O	27-30
-	O	30-31
small	O	31-36
cell	O	37-41
lung	O	42-46
carcinoma	O	47-56
using	O	57-62
a	O	63-64
novel	O	65-70
microRNA	O	71-79
-	O	79-80
based	O	80-85
approach	O	86-94
.	O	94-95

PURPOSE	O	96-103
:	O	103-104
Advances	O	105-113
in	O	114-116
targeted	O	117-125
lung	O	126-130
cancer	O	131-137
therapy	O	138-145
now	O	146-149
demand	O	150-156
accurate	O	157-165
classification	O	166-180
of	O	181-183
non	O	184-187
-	O	187-188
small	O	188-193
cell	O	194-198
lung	O	199-203
cancer	O	204-210
(	O	211-212
NSCLC	O	212-217
)	O	217-218
.	O	218-219

MicroRNAs	O	220-229
(	O	230-231
miRNA	O	231-236
)	O	236-237
are	O	238-241
recently	O	242-250
discovered	O	251-261
short	O	262-267
,	O	267-268
noncoding	O	269-278
genes	O	279-284
that	O	285-289
play	O	290-294
essential	O	295-304
roles	O	305-310
in	O	311-313
tissue	O	314-320
differentiation	O	321-336
during	O	337-343
normal	O	344-350
development	O	351-362
and	O	363-366
tumorigenesis	O	367-380
.	O	380-381

For	O	382-385
example	O	386-393
,	O	393-394
hsa	B	395-398
-	I	398-399
miR	I	399-402
-	I	402-403
205	I	403-406
is	O	407-409
a	O	410-411
miRNA	O	412-417
that	O	418-422
is	O	423-425
highly	O	426-432
expressed	O	433-442
in	O	443-445
lung	O	446-450
squamous	O	451-459
cell	O	460-464
carcinomas	O	465-475
(	O	476-477
SqCC	O	477-481
)	O	481-482
but	O	483-486
not	O	487-490
in	O	491-493
lung	O	494-498
adenocarcinomas	O	499-514
.	O	514-515

The	O	516-519
differential	O	520-532
expression	O	533-543
of	O	544-546
miRNAs	O	547-553
could	O	554-559
be	O	560-562
exploited	O	563-572
to	O	573-575
distinguish	O	576-587
these	O	588-593
tumor	O	594-599
types	O	600-605
.	O	605-606

EXPERIMENTAL	O	607-619
DESIGN	O	620-626
:	O	626-627
One	O	628-631
hundred	O	632-639
and	O	640-643
two	O	644-647
resected	O	648-656
NSCLCs	O	657-663
were	O	664-668
classified	O	669-679
as	O	680-682
SqCC	O	683-687
or	O	688-690
adenocarcinoma	O	691-705
based	O	706-711
on	O	712-714
their	O	715-720
histologic	O	721-731
features	O	732-740
and	O	741-744
immunohistochemical	O	745-764
profiles	O	765-773
.	O	773-774

Corresponding	O	775-788
preoperative	O	789-801
biopsies	O	802-810
/	O	810-811
aspirates	O	811-820
that	O	821-825
had	O	826-829
been	O	830-834
originally	O	835-845
diagnosed	O	846-855
as	O	856-858
poorly	O	859-865
differentiated	O	866-880
NSCLCs	O	881-887
were	O	888-892
available	O	893-902
for	O	903-906
21	O	907-909
cases	O	910-915
.	O	915-916

A	O	917-918
quantitative	O	919-931
reverse	O	932-939
transcription	O	940-953
-	O	953-954
PCR	O	954-957
diagnostic	O	958-968
assay	O	969-974
that	O	975-979
measures	O	980-988
the	O	989-992
expression	O	993-1003
level	O	1004-1009
of	O	1010-1012
hsa	B	1013-1016
-	I	1016-1017
miR	I	1017-1020
-	I	1020-1021
205	I	1021-1024
was	O	1025-1028
used	O	1029-1033
to	O	1034-1036
classify	O	1037-1045
the	O	1046-1049
carcinomas	O	1050-1060
as	O	1061-1063
SqCC	O	1064-1068
or	O	1069-1071
adenocarcinoma	O	1072-1086
based	O	1087-1092
solely	O	1093-1099
on	O	1100-1102
expression	O	1103-1113
levels	O	1114-1120
.	O	1120-1121

The	O	1122-1125
two	O	1126-1129
sets	O	1130-1134
of	O	1135-1137
diagnoses	O	1138-1147
were	O	1148-1152
compared	O	1153-1161
.	O	1161-1162

RESULTS	O	1163-1170
:	O	1170-1171
Using	O	1172-1177
standard	O	1178-1186
pathologic	O	1187-1197
methods	O	1198-1205
of	O	1206-1208
classification	O	1209-1223
(	O	1224-1225
i	O	1225-1226
.	O	1226-1227
e	O	1227-1228
.	O	1228-1229
,	O	1229-1230
microscopy	O	1231-1241
and	O	1242-1245
immunohistochemistry	O	1246-1266
)	O	1266-1267
,	O	1267-1268
52	O	1269-1271
resected	O	1272-1280
lung	O	1281-1285
carcinomas	O	1286-1296
were	O	1297-1301
classified	O	1302-1312
as	O	1313-1315
SqCCs	O	1316-1321
and	O	1322-1325
50	O	1326-1328
as	O	1329-1331
adenocarcinomas	O	1332-1347
.	O	1347-1348

There	O	1349-1354
was	O	1355-1358
100	O	1359-1362
%	O	1362-1363
concordance	O	1364-1375
between	O	1376-1383
the	O	1384-1387
diagnoses	O	1388-1397
established	O	1398-1409
by	O	1410-1412
conventional	O	1413-1425
and	O	1426-1429
miRNA	O	1430-1435
-	O	1435-1436
based	O	1436-1441
methods	O	1442-1449
.	O	1449-1450

MiRNA	O	1451-1456
profiling	O	1457-1466
also	O	1467-1471
correctly	O	1472-1481
classified	O	1482-1492
20	O	1493-1495
of	O	1496-1498
the	O	1499-1502
21	O	1503-1505
preoperative	O	1506-1518
biopsy	O	1519-1525
specimens	O	1526-1535
.	O	1535-1536

CONCLUSIONS	O	1537-1548
:	O	1548-1549
MiRNA	O	1550-1555
profiling	O	1556-1565
is	O	1566-1568
a	O	1569-1570
highly	O	1571-1577
reliable	O	1578-1586
strategy	O	1587-1595
for	O	1596-1599
classifying	O	1600-1611
NSCLCs	O	1612-1618
.	O	1618-1619

Indeed	O	1620-1626
,	O	1626-1627
classification	O	1628-1642
is	O	1643-1645
consistently	O	1646-1658
accurate	O	1659-1667
even	O	1668-1672
in	O	1673-1675
small	O	1676-1681
biopsies	O	1682-1690
/	O	1690-1691
aspirates	O	1691-1700
of	O	1701-1703
poorly	O	1704-1710
differentiated	O	1711-1725
tumors	O	1726-1732
.	O	1732-1733

Confirmation	O	1734-1746
of	O	1747-1749
its	O	1750-1753
reliability	O	1754-1765
across	O	1766-1772
the	O	1773-1776
full	O	1777-1781
range	O	1782-1787
of	O	1788-1790
tumor	O	1791-1796
grades	O	1797-1803
and	O	1804-1807
specimen	O	1808-1816
types	O	1817-1822
represents	O	1823-1833
an	O	1834-1836
important	O	1837-1846
step	O	1847-1851
toward	O	1852-1858
broad	O	1859-1864
application	O	1865-1876
.	O	1876-1877

Discovery	O	0-9
of	O	10-12
chicken	O	13-20
microRNAs	O	21-30
associated	O	31-41
with	O	42-46
lipogenesis	O	47-58
and	O	59-62
cell	O	63-67
proliferation	O	68-81
.	O	81-82

The	O	83-86
primary	O	87-94
function	O	95-103
of	O	104-106
microRNA	O	107-115
(	O	116-117
miRNA	O	117-122
,	O	122-123
a	O	124-125
class	O	126-131
of	O	132-134
small	O	135-140
regulatory	O	141-151
RNA	O	152-155
)	O	155-156
is	O	157-159
to	O	160-162
regulate	O	163-171
gene	O	172-176
expression	O	177-187
.	O	187-188

Studies	O	189-196
of	O	197-199
miRNA	O	200-205
in	O	206-208
mammals	O	209-216
suggest	O	217-224
that	O	225-229
many	O	230-234
liver	O	235-240
-	O	240-241
associated	O	241-251
miRNAs	O	252-258
are	O	259-262
expressed	O	263-272
,	O	272-273
with	O	274-278
a	O	279-280
wide	O	281-285
range	O	286-291
of	O	292-294
functions	O	295-304
.	O	304-305

To	O	306-308
characterize	O	309-321
miRNA	O	322-327
expressed	O	328-337
in	O	338-340
the	O	341-344
avian	O	345-350
liver	O	351-356
,	O	356-357
we	O	358-360
created	O	361-368
two	O	369-372
small	O	373-378
RNA	O	379-382
libraries	O	383-392
from	O	393-397
embryonic	O	398-407
chick	O	408-413
livers	O	414-420
at	O	421-423
embryonic	O	424-433
day	O	434-437
(	O	438-439
E	O	439-440
)	O	440-441
15	O	441-443
and	O	444-447
E20	O	448-451
,	O	451-452
a	O	453-454
time	O	455-459
at	O	460-462
which	O	463-468
the	O	469-472
embryo	O	473-479
begins	O	480-486
to	O	487-489
grow	O	490-494
rapidly	O	495-502
and	O	503-506
so	O	507-509
its	O	510-513
energy	O	514-520
demands	O	521-528
increase	O	529-537
.	O	537-538

It	O	539-541
is	O	542-544
of	O	545-547
interest	O	548-556
to	O	557-559
examine	O	560-567
miRNAs	O	568-574
expressed	O	575-584
at	O	585-587
these	O	588-593
developmental	O	594-607
stages	O	608-614
because	O	615-622
miRNAs	O	623-629
involved	O	630-638
in	O	639-641
regulating	O	642-652
metabolic	O	653-662
pathways	O	663-671
and	O	672-675
cell	O	676-680
proliferation	O	681-694
are	O	695-698
likely	O	699-705
to	O	706-708
be	O	709-711
identified	O	712-722
.	O	722-723

The	O	724-727
small	O	728-733
RNA	O	734-737
libraries	O	738-747
were	O	748-752
sequenced	O	753-762
with	O	763-767
454	O	768-771
Life	O	772-776
Sciences	O	777-785
deep	O	786-790
sequencing	O	791-801
.	O	801-802

Of	O	803-805
the	O	806-809
49	O	810-812
,	O	812-813
937	O	813-816
sequences	O	817-826
obtained	O	827-835
,	O	835-836
29	O	837-839
,	O	839-840
390	O	840-843
represented	O	844-855
known	O	856-861
chicken	O	862-869
miRNAs	O	870-876
and	O	877-880
1	O	881-882
,	O	882-883
233	O	883-886
reads	O	887-892
represented	O	893-904
homologous	O	905-915
miRNAs	O	916-922
that	O	923-927
have	O	928-932
not	O	933-936
been	O	937-941
previously	O	942-952
identified	O	953-963
in	O	964-966
chickens	O	967-975
.	O	975-976

Additionally	O	977-989
,	O	989-990
1	O	991-992
,	O	992-993
032	O	993-996
reads	O	997-1002
represented	O	1003-1014
17	O	1015-1017
potential	O	1018-1027
novel	O	1028-1033
miRNAs	O	1034-1040
not	O	1041-1044
previously	O	1045-1055
identified	O	1056-1066
in	O	1067-1069
any	O	1070-1073
species	O	1074-1081
.	O	1081-1082

To	O	1083-1085
further	O	1086-1093
investigate	O	1094-1105
the	O	1106-1109
possible	O	1110-1118
functions	O	1119-1128
of	O	1129-1131
avian	O	1132-1137
liver	O	1138-1143
miRNAs	O	1144-1150
we	O	1151-1153
identified	O	1154-1164
the	O	1165-1168
potential	O	1169-1178
targets	O	1179-1186
of	O	1187-1189
two	O	1190-1193
differentially	O	1194-1208
expressed	O	1209-1218
novel	O	1219-1224
miRNAs	O	1225-1231
,	O	1231-1232
nc	B	1233-1235
-	I	1235-1236
miR	I	1236-1239
-	I	1239-1240
5	I	1240-1241
and	O	1242-1245
nc	B	1246-1248
-	I	1248-1249
miR	I	1249-1252
-	I	1252-1253
33	I	1253-1255
.	O	1255-1256

These	O	1257-1262
two	O	1263-1266
miRNAs	O	1267-1273
were	O	1274-1278
predicted	O	1279-1288
to	O	1289-1291
target	O	1292-1298
metabolic	O	1299-1308
genes	O	1309-1314
,	O	1314-1315
including	O	1316-1325
the	O	1326-1329
lipid	O	1330-1335
metabolism	O	1336-1346
-	O	1346-1347
associated	O	1347-1357
gene	O	1358-1362
fatty	O	1363-1368
acid	O	1369-1373
synthase	O	1374-1382
(	O	1383-1384
FAS	O	1384-1387
)	O	1387-1388
,	O	1388-1389
and	O	1390-1393
genes	O	1394-1399
involved	O	1400-1408
in	O	1409-1411
the	O	1412-1415
control	O	1416-1423
of	O	1424-1426
cell	O	1427-1431
proliferation	O	1432-1445
,	O	1445-1446
such	O	1447-1451
as	O	1452-1454
peroxisome	O	1455-1465
proliferator	O	1466-1478
-	O	1478-1479
activated	O	1479-1488
binding	O	1489-1496
protein	O	1497-1504
(	O	1505-1506
Pparbp	O	1506-1512
)	O	1512-1513
and	O	1514-1517
bone	O	1518-1522
morphogenetic	O	1523-1536
protein	O	1537-1544
4	O	1545-1546
(	O	1547-1548
BMP4	O	1548-1552
)	O	1552-1553
.	O	1553-1554

Our	O	1555-1558
findings	O	1559-1567
demonstrate	O	1568-1579
that	O	1580-1584
a	O	1585-1586
diverse	O	1587-1594
group	O	1595-1600
of	O	1601-1603
miRNAs	O	1604-1610
are	O	1611-1614
expressed	O	1615-1624
in	O	1625-1627
developing	O	1628-1638
avian	O	1639-1644
livers	O	1645-1651
.	O	1651-1652

In	O	1653-1655
addition	O	1656-1664
,	O	1664-1665
some	O	1666-1670
of	O	1671-1673
the	O	1674-1677
identified	O	1678-1688
miRNAs	O	1689-1695
have	O	1696-1700
been	O	1701-1705
suggested	O	1706-1715
to	O	1716-1718
play	O	1719-1723
a	O	1724-1725
key	O	1726-1729
role	O	1730-1734
(	O	1734-1735
s	O	1735-1736
)	O	1736-1737
in	O	1738-1740
regulating	O	1741-1751
metabolic	O	1752-1761
pathways	O	1762-1770
.	O	1770-1771

Targeting	O	0-9
viral	O	10-15
infection	O	16-25
by	O	26-28
microRNA	O	29-37
inhibition	O	38-48
.	O	48-49

An	O	50-52
inhibitor	O	53-62
of	O	63-65
microRNA	B	66-74
-	I	74-75
122	I	75-78
reduces	O	79-86
viral	O	87-92
load	O	93-97
in	O	98-100
chimpanzees	O	101-112
that	O	113-117
are	O	118-121
chronically	O	122-133
infected	O	134-142
with	O	143-147
hepatitis	O	148-157
C	O	158-159
virus	O	160-165
,	O	165-166
suggesting	O	167-177
that	O	178-182
such	O	183-187
an	O	188-190
approach	O	191-199
might	O	200-205
have	O	206-210
therapeutic	O	211-222
potential	O	223-232
in	O	233-235
humans	O	236-242
.	O	242-243

MicroRNA	O	0-8
miR	B	9-12
-	I	12-13
1	I	13-14
is	O	15-17
up	O	18-20
-	O	20-21
regulated	O	21-30
in	O	31-33
remote	O	34-40
myocardium	O	41-51
in	O	52-54
patients	O	55-63
with	O	64-68
myocardial	O	69-79
infarction	O	80-90
.	O	90-91

MicroRNAs	O	92-101
are	O	102-105
small	O	106-111
regulatory	O	112-122
RNA	O	123-126
molecules	O	127-136
that	O	137-141
mediate	O	142-149
regulation	O	150-160
of	O	161-163
gene	O	164-168
expression	O	169-179
,	O	179-180
thus	O	181-185
affecting	O	186-195
a	O	196-197
variety	O	198-205
of	O	206-208
physiological	O	209-222
,	O	222-223
developmental	O	224-237
and	O	238-241
pathological	O	242-254
conditions	O	255-265
.	O	265-266

They	O	267-271
are	O	272-275
believed	O	276-284
to	O	285-287
be	O	288-290
new	O	291-294
promising	O	295-304
therapeutic	O	305-316
targets	O	317-324
.	O	324-325

In	O	326-328
recent	O	329-335
studies	O	336-343
two	O	344-347
muscle	O	348-354
-	O	354-355
specific	O	355-363
microRNAs	O	364-373
were	O	374-378
discovered	O	379-389
to	O	390-392
contribute	O	393-403
to	O	404-406
heart	O	407-412
diseases	O	413-421
and	O	422-425
development	O	426-437
:	O	437-438
miR	B	439-442
-	I	442-443
1	I	443-444
and	O	445-448
miR	B	449-452
-	I	452-453
133	I	453-456
,	O	456-457
but	O	458-461
there	O	462-467
is	O	468-470
little	O	471-477
data	O	478-482
on	O	483-485
their	O	486-491
expression	O	492-502
patterns	O	503-511
in	O	512-514
human	O	515-520
myocardial	O	521-531
infarction	O	532-542
.	O	542-543

We	O	544-546
performed	O	547-556
simultaneous	O	557-569
expression	O	570-580
analysis	O	581-589
of	O	590-592
miR	B	593-596
-	I	596-597
1	I	597-598
,	O	598-599
miR	B	600-603
-	I	603-604
133a	I	604-608
,	O	608-609
miR	B	610-613
-	I	613-614
133b	I	614-618
in	O	619-621
samples	O	622-629
of	O	630-632
infarcted	O	633-642
tissue	O	643-649
and	O	650-653
remote	O	654-660
myocardium	O	661-671
from	O	672-676
twenty	O	677-683
-	O	683-684
four	O	685-689
patients	O	690-698
with	O	699-703
acute	O	704-709
myocardial	O	710-720
infarction	O	721-731
.	O	731-732

MicroRNA	O	733-741
expression	O	742-752
was	O	753-756
analysed	O	757-765
using	O	766-771
quantitative	O	772-784
real	O	785-789
-	O	789-790
time	O	790-794
PCR	O	795-798
and	O	799-802
compared	O	803-811
to	O	812-814
the	O	815-818
expression	O	819-829
patterns	O	830-838
in	O	839-841
myocardium	O	842-852
of	O	853-855
eight	O	856-861
healthy	O	862-869
adults	O	870-876
who	O	877-880
died	O	881-885
in	O	886-888
accidents	O	889-898
.	O	898-899

We	O	900-902
found	O	903-908
~	O	909-910
3	O	910-911
.	O	911-912
8	O	912-913
-	O	913-914
fold	O	914-918
miR	B	919-922
-	I	922-923
1	I	923-924
up	O	925-927
-	O	927-928
regulation	O	928-938
in	O	939-941
remote	O	942-948
myocardium	O	949-959
when	O	960-964
compared	O	965-973
to	O	974-976
infarcted	O	977-986
tissue	O	987-993
or	O	994-996
healthy	O	997-1004
adult	O	1005-1010
hearts	O	1011-1017
.	O	1017-1018

As	O	1019-1021
miR	B	1022-1025
-	I	1025-1026
1	I	1026-1027
has	O	1028-1031
been	O	1032-1036
shown	O	1037-1042
in	O	1043-1045
animal	O	1046-1052
models	O	1053-1059
and	O	1060-1063
clinical	O	1064-1072
studies	O	1073-1080
to	O	1081-1083
contribute	O	1084-1094
to	O	1095-1097
arrhythmogenesis	O	1098-1114
by	O	1115-1117
regulating	O	1118-1128
pacemaker	O	1129-1138
channel	O	1139-1146
genes	O	1147-1152
,	O	1152-1153
our	O	1154-1157
finding	O	1158-1165
of	O	1166-1168
miR	B	1169-1172
-	I	1172-1173
1	I	1173-1174
up	O	1175-1177
-	O	1177-1178
regulation	O	1178-1188
in	O	1189-1191
patients	O	1192-1200
with	O	1201-1205
myocardial	O	1206-1216
infarction	O	1217-1227
indicates	O	1228-1237
that	O	1238-1242
it	O	1243-1245
might	O	1246-1251
be	O	1252-1254
responsible	O	1255-1266
for	O	1267-1270
the	O	1271-1274
higher	O	1275-1281
risk	O	1282-1286
for	O	1287-1290
arrhythmias	O	1291-1302
in	O	1303-1305
these	O	1306-1311
patients	O	1312-1320
.	O	1320-1321

In	O	1322-1324
addition	O	1325-1333
,	O	1333-1334
miR	B	1335-1338
-	I	1338-1339
133a	I	1339-1343
/	O	1343-1344
b	B	1344-1345
down	O	1346-1350
-	O	1350-1351
regulation	O	1351-1361
in	O	1362-1364
infarcted	O	1365-1374
tissue	O	1375-1381
and	O	1382-1385
remote	O	1386-1392
myocardium	O	1393-1403
was	O	1404-1407
observed	O	1408-1416
,	O	1416-1417
indicating	O	1418-1428
miR	B	1429-1432
-	I	1432-1433
133a	I	1433-1437
/	O	1437-1438
b	B	1438-1439
involvement	O	1440-1451
in	O	1452-1454
the	O	1455-1458
heart	O	1459-1464
response	O	1465-1473
to	O	1474-1476
myocardial	O	1477-1487
infarction	O	1488-1498
.	O	1498-1499

We	O	1500-1502
conclude	O	1503-1511
that	O	1512-1516
miR	B	1517-1520
-	I	1520-1521
1	I	1521-1522
and	O	1523-1526
miR	B	1527-1530
-	I	1530-1531
133	I	1531-1534
seem	O	1535-1539
to	O	1540-1542
be	O	1543-1545
important	O	1546-1555
regulators	O	1556-1566
of	O	1567-1569
heart	O	1570-1575
adaptation	O	1576-1586
after	O	1587-1592
ischaemic	O	1593-1602
stress	O	1603-1609
.	O	1609-1610

Network	O	0-7
modeling	O	8-16
identifies	O	17-27
molecular	O	28-37
functions	O	38-47
targeted	O	48-56
by	O	57-59
miR	B	60-63
-	I	63-64
204	I	64-67
to	O	68-70
suppress	O	71-79
head	O	80-84
and	O	85-88
neck	O	89-93
tumor	O	94-99
metastasis	O	100-110
.	O	110-111

Due	O	112-115
to	O	116-118
the	O	119-122
large	O	123-128
number	O	129-135
of	O	136-138
putative	O	139-147
microRNA	O	148-156
gene	O	157-161
targets	O	162-169
predicted	O	170-179
by	O	180-182
sequence	O	183-191
-	O	191-192
alignment	O	192-201
databases	O	202-211
and	O	212-215
the	O	216-219
relative	O	220-228
low	O	229-232
accuracy	O	233-241
of	O	242-244
such	O	245-249
predictions	O	250-261
which	O	262-267
are	O	268-271
conducted	O	272-281
independently	O	282-295
of	O	296-298
biological	O	299-309
context	O	310-317
by	O	318-320
design	O	321-327
,	O	327-328
systematic	O	329-339
experimental	O	340-352
identification	O	353-367
and	O	368-371
validation	O	372-382
of	O	383-385
every	O	386-391
functional	O	392-402
microRNA	O	403-411
target	O	412-418
is	O	419-421
currently	O	422-431
challenging	O	432-443
.	O	443-444

Consequently	O	445-457
,	O	457-458
biological	O	459-469
studies	O	470-477
have	O	478-482
yet	O	483-486
to	O	487-489
identify	O	490-498
,	O	498-499
on	O	500-502
a	O	503-504
genome	O	505-511
scale	O	512-517
,	O	517-518
key	O	519-522
regulatory	O	523-533
networks	O	534-542
perturbed	O	543-552
by	O	553-555
altered	O	556-563
microRNA	O	564-572
functions	O	573-582
in	O	583-585
the	O	586-589
context	O	590-597
of	O	598-600
cancer	O	601-607
.	O	607-608

In	O	609-611
this	O	612-616
report	O	617-623
,	O	623-624
we	O	625-627
demonstrate	O	628-639
for	O	640-643
the	O	644-647
first	O	648-653
time	O	654-658
how	O	659-662
phenotypic	O	663-673
knowledge	O	674-683
of	O	684-686
inheritable	O	687-698
cancer	O	699-705
traits	O	706-712
and	O	713-716
of	O	717-719
risk	O	720-724
factor	O	725-731
loci	O	732-736
can	O	737-740
be	O	741-743
utilized	O	744-752
jointly	O	753-760
with	O	761-765
gene	O	766-770
expression	O	771-781
analysis	O	782-790
to	O	791-793
efficiently	O	794-805
prioritize	O	806-816
deregulated	O	817-828
microRNAs	O	829-838
for	O	839-842
biological	O	843-853
characterization	O	854-870
.	O	870-871

Using	O	872-877
this	O	878-882
approach	O	883-891
we	O	892-894
characterize	O	895-907
miR	B	908-911
-	I	911-912
204	I	912-915
as	O	916-918
a	O	919-920
tumor	O	921-926
suppressor	O	927-937
microRNA	O	938-946
and	O	947-950
uncover	O	951-958
previously	O	959-969
unknown	O	970-977
connections	O	978-989
between	O	990-997
microRNA	O	998-1006
regulation	O	1007-1017
,	O	1017-1018
network	O	1019-1026
topology	O	1027-1035
,	O	1035-1036
and	O	1037-1040
expression	O	1041-1051
dynamics	O	1052-1060
.	O	1060-1061

Specifically	O	1062-1074
,	O	1074-1075
we	O	1076-1078
validate	O	1079-1087
18	O	1088-1090
gene	O	1091-1095
targets	O	1096-1103
of	O	1104-1106
miR	B	1107-1110
-	I	1110-1111
204	I	1111-1114
that	O	1115-1119
show	O	1120-1124
elevated	O	1125-1133
mRNA	O	1134-1138
expression	O	1139-1149
and	O	1150-1153
are	O	1154-1157
enriched	O	1158-1166
in	O	1167-1169
biological	O	1170-1180
processes	O	1181-1190
associated	O	1191-1201
with	O	1202-1206
tumor	O	1207-1212
progression	O	1213-1224
in	O	1225-1227
squamous	O	1228-1236
cell	O	1237-1241
carcinoma	O	1242-1251
of	O	1252-1254
the	O	1255-1258
head	O	1259-1263
and	O	1264-1267
neck	O	1268-1272
(	O	1273-1274
HNSCC	O	1274-1279
)	O	1279-1280
.	O	1280-1281

We	O	1282-1284
further	O	1285-1292
demonstrate	O	1293-1304
the	O	1305-1308
enrichment	O	1309-1319
of	O	1320-1322
bottleneckness	O	1323-1337
,	O	1337-1338
a	O	1339-1340
key	O	1341-1344
molecular	O	1345-1354
network	O	1355-1362
topology	O	1363-1371
,	O	1371-1372
among	O	1373-1378
miR	B	1379-1382
-	I	1382-1383
204	I	1383-1386
gene	O	1387-1391
targets	O	1392-1399
.	O	1399-1400

Restoration	O	1401-1412
of	O	1413-1415
miR	B	1416-1419
-	I	1419-1420
204	I	1420-1423
function	O	1424-1432
in	O	1433-1435
HNSCC	O	1436-1441
cell	O	1442-1446
lines	O	1447-1452
inhibits	O	1453-1461
the	O	1462-1465
expression	O	1466-1476
of	O	1477-1479
its	O	1480-1483
functionally	O	1484-1496
related	O	1497-1504
gene	O	1505-1509
targets	O	1510-1517
,	O	1517-1518
leads	O	1519-1524
to	O	1525-1527
the	O	1528-1531
reduced	O	1532-1539
adhesion	O	1540-1548
,	O	1548-1549
migration	O	1550-1559
and	O	1560-1563
invasion	O	1564-1572
in	O	1573-1575
vitro	O	1576-1581
and	O	1582-1585
attenuates	O	1586-1596
experimental	O	1597-1609
lung	O	1610-1614
metastasis	O	1615-1625
in	O	1626-1628
vivo	O	1629-1633
.	O	1633-1634

As	O	1635-1637
importantly	O	1638-1649
,	O	1649-1650
our	O	1651-1654
investigation	O	1655-1668
also	O	1669-1673
provides	O	1674-1682
experimental	O	1683-1695
evidence	O	1696-1704
linking	O	1705-1712
the	O	1713-1716
function	O	1717-1725
of	O	1726-1728
microRNAs	O	1729-1738
that	O	1739-1743
are	O	1744-1747
located	O	1748-1755
in	O	1756-1758
the	O	1759-1762
cancer	O	1763-1769
-	O	1769-1770
associated	O	1770-1780
genomic	O	1781-1788
regions	O	1789-1796
(	O	1797-1798
CAGRs	O	1798-1803
)	O	1803-1804
to	O	1805-1807
the	O	1808-1811
observed	O	1812-1820
predisposition	O	1821-1835
to	O	1836-1838
human	O	1839-1844
cancers	O	1845-1852
.	O	1852-1853

Specifically	O	1854-1866
,	O	1866-1867
we	O	1868-1870
show	O	1871-1875
miR	B	1876-1879
-	I	1879-1880
204	I	1880-1883
may	O	1884-1887
serve	O	1888-1893
as	O	1894-1896
a	O	1897-1898
tumor	O	1899-1904
suppressor	O	1905-1915
gene	O	1916-1920
at	O	1921-1923
the	O	1924-1927
9q21	O	1928-1932
.	O	1932-1933
1	O	1933-1934
-	O	1934-1935
22	O	1935-1937
.	O	1937-1938
3	O	1938-1939
CAGR	O	1940-1944
locus	O	1945-1950
,	O	1950-1951
a	O	1952-1953
well	O	1954-1958
established	O	1959-1970
risk	O	1971-1975
factor	O	1976-1982
locus	O	1983-1988
in	O	1989-1991
head	O	1992-1996
and	O	1997-2000
neck	O	2001-2005
cancers	O	2006-2013
for	O	2014-2017
which	O	2018-2023
tumor	O	2024-2029
suppressor	O	2030-2040
genes	O	2041-2046
have	O	2047-2051
not	O	2052-2055
been	O	2056-2060
identified	O	2061-2071
.	O	2071-2072

This	O	2073-2077
new	O	2078-2081
strategy	O	2082-2090
that	O	2091-2095
integrates	O	2096-2106
expression	O	2107-2117
profiling	O	2118-2127
,	O	2127-2128
genetics	O	2129-2137
and	O	2138-2141
novel	O	2142-2147
computational	O	2148-2161
biology	O	2162-2169
approaches	O	2170-2180
provides	O	2181-2189
for	O	2190-2193
improved	O	2194-2202
efficiency	O	2203-2213
in	O	2214-2216
characterization	O	2217-2233
and	O	2234-2237
modeling	O	2238-2246
of	O	2247-2249
microRNA	O	2250-2258
functions	O	2259-2268
in	O	2269-2271
cancer	O	2272-2278
as	O	2279-2281
compared	O	2282-2290
to	O	2291-2293
the	O	2294-2297
state	O	2298-2303
of	O	2304-2306
art	O	2307-2310
and	O	2311-2314
is	O	2315-2317
applicable	O	2318-2328
to	O	2329-2331
the	O	2332-2335
investigation	O	2336-2349
of	O	2350-2352
microRNA	O	2353-2361
functions	O	2362-2371
in	O	2372-2374
other	O	2375-2380
biological	O	2381-2391
processes	O	2392-2401
and	O	2402-2405
diseases	O	2406-2414
.	O	2414-2415

Gene	O	0-4
expression	O	5-15
profiling	O	16-25
of	O	26-28
drug	O	29-33
-	O	33-34
resistant	O	34-43
small	O	44-49
cell	O	50-54
lung	O	55-59
cancer	O	60-66
cells	O	67-72
by	O	73-75
combining	O	76-85
microRNA	O	86-94
and	O	95-98
cDNA	O	99-103
expression	O	104-114
analysis	O	115-123
.	O	123-124

MicroRNAs	O	125-134
(	O	135-136
miRNAs	O	136-142
)	O	142-143
are	O	144-147
now	O	148-151
known	O	152-157
to	O	158-160
play	O	161-165
important	O	166-175
roles	O	176-181
in	O	182-184
the	O	185-188
regulation	O	189-199
of	O	200-202
gene	O	203-207
expression	O	208-218
for	O	219-222
developmental	O	223-236
timing	O	237-243
,	O	243-244
cell	O	245-249
proliferation	O	250-263
and	O	264-267
apoptosis	O	268-277
.	O	277-278

Therefore	O	279-288
,	O	288-289
it	O	290-292
is	O	293-295
likely	O	296-302
that	O	303-307
they	O	308-312
also	O	313-317
modulate	O	318-326
sensitivity	O	327-338
and	O	339-342
resistance	O	343-353
to	O	354-356
anti	O	357-361
-	O	361-362
cancer	O	362-368
drugs	O	369-374
.	O	374-375

To	O	376-378
better	O	379-385
understand	O	386-396
the	O	397-400
molecular	O	401-410
mechanisms	O	411-421
of	O	422-424
multidrug	O	425-434
resistance	O	435-445
in	O	446-448
SCLC	O	449-453
and	O	454-457
identify	O	458-466
novel	O	467-472
molecular	O	473-482
markers	O	483-490
,	O	490-491
we	O	492-494
evaluated	O	495-504
the	O	505-508
expression	O	509-519
of	O	520-522
856	O	523-526
miRNAs	O	527-533
and	O	534-537
approximately	O	538-551
22	O	552-554
,	O	554-555
000	O	555-558
genes	O	559-564
using	O	565-570
miRNA	O	571-576
microarray	O	577-587
and	O	588-591
cDNA	O	592-596
microarray	O	597-607
in	O	608-610
cellular	O	611-619
models	O	620-626
of	O	627-629
SCLC	O	630-634
which	O	635-640
were	O	641-645
widely	O	646-652
used	O	653-657
as	O	658-660
sensitive	O	661-670
(	O	671-672
NCI	O	672-675
-	O	675-676
H69	O	676-679
)	O	679-680
and	O	681-684
resistant	O	685-694
cell	O	695-699
lines	O	700-705
(	O	706-707
NCI	O	707-710
-	O	710-711
H69AR	O	711-716
)	O	716-717
to	O	718-720
chemotherapy	O	721-733
.	O	733-734

We	O	735-737
also	O	738-742
analysed	O	743-751
the	O	752-755
correlations	O	756-768
between	O	769-776
miRNA	O	777-782
and	O	783-786
mRNA	O	787-791
expression	O	792-802
patterns	O	803-811
.	O	811-812

Further	O	813-820
studies	O	821-828
were	O	829-833
tested	O	834-840
to	O	841-843
determine	O	844-853
whether	O	854-861
the	O	862-865
differentially	O	866-880
expressed	O	881-890
miRNAs	O	891-897
were	O	898-902
involved	O	903-911
in	O	912-914
multidrug	O	915-924
resistance	O	925-935
in	O	936-938
SCLC	O	939-943
.	O	943-944

Our	O	945-948
results	O	949-956
showed	O	957-963
that	O	964-968
61	O	969-971
miRNAs	O	972-978
are	O	979-982
presented	O	983-992
significantly	O	993-1006
(	O	1007-1008
>	O	1008-1009
3	O	1009-1010
-	O	1010-1011
fold	O	1011-1015
)	O	1015-1016
including	O	1017-1026
up	O	1027-1029
-	O	1029-1030
regulation	O	1030-1040
of	O	1041-1043
24	O	1044-1046
miRNAs	O	1047-1053
and	O	1054-1057
down	O	1058-1062
-	O	1062-1063
regulation	O	1063-1073
of	O	1074-1076
37	O	1077-1079
miRNAs	O	1080-1086
.	O	1086-1087

Among	O	1088-1093
these	O	1094-1099
miRNAs	O	1100-1106
,	O	1106-1107
48	O	1108-1110
of	O	1111-1113
61	O	1114-1116
differentially	O	1117-1131
expressed	O	1132-1141
miRNAs	O	1142-1148
were	O	1149-1153
firstly	O	1154-1161
reported	O	1162-1170
to	O	1171-1173
be	O	1174-1176
closely	O	1177-1184
associated	O	1185-1195
with	O	1196-1200
drug	O	1201-1205
resistance	O	1206-1216
and	O	1217-1220
37	O	1221-1223
.	O	1223-1224
7	O	1224-1225
%	O	1225-1226
(	O	1227-1228
24	O	1228-1230
/	O	1230-1231
61	O	1231-1233
)	O	1233-1234
of	O	1235-1237
miRNA	O	1238-1243
genes	O	1244-1249
were	O	1250-1254
organised	O	1255-1264
as	O	1265-1267
10	O	1268-1270
clusters	O	1271-1279
in	O	1280-1282
total	O	1283-1288
61	O	1289-1291
significantly	O	1292-1305
expressed	O	1306-1315
miRNAs	O	1316-1322
.	O	1322-1323

We	O	1324-1326
also	O	1327-1331
found	O	1332-1337
that	O	1338-1342
only	O	1343-1347
27	O	1348-1350
of	O	1351-1353
69	O	1354-1356
miRNAs	O	1357-1363
were	O	1364-1368
significantly	O	1369-1382
correlated	O	1383-1393
with	O	1394-1398
604	O	1399-1402
of	O	1403-1405
21	O	1406-1408
,	O	1408-1409
522	O	1409-1412
70	O	1413-1415
mRNA	O	1416-1420
transcripts	O	1421-1432
by	O	1433-1435
MAS	O	1436-1439
database	O	1440-1448
.	O	1448-1449

The	O	1450-1453
sensitivity	O	1454-1465
to	O	1466-1468
anti	O	1469-1473
-	O	1473-1474
cancer	O	1474-1480
drugs	O	1481-1486
Cisplatin	O	1487-1496
,	O	1496-1497
Etoposide	O	1498-1507
and	O	1508-1511
Doxorubicin	O	1512-1523
greatly	O	1524-1531
increased	O	1532-1541
or	O	1542-1544
reduced	O	1545-1552
following	O	1553-1562
transfection	O	1563-1575
of	O	1576-1578
the	O	1579-1582
drug	O	1583-1587
-	O	1587-1588
resistant	O	1588-1597
H69AR	O	1598-1603
cells	O	1604-1609
with	O	1610-1614
the	O	1615-1618
mimics	O	1619-1625
or	O	1626-1628
antagomirs	O	1629-1639
of	O	1640-1642
miR	B	1643-1646
-	I	1646-1647
134	I	1647-1650
,	O	1650-1651
miR	B	1652-1655
-	I	1655-1656
379	I	1656-1659
and	O	1660-1663
miR	B	1664-1667
-	I	1667-1668
495	I	1668-1671
,	O	1671-1672
respectively	O	1673-1685
.	O	1685-1686

miR	B	1687-1690
-	I	1690-1691
134	I	1691-1694
increases	O	1695-1704
the	O	1705-1708
cell	O	1709-1713
survival	O	1714-1722
by	O	1723-1725
inducing	O	1726-1734
G1	O	1735-1737
arrest	O	1738-1744
in	O	1745-1747
H69AR	O	1748-1753
cells	O	1754-1759
.	O	1759-1760

MRP1	O	1761-1765
/	O	1765-1766
ABCC1	O	1766-1771
is	O	1772-1774
negatively	O	1775-1785
regulated	O	1786-1795
by	O	1796-1798
miR	B	1799-1802
-	I	1802-1803
134	I	1803-1806
and	O	1807-1810
down	O	1811-1815
-	O	1815-1816
regulation	O	1816-1826
of	O	1827-1829
MRP1	O	1830-1834
/	O	1834-1835
ABCC1	O	1835-1840
at	O	1841-1843
the	O	1844-1847
protein	O	1848-1855
level	O	1856-1861
largely	O	1862-1869
correlates	O	1870-1880
with	O	1881-1885
elevated	O	1886-1894
levels	O	1895-1901
of	O	1902-1904
miR	B	1905-1908
-	I	1908-1909
134	I	1909-1912
in	O	1913-1915
H69AR	O	1916-1921
cells	O	1922-1927
.	O	1927-1928

Our	O	1929-1932
results	O	1933-1940
support	O	1941-1948
for	O	1949-1952
the	O	1953-1956
first	O	1957-1962
time	O	1963-1967
a	O	1968-1969
substantial	O	1970-1981
role	O	1982-1986
for	O	1987-1990
miRNAs	O	1991-1997
in	O	1998-2000
multidrug	O	2001-2010
resistance	O	2011-2021
in	O	2022-2024
SCLC	O	2025-2029
.	O	2029-2030

miR	B	2031-2034
-	I	2034-2035
134	I	2035-2038
could	O	2039-2044
be	O	2045-2047
a	O	2048-2049
causal	O	2050-2056
factor	O	2057-2063
of	O	2064-2066
the	O	2067-2070
down	O	2071-2075
-	O	2075-2076
regulation	O	2076-2086
of	O	2087-2089
MRP1	O	2090-2094
/	O	2094-2095
ABCC1	O	2095-2100
in	O	2101-2103
H69AR	O	2104-2109
cells	O	2110-2115
.	O	2115-2116

These	O	2117-2122
findings	O	2123-2131
provide	O	2132-2139
valuable	O	2140-2148
information	O	2149-2160
for	O	2161-2164
potential	O	2165-2174
utility	O	2175-2182
of	O	2183-2185
these	O	2186-2191
miRNAs	O	2192-2198
as	O	2199-2201
specific	O	2202-2210
diagnostic	O	2211-2221
biomarkers	O	2222-2232
and	O	2233-2236
novel	O	2237-2242
therapeutic	O	2243-2254
approaches	O	2255-2265
for	O	2266-2269
drug	O	2270-2274
resistance	O	2275-2285
of	O	2286-2288
SCLC	O	2289-2293
.	O	2293-2294

MicroRNA	B	0-8
-	I	8-9
155	I	9-12
regulates	O	13-22
cell	O	23-27
survival	O	28-36
,	O	36-37
growth	O	38-44
,	O	44-45
and	O	46-49
chemosensitivity	O	50-66
by	O	67-69
targeting	O	70-79
FOXO3a	O	80-86
in	O	87-89
breast	O	90-96
cancer	O	97-103
.	O	103-104

Breast	O	105-111
cancer	O	112-118
is	O	119-121
the	O	122-125
second	O	126-132
leading	O	133-140
cause	O	141-146
of	O	147-149
cancer	O	150-156
death	O	157-162
in	O	163-165
women	O	166-171
.	O	171-172

Despite	O	173-180
improvement	O	181-192
in	O	193-195
treatment	O	196-205
over	O	206-210
the	O	211-214
past	O	215-219
few	O	220-223
decades	O	224-231
,	O	231-232
there	O	233-238
is	O	239-241
an	O	242-244
urgent	O	245-251
need	O	252-256
for	O	257-260
development	O	261-272
of	O	273-275
targeted	O	276-284
therapies	O	285-294
.	O	294-295

miR	B	296-299
-	I	299-300
155	I	300-303
(	O	304-305
microRNA	B	305-313
-	I	313-314
155	I	314-317
)	O	317-318
is	O	319-321
frequently	O	322-332
up	O	333-335
-	O	335-336
regulated	O	336-345
in	O	346-348
breast	O	349-355
cancer	O	356-362
.	O	362-363

In	O	364-366
this	O	367-371
study	O	372-377
,	O	377-378
we	O	379-381
demonstrate	O	382-393
the	O	394-397
critical	O	398-406
role	O	407-411
of	O	412-414
miR	B	415-418
-	I	418-419
155	I	419-422
in	O	423-425
regulation	O	426-436
of	O	437-439
cell	O	440-444
survival	O	445-453
and	O	454-457
chemosensitivity	O	458-474
through	O	475-482
down	O	483-487
-	O	487-488
regulation	O	488-498
of	O	499-501
FOXO3a	O	502-508
in	O	509-511
breast	O	512-518
cancer	O	519-525
.	O	525-526

Ectopic	O	527-534
expression	O	535-545
of	O	546-548
miR	B	549-552
-	I	552-553
155	I	553-556
induces	O	557-564
cell	O	565-569
survival	O	570-578
and	O	579-582
chemoresistance	O	583-598
to	O	599-601
multiple	O	602-610
agents	O	611-617
,	O	617-618
whereas	O	619-626
knockdown	O	627-636
of	O	637-639
miR	B	640-643
-	I	643-644
155	I	644-647
renders	O	648-655
cells	O	656-661
to	O	662-664
apoptosis	O	665-674
and	O	675-678
enhances	O	679-687
chemosensitivity	O	688-704
.	O	704-705

Further	O	706-713
,	O	713-714
we	O	715-717
identified	O	718-728
FOXO3a	O	729-735
as	O	736-738
a	O	739-740
direct	O	741-747
target	O	748-754
of	O	755-757
miR	B	758-761
-	I	761-762
155	I	762-765
.	O	765-766

Sustained	O	767-776
overexpression	O	777-791
of	O	792-794
miR	B	795-798
-	I	798-799
155	I	799-802
resulted	O	803-811
in	O	812-814
repression	O	815-825
of	O	826-828
FOXO3a	O	829-835
protein	O	836-843
without	O	844-851
changing	O	852-860
mRNA	O	861-865
levels	O	866-872
,	O	872-873
and	O	874-877
knockdown	O	878-887
of	O	888-890
miR	B	891-894
-	I	894-895
155	I	895-898
increases	O	899-908
FOXO3a	O	909-915
.	O	915-916

Introduction	O	917-929
of	O	930-932
FOXO3a	O	933-939
cDNA	O	940-944
lacking	O	945-952
the	O	953-956
3	O	957-958
'	O	958-959
-	O	959-960
untranslated	O	960-972
region	O	973-979
abrogates	O	980-989
miR	B	990-993
-	I	993-994
155	I	994-997
-	O	997-998
induced	O	998-1005
cell	O	1006-1010
survival	O	1011-1019
and	O	1020-1023
chemoresistance	O	1024-1039
.	O	1039-1040

Finally	O	1041-1048
,	O	1048-1049
inverse	O	1050-1057
correlation	O	1058-1069
between	O	1070-1077
miR	B	1078-1081
-	I	1081-1082
155	I	1082-1085
and	O	1086-1089
FOXO3a	O	1090-1096
levels	O	1097-1103
were	O	1104-1108
observed	O	1109-1117
in	O	1118-1120
a	O	1121-1122
panel	O	1123-1128
of	O	1129-1131
breast	O	1132-1138
cancer	O	1139-1145
cell	O	1146-1150
lines	O	1151-1156
and	O	1157-1160
tumors	O	1161-1167
.	O	1167-1168

In	O	1169-1171
conclusion	O	1172-1182
,	O	1182-1183
our	O	1184-1187
study	O	1188-1193
reveals	O	1194-1201
a	O	1202-1203
molecular	O	1204-1213
link	O	1214-1218
between	O	1219-1226
miR	B	1227-1230
-	I	1230-1231
155	I	1231-1234
and	O	1235-1238
FOXO3a	O	1239-1245
and	O	1246-1249
presents	O	1250-1258
evidence	O	1259-1267
that	O	1268-1272
miR	B	1273-1276
-	I	1276-1277
155	I	1277-1280
is	O	1281-1283
a	O	1284-1285
critical	O	1286-1294
therapeutic	O	1295-1306
target	O	1307-1313
in	O	1314-1316
breast	O	1317-1323
cancer	O	1324-1330
.	O	1330-1331

MicroRNA	B	0-8
-	I	8-9
27a	I	9-12
Indirectly	O	13-23
Regulates	O	24-33
Estrogen	O	34-42
Receptor	O	43-51
{	O	52-53
alpha	O	53-58
}	O	58-59
Expression	O	60-70
and	O	71-74
Hormone	O	75-82
Responsiveness	O	83-97
in	O	98-100
MCF	O	101-104
-	O	104-105
7	O	105-106
Breast	O	107-113
Cancer	O	114-120
Cells	O	121-126
.	O	126-127

MicroRNA	B	128-136
-	I	136-137
27a	I	137-140
(	O	141-142
miR	B	142-145
-	I	145-146
27a	I	146-149
)	O	149-150
is	O	151-153
expressed	O	154-163
in	O	164-166
MCF	O	167-170
-	O	170-171
7	O	171-172
breast	O	173-179
cancer	O	180-186
cells	O	187-192
,	O	192-193
and	O	194-197
antisense	O	198-207
miR	B	208-211
-	I	211-212
27a	I	212-215
(	O	216-217
as	O	217-219
-	O	219-220
miR	B	220-223
-	I	223-224
27a	I	224-227
)	O	227-228
induces	O	229-236
ZBTB10	O	237-243
,	O	243-244
a	O	245-246
specificity	O	247-258
protein	O	259-266
(	O	267-268
Sp	O	268-270
)	O	270-271
repressor	O	272-281
.	O	281-282

Both	O	283-287
as	O	288-290
-	O	290-291
miR	B	291-294
-	I	294-295
27a	I	295-298
and	O	299-302
overexpression	O	303-317
of	O	318-320
ZBTB10	O	321-327
decreased	O	328-337
Sp1	O	338-341
,	O	341-342
Sp3	O	343-346
,	O	346-347
and	O	348-351
Sp4	O	352-355
mRNA	O	356-360
and	O	361-364
protein	O	365-372
expression	O	373-383
in	O	384-386
MCF	O	387-390
-	O	390-391
7	O	391-392
cells	O	393-398
,	O	398-399
and	O	400-403
this	O	404-408
was	O	409-412
also	O	413-417
accompanied	O	418-429
by	O	430-432
decreased	O	433-442
levels	O	443-449
of	O	450-452
estrogen	O	453-461
receptor	O	462-470
alpha	O	471-476
(	O	477-478
ERalpha	O	478-485
)	O	485-486
mRNA	O	487-491
and	O	492-495
protein	O	496-503
.	O	503-504

RNA	O	505-508
interference	O	509-521
studies	O	522-529
confirmed	O	530-539
that	O	540-544
basal	O	545-550
expression	O	551-561
of	O	562-564
ERalpha	O	565-572
was	O	573-576
dependent	O	577-586
on	O	587-589
Sp1	O	590-593
but	O	594-597
not	O	598-601
Sp3	O	602-605
or	O	606-608
Sp4	O	609-612
in	O	613-615
MCF	O	616-619
-	O	619-620
7	O	620-621
cells	O	622-627
.	O	627-628

as	O	629-631
-	O	631-632
miR	B	632-635
-	I	635-636
27a	I	636-639
and	O	640-643
overexpression	O	644-658
of	O	659-661
ZBTB10	O	662-668
inhibited	O	669-678
17beta	O	679-685
-	O	685-686
estradiol	O	686-695
(	O	696-697
E2	O	697-699
)	O	699-700
-	O	700-701
induced	O	701-708
transactivation	O	709-724
in	O	725-727
MCF	O	728-731
-	O	731-732
7	O	732-733
cells	O	734-739
,	O	739-740
and	O	741-744
this	O	745-749
was	O	750-753
accompanied	O	754-765
by	O	766-768
decreased	O	769-778
binding	O	779-786
of	O	787-789
Sp	O	790-792
and	O	793-796
ER	O	797-799
proteins	O	800-808
in	O	809-811
cell	O	812-816
lysates	O	817-824
to	O	825-827
oligonucleotides	O	828-844
containing	O	845-855
GC	O	856-858
-	O	858-859
rich	O	859-863
motifs	O	864-870
or	O	871-873
estrogen	O	874-882
-	O	882-883
responsive	O	883-893
elements	O	894-902
,	O	902-903
respectively	O	904-916
.	O	916-917

as	O	918-920
-	O	920-921
miR	B	921-924
-	I	924-925
27a	I	925-928
and	O	929-932
overexpression	O	933-947
of	O	948-950
ZBTB10	O	951-957
arrested	O	958-966
MCF	O	967-970
-	O	970-971
7	O	971-972
cells	O	973-978
in	O	979-981
G	O	982-983
(	O	983-984
0	O	984-985
)	O	985-986
/	O	986-987
G	O	987-988
(	O	988-989
1	O	989-990
)	O	990-991
and	O	992-995
inhibited	O	996-1005
E2	O	1006-1008
-	O	1008-1009
induced	O	1009-1016
G	O	1017-1018
(	O	1018-1019
0	O	1019-1020
)	O	1020-1021
/	O	1021-1022
G	O	1022-1023
(	O	1023-1024
1	O	1024-1025
)	O	1025-1026
to	O	1027-1029
S	O	1030-1031
phase	O	1032-1037
progression	O	1038-1049
.	O	1049-1050

as	O	1051-1053
-	O	1053-1054
miR	B	1054-1057
-	I	1057-1058
27a	I	1058-1061
induced	O	1062-1069
only	O	1070-1074
a	O	1075-1076
minimal	O	1077-1084
increase	O	1085-1093
in	O	1094-1096
Myt	O	1097-1100
-	O	1100-1101
1	O	1101-1102
,	O	1102-1103
another	O	1104-1111
miR	B	1112-1115
-	I	1115-1116
27a	I	1116-1119
regulated	O	1120-1129
gene	O	1130-1134
,	O	1134-1135
and	O	1136-1139
this	O	1140-1144
was	O	1145-1148
not	O	1149-1152
accompanied	O	1153-1164
by	O	1165-1167
Myt	O	1168-1171
-	O	1171-1172
1	O	1172-1173
-	O	1173-1174
dependent	O	1174-1183
G	O	1184-1185
(	O	1185-1186
2	O	1186-1187
)	O	1187-1188
/	O	1188-1189
M	O	1189-1190
arrest	O	1191-1197
as	O	1198-1200
observed	O	1201-1209
previously	O	1210-1220
in	O	1221-1223
ER	O	1224-1226
-	O	1226-1227
negative	O	1227-1235
MDA	O	1236-1239
-	O	1239-1240
MB	O	1240-1242
-	O	1242-1243
231	O	1243-1246
breast	O	1247-1253
cancer	O	1254-1260
cells	O	1261-1266
.	O	1266-1267

Thus	O	1268-1272
,	O	1272-1273
miR	B	1274-1277
-	I	1277-1278
27a	I	1278-1281
indirectly	O	1282-1292
regulates	O	1293-1302
E2	O	1303-1305
-	O	1305-1306
responsiveness	O	1306-1320
in	O	1321-1323
MCF	O	1324-1327
-	O	1327-1328
7	O	1328-1329
cells	O	1330-1335
through	O	1336-1343
suppression	O	1344-1355
of	O	1356-1358
ZBTB10	O	1359-1365
,	O	1365-1366
thereby	O	1367-1374
enhancing	O	1375-1384
expression	O	1385-1395
of	O	1396-1398
ERalpha	O	1399-1406
.	O	1406-1407

MIR	B	0-3
-	I	3-4
23A	I	4-7
microRNA	O	8-16
cluster	O	17-24
inhibits	O	25-33
B	O	34-35
-	O	35-36
cell	O	36-40
development	O	41-52
.	O	52-53

OBJECTIVE	O	54-63
:	O	63-64
The	O	65-68
transcription	O	69-82
factor	O	83-89
PU	O	90-92
.	O	92-93
1	O	93-94
(	O	95-96
encoded	O	96-103
by	O	104-106
Sfpi1	O	107-112
)	O	112-113
promotes	O	114-122
myeloid	O	123-130
differentiation	O	131-146
,	O	146-147
but	O	148-151
it	O	152-154
is	O	155-157
unclear	O	158-165
what	O	166-170
downstream	O	171-181
genes	O	182-187
are	O	188-191
involved	O	192-200
.	O	200-201

Micro	O	202-207
RNAs	O	208-212
(	O	213-214
miRNAs	O	214-220
)	O	220-221
are	O	222-225
a	O	226-227
class	O	228-233
of	O	234-236
small	O	237-242
RNAs	O	243-247
that	O	248-252
regulate	O	253-261
many	O	262-266
cellular	O	267-275
pathways	O	276-284
,	O	284-285
including	O	286-295
proliferation	O	296-309
,	O	309-310
survival	O	311-319
,	O	319-320
and	O	321-324
differentiation	O	325-340
.	O	340-341

The	O	342-345
objective	O	346-355
of	O	356-358
this	O	359-363
study	O	364-369
was	O	370-373
to	O	374-376
identify	O	377-385
miRNAs	O	386-392
downstream	O	393-403
of	O	404-406
PU	O	407-409
.	O	409-410
1	O	410-411
that	O	412-416
regulate	O	417-425
hematopoietic	O	426-439
development	O	440-451
.	O	451-452

MATERIALS	O	453-462
AND	O	463-466
METHODS	O	467-474
:	O	474-475
miRNAs	O	476-482
that	O	483-487
change	O	488-494
expression	O	495-505
in	O	506-508
a	O	509-510
PU	O	511-513
.	O	513-514
1	O	514-515
-	O	515-516
inducible	O	516-525
cell	O	526-530
line	O	531-535
were	O	536-540
identified	O	541-551
with	O	552-556
microarrays	O	557-568
.	O	568-569

The	O	570-573
promoter	O	574-582
for	O	583-586
an	O	587-589
miRNA	O	590-595
cluster	O	596-603
upregulated	O	604-615
by	O	616-618
PU	O	619-621
.	O	621-622
1	O	622-623
induction	O	624-633
was	O	634-637
analyzed	O	638-646
for	O	647-650
PU	O	651-653
.	O	653-654
1	O	654-655
binding	O	656-663
by	O	664-666
electrophoretic	O	667-682
mobility	O	683-691
shift	O	692-697
and	O	698-701
chromatin	O	702-711
immunoprecipitation	O	712-731
assays	O	732-738
.	O	738-739

Retroviral	O	740-750
transduction	O	751-763
of	O	764-766
hematopoietic	O	767-780
progenitors	O	781-792
was	O	793-796
performed	O	797-806
to	O	807-809
evaluate	O	810-818
the	O	819-822
effect	O	823-829
of	O	830-832
miRNA	O	833-838
expression	O	839-849
on	O	850-852
hematopoietic	O	853-866
development	O	867-878
in	O	879-881
vitro	O	882-887
and	O	888-891
in	O	892-894
vivo	O	895-899
.	O	899-900

RESULTS	O	901-908
:	O	908-909
We	O	910-912
identified	O	913-923
an	O	924-926
miRNA	O	927-932
cluster	O	933-940
whose	O	941-946
pri	O	947-950
-	O	950-951
transcript	O	951-961
is	O	962-964
regulated	O	965-974
by	O	975-977
PU	O	978-980
.	O	980-981
1	O	981-982
.	O	982-983

The	O	984-987
pri	O	988-991
-	O	991-992
miRNA	O	992-997
encodes	O	998-1005
three	O	1006-1011
mature	O	1012-1018
miRNAs	O	1019-1025
:	O	1025-1026
miR	B	1027-1030
-	I	1030-1031
23a	I	1031-1034
,	O	1034-1035
miR	B	1036-1039
-	I	1039-1040
27a	I	1040-1043
,	O	1043-1044
and	O	1045-1048
miR	B	1049-1052
-	I	1052-1053
24	I	1053-1055
-	I	1055-1056
2	I	1056-1057
.	O	1057-1058

Each	O	1059-1063
miRNA	O	1064-1069
is	O	1070-1072
more	O	1073-1077
abundant	O	1078-1086
in	O	1087-1089
myeloid	O	1090-1097
cells	O	1098-1103
compared	O	1104-1112
to	O	1113-1115
lymphoid	O	1116-1124
cells	O	1125-1130
.	O	1130-1131

When	O	1132-1136
hematopoietic	O	1137-1150
progenitors	O	1151-1162
expressing	O	1163-1173
the	O	1174-1177
23a	O	1178-1181
cluster	O	1182-1189
miRNAs	O	1190-1196
were	O	1197-1201
cultured	O	1202-1210
in	O	1211-1213
B	O	1214-1215
-	O	1215-1216
cell	O	1216-1220
-	O	1220-1221
promoting	O	1221-1230
conditions	O	1231-1241
,	O	1241-1242
we	O	1243-1245
observed	O	1246-1254
a	O	1255-1256
dramatic	O	1257-1265
decrease	O	1266-1274
in	O	1275-1277
B	O	1278-1279
lymphopoiesis	O	1280-1293
and	O	1294-1297
an	O	1298-1300
increase	O	1301-1309
in	O	1310-1312
myelopoiesis	O	1313-1325
compared	O	1326-1334
to	O	1335-1337
control	O	1338-1345
cultures	O	1346-1354
.	O	1354-1355

In	O	1356-1358
vivo	O	1359-1363
,	O	1363-1364
hematopoietic	O	1365-1378
progenitors	O	1379-1390
expressing	O	1391-1401
the	O	1402-1405
miR	B	1406-1409
-	I	1409-1410
23a	I	1410-1413
cluster	O	1414-1421
generate	O	1422-1430
reduced	O	1431-1438
numbers	O	1439-1446
of	O	1447-1449
B	O	1450-1451
cells	O	1452-1457
compared	O	1458-1466
to	O	1467-1469
control	O	1470-1477
cells	O	1478-1483
.	O	1483-1484

CONCLUSIONS	O	1485-1496
:	O	1496-1497
The	O	1498-1501
miR	B	1502-1505
-	I	1505-1506
23a	I	1506-1509
cluster	O	1510-1517
is	O	1518-1520
a	O	1521-1522
downstream	O	1523-1533
target	O	1534-1540
of	O	1541-1543
PU	O	1544-1546
.	O	1546-1547
1	O	1547-1548
involved	O	1549-1557
in	O	1558-1560
antagonizing	O	1561-1573
lymphoid	O	1574-1582
cell	O	1583-1587
fate	O	1588-1592
acquisition	O	1593-1604
.	O	1604-1605

Although	O	1606-1614
miRNAs	O	1615-1621
have	O	1622-1626
been	O	1627-1631
identified	O	1632-1642
downstream	O	1643-1653
of	O	1654-1656
PU	O	1657-1659
.	O	1659-1660
1	O	1660-1661
in	O	1662-1664
mediating	O	1665-1674
development	O	1675-1686
of	O	1687-1689
monocytes	O	1690-1699
and	O	1700-1703
granulocytes	O	1704-1716
,	O	1716-1717
the	O	1718-1721
23a	O	1722-1725
cluster	O	1726-1733
is	O	1734-1736
the	O	1737-1740
first	O	1741-1746
downstream	O	1747-1757
miRNA	O	1758-1763
target	O	1764-1770
implicated	O	1771-1781
in	O	1782-1784
regulating	O	1785-1795
development	O	1796-1807
of	O	1808-1810
myeloid	O	1811-1818
vs	O	1819-1821
lymphoid	O	1822-1830
cells	O	1831-1836
.	O	1836-1837

Yin	O	0-3
Yang	O	4-8
1	O	9-10
phosphorylation	O	11-26
contributes	O	27-38
to	O	39-41
the	O	42-45
differential	O	46-58
effects	O	59-66
of	O	67-69
mu	O	70-72
-	O	72-73
opioid	O	73-79
receptor	O	80-88
agonists	O	89-97
on	O	98-100
microRNA	B	101-109
-	I	109-110
190	I	110-113
expression	O	114-124
.	O	124-125

Mu	O	126-128
-	O	128-129
opioid	O	129-135
receptor	O	136-144
regulates	O	145-154
microRNA	B	155-163
-	I	163-164
190	I	164-167
(	O	168-169
miR	B	169-172
-	I	172-173
190	I	173-176
)	O	176-177
in	O	178-180
an	O	181-183
agonist	O	184-191
-	O	191-192
dependent	O	192-201
manner	O	202-208
;	O	208-209
fentanyl	O	210-218
,	O	218-219
but	O	220-223
not	O	224-227
morphine	O	228-236
,	O	236-237
decreases	O	238-247
the	O	248-251
miR	B	252-255
-	I	255-256
190	I	256-259
level	O	260-265
in	O	266-268
rat	O	269-272
primary	O	273-280
hippocampal	O	281-292
neuron	O	293-299
cultures	O	300-308
and	O	309-312
in	O	313-315
mouse	O	316-321
hippocampi	O	322-332
.	O	332-333

In	O	334-336
this	O	337-341
study	O	342-347
,	O	347-348
the	O	349-352
correlation	O	353-364
between	O	365-372
the	O	373-376
cellular	O	377-385
content	O	386-393
of	O	394-396
miR	B	397-400
-	I	400-401
190	I	401-404
and	O	405-408
the	O	409-412
mRNA	O	413-417
level	O	418-423
of	O	424-426
its	O	427-430
host	O	431-435
gene	O	436-440
,	O	440-441
talin2	O	442-448
,	O	448-449
suggested	O	450-459
that	O	460-464
fentanyl	O	465-473
decreases	O	474-483
the	O	484-487
miR	B	488-491
-	I	491-492
190	I	492-495
level	O	496-501
by	O	502-504
inhibiting	O	505-515
the	O	516-519
transcription	O	520-533
of	O	534-536
talin2	O	537-543
.	O	543-544

Fentanyl	O	545-553
-	O	553-554
induced	O	554-561
beta	O	562-566
-	O	566-567
arrestin2	O	567-576
-	O	576-577
mediated	O	577-585
ERK	O	586-589
phosphorylation	O	590-605
led	O	606-609
to	O	610-612
the	O	613-616
phosphorylation	O	617-632
of	O	633-635
Yin	O	636-639
Yang	O	640-644
1	O	645-646
(	O	647-648
YY1	O	648-651
)	O	651-652
.	O	652-653

In	O	654-656
addition	O	657-665
,	O	665-666
YY1	O	667-670
phosphorylation	O	671-686
impaired	O	687-695
the	O	696-699
association	O	700-711
of	O	712-714
YY1	O	715-718
with	O	719-723
the	O	724-727
-	O	728-729
208	O	729-732
to	O	733-735
-	O	736-737
200	O	737-740
region	O	741-747
on	O	748-750
the	O	751-754
Talin2	O	755-761
promoter	O	762-770
,	O	770-771
and	O	772-775
this	O	776-780
association	O	781-792
was	O	793-796
essential	O	797-806
for	O	807-810
YY1	O	811-814
to	O	815-817
stimulate	O	818-827
the	O	828-831
transcription	O	832-845
of	O	846-848
talin2	O	849-855
.	O	855-856

Thus	O	857-861
,	O	861-862
fentanyl	O	863-871
decreased	O	872-881
the	O	882-885
transcription	O	886-899
of	O	900-902
talin2	O	903-909
and	O	910-913
subsequently	O	914-926
the	O	927-930
cellular	O	931-939
level	O	940-945
of	O	946-948
miR	B	949-952
-	I	952-953
190	I	953-956
by	O	957-959
inducing	O	960-968
YY1	O	969-972
phosphorylation	O	973-988
.	O	988-989

In	O	990-992
contrast	O	993-1001
,	O	1001-1002
because	O	1003-1010
morphine	O	1011-1019
induces	O	1020-1027
ERK	O	1028-1031
phosphorylation	O	1032-1047
via	O	1048-1051
the	O	1052-1055
protein	O	1056-1063
kinase	O	1064-1070
C	O	1071-1072
pathway	O	1073-1080
,	O	1080-1081
morphine	O	1082-1090
did	O	1091-1094
not	O	1095-1098
induce	O	1099-1105
YY1	O	1106-1109
phosphorylation	O	1110-1125
and	O	1126-1129
had	O	1130-1133
no	O	1134-1136
effect	O	1137-1143
on	O	1144-1146
the	O	1147-1150
transcription	O	1151-1164
of	O	1165-1167
talin2	O	1168-1174
and	O	1175-1178
the	O	1179-1182
cellular	O	1183-1191
content	O	1192-1199
of	O	1200-1202
miR	B	1203-1206
-	I	1206-1207
190	I	1207-1210
.	O	1210-1211

This	O	1212-1216
study	O	1217-1222
therefore	O	1223-1232
delineates	O	1233-1243
a	O	1244-1245
signaling	O	1246-1255
pathway	O	1256-1263
that	O	1264-1268
mediates	O	1269-1277
the	O	1278-1281
effects	O	1282-1289
of	O	1290-1292
fentanyl	O	1293-1301
on	O	1302-1304
miR	B	1305-1308
-	I	1308-1309
190	I	1309-1312
expression	O	1313-1323
.	O	1323-1324

Hypoxia	O	0-7
-	O	7-8
regulated	O	8-17
microRNA	B	18-26
-	I	26-27
210	I	27-30
modulates	O	31-40
mitochondrial	O	41-54
function	O	55-63
and	O	64-67
decreases	O	68-77
ISCU	O	78-82
and	O	83-86
COX10	O	87-92
expression	O	93-103
.	O	103-104

The	O	105-108
mechanisms	O	109-119
of	O	120-122
compromised	O	123-134
mitochondrial	O	135-148
function	O	149-157
under	O	158-163
various	O	164-171
pathological	O	172-184
conditions	O	185-195
,	O	195-196
including	O	197-206
hypoxia	O	207-214
,	O	214-215
remain	O	216-222
largely	O	223-230
unknown	O	231-238
.	O	238-239

Recent	O	240-246
studies	O	247-254
have	O	255-259
shown	O	260-265
that	O	266-270
microRNA	B	271-279
-	I	279-280
210	I	280-283
(	O	284-285
miR	B	285-288
-	I	288-289
210	I	289-292
)	O	292-293
is	O	294-296
induced	O	297-304
by	O	305-307
hypoxia	O	308-315
under	O	316-321
the	O	322-325
regulation	O	326-336
of	O	337-339
hypoxia	O	340-347
-	O	347-348
inducible	O	348-357
factor	O	358-364
-	O	364-365
1alpha	O	365-371
and	O	372-375
has	O	376-379
an	O	380-382
important	O	383-392
role	O	393-397
in	O	398-400
cell	O	401-405
survival	O	406-414
under	O	415-420
hypoxic	O	421-428
microenvironment	O	429-445
.	O	445-446

Hence	O	447-452
,	O	452-453
we	O	454-456
hypothesized	O	457-469
that	O	470-474
miR	B	475-478
-	I	478-479
210	I	479-482
has	O	483-486
a	O	487-488
role	O	489-493
in	O	494-496
regulating	O	497-507
mitochondrial	O	508-521
metabolism	O	522-532
and	O	533-536
investigated	O	537-549
miR	B	550-553
-	I	553-554
210	I	554-557
effects	O	558-565
on	O	566-568
mitochondrial	O	569-582
function	O	583-591
in	O	592-594
cancer	O	595-601
cell	O	602-606
lines	O	607-612
under	O	613-618
normal	O	619-625
and	O	626-629
hypoxic	O	630-637
conditions	O	638-648
.	O	648-649

Our	O	650-653
results	O	654-661
demonstrate	O	662-673
that	O	674-678
miR	B	679-682
-	I	682-683
210	I	683-686
decreases	O	687-696
mitochondrial	O	697-710
function	O	711-719
and	O	720-723
upregulates	O	724-735
the	O	736-739
glycolysis	O	740-750
,	O	750-751
thus	O	752-756
make	O	757-761
cancer	O	762-768
cells	O	769-774
more	O	775-779
sensitive	O	780-789
to	O	790-792
glycolysis	O	793-803
inhibitor	O	804-813
.	O	813-814

miR	B	815-818
-	I	818-819
210	I	819-822
can	O	823-826
also	O	827-831
activate	O	832-840
the	O	841-844
generation	O	845-855
of	O	856-858
reactive	O	859-867
oxygen	O	868-874
species	O	875-882
(	O	883-884
ROS	O	884-887
)	O	887-888
.	O	888-889

ISCU	O	890-894
(	O	895-896
iron	O	896-900
-	O	900-901
sulfur	O	901-907
cluster	O	908-915
scaffold	O	916-924
homolog	O	925-932
)	O	932-933
and	O	934-937
COX10	O	938-943
(	O	944-945
cytochrome	O	945-955
c	O	956-957
oxidase	O	958-965
assembly	O	966-974
protein	O	975-982
)	O	982-983
,	O	983-984
two	O	985-988
important	O	989-998
factors	O	999-1006
of	O	1007-1009
the	O	1010-1013
mitochondria	O	1014-1026
electron	O	1027-1035
transport	O	1036-1045
chain	O	1046-1051
and	O	1052-1055
the	O	1056-1059
tricarboxylic	O	1060-1073
acid	O	1074-1078
cycle	O	1079-1084
have	O	1085-1089
been	O	1090-1094
identified	O	1095-1105
as	O	1106-1108
potential	O	1109-1118
targets	O	1119-1126
of	O	1127-1129
miR	B	1130-1133
-	I	1133-1134
210	I	1134-1137
.	O	1137-1138

The	O	1139-1142
unique	O	1143-1149
means	O	1150-1155
by	O	1156-1158
which	O	1159-1164
miR	B	1165-1168
-	I	1168-1169
210	I	1169-1172
regulates	O	1173-1182
mitochondrial	O	1183-1196
function	O	1197-1205
reveals	O	1206-1213
an	O	1214-1216
miRNA	O	1217-1222
-	O	1222-1223
mediated	O	1223-1231
link	O	1232-1236
between	O	1237-1244
microenvironmental	O	1245-1263
stress	O	1264-1270
,	O	1270-1271
oxidative	O	1272-1281
phosphorylation	O	1282-1297
,	O	1297-1298
ROS	O	1299-1302
and	O	1303-1306
iron	O	1307-1311
homeostasis	O	1312-1323
.	O	1323-1324

Transcriptional	O	0-15
modulation	O	16-26
of	O	27-29
micro	O	30-35
-	O	35-36
RNA	O	36-39
in	O	40-42
human	O	43-48
cells	O	49-54
differing	O	55-64
in	O	65-67
radiation	O	68-77
sensitivity	O	78-89
.	O	89-90

PURPOSE	O	91-98
:	O	98-99
The	O	100-103
molecular	O	104-113
basis	O	114-119
of	O	120-122
gene	O	123-127
regulation	O	128-138
in	O	139-141
cells	O	142-147
exposed	O	148-155
to	O	156-158
ionising	O	159-167
radiation	O	168-177
is	O	178-180
not	O	181-184
fully	O	185-190
understood	O	191-201
.	O	201-202

Gene	O	203-207
regulation	O	208-218
occurs	O	219-225
at	O	226-228
the	O	229-232
transcriptional	O	233-248
and	O	249-252
post	O	253-257
-	O	257-258
transcriptional	O	258-273
levels	O	274-280
.	O	280-281

Recent	O	282-288
studies	O	289-296
have	O	297-301
suggested	O	302-311
that	O	312-316
micro	O	317-322
-	O	322-323
RNA	O	323-326
(	O	327-328
miRNA	O	328-333
)	O	333-334
plays	O	335-340
a	O	341-342
significant	O	343-354
role	O	355-359
at	O	360-362
the	O	363-366
post	O	367-371
-	O	371-372
transcriptional	O	372-387
gene	O	388-392
regulation	O	393-403
.	O	403-404

miRNA	O	405-410
are	O	411-414
a	O	415-416
recently	O	417-425
identified	O	426-436
class	O	437-442
of	O	443-445
RNA	O	446-449
molecules	O	450-459
18	O	460-462
-	O	462-463
24	O	463-465
nucleotides	O	466-477
in	O	478-480
length	O	481-487
that	O	488-492
have	O	493-497
been	O	498-502
shown	O	503-508
to	O	509-511
negatively	O	512-522
regulate	O	523-531
the	O	532-535
stability	O	536-545
or	O	546-548
translation	O	549-560
of	O	561-563
target	O	564-570
messenger	O	571-580
RNA	O	581-584
.	O	584-585

We	O	586-588
hypothesised	O	589-601
that	O	602-606
ionising	O	607-615
radiation	O	616-625
induced	O	626-633
stress	O	634-640
response	O	641-649
is	O	650-652
controlled	O	653-663
in	O	664-666
part	O	667-671
by	O	672-674
miRNA	O	675-680
and	O	681-684
that	O	685-689
a	O	690-691
difference	O	692-702
in	O	703-705
tumour	O	706-712
protein	O	713-720
53	O	721-723
(	O	724-725
p53	O	725-728
)	O	728-729
status	O	730-736
corresponds	O	737-748
with	O	749-753
altered	O	754-761
expression	O	762-772
in	O	773-775
miRNA	O	776-781
responses	O	782-791
to	O	792-794
ionising	O	795-803
radiation	O	804-813
.	O	813-814

MATERIALS	O	815-824
AND	O	825-828
METHODS	O	829-836
:	O	836-837
To	O	838-840
test	O	841-845
this	O	846-850
hypothesis	O	851-861
,	O	861-862
we	O	863-865
investigated	O	866-878
the	O	879-882
relative	O	883-891
expression	O	892-902
of	O	903-905
several	O	906-913
miRNA	O	914-919
by	O	920-922
quantitative	O	923-935
real	O	936-940
-	O	940-941
time	O	941-945
polymerase	O	946-956
chain	O	957-962
reaction	O	963-971
(	O	972-973
QPCR	O	973-977
)	O	977-978
in	O	979-981
human	O	982-987
cell	O	988-992
lines	O	993-998
TK6	O	999-1002
and	O	1003-1006
WTK1	O	1007-1011
that	O	1012-1016
differ	O	1017-1023
in	O	1024-1026
p53	O	1027-1030
status	O	1031-1037
and	O	1038-1041
radiosensitivity	O	1042-1058
after	O	1059-1064
exposure	O	1065-1073
to	O	1074-1076
high	O	1077-1081
and	O	1082-1085
low	O	1086-1089
doses	O	1090-1095
of	O	1096-1098
X	O	1099-1100
-	O	1100-1101
radiation	O	1101-1110
.	O	1110-1111

RESULTS	O	1112-1119
:	O	1119-1120
The	O	1121-1124
suitability	O	1125-1136
of	O	1137-1139
several	O	1140-1147
endogenous	O	1148-1158
miRNA	O	1159-1164
controls	O	1165-1173
was	O	1174-1177
tested	O	1178-1184
for	O	1185-1188
relative	O	1189-1197
quantification	O	1198-1212
by	O	1213-1215
QPCR	O	1216-1220
.	O	1220-1221

The	O	1222-1225
baseline	O	1226-1234
expression	O	1235-1245
of	O	1246-1248
21	O	1249-1251
miRNA	O	1252-1257
targets	O	1258-1265
in	O	1266-1268
TK6	O	1269-1272
and	O	1273-1276
WTK1	O	1277-1281
cells	O	1282-1287
indicated	O	1288-1297
a	O	1298-1299
wide	O	1300-1304
range	O	1305-1310
of	O	1311-1313
modulation	O	1314-1324
between	O	1325-1332
the	O	1333-1336
two	O	1337-1340
cell	O	1341-1345
lines	O	1346-1351
without	O	1352-1359
exposure	O	1360-1368
to	O	1369-1371
ionising	O	1372-1380
radiation	O	1381-1390
.	O	1390-1391

Differences	O	1392-1403
in	O	1404-1406
the	O	1407-1410
relative	O	1411-1419
expression	O	1420-1430
of	O	1431-1433
miRNA	O	1434-1439
were	O	1440-1444
observed	O	1445-1453
among	O	1454-1459
the	O	1460-1463
two	O	1464-1467
cell	O	1468-1472
lines	O	1473-1478
after	O	1479-1484
radiation	O	1485-1494
treatment	O	1495-1504
.	O	1504-1505

The	O	1506-1509
expression	O	1510-1520
patterns	O	1521-1529
of	O	1530-1532
many	O	1533-1537
miRNA	O	1538-1543
markedly	O	1544-1552
differed	O	1553-1561
within	O	1562-1568
the	O	1569-1572
same	O	1573-1577
cell	O	1578-1582
line	O	1583-1587
after	O	1588-1593
exposure	O	1594-1602
to	O	1603-1605
either	O	1606-1612
0	O	1613-1614
.	O	1614-1615
5	O	1615-1616
Gy	O	1617-1619
or	O	1620-1622
2	O	1623-1624
Gy	O	1625-1627
doses	O	1628-1633
of	O	1634-1636
X	O	1637-1638
-	O	1638-1639
rays	O	1639-1643
.	O	1643-1644

The	O	1645-1648
expression	O	1649-1659
of	O	1660-1662
eight	O	1663-1668
miRNA	O	1669-1674
belonging	O	1675-1684
to	O	1685-1687
the	O	1688-1691
lethal	B	1692-1698
-	I	1698-1699
7	I	1699-1700
(	O	1701-1702
let	B	1702-1705
-	I	1705-1706
7	I	1706-1707
)	O	1707-1708
family	O	1709-1715
,	O	1715-1716
which	O	1717-1722
are	O	1723-1726
negative	O	1727-1735
regulators	O	1736-1746
of	O	1747-1749
the	O	1750-1753
rat	O	1754-1757
sarcoma	O	1758-1765
,	O	1765-1766
RAS	O	1767-1770
oncogene	O	1771-1779
,	O	1779-1780
was	O	1781-1784
upregulated	O	1785-1796
in	O	1797-1799
irradiated	O	1800-1810
TK6	O	1811-1814
cells	O	1815-1820
but	O	1821-1824
was	O	1825-1828
downregulated	O	1829-1842
in	O	1843-1845
WTK1	O	1846-1850
cells	O	1851-1856
.	O	1856-1857

Alterations	O	1858-1869
in	O	1870-1872
the	O	1873-1876
myelocytomatosis	O	1877-1893
oncogene	O	1894-1902
,	O	1902-1903
c	O	1904-1905
-	O	1905-1906
MYC	O	1906-1909
induced	O	1910-1917
cluster	O	1918-1925
of	O	1926-1928
miRNA	O	1929-1934
were	O	1935-1939
also	O	1940-1944
observed	O	1945-1953
.	O	1953-1954

The	O	1955-1958
micro	O	1959-1964
RNA	O	1965-1968
,	O	1968-1969
miR	B	1970-1973
-	I	1973-1974
15a	I	1974-1977
and	O	1978-1981
miR	B	1982-1985
-	I	1985-1986
16	I	1986-1988
were	O	1989-1993
upregulated	O	1994-2005
in	O	2006-2008
0	O	2009-2010
.	O	2010-2011
5	O	2011-2012
Gy	O	2013-2015
-	O	2015-2016
irradiated	O	2016-2026
TK6	O	2027-2030
cells	O	2031-2036
but	O	2037-2040
were	O	2041-2045
downregulated	O	2046-2059
after	O	2060-2065
a	O	2066-2067
2	O	2068-2069
Gy	O	2070-2072
dose	O	2073-2077
of	O	2078-2080
X	O	2081-2082
-	O	2082-2083
rays	O	2083-2087
.	O	2087-2088

In	O	2089-2091
contrast	O	2092-2100
miR	B	2101-2104
-	I	2104-2105
15	I	2105-2107
and	O	2108-2111
miR	B	2112-2115
-	I	2115-2116
16	I	2116-2118
were	O	2119-2123
repressed	O	2124-2133
in	O	2134-2136
0	O	2137-2138
.	O	2138-2139
5	O	2139-2140
Gy	O	2141-2143
-	O	2143-2144
exposed	O	2144-2151
WTK1	O	2152-2156
.	O	2156-2157

The	O	2158-2161
miR	B	2162-2165
-	I	2165-2166
21	I	2166-2168
was	O	2169-2172
upregulated	O	2173-2184
in	O	2185-2187
0	O	2188-2189
.	O	2189-2190
5	O	2190-2191
Gy	O	2192-2194
-	O	2194-2195
treated	O	2195-2202
TK6	O	2203-2206
cells	O	2207-2212
and	O	2213-2216
its	O	2217-2220
target	O	2221-2227
genes	O	2228-2233
programmed	O	2234-2244
cell	O	2245-2249
death	O	2250-2255
factor	O	2256-2262
4	O	2263-2264
(	O	2265-2266
hPDCD4	O	2266-2272
)	O	2272-2273
phosphatase	O	2274-2285
and	O	2286-2289
tensin	O	2290-2296
homolog	O	2297-2304
(	O	2305-2306
hPTEN	O	2306-2311
)	O	2311-2312
,	O	2312-2313
and	O	2314-2317
sprouty	O	2318-2325
homolog	O	2326-2333
2	O	2334-2335
(	O	2336-2337
hSPRY2	O	2337-2343
)	O	2343-2344
were	O	2345-2349
found	O	2350-2355
to	O	2356-2358
be	O	2359-2361
downregulated	O	2362-2375
in	O	2376-2378
these	O	2379-2384
cells	O	2385-2390
.	O	2390-2391

The	O	2392-2395
miR	B	2396-2399
-	I	2399-2400
21	I	2400-2402
was	O	2403-2406
downregulated	O	2407-2420
in	O	2421-2423
2	O	2424-2425
Gy	O	2426-2428
-	O	2428-2429
irradiated	O	2429-2439
TK6	O	2440-2443
cells	O	2444-2449
,	O	2449-2450
and	O	2451-2454
all	O	2455-2458
three	O	2459-2464
of	O	2465-2467
its	O	2468-2471
target	O	2472-2478
genes	O	2479-2484
were	O	2485-2489
upregulated	O	2490-2501
in	O	2502-2504
2	O	2505-2506
Gy	O	2507-2509
-	O	2509-2510
exposed	O	2510-2517
TK6	O	2518-2521
cells	O	2522-2527
.	O	2527-2528

CONCLUSION	O	2529-2539
:	O	2539-2540
Taken	O	2541-2546
together	O	2547-2555
,	O	2555-2556
these	O	2557-2562
results	O	2563-2570
establish	O	2571-2580
the	O	2581-2584
involvement	O	2585-2596
of	O	2597-2599
miRNA	O	2600-2605
in	O	2606-2608
radiation	O	2609-2618
response	O	2619-2627
and	O	2628-2631
may	O	2632-2635
potentially	O	2636-2647
help	O	2648-2652
explain	O	2653-2660
the	O	2661-2664
mechanisms	O	2665-2675
of	O	2676-2678
gene	O	2679-2683
regulation	O	2684-2694
in	O	2695-2697
the	O	2698-2701
cellular	O	2702-2710
response	O	2711-2719
to	O	2720-2722
ionising	O	2723-2731
radiation	O	2732-2741
exposure	O	2742-2750
.	O	2750-2751

Mammalian	O	0-9
target	O	10-16
of	O	17-19
rapamycin	O	20-29
regulates	O	30-39
miRNA	B	40-45
-	I	45-46
1	I	46-47
and	O	48-51
follistatin	O	52-63
in	O	64-66
skeletal	O	67-75
myogenesis	O	76-86
.	O	86-87

Mammalian	O	88-97
target	O	98-104
of	O	105-107
rapamycin	O	108-117
(	O	118-119
mTOR	O	119-123
)	O	123-124
has	O	125-128
emerged	O	129-136
as	O	137-139
a	O	140-141
key	O	142-145
regulator	O	146-155
of	O	156-158
skeletal	O	159-167
muscle	O	168-174
development	O	175-186
by	O	187-189
governing	O	190-199
distinct	O	200-208
stages	O	209-215
of	O	216-218
myogenesis	O	219-229
,	O	229-230
but	O	231-234
the	O	235-238
molecular	O	239-248
pathways	O	249-257
downstream	O	258-268
of	O	269-271
mTOR	O	272-276
are	O	277-280
not	O	281-284
fully	O	285-290
understood	O	291-301
.	O	301-302

In	O	303-305
this	O	306-310
study	O	311-316
,	O	316-317
we	O	318-320
report	O	321-327
that	O	328-332
expression	O	333-343
of	O	344-346
the	O	347-350
muscle	O	351-357
-	O	357-358
specific	O	358-366
micro	O	367-372
-	O	372-373
RNA	O	373-376
(	O	377-378
miRNA	O	378-383
)	O	383-384
miR	B	385-388
-	I	388-389
1	I	389-390
is	O	391-393
regulated	O	394-403
by	O	404-406
mTOR	O	407-411
both	O	412-416
in	O	417-419
differentiating	O	420-435
myoblasts	O	436-445
and	O	446-449
in	O	450-452
mouse	O	453-458
regenerating	O	459-471
skeletal	O	472-480
muscle	O	481-487
.	O	487-488

We	O	489-491
have	O	492-496
found	O	497-502
that	O	503-507
mTOR	O	508-512
controls	O	513-521
MyoD	O	522-526
-	O	526-527
dependent	O	527-536
transcription	O	537-550
of	O	551-553
miR	B	554-557
-	I	557-558
1	I	558-559
through	O	560-567
its	O	568-571
upstream	O	572-580
enhancer	O	581-589
,	O	589-590
most	O	591-595
likely	O	596-602
by	O	603-605
regulating	O	606-616
MyoD	O	617-621
protein	O	622-629
stability	O	630-639
.	O	639-640

Moreover	O	641-649
,	O	649-650
a	O	651-652
functional	O	653-663
pathway	O	664-671
downstream	O	672-682
of	O	683-685
mTOR	O	686-690
and	O	691-694
miR	B	695-698
-	I	698-699
1	I	699-700
is	O	701-703
delineated	O	704-714
,	O	714-715
in	O	716-718
which	O	719-724
miR	B	725-728
-	I	728-729
1	I	729-730
suppression	O	731-742
of	O	743-745
histone	O	746-753
deacetylase	O	754-765
4	O	766-767
(	O	768-769
HDAC4	O	769-774
)	O	774-775
results	O	776-783
in	O	784-786
production	O	787-797
of	O	798-800
follistatin	O	801-812
and	O	813-816
subsequent	O	817-827
myocyte	O	828-835
fusion	O	836-842
.	O	842-843

Collective	O	844-854
evidence	O	855-863
strongly	O	864-872
suggests	O	873-881
that	O	882-886
follistatin	O	887-898
is	O	899-901
the	O	902-905
long	O	906-910
-	O	910-911
sought	O	911-917
mTOR	O	918-922
-	O	922-923
regulated	O	923-932
fusion	O	933-939
factor	O	940-946
.	O	946-947

In	O	948-950
summary	O	951-958
,	O	958-959
our	O	960-963
findings	O	964-972
unravel	O	973-980
for	O	981-984
the	O	985-988
first	O	989-994
time	O	995-999
a	O	1000-1001
link	O	1002-1006
between	O	1007-1014
mTOR	O	1015-1019
and	O	1020-1023
miRNA	O	1024-1029
biogenesis	O	1030-1040
and	O	1041-1044
identify	O	1045-1053
an	O	1054-1056
mTOR	O	1057-1061
-	O	1061-1062
miR	B	1062-1065
-	I	1065-1066
1	I	1066-1067
-	O	1067-1068
HDAC4	O	1068-1073
-	O	1073-1074
follistatin	O	1074-1085
pathway	O	1086-1093
that	O	1094-1098
regulates	O	1099-1108
myocyte	O	1109-1116
fusion	O	1117-1123
during	O	1124-1130
myoblast	O	1131-1139
differentiation	O	1140-1155
in	O	1156-1158
vitro	O	1159-1164
and	O	1165-1168
skeletal	O	1169-1177
muscle	O	1178-1184
regeneration	O	1185-1197
in	O	1198-1200
vivo	O	1201-1205
.	O	1205-1206

Genome	O	0-6
-	O	6-7
wide	O	7-11
expression	O	12-22
profiling	O	23-32
and	O	33-36
functional	O	37-47
network	O	48-55
analysis	O	56-64
upon	O	65-69
neuroectodermal	O	70-85
conversion	O	86-96
of	O	97-99
human	O	100-105
mesenchymal	O	106-117
stem	O	118-122
cells	O	123-128
suggest	O	129-136
HIF	O	137-140
-	O	140-141
1	O	141-142
and	O	143-146
miR	B	147-150
-	I	150-151
124a	I	151-155
as	O	156-158
important	O	159-168
regulators	O	169-179
.	O	179-180

Tissue	O	181-187
-	O	187-188
specific	O	188-196
stem	O	197-201
cells	O	202-207
,	O	207-208
such	O	209-213
as	O	214-216
bone	O	217-221
-	O	221-222
marrow	O	222-228
-	O	228-229
derived	O	229-236
human	O	237-242
mesenchymal	O	243-254
stem	O	255-259
cells	O	260-265
(	O	266-267
hMSCs	O	267-272
)	O	272-273
,	O	273-274
are	O	275-278
thought	O	279-286
to	O	287-289
be	O	290-292
lineage	O	293-300
restricted	O	301-311
and	O	312-315
therefore	O	316-325
,	O	325-326
could	O	327-332
only	O	333-337
be	O	338-340
differentiated	O	341-355
into	O	356-360
cell	O	361-365
types	O	366-371
of	O	372-374
the	O	375-378
tissue	O	379-385
of	O	386-388
origin	O	389-395
.	O	395-396

Several	O	397-404
recent	O	405-411
studies	O	412-419
however	O	420-427
have	O	428-432
suggested	O	433-442
that	O	443-447
these	O	448-453
types	O	454-459
of	O	460-462
stem	O	463-467
cells	O	468-473
might	O	474-479
be	O	480-482
able	O	483-487
to	O	488-490
break	O	491-496
barriers	O	497-505
of	O	506-508
germ	O	509-513
layer	O	514-519
commitment	O	520-530
and	O	531-534
differentiate	O	535-548
in	O	549-551
vitro	O	552-557
into	O	558-562
cells	O	563-568
with	O	569-573
neuroectodermal	O	574-589
properties	O	590-600
.	O	600-601

We	O	602-604
reported	O	605-613
earlier	O	614-621
about	O	622-627
efficient	O	628-637
conversion	O	638-648
of	O	649-651
adult	O	652-657
hMSCs	O	658-663
into	O	664-668
a	O	669-670
neural	O	671-677
stem	O	678-682
cell	O	683-687
(	O	688-689
NSC	O	689-692
)	O	692-693
-	O	693-694
like	O	694-698
population	O	699-709
(	O	710-711
hmNSCs	O	711-717
,	O	717-718
for	O	719-722
human	O	723-728
marrow	O	729-735
-	O	735-736
derived	O	736-743
NSC	O	744-747
-	O	747-748
like	O	748-752
cells	O	753-758
)	O	758-759
with	O	760-764
all	O	765-768
major	O	769-774
properties	O	775-785
of	O	786-788
NSCs	O	789-793
including	O	794-803
functional	O	804-814
neuronal	O	815-823
differentiation	O	824-839
capacity	O	840-848
.	O	848-849

Here	O	850-854
we	O	855-857
compared	O	858-866
the	O	867-870
transcriptomes	O	871-885
from	O	886-890
hMSCs	O	891-896
and	O	897-900
hmNSCs	O	901-907
using	O	908-913
a	O	914-915
novel	O	916-921
strategy	O	922-930
by	O	931-933
combining	O	934-943
classic	O	944-951
Affymetrix	O	952-962
oligonucleotide	O	963-978
microarray	O	979-989
profiling	O	990-999
with	O	1000-1004
regulatory	O	1005-1015
and	O	1016-1019
protein	O	1020-1027
interaction	O	1028-1039
network	O	1040-1047
analyses	O	1048-1056
to	O	1057-1059
shed	O	1060-1064
light	O	1065-1070
on	O	1071-1073
regulatory	O	1074-1084
protein	O	1085-1092
networks	O	1093-1101
involved	O	1102-1110
in	O	1111-1113
this	O	1114-1118
neuroectodermal	O	1119-1134
conversion	O	1135-1145
process	O	1146-1153
.	O	1153-1154

We	O	1155-1157
found	O	1158-1163
differential	O	1164-1176
regulation	O	1177-1187
of	O	1188-1190
extracellular	O	1191-1204
matrix	O	1205-1211
protein	O	1212-1219
transcripts	O	1220-1231
,	O	1231-1232
up	O	1233-1235
-	O	1235-1236
regulation	O	1236-1246
of	O	1247-1249
distinct	O	1250-1258
neuroectodermal	O	1259-1274
and	O	1275-1278
NSCs	O	1279-1283
marker	O	1284-1290
genes	O	1291-1296
and	O	1297-1300
local	O	1301-1306
chromosomal	O	1307-1318
transcriptional	O	1319-1334
up	O	1335-1337
-	O	1337-1338
regulation	O	1338-1348
at	O	1349-1351
chromosome	O	1352-1362
4q13	O	1363-1367
.	O	1367-1368
3	O	1368-1369
.	O	1369-1370

In	O	1371-1373
comparison	O	1374-1384
to	O	1385-1387
hMSCs	O	1388-1393
and	O	1394-1397
primary	O	1398-1405
adult	O	1406-1411
hippocampal	O	1412-1423
NSCs	O	1424-1428
,	O	1428-1429
the	O	1430-1433
transcriptome	O	1434-1447
of	O	1448-1450
hmNSCs	O	1451-1457
displayed	O	1458-1467
minor	O	1468-1473
overlap	O	1474-1481
with	O	1482-1486
both	O	1487-1491
other	O	1492-1497
cell	O	1498-1502
populations	O	1503-1514
.	O	1514-1515

Advanced	O	1516-1524
bioinformatics	O	1525-1539
of	O	1540-1542
regulated	O	1543-1552
genes	O	1553-1558
upon	O	1559-1563
neuroectodermal	O	1564-1579
conversion	O	1580-1590
identified	O	1591-1601
transcription	O	1602-1615
factor	O	1616-1622
networks	O	1623-1631
with	O	1632-1636
HIF	O	1637-1640
-	O	1640-1641
1	O	1641-1642
and	O	1643-1646
microRNA	O	1647-1655
miR	B	1656-1659
-	I	1659-1660
124a	I	1660-1664
as	O	1665-1667
potential	O	1668-1677
major	O	1678-1683
regulators	O	1684-1694
.	O	1694-1695

Together	O	1696-1704
,	O	1704-1705
transgerminal	O	1706-1719
neuroectodermal	O	1720-1735
conversion	O	1736-1746
of	O	1747-1749
hMSCs	O	1750-1755
into	O	1756-1760
NSC	O	1761-1764
-	O	1764-1765
like	O	1765-1769
cells	O	1770-1775
is	O	1776-1778
accompanied	O	1779-1790
by	O	1791-1793
extensive	O	1794-1803
changes	O	1804-1811
of	O	1812-1814
their	O	1815-1820
global	O	1821-1827
gene	O	1828-1832
expression	O	1833-1843
profile	O	1844-1851
,	O	1851-1852
which	O	1853-1858
might	O	1859-1864
be	O	1865-1867
controlled	O	1868-1878
in	O	1879-1881
part	O	1882-1886
by	O	1887-1889
transcription	O	1890-1903
factor	O	1904-1910
networks	O	1911-1919
related	O	1920-1927
to	O	1928-1930
HIF	O	1931-1934
-	O	1934-1935
1	O	1935-1936
and	O	1937-1940
miR	B	1941-1944
-	I	1944-1945
124a	I	1945-1949
.	O	1949-1950

Curcumin	O	0-8
promotes	O	9-17
apoptosis	O	18-27
in	O	28-30
A549	O	31-35
/	O	35-36
DDP	O	36-39
multidrug	O	40-49
-	O	49-50
resistant	O	50-59
human	O	60-65
lung	O	66-70
adenocarcinoma	O	71-85
cells	O	86-91
through	O	92-99
an	O	100-102
miRNA	O	103-108
signaling	O	109-118
pathway	O	119-126
.	O	126-127

Curcumin	O	128-136
extracted	O	137-146
from	O	147-151
the	O	152-155
rhizomes	O	156-164
of	O	165-167
Curcuma	O	168-175
longa	O	176-181
L	O	182-183
.	O	183-184
has	O	185-188
been	O	189-193
shown	O	194-199
to	O	200-202
have	O	203-207
inhibitory	O	208-218
effects	O	219-226
on	O	227-229
cancers	O	230-237
through	O	238-245
its	O	246-249
anti	O	250-254
-	O	254-255
proliferative	O	255-268
and	O	269-272
pro	O	273-276
-	O	276-277
apoptotic	O	277-286
activities	O	287-297
.	O	297-298

Emerging	O	299-307
evidence	O	308-316
demonstrates	O	317-329
that	O	330-334
curcumin	O	335-343
can	O	344-347
overcome	O	348-356
drug	O	357-361
resistance	O	362-372
to	O	373-375
classical	O	376-385
chemotherapies	O	386-400
.	O	400-401

Thus	O	402-406
,	O	406-407
the	O	408-411
mechanisms	O	412-422
underlying	O	423-433
the	O	434-437
anti	O	438-442
-	O	442-443
tumor	O	443-448
activities	O	449-459
of	O	460-462
curcumin	O	463-471
require	O	472-479
further	O	480-487
study	O	488-493
.	O	493-494

In	O	495-497
our	O	498-501
study	O	502-507
,	O	507-508
we	O	509-511
first	O	512-517
demonstrated	O	518-530
that	O	531-535
curcumin	O	536-544
had	O	545-548
anti	O	549-553
-	O	553-554
cancer	O	554-560
effects	O	561-568
on	O	569-571
A549	O	572-576
/	O	576-577
DDP	O	577-580
multidrug	O	581-590
-	O	590-591
resistant	O	591-600
human	O	601-606
lung	O	607-611
adenocarcinoma	O	612-626
cells	O	627-632
.	O	632-633

Further	O	634-641
studies	O	642-649
showed	O	650-656
that	O	657-661
curcumin	O	662-670
altered	O	671-678
miRNA	O	679-684
expression	O	685-695
;	O	695-696
in	O	697-699
particular	O	700-710
,	O	710-711
significantly	O	712-725
downregulated	O	726-739
the	O	740-743
expression	O	744-754
of	O	755-757
miR	B	758-761
-	I	761-762
186	I	762-765
*	O	766-767
in	O	768-770
A549	O	771-775
/	O	775-776
DDP	O	776-779
.	O	779-780

In	O	781-783
addition	O	784-792
,	O	792-793
transfection	O	794-806
of	O	807-809
cells	O	810-815
with	O	816-820
a	O	821-822
miR	B	823-826
-	I	826-827
186	I	827-830
*	O	831-832
inhibitor	O	833-842
promoted	O	843-851
A549	O	852-856
/	O	856-857
DDP	O	857-860
apoptosis	O	861-870
,	O	870-871
and	O	872-875
overexpression	O	876-890
of	O	891-893
miR	B	894-897
-	I	897-898
186	I	898-901
*	O	902-903
significantly	O	904-917
inhibited	O	918-927
curcumin	O	928-936
-	O	936-937
induced	O	937-944
apoptosis	O	945-954
in	O	955-957
A549	O	958-962
/	O	962-963
DDP	O	963-966
cells	O	967-972
.	O	972-973

These	O	974-979
observations	O	980-992
suggest	O	993-1000
that	O	1001-1005
miR	B	1006-1009
-	I	1009-1010
186	I	1010-1013
*	O	1014-1015
may	O	1016-1019
serve	O	1020-1025
as	O	1026-1028
a	O	1029-1030
potential	O	1031-1040
gene	O	1041-1045
therapy	O	1046-1053
target	O	1054-1060
for	O	1061-1064
refractory	O	1065-1075
lung	O	1076-1080
cancer	O	1081-1087
that	O	1088-1092
is	O	1093-1095
sensitive	O	1096-1105
to	O	1106-1108
curcumin	O	1109-1117
.	O	1117-1118

Altered	O	0-7
miRNA	O	8-13
expression	O	14-24
in	O	25-27
T	O	28-29
regulatory	O	30-40
cells	O	41-46
in	O	47-49
course	O	50-56
of	O	57-59
multiple	O	60-68
sclerosis	O	69-78
.	O	78-79

OBJECTIVES	O	80-90
:	O	90-91
Multiple	O	92-100
sclerosis	O	101-110
(	O	111-112
MS	O	112-114
)	O	114-115
is	O	116-118
a	O	119-120
chronic	O	121-128
inflammatory	O	129-141
response	O	142-150
against	O	151-158
constituents	O	159-171
of	O	172-174
the	O	175-178
central	O	179-186
nervous	O	187-194
system	O	195-201
.	O	201-202

It	O	203-205
is	O	206-208
known	O	209-214
that	O	215-219
regulatory	O	220-230
T	O	231-232
cells	O	233-238
(	O	239-240
Tregs	O	240-245
)	O	245-246
play	O	247-251
a	O	252-253
key	O	254-257
role	O	258-262
in	O	263-265
the	O	266-269
autoimmune	O	270-280
balance	O	281-288
and	O	289-292
their	O	293-298
improper	O	299-307
function	O	308-316
may	O	317-320
facilitate	O	321-331
the	O	332-335
expansion	O	336-345
of	O	346-348
autoaggressive	O	349-363
T	O	364-365
cell	O	366-370
clones	O	371-377
.	O	377-378

Recently	O	379-387
,	O	387-388
microRNAs	O	389-398
(	O	399-400
miRNAs	O	400-406
)	O	406-407
have	O	408-412
been	O	413-417
involved	O	418-426
in	O	427-429
autoimmune	O	430-440
disorders	O	441-450
and	O	451-454
their	O	455-460
loss	O	461-465
-	O	465-466
of	O	466-468
-	O	468-469
function	O	469-477
in	O	478-480
immune	O	481-487
cells	O	488-493
was	O	494-497
shown	O	498-503
to	O	504-506
facilitate	O	507-517
systemic	O	518-526
autoimmune	O	527-537
disorders	O	538-547
.	O	547-548

Here	O	549-553
,	O	553-554
we	O	555-557
analyzed	O	558-566
the	O	567-570
miRNA	O	571-576
expression	O	577-587
profile	O	588-595
in	O	596-598
Tregs	O	599-604
from	O	605-609
MS	O	610-612
-	O	612-613
RR	O	613-615
.	O	615-616

METHODS	O	617-624
:	O	624-625
We	O	626-628
assessed	O	629-637
miRNA	O	638-643
genome	O	644-650
-	O	650-651
wide	O	651-655
expression	O	656-666
profile	O	667-674
by	O	675-677
microarray	O	678-688
analysis	O	689-697
on	O	698-700
CD4	O	701-704
(	O	704-705
+	O	705-706
)	O	706-707
CD25	O	707-711
(	O	711-712
+	O	712-713
high	O	713-717
)	O	717-718
T	O	719-720
cells	O	721-726
from	O	727-731
12	O	732-734
MS	O	735-737
relapsing	O	738-747
-	O	747-748
remitting	O	748-757
patients	O	758-766
in	O	767-769
stable	O	770-776
condition	O	777-786
and	O	787-790
14	O	791-793
healthy	O	794-801
controls	O	802-810
.	O	810-811

Since	O	812-817
CD4	O	818-821
(	O	821-822
+	O	822-823
)	O	823-824
CD25	O	824-828
(	O	828-829
+	O	829-830
high	O	830-834
)	O	834-835
T	O	836-837
cells	O	838-843
comprise	O	844-852
both	O	853-857
T	O	858-859
regulatory	O	860-870
cells	O	871-876
(	O	877-878
CD4	O	878-881
(	O	881-882
+	O	882-883
)	O	883-884
CD25	O	884-888
(	O	888-889
+	O	889-890
high	O	890-894
)	O	894-895
CD127	O	895-900
(	O	900-901
dim	O	901-904
/	O	904-905
-	O	905-906
)	O	906-907
)	O	907-908
and	O	909-912
T	O	913-914
effector	O	915-923
cells	O	924-929
(	O	930-931
CD4	O	931-934
(	O	934-935
+	O	935-936
)	O	936-937
CD25	O	937-941
(	O	941-942
+	O	942-943
high	O	943-947
)	O	947-948
CD127	O	948-953
(	O	953-954
+	O	954-955
)	O	955-956
)	O	956-957
,	O	957-958
we	O	959-961
performed	O	962-971
a	O	972-973
quantitative	O	974-986
RT	O	987-989
-	O	989-990
PCR	O	990-993
on	O	994-996
CD4	O	997-1000
(	O	1000-1001
+	O	1001-1002
)	O	1002-1003
CD25	O	1003-1007
(	O	1007-1008
+	O	1008-1009
high	O	1009-1013
)	O	1013-1014
CD127	O	1014-1019
(	O	1019-1020
dim	O	1020-1023
/	O	1023-1024
-	O	1024-1025
)	O	1025-1026
and	O	1027-1030
CD4	O	1031-1034
(	O	1034-1035
+	O	1035-1036
)	O	1036-1037
CD25	O	1037-1041
(	O	1041-1042
+	O	1042-1043
high	O	1043-1047
)	O	1047-1048
CD127	O	1048-1053
(	O	1053-1054
+	O	1054-1055
)	O	1055-1056
cells	O	1057-1062
isolated	O	1063-1071
from	O	1072-1076
the	O	1077-1080
same	O	1081-1085
blood	O	1086-1091
sample	O	1092-1098
.	O	1098-1099

RESULTS	O	1100-1107
:	O	1107-1108
We	O	1109-1111
found	O	1112-1117
23	O	1118-1120
human	O	1121-1126
miRNAs	O	1127-1133
differentially	O	1134-1148
expressed	O	1149-1158
between	O	1159-1166
CD4	O	1167-1170
(	O	1170-1171
+	O	1171-1172
)	O	1172-1173
CD25	O	1173-1177
(	O	1177-1178
high	O	1178-1182
)	O	1182-1183
bona	O	1183-1187
fide	O	1188-1192
Treg	O	1193-1197
cells	O	1198-1203
from	O	1204-1208
MS	O	1209-1211
patients	O	1212-1220
vs	O	1221-1223
.	O	1223-1224
healthy	O	1225-1232
donors	O	1233-1239
,	O	1239-1240
but	O	1241-1244
,	O	1244-1245
conversely	O	1246-1256
,	O	1256-1257
among	O	1258-1263
the	O	1264-1267
deregulated	O	1268-1279
miRNAs	O	1280-1286
,	O	1286-1287
members	O	1288-1295
of	O	1296-1298
the	O	1299-1302
miR	B	1303-1306
-	I	1306-1307
106b	I	1307-1311
-	I	1311-1312
25	I	1312-1314
were	O	1315-1319
found	O	1320-1325
down	O	1326-1330
-	O	1330-1331
regulated	O	1331-1340
in	O	1341-1343
MS	O	1344-1346
patients	O	1347-1355
when	O	1356-1360
compared	O	1361-1369
to	O	1370-1372
healthy	O	1373-1380
donors	O	1381-1387
in	O	1388-1390
CD4	O	1391-1394
(	O	1394-1395
+	O	1395-1396
)	O	1396-1397
CD25	O	1397-1401
(	O	1401-1402
high	O	1402-1406
)	O	1406-1407
CD127	O	1407-1412
(	O	1412-1413
dim	O	1413-1416
/	O	1416-1417
-	O	1417-1418
)	O	1418-1419
T	O	1420-1421
regulatory	O	1422-1432
cells	O	1433-1438
.	O	1438-1439

More	O	1440-1444
interesting	O	1445-1456
,	O	1456-1457
the	O	1458-1461
ratio	O	1462-1467
between	O	1468-1475
Treg	O	1476-1480
/	O	1480-1481
Teff	O	1481-1485
showed	O	1486-1492
an	O	1493-1495
enrichment	O	1496-1506
of	O	1507-1509
these	O	1510-1515
microRNA	O	1516-1524
in	O	1525-1527
T	O	1528-1529
regulatory	O	1530-1540
cells	O	1541-1546
derived	O	1547-1554
from	O	1555-1559
patients	O	1560-1568
if	O	1569-1571
compared	O	1572-1580
to	O	1581-1583
healthy	O	1584-1591
controls	O	1592-1600
.	O	1600-1601

CONCLUSION	O	1602-1612
:	O	1612-1613
miR	B	1614-1617
-	I	1617-1618
106b	I	1618-1622
and	O	1623-1626
miR	B	1627-1630
-	I	1630-1631
25	I	1631-1633
were	O	1634-1638
previously	O	1639-1649
shown	O	1650-1655
to	O	1656-1658
modulate	O	1659-1667
the	O	1668-1671
TGF	O	1672-1675
-	O	1675-1676
beta	O	1676-1680
signaling	O	1681-1690
pathway	O	1691-1698
through	O	1699-1706
their	O	1707-1712
action	O	1713-1719
on	O	1720-1722
CDKN1A	O	1723-1729
/	O	1729-1730
p21	O	1730-1733
and	O	1734-1737
BCL2L11	O	1738-1745
/	O	1745-1746
Bim	O	1746-1749
.	O	1749-1750

TGF	O	1751-1754
-	O	1754-1755
beta	O	1755-1759
is	O	1760-1762
involved	O	1763-1771
in	O	1772-1774
T	O	1775-1776
regulatory	O	1777-1787
cells	O	1788-1793
differentiation	O	1794-1809
and	O	1810-1813
maturation	O	1814-1824
.	O	1824-1825

Therefore	O	1826-1835
,	O	1835-1836
the	O	1837-1840
deregulation	O	1841-1853
of	O	1854-1856
this	O	1857-1861
miRNA	O	1862-1867
cluster	O	1868-1875
may	O	1876-1879
alter	O	1880-1885
Treg	O	1886-1890
cells	O	1891-1896
activity	O	1897-1905
in	O	1906-1908
course	O	1909-1915
of	O	1916-1918
MS	O	1919-1921
,	O	1921-1922
by	O	1923-1925
altering	O	1926-1934
TGF	O	1935-1938
-	O	1938-1939
beta	O	1939-1943
biological	O	1944-1954
functions	O	1955-1964
.	O	1964-1965

Effect	O	0-6
of	O	7-9
microRNA	O	10-18
modulation	O	19-29
on	O	30-32
bioartificial	O	33-46
muscle	O	47-53
function	O	54-62
.	O	62-63

Cellular	O	64-72
therapies	O	73-82
have	O	83-87
recently	O	88-96
employed	O	97-105
the	O	106-109
use	O	110-113
of	O	114-116
small	O	117-122
RNA	O	123-126
molecules	O	127-136
,	O	136-137
particularly	O	138-150
microRNAs	O	151-160
(	O	161-162
miRNAs	O	162-168
)	O	168-169
,	O	169-170
to	O	171-173
regulate	O	174-182
various	O	183-190
cellular	O	191-199
processes	O	200-209
that	O	210-214
may	O	215-218
be	O	219-221
altered	O	222-229
in	O	230-232
disease	O	233-240
states	O	241-247
.	O	247-248

In	O	249-251
this	O	252-256
study	O	257-262
,	O	262-263
we	O	264-266
examined	O	267-275
the	O	276-279
effect	O	280-286
of	O	287-289
transient	O	290-299
muscle	O	300-306
-	O	306-307
specific	O	307-315
miRNA	O	316-321
inhibition	O	322-332
on	O	333-335
the	O	336-339
function	O	340-348
of	O	349-351
three	O	352-357
-	O	357-358
dimensional	O	358-369
skeletal	O	370-378
muscle	O	379-385
cultures	O	386-394
,	O	394-395
or	O	396-398
bioartificial	O	399-412
muscles	O	413-420
(	O	421-422
BAMs	O	422-426
)	O	426-427
.	O	427-428

Skeletal	O	429-437
myoblast	O	438-446
differentiation	O	447-462
in	O	463-465
vitro	O	466-471
is	O	472-474
enhanced	O	475-483
by	O	484-486
inhibiting	O	487-497
a	O	498-499
proliferation	O	500-513
-	O	513-514
promoting	O	514-523
miRNA	O	524-529
(	O	530-531
miR	B	531-534
-	I	534-535
133	I	535-538
)	O	538-539
expressed	O	540-549
in	O	550-552
muscle	O	553-559
tissues	O	560-567
.	O	567-568

As	O	569-571
assessed	O	572-580
by	O	581-583
functional	O	584-594
force	O	595-600
measurements	O	601-613
in	O	614-616
response	O	617-625
to	O	626-628
electrical	O	629-639
stimulation	O	640-651
at	O	652-654
frequencies	O	655-666
ranging	O	667-674
from	O	675-679
0	O	680-681
to	O	682-684
20	O	685-687
Hz	O	688-690
,	O	690-691
peak	O	692-696
forces	O	697-703
exhibited	O	704-713
by	O	714-716
BAMs	O	717-721
with	O	722-726
miR	B	727-730
-	I	730-731
133	I	731-734
inhibition	O	735-745
(	O	746-747
anti	O	747-751
-	O	751-752
miR	B	752-755
-	I	755-756
133	I	756-759
)	O	759-760
were	O	761-765
on	O	766-768
average	O	769-776
20	O	777-779
%	O	779-780
higher	O	781-787
than	O	788-792
the	O	793-796
corresponding	O	797-810
negative	O	811-819
control	O	820-827
,	O	827-828
although	O	829-837
dynamic	O	838-845
responses	O	846-855
to	O	856-858
electrical	O	859-869
stimulation	O	870-881
in	O	882-884
miRNA	O	885-890
-	O	890-891
transfected	O	891-902
BAMs	O	903-907
and	O	908-911
negative	O	912-920
controls	O	921-929
were	O	930-934
similar	O	935-942
to	O	943-945
nontransfected	O	946-960
controls	O	961-969
.	O	969-970

Immunostaining	O	971-985
for	O	986-989
alpha	O	990-995
-	O	995-996
actinin	O	996-1003
and	O	1004-1007
myosin	O	1008-1014
also	O	1015-1019
showed	O	1020-1026
more	O	1027-1031
distinct	O	1032-1040
striations	O	1041-1051
and	O	1052-1055
myofiber	O	1056-1064
organization	O	1065-1077
in	O	1078-1080
anti	O	1081-1085
-	O	1085-1086
miR	B	1086-1089
-	I	1089-1090
133	I	1090-1093
BAMs	O	1094-1098
,	O	1098-1099
and	O	1100-1103
fiber	O	1104-1109
diameters	O	1110-1119
were	O	1120-1124
significantly	O	1125-1138
larger	O	1139-1145
in	O	1146-1148
these	O	1149-1154
BAMs	O	1155-1159
over	O	1160-1164
both	O	1165-1169
the	O	1170-1173
nontransfected	O	1174-1188
and	O	1189-1192
negative	O	1193-1201
controls	O	1202-1210
.	O	1210-1211

Compared	O	1212-1220
to	O	1221-1223
the	O	1224-1227
negative	O	1228-1236
control	O	1237-1244
,	O	1244-1245
anti	O	1246-1250
-	O	1250-1251
miR	B	1251-1254
-	I	1254-1255
133	I	1255-1258
BAMs	O	1259-1263
exhibited	O	1264-1273
more	O	1274-1278
intense	O	1279-1286
nuclear	O	1287-1294
staining	O	1295-1303
for	O	1304-1307
Mef2	O	1308-1312
,	O	1312-1313
a	O	1314-1315
key	O	1316-1319
myogenic	O	1320-1328
differentiation	O	1329-1344
marker	O	1345-1351
.	O	1351-1352

To	O	1353-1355
our	O	1356-1359
knowledge	O	1360-1369
,	O	1369-1370
this	O	1371-1375
study	O	1376-1381
is	O	1382-1384
the	O	1385-1388
first	O	1389-1394
to	O	1395-1397
demonstrate	O	1398-1409
that	O	1410-1414
miRNA	O	1415-1420
mediation	O	1421-1430
has	O	1431-1434
functional	O	1435-1445
effects	O	1446-1453
on	O	1454-1456
tissue	O	1457-1463
-	O	1463-1464
engineered	O	1464-1474
constructs	O	1475-1485
.	O	1485-1486

MicroRNA	B	0-8
-	I	8-9
125b	I	9-13
suppressesed	O	14-26
human	O	27-32
liver	O	33-38
cancer	O	39-45
cell	O	46-50
proliferation	O	51-64
and	O	65-68
metastasis	O	69-79
by	O	80-82
directly	O	83-91
targeting	O	92-101
oncogene	O	102-110
LIN28B2	O	111-118
.	O	118-119

MicroRNAs	O	120-129
(	O	130-131
miRNAs	O	131-137
)	O	137-138
are	O	139-142
small	O	143-148
,	O	148-149
noncoding	O	150-159
RNAs	O	160-164
that	O	165-169
can	O	170-173
act	O	174-177
as	O	178-180
oncogenes	O	181-190
or	O	191-193
tumor	O	194-199
suppressors	O	200-211
in	O	212-214
human	O	215-220
cancer	O	221-227
.	O	227-228

Our	O	229-232
previous	O	233-241
study	O	242-247
showed	O	248-254
that	O	255-259
miR	B	260-263
-	I	263-264
125b	I	264-268
was	O	269-272
a	O	273-274
prognostic	O	275-285
indicator	O	286-295
for	O	296-299
patients	O	300-308
with	O	309-313
hepatocellular	O	314-328
carcinoma	O	329-338
(	O	339-340
HCC	O	340-343
)	O	343-344
,	O	344-345
but	O	346-349
its	O	350-353
functions	O	354-363
and	O	364-367
exact	O	368-373
mechanisms	O	374-384
in	O	385-387
hepatic	O	388-395
carcinogenesis	O	396-410
are	O	411-414
still	O	415-420
unknown	O	421-428
.	O	428-429

Here	O	430-434
we	O	435-437
demonstrate	O	438-449
that	O	450-454
miR	B	455-458
-	I	458-459
125b	I	459-463
suppressed	O	464-474
HCC	O	475-478
cell	O	479-483
growth	O	484-490
in	O	491-493
vitro	O	494-499
and	O	500-503
in	O	504-506
vivo	O	507-511
.	O	511-512

Moreover	O	513-521
,	O	521-522
miR	B	523-526
-	I	526-527
125b	I	527-531
increased	O	532-541
p21Cip1	O	542-549
/	O	549-550
Waf1	O	550-554
expression	O	555-565
and	O	566-569
arrested	O	570-578
cell	O	579-583
cycle	O	584-589
at	O	590-592
G	O	593-594
(	O	594-595
1	O	595-596
)	O	596-597
to	O	598-600
S	O	601-602
transition	O	603-613
.	O	613-614

In	O	615-617
addition	O	618-626
,	O	626-627
miR	B	628-631
-	I	631-632
125b	I	632-636
inhibited	O	637-646
HCC	O	647-650
cell	O	651-655
migration	O	656-665
and	O	666-669
invasion	O	670-678
.	O	678-679

Further	O	680-687
studies	O	688-695
revealed	O	696-704
that	O	705-709
LIN28B	O	710-716
was	O	717-720
a	O	721-722
downstream	O	723-733
target	O	734-740
of	O	741-743
miR	B	744-747
-	I	747-748
125b	I	748-752
in	O	753-755
HCC	O	756-759
cells	O	760-765
as	O	766-768
miR	B	769-772
-	I	772-773
125b	I	773-777
bound	O	778-783
directly	O	784-792
to	O	793-795
the	O	796-799
3	O	800-801
'	O	801-802
untranslated	O	803-815
region	O	816-822
of	O	823-825
LIN28B	O	826-832
,	O	832-833
thus	O	834-838
reducing	O	839-847
both	O	848-852
the	O	853-856
messenger	O	857-866
RNA	O	867-870
and	O	871-874
protein	O	875-882
levels	O	883-889
of	O	890-892
LIN28B	O	893-899
.	O	899-900

Silencing	O	901-910
of	O	911-913
LIN28B	O	914-920
recapitulated	O	921-934
the	O	935-938
effects	O	939-946
of	O	947-949
miR	B	950-953
-	I	953-954
125b	I	954-958
overexpression	O	959-973
,	O	973-974
whereas	O	975-982
enforced	O	983-991
expression	O	992-1002
of	O	1003-1005
LIN28B	O	1006-1012
reversed	O	1013-1021
the	O	1022-1025
suppressive	O	1026-1037
effects	O	1038-1045
of	O	1046-1048
miR	B	1049-1052
-	I	1052-1053
125b	I	1053-1057
.	O	1057-1058

CONCLUSION	O	1059-1069
:	O	1069-1070
These	O	1071-1076
findings	O	1077-1085
indicate	O	1086-1094
that	O	1095-1099
miR	B	1100-1103
-	I	1103-1104
125b	I	1104-1108
exerts	O	1109-1115
tumor	O	1116-1121
-	O	1121-1122
suppressive	O	1122-1133
effects	O	1134-1141
in	O	1142-1144
hepatic	O	1145-1152
carcinogenesis	O	1153-1167
through	O	1168-1175
the	O	1176-1179
suppression	O	1180-1191
of	O	1192-1194
oncogene	O	1195-1203
LIN28B	O	1204-1210
expression	O	1211-1221
and	O	1222-1225
suggest	O	1226-1233
a	O	1234-1235
therapeutic	O	1236-1247
application	O	1248-1259
of	O	1260-1262
miR	B	1263-1266
-	I	1266-1267
125b	I	1267-1271
in	O	1272-1274
HCC	O	1275-1278
.	O	1278-1279

MicroRNA	O	0-8
in	O	9-11
ischemic	O	12-20
stroke	O	21-27
etiology	O	28-36
and	O	37-40
pathology	O	41-50
.	O	50-51

Small	O	52-57
,	O	57-58
noncoding	O	59-68
,	O	68-69
microRNAs	O	70-79
(	O	80-81
miRNAs	O	81-87
)	O	87-88
have	O	89-93
emerged	O	94-101
as	O	102-104
key	O	105-108
mediators	O	109-118
of	O	119-121
posttranscriptional	O	122-141
gene	O	142-146
silencing	O	147-156
in	O	157-159
both	O	160-164
pathogenic	O	165-175
and	O	176-179
pathological	O	180-192
aspects	O	193-200
of	O	201-203
ischemic	O	204-212
stroke	O	213-219
biology	O	220-227
.	O	227-228

In	O	229-231
stroke	O	232-238
etiology	O	239-247
,	O	247-248
miRNA	O	249-254
have	O	255-259
distinct	O	260-268
expression	O	269-279
patterns	O	280-288
that	O	289-293
modulate	O	294-302
pathogenic	O	303-313
processes	O	314-323
including	O	324-333
atherosclerosis	O	334-349
(	O	350-351
miR	B	351-354
-	I	354-355
21	I	355-357
,	O	357-358
miR	B	359-362
-	I	362-363
126	I	363-366
)	O	366-367
,	O	367-368
hyperlipidemia	O	369-383
(	O	384-385
miR	B	385-388
-	I	388-389
33	I	389-391
,	O	391-392
miR	B	393-396
-	I	396-397
125a	I	397-401
-	I	401-402
5p	I	402-404
)	O	404-405
,	O	405-406
hypertension	O	407-419
(	O	420-421
miR	B	421-424
-	I	424-425
155	I	425-428
)	O	428-429
,	O	429-430
and	O	431-434
plaque	O	435-441
rupture	O	442-449
(	O	450-451
miR	B	451-454
-	I	454-455
222	I	455-458
,	O	458-459
miR	B	460-463
-	I	463-464
210	I	464-467
)	O	467-468
.	O	468-469

Following	O	470-479
focal	O	480-485
cerebral	O	486-494
ischemia	O	495-503
,	O	503-504
significant	O	505-516
changes	O	517-524
in	O	525-527
the	O	528-531
miRNA	O	532-537
transcriptome	O	538-551
,	O	551-552
independent	O	553-564
of	O	565-567
an	O	568-570
effect	O	571-577
on	O	578-580
expression	O	581-591
of	O	592-594
miRNA	O	595-600
machinery	O	601-610
,	O	610-611
implicate	O	612-621
miRNA	O	622-627
in	O	628-630
the	O	631-634
pathological	O	635-647
cascade	O	648-655
of	O	656-658
events	O	659-665
that	O	666-670
include	O	671-678
blood	O	679-684
brain	O	685-690
barrier	O	691-698
disruption	O	699-709
(	O	710-711
miR	B	711-714
-	I	714-715
15a	I	715-718
)	O	718-719
and	O	720-723
caspase	O	724-731
mediated	O	732-740
cell	O	741-745
death	O	746-751
signaling	O	752-761
(	O	762-763
miR	B	763-766
-	I	766-767
497	I	767-770
)	O	770-771
.	O	771-772

Early	O	773-778
activation	O	779-789
of	O	790-792
miR	B	793-796
-	I	796-797
200	I	797-800
family	O	801-807
members	O	808-815
improves	O	816-824
neural	O	825-831
cell	O	832-836
survival	O	837-845
via	O	846-849
prolyl	O	850-856
hydroxylase	O	857-868
mRNA	O	869-873
silencing	O	874-883
and	O	884-887
subsequent	O	888-898
HIF	O	899-902
-	O	902-903
1alpha	O	903-909
stabilization	O	910-923
.	O	923-924

Pro	O	925-928
-	O	928-929
(	O	930-931
miR	B	931-934
-	I	934-935
125b	I	935-939
)	O	939-940
and	O	941-944
anti	O	945-949
-	O	949-950
inflammatory	O	950-962
(	O	963-964
miR	B	964-967
-	I	967-968
26a	I	968-971
,	O	971-972
-	B	973-974
34a	I	974-977
,	O	977-978
-	B	979-980
145	I	980-983
,	O	983-984
and	O	985-988
let	B	989-992
-	I	992-993
7b	I	993-995
)	O	995-996
miRNA	O	997-1002
may	O	1003-1006
also	O	1007-1011
be	O	1012-1014
manipulated	O	1015-1026
to	O	1027-1029
positively	O	1030-1040
influence	O	1041-1050
stroke	O	1051-1057
outcomes	O	1058-1066
.	O	1066-1067

Recent	O	1068-1074
examples	O	1075-1083
of	O	1084-1086
successfully	O	1087-1099
implemented	O	1100-1111
miRNA	O	1112-1117
-	O	1117-1118
therapeutics	O	1118-1130
direct	O	1131-1137
the	O	1138-1141
future	O	1142-1148
of	O	1149-1151
gene	O	1152-1156
therapy	O	1157-1164
and	O	1165-1168
offer	O	1169-1174
new	O	1175-1178
therapeutic	O	1179-1190
strategies	O	1191-1201
by	O	1202-1204
regulating	O	1205-1215
large	O	1216-1221
sets	O	1222-1226
of	O	1227-1229
genes	O	1230-1235
in	O	1236-1238
related	O	1239-1246
pathways	O	1247-1255
of	O	1256-1258
the	O	1259-1262
ischemic	O	1263-1271
stroke	O	1272-1278
cascade	O	1279-1286
.	O	1286-1287

MicroRNA	B	0-8
-	I	8-9
146a	I	9-13
disrupts	O	14-22
hematopoietic	O	23-36
differentiation	O	37-52
and	O	53-56
survival	O	57-65
.	O	65-66

OBJECTIVE	O	67-76
:	O	76-77
MicroRNAs	O	78-87
(	O	88-89
miRNAs	O	89-95
)	O	95-96
are	O	97-100
short	O	101-106
noncoding	O	107-116
RNAs	O	117-121
capable	O	122-129
of	O	130-132
exerting	O	133-141
dramatic	O	142-150
effects	O	151-158
by	O	159-161
postranscriptionally	O	162-182
regulating	O	183-193
numerous	O	194-202
messenger	O	203-212
RNA	O	213-216
targets	O	217-224
.	O	224-225

Toll	O	226-230
-	O	230-231
like	O	231-235
receptor	O	236-244
-	O	244-245
4	O	245-246
(	O	247-248
TLR	O	248-251
-	O	251-252
4	O	252-253
)	O	253-254
activation	O	255-265
by	O	266-268
lipopolysaccharide	O	269-287
(	O	288-289
LPS	O	289-292
)	O	292-293
induces	O	294-301
the	O	302-305
expression	O	306-316
of	O	317-319
three	O	320-325
miRNAs	O	326-332
in	O	333-335
myeloid	O	336-343
cells	O	344-349
.	O	349-350

The	O	351-354
aim	O	355-358
of	O	359-361
this	O	362-366
study	O	367-372
was	O	373-376
to	O	377-379
investigate	O	380-391
the	O	392-395
in	O	396-398
vivo	O	399-403
consequences	O	404-416
of	O	417-419
expressing	O	420-430
one	O	431-434
of	O	435-437
the	O	438-441
LPS	O	442-445
-	O	445-446
induced	O	446-453
miRNA	O	454-459
,	O	459-460
miR	B	461-464
-	I	464-465
146a	I	465-469
,	O	469-470
in	O	471-473
bone	O	474-478
marrow	O	479-485
cells	O	486-491
.	O	491-492

MATERIAL	O	493-501
AND	O	502-505
METHODS	O	506-513
:	O	513-514
The	O	515-518
role	O	519-523
of	O	524-526
miR	B	527-530
-	I	530-531
146a	I	531-535
in	O	536-538
hematopoiesis	O	539-552
was	O	553-556
investigated	O	557-569
by	O	570-572
using	O	573-578
retroviral	O	579-589
infection	O	590-599
and	O	600-603
overexpression	O	604-618
of	O	619-621
miR	B	622-625
-	I	625-626
146a	I	626-630
in	O	631-633
mouse	O	634-639
hematopoietic	O	640-653
stem	O	654-658
/	O	658-659
progenitor	O	659-669
cells	O	670-675
,	O	675-676
followed	O	677-685
by	O	686-688
bone	O	689-693
marrow	O	694-700
transplantations	O	701-717
.	O	717-718

RESULTS	O	719-726
:	O	726-727
miR	B	728-731
-	I	731-732
146a	I	732-736
is	O	737-739
mainly	O	740-746
expressed	O	747-756
in	O	757-759
primitive	O	760-769
hematopoietic	O	770-783
stem	O	784-788
cells	O	789-794
and	O	795-798
T	O	799-800
lymphocytes	O	801-812
.	O	812-813

Overexpression	O	814-828
of	O	829-831
miR	B	832-835
-	I	835-836
146a	I	836-840
in	O	841-843
hematopoietic	O	844-857
stem	O	858-862
cells	O	863-868
,	O	868-869
followed	O	870-878
by	O	879-881
bone	O	882-886
marrow	O	887-893
transplantation	O	894-909
,	O	909-910
resulted	O	911-919
in	O	920-922
a	O	923-924
transient	O	925-934
myeloid	O	935-942
expansion	O	943-952
,	O	952-953
decreased	O	954-963
erythropoiesis	O	964-978
,	O	978-979
and	O	980-983
impaired	O	984-992
lymphopoiesis	O	993-1006
in	O	1007-1009
select	O	1010-1016
anatomical	O	1017-1027
locations	O	1028-1037
.	O	1037-1038

Enforced	O	1039-1047
expression	O	1048-1058
of	O	1059-1061
miR	B	1062-1065
-	I	1065-1066
146a	I	1066-1070
also	O	1071-1075
impaired	O	1076-1084
bone	O	1085-1089
marrow	O	1090-1096
reconstitution	O	1097-1111
in	O	1112-1114
recipient	O	1115-1124
mice	O	1125-1129
and	O	1130-1133
reduced	O	1134-1141
survival	O	1142-1150
of	O	1151-1153
hematopoietic	O	1154-1167
stem	O	1168-1172
cells	O	1173-1178
.	O	1178-1179

CONCLUSIONS	O	1180-1191
:	O	1191-1192
Our	O	1193-1196
results	O	1197-1204
indicate	O	1205-1213
that	O	1214-1218
miR	B	1219-1222
-	I	1222-1223
146a	I	1223-1227
,	O	1227-1228
an	O	1229-1231
LPS	O	1232-1235
-	O	1235-1236
induced	O	1236-1243
miRNA	O	1244-1249
,	O	1249-1250
regulates	O	1251-1260
multiple	O	1261-1269
aspects	O	1270-1277
of	O	1278-1280
hematopoietic	O	1281-1294
differentiation	O	1295-1310
and	O	1311-1314
survival	O	1315-1323
.	O	1323-1324

Furthermore	O	1325-1336
,	O	1336-1337
the	O	1338-1341
consequences	O	1342-1354
of	O	1355-1357
miR	B	1358-1361
-	I	1361-1362
146a	I	1362-1366
expression	O	1367-1377
in	O	1378-1380
hematopoietic	O	1381-1394
cells	O	1395-1400
mimics	O	1401-1407
some	O	1408-1412
of	O	1413-1415
the	O	1416-1419
reported	O	1420-1428
effects	O	1429-1436
with	O	1437-1441
acute	O	1442-1447
LPS	O	1448-1451
exposure	O	1452-1460
.	O	1460-1461

Xenopus	O	0-7
furry	O	8-13
contributes	O	14-25
to	O	26-28
release	O	29-36
of	O	37-39
microRNA	O	40-48
gene	O	49-53
silencing	O	54-63
.	O	63-64

A	O	65-66
transcriptional	O	67-82
corepressor	O	83-94
,	O	94-95
Xenopus	O	96-103
furry	O	104-109
(	O	110-111
Xfurry	O	111-117
)	O	117-118
,	O	118-119
is	O	120-122
expressed	O	123-132
in	O	133-135
the	O	136-139
chordamesodermal	O	140-156
region	O	157-163
and	O	164-167
induces	O	168-175
secondary	O	176-185
dorsal	O	186-192
axes	O	193-197
when	O	198-202
overexpressed	O	203-216
on	O	217-219
the	O	220-223
ventral	O	224-231
side	O	232-236
of	O	237-239
the	O	240-243
embryo	O	244-250
.	O	250-251

The	O	252-255
N	O	256-257
-	O	257-258
terminal	O	258-266
furry	O	267-272
domain	O	273-279
functions	O	280-289
as	O	290-292
a	O	293-294
repressor	O	295-304
,	O	304-305
and	O	306-309
the	O	310-313
C	O	314-315
-	O	315-316
terminal	O	316-324
leucine	O	325-332
zipper	O	333-339
(	O	340-341
LZ	O	341-343
)	O	343-344
motifs	O	345-351
/	O	352-353
coiled	O	353-359
-	O	359-360
coil	O	360-364
structure	O	365-374
,	O	374-375
found	O	376-381
only	O	382-386
in	O	387-389
vertebrate	O	390-400
homologs	O	401-409
,	O	409-410
contributes	O	411-422
to	O	423-425
the	O	426-429
nuclear	O	430-437
localization	O	438-450
.	O	450-451

The	O	452-455
engrailed	O	456-465
repressor	O	466-475
(	O	476-477
enR	O	477-480
)	O	480-481
+	O	481-482
LZ	O	482-484
repressor	O	485-494
construct	O	495-504
,	O	504-505
which	O	506-511
has	O	512-515
properties	O	516-526
similar	O	527-534
to	O	535-537
Xfurry	O	538-544
,	O	544-545
induced	O	546-553
several	O	554-561
chordamesodermal	O	562-578
genes	O	579-584
.	O	584-585

In	O	586-588
contrast	O	589-597
,	O	597-598
an	O	599-601
antisense	O	602-611
morpholino	O	612-622
oligonucleotide	O	623-638
,	O	638-639
Xfurry	O	640-646
-	O	646-647
MO	O	647-649
,	O	649-650
and	O	651-654
the	O	655-658
activating	O	659-669
construct	O	670-679
,	O	679-680
herpes	O	681-687
simplex	O	688-695
virus	O	696-701
protein	O	702-709
(	O	710-711
VP16	O	711-715
)	O	715-716
+	O	716-717
LZ	O	717-719
,	O	719-720
had	O	721-724
effects	O	725-732
opposite	O	733-741
those	O	742-747
of	O	748-750
Xfurry	O	751-757
overexpression	O	758-772
.	O	772-773

Because	O	774-781
blocking	O	782-790
protein	O	791-798
synthesis	O	799-808
with	O	809-813
cycloheximide	O	814-827
superinduced	O	828-840
several	O	841-848
Xfurry	O	849-855
transcriptional	O	856-871
targets	O	872-879
,	O	879-880
and	O	881-884
because	O	885-892
expression	O	893-903
of	O	904-906
enR	O	907-910
+	O	910-911
LZ	O	911-913
induced	O	914-921
such	O	922-926
genes	O	927-932
under	O	933-938
cycloheximide	O	939-952
treatment	O	953-962
,	O	962-963
we	O	964-966
analyzed	O	967-975
the	O	976-979
role	O	980-984
of	O	985-987
an	O	988-990
Xfurry	O	991-997
transcriptional	O	998-1013
target	O	1014-1020
,	O	1020-1021
microRNA	O	1022-1030
miR	B	1031-1034
-	I	1034-1035
15	I	1035-1037
.	O	1037-1038

Cycloheximide	O	1039-1052
reduced	O	1053-1060
the	O	1061-1064
expression	O	1065-1075
of	O	1076-1078
primary	O	1079-1086
miR	B	1087-1090
-	I	1090-1091
15	I	1091-1093
(	O	1094-1095
pri	B	1095-1098
-	I	1098-1099
miR	I	1099-1102
-	I	1102-1103
15	I	1103-1105
)	O	1105-1106
,	O	1106-1107
whereas	O	1108-1115
miR	B	1116-1119
-	I	1119-1120
15	I	1120-1122
reduced	O	1123-1130
the	O	1131-1134
expression	O	1135-1145
of	O	1146-1148
genes	O	1149-1154
superinduced	O	1155-1167
by	O	1168-1170
cycloheximide	O	1171-1184
treatment	O	1185-1194
.	O	1194-1195

These	O	1196-1201
results	O	1202-1209
show	O	1210-1214
that	O	1215-1219
Xfurry	O	1220-1226
regulates	O	1227-1236
chordamesodermal	O	1237-1253
genes	O	1254-1259
by	O	1260-1262
contributing	O	1263-1275
to	O	1276-1278
repression	O	1279-1289
of	O	1290-1292
pretranscriptional	O	1293-1311
gene	O	1312-1316
silencing	O	1317-1326
by	O	1327-1329
miR	B	1330-1333
-	I	1333-1334
15	I	1334-1336
.	O	1336-1337

Downregulation	O	0-14
of	O	15-17
miR	B	18-21
-	I	21-22
342	I	22-25
is	O	26-28
associated	O	29-39
with	O	40-44
tamoxifen	O	45-54
resistant	O	55-64
breast	O	65-71
tumors	O	72-78
.	O	78-79

BACKGROUND	O	80-90
:	O	90-91
Tumor	O	92-97
resistance	O	98-108
to	O	109-111
the	O	112-115
selective	O	116-125
estrogen	O	126-134
receptor	O	135-143
modulator	O	144-153
tamoxifen	O	154-163
remains	O	164-171
a	O	172-173
serious	O	174-181
clinical	O	182-190
problem	O	191-198
especially	O	199-209
in	O	210-212
patients	O	213-221
with	O	222-226
tumors	O	227-233
that	O	234-238
also	O	239-243
overexpress	O	244-255
HER2	O	256-260
.	O	260-261

We	O	262-264
have	O	265-269
recently	O	270-278
demonstrated	O	279-291
that	O	292-296
the	O	297-300
clinically	O	301-311
important	O	312-321
isoform	O	322-329
of	O	330-332
HER2	O	333-337
,	O	337-338
HERDelta16	O	339-349
,	O	349-350
promotes	O	351-359
therapeutically	O	360-375
refractory	O	376-386
breast	O	387-393
cancer	O	394-400
including	O	401-410
resistance	O	411-421
to	O	422-424
endocrine	O	425-434
therapy	O	435-442
.	O	442-443

Likewise	O	444-452
additional	O	453-463
breast	O	464-470
tumor	O	471-476
cell	O	477-481
models	O	482-488
of	O	489-491
tamoxifen	O	492-501
resistance	O	502-512
have	O	513-517
been	O	518-522
developed	O	523-532
that	O	533-537
do	O	538-540
not	O	541-544
involve	O	545-552
HER2	O	553-557
overexpression	O	558-572
.	O	572-573

However	O	574-581
,	O	581-582
a	O	583-584
unifying	O	585-593
molecular	O	594-603
mechanism	O	604-613
of	O	614-616
tamoxifen	O	617-626
resistance	O	627-637
has	O	638-641
remained	O	642-650
elusive	O	651-658
.	O	658-659

RESULTS	O	660-667
:	O	667-668
Here	O	669-673
we	O	674-676
analyzed	O	677-685
multiple	O	686-694
cell	O	695-699
models	O	700-706
of	O	707-709
tamoxifen	O	710-719
resistance	O	720-730
derived	O	731-738
from	O	739-743
MCF	O	744-747
-	O	747-748
7	O	748-749
cells	O	750-755
to	O	756-758
examine	O	759-766
the	O	767-770
influence	O	771-780
of	O	781-783
microRNAs	O	784-793
(	O	794-795
miRNAs	O	795-801
)	O	801-802
on	O	803-805
tamoxifen	O	806-815
resistance	O	816-826
.	O	826-827

We	O	828-830
compared	O	831-839
miRNA	O	840-845
expression	O	846-856
profiles	O	857-865
of	O	866-868
tamoxifen	O	869-878
sensitive	O	879-888
MCF	O	889-892
-	O	892-893
7	O	893-894
cells	O	895-900
and	O	901-904
tamoxifen	O	905-914
resistant	O	915-924
MCF	O	925-928
-	O	928-929
7	O	929-930
/	O	930-931
HER2Delta16	O	931-942
cells	O	943-948
.	O	948-949

We	O	950-952
observed	O	953-961
significant	O	962-973
and	O	974-977
dramatic	O	978-986
downregulation	O	987-1001
of	O	1002-1004
miR	B	1005-1008
-	I	1008-1009
342	I	1009-1012
in	O	1013-1015
the	O	1016-1019
MCF	O	1020-1023
-	O	1023-1024
7	O	1024-1025
/	O	1025-1026
HER2Delta16	O	1026-1037
cell	O	1038-1042
line	O	1043-1047
as	O	1048-1050
well	O	1051-1055
as	O	1056-1058
the	O	1059-1062
HER2	O	1063-1067
negative	O	1068-1076
but	O	1077-1080
tamoxifen	O	1081-1090
resistant	O	1091-1100
MCF	O	1101-1104
-	O	1104-1105
7	O	1105-1106
variants	O	1107-1115
TAMR1	O	1116-1121
and	O	1122-1125
LCC2	O	1126-1130
.	O	1130-1131

Restoring	O	1132-1141
miR	B	1142-1145
-	I	1145-1146
342	I	1146-1149
expression	O	1150-1160
in	O	1161-1163
the	O	1164-1167
MCF	O	1168-1171
-	O	1171-1172
7	O	1172-1173
/	O	1173-1174
HER2Delta16	O	1174-1185
and	O	1186-1189
TAMR1	O	1190-1195
cell	O	1196-1200
lines	O	1201-1206
sensitized	O	1207-1217
these	O	1218-1223
cells	O	1224-1229
to	O	1230-1232
tamoxifen	O	1233-1242
-	O	1242-1243
induced	O	1243-1250
apoptosis	O	1251-1260
with	O	1261-1265
a	O	1266-1267
dramatic	O	1268-1276
reduction	O	1277-1286
in	O	1287-1289
cell	O	1290-1294
growth	O	1295-1301
.	O	1301-1302

Expression	O	1303-1313
of	O	1314-1316
miR	B	1317-1320
-	I	1320-1321
342	I	1321-1324
was	O	1325-1328
also	O	1329-1333
reduced	O	1334-1341
in	O	1342-1344
a	O	1345-1346
panel	O	1347-1352
of	O	1353-1355
tamoxifen	O	1356-1365
refractory	O	1366-1376
human	O	1377-1382
breast	O	1383-1389
tumors	O	1390-1396
,	O	1396-1397
underscoring	O	1398-1410
the	O	1411-1414
potential	O	1415-1424
clinical	O	1425-1433
importance	O	1434-1444
of	O	1445-1447
miR	B	1448-1451
-	I	1451-1452
342	I	1452-1455
downregulation	O	1456-1470
.	O	1470-1471

Towards	O	1472-1479
the	O	1480-1483
goal	O	1484-1488
of	O	1489-1491
identifying	O	1492-1503
direct	O	1504-1510
and	O	1511-1514
indirect	O	1515-1523
targets	O	1524-1531
of	O	1532-1534
miR	B	1535-1538
-	I	1538-1539
342	I	1539-1542
we	O	1543-1545
restored	O	1546-1554
miR	B	1555-1558
-	I	1558-1559
342	I	1559-1562
expression	O	1563-1573
in	O	1574-1576
MCF	O	1577-1580
-	O	1580-1581
7	O	1581-1582
/	O	1582-1583
HER2Delta16	O	1583-1594
cells	O	1595-1600
and	O	1601-1604
analyzed	O	1605-1613
changes	O	1614-1621
in	O	1622-1624
global	O	1625-1631
gene	O	1632-1636
expression	O	1637-1647
by	O	1648-1650
microarray	O	1651-1661
.	O	1661-1662

The	O	1663-1666
impact	O	1667-1673
of	O	1674-1676
miR	B	1677-1680
-	I	1680-1681
342	I	1681-1684
on	O	1685-1687
gene	O	1688-1692
expression	O	1693-1703
in	O	1704-1706
MCF	O	1707-1710
-	O	1710-1711
7	O	1711-1712
/	O	1712-1713
HER2Delta16	O	1713-1724
cells	O	1725-1730
was	O	1731-1734
not	O	1735-1738
limited	O	1739-1746
to	O	1747-1749
miR	B	1750-1753
-	I	1753-1754
342	I	1754-1757
in	O	1758-1760
silica	O	1761-1767
predicted	O	1768-1777
targets	O	1778-1785
.	O	1785-1786

Ingenuity	O	1787-1796
Pathways	O	1797-1805
Analysis	O	1806-1814
of	O	1815-1817
the	O	1818-1821
dataset	O	1822-1829
revealed	O	1830-1838
a	O	1839-1840
significant	O	1841-1852
influence	O	1853-1862
of	O	1863-1865
miR	B	1866-1869
-	I	1869-1870
342	I	1870-1873
on	O	1874-1876
multiple	O	1877-1885
tumor	O	1886-1891
cell	O	1892-1896
cycle	O	1897-1902
regulators	O	1903-1913
.	O	1913-1914

CONCLUSIONS	O	1915-1926
:	O	1926-1927
Our	O	1928-1931
findings	O	1932-1940
suggest	O	1941-1948
that	O	1949-1953
miR	B	1954-1957
-	I	1957-1958
342	I	1958-1961
regulates	O	1962-1971
tamoxifen	O	1972-1981
response	O	1982-1990
in	O	1991-1993
breast	O	1994-2000
tumor	O	2001-2006
cell	O	2007-2011
lines	O	2012-2017
and	O	2018-2021
our	O	2022-2025
clinical	O	2026-2034
data	O	2035-2039
indicates	O	2040-2049
a	O	2050-2051
trend	O	2052-2057
towards	O	2058-2065
reduced	O	2066-2073
miR	B	2074-2077
-	I	2077-2078
342	I	2078-2081
expression	O	2082-2092
and	O	2093-2096
tamoxifen	O	2097-2106
resistance	O	2107-2117
.	O	2117-2118

In	O	2119-2121
addition	O	2122-2130
,	O	2130-2131
our	O	2132-2135
results	O	2136-2143
suggest	O	2144-2151
that	O	2152-2156
miR	B	2157-2160
-	I	2160-2161
342	I	2161-2164
regulates	O	2165-2174
expression	O	2175-2185
of	O	2186-2188
genes	O	2189-2194
involved	O	2195-2203
in	O	2204-2206
tamoxifen	O	2207-2216
mediated	O	2217-2225
tumor	O	2226-2231
cell	O	2232-2236
apoptosis	O	2237-2246
and	O	2247-2250
cell	O	2251-2255
cycle	O	2256-2261
progression	O	2262-2273
.	O	2273-2274

Restoring	O	2275-2284
miR	B	2285-2288
-	I	2288-2289
342	I	2289-2292
expression	O	2293-2303
may	O	2304-2307
represent	O	2308-2317
a	O	2318-2319
novel	O	2320-2325
therapeutic	O	2326-2337
approach	O	2338-2346
to	O	2347-2349
sensitizing	O	2350-2361
and	O	2362-2365
suppressing	O	2366-2377
the	O	2378-2381
growth	O	2382-2388
of	O	2389-2391
tamoxifen	O	2392-2401
refractory	O	2402-2412
breast	O	2413-2419
tumors	O	2420-2426
.	O	2426-2427

MicroRNA	O	0-8
signatures	O	9-19
associated	O	20-30
with	O	31-35
immortalization	O	36-51
of	O	52-54
EBV	O	55-58
-	O	58-59
transformed	O	59-70
lymphoblastoid	O	71-85
cell	O	86-90
lines	O	91-96
and	O	97-100
their	O	101-106
clinical	O	107-115
traits	O	116-122
.	O	122-123

OBJECTIVE	O	124-133
:	O	133-134
MicroRNAs	O	135-144
(	O	145-146
miRNAs	O	146-152
)	O	152-153
are	O	154-157
negative	O	158-166
regulators	O	167-177
of	O	178-180
gene	O	181-185
expression	O	186-196
that	O	197-201
play	O	202-206
important	O	207-216
roles	O	217-222
in	O	223-225
cell	O	226-230
processes	O	231-240
such	O	241-245
as	O	246-248
proliferation	O	249-262
,	O	262-263
development	O	264-275
and	O	276-279
differentiation	O	280-295
.	O	295-296

Recently	O	297-305
,	O	305-306
it	O	307-309
has	O	310-313
been	O	314-318
reported	O	319-327
that	O	328-332
miRNAs	O	333-339
are	O	340-343
related	O	344-351
to	O	352-354
development	O	355-366
of	O	367-369
carcinogenesis	O	370-384
.	O	384-385

The	O	386-389
aim	O	390-393
of	O	394-396
this	O	397-401
study	O	402-407
was	O	408-411
to	O	412-414
identify	O	415-423
miRNAs	O	424-430
associated	O	431-441
with	O	442-446
terminal	O	447-455
immortalization	O	456-471
of	O	472-474
Epstein	O	475-482
-	O	482-483
Barr	O	483-487
virus	O	488-493
(	O	494-495
EBV	O	495-498
)	O	498-499
-	O	499-500
transformed	O	500-511
lymphoblastoid	O	512-526
cell	O	527-531
line	O	532-536
(	O	537-538
LCL	O	538-541
)	O	541-542
and	O	543-546
associated	O	547-557
clinical	O	558-566
traits	O	567-573
.	O	573-574

MATERIAL	O	575-583
AND	O	584-587
METHODS	O	588-595
:	O	595-596
Hence	O	597-602
,	O	602-603
we	O	604-606
performed	O	607-616
miRNA	O	617-622
microarray	O	623-633
approach	O	634-642
with	O	643-647
early	O	648-653
-	O	653-654
(	O	655-656
p6	O	656-658
)	O	658-659
and	O	660-663
late	O	664-668
-	O	668-669
passage	O	669-676
(	O	677-678
p161	O	678-682
)	O	682-683
LCLs	O	684-688
.	O	688-689

RESULTS	O	690-697
AND	O	698-701
CONCLUSION	O	702-712
:	O	712-713
Microarray	O	714-724
data	O	725-729
showed	O	730-736
that	O	737-741
nine	O	742-746
miRNAs	O	747-753
(	O	754-755
miR	B	755-758
-	I	758-759
20b	I	759-762
*	I	762-763
,	O	763-764
miR	B	765-768
-	I	768-769
28	I	769-771
-	I	771-772
5p	I	772-774
,	O	774-775
miR	B	776-779
-	I	779-780
99a	I	780-783
,	O	783-784
miR	B	785-788
-	I	788-789
125b	I	789-793
,	O	793-794
miR	B	795-798
-	I	798-799
151	I	799-802
-	I	802-803
3p	I	803-805
,	O	805-806
miR	B	807-810
-	I	810-811
151	I	811-814
:	O	814-815
9	O	815-816
.	O	816-817
1	O	817-818
,	O	818-819
miR	B	820-823
-	I	823-824
216a	I	824-828
,	O	828-829
miR	B	830-833
-	I	833-834
223	I	834-837
*	I	837-838
and	O	839-842
miR	B	843-846
-	I	846-847
1296	I	847-851
)	O	851-852
were	O	853-857
differentially	O	858-872
expressed	O	873-882
in	O	883-885
most	O	886-890
LCLs	O	891-895
during	O	896-902
long	O	903-907
-	O	907-908
term	O	908-912
culture	O	913-920
.	O	920-921

In	O	922-924
particular	O	925-935
,	O	935-936
miR	B	937-940
-	I	940-941
125b	I	941-945
was	O	946-949
up	O	950-952
-	O	952-953
regulated	O	953-962
in	O	963-965
all	O	966-969
the	O	970-973
tested	O	974-980
late	O	981-985
-	O	985-986
passage	O	986-993
LCLs	O	994-998
.	O	998-999

miR	B	1000-1003
-	I	1003-1004
99a	I	1004-1007
,	O	1007-1008
miR	B	1009-1012
-	I	1012-1013
125b	I	1013-1017
,	O	1017-1018
miR	B	1019-1022
-	I	1022-1023
216a	I	1023-1027
and	O	1028-1031
miR	B	1032-1035
-	I	1035-1036
1296	I	1036-1040
were	O	1041-1045
putative	O	1046-1054
negative	O	1055-1063
regulators	O	1064-1074
of	O	1075-1077
RASGRP3	O	1078-1085
,	O	1085-1086
GPR160	O	1087-1093
,	O	1093-1094
PRKCH	O	1095-1100
and	O	1101-1104
XAF1	O	1105-1109
,	O	1109-1110
respectively	O	1111-1123
,	O	1123-1124
which	O	1125-1130
were	O	1131-1135
found	O	1136-1141
to	O	1142-1144
be	O	1145-1147
differentially	O	1148-1162
expressed	O	1163-1172
in	O	1173-1175
LCLs	O	1176-1180
during	O	1181-1187
long	O	1188-1192
-	O	1192-1193
term	O	1193-1197
culture	O	1198-1205
in	O	1206-1208
a	O	1209-1210
previous	O	1211-1219
study	O	1220-1225
.	O	1225-1226

Linear	O	1227-1233
regression	O	1234-1244
analysis	O	1245-1253
showed	O	1254-1260
that	O	1261-1265
miR	B	1266-1269
-	I	1269-1270
200a	I	1270-1274
and	O	1275-1278
miR	B	1279-1282
-	I	1282-1283
296	I	1283-1286
-	I	1286-1287
3p	I	1287-1289
correlated	O	1290-1300
with	O	1301-1305
triglyceride	O	1306-1318
and	O	1319-1322
HbA1C	O	1323-1328
levels	O	1329-1335
,	O	1335-1336
respectively	O	1337-1349
,	O	1349-1350
suggesting	O	1351-1361
that	O	1362-1366
miRNA	O	1367-1372
signatures	O	1373-1383
of	O	1384-1386
LCLs	O	1387-1391
could	O	1392-1397
provide	O	1398-1405
information	O	1406-1417
on	O	1418-1420
the	O	1421-1424
donor	O	1425-1430
'	O	1430-1431
s	O	1431-1432
health	O	1433-1439
.	O	1439-1440

In	O	1441-1443
conclusion	O	1444-1454
,	O	1454-1455
our	O	1456-1459
study	O	1460-1465
suggests	O	1466-1474
that	O	1475-1479
expression	O	1480-1490
changes	O	1491-1498
of	O	1499-1501
specific	O	1502-1510
miRNAs	O	1511-1517
may	O	1518-1521
be	O	1522-1524
required	O	1525-1533
for	O	1534-1537
terminal	O	1538-1546
immortalization	O	1547-1562
of	O	1563-1565
LCLs	O	1566-1570
.	O	1570-1571

Thus	O	1572-1576
,	O	1576-1577
differentially	O	1578-1592
expressed	O	1593-1602
miRNAs	O	1603-1609
would	O	1610-1615
be	O	1616-1618
a	O	1619-1620
potential	O	1621-1630
marker	O	1631-1637
for	O	1638-1641
completion	O	1642-1652
of	O	1653-1655
cell	O	1656-1660
immortalization	O	1661-1676
during	O	1677-1683
EBV	O	1684-1687
-	O	1687-1688
mediated	O	1688-1696
tumorigenesis	O	1697-1710
.	O	1710-1711

Glucocorticoid	O	0-14
-	O	14-15
mediated	O	15-23
repression	O	24-34
of	O	35-37
the	O	38-41
oncogenic	O	42-51
microRNA	O	52-60
cluster	O	61-68
miR	B	69-72
-	I	72-73
17	I	73-75
~	I	75-76
92	I	76-78
contributes	O	79-90
to	O	91-93
the	O	94-97
induction	O	98-107
of	O	108-110
Bim	O	111-114
and	O	115-118
initiation	O	119-129
of	O	130-132
apoptosis	O	133-142
.	O	142-143

Synthetic	O	144-153
glucocorticoids	O	154-169
were	O	170-174
one	O	175-178
of	O	179-181
the	O	182-185
first	O	186-191
effective	O	192-201
treatments	O	202-212
for	O	213-216
lymphoid	O	217-225
malignancies	O	226-238
because	O	239-246
of	O	247-249
their	O	250-255
ability	O	256-263
to	O	264-266
induce	O	267-273
apoptosis	O	274-283
and	O	284-287
are	O	288-291
still	O	292-297
used	O	298-302
in	O	303-305
combination	O	306-317
with	O	318-322
other	O	323-328
chemotherapeutic	O	329-345
agents	O	346-352
.	O	352-353

Up	O	354-356
-	O	356-357
regulation	O	357-367
of	O	368-370
Bim	O	371-374
,	O	374-375
a	O	376-377
proapoptotic	O	378-390
member	O	391-397
of	O	398-400
the	O	401-404
B	O	405-406
-	O	406-407
cell	O	407-411
lymphoma	O	412-420
-	O	420-421
2	O	421-422
family	O	423-429
,	O	429-430
is	O	431-433
an	O	434-436
important	O	437-446
mediator	O	447-455
of	O	456-458
glucocorticoid	O	459-473
-	O	473-474
induced	O	474-481
apoptosis	O	482-491
.	O	491-492

Although	O	493-501
glucocorticoids	O	502-517
are	O	518-521
known	O	522-527
to	O	528-530
elevate	O	531-538
Bim	O	539-542
mRNA	O	543-547
and	O	548-551
protein	O	552-559
,	O	559-560
little	O	561-567
is	O	568-570
known	O	571-576
about	O	577-582
the	O	583-586
mechanism	O	587-596
.	O	596-597

Here	O	598-602
,	O	602-603
we	O	604-606
report	O	607-613
that	O	614-618
glucocorticoids	O	619-634
repress	O	635-642
the	O	643-646
expression	O	647-657
of	O	658-660
the	O	661-664
microRNA	O	665-673
cluster	O	674-681
miR	B	682-685
-	I	685-686
17	I	686-688
approximately	I	689-702
92	I	703-705
,	O	705-706
which	O	707-712
results	O	713-720
in	O	721-723
elevated	O	724-732
Bim	O	733-736
protein	O	737-744
expression	O	745-755
as	O	756-758
a	O	759-760
mechanism	O	761-770
by	O	771-773
which	O	774-779
glucocorticoids	O	780-795
induce	O	796-802
Bim	O	803-806
.	O	806-807

Using	O	808-813
a	O	814-815
luciferase	O	816-826
-	O	826-827
Bim	O	827-830
3	O	831-832
'	O	832-833
untranslated	O	834-846
region	O	847-853
construct	O	854-863
,	O	863-864
we	O	865-867
demonstrate	O	868-879
that	O	880-884
glucocorticoids	O	885-900
mediate	O	901-908
Bim	O	909-912
induction	O	913-922
posttranscriptionally	O	923-944
after	O	945-950
miR	B	951-954
-	I	954-955
17	I	955-957
approximately	I	958-971
92	I	972-974
repression	O	975-985
,	O	985-986
resulting	O	987-996
in	O	997-999
increased	O	1000-1009
Bim	O	1010-1013
protein	O	1014-1021
expression	O	1022-1032
.	O	1032-1033

Overexpression	O	1034-1048
of	O	1049-1051
miR	B	1052-1055
-	I	1055-1056
17	I	1056-1058
approximately	I	1059-1072
92	I	1073-1075
microRNAs	O	1076-1085
decreases	O	1086-1095
Bim	O	1096-1099
induction	O	1100-1109
and	O	1110-1113
attenuates	O	1114-1124
glucocorticoid	O	1125-1139
-	O	1139-1140
mediated	O	1140-1148
apoptosis	O	1149-1158
.	O	1158-1159

Conversely	O	1160-1170
,	O	1170-1171
knockdown	O	1172-1181
of	O	1182-1184
miR	B	1185-1188
-	I	1188-1189
17	I	1189-1191
approximately	I	1192-1205
92	I	1206-1208
increases	O	1209-1218
Bim	O	1219-1222
protein	O	1223-1230
expression	O	1231-1241
and	O	1242-1245
glucocorticoid	O	1246-1260
-	O	1260-1261
mediated	O	1261-1269
apoptosis	O	1270-1279
.	O	1279-1280

These	O	1281-1286
findings	O	1287-1295
indicate	O	1296-1304
that	O	1305-1309
endogenous	O	1310-1320
levels	O	1321-1327
of	O	1328-1330
miR	B	1331-1334
-	I	1334-1335
17	I	1335-1337
approximately	I	1338-1351
92	I	1352-1354
repress	O	1355-1362
Bim	O	1363-1366
expression	O	1367-1377
in	O	1378-1380
T	O	1381-1382
-	O	1382-1383
cell	O	1383-1387
lymphoid	O	1388-1396
malignancies	O	1397-1409
and	O	1410-1413
that	O	1414-1418
glucocorticoids	O	1419-1434
induce	O	1435-1441
Bim	O	1442-1445
expression	O	1446-1456
via	O	1457-1460
down	O	1461-1465
-	O	1465-1466
regulation	O	1466-1476
of	O	1477-1479
the	O	1480-1483
miR	B	1484-1487
-	I	1487-1488
17	I	1488-1490
approximately	O	1491-1504
92	O	1505-1507
microRNA	O	1508-1516
cluster	O	1517-1524
.	O	1524-1525

Our	O	1526-1529
findings	O	1530-1538
present	O	1539-1546
a	O	1547-1548
novel	O	1549-1554
mechanism	O	1555-1564
that	O	1565-1569
contributes	O	1570-1581
to	O	1582-1584
the	O	1585-1588
up	O	1589-1591
-	O	1591-1592
regulation	O	1592-1602
of	O	1603-1605
Bim	O	1606-1609
and	O	1610-1613
induction	O	1614-1623
of	O	1624-1626
apoptosis	O	1627-1636
in	O	1637-1639
lymphocytes	O	1640-1651
after	O	1652-1657
glucocorticoid	O	1658-1672
treatment	O	1673-1682
.	O	1682-1683

Furthermore	O	1684-1695
,	O	1695-1696
our	O	1697-1700
work	O	1701-1705
demonstrating	O	1706-1719
that	O	1720-1724
inhibition	O	1725-1735
of	O	1736-1738
miR	B	1739-1742
-	I	1742-1743
17	I	1743-1745
approximately	I	1746-1759
92	I	1760-1762
increases	O	1763-1772
glucocorticoid	O	1773-1787
-	O	1787-1788
induced	O	1788-1795
apoptosis	O	1796-1805
highlights	O	1806-1816
the	O	1817-1820
potential	O	1821-1830
importance	O	1831-1841
of	O	1842-1844
miR	B	1845-1848
-	I	1848-1849
17	I	1849-1851
approximately	I	1852-1865
92	I	1866-1868
as	O	1869-1871
a	O	1872-1873
therapeutic	O	1874-1885
target	O	1886-1892
in	O	1893-1895
leukemias	O	1896-1905
and	O	1906-1909
lymphomas	O	1910-1919
.	O	1919-1920

miR	B	0-3
-	I	3-4
153	I	4-7
sensitized	O	8-18
the	O	19-22
K562	O	23-27
cells	O	28-33
to	O	34-36
As2O3	O	37-42
-	O	42-43
induced	O	43-50
apoptosis	O	51-60
.	O	60-61

Relapse	O	62-69
remains	O	70-77
the	O	78-81
biggest	O	82-89
hurdle	O	90-96
of	O	97-99
leukemia	O	100-108
therapy	O	109-116
,	O	116-117
while	O	118-123
elucidating	O	124-135
the	O	136-139
molecular	O	140-149
mechanism	O	150-159
holds	O	160-165
promise	O	166-173
for	O	174-177
the	O	178-181
solution	O	182-190
.	O	190-191

Recently	O	192-200
,	O	200-201
microRNAs	O	202-211
are	O	212-215
emerging	O	216-224
as	O	225-227
an	O	228-230
important	O	231-240
regulator	O	241-250
of	O	251-253
cell	O	254-258
function	O	259-267
.	O	267-268

In	O	269-271
this	O	272-276
study	O	277-282
,	O	282-283
we	O	284-286
for	O	287-290
the	O	291-294
first	O	295-300
time	O	301-305
found	O	306-311
that	O	312-316
miR	B	317-320
-	I	320-321
153	I	321-324
was	O	325-328
downregulated	O	329-342
in	O	343-345
As2O3	O	346-351
-	O	351-352
induced	O	352-359
drug	O	360-364
-	O	364-365
resistant	O	365-374
K562	O	375-379
cells	O	380-385
.	O	385-386

In	O	387-389
the	O	390-393
CD34	O	394-398
+	O	398-399
K562	O	400-404
subpopulation	O	405-418
,	O	418-419
which	O	420-425
is	O	426-428
characteristic	O	429-443
of	O	444-446
leukemia	O	447-455
stem	O	456-460
cell	O	461-465
and	O	466-469
resembles	O	470-479
the	O	480-483
drug	O	484-488
-	O	488-489
resistant	O	489-498
subgroup	O	499-507
,	O	507-508
miR	B	509-512
-	I	512-513
153	I	513-516
expression	O	517-527
level	O	528-533
was	O	534-537
also	O	538-542
much	O	543-547
lower	O	548-553
than	O	554-558
that	O	559-563
in	O	564-566
the	O	567-570
bulk	O	571-575
.	O	575-576

Forced	O	577-583
expression	O	584-594
of	O	595-597
miR	B	598-601
-	I	601-602
153	I	602-605
only	O	606-610
in	O	611-613
K562	O	614-618
cells	O	619-624
has	O	625-628
no	O	629-631
significant	O	632-643
effects	O	644-651
on	O	652-654
cell	O	655-659
growth	O	660-666
and	O	667-670
apoptosis	O	671-680
.	O	680-681

However	O	682-689
,	O	689-690
when	O	691-695
cells	O	696-701
were	O	702-706
additionally	O	707-719
treated	O	720-727
with	O	728-732
As2O3	O	733-738
,	O	738-739
significant	O	740-751
greater	O	752-759
apoptosis	O	760-769
was	O	770-773
observed	O	774-782
in	O	783-785
the	O	786-789
miR	B	790-793
-	I	793-794
153	I	794-797
overexpressed	O	798-811
group	O	812-817
.	O	817-818

Our	O	819-822
data	O	823-827
here	O	828-832
suggest	O	833-840
that	O	841-845
strategies	O	846-856
increasing	O	857-867
the	O	868-871
endogenous	O	872-882
miR	B	883-886
-	I	886-887
153	I	887-890
might	O	891-896
hold	O	897-901
promise	O	902-909
for	O	910-913
an	O	914-916
alternative	O	917-928
adjuvant	O	929-937
therapy	O	938-945
of	O	946-948
leukemia	O	949-957
.	O	957-958

Hormonal	O	0-8
regulation	O	9-19
of	O	20-22
sertoli	O	23-30
cell	O	31-35
micro	O	36-41
-	O	41-42
RNAs	O	42-46
at	O	47-49
spermiation	O	50-61
.	O	61-62

Spermatogenesis	O	63-78
is	O	79-81
absolutely	O	82-92
dependent	O	93-102
on	O	103-105
FSH	O	106-109
and	O	110-113
androgens	O	114-123
;	O	123-124
suppression	O	125-136
of	O	137-139
these	O	140-145
hormones	O	146-154
inhibits	O	155-163
germ	O	164-168
cell	O	169-173
development	O	174-185
and	O	186-189
thus	O	190-194
sperm	O	195-200
production	O	201-211
.	O	211-212

The	O	213-216
final	O	217-222
release	O	223-230
of	O	231-233
spermatids	O	234-244
by	O	245-247
the	O	248-251
Sertoli	O	252-259
cell	O	260-264
,	O	264-265
a	O	266-267
process	O	268-275
known	O	276-281
as	O	282-284
spermiation	O	285-296
,	O	296-297
is	O	298-300
particularly	O	301-313
sensitive	O	314-323
to	O	324-326
hormone	O	327-334
suppression	O	335-346
.	O	346-347

To	O	348-350
define	O	351-357
the	O	358-361
molecular	O	362-371
mechanisms	O	372-382
that	O	383-387
mediate	O	388-395
FSH	O	396-399
and	O	400-403
androgen	O	404-412
effects	O	413-420
in	O	421-423
the	O	424-427
Sertoli	O	428-435
cell	O	436-440
,	O	440-441
we	O	442-444
investigated	O	445-457
the	O	458-461
expression	O	462-472
and	O	473-476
regulation	O	477-487
of	O	488-490
micro	O	491-496
-	O	496-497
RNAs	O	497-501
(	O	502-503
miRNAs	O	503-509
)	O	509-510
,	O	510-511
small	O	512-517
noncoding	O	518-527
RNAs	O	528-532
that	O	533-537
regulate	O	538-546
protein	O	547-554
translation	O	555-566
and	O	567-570
modify	O	571-577
cellular	O	578-586
responses	O	587-596
.	O	596-597

By	O	598-600
array	O	601-606
analysis	O	607-615
,	O	615-616
we	O	617-619
identified	O	620-630
23	O	631-633
miRNAs	O	634-640
up	O	641-643
-	O	643-644
regulated	O	644-653
more	O	654-658
than	O	659-663
2	O	664-665
-	O	665-666
fold	O	666-670
after	O	671-676
hormone	O	677-684
suppression	O	685-696
in	O	697-699
vivo	O	700-704
and	O	705-708
in	O	709-711
vitro	O	712-717
in	O	718-720
primary	O	721-728
Sertoli	O	729-736
cell	O	737-741
cultures	O	742-750
.	O	750-751

The	O	752-755
regulation	O	756-766
of	O	767-769
four	O	770-774
of	O	775-777
these	O	778-783
miRNAs	O	784-790
(	O	791-792
miR	B	792-795
-	I	795-796
23b	I	796-799
,	O	799-800
-	B	801-802
30c	I	802-805
,	O	805-806
-	B	807-808
30d	I	808-811
,	O	811-812
and	O	813-816
-	B	817-818
690	I	818-821
)	O	821-822
was	O	823-826
confirmed	O	827-836
by	O	837-839
quantitative	O	840-852
RT	O	853-855
-	O	855-856
PCR	O	856-859
.	O	859-860

Bioinformatic	O	861-874
analysis	O	875-883
of	O	884-886
potential	O	887-896
targets	O	897-904
of	O	905-907
hormonally	O	908-918
regulated	O	919-928
miRNAs	O	929-935
identified	O	936-946
genes	O	947-952
important	O	953-962
for	O	963-966
focal	O	967-972
adhesion	O	973-981
and	O	982-985
regulation	O	986-996
of	O	997-999
the	O	1000-1003
actin	O	1004-1009
cytoskeleton	O	1010-1022
,	O	1022-1023
processes	O	1024-1033
known	O	1034-1039
to	O	1040-1042
be	O	1043-1045
intimately	O	1046-1056
associated	O	1057-1067
with	O	1068-1072
adhesion	O	1073-1081
of	O	1082-1084
spermatids	O	1085-1095
to	O	1096-1098
Sertoli	O	1099-1106
cells	O	1107-1112
.	O	1112-1113

Two	O	1114-1117
of	O	1118-1120
the	O	1121-1124
identified	O	1125-1135
genes	O	1136-1141
,	O	1141-1142
Pten	O	1143-1147
,	O	1147-1148
an	O	1149-1151
intracellular	O	1152-1165
phosphatase	O	1166-1177
,	O	1177-1178
and	O	1179-1182
Eps15	O	1183-1188
,	O	1188-1189
a	O	1190-1191
mediator	O	1192-1200
of	O	1201-1203
endocytosis	O	1204-1215
,	O	1215-1216
were	O	1217-1221
down	O	1222-1226
-	O	1226-1227
regulated	O	1227-1236
by	O	1237-1239
the	O	1240-1243
withdrawal	O	1244-1254
of	O	1255-1257
hormones	O	1258-1266
in	O	1267-1269
vivo	O	1270-1274
and	O	1275-1278
possess	O	1279-1286
miR	B	1287-1290
-	I	1290-1291
23b	I	1291-1294
target	O	1295-1301
sites	O	1302-1307
in	O	1308-1310
their	O	1311-1316
3	O	1317-1318
'	O	1318-1319
-	O	1319-1320
untranslated	O	1320-1332
regions	O	1333-1340
.	O	1340-1341

Overexpression	O	1342-1356
of	O	1357-1359
miR	B	1360-1363
-	I	1363-1364
23b	I	1364-1367
in	O	1368-1370
vitro	O	1371-1376
resulted	O	1377-1385
in	O	1386-1388
decreased	O	1389-1398
translation	O	1399-1410
of	O	1411-1413
PTEN	O	1414-1418
and	O	1419-1422
EPS15	O	1423-1428
protein	O	1429-1436
as	O	1437-1439
assessed	O	1440-1448
by	O	1449-1451
Western	O	1452-1459
blot	O	1460-1464
and	O	1465-1468
luciferase	O	1469-1479
analysis	O	1480-1488
.	O	1488-1489

We	O	1490-1492
conclude	O	1493-1501
that	O	1502-1506
FSH	O	1507-1510
and	O	1511-1514
androgens	O	1515-1524
act	O	1525-1528
on	O	1529-1531
Sertoli	O	1532-1539
cells	O	1540-1545
in	O	1546-1548
stage	O	1549-1554
VIII	O	1555-1559
to	O	1560-1562
control	O	1563-1570
the	O	1571-1574
expression	O	1575-1585
of	O	1586-1588
miRNAs	O	1589-1595
that	O	1596-1600
operate	O	1601-1608
in	O	1609-1611
a	O	1612-1613
coordinated	O	1614-1625
manner	O	1626-1632
to	O	1633-1635
regulate	O	1636-1644
cell	O	1645-1649
adhesion	O	1650-1658
pathways	O	1659-1667
and	O	1668-1671
male	O	1672-1676
fertility	O	1677-1686
and	O	1687-1690
that	O	1691-1695
miRNA	O	1696-1701
transcription	O	1702-1715
is	O	1716-1718
a	O	1719-1720
new	O	1721-1724
paradigm	O	1725-1733
in	O	1734-1736
the	O	1737-1740
hormone	O	1741-1748
dependence	O	1749-1759
of	O	1760-1762
spermiation	O	1763-1774
.	O	1774-1775

Expression	O	0-10
of	O	11-13
CD19	O	14-18
and	O	19-22
lack	O	23-27
of	O	28-30
miR	B	31-34
-	I	34-35
223	I	35-38
distinguish	O	39-50
extramedullary	O	51-65
plasmacytoma	O	66-78
from	O	79-83
multiple	O	84-92
myeloma	O	93-100
.	O	100-101

AIMS	O	102-106
:	O	106-107
Extramedullary	O	108-122
plasmacytoma	O	123-135
(	O	136-137
EMP	O	137-140
)	O	140-141
and	O	142-145
multiple	O	146-154
myeloma	O	155-162
(	O	163-164
MM	O	164-166
)	O	166-167
are	O	168-171
both	O	172-176
plasma	O	177-183
cell	O	184-188
(	O	189-190
PC	O	190-192
)	O	192-193
tumours	O	194-201
that	O	202-206
are	O	207-210
usually	O	211-218
distinguished	O	219-232
by	O	233-235
clinical	O	236-244
manifestations	O	245-259
,	O	259-260
but	O	261-264
not	O	265-268
by	O	269-271
histopathological	O	272-289
examination	O	290-301
alone	O	302-307
.	O	307-308

However	O	309-316
,	O	316-317
EMP	O	318-321
may	O	322-325
express	O	326-333
B	O	334-335
-	O	335-336
cell	O	336-340
markers	O	341-348
,	O	348-349
such	O	350-354
as	O	355-357
CD79a	O	358-363
and	O	364-367
CD20	O	368-372
,	O	372-373
and	O	374-377
MM	O	378-380
may	O	381-384
express	O	385-392
germinal	O	393-401
centre	O	402-408
B	O	409-410
-	O	410-411
cell	O	411-415
(	O	416-417
GCBC	O	417-421
)	O	421-422
-	O	422-423
associated	O	423-433
microRNAs	O	434-443
,	O	443-444
such	O	445-449
as	O	450-452
miR	B	453-456
-	I	456-457
93	I	457-459
and	O	460-463
miR	B	464-467
-	I	467-468
181b	I	468-472
.	O	472-473

Down	O	474-478
-	O	478-479
regulation	O	479-489
of	O	490-492
miR	B	493-496
-	I	496-497
30a	I	497-500
or	O	501-503
up	O	504-506
-	O	506-507
regulation	O	507-517
of	O	518-520
miR	B	521-524
-	I	524-525
223	I	525-528
is	O	529-531
associated	O	532-542
with	O	543-547
the	O	548-551
transition	O	552-562
from	O	563-567
GCBCs	O	568-573
into	O	574-578
PCs	O	579-582
or	O	583-585
memory	O	586-592
B	O	593-594
-	O	594-595
cells	O	595-600
,	O	600-601
respectively	O	602-614
.	O	614-615

We	O	616-618
studied	O	619-626
B	O	627-628
-	O	628-629
cell	O	629-633
markers	O	634-641
and	O	642-645
microRNAs	O	646-655
to	O	656-658
establish	O	659-668
criteria	O	669-677
that	O	678-682
could	O	683-688
distinguish	O	689-700
EMP	O	701-704
from	O	705-709
MM	O	710-712
.	O	712-713

METHODS	O	714-721
AND	O	722-725
RESULTS	O	726-733
:	O	733-734
Immunostains	O	735-747
for	O	748-751
the	O	752-755
B	O	756-757
-	O	757-758
cell	O	758-762
markers	O	763-770
CD19	O	771-775
,	O	775-776
CD20	O	777-781
,	O	781-782
CD79a	O	783-788
and	O	789-792
PAX5	O	793-797
were	O	798-802
performed	O	803-812
.	O	812-813

Expression	O	814-824
levels	O	825-831
of	O	832-834
microRNAs	O	835-844
30a	B	845-848
,	O	848-849
93	B	850-852
,	O	852-853
181b	B	854-858
and	O	859-862
223	B	863-866
were	O	867-871
measured	O	872-880
by	O	881-883
real	O	884-888
-	O	888-889
time	O	889-893
reverse	O	894-901
transcription	O	902-915
polymerase	O	916-926
chain	O	927-932
reactions	O	933-942
.	O	942-943

73	O	944-946
%	O	946-947
of	O	948-950
EMPs	O	951-955
expressed	O	956-965
CD19	O	966-970
whereas	O	971-978
MM	O	979-981
cases	O	982-987
were	O	988-992
negative	O	993-1001
.	O	1001-1002

EMP	O	1003-1006
and	O	1007-1010
MM	O	1011-1013
had	O	1014-1017
similar	O	1018-1025
levels	O	1026-1032
of	O	1033-1035
miR	B	1036-1039
-	I	1039-1040
30a	I	1040-1043
,	O	1043-1044
miR	B	1045-1048
-	I	1048-1049
93	I	1049-1051
,	O	1051-1052
and	O	1053-1056
miR	B	1057-1060
-	I	1060-1061
181b	I	1061-1065
,	O	1065-1066
but	O	1067-1070
EMP	O	1071-1074
lacked	O	1075-1081
expression	O	1082-1092
of	O	1093-1095
miR	B	1096-1099
-	I	1099-1100
223	I	1100-1103
.	O	1103-1104

CONCLUSIONS	O	1105-1116
:	O	1116-1117
The	O	1118-1121
presence	O	1122-1130
of	O	1131-1133
CD19	O	1134-1138
and	O	1139-1142
lack	O	1143-1147
of	O	1148-1150
miR	B	1151-1154
-	I	1154-1155
223	I	1155-1158
suggested	O	1159-1168
aberrant	O	1169-1177
B	O	1178-1179
-	O	1179-1180
cell	O	1180-1184
differentiation	O	1185-1200
in	O	1201-1203
EMP	O	1204-1207
.	O	1207-1208

Although	O	1209-1217
the	O	1218-1221
underlying	O	1222-1232
mechanism	O	1233-1242
for	O	1243-1246
this	O	1247-1251
differential	O	1252-1264
expression	O	1265-1275
was	O	1276-1279
unclear	O	1280-1287
,	O	1287-1288
a	O	1289-1290
CD19	O	1291-1295
(	O	1295-1296
+	O	1296-1297
)	O	1297-1298
/	O	1299-1300
miR	B	1300-1303
-	I	1303-1304
223	I	1304-1307
(	O	1307-1308
-	O	1308-1309
)	O	1309-1310
phenotype	O	1311-1320
could	O	1321-1326
be	O	1327-1329
used	O	1330-1334
to	O	1335-1337
distinguish	O	1338-1349
EMP	O	1350-1353
from	O	1354-1358
the	O	1359-1362
CD19	O	1363-1367
(	O	1367-1368
-	O	1368-1369
)	O	1369-1370
/	O	1371-1372
miR	B	1372-1375
-	I	1375-1376
223	I	1376-1379
(	O	1379-1380
+	O	1380-1381
)	O	1381-1382
phenotype	O	1383-1392
of	O	1393-1395
MM	O	1396-1398
.	O	1398-1399

Gain	O	0-4
of	O	5-7
survival	O	8-16
signaling	O	17-26
by	O	27-29
down	O	30-34
-	O	34-35
regulation	O	35-45
of	O	46-48
three	O	49-54
key	O	55-58
miRNAs	O	59-65
in	O	66-68
brain	O	69-74
of	O	75-77
calorie	O	78-85
-	O	85-86
restricted	O	86-96
mice	O	97-101
.	O	101-102

The	O	103-106
decline	O	107-114
in	O	115-117
cognitive	O	118-127
robustness	O	128-138
with	O	139-143
aging	O	144-149
can	O	150-153
be	O	154-156
attributed	O	157-167
to	O	168-170
complex	O	171-178
genetic	O	179-186
pathways	O	187-195
involving	O	196-205
many	O	206-210
cellular	O	211-219
dysfunctions	O	220-232
,	O	232-233
cumulative	O	234-244
over	O	245-249
time	O	250-254
,	O	254-255
precipitating	O	256-269
in	O	270-272
frailty	O	273-280
and	O	281-284
loss	O	285-289
of	O	290-292
wellness	O	293-301
in	O	302-304
the	O	305-308
elderly	O	309-316
brain	O	317-322
.	O	322-323

The	O	324-327
size	O	328-332
and	O	333-336
health	O	337-343
of	O	344-346
the	O	347-350
neuronal	O	351-359
cell	O	360-364
population	O	365-375
determines	O	376-386
cognitive	O	387-396
robustness	O	397-407
in	O	408-410
mammals	O	411-418
.	O	418-419

A	O	420-421
transgenic	O	422-432
mouse	O	433-438
model	O	439-444
over	O	445-449
-	O	449-450
expressing	O	450-460
Bcl	O	461-464
-	O	464-465
2	O	465-466
has	O	467-470
been	O	471-475
shown	O	476-481
to	O	482-484
rescue	O	485-491
neurons	O	492-499
from	O	500-504
naturally	O	505-514
occurring	O	515-524
cell	O	525-529
death	O	530-535
(	O	536-537
NOCD	O	537-541
)	O	541-542
.	O	542-543

Here	O	544-548
we	O	549-551
show	O	552-556
that	O	557-561
in	O	562-564
the	O	565-568
brain	O	569-574
of	O	575-577
calorie	O	578-585
-	O	585-586
restricted	O	586-596
(	O	597-598
CR	O	598-600
)	O	600-601
mice	O	602-606
,	O	606-607
there	O	608-613
is	O	614-616
an	O	617-619
age	O	620-623
-	O	623-624
dependent	O	624-633
decreased	O	634-643
expression	O	644-654
of	O	655-657
microRNAs	O	658-667
mmu	B	668-671
-	I	671-672
miR	I	672-675
-	I	675-676
181a	I	676-680
-	I	680-681
1	I	681-682
*	I	682-683
,	O	683-684
mmu	B	685-688
-	I	688-689
miR	I	689-692
-	I	692-693
30e	I	693-696
and	O	697-700
mmu	B	701-704
-	I	704-705
miR	I	705-708
-	I	708-709
34a	I	709-712
,	O	712-713
with	O	714-718
a	O	719-720
corresponding	O	721-734
gain	O	735-739
in	O	740-742
Bcl	O	743-746
-	O	746-747
2	O	747-748
expression	O	749-759
,	O	759-760
and	O	761-764
decreases	O	765-774
in	O	775-777
pro	O	778-781
-	O	781-782
apoptosis	O	782-791
genes	O	792-797
such	O	798-802
as	O	803-805
Bax	O	806-809
and	O	810-813
cleavage	O	814-822
of	O	823-825
Caspases	O	826-834
.	O	834-835

Functional	O	836-846
characterization	O	847-863
shows	O	864-869
that	O	870-874
these	O	875-880
miRNAs	O	881-887
repress	O	888-895
Bcl	O	896-899
-	O	899-900
2	O	900-901
expression	O	902-912
by	O	913-915
the	O	916-919
3	O	920-921
'	O	921-922
UTR	O	922-925
reporter	O	926-934
assays	O	935-941
,	O	941-942
accompanied	O	943-954
by	O	955-957
loss	O	958-962
of	O	963-965
this	O	966-970
gene	O	971-975
'	O	975-976
s	O	976-977
endogenous	O	978-988
expression	O	989-999
,	O	999-1000
and	O	1001-1004
a	O	1005-1006
gain	O	1007-1011
in	O	1012-1014
pro	O	1015-1018
-	O	1018-1019
apoptosome	O	1019-1029
-	O	1029-1030
specific	O	1030-1038
proteins	O	1039-1047
.	O	1047-1048

Over	O	1049-1053
-	O	1053-1054
expression	O	1054-1064
of	O	1065-1067
these	O	1068-1073
miRNAs	O	1074-1080
increases	O	1081-1090
the	O	1091-1094
rate	O	1095-1099
of	O	1100-1102
apoptosis	O	1103-1112
,	O	1112-1113
accompanied	O	1114-1125
by	O	1126-1128
a	O	1129-1130
decline	O	1131-1138
in	O	1139-1141
Bcl	O	1142-1145
-	O	1145-1146
2	O	1146-1147
expression	O	1148-1158
in	O	1159-1161
miRNA	O	1162-1167
-	O	1167-1168
transfected	O	1168-1179
mouse	O	1180-1185
and	O	1186-1189
human	O	1190-1195
cell	O	1196-1200
lines	O	1201-1206
.	O	1206-1207

We	O	1208-1210
report	O	1211-1217
here	O	1218-1222
that	O	1223-1227
down	O	1228-1232
-	O	1232-1233
regulation	O	1233-1243
of	O	1244-1246
miR	B	1247-1250
-	I	1250-1251
34a	I	1251-1254
,	O	1254-1255
-	B	1256-1257
30e	I	1257-1260
,	O	1260-1261
and	O	1262-1265
-	B	1266-1267
181a	I	1267-1271
permits	O	1272-1279
their	O	1280-1285
shared	O	1286-1292
target	O	1293-1299
gene	O	1300-1304
expression	O	1305-1315
(	O	1316-1317
Bcl	O	1317-1320
-	O	1320-1321
2	O	1321-1322
)	O	1322-1323
to	O	1324-1326
remain	O	1327-1333
at	O	1334-1336
a	O	1337-1338
high	O	1339-1343
level	O	1344-1349
without	O	1350-1357
post	O	1358-1362
-	O	1362-1363
transcriptional	O	1363-1378
repression	O	1379-1389
,	O	1389-1390
accompanied	O	1391-1402
by	O	1403-1405
concomitant	O	1406-1417
low	O	1418-1421
levels	O	1422-1428
of	O	1429-1431
Bax	O	1432-1435
expression	O	1436-1446
and	O	1447-1450
Caspase	O	1451-1458
cleaving	O	1459-1467
;	O	1467-1468
this	O	1469-1473
chain	O	1474-1479
event	O	1480-1485
may	O	1486-1489
be	O	1490-1492
a	O	1493-1494
part	O	1495-1499
of	O	1500-1502
the	O	1503-1506
underlying	O	1507-1517
mechanism	O	1518-1527
contributing	O	1528-1540
to	O	1541-1543
the	O	1544-1547
gain	O	1548-1552
in	O	1553-1555
neuronal	O	1556-1564
survival	O	1565-1573
in	O	1574-1576
long	O	1577-1581
-	O	1581-1582
lived	O	1582-1587
CR	O	1588-1590
-	O	1590-1591
fed	O	1591-1594
mice	O	1595-1599
.	O	1599-1600

MicroRNA	B	0-8
-	I	8-9
328	I	9-12
is	O	13-15
associated	O	16-26
with	O	27-31
(	O	32-33
non	O	33-36
-	O	36-37
small	O	37-42
)	O	42-43
cell	O	44-48
lung	O	49-53
cancer	O	54-60
(	O	61-62
NSCLC	O	62-67
)	O	67-68
brain	O	69-74
metastasis	O	75-85
and	O	86-89
mediates	O	90-98
NSCLC	O	99-104
migration	O	105-114
.	O	114-115

Brain	O	116-121
metastasis	O	122-132
(	O	133-134
BM	O	134-136
)	O	136-137
can	O	138-141
affect	O	142-148
approximately	O	149-162
25	O	163-165
%	O	165-166
of	O	167-169
nonsmall	O	170-178
cell	O	179-183
lung	O	184-188
cancer	O	189-195
(	O	196-197
NSCLC	O	197-202
)	O	202-203
patients	O	204-212
during	O	213-219
their	O	220-225
lifetime	O	226-234
.	O	234-235

Efforts	O	236-243
to	O	244-246
characterize	O	247-259
patients	O	260-268
that	O	269-273
will	O	274-278
develop	O	279-286
BM	O	287-289
have	O	290-294
been	O	295-299
disappointing	O	300-313
.	O	313-314

microRNAs	O	315-324
(	O	325-326
miRNAs	O	326-332
)	O	332-333
regulate	O	334-342
the	O	343-346
expression	O	347-357
of	O	358-360
target	O	361-367
mRNAs	O	368-373
.	O	373-374

miRNAs	O	375-381
play	O	382-386
a	O	387-388
role	O	389-393
in	O	394-396
regulating	O	397-407
a	O	408-409
variety	O	410-417
of	O	418-420
targets	O	421-428
and	O	429-432
,	O	432-433
consequently	O	434-446
,	O	446-447
multiple	O	448-456
pathways	O	457-465
,	O	465-466
which	O	467-472
make	O	473-477
them	O	478-482
a	O	483-484
powerful	O	485-493
tool	O	494-498
for	O	499-502
early	O	503-508
detection	O	509-518
of	O	519-521
disease	O	522-529
,	O	529-530
risk	O	531-535
assessment	O	536-546
,	O	546-547
and	O	548-551
prognosis	O	552-561
.	O	561-562

We	O	563-565
investigated	O	566-578
miRNAs	O	579-585
that	O	586-590
may	O	591-594
serve	O	595-600
as	O	601-603
biomarkers	O	604-614
to	O	615-617
differentiate	O	618-631
between	O	632-639
NSCLC	O	640-645
patients	O	646-654
with	O	655-659
and	O	660-663
without	O	664-671
BM	O	672-674
.	O	674-675

miRNA	O	676-681
microarray	O	682-692
profiling	O	693-702
was	O	703-706
performed	O	707-716
on	O	717-719
samples	O	720-727
from	O	728-732
clinically	O	733-743
matched	O	744-751
NSCLC	O	752-757
from	O	758-762
seven	O	763-768
patients	O	769-777
with	O	778-782
BM	O	783-785
(	O	786-787
BM	O	787-789
+	O	789-790
)	O	790-791
and	O	792-795
six	O	796-799
without	O	800-807
BM	O	808-810
(	O	811-812
BM	O	812-814
-	O	814-815
)	O	815-816
.	O	816-817

Using	O	818-823
t	O	824-825
-	O	825-826
test	O	826-830
and	O	831-834
further	O	835-842
qRT	O	843-846
-	O	846-847
PCR	O	847-850
validation	O	851-861
,	O	861-862
eight	O	863-868
miRNAs	O	869-875
were	O	876-880
confirmed	O	881-890
to	O	891-893
be	O	894-896
significantly	O	897-910
differentially	O	911-925
expressed	O	926-935
.	O	935-936

Of	O	937-939
these	O	940-945
,	O	945-946
expression	O	947-957
of	O	958-960
miR	B	961-964
-	I	964-965
328	I	965-968
and	O	969-972
miR	B	973-976
-	I	976-977
330	I	977-980
-	I	980-981
3p	I	981-983
were	O	984-988
able	O	989-993
to	O	994-996
correctly	O	997-1006
classify	O	1007-1015
BM	O	1016-1018
+	O	1018-1019
vs	O	1020-1022
.	O	1022-1023
BM	O	1024-1026
-	O	1026-1027
patients	O	1028-1036
.	O	1036-1037

This	O	1038-1042
classifier	O	1043-1053
was	O	1054-1057
used	O	1058-1062
on	O	1063-1065
a	O	1066-1067
validation	O	1068-1078
cohort	O	1079-1085
(	O	1086-1087
n	O	1087-1088
=	O	1089-1090
15	O	1091-1093
)	O	1093-1094
,	O	1094-1095
and	O	1096-1099
it	O	1100-1102
correctly	O	1103-1112
classified	O	1113-1123
12	O	1124-1126
/	O	1126-1127
15	O	1127-1129
patients	O	1130-1138
.	O	1138-1139

Gene	O	1140-1144
expression	O	1145-1155
analysis	O	1156-1164
comparing	O	1165-1174
A549	O	1175-1179
parental	O	1180-1188
and	O	1189-1192
A549	O	1193-1197
cells	O	1198-1203
stably	O	1204-1210
transfected	O	1211-1222
to	O	1223-1225
over	O	1226-1230
-	O	1230-1231
express	O	1231-1238
miR	B	1239-1242
-	I	1242-1243
328	I	1243-1246
(	O	1247-1248
A549	O	1248-1252
-	O	1252-1253
328	O	1253-1256
)	O	1256-1257
identified	O	1258-1268
several	O	1269-1276
significantly	O	1277-1290
differentially	O	1291-1305
expressed	O	1306-1315
genes	O	1316-1321
.	O	1321-1322

PRKCA	O	1323-1328
was	O	1329-1332
one	O	1333-1336
of	O	1337-1339
the	O	1340-1343
genes	O	1344-1349
over	O	1350-1354
-	O	1354-1355
expressed	O	1355-1364
in	O	1365-1367
A549	O	1368-1372
-	O	1372-1373
328	O	1373-1376
cells	O	1377-1382
.	O	1382-1383

Additionally	O	1384-1396
,	O	1396-1397
A549	O	1398-1402
-	O	1402-1403
328	O	1403-1406
cells	O	1407-1412
had	O	1413-1416
significantly	O	1417-1430
increased	O	1431-1440
cell	O	1441-1445
migration	O	1446-1455
compared	O	1456-1464
to	O	1465-1467
A549	O	1468-1472
cells	O	1473-1478
,	O	1478-1479
which	O	1480-1485
was	O	1486-1489
significantly	O	1490-1503
reduced	O	1504-1511
upon	O	1512-1516
PRKCA	O	1517-1522
knockdown	O	1523-1532
.	O	1532-1533

In	O	1534-1536
summary	O	1537-1544
,	O	1544-1545
miR	B	1546-1549
-	I	1549-1550
328	I	1550-1553
has	O	1554-1557
a	O	1558-1559
role	O	1560-1564
in	O	1565-1567
conferring	O	1568-1578
migratory	O	1579-1588
potential	O	1589-1598
to	O	1599-1601
NSCLC	O	1602-1607
cells	O	1608-1613
working	O	1614-1621
in	O	1622-1624
part	O	1625-1629
through	O	1630-1637
PRKCA	O	1638-1643
and	O	1644-1647
with	O	1648-1652
further	O	1653-1660
corroboration	O	1661-1674
in	O	1675-1677
additional	O	1678-1688
independent	O	1689-1700
cohorts	O	1701-1708
,	O	1708-1709
these	O	1710-1715
miRNAs	O	1716-1722
may	O	1723-1726
be	O	1727-1729
incorporated	O	1730-1742
into	O	1743-1747
clinical	O	1748-1756
treatment	O	1757-1766
decision	O	1767-1775
making	O	1776-1782
to	O	1783-1785
stratify	O	1786-1794
NSCLC	O	1795-1800
patients	O	1801-1809
at	O	1810-1812
higher	O	1813-1819
risk	O	1820-1824
for	O	1825-1828
developing	O	1829-1839
BM	O	1840-1842
.	O	1842-1843

MicroRNA	O	0-8
profiling	O	9-18
of	O	19-21
adrenocortical	O	22-36
tumors	O	37-43
reveals	O	44-51
miR	B	52-55
-	I	55-56
483	I	56-59
as	O	60-62
a	O	63-64
marker	O	65-71
of	O	72-74
malignancy	O	75-85
.	O	85-86

BACKGROUND	O	87-97
:	O	97-98
The	O	99-102
authors	O	103-110
are	O	111-114
interested	O	115-125
in	O	126-128
identifying	O	129-140
molecular	O	141-150
markers	O	151-158
that	O	159-163
can	O	164-167
aid	O	168-171
in	O	172-174
the	O	175-178
diagnosis	O	179-188
of	O	189-191
adrenocortical	O	192-206
carcinoma	O	207-216
(	O	217-218
ACC	O	218-221
)	O	221-222
.	O	222-223

The	O	224-227
aim	O	228-231
of	O	232-234
this	O	235-239
study	O	240-245
was	O	246-249
to	O	250-252
identify	O	253-261
microRNAs	O	262-271
(	O	272-273
miRNAs	O	273-279
or	O	280-282
miRs	O	283-287
)	O	287-288
that	O	289-293
are	O	294-297
differentially	O	298-312
expressed	O	313-322
in	O	323-325
malignant	O	326-335
adrenocortical	O	336-350
tumors	O	351-357
as	O	358-360
compared	O	361-369
with	O	370-374
benign	O	375-381
tumors	O	382-388
and	O	389-392
assess	O	393-399
their	O	400-405
potential	O	406-415
as	O	416-418
diagnostic	O	419-429
predictors	O	430-440
.	O	440-441

METHODS	O	442-449
:	O	449-450
Differentially	O	451-465
expressed	O	466-475
miRNAs	O	476-482
were	O	483-487
identified	O	488-498
using	O	499-504
microarray	O	505-515
profiling	O	516-525
of	O	526-528
adrenocortical	O	529-543
tumors	O	544-550
and	O	551-554
validated	O	555-564
by	O	565-567
quantitative	O	568-580
real	O	581-585
-	O	585-586
time	O	586-590
RT	O	591-593
-	O	593-594
PCR	O	594-597
.	O	597-598

RESULTS	O	599-606
:	O	606-607
Microarray	O	608-618
profiling	O	619-628
in	O	629-631
benign	O	632-638
and	O	639-642
primary	O	643-650
malignant	O	651-660
adrenocortical	O	661-675
tumors	O	676-682
revealed	O	683-691
several	O	692-699
significant	O	700-711
differences	O	712-723
between	O	724-731
these	O	732-737
histological	O	738-750
groups	O	751-757
.	O	757-758

By	O	759-761
using	O	762-767
directed	O	768-776
quantitative	O	777-789
RT	O	790-792
-	O	792-793
PCR	O	793-796
analysis	O	797-805
on	O	806-808
a	O	809-810
subset	O	811-817
of	O	818-820
these	O	821-826
differentially	O	827-841
expressed	O	842-851
miRNAs	O	852-858
,	O	858-859
the	O	860-863
authors	O	864-871
determined	O	872-882
that	O	883-887
miRs	O	888-892
-	B	893-894
100	I	894-897
,	O	897-898
-	B	899-900
125b	I	900-904
,	O	904-905
and	O	906-909
-	B	910-911
195	I	911-914
were	O	915-919
significantly	O	920-933
down	O	934-938
-	O	938-939
regulated	O	939-948
,	O	948-949
whereas	O	950-957
miR	B	958-961
-	I	961-962
483	I	962-965
-	I	965-966
5p	I	966-968
was	O	969-972
significantly	O	973-986
up	O	987-989
-	O	989-990
regulated	O	990-999
in	O	1000-1002
malignant	O	1003-1012
as	O	1013-1015
compared	O	1016-1024
with	O	1025-1029
benign	O	1030-1036
tumors	O	1037-1043
.	O	1043-1044

Furthermore	O	1045-1056
,	O	1056-1057
the	O	1058-1061
current	O	1062-1069
study	O	1070-1075
shows	O	1076-1081
that	O	1082-1086
miR	B	1087-1090
-	I	1090-1091
483	I	1091-1094
-	I	1094-1095
5p	I	1095-1097
expression	O	1098-1108
can	O	1109-1112
accurately	O	1113-1123
categorize	O	1124-1134
tumors	O	1135-1141
as	O	1142-1144
benign	O	1145-1151
or	O	1152-1154
malignant	O	1155-1164
.	O	1164-1165

CONCLUSIONS	O	1166-1177
:	O	1177-1178
The	O	1179-1182
authors	O	1183-1190
identified	O	1191-1201
4	O	1202-1203
miRNAs	O	1204-1210
that	O	1211-1215
are	O	1216-1219
dysregulated	O	1220-1232
in	O	1233-1235
adrenocortical	O	1236-1250
carcinoma	O	1251-1260
.	O	1260-1261

The	O	1262-1265
high	O	1266-1270
expression	O	1271-1281
of	O	1282-1284
one	O	1285-1288
of	O	1289-1291
these	O	1292-1297
,	O	1297-1298
miR	B	1299-1302
-	I	1302-1303
483	I	1303-1306
-	I	1306-1307
5p	I	1307-1309
,	O	1309-1310
appears	O	1311-1318
to	O	1319-1321
be	O	1322-1324
a	O	1325-1326
defining	O	1327-1335
characteristic	O	1336-1350
of	O	1351-1353
adrenocortical	O	1354-1368
malignancies	O	1369-1381
,	O	1381-1382
and	O	1383-1386
can	O	1387-1390
thus	O	1391-1395
be	O	1396-1398
used	O	1399-1403
to	O	1404-1406
accurately	O	1407-1417
distinguish	O	1418-1429
between	O	1430-1437
benign	O	1438-1444
and	O	1445-1448
malignant	O	1449-1458
adrenocortical	O	1459-1473
tumors	O	1474-1480
.	O	1480-1481

A	O	0-1
sensitive	O	2-11
alternative	O	12-23
for	O	24-27
microRNA	O	28-36
in	O	37-39
situ	O	40-44
hybridizations	O	45-59
using	O	60-65
probes	O	66-72
of	O	73-75
2	O	76-77
'	O	77-78
-	O	78-79
O	O	79-80
-	O	80-81
methyl	O	81-87
RNA	O	88-91
+	O	92-93
LNA	O	94-97
.	O	97-98

The	O	99-102
use	O	103-106
of	O	107-109
short	O	110-115
,	O	115-116
high	O	117-121
-	O	121-122
affinity	O	122-130
probes	O	131-137
consisting	O	138-148
of	O	149-151
a	O	152-153
combination	O	154-165
of	O	166-168
DNA	O	169-172
and	O	173-176
locked	O	177-183
nucleic	O	184-191
acid	O	192-196
(	O	197-198
LNA	O	198-201
)	O	201-202
has	O	203-206
enabled	O	207-214
the	O	215-218
specific	O	219-227
detection	O	228-237
of	O	238-240
microRNAs	O	241-250
(	O	251-252
miRNAs	O	252-258
)	O	258-259
by	O	260-262
in	O	263-265
situ	O	266-270
hybridization	O	271-284
(	O	285-286
ISH	O	286-289
)	O	289-290
.	O	290-291

However	O	292-299
,	O	299-300
detection	O	301-310
of	O	311-313
low	O	314-317
-	O	317-318
copy	O	318-322
number	O	323-329
miRNAs	O	330-336
is	O	337-339
still	O	340-345
not	O	346-349
always	O	350-356
possible	O	357-365
.	O	365-366

Here	O	367-371
the	O	372-375
authors	O	376-383
show	O	384-388
that	O	389-393
probes	O	394-400
consisting	O	401-411
of	O	412-414
2	O	415-416
'	O	416-417
-	O	417-418
O	O	418-419
-	O	419-420
methyl	O	420-426
RNAs	O	427-431
(	O	432-433
2OMe	O	433-437
)	O	437-438
and	O	439-442
LNA	O	443-446
at	O	447-449
every	O	450-455
third	O	456-461
base	O	462-466
(	O	467-468
2	O	468-469
:	O	469-470
1	O	470-471
ratio	O	472-477
)	O	477-478
,	O	478-479
under	O	480-485
optimized	O	486-495
hybridization	O	496-509
conditions	O	510-520
,	O	520-521
excluding	O	522-531
yeast	O	532-537
RNA	O	538-541
from	O	542-546
the	O	547-550
hybridization	O	551-564
buffer	O	565-571
,	O	571-572
can	O	573-576
provide	O	577-584
superior	O	585-593
performance	O	594-605
in	O	606-608
detection	O	609-618
of	O	619-621
miRNA	O	622-627
targets	O	628-635
in	O	636-638
terms	O	639-644
of	O	645-647
sensitivity	O	648-659
and	O	660-663
signal	O	664-670
-	O	670-671
to	O	671-673
-	O	673-674
noise	O	674-679
ratio	O	680-685
compared	O	686-694
to	O	695-697
DNA	O	698-701
+	O	702-703
LNA	O	704-707
probes	O	708-714
.	O	714-715

Furthermore	O	716-727
,	O	727-728
they	O	729-733
show	O	734-738
that	O	739-743
hybridizations	O	744-758
can	O	759-762
be	O	763-765
performed	O	766-775
in	O	776-778
buffers	O	779-786
of	O	787-789
4M	O	790-792
urea	O	793-797
instead	O	798-805
of	O	806-808
50	O	809-811
%	O	811-812
formamide	O	813-822
,	O	822-823
thereby	O	824-831
yielding	O	832-840
an	O	841-843
equally	O	844-851
specific	O	852-860
but	O	861-864
nontoxic	O	865-873
assay	O	874-879
.	O	879-880

The	O	881-884
use	O	885-888
of	O	889-891
2OMe	O	892-896
+	O	897-898
LNA	O	899-902
-	O	902-903
based	O	903-908
probes	O	909-915
and	O	916-919
the	O	920-923
optimized	O	924-933
ISH	O	934-937
assay	O	938-943
enable	O	944-950
simple	O	951-957
and	O	958-961
fast	O	962-966
detection	O	967-976
of	O	977-979
low	O	980-983
-	O	983-984
copy	O	984-988
number	O	989-995
miRNA	O	996-1001
targets	O	1002-1009
,	O	1009-1010
such	O	1011-1015
as	O	1016-1018
miR	B	1019-1022
-	I	1022-1023
130a	I	1023-1027
in	O	1028-1030
mouse	O	1031-1036
brain	O	1037-1042
.	O	1042-1043

Downregulation	O	0-14
of	O	15-17
Sec23A	O	18-24
protein	O	25-32
by	O	33-35
miRNA	B	36-41
-	I	41-42
375	I	42-45
in	O	46-48
prostate	O	49-57
carcinoma	O	58-67
.	O	67-68

Prostate	O	69-77
carcinoma	O	78-87
(	O	88-89
CaP	O	89-92
)	O	92-93
is	O	94-96
a	O	97-98
leading	O	99-106
cause	O	107-112
of	O	113-115
cancer	O	116-122
-	O	122-123
related	O	123-130
death	O	131-136
in	O	137-139
men	O	140-143
.	O	143-144

We	O	145-147
have	O	148-152
previously	O	153-163
determined	O	164-174
the	O	175-178
microRNA	O	179-187
(	O	188-189
miRNA	O	189-194
)	O	194-195
profile	O	196-203
of	O	204-206
primary	O	207-214
CaP	O	215-218
in	O	219-221
comparison	O	222-232
with	O	233-237
nontumor	O	238-246
prostate	O	247-255
tissue	O	256-262
.	O	262-263

miRNAs	O	264-270
are	O	271-274
small	O	275-280
,	O	280-281
noncoding	O	282-291
RNAs	O	292-296
that	O	297-301
inhibit	O	302-309
protein	O	310-317
synthesis	O	318-327
on	O	328-330
a	O	331-332
posttranscriptional	O	333-352
level	O	353-358
by	O	359-361
binding	O	362-369
to	O	370-372
the	O	373-376
3	O	377-378
'	O	378-379
-	O	379-380
untranslated	O	380-392
region	O	393-399
(	O	400-401
3	O	401-402
'	O	402-403
-	O	403-404
UTR	O	404-407
)	O	407-408
of	O	409-411
their	O	412-417
target	O	418-424
genes	O	425-430
.	O	430-431

In	O	432-434
primary	O	435-442
CaP	O	443-446
tissue	O	447-453
,	O	453-454
we	O	455-457
have	O	458-462
previously	O	463-473
found	O	474-479
by	O	480-482
miRNA	O	483-488
sequencing	O	489-499
that	O	500-504
miR	B	505-508
-	I	508-509
375	I	509-512
and	O	513-516
miR	B	517-520
-	I	520-521
200c	I	521-525
were	O	526-530
upregulated	O	531-542
9	O	543-544
.	O	544-545
1	O	545-546
-	O	546-547
and	O	548-551
4	O	552-553
.	O	553-554
5	O	554-555
-	O	555-556
fold	O	556-560
,	O	560-561
respectively	O	562-574
.	O	574-575

A	O	576-577
computational	O	578-591
analysis	O	592-600
predicted	O	601-610
the	O	611-614
3	O	615-616
'	O	616-617
-	O	617-618
UTR	O	618-621
of	O	622-624
the	O	625-628
SEC23A	O	629-635
gene	O	636-640
as	O	641-643
a	O	644-645
potential	O	646-655
target	O	656-662
for	O	663-666
both	O	667-671
miR	B	672-675
-	I	675-676
375	I	676-679
and	O	680-683
miR	B	684-687
-	I	687-688
200c	I	688-692
.	O	692-693

Here	O	694-698
,	O	698-699
we	O	700-702
show	O	703-707
that	O	708-712
the	O	713-716
3	O	717-718
'	O	718-719
-	O	719-720
UTR	O	720-723
of	O	724-726
SEC23A	O	727-733
mRNA	O	734-738
is	O	739-741
indeed	O	742-748
a	O	749-750
target	O	751-757
for	O	758-761
miR	B	762-765
-	I	765-766
375	I	766-769
and	O	770-773
miR	B	774-777
-	I	777-778
200c	I	778-782
and	O	783-786
that	O	787-791
both	O	792-796
miRNAs	O	797-803
downregulate	O	804-816
Sec23A	O	817-823
protein	O	824-831
expression	O	832-842
when	O	843-847
ectopically	O	848-859
expressed	O	860-869
in	O	870-872
human	O	873-878
293T	O	879-883
cells	O	884-889
.	O	889-890

In	O	891-893
primary	O	894-901
samples	O	902-909
of	O	910-912
CaP	O	913-916
,	O	916-917
we	O	918-920
found	O	921-926
a	O	927-928
direct	O	929-935
correlation	O	936-947
between	O	948-955
reduction	O	956-965
of	O	966-968
SEC23A	O	969-975
mRNA	O	976-980
and	O	981-984
overexpression	O	985-999
of	O	1000-1002
miR	B	1003-1006
-	I	1006-1007
375	I	1007-1010
but	O	1011-1014
not	O	1015-1018
of	O	1019-1021
miR	B	1022-1025
-	I	1025-1026
200c	I	1026-1030
.	O	1030-1031

The	O	1032-1035
reduced	O	1036-1043
levels	O	1044-1050
of	O	1051-1053
Sec23A	O	1054-1060
protein	O	1061-1068
were	O	1069-1073
inversely	O	1074-1083
correlated	O	1084-1094
to	O	1095-1097
the	O	1098-1101
increased	O	1102-1111
amount	O	1112-1118
of	O	1119-1121
miR	B	1122-1125
-	I	1125-1126
375	I	1126-1129
in	O	1130-1132
the	O	1133-1136
LNCaP	O	1137-1142
and	O	1143-1146
DU145	O	1147-1152
CaP	O	1153-1156
cell	O	1157-1161
lines	O	1162-1167
when	O	1168-1172
compared	O	1173-1181
with	O	1182-1186
normal	O	1187-1193
prostate	O	1194-1202
fibroblasts	O	1203-1214
.	O	1214-1215

In	O	1216-1218
primary	O	1219-1226
CaP	O	1227-1230
,	O	1230-1231
we	O	1232-1234
also	O	1235-1239
detected	O	1240-1248
decreased	O	1249-1258
amounts	O	1259-1266
of	O	1267-1269
Sec23A	O	1270-1276
protein	O	1277-1284
when	O	1285-1289
compared	O	1290-1298
with	O	1299-1303
corresponding	O	1304-1317
normal	O	1318-1324
prostate	O	1325-1333
tissue	O	1334-1340
.	O	1340-1341

Ectopically	O	1342-1353
overexpressed	O	1354-1367
Sec23A	O	1368-1374
in	O	1375-1377
LNCaP	O	1378-1383
and	O	1384-1387
DU145	O	1388-1393
CaP	O	1394-1397
cells	O	1398-1403
significantly	O	1404-1417
reduced	O	1418-1425
the	O	1426-1429
growth	O	1430-1436
properties	O	1437-1447
,	O	1447-1448
indicating	O	1449-1459
that	O	1460-1464
Sec23A	O	1465-1471
might	O	1472-1477
play	O	1478-1482
a	O	1483-1484
role	O	1485-1489
in	O	1490-1492
the	O	1493-1496
induction	O	1497-1506
or	O	1507-1509
growth	O	1510-1516
of	O	1517-1519
prostate	O	1520-1528
carcinoma	O	1529-1538
.	O	1538-1539

Sec23A	O	1540-1546
overexpression	O	1547-1561
reduced	O	1562-1569
cell	O	1570-1574
growth	O	1575-1581
but	O	1582-1585
did	O	1586-1589
not	O	1590-1593
induce	O	1594-1600
apoptosis	O	1601-1610
,	O	1610-1611
whereas	O	1612-1619
inhibition	O	1620-1630
of	O	1631-1633
Sec23A	O	1634-1640
stimulated	O	1641-1651
cell	O	1652-1656
proliferation	O	1657-1670
.	O	1670-1671

Polyphenolics	O	0-13
from	O	14-18
acai	O	19-23
(	O	24-25
Euterpe	O	26-33
oleracea	O	34-42
Mart	O	43-47
.	O	47-48
)	O	48-49

and	O	50-53
red	O	54-57
muscadine	O	58-67
grape	O	68-73
(	O	74-75
Vitis	O	75-80
rotundifolia	O	81-93
)	O	94-95
protect	O	96-103
human	O	104-109
umbilical	O	110-119
vascular	O	120-128
Endothelial	O	129-140
cells	O	141-146
(	O	147-148
HUVEC	O	148-153
)	O	153-154
from	O	155-159
glucose	O	160-167
-	O	167-168
and	O	169-172
lipopolysaccharide	O	173-191
(	O	192-193
LPS	O	193-196
)	O	196-197
-	O	197-198
induced	O	198-205
inflammation	O	206-218
and	O	219-222
target	O	223-229
microRNA	B	230-238
-	I	238-239
126	I	239-242
.	O	242-243

Endothelial	O	244-255
anti	O	256-260
-	O	260-261
inflammatory	O	261-273
effects	O	274-281
of	O	282-284
acai	O	285-289
(	O	290-291
Ac	O	291-293
)	O	293-294
and	O	295-298
red	O	299-302
muscadine	O	303-312
grape	O	313-318
(	O	319-320
Gp	O	320-322
)	O	322-323
polyphenolics	O	324-337
have	O	338-342
not	O	343-346
been	O	347-351
extensively	O	352-363
investigated	O	364-376
.	O	376-377

It	O	378-380
was	O	381-384
hypothesized	O	385-397
that	O	398-402
polyphenolics	O	403-416
from	O	417-421
Ac	O	422-424
and	O	425-428
Gp	O	429-431
exert	O	432-437
comparable	O	438-448
protective	O	449-459
effects	O	460-467
in	O	468-470
human	O	471-476
vascular	O	477-485
endothelial	O	486-497
cells	O	498-503
(	O	504-505
HUVEC	O	505-510
)	O	510-511
upon	O	512-516
inflammatory	O	517-529
stress	O	530-536
.	O	536-537

Furthermore	O	538-549
,	O	549-550
this	O	551-555
study	O	556-561
investigated	O	562-574
whether	O	575-582
microRNAs	O	583-592
relevant	O	593-601
to	O	602-604
endothelial	O	605-616
function	O	617-625
might	O	626-631
be	O	632-634
regulated	O	635-644
by	O	645-647
Ac	O	648-650
and	O	651-654
Gp	O	655-657
.	O	657-658

Results	O	659-666
showed	O	667-673
that	O	674-678
Ac	O	679-681
and	O	682-685
Gp	O	686-688
(	O	689-690
5	O	690-691
-	O	691-692
20	O	692-694
mg	O	695-697
gallic	O	698-704
acid	O	705-709
equivalent	O	710-720
/	O	720-721
L	O	721-722
)	O	722-723
protected	O	724-733
HUVEC	O	734-739
against	O	740-747
glucose	O	748-755
-	O	755-756
induced	O	756-763
oxidative	O	764-773
stress	O	774-780
and	O	781-784
inflammation	O	785-797
.	O	797-798

Glucose	O	799-806
-	O	806-807
induced	O	807-814
expression	O	815-825
of	O	826-828
interleukin	O	829-840
-	O	840-841
6	O	841-842
and	O	843-846
-	O	847-848
8	O	848-849
was	O	850-853
down	O	854-858
-	O	858-859
regulated	O	859-868
by	O	869-871
Ac	O	872-874
and	O	875-878
Gp	O	879-881
at	O	882-884
mRNA	O	885-889
and	O	890-893
protein	O	894-901
levels	O	902-908
.	O	908-909

Upon	O	910-914
lipopolysaccharide	O	915-933
(	O	934-935
LPS	O	935-938
;	O	938-939
1	O	940-941
mug	O	942-945
/	O	945-946
L	O	946-947
)	O	947-948
-	O	948-949
induced	O	949-956
inflammation	O	957-969
,	O	969-970
Ac	O	971-973
and	O	974-977
Gp	O	978-980
inhibited	O	981-990
gene	O	991-995
expression	O	996-1006
of	O	1007-1009
adhesion	O	1010-1018
molecules	O	1019-1028
and	O	1029-1032
NF	O	1033-1035
-	O	1035-1036
kappaB	O	1036-1042
activation	O	1043-1053
to	O	1054-1056
similar	O	1057-1064
extents	O	1065-1072
,	O	1072-1073
although	O	1074-1082
Gp	O	1083-1085
was	O	1086-1089
more	O	1090-1094
effective	O	1095-1104
in	O	1105-1107
decreasing	O	1108-1118
PECAM	O	1119-1124
-	O	1124-1125
1	O	1125-1126
and	O	1127-1130
ICAM	O	1131-1135
-	O	1135-1136
1	O	1136-1137
protein	O	1138-1145
.	O	1145-1146

Of	O	1147-1149
the	O	1150-1153
screened	O	1154-1162
microRNAs	O	1163-1172
,	O	1172-1173
only	O	1174-1178
microRNA	B	1179-1187
-	I	1187-1188
126	I	1188-1191
expression	O	1192-1202
was	O	1203-1206
found	O	1207-1212
to	O	1213-1215
be	O	1216-1218
modulated	O	1219-1228
by	O	1229-1231
Ac	O	1232-1234
and	O	1235-1238
Gp	O	1239-1241
as	O	1242-1244
the	O	1245-1248
underlying	O	1249-1259
mechanism	O	1260-1269
to	O	1270-1272
inhibit	O	1273-1280
gene	O	1281-1285
and	O	1286-1289
protein	O	1290-1297
expression	O	1298-1308
of	O	1309-1311
VCAM	O	1312-1316
-	O	1316-1317
1	O	1317-1318
.	O	1318-1319

Overexpression	O	0-14
of	O	15-17
microRNAs	O	18-27
from	O	28-32
the	O	33-36
miR	B	37-40
-	I	40-41
17	I	41-43
-	I	43-44
92	I	44-46
paralog	O	47-54
clusters	O	55-63
in	O	64-66
AIDS	O	67-71
-	O	71-72
related	O	72-79
non	O	80-83
-	O	83-84
Hodgkin	O	84-91
'	O	91-92
s	O	92-93
lymphomas	O	94-103
.	O	103-104

BACKGROUND	O	105-115
:	O	115-116
Individuals	O	117-128
infected	O	129-137
by	O	138-140
HIV	O	141-144
are	O	145-148
at	O	149-151
an	O	152-154
increased	O	155-164
risk	O	165-169
for	O	170-173
developing	O	174-184
non	O	185-188
-	O	188-189
Hodgkin	O	189-196
'	O	196-197
s	O	197-198
lymphomas	O	199-208
(	O	209-210
AIDS	O	210-214
-	O	214-215
NHL	O	215-218
)	O	218-219
.	O	219-220

In	O	221-223
the	O	224-227
highly	O	228-234
active	O	235-241
antiretroviral	O	242-256
therapy	O	257-264
(	O	265-266
HAART	O	266-271
)	O	271-272
era	O	273-276
,	O	276-277
there	O	278-283
has	O	284-287
been	O	288-292
a	O	293-294
significant	O	295-306
decline	O	307-314
in	O	315-317
the	O	318-321
incidence	O	322-331
of	O	332-334
AIDS	O	335-339
-	O	339-340
associated	O	340-350
primary	O	351-358
central	O	359-366
nervous	O	367-374
system	O	375-381
lymphoma	O	382-390
(	O	391-392
PCNSL	O	392-397
)	O	397-398
.	O	398-399

However	O	400-407
,	O	407-408
only	O	409-413
a	O	414-415
modest	O	416-422
decrease	O	423-431
in	O	432-434
incidence	O	435-444
has	O	445-448
been	O	449-453
reported	O	454-462
for	O	463-466
other	O	467-472
AIDS	O	473-477
-	O	477-478
NHL	O	478-481
subtypes	O	482-490
.	O	490-491

Thus	O	492-496
,	O	496-497
AIDS	O	498-502
-	O	502-503
NHLs	O	503-507
remain	O	508-514
a	O	515-516
significant	O	517-528
cause	O	529-534
of	O	535-537
morbidity	O	538-547
and	O	548-551
mortality	O	552-561
in	O	562-564
HIV	O	565-568
infected	O	569-577
individuals	O	578-589
.	O	589-590

Recently	O	591-599
,	O	599-600
much	O	601-605
attention	O	606-615
has	O	616-619
been	O	620-624
directed	O	625-633
toward	O	634-640
the	O	641-644
role	O	645-649
of	O	650-652
miRNAs	O	653-659
in	O	660-662
cancer	O	663-669
,	O	669-670
including	O	671-680
NHL	O	681-684
.	O	684-685

Several	O	686-693
miRNAs	O	694-700
,	O	700-701
including	O	702-711
those	O	712-717
encoded	O	718-725
by	O	726-728
the	O	729-732
miR	B	733-736
-	I	736-737
17	I	737-739
-	I	739-740
92	I	740-742
polycistron	O	743-754
,	O	754-755
have	O	756-760
been	O	761-765
shown	O	766-771
to	O	772-774
play	O	775-779
significant	O	780-791
roles	O	792-797
in	O	798-800
B	O	801-802
cell	O	803-807
tumorigenesis	O	808-821
.	O	821-822

However	O	823-830
,	O	830-831
the	O	832-835
role	O	836-840
of	O	841-843
miRNAs	O	844-850
in	O	851-853
NHL	O	854-857
in	O	858-860
the	O	861-864
setting	O	865-872
of	O	873-875
HIV	O	876-879
infection	O	880-889
has	O	890-893
not	O	894-897
been	O	898-902
defined	O	903-910
.	O	910-911

METHODOLOGY	O	912-923
/	O	923-924
PRINCIPAL	O	924-933
FINDINGS	O	934-942
:	O	942-943
We	O	944-946
used	O	947-951
quantitative	O	952-964
realtime	O	965-973
PCR	O	974-977
to	O	978-980
assess	O	981-987
the	O	988-991
expression	O	992-1002
of	O	1003-1005
miRNAs	O	1006-1012
from	O	1013-1017
three	O	1018-1023
different	O	1024-1033
paralog	O	1034-1041
clusters	O	1042-1050
,	O	1050-1051
miR	B	1052-1055
-	I	1055-1056
17	I	1056-1058
-	I	1058-1059
92	I	1059-1061
,	O	1061-1062
miR	B	1063-1066
-	I	1066-1067
106a	I	1067-1071
-	I	1071-1072
363	I	1072-1075
,	O	1075-1076
and	O	1077-1080
miR	B	1081-1084
-	I	1084-1085
106b	I	1085-1089
-	I	1089-1090
25	I	1090-1092
in	O	1093-1095
24	O	1096-1098
cases	O	1099-1104
of	O	1105-1107
AIDS	O	1108-1112
-	O	1112-1113
NHLs	O	1113-1117
representing	O	1118-1130
four	O	1131-1135
tumor	O	1136-1141
types	O	1142-1147
,	O	1147-1148
Burkitt	O	1149-1156
'	O	1156-1157
s	O	1157-1158
lymphoma	O	1159-1167
(	O	1168-1169
BL	O	1169-1171
,	O	1171-1172
n	O	1173-1174
=	O	1175-1176
6	O	1177-1178
)	O	1178-1179
,	O	1179-1180
diffuse	O	1181-1188
large	O	1189-1194
B	O	1195-1196
-	O	1196-1197
cell	O	1197-1201
lymphoma	O	1202-1210
(	O	1211-1212
DLBCL	O	1212-1217
,	O	1217-1218
n	O	1219-1220
=	O	1221-1222
8	O	1223-1224
)	O	1224-1225
,	O	1225-1226
primary	O	1227-1234
central	O	1235-1242
nervous	O	1243-1250
system	O	1251-1257
lymphoma	O	1258-1266
(	O	1267-1268
PCNSL	O	1268-1273
,	O	1273-1274
n	O	1275-1276
=	O	1277-1278
5	O	1279-1280
)	O	1280-1281
,	O	1281-1282
and	O	1283-1286
primary	O	1287-1294
effusion	O	1295-1303
lymphoma	O	1304-1312
(	O	1313-1314
PEL	O	1314-1317
,	O	1317-1318
n	O	1319-1320
=	O	1321-1322
5	O	1323-1324
)	O	1324-1325
.	O	1325-1326

We	O	1327-1329
also	O	1330-1334
used	O	1335-1339
microarray	O	1340-1350
analysis	O	1351-1359
to	O	1360-1362
identify	O	1363-1371
a	O	1372-1373
differentiation	O	1374-1389
specific	O	1390-1398
miRNA	O	1399-1404
signature	O	1405-1414
of	O	1415-1417
naive	O	1418-1423
,	O	1423-1424
germinal	O	1425-1433
center	O	1434-1440
,	O	1440-1441
and	O	1442-1445
memory	O	1446-1452
B	O	1453-1454
cell	O	1455-1459
subsets	O	1460-1467
from	O	1468-1472
tonsils	O	1473-1480
(	O	1481-1482
n	O	1482-1483
=	O	1484-1485
4	O	1486-1487
)	O	1487-1488
.	O	1488-1489

miRNAs	O	1490-1496
from	O	1497-1501
the	O	1502-1505
miR	B	1506-1509
-	I	1509-1510
17	I	1510-1512
-	I	1512-1513
92	I	1513-1515
paralog	O	1516-1523
clusters	O	1524-1532
were	O	1533-1537
upregulated	O	1538-1549
by	O	1550-1552
B	O	1553-1554
cells	O	1555-1560
,	O	1560-1561
specifically	O	1562-1574
during	O	1575-1581
the	O	1582-1585
GC	O	1586-1588
differentiation	O	1589-1604
stage	O	1605-1610
.	O	1610-1611

We	O	1612-1614
also	O	1615-1619
found	O	1620-1625
overexpression	O	1626-1640
of	O	1641-1643
these	O	1644-1649
miRNA	O	1650-1655
clusters	O	1656-1664
in	O	1665-1667
all	O	1668-1671
four	O	1672-1676
AIDS	O	1677-1681
-	O	1681-1682
NHL	O	1682-1685
subtypes	O	1686-1694
.	O	1694-1695

Finally	O	1696-1703
,	O	1703-1704
we	O	1705-1707
also	O	1708-1712
show	O	1713-1717
that	O	1718-1722
select	O	1723-1729
miRNAs	O	1730-1736
from	O	1737-1741
these	O	1742-1747
clusters	O	1748-1756
(	O	1757-1758
miR	B	1758-1761
-	I	1761-1762
17	I	1762-1764
,	O	1764-1765
miR	B	1766-1769
-	I	1769-1770
106a	I	1770-1774
,	O	1774-1775
and	O	1776-1779
miR	B	1780-1783
-	I	1783-1784
106b	I	1784-1788
)	O	1788-1789
inhibited	O	1790-1799
p21	O	1800-1803
in	O	1804-1806
AIDS	O	1807-1811
-	O	1811-1812
BL	O	1812-1814
and	O	1815-1818
DLBCL	O	1819-1824
cases	O	1825-1830
,	O	1830-1831
thus	O	1832-1836
providing	O	1837-1846
a	O	1847-1848
mechanistic	O	1849-1860
role	O	1861-1865
for	O	1866-1869
these	O	1870-1875
miRNAs	O	1876-1882
in	O	1883-1885
AIDS	O	1886-1890
-	O	1890-1891
NHL	O	1891-1894
pathogenesis	O	1895-1907
.	O	1907-1908

CONCLUSION	O	1909-1919
:	O	1919-1920
Dysregulation	O	1921-1934
of	O	1935-1937
miR	B	1938-1941
-	I	1941-1942
17	I	1942-1944
-	I	1944-1945
92	I	1945-1947
paralog	O	1948-1955
clusters	O	1956-1964
is	O	1965-1967
a	O	1968-1969
common	O	1970-1976
feature	O	1977-1984
of	O	1985-1987
AIDS	O	1988-1992
-	O	1992-1993
associated	O	1993-2003
NHLs	O	2004-2008
.	O	2008-2009

Aerobic	O	0-7
exercise	O	8-16
training	O	17-25
-	O	25-26
induced	O	26-33
left	O	34-38
ventricular	O	39-50
hypertrophy	O	51-62
involves	O	63-71
regulatory	O	72-82
MicroRNAs	O	83-92
,	O	92-93
decreased	O	94-103
angiotensin	O	104-115
-	O	115-116
converting	O	116-126
enzyme	O	127-133
-	O	133-134
angiotensin	O	134-145
ii	O	146-148
,	O	148-149
and	O	150-153
synergistic	O	154-165
regulation	O	166-176
of	O	177-179
angiotensin	O	180-191
-	O	191-192
converting	O	192-202
enzyme	O	203-209
2	O	210-211
-	O	211-212
angiotensin	O	212-223
(	O	224-225
1	O	225-226
-	O	226-227
7	O	227-228
)	O	228-229
.	O	229-230

Aerobic	O	231-238
exercise	O	239-247
training	O	248-256
leads	O	257-262
to	O	263-265
a	O	266-267
physiological	O	268-281
,	O	281-282
nonpathological	O	283-298
left	O	299-303
ventricular	O	304-315
hypertrophy	O	316-327
;	O	327-328
however	O	329-336
,	O	336-337
the	O	338-341
underlying	O	342-352
biochemical	O	353-364
and	O	365-368
molecular	O	369-378
mechanisms	O	379-389
of	O	390-392
physiological	O	393-406
left	O	407-411
ventricular	O	412-423
hypertrophy	O	424-435
are	O	436-439
unknown	O	440-447
.	O	447-448

The	O	449-452
role	O	453-457
of	O	458-460
microRNAs	O	461-470
regulating	O	471-481
the	O	482-485
classic	O	486-493
and	O	494-497
the	O	498-501
novel	O	502-507
cardiac	O	508-515
renin	O	516-521
-	O	521-522
angiotensin	O	522-533
(	O	534-535
Ang	O	535-538
)	O	538-539
system	O	540-546
was	O	547-550
studied	O	551-558
in	O	559-561
trained	O	562-569
rats	O	570-574
assigned	O	575-583
to	O	584-586
3	O	587-588
groups	O	589-595
:	O	595-596
(	O	597-598
1	O	598-599
)	O	599-600
sedentary	O	601-610
;	O	610-611
(	O	612-613
2	O	613-614
)	O	614-615
swimming	O	616-624
trained	O	625-632
with	O	633-637
protocol	O	638-646
1	O	647-648
(	O	649-650
T1	O	650-652
,	O	652-653
moderate	O	654-662
-	O	662-663
volume	O	663-669
training	O	670-678
)	O	678-679
;	O	679-680
and	O	681-684
(	O	685-686
3	O	686-687
)	O	687-688
protocol	O	689-697
2	O	698-699
(	O	700-701
T2	O	701-703
,	O	703-704
high	O	705-709
-	O	709-710
volume	O	710-716
training	O	717-725
)	O	725-726
.	O	726-727

Cardiac	O	728-735
Ang	O	736-739
I	O	740-741
levels	O	742-748
,	O	748-749
Ang	O	750-753
-	O	753-754
converting	O	754-764
enzyme	O	765-771
(	O	772-773
ACE	O	773-776
)	O	776-777
activity	O	778-786
,	O	786-787
and	O	788-791
protein	O	792-799
expression	O	800-810
,	O	810-811
as	O	812-814
well	O	815-819
as	O	820-822
Ang	O	823-826
II	O	827-829
levels	O	830-836
,	O	836-837
were	O	838-842
lower	O	843-848
in	O	849-851
T1	O	852-854
and	O	855-858
T2	O	859-861
;	O	861-862
however	O	863-870
,	O	870-871
Ang	O	872-875
II	O	876-878
type	O	879-883
1	O	884-885
receptor	O	886-894
mRNA	O	895-899
levels	O	900-906
(	O	907-908
69	O	908-910
%	O	910-911
in	O	912-914
T1	O	915-917
and	O	918-921
99	O	922-924
%	O	924-925
in	O	926-928
T2	O	929-931
)	O	931-932
and	O	933-936
protein	O	937-944
expression	O	945-955
(	O	956-957
240	O	957-960
%	O	960-961
in	O	962-964
T1	O	965-967
and	O	968-971
300	O	972-975
%	O	975-976
in	O	977-979
T2	O	980-982
)	O	982-983
increased	O	984-993
after	O	994-999
training	O	1000-1008
.	O	1008-1009

Ang	O	1010-1013
II	O	1014-1016
type	O	1017-1021
2	O	1022-1023
receptor	O	1024-1032
mRNA	O	1033-1037
levels	O	1038-1044
(	O	1045-1046
220	O	1046-1049
%	O	1049-1050
)	O	1050-1051
and	O	1052-1055
protein	O	1056-1063
expression	O	1064-1074
(	O	1075-1076
332	O	1076-1079
%	O	1079-1080
)	O	1080-1081
were	O	1082-1086
shown	O	1087-1092
to	O	1093-1095
be	O	1096-1098
increased	O	1099-1108
in	O	1109-1111
T2	O	1112-1114
.	O	1114-1115

In	O	1116-1118
addition	O	1119-1127
,	O	1127-1128
T1	O	1129-1131
and	O	1132-1135
T2	O	1136-1138
were	O	1139-1143
shown	O	1144-1149
to	O	1150-1152
increase	O	1153-1161
ACE2	O	1162-1166
activity	O	1167-1175
and	O	1176-1179
protein	O	1180-1187
expression	O	1188-1198
and	O	1199-1202
Ang	O	1203-1206
(	O	1207-1208
1	O	1208-1209
-	O	1209-1210
7	O	1210-1211
)	O	1211-1212
levels	O	1213-1219
in	O	1220-1222
the	O	1223-1226
heart	O	1227-1232
.	O	1232-1233

Exercise	O	1234-1242
increased	O	1243-1252
microRNA	B	1253-1261
-	I	1261-1262
27a	I	1262-1265
and	O	1266-1269
27b	B	1270-1273
,	O	1273-1274
targeting	O	1275-1284
ACE	O	1285-1288
and	O	1289-1292
decreasing	O	1293-1303
microRNA	B	1304-1312
-	I	1312-1313
143	I	1313-1316
targeting	O	1317-1326
ACE2	O	1327-1331
in	O	1332-1334
the	O	1335-1338
heart	O	1339-1344
.	O	1344-1345

Left	O	1346-1350
ventricular	O	1351-1362
hypertrophy	O	1363-1374
induced	O	1375-1382
by	O	1383-1385
aerobic	O	1386-1393
training	O	1394-1402
involves	O	1403-1411
microRNA	O	1412-1420
regulation	O	1421-1431
and	O	1432-1435
an	O	1436-1438
increase	O	1439-1447
in	O	1448-1450
cardiac	O	1451-1458
Ang	O	1459-1462
II	O	1463-1465
type	O	1466-1470
1	O	1471-1472
receptor	O	1473-1481
without	O	1482-1489
the	O	1490-1493
participation	O	1494-1507
of	O	1508-1510
Ang	O	1511-1514
II	O	1515-1517
.	O	1517-1518

Parallel	O	1519-1527
to	O	1528-1530
this	O	1531-1535
,	O	1535-1536
an	O	1537-1539
increase	O	1540-1548
in	O	1549-1551
ACE2	O	1552-1556
,	O	1556-1557
Ang	O	1558-1561
(	O	1562-1563
1	O	1563-1564
-	O	1564-1565
7	O	1565-1566
)	O	1566-1567
,	O	1567-1568
and	O	1569-1572
Ang	O	1573-1576
II	O	1577-1579
type	O	1580-1584
2	O	1585-1586
receptor	O	1587-1595
in	O	1596-1598
the	O	1599-1602
heart	O	1603-1608
by	O	1609-1611
exercise	O	1612-1620
suggests	O	1621-1629
that	O	1630-1634
this	O	1635-1639
nonclassic	O	1640-1650
cardiac	O	1651-1658
renin	O	1659-1664
-	O	1664-1665
angiotensin	O	1665-1676
system	O	1677-1683
counteracts	O	1684-1695
the	O	1696-1699
classic	O	1700-1707
cardiac	O	1708-1715
renin	O	1716-1721
-	O	1721-1722
angiotensin	O	1722-1733
system	O	1734-1740
.	O	1740-1741

These	O	1742-1747
findings	O	1748-1756
are	O	1757-1760
consistent	O	1761-1771
with	O	1772-1776
a	O	1777-1778
model	O	1779-1784
in	O	1785-1787
which	O	1788-1793
exercise	O	1794-1802
may	O	1803-1806
induce	O	1807-1813
left	O	1814-1818
ventricular	O	1819-1830
hypertrophy	O	1831-1842
,	O	1842-1843
at	O	1844-1846
least	O	1847-1852
in	O	1853-1855
part	O	1856-1860
,	O	1860-1861
altering	O	1862-1870
the	O	1871-1874
expression	O	1875-1885
of	O	1886-1888
specific	O	1889-1897
microRNAs	O	1898-1907
targeting	O	1908-1917
renin	O	1918-1923
-	O	1923-1924
angiotensin	O	1924-1935
system	O	1936-1942
genes	O	1943-1948
.	O	1948-1949

Together	O	1950-1958
these	O	1959-1964
effects	O	1965-1972
might	O	1973-1978
provide	O	1979-1986
the	O	1987-1990
additional	O	1991-2001
aerobic	O	2002-2009
capacity	O	2010-2018
required	O	2019-2027
by	O	2028-2030
the	O	2031-2034
exercised	O	2035-2044
heart	O	2045-2050
.	O	2050-2051

CTNNB1	O	0-6
gene	O	7-11
mutations	O	12-21
,	O	21-22
pituitary	O	23-32
transcription	O	33-46
factors	O	47-54
,	O	54-55
and	O	56-59
MicroRNA	O	60-68
expression	O	69-79
involvement	O	80-91
in	O	92-94
the	O	95-98
pathogenesis	O	99-111
of	O	112-114
adamantinomatous	O	115-131
craniopharyngiomas	O	132-150
.	O	150-151

Genes	O	152-157
involved	O	158-166
in	O	167-169
formation	O	170-179
/	O	179-180
development	O	180-191
of	O	192-194
the	O	195-198
adenohypophysis	O	199-214
,	O	214-215
CTNNB1	O	216-222
gene	O	223-227
,	O	227-228
and	O	229-232
microRNAs	O	233-242
might	O	243-248
be	O	249-251
implicated	O	252-262
in	O	263-265
the	O	266-269
craniopharyngioma	O	270-287
pathogenesis	O	288-300
.	O	300-301

The	O	302-305
objective	O	306-315
of	O	316-318
this	O	319-323
study	O	324-329
is	O	330-332
to	O	333-335
perform	O	336-343
the	O	344-347
molecular	O	348-357
analysis	O	358-366
of	O	367-369
HESX1	O	370-375
,	O	375-376
PROP1	O	377-382
,	O	382-383
POU1F1	O	384-390
,	O	390-391
and	O	392-395
CTNNB1	O	396-402
genes	O	403-408
and	O	409-412
evaluate	O	413-421
a	O	422-423
panel	O	424-429
of	O	430-432
miRNA	O	433-438
expression	O	439-449
in	O	450-452
craniopharyngioma	O	453-470
.	O	470-471

We	O	472-474
also	O	475-479
verified	O	480-488
whether	O	489-496
the	O	497-500
presence	O	501-509
of	O	510-512
CTNNB1	O	513-519
mutation	O	520-528
is	O	529-531
associated	O	532-542
with	O	543-547
clinical	O	548-556
findings	O	557-565
and	O	566-569
miRNA	O	570-575
expression	O	576-586
.	O	586-587

The	O	588-591
study	O	592-597
included	O	598-606
16	O	607-609
patients	O	610-618
with	O	619-623
adamantinomatous	O	624-640
craniopharyngioma	O	641-658
(	O	659-660
nine	O	660-664
children	O	665-673
and	O	674-677
seven	O	678-683
adults	O	684-690
;	O	690-691
eight	O	692-697
females	O	698-705
and	O	706-709
eight	O	710-715
males	O	716-721
;	O	721-722
6	O	723-724
-	O	724-725
55	O	725-727
years	O	728-733
,	O	733-734
median	O	735-741
15	O	742-744
.	O	744-745
5	O	745-746
years	O	747-752
)	O	752-753
.	O	753-754

DNA	O	755-758
,	O	758-759
RNA	O	760-763
,	O	763-764
and	O	765-768
cDNA	O	769-773
were	O	774-778
obtained	O	779-787
from	O	788-792
craniopharyngioma	O	793-810
and	O	811-814
normal	O	815-821
pituitaries	O	822-833
.	O	833-834

DNA	O	835-838
was	O	839-842
also	O	843-847
extracted	O	848-857
from	O	858-862
peripheral	O	863-873
blood	O	874-879
of	O	880-882
healthy	O	883-890
subjects	O	891-899
.	O	899-900

All	O	901-904
genes	O	905-910
were	O	911-915
amplified	O	916-925
by	O	926-928
polymerase	O	929-939
chain	O	940-945
reaction	O	946-954
and	O	955-958
direct	O	959-965
sequenced	O	966-975
.	O	975-976

Relative	O	977-985
quantification	O	986-1000
of	O	1001-1003
miRNA	O	1004-1009
expression	O	1010-1020
was	O	1021-1024
calculated	O	1025-1035
using	O	1036-1041
the	O	1042-1045
2	O	1046-1047
(	O	1047-1048
-	O	1048-1049
DeltaDeltaCt	O	1049-1061
)	O	1061-1062
method	O	1063-1069
.	O	1069-1070

We	O	1071-1073
found	O	1074-1079
no	O	1080-1082
mutations	O	1083-1092
in	O	1093-1095
HESX1	O	1096-1101
,	O	1101-1102
PROP1	O	1103-1108
,	O	1108-1109
and	O	1110-1113
POU1F1	O	1114-1120
genes	O	1121-1126
and	O	1127-1130
four	O	1131-1135
polymorphisms	O	1136-1149
in	O	1150-1152
PROP1	O	1153-1158
gene	O	1159-1163
which	O	1164-1169
were	O	1170-1174
in	O	1175-1177
Hardy	O	1178-1183
-	O	1183-1184
Weinberg	O	1184-1192
equilibrium	O	1193-1204
and	O	1205-1208
had	O	1209-1212
similar	O	1213-1220
allelic	O	1221-1228
frequencies	O	1229-1240
in	O	1241-1243
craniopharyngioma	O	1244-1261
and	O	1262-1265
controls	O	1266-1274
.	O	1274-1275

We	O	1276-1278
found	O	1279-1284
seven	O	1285-1290
different	O	1291-1300
mutations	O	1301-1310
in	O	1311-1313
CTNNB1	O	1314-1320
in	O	1321-1323
eight	O	1324-1329
of	O	1330-1332
16	O	1333-1335
patients	O	1336-1344
.	O	1344-1345

Younger	O	1346-1353
patients	O	1354-1362
presented	O	1363-1372
more	O	1373-1377
frequently	O	1378-1388
CTNNB1	O	1389-1395
mutation	O	1396-1404
than	O	1405-1409
adults	O	1410-1416
.	O	1416-1417

We	O	1418-1420
observed	O	1421-1429
hyperexpression	O	1430-1445
of	O	1446-1448
miR	B	1449-1452
-	I	1452-1453
150	I	1453-1456
(	O	1457-1458
1	O	1458-1459
.	O	1459-1460
7	O	1460-1461
-	O	1461-1462
fold	O	1462-1466
)	O	1466-1467
;	O	1467-1468
no	O	1469-1471
different	O	1472-1481
expression	O	1482-1492
of	O	1493-1495
miR	B	1496-1499
-	I	1499-1500
16	I	1500-1502
-	I	1502-1503
1	I	1503-1504
,	O	1504-1505
miR	B	1506-1509
-	I	1509-1510
21	I	1510-1512
,	O	1512-1513
and	O	1514-1517
miR23a	B	1518-1524
;	O	1524-1525
and	O	1526-1529
an	O	1530-1532
underexpression	O	1533-1548
of	O	1549-1551
miR	B	1552-1555
-	I	1555-1556
141	I	1556-1559
,	O	1559-1560
let	B	1561-1564
-	I	1564-1565
7a	I	1565-1567
,	O	1567-1568
miR	B	1569-1572
-	I	1572-1573
16	I	1573-1575
,	O	1575-1576
miR	B	1577-1580
-	I	1580-1581
449	I	1581-1584
,	O	1584-1585
miR	B	1586-1589
-	I	1589-1590
145	I	1590-1593
,	O	1593-1594
miR	B	1595-1598
-	I	1598-1599
143	I	1599-1602
,	O	1602-1603
miR	B	1604-1607
-	I	1607-1608
23b	I	1608-1611
,	O	1611-1612
miR	B	1613-1616
-	I	1616-1617
15a	I	1617-1620
,	O	1620-1621
and	O	1622-1625
miR	B	1626-1629
-	I	1629-1630
24	I	1630-1632
-	I	1632-1633
2	I	1633-1634
(	O	1635-1636
ranging	O	1636-1643
from	O	1644-1648
-	O	1649-1650
7	O	1650-1651
.	O	1651-1652
5	O	1652-1653
to	O	1654-1656
-	O	1657-1658
2	O	1658-1659
.	O	1659-1660
5	O	1660-1661
-	O	1661-1662
fold	O	1662-1666
;	O	1666-1667
p	O	1668-1669
=	O	1670-1671
0	O	1672-1673
.	O	1673-1674
02	O	1674-1676
)	O	1676-1677
in	O	1678-1680
craniopharyngioma	O	1681-1698
.	O	1698-1699

There	O	1700-1705
was	O	1706-1709
no	O	1710-1712
association	O	1713-1724
between	O	1725-1732
tumor	O	1733-1738
size	O	1739-1743
or	O	1744-1746
the	O	1747-1750
recurrence	O	1751-1761
and	O	1762-1765
the	O	1766-1769
presence	O	1770-1778
of	O	1779-1781
CTNNB1mutations	O	1782-1797
.	O	1797-1798

miR	B	1799-1802
-	I	1802-1803
16	I	1803-1805
and	O	1806-1809
miR	B	1810-1813
-	I	1813-1814
141	I	1814-1817
were	O	1818-1822
underexpressed	O	1823-1837
in	O	1838-1840
craniopharyngioma	O	1841-1858
presenting	O	1859-1869
CTNNB1	O	1870-1876
mutations	O	1877-1886
.	O	1886-1887

miR	B	1888-1891
-	I	1891-1892
23a	I	1892-1895
and	O	1896-1899
miR24	B	1900-1905
-	I	1905-1906
2	I	1906-1907
were	O	1908-1912
hyperexpressed	O	1913-1927
in	O	1928-1930
patients	O	1931-1939
who	O	1940-1943
underwent	O	1944-1953
only	O	1954-1958
one	O	1959-1962
surgery	O	1963-1970
.	O	1970-1971

Mutations	O	1972-1981
or	O	1982-1984
polymorphisms	O	1985-1998
in	O	1999-2001
pituitary	O	2002-2011
transcription	O	2012-2025
factors	O	2026-2033
are	O	2034-2037
unlikely	O	2038-2046
to	O	2047-2049
contribute	O	2050-2060
to	O	2061-2063
the	O	2064-2067
adamantinomatous	O	2068-2084
craniopharyngioma	O	2085-2102
pathogenesis	O	2103-2115
,	O	2115-2116
differently	O	2117-2128
of	O	2129-2131
CTNNB1	O	2132-2138
mutations	O	2139-2148
.	O	2148-2149

Our	O	2150-2153
data	O	2154-2158
suggest	O	2159-2166
the	O	2167-2170
potential	O	2171-2180
involvement	O	2181-2192
of	O	2193-2195
the	O	2196-2199
deregulation	O	2200-2212
of	O	2213-2215
miRNA	O	2216-2221
expression	O	2222-2232
in	O	2233-2235
the	O	2236-2239
craniopharyngioma	O	2240-2257
pathogenesis	O	2258-2270
and	O	2271-2274
outcome	O	2275-2282
and	O	2283-2286
also	O	2287-2291
that	O	2292-2296
the	O	2297-2300
miRNA	O	2301-2306
could	O	2307-2312
modulate	O	2313-2321
the	O	2322-2325
Wnt	O	2326-2329
signaling	O	2330-2339
pathway	O	2340-2347
in	O	2348-2350
craniopharyngioma	O	2351-2368
tumorigenesis	O	2369-2382
.	O	2382-2383

Silencing	O	0-9
microRNA	B	10-18
-	I	18-19
155	I	19-22
ameliorates	O	23-34
experimental	O	35-47
autoimmune	O	48-58
encephalomyelitis	O	59-76
.	O	76-77

IFN	O	78-81
-	O	81-82
gamma	O	82-87
-	O	87-88
producing	O	88-97
Th1	O	98-101
and	O	102-105
IL	O	106-108
-	O	108-109
17	O	109-111
-	O	111-112
producing	O	112-121
Th17	O	122-126
cells	O	127-132
are	O	133-136
the	O	137-140
key	O	141-144
participants	O	145-157
in	O	158-160
various	O	161-168
autoimmune	O	169-179
diseases	O	180-188
,	O	188-189
including	O	190-199
multiple	O	200-208
sclerosis	O	209-218
and	O	219-222
its	O	223-226
animal	O	227-233
model	O	234-239
,	O	239-240
experimental	O	241-253
autoimmune	O	254-264
encephalomyelitis	O	265-282
(	O	283-284
EAE	O	284-287
)	O	287-288
.	O	288-289

Although	O	290-298
both	O	299-303
of	O	304-306
these	O	307-312
T	O	313-314
cell	O	315-319
subsets	O	320-327
are	O	328-331
known	O	332-337
to	O	338-340
be	O	341-343
regulated	O	344-353
by	O	354-356
specific	O	357-365
transcription	O	366-379
factors	O	380-387
and	O	388-391
cytokines	O	392-401
,	O	401-402
the	O	403-406
role	O	407-411
of	O	412-414
microRNAs	O	415-424
that	O	425-429
control	O	430-437
these	O	438-443
two	O	444-447
inflammatory	O	448-460
T	O	461-462
cell	O	463-467
subsets	O	468-475
and	O	476-479
whether	O	480-487
targeting	O	488-497
microRNAs	O	498-507
can	O	508-511
have	O	512-516
therapeutic	O	517-528
effects	O	529-536
are	O	537-540
not	O	541-544
known	O	545-550
.	O	550-551

In	O	552-554
this	O	555-559
study	O	560-565
,	O	565-566
we	O	567-569
show	O	570-574
that	O	575-579
microRNA	B	580-588
-	I	588-589
155	I	589-592
(	O	593-594
Mir	B	594-597
-	I	597-598
155	I	598-601
)	O	601-602
expression	O	603-613
is	O	614-616
elevated	O	617-625
in	O	626-628
CD4	O	629-632
(	O	632-633
+	O	633-634
)	O	634-635
T	O	636-637
cells	O	638-643
during	O	644-650
EAE	O	651-654
,	O	654-655
and	O	656-659
Mir	B	660-663
-	I	663-664
155	I	664-667
(	O	667-668
-	O	668-669
/	O	669-670
-	O	670-671
)	O	671-672
mice	O	673-677
had	O	678-681
a	O	682-683
delayed	O	684-691
course	O	692-698
and	O	699-702
reduced	O	703-710
severity	O	711-719
of	O	720-722
disease	O	723-730
and	O	731-734
less	O	735-739
inflammation	O	740-752
in	O	753-755
the	O	756-759
CNS	O	760-763
.	O	763-764

The	O	765-768
attenuation	O	769-780
of	O	781-783
EAE	O	784-787
in	O	788-790
Mir	B	791-794
-	I	794-795
155	I	795-798
(	O	798-799
-	O	799-800
/	O	800-801
-	O	801-802
)	O	802-803
mice	O	804-808
was	O	809-812
associated	O	813-823
with	O	824-828
a	O	829-830
decrease	O	831-839
in	O	840-842
Th1	O	843-846
and	O	847-850
Th17	O	851-855
responses	O	856-865
in	O	866-868
the	O	869-872
CNS	O	873-876
and	O	877-880
peripheral	O	881-891
lymphoid	O	892-900
organs	O	901-907
.	O	907-908

The	O	909-912
T	O	913-914
cell	O	915-919
-	O	919-920
intrinsic	O	920-929
function	O	930-938
of	O	939-941
Mir	B	942-945
-	I	945-946
155	I	946-949
(	O	949-950
-	O	950-951
/	O	951-952
-	O	952-953
)	O	953-954
was	O	955-958
demonstrated	O	959-971
by	O	972-974
the	O	975-978
resistance	O	979-989
of	O	990-992
Mir	B	993-996
-	I	996-997
155	I	997-1000
(	O	1000-1001
-	O	1001-1002
/	O	1002-1003
-	O	1003-1004
)	O	1004-1005
CD4	O	1006-1009
(	O	1009-1010
+	O	1010-1011
)	O	1011-1012
T	O	1013-1014
cell	O	1015-1019
-	O	1019-1020
repleted	O	1020-1028
Rag	O	1029-1032
-	O	1032-1033
1	O	1033-1034
(	O	1034-1035
-	O	1035-1036
/	O	1036-1037
-	O	1037-1038
)	O	1038-1039
mice	O	1040-1044
to	O	1045-1047
EAE	O	1048-1051
.	O	1051-1052

Finally	O	1053-1060
,	O	1060-1061
we	O	1062-1064
found	O	1065-1070
that	O	1071-1075
anti	O	1076-1080
-	O	1080-1081
Mir	B	1081-1084
-	I	1084-1085
155	I	1085-1088
treatment	O	1089-1098
reduced	O	1099-1106
clinical	O	1107-1115
severity	O	1116-1124
of	O	1125-1127
EAE	O	1128-1131
when	O	1132-1136
given	O	1137-1142
before	O	1143-1149
and	O	1150-1153
after	O	1154-1159
the	O	1160-1163
appearance	O	1164-1174
of	O	1175-1177
clinical	O	1178-1186
symptoms	O	1187-1195
.	O	1195-1196

These	O	1197-1202
findings	O	1203-1211
demonstrate	O	1212-1223
that	O	1224-1228
Mir	B	1229-1232
-	I	1232-1233
155	I	1233-1236
confers	O	1237-1244
susceptibility	O	1245-1259
to	O	1260-1262
EAE	O	1263-1266
by	O	1267-1269
affecting	O	1270-1279
inflammatory	O	1280-1292
T	O	1293-1294
cell	O	1295-1299
responses	O	1300-1309
and	O	1310-1313
identify	O	1314-1322
Mir	B	1323-1326
-	I	1326-1327
155	I	1327-1330
as	O	1331-1333
a	O	1334-1335
new	O	1336-1339
target	O	1340-1346
for	O	1347-1350
therapeutic	O	1351-1362
intervention	O	1363-1375
in	O	1376-1378
multiple	O	1379-1387
sclerosis	O	1388-1397
.	O	1397-1398

Germ	O	0-4
line	O	5-9
differentiation	O	10-25
factor	O	26-32
Bag	O	33-36
of	O	37-39
Marbles	O	40-47
is	O	48-50
a	O	51-52
regulator	O	53-62
of	O	63-65
hematopoietic	O	66-79
progenitor	O	80-90
maintenance	O	91-102
during	O	103-109
Drosophila	O	110-120
hematopoiesis	O	121-134
.	O	134-135

Bag	O	136-139
of	O	140-142
Marbles	O	143-150
(	O	151-152
Bam	O	152-155
)	O	155-156
is	O	157-159
a	O	160-161
stem	O	162-166
cell	O	167-171
differentiation	O	172-187
factor	O	188-194
in	O	195-197
the	O	198-201
Drosophila	O	202-212
germ	O	213-217
line	O	218-222
.	O	222-223

Here	O	224-228
,	O	228-229
we	O	230-232
demonstrate	O	233-244
that	O	245-249
Bam	O	250-253
has	O	254-257
a	O	258-259
crucial	O	260-267
function	O	268-276
in	O	277-279
the	O	280-283
lymph	O	284-289
gland	O	290-295
,	O	295-296
the	O	297-300
tissue	O	301-307
that	O	308-312
orchestrates	O	313-325
the	O	326-329
second	O	330-336
phase	O	337-342
of	O	343-345
Drosophila	O	346-356
hematopoiesis	O	357-370
.	O	370-371

In	O	372-374
bam	O	375-378
mutant	O	379-385
larvae	O	386-392
,	O	392-393
depletion	O	394-403
of	O	404-406
hematopoietic	O	407-420
progenitors	O	421-432
is	O	433-435
observed	O	436-444
,	O	444-445
coupled	O	446-453
with	O	454-458
prodigious	O	459-469
production	O	470-480
of	O	481-483
differentiated	O	484-498
hemocytes	O	499-508
.	O	508-509

Conversely	O	510-520
,	O	520-521
forced	O	522-528
expression	O	529-539
of	O	540-542
Bam	O	543-546
in	O	547-549
the	O	550-553
lymph	O	554-559
gland	O	560-565
results	O	566-573
in	O	574-576
expansion	O	577-586
of	O	587-589
prohemocytes	O	590-602
and	O	603-606
substantial	O	607-618
reduction	O	619-628
of	O	629-631
differentiated	O	632-646
blood	O	647-652
cells	O	653-658
.	O	658-659

These	O	660-665
findings	O	666-674
identify	O	675-683
Bam	O	684-687
as	O	688-690
a	O	691-692
regulatory	O	693-703
protein	O	704-711
that	O	712-716
promotes	O	717-725
blood	O	726-731
cell	O	732-736
precursor	O	737-746
maintenance	O	747-758
and	O	759-762
prevents	O	763-771
hemocyte	O	772-780
differentiation	O	781-796
during	O	797-803
larval	O	804-810
hematopoiesis	O	811-824
.	O	824-825

Cell	O	826-830
-	O	830-831
specific	O	831-839
knockdown	O	840-849
of	O	850-852
bam	O	853-856
function	O	857-865
via	O	866-869
RNAi	O	870-874
expression	O	875-885
revealed	O	886-894
that	O	895-899
Bam	O	900-903
activity	O	904-912
is	O	913-915
required	O	916-924
cell	O	925-929
-	O	929-930
autonomously	O	930-942
in	O	943-945
hematopoietic	O	946-959
progenitors	O	960-971
for	O	972-975
their	O	976-981
maintenance	O	982-993
.	O	993-994

microRNA	B	995-1003
-	I	1003-1004
7	I	1004-1005
(	O	1006-1007
mir	B	1007-1010
-	I	1010-1011
7	I	1011-1012
)	O	1012-1013
mutant	O	1014-1020
lymph	O	1021-1026
glands	O	1027-1033
present	O	1034-1041
with	O	1042-1046
phenotypes	O	1047-1057
identical	O	1058-1067
to	O	1068-1070
those	O	1071-1076
seen	O	1077-1081
in	O	1082-1084
bam	O	1085-1088
-	O	1088-1089
null	O	1089-1093
animals	O	1094-1101
and	O	1102-1105
mutants	O	1106-1113
double	O	1114-1120
-	O	1120-1121
heterozygous	O	1121-1133
for	O	1134-1137
bam	O	1138-1141
and	O	1142-1145
mir	B	1146-1149
-	I	1149-1150
7	I	1150-1151
reveal	O	1152-1158
that	O	1159-1163
the	O	1164-1167
two	O	1168-1171
cooperate	O	1172-1181
to	O	1182-1184
maintain	O	1185-1193
the	O	1194-1197
hematopoietic	O	1198-1211
progenitor	O	1212-1222
population	O	1223-1233
.	O	1233-1234

By	O	1235-1237
contrast	O	1238-1246
,	O	1246-1247
analysis	O	1248-1256
of	O	1257-1259
yan	O	1260-1263
mutant	O	1264-1270
lymph	O	1271-1276
glands	O	1277-1283
revealed	O	1284-1292
that	O	1293-1297
this	O	1298-1302
transcriptional	O	1303-1318
regulator	O	1319-1328
promotes	O	1329-1337
blood	O	1338-1343
cell	O	1344-1348
differentiation	O	1349-1364
and	O	1365-1368
the	O	1369-1372
loss	O	1373-1377
of	O	1378-1380
prohemocyte	O	1381-1392
maintenance	O	1393-1404
.	O	1404-1405

Expression	O	1406-1416
of	O	1417-1419
Bam	O	1420-1423
or	O	1424-1426
mir	B	1427-1430
-	I	1430-1431
7	I	1431-1432
in	O	1433-1435
hematopoietic	O	1436-1449
progenitors	O	1450-1461
leads	O	1462-1467
to	O	1468-1470
a	O	1471-1472
reduction	O	1473-1482
of	O	1483-1485
Yan	O	1486-1489
protein	O	1490-1497
.	O	1497-1498

Together	O	1499-1507
,	O	1507-1508
these	O	1509-1514
results	O	1515-1522
demonstrate	O	1523-1534
that	O	1535-1539
Bam	O	1540-1543
and	O	1544-1547
mir	B	1548-1551
-	I	1551-1552
7	I	1552-1553
antagonize	O	1554-1564
the	O	1565-1568
differentiation	O	1569-1584
-	O	1584-1585
promoting	O	1585-1594
function	O	1595-1603
of	O	1604-1606
Yan	O	1607-1610
to	O	1611-1613
maintain	O	1614-1622
the	O	1623-1626
stem	O	1627-1631
-	O	1631-1632
like	O	1632-1636
hematopoietic	O	1637-1650
progenitor	O	1651-1661
state	O	1662-1667
during	O	1668-1674
hematopoiesis	O	1675-1688
.	O	1688-1689

miR	B	0-3
-	I	3-4
98	I	4-6
regulates	O	7-16
cisplatin	O	17-26
-	O	26-27
induced	O	27-34
A549	O	35-39
cell	O	40-44
death	O	45-50
by	O	51-53
inhibiting	O	54-64
TP53	O	65-69
pathway	O	70-77
.	O	77-78

To	O	79-81
explore	O	82-89
the	O	90-93
possible	O	94-102
microRNAs	O	103-112
(	O	113-114
miRNAs	O	114-120
)	O	120-121
in	O	122-124
the	O	125-128
TP53	O	129-133
pathway	O	134-141
and	O	142-145
their	O	146-151
roles	O	152-157
in	O	158-160
A549	O	161-165
cell	O	166-170
death	O	171-176
induced	O	177-184
by	O	185-187
cisplatin	O	188-197
,	O	197-198
the	O	199-202
miRNAs	O	203-209
relative	O	210-218
to	O	219-221
3	O	222-223
'	O	223-224
-	O	224-225
untranslated	O	225-237
region	O	238-244
(	O	245-246
3	O	246-247
'	O	247-248
-	O	248-249
UTR	O	249-252
)	O	252-253
of	O	254-256
TP53	O	257-261
were	O	262-266
predicted	O	267-276
by	O	277-279
microRNA	O	280-288
analysis	O	289-297
softwares	O	298-307
,	O	307-308
which	O	309-314
showed	O	315-321
that	O	322-326
TP53	O	327-331
expression	O	332-342
might	O	343-348
be	O	349-351
targeted	O	352-360
by	O	361-363
miR	B	364-367
-	I	367-368
98	I	368-370
,	O	370-371
miR	B	372-375
-	I	375-376
453	I	376-379
and	O	380-383
miR	B	384-387
-	I	387-388
485	I	388-391
.	O	391-392

Then	O	393-397
,	O	397-398
GFP	O	399-402
was	O	403-406
used	O	407-411
as	O	412-414
a	O	415-416
reporter	O	417-425
gene	O	426-430
to	O	431-433
reflect	O	434-441
whether	O	442-449
the	O	450-453
3	O	454-455
'	O	455-456
-	O	456-457
UTR	O	457-460
of	O	461-463
TP53	O	464-468
was	O	469-472
targeted	O	473-481
by	O	482-484
the	O	485-488
predicted	O	489-498
miRNAs	O	499-505
.	O	505-506

After	O	507-512
pcDNA	O	513-518
-	O	518-519
GFP	O	519-522
-	O	522-523
UTR	O	523-526
was	O	527-530
constructed	O	531-542
,	O	542-543
the	O	544-547
GFP	O	548-551
expression	O	552-562
was	O	563-566
estimated	O	567-576
in	O	577-579
A549	O	580-584
cells	O	585-590
by	O	591-593
the	O	594-597
examination	O	598-609
of	O	610-612
fluorescence	O	613-625
microscopy	O	626-636
and	O	637-640
flow	O	641-645
cytometry	O	646-655
.	O	655-656

The	O	657-660
intensity	O	661-670
of	O	671-673
fluorescence	O	674-686
in	O	687-689
the	O	690-693
miR	B	694-697
-	I	697-698
98	I	698-700
and	O	701-704
miR	B	705-708
-	I	708-709
453	I	709-712
groups	O	713-719
decreased	O	720-729
significantly	O	730-743
compared	O	744-752
with	O	753-757
the	O	758-761
control	O	762-769
group	O	770-775
.	O	775-776

The	O	777-780
percentage	O	781-791
of	O	792-794
positive	O	795-803
GFP	O	804-807
cells	O	808-813
in	O	814-816
miR	B	817-820
-	I	820-821
98	I	821-823
and	O	824-827
miR	B	828-831
-	I	831-832
453	I	832-835
groups	O	836-842
were	O	843-847
30	O	848-850
.	O	850-851
24	O	851-853
%	O	853-854
and	O	855-858
32	O	859-861
.	O	861-862
58	O	862-864
%	O	864-865
,	O	865-866
respectively	O	867-879
,	O	879-880
much	O	881-885
lower	O	886-891
than	O	892-896
that	O	897-901
of	O	902-904
NC	O	905-907
group	O	908-913
(	O	914-915
41	O	915-917
.	O	917-918
86	O	918-920
%	O	920-921
)	O	921-922
.	O	922-923

The	O	924-927
TP53	O	928-932
expression	O	933-943
was	O	944-947
inhibited	O	948-957
after	O	958-963
transfection	O	964-976
with	O	977-981
miR	B	982-985
-	I	985-986
98	I	986-988
/	O	988-989
miR	B	989-992
-	I	992-993
453	I	993-996
by	O	997-999
western	O	1000-1007
blot	O	1008-1012
.	O	1012-1013

As	O	1014-1016
the	O	1017-1020
factors	O	1021-1028
in	O	1029-1031
TP53	O	1032-1036
pathway	O	1037-1044
,	O	1044-1045
Bcl	O	1046-1049
-	O	1049-1050
2	O	1050-1051
expression	O	1052-1062
was	O	1063-1066
found	O	1067-1072
to	O	1073-1075
be	O	1076-1078
enhanced	O	1079-1087
,	O	1087-1088
and	O	1089-1092
the	O	1093-1096
expression	O	1097-1107
of	O	1108-1110
miR	B	1111-1114
-	I	1114-1115
34a	I	1115-1118
-	I	1118-1119
c	I	1119-1120
was	O	1121-1124
decreased	O	1125-1134
in	O	1135-1137
A549	O	1138-1142
cells	O	1143-1148
after	O	1149-1154
miR	B	1155-1158
-	I	1158-1159
98	I	1159-1161
/	O	1161-1162
miR	B	1162-1165
-	I	1165-1166
453	I	1166-1169
treatment	O	1170-1179
.	O	1179-1180

Moreover	O	1181-1189
,	O	1189-1190
the	O	1191-1194
expression	O	1195-1205
of	O	1206-1208
miR	B	1209-1212
-	I	1212-1213
98	I	1213-1215
and	O	1216-1219
Bcl	O	1220-1223
-	O	1223-1224
2	O	1224-1225
was	O	1226-1229
decreased	O	1230-1239
,	O	1239-1240
while	O	1241-1246
miR	B	1247-1250
-	I	1250-1251
34a	I	1251-1254
-	I	1254-1255
c	I	1255-1256
and	O	1257-1260
TP53	O	1261-1265
was	O	1266-1269
increased	O	1270-1279
after	O	1280-1285
A549	O	1286-1290
treated	O	1291-1298
with	O	1299-1303
cisplatin	O	1304-1313
.	O	1313-1314

Our	O	1315-1318
study	O	1319-1324
demonstrated	O	1325-1337
that	O	1338-1342
miR	B	1343-1346
-	I	1346-1347
98	I	1347-1349
and	O	1350-1353
miR	B	1354-1357
-	I	1357-1358
453	I	1358-1361
down	O	1362-1366
-	O	1366-1367
regulated	O	1367-1376
TP53	O	1377-1381
expression	O	1382-1392
by	O	1393-1395
targeting	O	1396-1405
the	O	1406-1409
3	O	1410-1411
'	O	1411-1412
-	O	1412-1413
UTR	O	1413-1416
of	O	1417-1419
TP53	O	1420-1424
,	O	1424-1425
and	O	1426-1429
that	O	1430-1434
cisplatin	O	1435-1444
might	O	1445-1450
inhibit	O	1451-1458
A549	O	1459-1463
cell	O	1464-1468
growth	O	1469-1475
by	O	1476-1478
miR	B	1479-1482
-	I	1482-1483
98	I	1483-1485
regulating	O	1486-1496
TP53	O	1497-1501
pathway	O	1502-1509
.	O	1509-1510

Our	O	1511-1514
results	O	1515-1522
indicated	O	1523-1532
that	O	1533-1537
TP53	O	1538-1542
relevant	O	1543-1551
miRNAs	O	1552-1558
might	O	1559-1564
be	O	1565-1567
the	O	1568-1571
new	O	1572-1575
targets	O	1576-1583
for	O	1584-1587
gene	O	1588-1592
therapy	O	1593-1600
or	O	1601-1603
new	O	1604-1607
drug	O	1608-1612
design	O	1613-1619
.	O	1619-1620

Role	O	0-4
of	O	5-7
stem	O	8-12
cell	O	13-17
factor	O	18-24
and	O	25-28
granulocyte	O	29-40
colony	O	41-47
-	O	47-48
stimulating	O	48-59
factor	O	60-66
in	O	67-69
remodeling	O	70-80
during	O	81-87
liver	O	88-93
regeneration	O	94-106
.	O	106-107

Functional	O	108-118
pluripotent	O	119-130
characteristics	O	131-146
have	O	147-151
been	O	152-156
observed	O	157-165
in	O	166-168
specific	O	169-177
subpopulations	O	178-192
of	O	193-195
hepatic	O	196-203
cells	O	204-209
that	O	210-214
express	O	215-222
some	O	223-227
of	O	228-230
the	O	231-234
known	O	235-240
cholangiocyte	O	241-254
markers	O	255-262
.	O	262-263

Although	O	264-272
evidence	O	273-281
indicates	O	282-291
that	O	292-296
specific	O	297-305
cytokines	O	306-315
,	O	315-316
granulocyte	O	317-328
macrophage	O	329-339
colony	O	340-346
-	O	346-347
stimulating	O	347-358
factors	O	359-366
(	O	367-368
GM	O	368-370
-	O	370-371
CSFs	O	371-375
)	O	375-376
,	O	376-377
and	O	378-381
stem	O	382-386
cell	O	387-391
factors	O	392-399
(	O	400-401
SCFs	O	401-405
)	O	405-406
may	O	407-410
be	O	411-413
candidate	O	414-423
treatments	O	424-434
for	O	435-438
liver	O	439-444
injury	O	445-451
,	O	451-452
the	O	453-456
role	O	457-461
of	O	462-464
these	O	465-470
cytokines	O	471-480
in	O	481-483
intrahepatic	O	484-496
biliary	O	497-504
epithelium	O	505-515
remodeling	O	516-526
is	O	527-529
unknown	O	530-537
.	O	537-538

Thus	O	539-543
,	O	543-544
our	O	545-548
aim	O	549-552
was	O	553-556
to	O	557-559
characterize	O	560-572
the	O	573-576
specific	O	577-585
cytokines	O	586-595
that	O	596-600
regulate	O	601-609
the	O	610-613
remodeling	O	614-624
potentials	O	625-635
of	O	636-638
cholangiocytes	O	639-653
after	O	654-659
70	O	660-662
%	O	662-663
partial	O	664-671
hepatectomy	O	672-683
(	O	684-685
PH	O	685-687
)	O	687-688
.	O	688-689

The	O	690-693
expression	O	694-704
of	O	705-707
the	O	708-711
cytokines	O	712-721
and	O	722-725
their	O	726-731
downstream	O	732-742
signaling	O	743-752
molecules	O	753-762
was	O	763-766
studied	O	767-774
in	O	775-777
rats	O	778-782
after	O	783-788
70	O	789-791
%	O	791-792
PH	O	793-795
by	O	796-798
immunoblotting	O	799-813
and	O	814-817
in	O	818-820
small	O	821-826
and	O	827-830
large	O	831-836
murine	O	837-843
cholangiocyte	O	844-857
cultures	O	858-866
(	O	867-868
SMCCs	O	868-873
and	O	874-877
LMCCs	O	878-883
)	O	883-884
by	O	885-887
immunocytochemistry	O	888-907
and	O	908-911
real	O	912-916
-	O	916-917
time	O	917-921
polymerase	O	922-932
chain	O	933-938
reaction	O	939-947
(	O	948-949
PCR	O	949-952
)	O	952-953
.	O	953-954

There	O	955-960
was	O	961-964
a	O	965-966
significant	O	967-978
,	O	978-979
stable	O	980-986
increase	O	987-995
in	O	996-998
SCF	O	999-1002
and	O	1003-1006
GM	O	1007-1009
-	O	1009-1010
CSF	O	1010-1013
levels	O	1014-1020
until	O	1021-1026
7	O	1027-1028
days	O	1029-1033
after	O	1034-1039
PH	O	1040-1042
.	O	1042-1043

Real	O	1044-1048
-	O	1048-1049
time	O	1049-1053
PCR	O	1054-1057
analysis	O	1058-1066
revealed	O	1067-1075
significant	O	1076-1087
increases	O	1088-1097
of	O	1098-1100
key	O	1101-1104
remodeling	O	1105-1115
molecules	O	1116-1125
,	O	1125-1126
such	O	1127-1131
as	O	1132-1134
S100	O	1135-1139
calcium	O	1140-1147
-	O	1147-1148
binding	O	1148-1155
protein	O	1156-1163
A4	O	1164-1166
(	O	1167-1168
S100A4	O	1168-1174
)	O	1174-1175
and	O	1176-1179
miR	B	1180-1183
-	I	1183-1184
181b	I	1184-1188
,	O	1188-1189
after	O	1190-1195
SCF	O	1196-1199
plus	O	1200-1204
GM	O	1205-1207
-	O	1207-1208
CSF	O	1208-1211
administration	O	1212-1226
in	O	1227-1229
SMCCs	O	1230-1235
.	O	1235-1236

SMCCs	O	1237-1242
produced	O	1243-1251
significant	O	1252-1263
amounts	O	1264-1271
of	O	1272-1274
soluble	O	1275-1282
and	O	1283-1286
bound	O	1287-1292
SCFs	O	1293-1297
and	O	1298-1301
GM	O	1302-1304
-	O	1304-1305
CSFs	O	1305-1309
in	O	1310-1312
response	O	1313-1321
to	O	1322-1324
transforming	O	1325-1337
growth	O	1338-1344
factor	O	1345-1351
-	O	1351-1352
beta	O	1352-1356
(	O	1357-1358
TGF	O	1358-1361
-	O	1361-1362
beta	O	1362-1366
)	O	1366-1367
.	O	1367-1368

When	O	1369-1373
SMCCs	O	1374-1379
were	O	1380-1384
incubated	O	1385-1394
with	O	1395-1399
TGF	O	1400-1403
-	O	1403-1404
beta	O	1404-1408
plus	O	1409-1413
anti	O	1414-1418
-	O	1418-1419
SCF	O	1419-1422
+	O	1422-1423
GM	O	1423-1425
-	O	1425-1426
CSF	O	1426-1429
antibodies	O	1430-1440
,	O	1440-1441
there	O	1442-1447
was	O	1448-1451
a	O	1452-1453
significant	O	1454-1465
decrease	O	1466-1474
in	O	1475-1477
S100A4	O	1478-1484
expression	O	1485-1495
.	O	1495-1496

Furthermore	O	1497-1508
,	O	1508-1509
treatment	O	1510-1519
of	O	1520-1522
SMCCs	O	1523-1528
with	O	1529-1533
SCF	O	1534-1537
+	O	1537-1538
GM	O	1538-1540
-	O	1540-1541
CSF	O	1541-1544
significantly	O	1545-1558
increased	O	1559-1568
matrix	O	1569-1575
metalloproteinases	O	1576-1594
(	O	1595-1596
MMP	O	1596-1599
-	O	1599-1600
2	O	1600-1601
and	O	1602-1605
MMP	O	1606-1609
-	O	1609-1610
9	O	1610-1611
)	O	1611-1612
messenger	O	1613-1622
RNA	O	1623-1626
as	O	1627-1629
well	O	1630-1634
as	O	1635-1637
miR	B	1638-1641
-	I	1641-1642
181b	I	1642-1646
expression	O	1647-1657
,	O	1657-1658
along	O	1659-1664
with	O	1665-1669
a	O	1670-1671
reduction	O	1672-1681
of	O	1682-1684
metalloproteinase	O	1685-1702
inhibitor	O	1703-1712
3	O	1713-1714
.	O	1714-1715

Levels	O	1716-1722
of	O	1723-1725
MMP	O	1726-1729
-	O	1729-1730
2	O	1730-1731
,	O	1731-1732
MMP	O	1733-1736
-	O	1736-1737
9	O	1737-1738
,	O	1738-1739
and	O	1740-1743
miR	B	1744-1747
-	I	1747-1748
181b	I	1748-1752
were	O	1753-1757
also	O	1758-1762
up	O	1763-1765
-	O	1765-1766
regulated	O	1766-1775
in	O	1776-1778
rat	O	1779-1782
liver	O	1783-1788
and	O	1789-1792
isolated	O	1793-1801
cholangiocytes	O	1802-1816
after	O	1817-1822
PH	O	1823-1825
.	O	1825-1826

CONCLUSION	O	1827-1837
:	O	1837-1838
Our	O	1839-1842
data	O	1843-1847
suggest	O	1848-1855
that	O	1856-1860
altered	O	1861-1868
expression	O	1869-1879
of	O	1880-1882
SCF	O	1883-1886
+	O	1886-1887
GM	O	1887-1889
-	O	1889-1890
CSF	O	1890-1893
after	O	1894-1899
PH	O	1900-1902
can	O	1903-1906
contribute	O	1907-1917
to	O	1918-1920
biliary	O	1921-1928
remodeling	O	1929-1939
(	O	1940-1941
e	O	1941-1942
.	O	1942-1943
g	O	1943-1944
.	O	1944-1945
,	O	1945-1946
post	O	1947-1951
-	O	1951-1952
transplantation	O	1952-1967
)	O	1967-1968
by	O	1969-1971
functional	O	1972-1982
deregulation	O	1983-1995
of	O	1996-1998
the	O	1999-2002
activity	O	2003-2011
of	O	2012-2014
key	O	2015-2018
signaling	O	2019-2028
intermediates	O	2029-2042
involved	O	2043-2051
in	O	2052-2054
cell	O	2055-2059
expansion	O	2060-2069
and	O	2070-2073
multipotent	O	2074-2085
differentiation	O	2086-2101
.	O	2101-2102

MicroRNA	B	0-8
-	I	8-9
499	I	9-12
-	I	12-13
5p	I	13-15
promotes	O	16-24
cellular	O	25-33
invasion	O	34-42
and	O	43-46
tumor	O	47-52
metastasis	O	53-63
in	O	64-66
colorectal	O	67-77
cancer	O	78-84
by	O	85-87
targeting	O	88-97
FOXO4	O	98-103
and	O	104-107
PDCD4	O	108-113
.	O	113-114

MicroRNAs	O	115-124
(	O	125-126
miRNAs	O	126-132
)	O	132-133
regulate	O	134-142
tumor	O	143-148
progression	O	149-160
and	O	161-164
invasion	O	165-173
via	O	174-177
direct	O	178-184
interaction	O	185-196
with	O	197-201
target	O	202-208
messenger	O	209-218
RNAs	O	219-223
(	O	224-225
mRNAs	O	225-230
)	O	230-231
.	O	231-232

We	O	233-235
defined	O	236-243
miRNAs	O	244-250
involved	O	251-259
in	O	260-262
cancer	O	263-269
metastasis	O	270-280
(	O	281-282
metastamirs	O	282-293
)	O	293-294
using	O	295-300
an	O	301-303
established	O	304-315
in	O	316-318
vitro	O	319-324
colorectal	O	325-335
cancer	O	336-342
(	O	343-344
CRC	O	344-347
)	O	347-348
model	O	349-354
of	O	355-357
minimally	O	358-367
metastatic	O	368-378
cells	O	379-384
(	O	385-386
SW480	O	386-391
line	O	392-396
)	O	396-397
from	O	398-402
a	O	403-404
colon	O	405-410
adenocarcinoma	O	411-425
primary	O	426-433
lesion	O	434-440
and	O	441-444
highly	O	445-451
metastatic	O	452-462
cells	O	463-468
(	O	469-470
SW620	O	470-475
line	O	476-480
)	O	480-481
from	O	482-486
a	O	487-488
metastatic	O	489-499
lymph	O	500-505
node	O	506-510
from	O	511-515
the	O	516-519
same	O	520-524
patient	O	525-532
1	O	533-534
year	O	535-539
later	O	540-545
.	O	545-546

We	O	547-549
used	O	550-554
microarray	O	555-565
analysis	O	566-574
to	O	575-577
identify	O	578-586
miRNAs	O	587-593
differentially	O	594-608
expressed	O	609-618
in	O	619-621
SW480	O	622-627
and	O	628-631
SW620	O	632-637
cells	O	638-643
,	O	643-644
focusing	O	645-653
on	O	654-656
miR	B	657-660
-	I	660-661
499	I	661-664
-	I	664-665
5p	I	665-667
as	O	668-670
a	O	671-672
novel	O	673-678
candidate	O	679-688
prometastatic	O	689-702
miRNA	O	703-708
whose	O	709-714
functions	O	715-724
in	O	725-727
cancer	O	728-734
had	O	735-738
not	O	739-742
been	O	743-747
studied	O	748-755
.	O	755-756

We	O	757-759
confirmed	O	760-769
increased	O	770-779
miR	B	780-783
-	I	783-784
499	I	784-787
-	I	787-788
5p	I	788-790
levels	O	791-797
in	O	798-800
highly	O	801-807
invasive	O	808-816
CRC	O	817-820
cell	O	821-825
lines	O	826-831
and	O	832-835
lymph	O	836-841
node	O	842-846
-	O	846-847
positive	O	847-855
CRC	O	856-859
specimens	O	860-869
.	O	869-870

Furthermore	O	871-882
,	O	882-883
enhancing	O	884-893
the	O	894-897
expression	O	898-908
of	O	909-911
miR	B	912-915
-	I	915-916
499	I	916-919
-	I	919-920
5p	I	920-922
promoted	O	923-931
CRC	O	932-935
cell	O	936-940
migration	O	941-950
and	O	951-954
invasion	O	955-963
in	O	964-966
vitro	O	967-972
and	O	973-976
lung	O	977-981
and	O	982-985
liver	O	986-991
metastasis	O	992-1002
in	O	1003-1005
vivo	O	1006-1010
,	O	1010-1011
while	O	1012-1017
silencing	O	1018-1027
its	O	1028-1031
expression	O	1032-1042
resulted	O	1043-1051
in	O	1052-1054
reduced	O	1055-1062
migration	O	1063-1072
and	O	1073-1076
invasion	O	1077-1085
.	O	1085-1086

Additionally	O	1087-1099
,	O	1099-1100
we	O	1101-1103
identified	O	1104-1114
FOXO4	O	1115-1120
and	O	1121-1124
PDCD4	O	1125-1130
as	O	1131-1133
direct	O	1134-1140
and	O	1141-1144
functional	O	1145-1155
targets	O	1156-1163
of	O	1164-1166
miR	B	1167-1170
-	I	1170-1171
499	I	1171-1174
-	I	1174-1175
5p	I	1175-1177
.	O	1177-1178

Collectively	O	1179-1191
,	O	1191-1192
these	O	1193-1198
findings	O	1199-1207
suggested	O	1208-1217
that	O	1218-1222
miR	B	1223-1226
-	I	1226-1227
499	I	1227-1230
-	I	1230-1231
5p	I	1231-1233
promoted	O	1234-1242
metastasis	O	1243-1253
of	O	1254-1256
CRC	O	1257-1260
cells	O	1261-1266
and	O	1267-1270
may	O	1271-1274
be	O	1275-1277
useful	O	1278-1284
as	O	1285-1287
a	O	1288-1289
new	O	1290-1293
potential	O	1294-1303
therapeutic	O	1304-1315
target	O	1316-1322
for	O	1323-1326
CRC	O	1327-1330
.	O	1330-1331

Molecular	O	0-9
imaging	O	10-17
of	O	18-20
a	O	21-22
cancer	O	23-29
-	O	29-30
targeting	O	30-39
theragnostics	O	40-53
probe	O	54-59
using	O	60-65
a	O	66-67
nucleolin	O	68-77
aptamer	O	78-85
-	O	85-86
and	O	87-90
microRNA	B	91-99
-	I	99-100
221	I	100-103
molecular	O	104-113
beacon	O	114-120
-	O	120-121
conjugated	O	121-131
nanoparticle	O	132-144
.	O	144-145

MicroRNAs	O	146-155
(	O	156-157
miRNA	O	157-162
,	O	162-163
miR	O	164-167
)	O	167-168
have	O	169-173
been	O	174-178
reported	O	179-187
as	O	188-190
cancer	O	191-197
biomarkers	O	198-208
that	O	209-213
regulate	O	214-222
tumor	O	223-228
suppressor	O	229-239
genes	O	240-245
.	O	245-246

Hence	O	247-252
,	O	252-253
simultaneous	O	254-266
detecting	O	267-276
and	O	277-280
inhibiting	O	281-291
of	O	292-294
miRNA	O	295-300
function	O	301-309
will	O	310-314
be	O	315-317
useful	O	318-324
as	O	325-327
a	O	328-329
cancer	O	330-336
theragnostics	O	337-350
probe	O	351-356
to	O	357-359
minimize	O	360-368
side	O	369-373
effects	O	374-381
and	O	382-385
invasiveness	O	386-398
.	O	398-399

In	O	400-402
this	O	403-407
study	O	408-413
,	O	413-414
we	O	415-417
developed	O	418-427
a	O	428-429
cancer	O	430-436
-	O	436-437
targeting	O	437-446
therangostics	O	447-460
probe	O	461-466
in	O	467-469
a	O	470-471
single	O	472-478
system	O	479-485
using	O	486-491
an	O	492-494
AS1411	O	495-501
aptamer	O	502-509
-	O	510-511
and	O	512-515
miRNA	B	516-521
-	I	521-522
221	I	522-525
molecular	O	526-535
beacon	O	536-542
(	O	543-544
miR	B	544-547
-	I	547-548
221	I	548-551
MB	O	552-554
)	O	554-555
-	O	555-556
conjugated	O	556-566
magnetic	O	567-575
fluorescence	O	576-588
(	O	589-590
MF	O	590-592
)	O	592-593
nanoparticle	O	594-606
(	O	607-608
MFAS	O	608-612
miR	B	613-616
-	I	616-617
221	I	617-620
MB	O	621-623
)	O	623-624
to	O	625-627
simultaneously	O	628-642
target	O	643-649
to	O	650-652
cancer	O	653-659
tissue	O	660-666
,	O	666-667
image	O	668-673
intracellularly	O	674-689
expressed	O	690-699
miRNA	B	700-705
-	I	705-706
221	I	706-709
and	O	710-713
treat	O	714-719
miRNA	B	720-725
-	I	725-726
221	I	726-729
-	O	729-730
involved	O	730-738
carcinogenesis	O	739-753
.	O	753-754

AS1411	O	755-761
aptamer	O	762-769
-	O	769-770
conjugated	O	770-780
MF	O	781-783
(	O	784-785
MFAS	O	785-789
)	O	789-790
nanoparticles	O	791-804
displayed	O	805-814
a	O	815-816
great	O	817-822
selectivity	O	823-834
and	O	835-838
delivery	O	839-847
into	O	848-852
various	O	853-860
cancer	O	861-867
cell	O	868-872
lines	O	873-878
.	O	878-879

The	O	880-883
miR	B	884-887
-	I	887-888
221	I	888-891
MB	O	892-894
detached	O	895-903
from	O	904-908
the	O	909-912
MFAS	O	913-917
miR	B	918-921
-	I	921-922
221	I	922-925
MB	O	926-928
in	O	929-931
the	O	932-935
cytoplasm	O	936-945
of	O	946-948
C6	O	949-951
cells	O	952-957
clearly	O	958-965
imaged	O	966-972
miRNA	B	973-978
-	I	978-979
221	I	979-982
biogenesis	O	983-993
and	O	994-997
simultaneously	O	998-1012
resulted	O	1013-1021
in	O	1022-1024
antitumor	O	1025-1034
therapeutic	O	1035-1046
effects	O	1047-1054
by	O	1055-1057
inhibiting	O	1058-1068
miRNA	O	1069-1074
function	O	1075-1083
,	O	1083-1084
indicating	O	1085-1095
a	O	1096-1097
successful	O	1098-1108
astrocytoma	O	1109-1120
-	O	1120-1121
targeting	O	1121-1130
theragnostics	O	1131-1144
.	O	1144-1145

MFAS	O	1146-1150
miRNA	O	1151-1156
MB	O	1157-1159
can	O	1160-1163
be	O	1164-1166
easily	O	1167-1173
applied	O	1174-1181
to	O	1182-1184
other	O	1185-1190
cancers	O	1191-1198
by	O	1199-1201
simply	O	1202-1208
changing	O	1209-1217
a	O	1218-1219
targeted	O	1220-1228
miRNA	O	1229-1234
highly	O	1235-1241
expressed	O	1242-1251
in	O	1252-1254
cancers	O	1255-1262
.	O	1262-1263

Changes	O	0-7
in	O	8-10
microRNA	O	11-19
expression	O	20-30
in	O	31-33
peripheral	O	34-44
mononuclear	O	45-56
cells	O	57-62
according	O	63-72
to	O	73-75
the	O	76-79
progression	O	80-91
of	O	92-94
osteoarthritis	O	95-109
.	O	109-110

MicroRNAs	O	111-120
(	O	121-122
miRNAs	O	122-128
)	O	128-129
are	O	130-133
a	O	134-135
family	O	136-142
of	O	143-145
non	O	146-149
-	O	149-150
coding	O	150-156
RNAs	O	157-161
that	O	162-166
play	O	167-171
an	O	172-174
important	O	175-184
role	O	185-189
in	O	190-192
human	O	193-198
diseases	O	199-207
,	O	207-208
including	O	209-218
osteoarthritis	O	219-233
(	O	234-235
OA	O	235-237
)	O	237-238
.	O	238-239

The	O	240-243
objective	O	244-253
of	O	254-256
this	O	257-261
study	O	262-267
was	O	268-271
to	O	272-274
investigate	O	275-286
the	O	287-290
expression	O	291-301
patterns	O	302-310
of	O	311-313
miRNAs	O	314-320
in	O	321-323
the	O	324-327
peripheral	O	328-338
blood	O	339-344
mononuclear	O	345-356
cells	O	357-362
(	O	363-364
PBMCs	O	364-369
)	O	369-370
of	O	371-373
OA	O	374-376
patients	O	377-385
.	O	385-386

PBMCs	O	387-392
were	O	393-397
isolated	O	398-406
from	O	407-411
36	O	412-414
patients	O	415-423
with	O	424-428
OA	O	429-431
,	O	431-432
6	O	433-434
RA	O	435-437
patients	O	438-446
,	O	446-447
and	O	448-451
36	O	452-454
healthy	O	455-462
controls	O	463-471
.	O	471-472

The	O	473-476
expression	O	477-487
patterns	O	488-496
of	O	497-499
miR	B	500-503
-	I	503-504
146a	I	504-508
,	O	508-509
155	B	510-513
,	O	513-514
181a	B	515-519
,	O	519-520
and	O	521-524
223	B	525-528
in	O	529-531
PBMCs	O	532-537
were	O	538-542
analyzed	O	543-551
using	O	552-557
quantitative	O	558-570
reverse	O	571-578
transcription	O	579-592
-	O	592-593
polymerase	O	593-603
chain	O	604-609
reaction	O	610-618
(	O	619-620
qPCR	O	620-624
)	O	624-625
.	O	625-626

We	O	627-629
investigated	O	630-642
the	O	643-646
expression	O	647-657
patterns	O	658-666
of	O	667-669
the	O	670-673
miRNAs	O	674-680
in	O	681-683
OA	O	684-686
progression	O	687-698
,	O	698-699
and	O	700-703
their	O	704-709
relationships	O	710-723
with	O	724-728
the	O	729-732
parameters	O	733-743
of	O	744-746
age	O	747-750
,	O	750-751
body	O	752-756
mass	O	757-761
index	O	762-767
(	O	768-769
BMI	O	769-772
)	O	772-773
,	O	773-774
the	O	775-778
femorotibial	O	779-791
angle	O	792-797
(	O	798-799
FTA	O	799-802
)	O	802-803
,	O	803-804
and	O	805-808
serum	O	809-814
keratan	O	815-822
sulfate	O	823-830
(	O	831-832
KS	O	832-834
)	O	834-835
.	O	835-836

The	O	837-840
relative	O	841-849
expression	O	850-860
levels	O	861-867
of	O	868-870
miR	B	871-874
-	I	874-875
146a	I	875-879
,	O	879-880
155	B	881-884
,	O	884-885
181a	B	886-890
,	O	890-891
and	O	892-895
223	B	896-899
in	O	900-902
the	O	903-906
OA	O	907-909
patients	O	910-918
were	O	919-923
significantly	O	924-937
higher	O	938-944
than	O	945-949
those	O	950-955
found	O	956-961
in	O	962-964
healthy	O	965-972
controls	O	973-981
.	O	981-982

In	O	983-985
the	O	986-989
early	O	990-995
stages	O	996-1002
of	O	1003-1005
OA	O	1006-1008
,	O	1008-1009
miR	B	1010-1013
-	I	1013-1014
146a	I	1014-1018
and	O	1019-1022
223	B	1023-1026
expressions	O	1027-1038
were	O	1039-1043
significantly	O	1044-1057
higher	O	1058-1064
than	O	1065-1069
they	O	1070-1074
were	O	1075-1079
at	O	1080-1082
later	O	1083-1088
stages	O	1089-1095
.	O	1095-1096

There	O	1097-1102
was	O	1103-1106
a	O	1107-1108
significant	O	1109-1120
correlation	O	1121-1132
between	O	1133-1140
the	O	1141-1144
expression	O	1145-1155
of	O	1156-1158
miR	B	1159-1162
-	I	1162-1163
223	I	1163-1166
and	O	1167-1170
KS	O	1171-1173
.	O	1173-1174

This	O	1175-1179
study	O	1180-1185
demonstrated	O	1186-1198
that	O	1199-1203
high	O	1204-1208
expression	O	1209-1219
levels	O	1220-1226
of	O	1227-1229
miR	B	1230-1233
-	I	1233-1234
146a	I	1234-1238
,	O	1238-1239
155	B	1240-1243
,	O	1243-1244
181a	B	1245-1249
,	O	1249-1250
and	O	1251-1254
223	B	1255-1258
in	O	1259-1261
the	O	1262-1265
PBMCs	O	1266-1271
of	O	1272-1274
OA	O	1275-1277
patients	O	1278-1286
might	O	1287-1292
be	O	1293-1295
related	O	1296-1303
to	O	1304-1306
the	O	1307-1310
pathogenesis	O	1311-1323
of	O	1324-1326
OA	O	1327-1329
.	O	1329-1330

This	O	1331-1335
evidence	O	1336-1344
could	O	1345-1350
lead	O	1351-1355
to	O	1356-1358
the	O	1359-1362
elucidation	O	1363-1374
of	O	1375-1377
the	O	1378-1381
mechanism	O	1382-1391
underlying	O	1392-1402
OA	O	1403-1405
pathogenesis	O	1406-1418
and	O	1419-1422
hence	O	1423-1428
to	O	1429-1431
a	O	1432-1433
novel	O	1434-1439
therapeutic	O	1440-1451
strategy	O	1452-1460
for	O	1461-1464
OA	O	1465-1467
.	O	1467-1468

miR	B	0-3
-	I	3-4
221	I	4-7
silencing	O	8-17
blocks	O	18-24
hepatocellular	O	25-39
carcinoma	O	40-49
and	O	50-53
promotes	O	54-62
survival	O	63-71
.	O	71-72

Patients	O	73-81
with	O	82-86
advanced	O	87-95
hepatocellular	O	96-110
carcinoma	O	111-120
(	O	121-122
HCC	O	122-125
)	O	125-126
face	O	127-131
a	O	132-133
dismal	O	134-140
prognosis	O	141-150
because	O	151-158
of	O	159-161
a	O	162-163
lack	O	164-168
of	O	169-171
any	O	172-175
effective	O	176-185
therapies	O	186-195
.	O	195-196

To	O	197-199
address	O	200-207
this	O	208-212
situation	O	213-222
,	O	222-223
we	O	224-226
conducted	O	227-236
a	O	237-238
preclinical	O	239-250
investigation	O	251-264
of	O	265-267
the	O	268-271
therapeutic	O	272-283
efficacy	O	284-292
of	O	293-295
oligonucleotides	O	296-312
directed	O	313-321
against	O	322-329
the	O	330-333
oncogenic	O	334-343
microRNA	O	344-352
miR	B	353-356
-	I	356-357
221	I	357-360
,	O	360-361
which	O	362-367
has	O	368-371
been	O	372-376
implicated	O	377-387
in	O	388-390
HCC	O	391-394
.	O	394-395

Of	O	396-398
9	O	399-400
chemistries	O	401-412
evaluated	O	413-422
,	O	422-423
we	O	424-426
determined	O	427-437
that	O	438-442
a	O	443-444
2	O	445-446
'	O	446-447
-	O	447-448
O	O	448-449
-	O	449-450
methyl	O	450-456
phosphorothioate	O	457-473
-	O	473-474
modified	O	474-482
anti	O	483-487
-	O	487-488
miR	B	488-491
-	I	491-492
221	I	492-495
oligonucleotide	O	496-511
was	O	512-515
most	O	516-520
effective	O	521-530
at	O	531-533
reducing	O	534-542
proliferation	O	543-556
in	O	557-559
vitro	O	560-565
.	O	565-566

A	O	567-568
cholesterol	O	569-580
-	O	580-581
modified	O	581-589
isoform	O	590-597
of	O	598-600
anti	O	601-605
-	O	605-606
miR	B	606-609
-	I	609-610
221	I	610-613
(	O	614-615
chol	O	615-619
-	O	619-620
anti	O	620-624
-	O	624-625
miR	B	625-628
-	I	628-629
221	I	629-632
)	O	632-633
exhibited	O	634-643
improved	O	644-652
pharmacokinetics	O	653-669
and	O	670-673
liver	O	674-679
tissue	O	680-686
distribution	O	687-699
compared	O	700-708
with	O	709-713
unmodified	O	714-724
oligonucleotide	O	725-740
.	O	740-741

Chol	O	742-746
-	O	746-747
anti	O	747-751
-	O	751-752
miR	B	752-755
-	I	755-756
221	I	756-759
significantly	O	760-773
reduced	O	774-781
miR	B	782-785
-	I	785-786
221	I	786-789
levels	O	790-796
in	O	797-799
liver	O	800-805
within	O	806-812
a	O	813-814
week	O	815-819
of	O	820-822
intravenous	O	823-834
administration	O	835-849
and	O	850-853
in	O	854-856
situ	O	857-861
hybridization	O	862-875
studies	O	876-883
confirmed	O	884-893
accumulation	O	894-906
of	O	907-909
the	O	910-913
oligonucleotide	O	914-929
in	O	930-932
tumor	O	933-938
cells	O	939-944
in	O	945-947
vivo	O	948-952
.	O	952-953

Within	O	954-960
the	O	961-964
same	O	965-969
period	O	970-976
,	O	976-977
chol	O	978-982
-	O	982-983
anti	O	983-987
-	O	987-988
miR	B	988-991
-	I	991-992
221	I	992-995
reduced	O	996-1003
tumor	O	1004-1009
cell	O	1010-1014
proliferation	O	1015-1028
and	O	1029-1032
increased	O	1033-1042
markers	O	1043-1050
of	O	1051-1053
apoptosis	O	1054-1063
and	O	1064-1067
cell	O	1068-1072
-	O	1072-1073
cycle	O	1073-1078
arrest	O	1079-1085
,	O	1085-1086
elevating	O	1087-1096
the	O	1097-1100
tumor	O	1101-1106
doubling	O	1107-1115
time	O	1116-1120
and	O	1121-1124
increasing	O	1125-1135
mouse	O	1136-1141
survival	O	1142-1150
.	O	1150-1151

Taken	O	1152-1157
together	O	1158-1166
,	O	1166-1167
our	O	1168-1171
findings	O	1172-1180
offer	O	1181-1186
a	O	1187-1188
preclinical	O	1189-1200
proof	O	1201-1206
of	O	1207-1209
efficacy	O	1210-1218
for	O	1219-1222
chol	O	1223-1227
-	O	1227-1228
anti	O	1228-1232
-	O	1232-1233
miR	B	1233-1236
-	I	1236-1237
221	I	1237-1240
in	O	1241-1243
a	O	1244-1245
valid	O	1246-1251
orthotopic	O	1252-1262
mouse	O	1263-1268
model	O	1269-1274
of	O	1275-1277
HCC	O	1278-1281
,	O	1281-1282
suggesting	O	1283-1293
that	O	1294-1298
this	O	1299-1303
targeted	O	1304-1312
agent	O	1313-1318
could	O	1319-1324
benefit	O	1325-1332
treatment	O	1333-1342
for	O	1343-1346
patients	O	1347-1355
with	O	1356-1360
advanced	O	1361-1369
HCC	O	1370-1373
.	O	1373-1374

Inhibition	O	0-10
of	O	11-13
miR	B	14-17
-	I	17-18
33a	I	18-21
/	O	21-22
b	B	22-23
in	O	24-26
non	O	27-30
-	O	30-31
human	O	31-36
primates	O	37-45
raises	O	46-52
plasma	O	53-59
HDL	O	60-63
and	O	64-67
lowers	O	68-74
VLDL	O	75-79
triglycerides	O	80-93
.	O	93-94

Cardiovascular	O	95-109
disease	O	110-117
remains	O	118-125
the	O	126-129
leading	O	130-137
cause	O	138-143
of	O	144-146
mortality	O	147-156
in	O	157-159
westernized	O	160-171
countries	O	172-181
,	O	181-182
despite	O	183-190
optimum	O	191-198
medical	O	199-206
therapy	O	207-214
to	O	215-217
reduce	O	218-224
the	O	225-228
levels	O	229-235
of	O	236-238
low	O	239-242
-	O	242-243
density	O	243-250
lipoprotein	O	251-262
(	O	263-264
LDL	O	264-267
)	O	267-268
-	O	268-269
associated	O	269-279
cholesterol	O	280-291
.	O	291-292

The	O	293-296
pursuit	O	297-304
of	O	305-307
novel	O	308-313
therapies	O	314-323
to	O	324-326
target	O	327-333
the	O	334-337
residual	O	338-346
risk	O	347-351
has	O	352-355
focused	O	356-363
on	O	364-366
raising	O	367-374
the	O	375-378
levels	O	379-385
of	O	386-388
high	O	389-393
-	O	393-394
density	O	394-401
lipoprotein	O	402-413
(	O	414-415
HDL	O	415-418
)	O	418-419
-	O	419-420
associated	O	420-430
cholesterol	O	431-442
in	O	443-445
order	O	446-451
to	O	452-454
exploit	O	455-462
its	O	463-466
atheroprotective	O	467-483
effects	O	484-491
.	O	491-492

MicroRNAs	O	493-502
(	O	503-504
miRNAs	O	504-510
)	O	510-511
have	O	512-516
emerged	O	517-524
as	O	525-527
important	O	528-537
post	O	538-542
-	O	542-543
transcriptional	O	543-558
regulators	O	559-569
of	O	570-572
lipid	O	573-578
metabolism	O	579-589
and	O	590-593
are	O	594-597
thus	O	598-602
a	O	603-604
new	O	605-608
class	O	609-614
of	O	615-617
target	O	618-624
for	O	625-628
therapeutic	O	629-640
intervention	O	641-653
.	O	653-654

MicroRNA	B	655-663
-	I	663-664
33a	I	664-667
and	O	668-671
microRNA	B	672-680
-	I	680-681
33b	I	681-684
(	O	685-686
miR	B	686-689
-	I	689-690
33a	I	690-693
/	O	693-694
b	B	694-695
)	O	695-696
are	O	697-700
intronic	O	701-709
miRNAs	O	710-716
whose	O	717-722
encoding	O	723-731
regions	O	732-739
are	O	740-743
embedded	O	744-752
in	O	753-755
the	O	756-759
sterol	O	760-766
-	O	766-767
response	O	767-775
-	O	775-776
element	O	776-783
-	O	783-784
binding	O	784-791
protein	O	792-799
genes	O	800-805
SREBF2	O	806-812
and	O	813-816
SREBF1	O	817-823
(	O	824-825
refs	O	825-829
3	O	830-831
-	O	831-832
5	O	832-833
)	O	833-834
,	O	834-835
respectively	O	836-848
.	O	848-849

These	O	850-855
miRNAs	O	856-862
repress	O	863-870
expression	O	871-881
of	O	882-884
the	O	885-888
cholesterol	O	889-900
transporter	O	901-912
ABCA1	O	913-918
,	O	918-919
which	O	920-925
is	O	926-928
a	O	929-930
key	O	931-934
regulator	O	935-944
of	O	945-947
HDL	O	948-951
biogenesis	O	952-962
.	O	962-963

Recent	O	964-970
studies	O	971-978
in	O	979-981
mice	O	982-986
suggest	O	987-994
that	O	995-999
antagonizing	O	1000-1012
miR	B	1013-1016
-	I	1016-1017
33a	I	1017-1020
may	O	1021-1024
be	O	1025-1027
an	O	1028-1030
effective	O	1031-1040
strategy	O	1041-1049
for	O	1050-1053
raising	O	1054-1061
plasma	O	1062-1068
HDL	O	1069-1072
levels	O	1073-1079
and	O	1080-1083
providing	O	1084-1093
protection	O	1094-1104
against	O	1105-1112
atherosclerosis	O	1113-1128
;	O	1128-1129
however	O	1130-1137
,	O	1137-1138
extrapolating	O	1139-1152
these	O	1153-1158
findings	O	1159-1167
to	O	1168-1170
humans	O	1171-1177
is	O	1178-1180
complicated	O	1181-1192
by	O	1193-1195
the	O	1196-1199
fact	O	1200-1204
that	O	1205-1209
mice	O	1210-1214
lack	O	1215-1219
miR	B	1220-1223
-	I	1223-1224
33b	I	1224-1227
,	O	1227-1228
which	O	1229-1234
is	O	1235-1237
present	O	1238-1245
only	O	1246-1250
in	O	1251-1253
the	O	1254-1257
SREBF1	O	1258-1264
gene	O	1265-1269
of	O	1270-1272
medium	O	1273-1279
and	O	1280-1283
large	O	1284-1289
mammals	O	1290-1297
.	O	1297-1298

Here	O	1299-1303
we	O	1304-1306
show	O	1307-1311
in	O	1312-1314
African	O	1315-1322
green	O	1323-1328
monkeys	O	1329-1336
that	O	1337-1341
systemic	O	1342-1350
delivery	O	1351-1359
of	O	1360-1362
an	O	1363-1365
anti	O	1366-1370
-	O	1370-1371
miRNA	O	1371-1376
oligonucleotide	O	1377-1392
that	O	1393-1397
targets	O	1398-1405
both	O	1406-1410
miR	B	1411-1414
-	I	1414-1415
33a	I	1415-1418
and	O	1419-1422
miR	B	1423-1426
-	I	1426-1427
33b	I	1427-1430
increased	O	1431-1440
hepatic	O	1441-1448
expression	O	1449-1459
of	O	1460-1462
ABCA1	O	1463-1468
and	O	1469-1472
induced	O	1473-1480
a	O	1481-1482
sustained	O	1483-1492
increase	O	1493-1501
in	O	1502-1504
plasma	O	1505-1511
HDL	O	1512-1515
levels	O	1516-1522
over	O	1523-1527
12	O	1528-1530
weeks	O	1531-1536
.	O	1536-1537

Notably	O	1538-1545
,	O	1545-1546
miR	B	1547-1550
-	I	1550-1551
33	I	1551-1553
antagonism	O	1554-1564
in	O	1565-1567
this	O	1568-1572
non	O	1573-1576
-	O	1576-1577
human	O	1577-1582
primate	O	1583-1590
model	O	1591-1596
also	O	1597-1601
increased	O	1602-1611
the	O	1612-1615
expression	O	1616-1626
of	O	1627-1629
miR	B	1630-1633
-	I	1633-1634
33	I	1634-1636
target	O	1637-1643
genes	O	1644-1649
involved	O	1650-1658
in	O	1659-1661
fatty	O	1662-1667
acid	O	1668-1672
oxidation	O	1673-1682
(	O	1683-1684
CROT	O	1684-1688
,	O	1688-1689
CPT1A	O	1690-1695
,	O	1695-1696
HADHB	O	1697-1702
and	O	1703-1706
PRKAA1	O	1707-1713
)	O	1713-1714
and	O	1715-1718
reduced	O	1719-1726
the	O	1727-1730
expression	O	1731-1741
of	O	1742-1744
genes	O	1745-1750
involved	O	1751-1759
in	O	1760-1762
fatty	O	1763-1768
acid	O	1769-1773
synthesis	O	1774-1783
(	O	1784-1785
SREBF1	O	1785-1791
,	O	1791-1792
FASN	O	1793-1797
,	O	1797-1798
ACLY	O	1799-1803
and	O	1804-1807
ACACA	O	1808-1813
)	O	1813-1814
,	O	1814-1815
resulting	O	1816-1825
in	O	1826-1828
a	O	1829-1830
marked	O	1831-1837
suppression	O	1838-1849
of	O	1850-1852
the	O	1853-1856
plasma	O	1857-1863
levels	O	1864-1870
of	O	1871-1873
very	O	1874-1878
-	O	1878-1879
low	O	1879-1882
-	O	1882-1883
density	O	1883-1890
lipoprotein	O	1891-1902
(	O	1903-1904
VLDL	O	1904-1908
)	O	1908-1909
-	O	1909-1910
associated	O	1910-1920
triglycerides	O	1921-1934
,	O	1934-1935
a	O	1936-1937
finding	O	1938-1945
that	O	1946-1950
has	O	1951-1954
not	O	1955-1958
previously	O	1959-1969
been	O	1970-1974
observed	O	1975-1983
in	O	1984-1986
mice	O	1987-1991
.	O	1991-1992

These	O	1993-1998
data	O	1999-2003
establish	O	2004-2013
,	O	2013-2014
in	O	2015-2017
a	O	2018-2019
model	O	2020-2025
that	O	2026-2030
is	O	2031-2033
highly	O	2034-2040
relevant	O	2041-2049
to	O	2050-2052
humans	O	2053-2059
,	O	2059-2060
that	O	2061-2065
pharmacological	O	2066-2081
inhibition	O	2082-2092
of	O	2093-2095
miR	B	2096-2099
-	I	2099-2100
33a	I	2100-2103
and	O	2104-2107
miR	B	2108-2111
-	I	2111-2112
33b	I	2112-2115
is	O	2116-2118
a	O	2119-2120
promising	O	2121-2130
therapeutic	O	2131-2142
strategy	O	2143-2151
to	O	2152-2154
raise	O	2155-2160
plasma	O	2161-2167
HDL	O	2168-2171
and	O	2172-2175
lower	O	2176-2181
VLDL	O	2182-2186
triglyceride	O	2187-2199
levels	O	2200-2206
for	O	2207-2210
the	O	2211-2214
treatment	O	2215-2224
of	O	2225-2227
dyslipidaemias	O	2228-2242
that	O	2243-2247
increase	O	2248-2256
cardiovascular	O	2257-2271
disease	O	2272-2279
risk	O	2280-2284
.	O	2284-2285

A	O	0-1
combined	O	2-10
array	O	11-16
-	O	16-17
based	O	17-22
comparative	O	23-34
genomic	O	35-42
hybridization	O	43-56
and	O	57-60
functional	O	61-71
library	O	72-79
screening	O	80-89
approach	O	90-98
identifies	O	99-109
mir	B	110-113
-	I	113-114
30d	I	114-117
as	O	118-120
an	O	121-123
oncomir	O	124-131
in	O	132-134
cancer	O	135-141
.	O	141-142

Oncomirs	O	143-151
are	O	152-155
microRNAs	O	156-165
(	O	166-167
miRNA	O	167-172
)	O	172-173
that	O	174-178
acts	O	179-183
as	O	184-186
oncogenes	O	187-196
or	O	197-199
tumor	O	200-205
suppressor	O	206-216
genes	O	217-222
.	O	222-223

Efficient	O	224-233
identification	O	234-248
of	O	249-251
oncomirs	O	252-260
remains	O	261-268
a	O	269-270
challenge	O	271-280
.	O	280-281

Here	O	282-286
we	O	287-289
report	O	290-296
a	O	297-298
novel	O	299-304
,	O	304-305
clinically	O	306-316
guided	O	317-323
genetic	O	324-331
screening	O	332-341
approach	O	342-350
for	O	351-354
the	O	355-358
identification	O	359-373
of	O	374-376
oncomirs	O	377-385
,	O	385-386
identifying	O	387-398
mir	B	399-402
-	I	402-403
30d	I	403-406
through	O	407-414
this	O	415-419
strategy	O	420-428
.	O	428-429

mir	B	430-433
-	I	433-434
30d	I	434-437
regulates	O	438-447
tumor	O	448-453
cell	O	454-458
proliferation	O	459-472
,	O	472-473
apoptosis	O	474-483
,	O	483-484
senescence	O	485-495
,	O	495-496
and	O	497-500
migration	O	501-510
.	O	510-511

The	O	512-515
chromosomal	O	516-527
locus	O	528-533
harboring	O	534-543
mir	B	544-547
-	I	547-548
30d	I	548-551
was	O	552-555
amplified	O	556-565
in	O	566-568
more	O	569-573
than	O	574-578
30	O	579-581
%	O	581-582
of	O	583-585
multiple	O	586-594
types	O	595-600
of	O	601-603
human	O	604-609
solid	O	610-615
tumors	O	616-622
(	O	623-624
n	O	624-625
=	O	626-627
1	O	628-629
,	O	629-630
283	O	630-633
)	O	633-634
.	O	634-635

Importantly	O	636-647
,	O	647-648
higher	O	649-655
levels	O	656-662
of	O	663-665
mir	B	666-669
-	I	669-670
30d	I	670-673
expression	O	674-684
were	O	685-689
associated	O	690-700
significantly	O	701-714
with	O	715-719
poor	O	720-724
clinical	O	725-733
outcomes	O	734-742
in	O	743-745
ovarian	O	746-753
cancer	O	754-760
patients	O	761-769
(	O	770-771
n	O	771-772
=	O	773-774
330	O	775-778
,	O	778-779
P	O	780-781
=	O	782-783
0	O	784-785
.	O	785-786
0016	O	786-790
)	O	790-791
.	O	791-792

Mechanistic	O	793-804
investigations	O	805-819
suggested	O	820-829
that	O	830-834
mir	B	835-838
-	I	838-839
30d	I	839-842
regulates	O	843-852
a	O	853-854
large	O	855-860
number	O	861-867
of	O	868-870
cancer	O	871-877
-	O	877-878
associated	O	878-888
genes	O	889-894
,	O	894-895
including	O	896-905
the	O	906-909
apoptotic	O	910-919
caspase	O	920-927
CASP3	O	928-933
.	O	933-934

The	O	935-938
guided	O	939-945
genetic	O	946-953
screening	O	954-963
approach	O	964-972
validated	O	973-982
by	O	983-985
this	O	986-990
study	O	991-996
offers	O	997-1003
a	O	1004-1005
powerful	O	1006-1014
tool	O	1015-1019
to	O	1020-1022
identify	O	1023-1031
oncomirs	O	1032-1040
that	O	1041-1045
may	O	1046-1049
have	O	1050-1054
utility	O	1055-1062
as	O	1063-1065
biomarkers	O	1066-1076
or	O	1077-1079
targets	O	1080-1087
for	O	1088-1091
drug	O	1092-1096
development	O	1097-1108
.	O	1108-1109

Regulation	O	0-10
of	O	11-13
miR	B	14-17
-	I	17-18
200c	I	18-22
by	O	23-25
nuclear	O	26-33
receptors	O	34-43
PPARalpha	O	44-53
,	O	53-54
LRH	O	55-58
-	O	58-59
1	O	59-60
and	O	61-64
SHP	O	65-68
.	O	68-69

We	O	70-72
investigated	O	73-85
regulation	O	86-96
of	O	97-99
miR	B	100-103
-	I	103-104
200c	I	104-108
expression	O	109-119
by	O	120-122
nuclear	O	123-130
receptors	O	131-140
.	O	140-141

Ectopic	O	142-149
expression	O	150-160
of	O	161-163
miR	B	164-167
-	I	167-168
200c	I	168-172
inhibited	O	173-182
MHCC97H	O	183-190
cell	O	191-195
migration	O	196-205
,	O	205-206
which	O	207-212
was	O	213-216
abrogated	O	217-226
by	O	227-229
the	O	230-233
synergistic	O	234-245
effects	O	246-253
of	O	254-256
PPARalpha	O	257-266
and	O	267-270
LRH	O	271-274
-	O	274-275
1	O	275-276
siRNAs	O	277-283
.	O	283-284

The	O	285-288
expression	O	289-299
of	O	300-302
miR	B	303-306
-	I	306-307
200c	I	307-311
was	O	312-315
decreased	O	316-325
by	O	326-328
PPARalpha	O	329-338
/	O	338-339
LRH	O	339-342
-	O	342-343
1	O	343-344
siRNAs	O	345-351
and	O	352-355
increased	O	356-365
by	O	366-368
SHP	O	369-372
siRNAs	O	373-379
,	O	379-380
and	O	381-384
overexpression	O	385-399
of	O	400-402
the	O	403-406
receptors	O	407-416
reversed	O	417-425
the	O	426-429
effects	O	430-437
of	O	438-440
their	O	441-446
respective	O	447-457
siRNAs	O	458-464
.	O	464-465

SHP	O	466-469
siRNAs	O	470-476
also	O	477-481
drastically	O	482-493
enhanced	O	494-502
the	O	503-506
ability	O	507-514
of	O	515-517
the	O	518-521
LRH	O	522-525
-	O	525-526
1	O	526-527
agonist	O	528-535
RJW100	O	536-542
to	O	543-545
induce	O	546-552
miR	B	553-556
-	I	556-557
200c	I	557-561
and	O	562-565
downregulate	O	566-578
ZEB1	O	579-583
and	O	584-587
ZEB2	O	588-592
proteins	O	593-601
.	O	601-602

Co	O	603-605
-	O	605-606
expression	O	606-616
of	O	617-619
PPARalpha	O	620-629
and	O	630-633
LRH	O	634-637
-	O	637-638
1	O	638-639
moderately	O	640-650
transactivated	O	651-665
the	O	666-669
miR	B	670-673
-	I	673-674
200c	I	674-678
promoter	O	679-687
,	O	687-688
which	O	689-694
was	O	695-698
repressed	O	699-708
by	O	709-711
SHP	O	712-715
co	O	716-718
-	O	718-719
expression	O	719-729
.	O	729-730

RJW100	O	731-737
caused	O	738-744
strong	O	745-751
activation	O	752-762
of	O	763-765
the	O	766-769
miR	B	770-773
-	I	773-774
200c	I	774-778
promoter	O	779-787
.	O	787-788

This	O	789-793
is	O	794-796
the	O	797-800
first	O	801-806
report	O	807-813
to	O	814-816
demonstrate	O	817-828
that	O	829-833
miR	B	834-837
-	I	837-838
200c	I	838-842
expression	O	843-853
is	O	854-856
controlled	O	857-867
by	O	868-870
nuclear	O	871-878
receptors	O	879-888
.	O	888-889

Tracheobronchial	O	0-16
transplantation	O	17-32
with	O	33-37
a	O	38-39
stem	O	40-44
-	O	44-45
cell	O	45-49
-	O	49-50
seeded	O	50-56
bioartificial	O	57-70
nanocomposite	O	71-84
:	O	84-85
a	O	86-87
proof	O	88-93
-	O	93-94
of	O	94-96
-	O	96-97
concept	O	97-104
study	O	105-110
.	O	110-111

BACKGROUND	O	112-122
:	O	122-123
Tracheal	O	124-132
tumours	O	133-140
can	O	141-144
be	O	145-147
surgically	O	148-158
resected	O	159-167
but	O	168-171
most	O	172-176
are	O	177-180
an	O	181-183
inoperable	O	184-194
size	O	195-199
at	O	200-202
the	O	203-206
time	O	207-211
of	O	212-214
diagnosis	O	215-224
;	O	224-225
therefore	O	226-235
,	O	235-236
new	O	237-240
therapeutic	O	241-252
options	O	253-260
are	O	261-264
needed	O	265-271
.	O	271-272

We	O	273-275
report	O	276-282
the	O	283-286
clinical	O	287-295
transplantation	O	296-311
of	O	312-314
the	O	315-318
tracheobronchial	O	319-335
airway	O	336-342
with	O	343-347
a	O	348-349
stem	O	350-354
-	O	354-355
cell	O	355-359
-	O	359-360
seeded	O	360-366
bioartificial	O	367-380
nanocomposite	O	381-394
.	O	394-395

METHODS	O	396-403
:	O	403-404
A	O	405-406
36	O	407-409
-	O	409-410
year	O	410-414
-	O	414-415
old	O	415-418
male	O	419-423
patient	O	424-431
,	O	431-432
previously	O	433-443
treated	O	444-451
with	O	452-456
debulking	O	457-466
surgery	O	467-474
and	O	475-478
radiation	O	479-488
therapy	O	489-496
,	O	496-497
presented	O	498-507
with	O	508-512
recurrent	O	513-522
primary	O	523-530
cancer	O	531-537
of	O	538-540
the	O	541-544
distal	O	545-551
trachea	O	552-559
and	O	560-563
main	O	564-568
bronchi	O	569-576
.	O	576-577

After	O	578-583
complete	O	584-592
tumour	O	593-599
resection	O	600-609
,	O	609-610
the	O	611-614
airway	O	615-621
was	O	622-625
replaced	O	626-634
with	O	635-639
a	O	640-641
tailored	O	642-650
bioartificial	O	651-664
nanocomposite	O	665-678
previously	O	679-689
seeded	O	690-696
with	O	697-701
autologous	O	702-712
bone	O	713-717
-	O	717-718
marrow	O	718-724
mononuclear	O	725-736
cells	O	737-742
via	O	743-746
a	O	747-748
bioreactor	O	749-759
for	O	760-763
36	O	764-766
h	O	767-768
.	O	768-769
Postoperative	O	770-783
granulocyte	O	784-795
colony	O	796-802
-	O	802-803
stimulating	O	803-814
factor	O	815-821
filgrastim	O	822-832
(	O	833-834
10	O	834-836
mug	O	837-840
/	O	840-841
kg	O	841-843
)	O	843-844
and	O	845-848
epoetin	O	849-856
beta	O	857-861
(	O	862-863
40	O	863-865
,	O	865-866
000	O	866-869
UI	O	870-872
)	O	872-873
were	O	874-878
given	O	879-884
over	O	885-889
14	O	890-892
days	O	893-897
.	O	897-898

We	O	899-901
undertook	O	902-911
flow	O	912-916
cytometry	O	917-926
,	O	926-927
scanning	O	928-936
electron	O	937-945
microscopy	O	946-956
,	O	956-957
confocal	O	958-966
microscopy	O	967-977
epigenetics	O	978-989
,	O	989-990
multiplex	O	991-1000
,	O	1000-1001
miRNA	O	1002-1007
,	O	1007-1008
and	O	1009-1012
gene	O	1013-1017
expression	O	1018-1028
analyses	O	1029-1037
.	O	1037-1038

FINDINGS	O	1039-1047
:	O	1047-1048
We	O	1049-1051
noted	O	1052-1057
an	O	1058-1060
extracellular	O	1061-1074
matrix	O	1075-1081
-	O	1081-1082
like	O	1082-1086
coating	O	1087-1094
and	O	1095-1098
proliferating	O	1099-1112
cells	O	1113-1118
including	O	1119-1128
a	O	1129-1130
CD105	O	1131-1136
+	O	1136-1137
subpopulation	O	1138-1151
in	O	1152-1154
the	O	1155-1158
scaffold	O	1159-1167
after	O	1168-1173
the	O	1174-1177
reseeding	O	1178-1187
and	O	1188-1191
bioreactor	O	1192-1202
process	O	1203-1210
.	O	1210-1211

There	O	1212-1217
were	O	1218-1222
no	O	1223-1225
major	O	1226-1231
complications	O	1232-1245
,	O	1245-1246
and	O	1247-1250
the	O	1251-1254
patient	O	1255-1262
was	O	1263-1266
asymptomatic	O	1267-1279
and	O	1280-1283
tumour	O	1284-1290
free	O	1291-1295
5	O	1296-1297
months	O	1298-1304
after	O	1305-1310
transplantation	O	1311-1326
.	O	1326-1327

The	O	1328-1331
bioartificial	O	1332-1345
nanocomposite	O	1346-1359
has	O	1360-1363
patent	O	1364-1370
anastomoses	O	1371-1382
,	O	1382-1383
lined	O	1384-1389
with	O	1390-1394
a	O	1395-1396
vascularised	O	1397-1409
neomucosa	O	1410-1419
,	O	1419-1420
and	O	1421-1424
was	O	1425-1428
partly	O	1429-1435
covered	O	1436-1443
by	O	1444-1446
nearly	O	1447-1453
healthy	O	1454-1461
epithelium	O	1462-1472
.	O	1472-1473

Postoperatively	O	1474-1489
,	O	1489-1490
we	O	1491-1493
detected	O	1494-1502
a	O	1503-1504
mobilisation	O	1505-1517
of	O	1518-1520
peripheral	O	1521-1531
cells	O	1532-1537
displaying	O	1538-1548
increased	O	1549-1558
mesenchymal	O	1559-1570
stromal	O	1571-1578
cell	O	1579-1583
phenotype	O	1584-1593
,	O	1593-1594
and	O	1595-1598
upregulation	O	1599-1611
of	O	1612-1614
epoetin	O	1615-1622
receptors	O	1623-1632
,	O	1632-1633
antiapoptotic	O	1634-1647
genes	O	1648-1653
,	O	1653-1654
and	O	1655-1658
miR	B	1659-1662
-	I	1662-1663
34	I	1663-1665
and	O	1666-1669
miR	B	1670-1673
-	I	1673-1674
449	I	1674-1677
biomarkers	O	1678-1688
.	O	1688-1689

These	O	1690-1695
findings	O	1696-1704
,	O	1704-1705
together	O	1706-1714
with	O	1715-1719
increased	O	1720-1729
levels	O	1730-1736
of	O	1737-1739
regenerative	O	1740-1752
-	O	1752-1753
associated	O	1753-1763
plasma	O	1764-1770
factors	O	1771-1778
,	O	1778-1779
strongly	O	1780-1788
suggest	O	1789-1796
stem	O	1797-1801
-	O	1801-1802
cell	O	1802-1806
homing	O	1807-1813
and	O	1814-1817
cell	O	1818-1822
-	O	1822-1823
mediated	O	1823-1831
wound	O	1832-1837
repair	O	1838-1844
,	O	1844-1845
extracellular	O	1846-1859
matrix	O	1860-1866
remodelling	O	1867-1878
,	O	1878-1879
and	O	1880-1883
neovascularisation	O	1884-1902
of	O	1903-1905
the	O	1906-1909
graft	O	1910-1915
.	O	1915-1916

INTERPRETATION	O	1917-1931
:	O	1931-1932
Tailor	O	1933-1939
-	O	1939-1940
made	O	1940-1944
bioartificial	O	1945-1958
scaffolds	O	1959-1968
can	O	1969-1972
be	O	1973-1975
used	O	1976-1980
to	O	1981-1983
replace	O	1984-1991
complex	O	1992-1999
airway	O	2000-2006
defects	O	2007-2014
.	O	2014-2015

The	O	2016-2019
bioreactor	O	2020-2030
reseeding	O	2031-2040
process	O	2041-2048
and	O	2049-2052
pharmacological	O	2053-2068
-	O	2068-2069
induced	O	2069-2076
site	O	2077-2081
-	O	2081-2082
specific	O	2082-2090
and	O	2091-2094
graft	O	2095-2100
-	O	2100-2101
specific	O	2101-2109
regeneration	O	2110-2122
and	O	2123-2126
tissue	O	2127-2133
protection	O	2134-2144
are	O	2145-2148
key	O	2149-2152
factors	O	2153-2160
for	O	2161-2164
successful	O	2165-2175
clinical	O	2176-2184
outcome	O	2185-2192
.	O	2192-2193

FUNDING	O	2194-2201
:	O	2201-2202
European	O	2203-2211
Commission	O	2212-2222
,	O	2222-2223
Knut	O	2224-2228
and	O	2229-2232
Alice	O	2233-2238
Wallenberg	O	2239-2249
Foundation	O	2250-2260
,	O	2260-2261
Swedish	O	2262-2269
Research	O	2270-2278
Council	O	2279-2286
,	O	2286-2287
StratRegen	O	2288-2298
,	O	2298-2299
Vinnova	O	2300-2307
Foundation	O	2308-2318
,	O	2318-2319
Radiumhemmet	O	2320-2332
,	O	2332-2333
Clinigene	O	2334-2343
EU	O	2344-2346
Network	O	2347-2354
of	O	2355-2357
Excellence	O	2358-2368
,	O	2368-2369
Swedish	O	2370-2377
Cancer	O	2378-2384
Society	O	2385-2392
,	O	2392-2393
Centre	O	2394-2400
for	O	2401-2404
Biosciences	O	2405-2416
(	O	2417-2418
The	O	2418-2421
Live	O	2422-2426
Cell	O	2427-2431
imaging	O	2432-2439
Unit	O	2440-2444
)	O	2444-2445
,	O	2445-2446
and	O	2447-2450
UCL	O	2451-2454
Business	O	2455-2463
.	O	2463-2464

Inhibition	O	0-10
of	O	11-13
microRNA	B	14-22
-	I	22-23
17	I	23-25
improves	O	26-34
lung	O	35-39
and	O	40-43
heart	O	44-49
function	O	50-58
in	O	59-61
experimental	O	62-74
pulmonary	O	75-84
hypertension	O	85-97
.	O	97-98

RATIONALE	O	99-108
:	O	108-109
MicroRNAs	O	110-119
(	O	120-121
miRs	O	121-125
)	O	125-126
control	O	127-134
various	O	135-142
cellular	O	143-151
processes	O	152-161
in	O	162-164
tissue	O	165-171
homeostasis	O	172-183
and	O	184-187
disease	O	188-195
by	O	196-198
regulating	O	199-209
gene	O	210-214
expression	O	215-225
on	O	226-228
the	O	229-232
posttranscriptional	O	233-252
level	O	253-258
.	O	258-259

Recently	O	260-268
,	O	268-269
it	O	270-272
was	O	273-276
demonstrated	O	277-289
that	O	290-294
the	O	295-298
expression	O	299-309
of	O	310-312
miR	B	313-316
-	I	316-317
21	I	317-319
and	O	320-323
members	O	324-331
of	O	332-334
the	O	335-338
miR	B	339-342
-	I	342-343
17	I	343-345
-	I	345-346
92	I	346-348
cluster	O	349-356
was	O	357-360
significantly	O	361-374
altered	O	375-382
in	O	383-385
experimental	O	386-398
pulmonary	O	399-408
hypertension	O	409-421
(	O	422-423
PH	O	423-425
)	O	425-426
.	O	426-427

OBJECTIVES	O	428-438
:	O	438-439
To	O	440-442
evaluate	O	443-451
the	O	452-455
therapeutic	O	456-467
efficacy	O	468-476
and	O	477-480
antiremodeling	O	481-495
potential	O	496-505
of	O	506-508
miR	O	509-512
inhibitors	O	513-523
in	O	524-526
the	O	527-530
pathogenesis	O	531-543
of	O	544-546
PH	O	547-549
.	O	549-550

METHODS	O	551-558
:	O	558-559
We	O	560-562
first	O	563-568
tested	O	569-575
the	O	576-579
effects	O	580-587
of	O	588-590
miR	O	591-594
inhibitors	O	595-605
(	O	606-607
antagomirs	O	607-617
)	O	617-618
,	O	618-619
which	O	620-625
were	O	626-630
specifically	O	631-643
designed	O	644-652
to	O	653-655
block	O	656-661
miR	B	662-665
-	I	665-666
17	I	666-668
(	O	669-670
A	O	670-671
-	O	671-672
17	O	672-674
)	O	674-675
,	O	675-676
miR	B	677-680
-	I	680-681
21	I	681-683
(	O	684-685
A	O	685-686
-	O	686-687
21	O	687-689
)	O	689-690
,	O	690-691
and	O	692-695
miR	B	696-699
-	I	699-700
92a	I	700-703
(	O	704-705
A	O	705-706
-	O	706-707
92a	O	707-710
)	O	710-711
in	O	712-714
chronic	O	715-722
hypoxia	O	723-730
-	O	730-731
induced	O	731-738
PH	O	739-741
in	O	742-744
mice	O	745-749
and	O	750-753
A	O	754-755
-	O	755-756
17	O	756-758
in	O	759-761
monocrotaline	O	762-775
-	O	775-776
induced	O	776-783
PH	O	784-786
in	O	787-789
rats	O	790-794
.	O	794-795

Moreover	O	796-804
,	O	804-805
biological	O	806-816
function	O	817-825
of	O	826-828
miR	B	829-832
-	I	832-833
17	I	833-835
was	O	836-839
analyzed	O	840-848
in	O	849-851
cultured	O	852-860
pulmonary	O	861-870
artery	O	871-877
smooth	O	878-884
muscle	O	885-891
cells	O	892-897
.	O	897-898

MEASUREMENTS	O	899-911
AND	O	912-915
MAIN	O	916-920
RESULTS	O	921-928
:	O	928-929
In	O	930-932
the	O	933-936
PH	O	937-939
mouse	O	940-945
model	O	946-951
,	O	951-952
A	O	953-954
-	O	954-955
17	O	955-957
and	O	958-961
A	O	962-963
-	O	963-964
21	O	964-966
reduced	O	967-974
right	O	975-980
ventricular	O	981-992
systolic	O	993-1001
pressure	O	1002-1010
,	O	1010-1011
and	O	1012-1015
all	O	1016-1019
antagomirs	O	1020-1030
decreased	O	1031-1040
pulmonary	O	1041-1050
arterial	O	1051-1059
muscularization	O	1060-1075
.	O	1075-1076

However	O	1077-1084
,	O	1084-1085
only	O	1086-1090
A	O	1091-1092
-	O	1092-1093
17	O	1093-1095
reduced	O	1096-1103
hypoxia	O	1104-1111
-	O	1111-1112
induced	O	1112-1119
right	O	1120-1125
ventricular	O	1126-1137
hypertrophy	O	1138-1149
and	O	1150-1153
improved	O	1154-1162
pulmonary	O	1163-1172
artery	O	1173-1179
acceleration	O	1180-1192
time	O	1193-1197
.	O	1197-1198

In	O	1199-1201
the	O	1202-1205
monocrotaline	O	1206-1219
-	O	1219-1220
induced	O	1220-1227
PH	O	1228-1230
rat	O	1231-1234
model	O	1235-1240
,	O	1240-1241
A	O	1242-1243
-	O	1243-1244
17	O	1244-1246
treatment	O	1247-1256
significantly	O	1257-1270
decreased	O	1271-1280
right	O	1281-1286
ventricular	O	1287-1298
systolic	O	1299-1307
pressure	O	1308-1316
and	O	1317-1320
total	O	1321-1326
pulmonary	O	1327-1336
vascular	O	1337-1345
resistance	O	1346-1356
index	O	1357-1362
,	O	1362-1363
increased	O	1364-1373
pulmonary	O	1374-1383
artery	O	1384-1390
acceleration	O	1391-1403
time	O	1404-1408
,	O	1408-1409
normalized	O	1410-1420
cardiac	O	1421-1428
output	O	1429-1435
,	O	1435-1436
and	O	1437-1440
decreased	O	1441-1450
pulmonary	O	1451-1460
vascular	O	1461-1469
remodeling	O	1470-1480
.	O	1480-1481

Among	O	1482-1487
the	O	1488-1491
tested	O	1492-1498
miR	B	1499-1502
-	I	1502-1503
17	I	1503-1505
targets	O	1506-1513
,	O	1513-1514
the	O	1515-1518
cyclin	O	1519-1525
-	O	1525-1526
dependent	O	1526-1535
kinase	O	1536-1542
inhibitor	O	1543-1552
1A	O	1553-1555
(	O	1556-1557
p21	O	1557-1560
)	O	1560-1561
was	O	1562-1565
up	O	1566-1568
-	O	1568-1569
regulated	O	1569-1578
in	O	1579-1581
lungs	O	1582-1587
undergoing	O	1588-1598
A	O	1599-1600
-	O	1600-1601
17	O	1601-1603
treatment	O	1604-1613
.	O	1613-1614

Likewise	O	1615-1623
,	O	1623-1624
in	O	1625-1627
human	O	1628-1633
pulmonary	O	1634-1643
artery	O	1644-1650
smooth	O	1651-1657
muscle	O	1658-1664
cells	O	1665-1670
,	O	1670-1671
A	O	1672-1673
-	O	1673-1674
17	O	1674-1676
increased	O	1677-1686
p21	O	1687-1690
.	O	1690-1691

Overexpression	O	1692-1706
of	O	1707-1709
miR	B	1710-1713
-	I	1713-1714
17	I	1714-1716
significantly	O	1717-1730
reduced	O	1731-1738
p21	O	1739-1742
expression	O	1743-1753
and	O	1754-1757
increased	O	1758-1767
proliferation	O	1768-1781
of	O	1782-1784
smooth	O	1785-1791
muscle	O	1792-1798
cells	O	1799-1804
.	O	1804-1805

CONCLUSIONS	O	1806-1817
:	O	1817-1818
Our	O	1819-1822
data	O	1823-1827
demonstrate	O	1828-1839
that	O	1840-1844
A	O	1845-1846
-	O	1846-1847
17	O	1847-1849
improves	O	1850-1858
heart	O	1859-1864
and	O	1865-1868
lung	O	1869-1873
function	O	1874-1882
in	O	1883-1885
experimental	O	1886-1898
PH	O	1899-1901
by	O	1902-1904
interfering	O	1905-1916
with	O	1917-1921
lung	O	1922-1926
vascular	O	1927-1935
and	O	1936-1939
right	O	1940-1945
ventricular	O	1946-1957
remodeling	O	1958-1968
.	O	1968-1969

The	O	1970-1973
beneficial	O	1974-1984
effects	O	1985-1992
may	O	1993-1996
be	O	1997-1999
related	O	2000-2007
to	O	2008-2010
the	O	2011-2014
up	O	2015-2017
-	O	2017-2018
regulation	O	2018-2028
of	O	2029-2031
p21	O	2032-2035
.	O	2035-2036

Thus	O	2037-2041
,	O	2041-2042
inhibition	O	2043-2053
of	O	2054-2056
miR	B	2057-2060
-	I	2060-2061
17	I	2061-2063
may	O	2064-2067
represent	O	2068-2077
a	O	2078-2079
novel	O	2080-2085
therapeutic	O	2086-2097
concept	O	2098-2105
to	O	2106-2108
ameliorate	O	2109-2119
disease	O	2120-2127
state	O	2128-2133
in	O	2134-2136
PH	O	2137-2139
.	O	2139-2140

Differential	O	0-12
stimulation	O	13-24
of	O	25-27
hepatitis	O	28-37
C	O	38-39
virus	O	40-45
RNA	O	46-49
translation	O	50-61
by	O	62-64
microRNA	B	65-73
-	I	73-74
122	I	74-77
in	O	78-80
different	O	81-90
cell	O	91-95
cycle	O	96-101
phases	O	102-108
.	O	108-109

Hepatitis	O	110-119
C	O	120-121
virus	O	122-127
(	O	128-129
HCV	O	129-132
)	O	132-133
replicates	O	134-144
preferentially	O	145-159
in	O	160-162
the	O	163-166
liver	O	167-172
,	O	172-173
and	O	174-177
in	O	178-180
most	O	181-185
cases	O	186-191
the	O	192-195
HCV	O	196-199
infection	O	200-209
becomes	O	210-217
chronic	O	218-225
and	O	226-229
often	O	230-235
results	O	236-243
in	O	244-246
hepatocellular	O	247-261
carcinoma	O	262-271
.	O	271-272

When	O	273-277
the	O	278-281
HCV	O	282-285
plus	O	286-290
-	O	290-291
strand	O	291-297
RNA	O	298-301
genome	O	302-308
has	O	309-312
been	O	313-317
delivered	O	318-327
to	O	328-330
the	O	331-334
cytosol	O	335-342
of	O	343-345
the	O	346-349
infected	O	350-358
cell	O	359-363
,	O	363-364
its	O	365-368
translation	O	369-380
is	O	381-383
directed	O	384-392
by	O	393-395
the	O	396-399
Internal	O	400-408
Ribosome	O	409-417
Entry	O	418-423
Site	O	424-428
(	O	429-430
IRES	O	430-434
)	O	434-435
in	O	436-438
the	O	439-442
5	O	443-444
'	O	444-445
-	O	445-446
untranslated	O	446-458
region	O	459-465
(	O	466-467
5	O	467-468
'	O	468-469
-	O	469-470
UTR	O	470-473
)	O	473-474
of	O	475-477
the	O	478-481
viral	O	482-487
RNA	O	488-491
.	O	491-492

Thereby	O	493-500
,	O	500-501
IRES	O	502-506
activity	O	507-515
is	O	516-518
modulated	O	519-528
by	O	529-531
several	O	532-539
host	O	540-544
factors	O	545-552
.	O	552-553

In	O	554-556
particular	O	557-567
,	O	567-568
the	O	569-572
liver	O	573-578
-	O	578-579
specific	O	579-587
microRNA	B	588-596
-	I	596-597
122	I	597-600
(	O	601-602
miR	B	602-605
-	I	605-606
122	I	606-609
)	O	609-610
interacts	O	611-620
with	O	621-625
two	O	626-629
target	O	630-636
sites	O	637-642
in	O	643-645
the	O	646-649
HCV	O	650-653
5	O	654-655
'	O	655-656
-	O	656-657
UTR	O	657-660
and	O	661-664
stimulates	O	665-675
HCV	O	676-679
translation	O	680-691
,	O	691-692
thereby	O	693-700
most	O	701-705
likely	O	706-712
contributing	O	713-725
to	O	726-728
HCV	O	729-732
liver	O	733-738
tropism	O	739-746
.	O	746-747

Here	O	748-752
we	O	753-755
show	O	756-760
that	O	761-765
HCV	O	766-769
IRES	O	770-774
-	O	774-775
dependent	O	775-784
translation	O	785-796
efficiency	O	797-807
in	O	808-810
the	O	811-814
hepatoma	O	815-823
cell	O	824-828
line	O	829-833
Huh7	O	834-838
is	O	839-841
highest	O	842-849
during	O	850-856
the	O	857-860
G	O	861-862
(	O	862-863
0	O	863-864
)	O	864-865
and	O	866-869
G	O	870-871
(	O	871-872
1	O	872-873
)	O	873-874
phases	O	875-881
of	O	882-884
the	O	885-888
cell	O	889-893
cycle	O	894-899
but	O	900-903
significantly	O	904-917
drops	O	918-923
during	O	924-930
the	O	931-934
S	O	935-936
phase	O	937-942
and	O	943-946
even	O	947-951
more	O	952-956
in	O	957-959
the	O	960-963
G	O	964-965
(	O	965-966
2	O	966-967
)	O	967-968
/	O	968-969
M	O	969-970
phase	O	971-976
.	O	976-977

The	O	978-981
superimposed	O	982-994
stimulation	O	995-1006
of	O	1007-1009
HCV	O	1010-1013
translation	O	1014-1025
by	O	1026-1028
ectopic	O	1029-1036
miR	B	1037-1040
-	I	1040-1041
122	I	1041-1044
works	O	1045-1050
best	O	1051-1055
during	O	1056-1062
the	O	1063-1066
G	O	1067-1068
(	O	1068-1069
0	O	1069-1070
)	O	1070-1071
,	O	1071-1072
G	O	1073-1074
(	O	1074-1075
1	O	1075-1076
)	O	1076-1077
and	O	1078-1081
G	O	1082-1083
(	O	1083-1084
2	O	1084-1085
)	O	1085-1086
/	O	1086-1087
M	O	1087-1088
phases	O	1089-1095
but	O	1096-1099
is	O	1100-1102
lower	O	1103-1108
during	O	1109-1115
the	O	1116-1119
S	O	1120-1121
phase	O	1122-1127
.	O	1127-1128

However	O	1129-1136
,	O	1136-1137
the	O	1138-1141
levels	O	1142-1148
of	O	1149-1151
Ago2	O	1152-1156
protein	O	1157-1164
do	O	1165-1167
not	O	1168-1171
substantially	O	1172-1185
change	O	1186-1192
during	O	1193-1199
cell	O	1200-1204
cycle	O	1205-1210
phases	O	1211-1217
,	O	1217-1218
indicating	O	1219-1229
that	O	1230-1234
other	O	1235-1240
cellular	O	1241-1249
factors	O	1250-1257
involved	O	1258-1266
in	O	1267-1269
HCV	O	1270-1273
translation	O	1274-1285
stimulation	O	1286-1297
by	O	1298-1300
miR	B	1301-1304
-	I	1304-1305
122	I	1305-1308
may	O	1309-1312
be	O	1313-1315
differentially	O	1316-1330
expressed	O	1331-1340
in	O	1341-1343
different	O	1344-1353
cell	O	1354-1358
cycle	O	1359-1364
phases	O	1365-1371
.	O	1371-1372

Moreover	O	1373-1381
,	O	1381-1382
the	O	1383-1386
levels	O	1387-1393
of	O	1394-1396
endogenously	O	1397-1409
expressed	O	1410-1419
miR	B	1420-1423
-	I	1423-1424
122	I	1424-1427
in	O	1428-1430
Huh7	O	1431-1435
cells	O	1436-1441
are	O	1442-1445
lowest	O	1446-1452
in	O	1453-1455
the	O	1456-1459
S	O	1460-1461
phase	O	1462-1467
,	O	1467-1468
indicating	O	1469-1479
that	O	1480-1484
the	O	1485-1488
predominant	O	1489-1500
G	O	1501-1502
(	O	1502-1503
0	O	1503-1504
)	O	1504-1505
/	O	1505-1506
G	O	1506-1507
(	O	1507-1508
1	O	1508-1509
)	O	1509-1510
state	O	1511-1516
of	O	1517-1519
non	O	1520-1523
-	O	1523-1524
dividing	O	1524-1532
hepatocytes	O	1533-1544
in	O	1545-1547
the	O	1548-1551
liver	O	1552-1557
facilitates	O	1558-1569
high	O	1570-1574
expression	O	1575-1585
of	O	1586-1588
the	O	1589-1592
HCV	O	1593-1596
genome	O	1597-1603
and	O	1604-1607
stimulation	O	1608-1619
by	O	1620-1622
miR	B	1623-1626
-	I	1626-1627
122	I	1627-1630
,	O	1630-1631
with	O	1632-1636
yet	O	1637-1640
unknown	O	1641-1648
factors	O	1649-1656
involved	O	1657-1665
in	O	1666-1668
the	O	1669-1672
differential	O	1673-1685
extent	O	1686-1692
of	O	1693-1695
stimulation	O	1696-1707
by	O	1708-1710
miR	B	1711-1714
-	I	1714-1715
122	I	1715-1718
.	O	1718-1719

Replication	O	0-11
in	O	12-14
cells	O	15-20
of	O	21-23
hematopoietic	O	24-37
origin	O	38-44
is	O	45-47
necessary	O	48-57
for	O	58-61
Dengue	O	62-68
virus	O	69-74
dissemination	O	75-88
.	O	88-89

Dengue	O	90-96
virus	O	97-102
(	O	103-104
DENV	O	104-108
)	O	108-109
is	O	110-112
a	O	113-114
mosquito	O	115-123
-	O	123-124
borne	O	124-129
pathogen	O	130-138
for	O	139-142
which	O	143-148
no	O	149-151
vaccine	O	152-159
or	O	160-162
specific	O	163-171
therapeutic	O	172-183
is	O	184-186
available	O	187-196
.	O	196-197

Although	O	198-206
it	O	207-209
is	O	210-212
well	O	213-217
established	O	218-229
that	O	230-234
dendritic	O	235-244
cells	O	245-250
and	O	251-254
macrophages	O	255-266
are	O	267-270
primary	O	271-278
sites	O	279-284
of	O	285-287
DENV	O	288-292
replication	O	293-304
,	O	304-305
it	O	306-308
remains	O	309-316
unclear	O	317-324
whether	O	325-332
non	O	333-336
-	O	336-337
hematopoietic	O	337-350
cellular	O	351-359
compartments	O	360-372
serve	O	373-378
as	O	379-381
virus	O	382-387
reservoirs	O	388-398
.	O	398-399

Here	O	400-404
,	O	404-405
we	O	406-408
exploited	O	409-418
hematopoietic	O	419-432
-	O	432-433
specific	O	433-441
microRNA	B	442-450
-	I	450-451
142	I	451-454
(	O	455-456
miR	B	456-459
-	I	459-460
142	I	460-463
)	O	463-464
to	O	465-467
control	O	468-475
virus	O	476-481
tropism	O	482-489
by	O	490-492
inserting	O	493-502
tandem	O	503-509
target	O	510-516
sites	O	517-522
into	O	523-527
the	O	528-531
virus	O	532-537
to	O	538-540
restrict	O	541-549
replication	O	550-561
exclusively	O	562-573
in	O	574-576
this	O	577-581
cell	O	582-586
population	O	587-597
.	O	597-598

In	O	599-601
vivo	O	602-606
use	O	607-610
of	O	611-613
this	O	614-618
virus	O	619-624
restricted	O	625-635
infection	O	636-645
of	O	646-648
CD11b	O	649-654
+	O	654-655
,	O	655-656
CD11c	O	657-662
+	O	662-663
,	O	663-664
and	O	665-668
CD45	O	669-673
+	O	673-674
cells	O	675-680
,	O	680-681
resulting	O	682-691
in	O	692-694
a	O	695-696
loss	O	697-701
of	O	702-704
virus	O	705-710
spread	O	711-717
,	O	717-718
regardless	O	719-729
of	O	730-732
the	O	733-736
route	O	737-742
of	O	743-745
administration	O	746-760
.	O	760-761

Furthermore	O	762-773
,	O	773-774
sequencing	O	775-785
of	O	786-788
the	O	789-792
targeted	O	793-801
virus	O	802-807
population	O	808-818
that	O	819-823
persisted	O	824-833
at	O	834-836
low	O	837-840
levels	O	841-847
,	O	847-848
demonstrated	O	849-861
total	O	862-867
excision	O	868-876
of	O	877-879
the	O	880-883
inserted	O	884-892
miR	B	893-896
-	I	896-897
142	I	897-900
target	O	901-907
sites	O	908-913
.	O	913-914

The	O	915-918
complete	O	919-927
conversion	O	928-938
of	O	939-941
the	O	942-945
virus	O	946-951
population	O	952-962
under	O	963-968
these	O	969-974
selective	O	975-984
conditions	O	985-995
suggests	O	996-1004
that	O	1005-1009
these	O	1010-1015
immune	O	1016-1022
cells	O	1023-1028
are	O	1029-1032
the	O	1033-1036
predominant	O	1037-1048
sources	O	1049-1056
of	O	1057-1059
virus	O	1060-1065
amplification	O	1066-1079
.	O	1079-1080

Taken	O	1081-1086
together	O	1087-1095
,	O	1095-1096
this	O	1097-1101
work	O	1102-1106
highlights	O	1107-1117
the	O	1118-1121
importance	O	1122-1132
of	O	1133-1135
hematopoietic	O	1136-1149
cells	O	1150-1155
for	O	1156-1159
DENV	O	1160-1164
replication	O	1165-1176
and	O	1177-1180
showcases	O	1181-1190
an	O	1191-1193
invaluable	O	1194-1204
tool	O	1205-1209
for	O	1210-1213
the	O	1214-1217
study	O	1218-1223
of	O	1224-1226
virus	O	1227-1232
pathogenesis	O	1233-1245
.	O	1245-1246

Integrated	O	0-10
analysis	O	11-19
of	O	20-22
mRNA	O	23-27
and	O	28-31
microRNA	O	32-40
expression	O	41-51
in	O	52-54
mature	O	55-61
neurons	O	62-69
,	O	69-70
neural	O	71-77
progenitor	O	78-88
cells	O	89-94
and	O	95-98
neuroblastoma	O	99-112
cells	O	113-118
.	O	118-119

Mature	O	120-126
neurons	O	127-134
(	O	135-136
MNs	O	136-139
)	O	139-140
,	O	140-141
neural	O	142-148
progenitor	O	149-159
cells	O	160-165
(	O	166-167
NPCs	O	167-171
)	O	171-172
and	O	173-176
neuroblastoma	O	177-190
cells	O	191-196
(	O	197-198
NBCs	O	198-202
)	O	202-203
are	O	204-207
all	O	208-211
neural	O	212-218
-	O	218-219
derived	O	219-226
cells	O	227-232
.	O	232-233

However	O	234-241
,	O	241-242
MNs	O	243-246
are	O	247-250
unable	O	251-257
to	O	258-260
divide	O	261-267
once	O	268-272
differentiated	O	273-287
;	O	287-288
NPCs	O	289-293
are	O	294-297
able	O	298-302
to	O	303-305
divide	O	306-312
a	O	313-314
limited	O	315-322
number	O	323-329
of	O	330-332
times	O	333-338
and	O	339-342
differentiate	O	343-356
to	O	357-359
normal	O	360-366
brain	O	367-372
cell	O	373-377
types	O	378-383
;	O	383-384
whereas	O	385-392
NBCs	O	393-397
can	O	398-401
divide	O	402-408
an	O	409-411
unlimited	O	412-421
number	O	422-428
of	O	429-431
times	O	432-437
but	O	438-441
rarely	O	442-448
differentiate	O	449-462
.	O	462-463

Here	O	464-468
,	O	468-469
we	O	470-472
perform	O	473-480
whole	O	481-486
transcriptome	O	487-500
(	O	501-502
mRNA	O	502-506
,	O	506-507
miRNA	O	508-513
)	O	513-514
profiling	O	515-524
of	O	525-527
these	O	528-533
cell	O	534-538
types	O	539-544
and	O	545-548
compare	O	549-556
expression	O	557-567
levels	O	568-574
of	O	575-577
each	O	578-582
cell	O	583-587
type	O	588-592
to	O	593-595
the	O	596-599
others	O	600-606
.	O	606-607

Integrated	O	608-618
mRNA	O	619-623
-	O	623-624
miRNA	O	624-629
functional	O	630-640
analyses	O	641-649
reveal	O	650-656
that	O	657-661
:	O	661-662
1	O	663-664
)	O	664-665
several	O	666-673
very	O	674-678
highly	O	679-685
expressed	O	686-695
genes	O	696-701
(	O	702-703
e	O	703-704
.	O	704-705
g	O	705-706
.	O	706-707
,	O	707-708
Robo1	O	709-714
,	O	714-715
Nrp1	O	716-720
,	O	720-721
Epha3	O	722-727
,	O	727-728
Unc5c	O	729-734
,	O	734-735
Dcc	O	736-739
,	O	739-740
Pak3	O	741-745
,	O	745-746
Limk4	O	747-752
)	O	752-753
and	O	754-757
a	O	758-759
few	O	760-763
under	O	764-769
-	O	769-770
expressed	O	770-779
miRNAs	O	780-786
(	O	787-788
e	O	788-789
.	O	789-790
g	O	790-791
.	O	791-792
,	O	792-793
miR	B	794-797
-	I	797-798
152	I	798-801
,	O	801-802
miR	B	803-806
-	I	806-807
146b	I	807-811
,	O	811-812
miR	B	813-816
-	I	816-817
339	I	817-820
-	I	820-821
5p	I	821-823
)	O	823-824
in	O	825-827
MNs	O	828-831
are	O	832-835
associated	O	836-846
with	O	847-851
one	O	852-855
important	O	856-865
cellular	O	866-874
process	O	875-882
-	O	882-883
axon	O	883-887
guidance	O	888-896
;	O	896-897
2	O	898-899
)	O	899-900
some	O	901-905
very	O	906-910
highly	O	911-917
expressed	O	918-927
mitogenic	O	928-937
pathway	O	938-945
genes	O	946-951
(	O	952-953
e	O	953-954
.	O	954-955
g	O	955-956
.	O	956-957
,	O	957-958
Map2k1	O	959-965
,	O	965-966
Igf1r	O	967-972
,	O	972-973
Rara	O	974-978
,	O	978-979
Runx1	O	980-985
)	O	985-986
and	O	987-990
under	O	991-996
-	O	996-997
expressed	O	997-1006
miRNAs	O	1007-1013
(	O	1014-1015
e	O	1015-1016
.	O	1016-1017
g	O	1017-1018
.	O	1018-1019
,	O	1019-1020
miR	B	1021-1024
-	I	1024-1025
370	I	1025-1028
,	O	1028-1029
miR	B	1030-1033
-	I	1033-1034
9	I	1034-1035
,	O	1035-1036
miR	B	1037-1040
-	I	1040-1041
672	I	1041-1044
)	O	1044-1045
in	O	1046-1048
NBCs	O	1049-1053
are	O	1054-1057
associated	O	1058-1068
with	O	1069-1073
cancer	O	1074-1080
pathways	O	1081-1089
.	O	1089-1090

These	O	1091-1096
results	O	1097-1104
provide	O	1105-1112
a	O	1113-1114
library	O	1115-1122
of	O	1123-1125
negative	O	1126-1134
mRNAmiRNA	O	1135-1144
networks	O	1145-1153
that	O	1154-1158
are	O	1159-1162
likely	O	1163-1169
involved	O	1170-1178
in	O	1179-1181
the	O	1182-1185
cellular	O	1186-1194
processes	O	1195-1204
of	O	1205-1207
differentiation	O	1208-1223
and	O	1224-1227
division	O	1228-1236
.	O	1236-1237

MiR	B	0-3
-	I	3-4
18a	I	4-7
regulates	O	8-17
expression	O	18-28
of	O	29-31
the	O	32-35
pancreatic	O	36-46
transcription	O	47-60
factor	O	61-67
Ptf1a	O	68-73
in	O	74-76
pancreatic	O	77-87
progenitor	O	88-98
and	O	99-102
acinar	O	103-109
cells	O	110-115
.	O	115-116

The	O	117-120
basic	O	121-126
helix	O	127-132
-	O	132-133
loop	O	133-137
-	O	137-138
helix	O	138-143
(	O	144-145
bHLH	O	145-149
)	O	149-150
transcription	O	151-164
factor	O	165-171
Ptf1a	O	172-177
plays	O	178-183
stage	O	184-189
-	O	189-190
specific	O	190-198
roles	O	199-204
in	O	205-207
the	O	208-211
developing	O	212-222
pancreas	O	223-231
.	O	231-232

During	O	233-239
early	O	240-245
pancreatic	O	246-256
development	O	257-268
,	O	268-269
low	O	270-273
levels	O	274-280
of	O	281-283
Ptf1a	O	284-289
preferentially	O	290-304
promote	O	305-312
the	O	313-316
differentiation	O	317-332
of	O	333-335
pancreatic	O	336-346
progenitor	O	347-357
cells	O	358-363
into	O	364-368
endocrine	O	369-378
cells	O	379-384
,	O	384-385
whereas	O	386-393
high	O	394-398
levels	O	399-405
of	O	406-408
Ptf1a	O	409-414
shift	O	415-420
pancreatic	O	421-431
progenitors	O	432-443
towards	O	444-451
an	O	452-454
exocrine	O	455-463
cell	O	464-468
fate	O	469-473
.	O	473-474

In	O	475-477
adults	O	478-484
,	O	484-485
Ptf1a	O	486-491
is	O	492-494
essential	O	495-504
for	O	505-508
the	O	509-512
production	O	513-523
of	O	524-526
exocrine	O	527-535
enzymes	O	536-543
by	O	544-546
pancreatic	O	547-557
acinar	O	558-564
cells	O	565-570
.	O	570-571

In	O	572-574
this	O	575-579
paper	O	580-585
,	O	585-586
we	O	587-589
show	O	590-594
that	O	595-599
Ptf1a	O	600-605
expression	O	606-616
is	O	617-619
repressed	O	620-629
by	O	630-632
miR	B	633-636
-	I	636-637
18a	I	637-640
in	O	641-643
pancreatic	O	644-654
progenitors	O	655-666
and	O	667-670
acinar	O	671-677
cells	O	678-683
via	O	684-687
its	O	688-691
binding	O	692-699
to	O	700-702
the	O	703-706
3	O	707-708
'	O	708-709
UTR	O	709-712
of	O	713-715
Ptf1a	O	716-721
mRNA	O	722-726
.	O	726-727

Furthermore	O	728-739
,	O	739-740
overexpression	O	741-755
of	O	756-758
miR	B	759-762
-	I	762-763
18a	I	763-766
exerts	O	767-773
little	O	774-780
effect	O	781-787
on	O	788-790
pancreatic	O	791-801
progenitors	O	802-813
and	O	814-817
acinar	O	818-824
cells	O	825-830
.	O	830-831

These	O	832-837
results	O	838-845
indicate	O	846-854
that	O	855-859
miR	B	860-863
-	I	863-864
18a	I	864-867
plays	O	868-873
a	O	874-875
fine	O	876-880
-	O	880-881
tuning	O	881-887
role	O	888-892
in	O	893-895
regulating	O	896-906
pancreatic	O	907-917
progenitors	O	918-929
and	O	930-933
exocrine	O	934-942
cells	O	943-948
through	O	949-956
the	O	957-960
repression	O	961-971
of	O	972-974
Ptf1a	O	975-980
expression	O	981-991
.	O	991-992

Increased	O	0-9
expression	O	10-20
of	O	21-23
microRNA	B	24-32
-	I	32-33
21and	O	33-38
its	O	39-42
association	O	43-54
with	O	55-59
chemotherapeutic	O	60-76
response	O	77-85
in	O	86-88
human	O	89-94
colorectal	O	95-105
cancer	O	106-112
.	O	112-113

The	O	114-117
expression	O	118-128
of	O	129-131
microRNA	B	132-140
-	I	140-141
21	I	141-143
(	O	144-145
miR	B	145-148
-	I	148-149
21	I	149-151
)	O	151-152
was	O	153-156
determined	O	157-167
in	O	168-170
42	O	171-173
patients	O	174-182
with	O	183-187
colorectal	O	188-198
cancer	O	199-205
(	O	206-207
CRC	O	207-210
)	O	210-211
using	O	212-217
real	O	218-222
-	O	222-223
time	O	223-227
reverse	O	228-235
transcription	O	236-249
-	O	249-250
polymerase	O	250-260
chain	O	261-266
reaction	O	267-275
.	O	275-276

The	O	277-280
level	O	281-286
of	O	287-289
miR	B	290-293
-	I	293-294
21	I	294-296
in	O	297-299
CRC	O	300-303
tumour	O	304-310
tissue	O	311-317
was	O	318-321
compared	O	322-330
with	O	331-335
paired	O	336-342
normal	O	343-349
adjacent	O	350-358
tissue	O	359-365
(	O	366-367
NAT	O	367-370
)	O	370-371
and	O	372-375
the	O	376-379
relationships	O	380-393
of	O	394-396
miR	B	397-400
-	I	400-401
21	I	401-403
levels	O	404-410
to	O	411-413
clinicopathological	O	414-433
characteristics	O	434-449
and	O	450-453
pathological	O	454-466
tumour	O	467-473
response	O	474-482
to	O	483-485
neoadjuvant	O	486-497
chemotherapy	O	498-510
were	O	511-515
investigated	O	516-528
.	O	528-529

There	O	530-535
was	O	536-539
a	O	540-541
significantly	O	542-555
higher	O	556-562
level	O	563-568
of	O	569-571
miR	B	572-575
-	I	575-576
21	I	576-578
in	O	579-581
CRC	O	582-585
tumour	O	586-592
tissue	O	593-599
than	O	600-604
in	O	605-607
NAT	O	608-611
and	O	612-615
high	O	616-620
expression	O	621-631
of	O	632-634
miR	B	635-638
-	I	638-639
21	I	639-641
was	O	642-645
significantly	O	646-659
correlated	O	660-670
with	O	671-675
advanced	O	676-684
clinical	O	685-693
stage	O	694-699
and	O	700-703
poor	O	704-708
cell	O	709-713
differentiation	O	714-729
.	O	729-730

Receiver	O	731-739
operating	O	740-749
characteristic	O	750-764
curve	O	765-770
analysis	O	771-779
indicated	O	780-789
a	O	790-791
maximum	O	792-799
optimal	O	800-807
cut	O	808-811
-	O	811-812
off	O	812-815
cycle	O	816-821
threshold	O	822-831
value	O	832-837
of	O	838-840
10	O	841-843
.	O	843-844
32	O	844-846
for	O	847-850
differentiating	O	851-866
pathological	O	867-879
responders	O	880-890
from	O	891-895
non	O	896-899
-	O	899-900
responders	O	900-910
,	O	910-911
with	O	912-916
a	O	917-918
sensitivity	O	919-930
of	O	931-933
80	O	934-936
.	O	936-937
0	O	937-938
%	O	938-939
and	O	940-943
specificity	O	944-955
of	O	956-958
88	O	959-961
.	O	961-962
2	O	962-963
%	O	963-964
.	O	964-965

These	O	966-971
data	O	972-976
showed	O	977-983
that	O	984-988
miR	B	989-992
-	I	992-993
21	I	993-995
was	O	996-999
significantly	O	1000-1013
overexpressed	O	1014-1027
in	O	1028-1030
CRC	O	1031-1034
tumour	O	1035-1041
tissue	O	1042-1048
and	O	1049-1052
was	O	1053-1056
associated	O	1057-1067
with	O	1068-1072
advanced	O	1073-1081
CRC	O	1082-1085
,	O	1085-1086
and	O	1087-1090
that	O	1091-1095
miR	B	1096-1099
-	I	1099-1100
21	I	1100-1102
may	O	1103-1106
be	O	1107-1109
a	O	1110-1111
potential	O	1112-1121
candidate	O	1122-1131
biomarker	O	1132-1141
for	O	1142-1145
predicting	O	1146-1156
pathological	O	1157-1169
tumour	O	1170-1176
response	O	1177-1185
to	O	1186-1188
chemotherapy	O	1189-1201
.	O	1201-1202

Modulation	O	0-10
of	O	11-13
microRNA	O	14-22
processing	O	23-33
by	O	34-36
mismatch	O	37-45
repair	O	46-52
protein	O	53-60
MutLalpha	O	61-70
.	O	70-71

MicroRNAs	O	72-81
(	O	82-83
miRNAs	O	83-89
)	O	89-90
are	O	91-94
critical	O	95-103
post	O	104-108
-	O	108-109
transcriptional	O	109-124
regulators	O	125-135
and	O	136-139
are	O	140-143
derived	O	144-151
from	O	152-156
hairpin	O	157-164
-	O	164-165
shaped	O	165-171
primary	O	172-179
transcripts	O	180-191
via	O	192-195
a	O	196-197
series	O	198-204
of	O	205-207
processing	O	208-218
steps	O	219-224
.	O	224-225

However	O	226-233
,	O	233-234
how	O	235-238
the	O	239-242
production	O	243-253
of	O	254-256
individual	O	257-267
miRNAs	O	268-274
is	O	275-277
regulated	O	278-287
remains	O	288-295
largely	O	296-303
unknown	O	304-311
.	O	311-312

Similarly	O	313-322
,	O	322-323
loss	O	324-328
or	O	329-331
overexpression	O	332-346
of	O	347-349
the	O	350-353
key	O	354-357
mismatch	O	358-366
repair	O	367-373
protein	O	374-381
MutLalpha	O	382-391
(	O	392-393
MLH1	O	393-397
-	O	397-398
PMS2	O	398-402
heterodimer	O	403-414
)	O	414-415
leads	O	416-421
to	O	422-424
genome	O	425-431
instability	O	432-443
and	O	444-447
tumorigenesis	O	448-461
,	O	461-462
but	O	463-466
the	O	467-470
mechanisms	O	471-481
controlling	O	482-493
MutLalpha	O	494-503
expression	O	504-514
are	O	515-518
unknown	O	519-526
.	O	526-527

Here	O	528-532
we	O	533-535
demonstrate	O	536-547
in	O	548-550
vitro	O	551-556
and	O	557-560
in	O	561-563
vivo	O	564-568
that	O	569-573
MLH1	O	574-578
and	O	579-582
miR	B	583-586
-	I	586-587
422a	I	587-591
participate	O	592-603
in	O	604-606
a	O	607-608
feedback	O	609-617
loop	O	618-622
that	O	623-627
regulates	O	628-637
the	O	638-641
level	O	642-647
of	O	648-650
both	O	651-655
molecules	O	656-665
.	O	665-666

Using	O	667-672
a	O	673-674
defined	O	675-682
in	O	683-685
-	O	685-686
vitro	O	686-691
miRNA	O	692-697
processing	O	698-708
system	O	709-715
,	O	715-716
we	O	717-719
show	O	720-724
that	O	725-729
MutLalpha	O	730-739
stimulates	O	740-750
the	O	751-754
conversion	O	755-765
of	O	766-768
pri	B	769-772
-	I	772-773
miR	I	773-776
-	I	776-777
422a	I	777-781
to	O	782-784
pre	O	785-788
-	O	788-789
miR	B	789-792
-	I	792-793
422a	I	793-797
,	O	797-798
as	O	799-801
well	O	802-806
as	O	807-809
the	O	810-813
processing	O	814-824
of	O	825-827
other	O	828-833
miRNAs	O	834-840
tested	O	841-847
,	O	847-848
implicating	O	849-860
MutLalpha	O	861-870
as	O	871-873
a	O	874-875
general	O	876-883
stimulating	O	884-895
factor	O	896-902
for	O	903-906
miRNA	O	907-912
biogenesis	O	913-923
.	O	923-924

This	O	925-929
newly	O	930-935
identified	O	936-946
MutLalpha	O	947-956
function	O	957-965
requires	O	966-974
its	O	975-978
ATPase	O	979-985
and	O	986-989
pri	O	990-993
-	O	993-994
miRNA	O	994-999
binding	O	1000-1007
activities	O	1008-1018
.	O	1018-1019

In	O	1020-1022
contrast	O	1023-1031
,	O	1031-1032
miR	B	1033-1036
-	I	1036-1037
422a	I	1037-1041
downregulates	O	1042-1055
MutLalpha	O	1056-1065
levels	O	1066-1072
by	O	1073-1075
suppressing	O	1076-1087
MLH1	O	1088-1092
expression	O	1093-1103
through	O	1104-1111
base	O	1112-1116
pairing	O	1117-1124
with	O	1125-1129
the	O	1130-1133
MLH1	O	1134-1138
3	O	1139-1140
'	O	1140-1141
-	O	1141-1142
untranslated	O	1142-1154
region	O	1155-1161
.	O	1161-1162

A	O	1163-1164
model	O	1165-1170
depicting	O	1171-1180
this	O	1181-1185
feedback	O	1186-1194
mechanism	O	1195-1204
is	O	1205-1207
discussed	O	1208-1217
.	O	1217-1218

An	O	0-2
Optimized	O	3-12
Sponge	O	13-19
for	O	20-23
microRNA	O	24-32
miR	B	33-36
-	I	36-37
9	I	37-38
Affects	O	39-46
Spinal	O	47-53
Motor	O	54-59
Neuron	O	60-66
Development	O	67-78
in	O	79-81
vivo	O	82-86
.	O	86-87

The	O	88-91
specification	O	92-105
of	O	106-108
motor	O	109-114
neuron	O	115-121
(	O	122-123
MN	O	123-125
)	O	125-126
subtypes	O	127-135
and	O	136-139
columnar	O	140-148
organization	O	149-161
in	O	162-164
developing	O	165-175
spinal	O	176-182
cord	O	183-187
is	O	188-190
controlled	O	191-201
by	O	202-204
multiple	O	205-213
transcription	O	214-227
factors	O	228-235
.	O	235-236

FoxP1	O	237-242
drives	O	243-249
specification	O	250-263
of	O	264-266
lateral	O	267-274
motor	O	275-280
neuron	O	281-287
(	O	288-289
LMN	O	289-292
)	O	292-293
subtypes	O	294-302
,	O	302-303
and	O	304-307
we	O	308-310
demonstrated	O	311-323
in	O	324-326
our	O	327-330
previous	O	331-339
work	O	340-344
that	O	345-349
FoxP1	O	350-355
expression	O	356-366
levels	O	367-373
are	O	374-377
regulated	O	378-387
by	O	388-390
the	O	391-394
microRNA	O	395-403
miR	B	404-407
-	I	407-408
9	I	408-409
.	O	409-410

Here	O	411-415
we	O	416-418
show	O	419-423
that	O	424-428
ectopic	O	429-436
FoxP1	O	437-442
expression	O	443-453
in	O	454-456
the	O	457-460
chick	O	461-466
spinal	O	467-473
cord	O	474-478
can	O	479-482
rescue	O	483-489
Lhx3	O	490-494
and	O	495-498
Hb9	O	499-502
expression	O	503-513
in	O	514-516
MNs	O	517-520
altered	O	521-528
by	O	529-531
miR	B	532-535
-	I	535-536
9	I	536-537
over	O	538-542
-	O	542-543
expression	O	543-553
,	O	553-554
demonstrating	O	555-568
that	O	569-573
FoxP1	O	574-579
is	O	580-582
a	O	583-584
critical	O	585-593
functional	O	594-604
interaction	O	605-616
partner	O	617-624
for	O	625-628
miR	B	629-632
-	I	632-633
9	I	633-634
in	O	635-637
LMN	O	638-641
development	O	642-653
.	O	653-654

Moreover	O	655-663
,	O	663-664
we	O	665-667
have	O	668-672
optimized	O	673-682
a	O	683-684
technique	O	685-694
called	O	695-701
a	O	702-703
miRNA	O	704-709
sponge	O	710-716
in	O	717-719
vitro	O	720-725
,	O	725-726
to	O	727-729
permit	O	730-736
easy	O	737-741
discovery	O	742-751
of	O	752-754
the	O	755-758
role	O	759-763
of	O	764-766
individual	O	767-777
miRNA	O	778-783
in	O	784-786
vivo	O	787-791
using	O	792-797
a	O	798-799
loss	O	800-804
-	O	804-805
of	O	805-807
-	O	807-808
function	O	808-816
approach	O	817-825
.	O	825-826

We	O	827-829
here	O	830-834
show	O	835-839
that	O	840-844
narrow	O	845-851
spacing	O	852-859
between	O	860-867
binding	O	868-875
sites	O	876-881
,	O	881-882
inclusion	O	883-892
of	O	893-895
a	O	896-897
coding	O	898-904
gene	O	905-909
,	O	909-910
and	O	911-914
optimizing	O	915-925
the	O	926-929
number	O	930-936
of	O	937-939
miRNA	O	940-945
binding	O	946-953
sites	O	954-959
can	O	960-963
significantly	O	964-977
increase	O	978-986
the	O	987-990
blocking	O	991-999
ability	O	1000-1007
of	O	1008-1010
a	O	1011-1012
sponge	O	1013-1019
.	O	1019-1020

We	O	1021-1023
go	O	1024-1026
on	O	1027-1029
to	O	1030-1032
show	O	1033-1037
that	O	1038-1042
a	O	1043-1044
miR	B	1045-1048
-	I	1048-1049
9	I	1049-1050
sponge	O	1051-1057
reduces	O	1058-1065
detectable	O	1066-1076
miR	B	1077-1080
-	I	1080-1081
9	I	1081-1082
in	O	1083-1085
the	O	1086-1089
ventral	O	1090-1097
horn	O	1098-1102
,	O	1102-1103
preventing	O	1104-1114
miR	B	1115-1118
-	I	1118-1119
9	I	1119-1120
silencing	O	1121-1130
of	O	1131-1133
FoxP1	O	1134-1139
in	O	1140-1142
vivo	O	1143-1147
,	O	1147-1148
and	O	1149-1152
in	O	1153-1155
turn	O	1156-1160
modifies	O	1161-1169
MN	O	1170-1172
subtypes	O	1173-1181
in	O	1182-1184
the	O	1185-1188
spinal	O	1189-1195
cord	O	1196-1200
.	O	1200-1201

Our	O	1202-1205
designs	O	1206-1213
for	O	1214-1217
optimized	O	1218-1227
sponges	O	1228-1235
provide	O	1236-1243
a	O	1244-1245
knockdown	O	1246-1255
tool	O	1256-1260
that	O	1261-1265
is	O	1266-1268
ready	O	1269-1274
to	O	1275-1277
be	O	1278-1280
used	O	1281-1285
to	O	1286-1288
study	O	1289-1294
the	O	1295-1298
function	O	1299-1307
of	O	1308-1310
miRNA	O	1311-1316
in	O	1317-1319
vivo	O	1320-1324
,	O	1324-1325
and	O	1326-1329
in	O	1330-1332
particular	O	1333-1343
for	O	1344-1347
generating	O	1348-1358
transgenic	O	1359-1369
animal	O	1370-1376
models	O	1377-1383
.	O	1383-1384

Aberrant	O	0-8
elevated	O	9-17
microRNA	B	18-26
-	I	26-27
146a	I	27-31
in	O	32-34
dendritic	O	35-44
cells	O	45-50
(	O	51-52
DC	O	52-54
)	O	54-55
induced	O	56-63
by	O	64-66
human	O	67-72
pancreatic	O	73-83
cancer	O	84-90
cell	O	91-95
line	O	96-100
BxPC	O	101-105
-	O	105-106
3	O	106-107
-	O	107-108
conditioned	O	108-119
medium	O	120-126
inhibits	O	127-135
DC	O	136-138
maturation	O	139-149
and	O	150-153
activation	O	154-164
.	O	164-165

It	O	166-168
has	O	169-172
been	O	173-177
shown	O	178-183
that	O	184-188
the	O	189-192
function	O	193-201
of	O	202-204
dendritic	O	205-214
cell	O	215-219
(	O	220-221
DC	O	221-223
)	O	223-224
is	O	225-227
suppressed	O	228-238
in	O	239-241
pancreatic	O	242-252
cancer	O	253-259
patients	O	260-268
;	O	268-269
however	O	270-277
,	O	277-278
the	O	279-282
detailed	O	283-291
mechanism	O	292-301
involved	O	302-310
in	O	311-313
it	O	314-316
remains	O	317-324
unclear	O	325-332
.	O	332-333

Here	O	334-338
,	O	338-339
we	O	340-342
used	O	343-347
medium	O	348-354
conditioned	O	355-366
by	O	367-369
a	O	370-371
highly	O	372-378
metastatic	O	379-389
human	O	390-395
pancreatic	O	396-406
cancer	O	407-413
cell	O	414-418
line	O	419-423
BxPC	O	424-428
-	O	428-429
3	O	429-430
[	O	431-432
BxPC	O	432-436
-	O	436-437
3	O	437-438
-	O	438-439
conditioned	O	439-450
medium	O	451-457
(	O	458-459
BxCM	O	459-463
)	O	463-464
]	O	464-465
to	O	466-468
culture	O	469-476
human	O	477-482
CD14	O	483-487
+	O	487-488
monocyte	O	489-497
-	O	497-498
derived	O	498-505
DCs	O	506-509
in	O	510-512
vitro	O	513-518
.	O	518-519

Both	O	520-524
DC	O	525-527
differentiation	O	528-543
and	O	544-547
antigen	O	548-555
presentation	O	556-568
function	O	569-577
were	O	578-582
inhibited	O	583-592
by	O	593-595
BxCM	O	596-600
.	O	600-601

The	O	602-605
microRNA	B	606-614
-	I	614-615
146a	I	615-619
(	O	620-621
miRNA	B	621-626
-	I	626-627
146a	I	627-631
)	O	631-632
expression	O	633-643
is	O	644-646
aberrantly	O	647-657
up	O	658-660
-	O	660-661
regulated	O	661-670
in	O	671-673
BxCM	O	674-678
-	O	678-679
treated	O	679-686
DCs	O	687-690
.	O	690-691

In	O	692-694
addition	O	695-703
,	O	703-704
inhibition	O	705-715
of	O	716-718
aberrant	O	719-727
miRNA	B	728-733
-	I	733-734
146a	I	734-738
expression	O	739-749
partly	O	750-756
rescues	O	757-764
the	O	765-768
BxCM	O	769-773
-	O	773-774
induced	O	774-781
defects	O	782-789
in	O	790-792
differentiation	O	793-808
and	O	809-812
function	O	813-821
of	O	822-824
DCs	O	825-828
,	O	828-829
which	O	830-835
may	O	836-839
be	O	840-842
through	O	843-850
regulation	O	851-861
of	O	862-864
Smad4	O	865-870
expression	O	871-881
.	O	881-882

Taken	O	883-888
together	O	889-897
,	O	897-898
our	O	899-902
findings	O	903-911
indicate	O	912-920
that	O	921-925
aberrant	O	926-934
miRNA	B	935-940
-	I	940-941
146a	I	941-945
expression	O	946-956
is	O	957-959
one	O	960-963
of	O	964-966
main	O	967-971
factors	O	972-979
responsible	O	980-991
for	O	992-995
inhibition	O	996-1006
of	O	1007-1009
DC	O	1010-1012
maturation	O	1013-1023
and	O	1024-1027
antigen	O	1028-1035
presentation	O	1036-1048
function	O	1049-1057
,	O	1057-1058
and	O	1059-1062
this	O	1063-1067
inhibitory	O	1068-1078
effect	O	1079-1085
on	O	1086-1088
DCs	O	1089-1092
may	O	1093-1096
be	O	1097-1099
due	O	1100-1103
to	O	1104-1106
the	O	1107-1110
repression	O	1111-1121
of	O	1122-1124
Smad4	O	1125-1130
mediated	O	1131-1139
signal	O	1140-1146
pathway	O	1147-1154
by	O	1155-1157
BxCM	O	1158-1162
.	O	1162-1163

[	O	0-1
Cellular	O	1-9
function	O	10-18
of	O	19-21
microRNA	B	22-30
-	I	30-31
15	I	31-33
family	O	34-40
]	O	40-41
.	O	41-42

microRNAs	O	43-52
(	O	53-54
miRNAs	O	54-60
)	O	60-61
are	O	62-65
non	O	66-69
-	O	69-70
coding	O	70-76
endogenous	O	77-87
short	O	88-93
RNAs	O	94-98
which	O	99-104
are	O	105-108
involved	O	109-117
in	O	118-120
regulating	O	121-131
gene	O	132-136
expression	O	137-147
at	O	148-150
the	O	151-154
post	O	155-159
-	O	159-160
transcriptional	O	160-175
level	O	176-181
.	O	181-182

miR	B	183-186
-	I	186-187
15	I	187-189
family	O	190-196
is	O	197-199
increasingly	O	200-212
found	O	213-218
to	O	219-221
play	O	222-226
great	O	227-232
roles	O	233-238
in	O	239-241
important	O	242-251
cell	O	252-256
processes	O	257-266
,	O	266-267
such	O	268-272
as	O	273-275
apoptosis	O	276-285
,	O	285-286
cell	O	287-291
differentiation	O	292-307
and	O	308-311
stress	O	312-318
response	O	319-327
.	O	327-328

Growing	O	329-336
evidence	O	337-345
indicates	O	346-355
that	O	356-360
miR	B	361-364
-	I	364-365
15	I	365-367
family	O	368-374
members	O	375-382
are	O	383-386
implicated	O	387-397
in	O	398-400
tumor	O	401-406
,	O	406-407
cardiovascular	O	408-422
disease	O	423-430
and	O	431-434
neurodegenerative	O	435-452
disease	O	453-460
.	O	460-461

miRNAs	O	462-468
have	O	469-473
emerged	O	474-481
as	O	482-484
a	O	485-486
new	O	487-490
promising	O	491-500
subset	O	501-507
of	O	508-510
therapeutic	O	511-522
targets	O	523-530
.	O	530-531

The	O	532-535
present	O	536-543
paper	O	544-549
reviewed	O	550-558
the	O	559-562
important	O	563-572
function	O	573-581
of	O	582-584
miR	B	585-588
-	I	588-589
15	I	589-591
family	O	592-598
and	O	599-602
new	O	603-606
approaches	O	607-617
for	O	618-621
miRNA	O	622-627
-	O	627-628
based	O	628-633
therapy	O	634-641
.	O	641-642

Regulation	O	0-10
of	O	11-13
acute	O	14-19
graft	O	20-25
-	O	25-26
versus	O	26-32
-	O	32-33
host	O	33-37
disease	O	38-45
by	O	46-48
microRNA	B	49-57
-	I	57-58
155	I	58-61
.	O	61-62

Acute	O	63-68
graft	O	69-74
-	O	74-75
versus	O	75-81
-	O	81-82
host	O	82-86
disease	O	87-94
(	O	95-96
aGVHD	O	96-101
)	O	101-102
remains	O	103-110
a	O	111-112
major	O	113-118
complication	O	119-131
of	O	132-134
allogeneic	O	135-145
hematopoietic	O	146-159
stem	O	160-164
cell	O	165-169
transplant	O	170-180
(	O	181-182
alloHSCT	O	182-190
)	O	190-191
,	O	191-192
underscoring	O	193-205
the	O	206-209
need	O	210-214
to	O	215-217
further	O	218-225
elucidate	O	226-235
its	O	236-239
mechanisms	O	240-250
and	O	251-254
develop	O	255-262
novel	O	263-268
treatments	O	269-279
.	O	279-280

Based	O	281-286
on	O	287-289
recent	O	290-296
observations	O	297-309
that	O	310-314
microRNA	B	315-323
-	I	323-324
155	I	324-327
(	O	328-329
miR	B	329-332
-	I	332-333
155	I	333-336
)	O	336-337
is	O	338-340
up	O	341-343
-	O	343-344
regulated	O	344-353
during	O	354-360
T	O	361-362
-	O	362-363
cell	O	363-367
activation	O	368-378
,	O	378-379
we	O	380-382
hypothesized	O	383-395
that	O	396-400
miR	B	401-404
-	I	404-405
155	I	405-408
is	O	409-411
involved	O	412-420
in	O	421-423
the	O	424-427
modulation	O	428-438
of	O	439-441
aGVHD	O	442-447
.	O	447-448

Here	O	449-453
we	O	454-456
show	O	457-461
that	O	462-466
miR	B	467-470
-	I	470-471
155	I	471-474
expression	O	475-485
was	O	486-489
up	O	490-492
-	O	492-493
regulated	O	493-502
in	O	503-505
T	O	506-507
cells	O	508-513
from	O	514-518
mice	O	519-523
developing	O	524-534
aGVHD	O	535-540
after	O	541-546
alloHSCT	O	547-555
.	O	555-556

Mice	O	557-561
receiving	O	562-571
miR	B	572-575
-	I	575-576
155	I	576-579
-	O	579-580
deficient	O	580-589
donor	O	590-595
lymphocytes	O	596-607
had	O	608-611
markedly	O	612-620
reduced	O	621-628
lethal	O	629-635
aGVHD	O	636-641
,	O	641-642
whereas	O	643-650
lethal	O	651-657
aGVHD	O	658-663
developed	O	664-673
rapidly	O	674-681
in	O	682-684
mice	O	685-689
recipients	O	690-700
of	O	701-703
miR	B	704-707
-	I	707-708
155	I	708-711
overexpressing	O	712-726
T	O	727-728
cells	O	729-734
.	O	734-735

Blocking	O	736-744
miR	B	745-748
-	I	748-749
155	I	749-752
expression	O	753-763
using	O	764-769
a	O	770-771
synthetic	O	772-781
anti	O	782-786
-	O	786-787
miR	B	787-790
-	I	790-791
155	I	791-794
after	O	795-800
alloHSCT	O	801-809
decreased	O	810-819
aGVHD	O	820-825
severity	O	826-834
and	O	835-838
prolonged	O	839-848
survival	O	849-857
in	O	858-860
mice	O	861-865
.	O	865-866

Finally	O	867-874
,	O	874-875
miR	B	876-879
-	I	879-880
155	I	880-883
up	O	884-886
-	O	886-887
regulation	O	887-897
was	O	898-901
shown	O	902-907
in	O	908-910
specimens	O	911-920
from	O	921-925
patients	O	926-934
with	O	935-939
pathologic	O	940-950
evidence	O	951-959
of	O	960-962
intestinal	O	963-973
aGVHD	O	974-979
.	O	979-980

Altogether	O	981-991
,	O	991-992
our	O	993-996
data	O	997-1001
indicate	O	1002-1010
a	O	1011-1012
role	O	1013-1017
for	O	1018-1021
miR	B	1022-1025
-	I	1025-1026
155	I	1026-1029
in	O	1030-1032
the	O	1033-1036
regulation	O	1037-1047
of	O	1048-1050
GVHD	O	1051-1055
and	O	1056-1059
point	O	1060-1065
to	O	1066-1068
miR	B	1069-1072
-	I	1072-1073
155	I	1073-1076
as	O	1077-1079
a	O	1080-1081
novel	O	1082-1087
target	O	1088-1094
for	O	1095-1098
therapeutic	O	1099-1110
intervention	O	1111-1123
in	O	1124-1126
this	O	1127-1131
disease	O	1132-1139
.	O	1139-1140

Identification	O	0-14
of	O	15-17
a	O	18-19
suitable	O	20-28
endogenous	O	29-39
control	O	40-47
gene	O	48-52
in	O	53-55
porcine	O	56-63
blastocysts	O	64-75
for	O	76-79
use	O	80-83
in	O	84-86
quantitative	O	87-99
PCR	O	100-103
analysis	O	104-112
of	O	113-115
microRNAs	O	116-125
.	O	125-126

To	O	127-129
obtain	O	130-136
reliable	O	137-145
results	O	146-153
in	O	154-156
quantitative	O	157-169
PCR	O	170-173
(	O	174-175
qPCR	O	175-179
)	O	179-180
reactions	O	181-190
,	O	190-191
an	O	192-194
endogenous	O	195-205
control	O	206-213
(	O	214-215
EC	O	215-217
)	O	217-218
gene	O	219-223
is	O	224-226
needed	O	227-233
to	O	234-236
correct	O	237-244
for	O	245-248
systematic	O	249-259
variations	O	260-270
.	O	270-271

In	O	272-274
this	O	275-279
study	O	280-285
,	O	285-286
a	O	287-288
TaqMan	O	289-295
low	O	296-299
density	O	300-307
array	O	308-313
was	O	314-317
used	O	318-322
to	O	323-325
quantify	O	326-334
the	O	335-338
expression	O	339-349
levels	O	350-356
of	O	357-359
microRNA	O	360-368
(	O	369-370
miRNA	O	370-375
)	O	375-376
genes	O	377-382
in	O	383-385
in	O	386-388
vivo	O	389-393
fertilized	O	394-404
,	O	404-405
in	O	406-408
vitro	O	409-414
fertilized	O	415-425
,	O	425-426
parthenogenetic	O	427-442
and	O	443-446
somatic	O	447-454
cell	O	455-459
nuclear	O	460-467
transfer	O	468-476
blastocysts	O	477-488
.	O	488-489

The	O	490-493
aim	O	494-497
was	O	498-501
to	O	502-504
identify	O	505-513
suitable	O	514-522
EC	O	523-525
genes	O	526-531
for	O	532-535
the	O	536-539
qPCR	O	540-544
analysis	O	545-553
of	O	554-556
miRNAs	O	557-563
in	O	564-566
porcine	O	567-574
blastocysts	O	575-586
.	O	586-587

The	O	588-591
results	O	592-599
showed	O	600-606
that	O	607-611
thirty	O	612-618
-	O	618-619
six	O	619-622
miRNAs	O	623-629
were	O	630-634
commonly	O	635-643
expressed	O	644-653
in	O	654-656
the	O	657-660
four	O	661-665
kinds	O	666-671
of	O	672-674
embryos	O	675-682
and	O	683-686
the	O	687-690
expression	O	691-701
levels	O	702-708
of	O	709-711
eleven	O	712-718
miRNAs	O	719-725
were	O	726-730
similar	O	731-738
in	O	739-741
the	O	742-745
different	O	746-755
embryo	O	756-762
types	O	763-768
(	O	769-770
P	O	770-771
-	O	771-772
value	O	772-777
>	O	777-778
0	O	778-779
.	O	779-780
05	O	780-782
)	O	782-783
.	O	783-784

These	O	785-790
11	O	791-793
miRNAs	O	794-800
were	O	801-805
selected	O	806-814
as	O	815-817
candidate	O	818-827
EC	O	828-830
genes	O	831-836
for	O	837-840
further	O	841-848
analysis	O	849-857
and	O	858-861
,	O	861-862
of	O	863-865
these	O	866-871
,	O	871-872
miR	B	873-876
-	I	876-877
16	I	877-879
was	O	880-883
identified	O	884-894
as	O	895-897
the	O	898-901
most	O	902-906
stable	O	907-913
EC	O	914-916
gene	O	917-921
by	O	922-924
the	O	925-928
GeNorm	O	929-935
(	O	936-937
a	O	937-938
tool	O	939-943
based	O	944-949
on	O	950-952
a	O	953-954
pair	O	955-959
-	O	959-960
wise	O	960-964
comparison	O	965-975
model	O	976-981
that	O	982-986
calculates	O	987-997
the	O	998-1001
internal	O	1002-1010
control	O	1011-1018
genes	O	1019-1024
stability	O	1025-1034
measure	O	1035-1042
and	O	1043-1046
determines	O	1047-1057
the	O	1058-1061
most	O	1062-1066
reliable	O	1067-1075
pair	O	1076-1080
of	O	1081-1083
EC	O	1084-1086
genes	O	1087-1092
)	O	1092-1093
and	O	1094-1097
NormFinder	O	1098-1108
(	O	1109-1110
an	O	1110-1112
excel	O	1113-1118
plug	O	1119-1123
-	O	1123-1124
in	O	1124-1126
that	O	1127-1131
uses	O	1132-1136
an	O	1137-1139
ANOVA	O	1140-1145
-	O	1145-1146
based	O	1146-1151
model	O	1152-1157
to	O	1158-1160
estimate	O	1161-1169
intra	O	1170-1175
-	O	1175-1176
and	O	1177-1180
inter	O	1181-1186
-	O	1186-1187
group	O	1187-1192
variation	O	1193-1202
to	O	1203-1205
indicate	O	1206-1214
the	O	1215-1218
single	O	1219-1225
most	O	1226-1230
stable	O	1231-1237
EC	O	1238-1240
gene	O	1241-1245
)	O	1245-1246
programs	O	1247-1255
.	O	1255-1256

In	O	1257-1259
addition	O	1260-1268
,	O	1268-1269
a	O	1270-1271
cell	O	1272-1276
number	O	1277-1283
normalization	O	1284-1297
method	O	1298-1304
validated	O	1305-1314
miR	B	1315-1318
-	I	1318-1319
16	I	1319-1321
as	O	1322-1324
a	O	1325-1326
suitable	O	1327-1335
EC	O	1336-1338
gene	O	1339-1343
for	O	1344-1347
use	O	1348-1351
in	O	1352-1354
future	O	1355-1361
qPCR	O	1362-1366
analysis	O	1367-1375
of	O	1376-1378
miRNAs	O	1379-1385
in	O	1386-1388
porcine	O	1389-1396
blastocysts	O	1397-1408
.	O	1408-1409

Identification	O	0-14
and	O	15-18
characterization	O	19-35
of	O	36-38
the	O	39-42
microRNAs	O	43-52
and	O	53-56
their	O	57-62
targets	O	63-70
in	O	71-73
Salmo	O	74-79
salar	O	80-85
.	O	85-86

MicroRNAs	O	87-96
(	O	97-98
miRNAs	O	98-104
)	O	104-105
are	O	106-109
small	O	110-115
,	O	115-116
non	O	117-120
-	O	120-121
coding	O	121-127
and	O	128-131
regulatory	O	132-142
RNAs	O	143-147
about	O	148-153
18	O	154-156
to	O	157-159
26	O	160-162
nucleotides	O	163-174
long	O	175-179
.	O	179-180

Their	O	181-186
conserved	O	187-196
nature	O	197-203
among	O	204-209
the	O	210-213
various	O	214-221
organisms	O	222-231
makes	O	232-237
them	O	238-242
a	O	243-244
good	O	245-249
source	O	250-256
of	O	257-259
new	O	260-263
miRNAs	O	264-270
discovery	O	271-280
by	O	281-283
comparative	O	284-295
genomics	O	296-304
approach	O	305-313
.	O	313-314

The	O	315-318
study	O	319-324
resulted	O	325-333
in	O	334-336
novel	O	337-342
75	O	343-345
precursor	O	346-355
miRNAs	O	356-362
containing	O	363-373
102	O	374-377
mature	O	378-384
sequences	O	385-394
belonging	O	395-404
to	O	405-407
46	O	408-410
families	O	411-419
in	O	420-422
an	O	423-425
important	O	426-435
aquatic	O	436-443
environmental	O	444-457
monitoring	O	458-468
fish	O	469-473
(	O	474-475
Salmo	O	475-480
salar	O	481-486
)	O	486-487
.	O	487-488

All	O	489-492
the	O	493-496
miRNA	O	497-502
families	O	503-511
(	O	512-513
let	B	513-516
-	I	516-517
7	I	517-518
,	O	518-519
mir	B	520-523
-	I	523-524
1	I	524-525
,	O	525-526
7	B	527-528
,	O	528-529
9	B	530-531
,	O	531-532
21	B	533-535
,	O	535-536
22	B	537-539
,	O	539-540
92	B	541-543
,	O	543-544
96	B	545-547
,	O	547-548
122	B	549-552
,	O	552-553
126	B	554-557
,	O	557-558
128	B	559-562
,	O	562-563
129	B	564-567
,	O	567-568
132	B	569-572
,	O	572-573
133	B	574-577
,	O	577-578
142	B	579-582
,	O	582-583
144	B	584-587
,	O	587-588
147	B	589-592
,	O	592-593
148	B	594-597
,	O	597-598
196	B	599-602
,	O	602-603
202	B	604-607
,	O	607-608
212	B	609-612
,	O	612-613
223	B	614-617
,	O	617-618
375	B	619-622
,	O	622-623
429	B	624-627
,	O	627-628
430	B	629-632
,	O	632-633
449	B	634-637
,	O	637-638
451	B	639-642
,	O	642-643
457	B	644-647
,	O	647-648
466	B	649-652
,	O	652-653
682	B	654-657
,	O	657-658
700	B	659-662
,	O	662-663
1388	B	664-668
,	O	668-669
1594	B	670-674
,	O	674-675
1600	B	676-680
,	O	680-681
1607	B	682-686
,	O	686-687
1616	B	688-692
,	O	692-693
1642	B	694-698
,	O	698-699
1681	B	700-704
,	O	704-705
1701	B	706-710
,	O	710-711
1720	B	712-716
,	O	716-717
1772	B	718-722
,	O	722-723
1782	B	724-728
,	O	728-729
1787	B	730-734
,	O	734-735
1814	B	736-740
,	O	740-741
2189	B	742-746
and	O	747-750
3540	B	751-755
)	O	755-756
are	O	757-760
found	O	761-766
for	O	767-770
the	O	771-774
first	O	775-780
time	O	781-785
in	O	786-788
S	O	789-790
.	O	790-791
salar	O	792-797
.	O	797-798

All	O	799-802
75	O	803-805
miRNA	O	806-811
precursors	O	812-822
form	O	823-827
stable	O	828-834
minimum	O	835-842
free	O	843-847
energy	O	848-854
stem	O	855-859
loop	O	860-864
and	O	865-868
the	O	869-872
mature	O	873-879
miRNAs	O	880-886
reside	O	887-893
in	O	894-896
the	O	897-900
stem	O	901-905
portion	O	906-913
of	O	914-916
the	O	917-920
stem	O	921-925
loop	O	926-930
structure	O	931-940
.	O	940-941

Their	O	942-947
target	O	948-954
proteins	O	955-963
are	O	964-967
involved	O	968-976
in	O	977-979
transcription	O	980-993
factors	O	994-1001
(	O	1002-1003
28	O	1003-1005
%	O	1005-1006
)	O	1006-1007
,	O	1007-1008
metabolism	O	1009-1019
(	O	1020-1021
23	O	1021-1023
%	O	1023-1024
)	O	1024-1025
,	O	1025-1026
signaling	O	1027-1036
(	O	1037-1038
18	O	1038-1040
%	O	1040-1041
)	O	1041-1042
,	O	1042-1043
transportation	O	1044-1058
(	O	1059-1060
9	O	1060-1061
%	O	1061-1062
)	O	1062-1063
,	O	1063-1064
immunity	O	1065-1073
(	O	1074-1075
8	O	1075-1076
%	O	1076-1077
)	O	1077-1078
,	O	1078-1079
stress	O	1080-1086
related	O	1087-1094
activity	O	1095-1103
(	O	1104-1105
5	O	1105-1106
%	O	1106-1107
)	O	1107-1108
,	O	1108-1109
cancer	O	1110-1116
and	O	1117-1120
tumor	O	1121-1126
related	O	1127-1134
activity	O	1135-1143
(	O	1144-1145
5	O	1145-1146
%	O	1146-1147
)	O	1147-1148
,	O	1148-1149
growth	O	1150-1156
and	O	1157-1160
development	O	1161-1172
(	O	1173-1174
3	O	1174-1175
%	O	1175-1176
)	O	1176-1177
,	O	1177-1178
and	O	1179-1182
cell	O	1183-1187
division	O	1188-1196
(	O	1197-1198
1	O	1198-1199
%	O	1199-1200
)	O	1200-1201
.	O	1201-1202

MicroRNAs	O	0-9
/	O	9-10
TP53	O	10-14
feedback	O	15-23
circuitry	O	24-33
in	O	34-36
glioblastoma	O	37-49
multiforme	O	50-60
.	O	60-61

MicroRNAs	O	62-71
(	O	72-73
miRNAs	O	73-79
)	O	79-80
are	O	81-84
increasingly	O	85-97
implicated	O	98-108
in	O	109-111
regulating	O	112-122
cancer	O	123-129
initiation	O	130-140
and	O	141-144
progression	O	145-156
.	O	156-157

In	O	158-160
this	O	161-165
study	O	166-171
,	O	171-172
two	O	173-176
miRNAs	O	177-183
,	O	183-184
miR	B	185-188
-	I	188-189
25	I	189-191
and	O	192-195
-	B	196-197
32	I	197-199
,	O	199-200
are	O	201-204
identified	O	205-215
as	O	216-218
p53	O	219-222
-	O	222-223
repressed	O	223-232
miRNAs	O	233-239
by	O	240-242
p53	O	243-246
-	O	246-247
dependent	O	247-256
negative	O	257-265
regulation	O	266-276
of	O	277-279
their	O	280-285
transcriptional	O	286-301
regulators	O	302-312
,	O	312-313
E2F1	O	314-318
and	O	319-322
MYC	O	323-326
.	O	326-327

However	O	328-335
,	O	335-336
miR	B	337-340
-	I	340-341
25	I	341-343
and	O	344-347
-	B	348-349
32	I	349-351
result	O	352-358
in	O	359-361
p53	O	362-365
accumulation	O	366-378
by	O	379-381
directly	O	382-390
targeting	O	391-400
Mdm2	O	401-405
and	O	406-409
TSC1	O	410-414
,	O	414-415
which	O	416-421
are	O	422-425
negative	O	426-434
regulators	O	435-445
of	O	446-448
p53	O	449-452
and	O	453-456
the	O	457-460
mTOR	O	461-465
(	O	466-467
mammalian	O	467-476
target	O	477-483
of	O	484-486
rapamycin	O	487-496
)	O	496-497
pathway	O	498-505
,	O	505-506
respectively	O	507-519
,	O	519-520
leading	O	521-528
to	O	529-531
inhibition	O	532-542
of	O	543-545
cellular	O	546-554
proliferation	O	555-568
through	O	569-576
cell	O	577-581
cycle	O	582-587
arrest	O	588-594
.	O	594-595

Thus	O	596-600
,	O	600-601
there	O	602-607
is	O	608-610
a	O	611-612
recurrent	O	613-622
autoregulatory	O	623-637
circuit	O	638-645
involving	O	646-655
expression	O	656-666
of	O	667-669
p53	O	670-673
,	O	673-674
E2F1	O	675-679
,	O	679-680
and	O	681-684
MYC	O	685-688
to	O	689-691
regulate	O	692-700
the	O	701-704
expression	O	705-715
of	O	716-718
miR	B	719-722
-	I	722-723
25	I	723-725
and	O	726-729
-	B	730-731
32	I	731-733
,	O	733-734
which	O	735-740
are	O	741-744
miRNAs	O	745-751
that	O	752-756
,	O	756-757
in	O	758-760
turn	O	761-765
,	O	765-766
control	O	767-774
p53	O	775-778
accumulation	O	779-791
.	O	791-792

Significantly	O	793-806
,	O	806-807
overexpression	O	808-822
of	O	823-825
transfected	O	826-837
miR	B	838-841
-	I	841-842
25	I	842-844
and	O	845-848
-	B	849-850
32	I	850-852
in	O	853-855
glioblastoma	O	856-868
multiforme	O	869-879
cells	O	880-885
inhibited	O	886-895
growth	O	896-902
of	O	903-905
the	O	906-909
glioblastoma	O	910-922
multiforme	O	923-933
cells	O	934-939
in	O	940-942
mouse	O	943-948
brain	O	949-954
in	O	955-957
vivo	O	958-962
.	O	962-963

The	O	964-967
results	O	968-975
define	O	976-982
miR	B	983-986
-	I	986-987
25	I	987-989
and	O	990-993
-	B	994-995
32	I	995-997
as	O	998-1000
positive	O	1001-1009
regulators	O	1010-1020
of	O	1021-1023
p53	O	1024-1027
,	O	1027-1028
underscoring	O	1029-1041
their	O	1042-1047
role	O	1048-1052
in	O	1053-1055
tumorigenesis	O	1056-1069
in	O	1070-1072
glioblastoma	O	1073-1085
.	O	1085-1086

Genetic	O	0-7
polymorphism	O	8-20
of	O	21-23
pri	B	24-27
-	I	27-28
microRNA	I	28-36
325	I	37-40
,	O	40-41
targeting	O	42-51
SLC6A4	O	52-58
3	O	59-60
'	O	60-61
-	O	61-62
UTR	O	62-65
,	O	65-66
is	O	67-69
closely	O	70-77
associated	O	78-88
with	O	89-93
the	O	94-97
risk	O	98-102
of	O	103-105
functional	O	106-116
dyspepsia	O	117-126
in	O	127-129
Japan	O	130-135
.	O	135-136

BACKGROUND	O	137-147
:	O	147-148
The	O	149-152
role	O	153-157
of	O	158-160
genetics	O	161-169
in	O	170-172
the	O	173-176
susceptibility	O	177-191
to	O	192-194
functional	O	195-205
dyspepsia	O	206-215
(	O	216-217
FD	O	217-219
)	O	219-220
remains	O	221-228
unclear	O	229-236
.	O	236-237

We	O	238-240
attempted	O	241-250
to	O	251-253
clarify	O	254-261
the	O	262-265
association	O	266-277
between	O	278-285
FD	O	286-288
and	O	289-292
polymorphisms	O	293-306
in	O	307-309
SLC6A4	O	310-316
.	O	316-317

In	O	318-320
addition	O	321-329
,	O	329-330
rs5981521	O	331-340
(	O	341-342
C	O	342-343
>	O	343-344
T	O	344-345
)	O	345-346
in	O	347-349
the	O	350-353
pri	B	354-357
-	I	357-358
microRNA	I	358-366
325	I	367-370
(	O	371-372
pri	B	372-375
-	I	375-376
miR	I	376-379
-	I	379-380
325	I	380-383
)	O	383-384
coding	O	385-391
region	O	392-398
was	O	399-402
also	O	403-407
investigated	O	408-420
.	O	420-421

METHODS	O	422-429
:	O	429-430
The	O	431-434
study	O	435-440
was	O	441-444
performed	O	445-454
in	O	455-457
395	O	458-461
subjects	O	462-470
(	O	471-472
172	O	472-475
with	O	476-480
no	O	481-483
upper	O	484-489
abdominal	O	490-499
symptoms	O	500-508
and	O	509-512
223	O	513-516
with	O	517-521
FD	O	522-524
,	O	524-525
including	O	526-535
medication	O	536-546
-	O	546-547
resistant	O	547-556
FD	O	557-559
)	O	559-560
.	O	560-561

We	O	562-564
employed	O	565-573
a	O	574-575
polymerase	O	576-586
chain	O	587-592
reaction	O	593-601
single	O	602-608
-	O	608-609
strand	O	609-615
conformation	O	616-628
polymorphism	O	629-641
(	O	642-643
PCR	O	643-646
-	O	646-647
SSCP	O	647-651
)	O	651-652
method	O	653-659
to	O	660-662
detect	O	663-669
gene	O	670-674
polymorphisms	O	675-688
.	O	688-689

RESULTS	O	690-697
:	O	697-698
Neither	O	699-706
SLC6A4	O	707-713
-	O	714-715
185	O	715-718
A	O	719-720
>	O	720-721
C	O	721-722
nor	O	723-726
*	O	727-728
463	O	728-731
G	O	732-733
>	O	733-734
T	O	734-735
was	O	736-739
associated	O	740-750
with	O	751-755
susceptibility	O	756-770
to	O	771-773
FD	O	774-776
.	O	776-777

The	O	778-781
number	O	782-788
of	O	789-791
rs5981521	O	792-801
T	O	802-803
alleles	O	804-811
was	O	812-815
significantly	O	816-829
correlated	O	830-840
with	O	841-845
an	O	846-848
increased	O	849-858
risk	O	859-863
for	O	864-867
FD	O	868-870
(	O	871-872
odds	O	872-876
ratio	O	877-882
[	O	883-884
OR	O	884-886
]	O	886-887
1	O	888-889
.	O	889-890
45	O	890-892
,	O	892-893
95	O	894-896
%	O	897-898
confidence	O	899-909
interval	O	910-918
[	O	919-920
CI	O	920-922
]	O	922-923
1	O	924-925
.	O	925-926
05	O	926-928
-	O	928-929
1	O	929-930
.	O	930-931
98	O	931-933
;	O	933-934
p	O	935-936
=	O	937-938
0	O	939-940
.	O	940-941
022	O	941-944
)	O	944-945
and	O	946-949
the	O	950-953
TT	O	954-956
homozygote	O	957-967
was	O	968-971
more	O	972-976
closely	O	977-984
associated	O	985-995
with	O	996-1000
the	O	1001-1004
risk	O	1005-1009
for	O	1010-1013
FD	O	1014-1016
(	O	1017-1018
OR	O	1018-1020
3	O	1021-1022
.	O	1022-1023
01	O	1023-1025
,	O	1025-1026
95	O	1027-1029
%	O	1030-1031
CI	O	1032-1034
1	O	1035-1036
.	O	1036-1037
41	O	1037-1039
-	O	1039-1040
6	O	1040-1041
.	O	1041-1042
42	O	1042-1044
;	O	1044-1045
p	O	1046-1047
=	O	1048-1049
0	O	1050-1051
.	O	1051-1052
0043	O	1052-1056
)	O	1056-1057
.	O	1057-1058

The	O	1059-1062
TT	O	1063-1065
homozygote	O	1066-1076
also	O	1077-1081
had	O	1082-1085
significantly	O	1086-1099
increased	O	1100-1109
risks	O	1110-1115
for	O	1116-1119
both	O	1120-1124
the	O	1125-1128
epigastric	O	1129-1139
pain	O	1140-1144
syndrome	O	1145-1153
(	O	1154-1155
EPS	O	1155-1158
)	O	1158-1159
and	O	1160-1163
postprandial	O	1164-1176
distress	O	1177-1185
syndrome	O	1186-1194
(	O	1195-1196
PDS	O	1196-1199
)	O	1199-1200
subtypes	O	1201-1209
of	O	1210-1212
FD	O	1213-1215
(	O	1216-1217
OR	O	1217-1219
3	O	1220-1221
.	O	1221-1222
04	O	1222-1224
,	O	1224-1225
95	O	1226-1228
%	O	1229-1230
CI	O	1231-1233
1	O	1234-1235
.	O	1235-1236
25	O	1236-1238
-	O	1238-1239
7	O	1239-1240
.	O	1240-1241
42	O	1241-1243
;	O	1243-1244
p	O	1245-1246
=	O	1247-1248
0	O	1249-1250
.	O	1250-1251
014	O	1251-1254
and	O	1255-1258
OR	O	1259-1261
3	O	1262-1263
.	O	1263-1264
05	O	1264-1266
,	O	1266-1267
95	O	1268-1270
%	O	1271-1272
CI	O	1273-1275
1	O	1276-1277
.	O	1277-1278
14	O	1278-1280
-	O	1280-1281
8	O	1281-1282
.	O	1282-1283
13	O	1283-1285
;	O	1285-1286
p	O	1287-1288
=	O	1289-1290
0	O	1291-1292
.	O	1292-1293
026	O	1293-1296
,	O	1296-1297
respectively	O	1298-1310
)	O	1310-1311
.	O	1311-1312

In	O	1313-1315
addition	O	1316-1324
,	O	1324-1325
Helicobacter	O	1326-1338
pylori	O	1339-1345
-	O	1345-1346
negative	O	1346-1354
TT	O	1355-1357
homozygotes	O	1358-1369
had	O	1370-1373
a	O	1374-1375
greater	O	1376-1383
risk	O	1384-1388
for	O	1389-1392
FD	O	1393-1395
(	O	1396-1397
OR	O	1397-1399
8	O	1400-1401
.	O	1401-1402
37	O	1402-1404
,	O	1404-1405
95	O	1406-1408
%	O	1409-1410
CI	O	1411-1413
1	O	1414-1415
.	O	1415-1416
78	O	1416-1418
-	O	1418-1419
39	O	1419-1421
.	O	1421-1422
5	O	1422-1423
;	O	1423-1424
p	O	1425-1426
=	O	1427-1428
0	O	1429-1430
.	O	1430-1431
0072	O	1431-1435
)	O	1435-1436
.	O	1436-1437

In	O	1438-1440
subjects	O	1441-1449
with	O	1450-1454
the	O	1455-1458
SLC6A4	O	1459-1465
5	O	1466-1467
'	O	1467-1468
-	O	1468-1469
untranslated	O	1469-1481
region	O	1482-1488
(	O	1489-1490
UTR	O	1490-1493
)	O	1493-1494
wild	O	1495-1499
homozygote	O	1500-1510
,	O	1510-1511
the	O	1512-1515
number	O	1516-1522
of	O	1523-1525
rs5981521	O	1526-1535
T	O	1536-1537
alleles	O	1538-1545
was	O	1546-1549
significantly	O	1550-1563
correlated	O	1564-1574
to	O	1575-1577
an	O	1578-1580
increased	O	1581-1590
risk	O	1591-1595
for	O	1596-1599
FD	O	1600-1602
(	O	1603-1604
OR	O	1604-1606
1	O	1607-1608
.	O	1608-1609
45	O	1609-1611
,	O	1611-1612
95	O	1613-1615
%	O	1616-1617
CI	O	1618-1620
1	O	1621-1622
.	O	1622-1623
03	O	1623-1625
-	O	1625-1626
2	O	1626-1627
.	O	1627-1628
04	O	1628-1630
,	O	1630-1631
p	O	1632-1633
=	O	1634-1635
0	O	1636-1637
.	O	1637-1638
033	O	1638-1641
)	O	1641-1642
.	O	1642-1643

Of	O	1644-1646
note	O	1647-1651
,	O	1651-1652
in	O	1653-1655
subjects	O	1656-1664
who	O	1665-1668
were	O	1669-1673
SLC6A4	O	1674-1680
3	O	1681-1682
'	O	1682-1683
-	O	1683-1684
UTR	O	1684-1687
mutant	O	1688-1694
carriers	O	1695-1703
,	O	1703-1704
the	O	1705-1708
number	O	1709-1715
of	O	1716-1718
rs5981521	O	1719-1728
T	O	1729-1730
alleles	O	1731-1738
was	O	1739-1742
also	O	1743-1747
significantly	O	1748-1761
correlated	O	1762-1772
with	O	1773-1777
an	O	1778-1780
increased	O	1781-1790
risk	O	1791-1795
for	O	1796-1799
FD	O	1800-1802
(	O	1803-1804
OR	O	1804-1806
2	O	1807-1808
.	O	1808-1809
07	O	1809-1811
,	O	1811-1812
95	O	1813-1815
%	O	1816-1817
CI	O	1818-1820
1	O	1821-1822
.	O	1822-1823
08	O	1823-1825
-	O	1825-1826
3	O	1826-1827
.	O	1827-1828
98	O	1828-1830
;	O	1830-1831
p	O	1832-1833
=	O	1834-1835
0	O	1836-1837
.	O	1837-1838
029	O	1838-1841
)	O	1841-1842
.	O	1842-1843

CONCLUSIONS	O	1844-1855
:	O	1855-1856
Our	O	1857-1860
results	O	1861-1868
suggest	O	1869-1876
that	O	1877-1881
the	O	1882-1885
genetic	O	1886-1893
polymorphism	O	1894-1906
pri	B	1907-1910
-	I	1910-1911
miR	I	1911-1914
-	I	1914-1915
325	I	1915-1918
is	O	1919-1921
associated	O	1922-1932
with	O	1933-1937
FD	O	1938-1940
and	O	1941-1944
interacts	O	1945-1954
with	O	1955-1959
SLC6A4	O	1960-1966
polymorphisms	O	1967-1980
in	O	1981-1983
increasing	O	1984-1994
susceptibility	O	1995-2009
to	O	2010-2012
FD	O	2013-2015
in	O	2016-2018
Japanese	O	2019-2027
.	O	2027-2028

Murine	O	0-6
cytomegalovirus	O	7-22
infection	O	23-32
of	O	33-35
cultured	O	36-44
mouse	O	45-50
cells	O	51-56
induces	O	57-64
expression	O	65-75
of	O	76-78
miR	B	79-82
-	I	82-83
7a	I	83-85
.	O	85-86

One	O	87-90
goal	O	91-95
of	O	96-98
virus	O	99-104
infection	O	105-114
is	O	115-117
to	O	118-120
reprogramme	O	121-132
the	O	133-136
host	O	137-141
cell	O	142-146
to	O	147-149
optimize	O	150-158
virus	O	159-164
replication	O	165-176
.	O	176-177

As	O	178-180
part	O	181-185
of	O	186-188
this	O	189-193
process	O	194-201
,	O	201-202
viral	O	203-208
microRNAs	O	209-218
(	O	219-220
miRNAs	O	220-226
)	O	226-227
may	O	228-231
compete	O	232-239
for	O	240-243
components	O	244-254
of	O	255-257
the	O	258-261
miRNA	O	262-267
/	O	267-268
small	O	268-273
interfering	O	274-285
RNA	O	286-289
pathway	O	290-297
,	O	297-298
as	O	299-301
well	O	302-306
as	O	307-309
regulate	O	310-318
cellular	O	319-327
targets	O	328-335
.	O	335-336

Murine	O	337-343
cytomegalovirus	O	344-359
(	O	360-361
MCMV	O	361-365
)	O	365-366
has	O	367-370
been	O	371-375
described	O	376-385
to	O	386-388
generate	O	389-397
large	O	398-403
numbers	O	404-411
of	O	412-414
viral	O	415-420
miRNAs	O	421-427
during	O	428-434
lytic	O	435-440
infection	O	441-450
and	O	451-454
was	O	455-458
therefore	O	459-468
used	O	469-473
to	O	474-476
analyse	O	477-484
the	O	485-488
impact	O	489-495
of	O	496-498
viral	O	499-504
miRNAs	O	505-511
on	O	512-514
the	O	515-518
host	O	519-523
-	O	523-524
cell	O	524-528
small	O	529-534
-	O	534-535
RNA	O	535-538
system	O	539-545
,	O	545-546
as	O	547-549
well	O	550-554
as	O	555-557
to	O	558-560
check	O	561-566
for	O	567-570
sorting	O	571-578
of	O	579-581
viral	O	582-587
small	O	588-593
RNAs	O	594-598
into	O	599-603
specific	O	604-612
Argonaute	O	613-622
(	O	623-624
Ago	O	624-627
)	O	627-628
proteins	O	629-637
.	O	637-638

Deep	O	639-643
-	O	643-644
sequencing	O	644-654
analysis	O	655-663
of	O	664-666
MCMV	O	667-671
-	O	671-672
infected	O	672-680
cells	O	681-686
revealed	O	687-695
that	O	696-700
viral	O	701-706
miRNAs	O	707-713
represented	O	714-725
only	O	726-730
~	O	731-732
13	O	732-734
%	O	734-735
of	O	736-738
all	O	739-742
detected	O	743-751
miRNAs	O	752-758
.	O	758-759

All	O	760-763
previously	O	764-774
described	O	775-784
MCMV	O	785-789
miRNAs	O	790-796
with	O	797-801
the	O	802-805
exception	O	806-815
of	O	816-818
miR	B	819-822
-	I	822-823
m88	I	823-826
-	I	826-827
1	I	827-828
*	I	828-829
were	O	830-834
confirmed	O	835-844
,	O	844-845
and	O	846-849
for	O	850-853
the	O	854-857
MCMV	O	858-862
miR	B	863-866
-	I	866-867
m01	I	867-870
-	I	870-871
1	I	871-872
hairpin	O	873-880
,	O	880-881
an	O	882-884
additional	O	885-895
miRNA	O	896-901
,	O	901-902
designated	O	903-913
miR	B	914-917
-	I	917-918
m01	I	918-921
-	I	921-922
1	I	922-923
-	I	923-924
3p	I	924-926
,	O	926-927
was	O	928-931
found	O	932-937
.	O	937-938

Its	O	939-942
presence	O	943-951
was	O	952-955
confirmed	O	956-965
by	O	966-968
quantitative	O	969-981
real	O	982-986
-	O	986-987
time	O	987-991
PCR	O	992-995
and	O	996-999
Northern	O	1000-1008
blotting	O	1009-1017
.	O	1017-1018

Deep	O	1019-1023
sequencing	O	1024-1034
after	O	1035-1040
RNA	O	1041-1044
-	O	1044-1045
induced	O	1045-1052
silencing	O	1053-1062
complex	O	1063-1070
(	O	1071-1072
RISC	O	1072-1076
)	O	1076-1077
immunoprecipitation	O	1078-1097
with	O	1098-1102
antibodies	O	1103-1113
specific	O	1114-1122
for	O	1123-1126
either	O	1127-1133
Ago1	O	1134-1138
or	O	1139-1141
Ago2	O	1142-1146
showed	O	1147-1153
that	O	1154-1158
all	O	1159-1162
MCMV	O	1163-1167
miRNAs	O	1168-1174
were	O	1175-1179
loaded	O	1180-1186
into	O	1187-1191
both	O	1192-1196
RISCs	O	1197-1202
.	O	1202-1203

The	O	1204-1207
ratio	O	1208-1213
of	O	1214-1216
MCMV	O	1217-1221
to	O	1222-1224
mouse	O	1225-1230
miRNAs	O	1231-1237
was	O	1238-1241
not	O	1242-1245
increased	O	1246-1255
after	O	1256-1261
immunoprecipitation	O	1262-1281
of	O	1282-1284
Ago	O	1285-1288
proteins	O	1289-1297
.	O	1297-1298

Viral	O	1299-1304
miRNAs	O	1305-1311
therefore	O	1312-1321
did	O	1322-1325
not	O	1326-1329
overwhelm	O	1330-1339
the	O	1340-1343
host	O	1344-1348
miRNA	O	1349-1354
processing	O	1355-1365
system	O	1366-1372
,	O	1372-1373
nor	O	1374-1377
were	O	1378-1382
they	O	1383-1387
incorporated	O	1388-1400
preferentially	O	1401-1415
into	O	1416-1420
RISCs	O	1421-1426
.	O	1426-1427

Three	O	1428-1433
mouse	O	1434-1439
miRNAs	O	1440-1446
were	O	1447-1451
found	O	1452-1457
that	O	1458-1462
showed	O	1463-1469
altered	O	1470-1477
expression	O	1478-1488
as	O	1489-1491
a	O	1492-1493
result	O	1494-1500
of	O	1501-1503
MCMV	O	1504-1508
infection	O	1509-1518
.	O	1518-1519

Downregulation	O	1520-1534
of	O	1535-1537
miR	B	1538-1541
-	I	1541-1542
27a	I	1542-1545
,	O	1545-1546
as	O	1547-1549
described	O	1550-1559
previously	O	1560-1570
,	O	1570-1571
could	O	1572-1577
be	O	1578-1580
confirmed	O	1581-1590
.	O	1590-1591

In	O	1592-1594
addition	O	1595-1603
,	O	1603-1604
miR	B	1605-1608
-	I	1608-1609
26a	I	1609-1612
was	O	1613-1616
downregulated	O	1617-1630
,	O	1630-1631
and	O	1632-1635
upregulation	O	1636-1648
of	O	1649-1651
miR	B	1652-1655
-	I	1655-1656
7a	I	1656-1658
dependent	O	1659-1668
on	O	1669-1671
viral	O	1672-1677
protein	O	1678-1685
expression	O	1686-1696
could	O	1697-1702
be	O	1703-1705
observed	O	1706-1714
.	O	1714-1715

MiR	B	0-3
-	I	3-4
499	I	4-7
induces	O	8-15
cardiac	O	16-23
differentiation	O	24-39
of	O	40-42
rat	O	43-46
mesenchymal	O	47-58
stem	O	59-63
cells	O	64-69
through	O	70-77
wnt	O	78-81
/	O	81-82
beta	O	82-86
-	O	86-87
catenin	O	87-94
signaling	O	95-104
pathway	O	105-112
.	O	112-113

OBJECTIVE	O	114-123
:	O	123-124
To	O	125-127
test	O	128-132
the	O	133-136
hypothesis	O	137-147
that	O	148-152
over	O	153-157
-	O	157-158
expressing	O	158-168
miR	B	169-172
-	I	172-173
499	I	173-176
in	O	177-179
rat	O	180-183
bone	O	184-188
marrow	O	189-195
-	O	195-196
derived	O	196-203
mesenchymal	O	204-215
stem	O	216-220
cells	O	221-226
(	O	227-228
BM	O	228-230
-	O	230-231
MSCs	O	231-235
)	O	235-236
induces	O	237-244
them	O	245-249
to	O	250-252
differentiate	O	253-266
into	O	267-271
cardiomyocyte	O	272-285
-	O	285-286
like	O	286-290
cells	O	291-296
through	O	297-304
the	O	305-308
wnt	O	309-312
/	O	312-313
beta	O	313-317
-	O	317-318
catenin	O	318-325
signaling	O	326-335
pathway	O	336-343
.	O	343-344

METHODS	O	345-352
:	O	352-353
Rat	O	354-357
BM	O	358-360
-	O	360-361
MSCs	O	361-365
were	O	366-370
infected	O	371-379
with	O	380-384
lentiviral	O	385-395
vectors	O	396-403
bearing	O	404-411
miR	B	412-415
-	I	415-416
499	I	416-419
.	O	419-420

The	O	421-424
expression	O	425-435
of	O	436-438
cardiac	O	439-446
-	O	446-447
specific	O	447-455
markers	O	456-463
,	O	463-464
NKx2	O	465-469
.	O	469-470
5	O	470-471
,	O	471-472
GATA4	O	473-478
,	O	478-479
MEF2C	O	480-485
,	O	485-486
and	O	487-490
cTnI	O	491-495
in	O	496-498
these	O	499-504
cells	O	505-510
were	O	511-515
examined	O	516-524
by	O	525-527
rtPCR	O	528-533
or	O	534-536
Western	O	537-544
blot	O	545-549
analysis	O	550-558
and	O	559-562
the	O	563-566
activity	O	567-575
of	O	576-578
the	O	579-582
wnt	O	583-586
/	O	586-587
beta	O	587-591
-	O	591-592
catenin	O	592-599
signaling	O	600-609
pathway	O	610-617
was	O	618-621
evaluated	O	622-631
by	O	632-634
measuring	O	635-644
the	O	645-648
phosphorylation	O	649-664
status	O	665-671
of	O	672-674
beta	O	675-679
-	O	679-680
catenin	O	680-687
.	O	687-688

RESULTS	O	689-696
:	O	696-697
Over	O	698-702
-	O	702-703
expression	O	703-713
of	O	714-716
miR	B	717-720
-	I	720-721
499	I	721-724
in	O	725-727
rat	O	728-731
BM	O	732-734
-	O	734-735
MSCs	O	735-739
increased	O	740-749
the	O	750-753
expression	O	754-764
of	O	765-767
cardiac	O	768-775
-	O	775-776
specific	O	776-784
genes	O	785-790
,	O	790-791
such	O	792-796
as	O	797-799
NKx2	O	800-804
.	O	804-805
5	O	805-806
,	O	806-807
GATA4	O	808-813
,	O	813-814
MEF2C	O	815-820
,	O	820-821
and	O	822-825
cTnI	O	826-830
and	O	831-834
decreased	O	835-844
the	O	845-848
ratio	O	849-854
of	O	855-857
phosphorylated	O	858-872
/	O	872-873
dephosphorylated	O	873-889
beta	O	890-894
-	O	894-895
catenin	O	895-902
in	O	903-905
the	O	906-909
wnt	O	910-913
/	O	913-914
beta	O	914-918
-	O	918-919
catenin	O	919-926
signaling	O	927-936
pathway	O	937-944
,	O	944-945
thus	O	946-950
activating	O	951-961
the	O	962-965
pathway	O	966-973
.	O	973-974

Knocking	O	975-983
down	O	984-988
the	O	989-992
expression	O	993-1003
of	O	1004-1006
Dvl	O	1007-1010
,	O	1010-1011
an	O	1012-1014
adaptor	O	1015-1022
molecule	O	1023-1031
in	O	1032-1034
the	O	1035-1038
wnt	O	1039-1042
/	O	1042-1043
beta	O	1043-1047
-	O	1047-1048
catenin	O	1048-1055
signaling	O	1056-1065
,	O	1065-1066
partially	O	1067-1076
blocked	O	1077-1084
the	O	1085-1088
role	O	1089-1093
of	O	1094-1096
the	O	1097-1100
miR	B	1101-1104
-	I	1104-1105
499	I	1105-1108
and	O	1109-1112
decreased	O	1113-1122
those	O	1123-1128
cardiac	O	1129-1136
-	O	1136-1137
specific	O	1137-1145
genes	O	1146-1151
.	O	1151-1152

CONCLUSION	O	1153-1163
:	O	1163-1164
Over	O	1165-1169
-	O	1169-1170
expression	O	1170-1180
of	O	1181-1183
miR	B	1184-1187
-	I	1187-1188
499	I	1188-1191
in	O	1192-1194
rat	O	1195-1198
BM	O	1199-1201
-	O	1201-1202
MSCs	O	1202-1206
induces	O	1207-1214
them	O	1215-1219
toward	O	1220-1226
cardiac	O	1227-1234
differentiation	O	1235-1250
through	O	1251-1258
the	O	1259-1262
activating	O	1263-1273
the	O	1274-1277
wnt	O	1278-1281
/	O	1281-1282
beta	O	1282-1286
-	O	1286-1287
catenin	O	1287-1294
signal	O	1295-1301
pathway	O	1302-1309
.	O	1309-1310

Modulating	O	0-10
Anti	O	11-15
-	O	15-16
MicroRNA	B	16-24
-	I	24-25
21	I	25-27
Activity	O	28-36
and	O	37-40
Specificity	O	41-52
Using	O	53-58
Oligonucleotide	O	59-74
Derivatives	O	75-86
and	O	87-90
Length	O	91-97
Optimization	O	98-110
.	O	110-111

MicroRNAs	O	112-121
are	O	122-125
short	O	126-131
,	O	131-132
endogenous	O	133-143
RNAs	O	144-148
that	O	149-153
direct	O	154-160
posttranscriptional	O	161-180
regulation	O	181-191
of	O	192-194
gene	O	195-199
expression	O	200-210
vital	O	211-216
for	O	217-220
many	O	221-225
developmental	O	226-239
and	O	240-243
cellular	O	244-252
functions	O	253-262
.	O	262-263

Implicated	O	264-274
in	O	275-277
the	O	278-281
pathogenesis	O	282-294
of	O	295-297
several	O	298-305
human	O	306-311
diseases	O	312-320
,	O	320-321
this	O	322-326
group	O	327-332
of	O	333-335
RNAs	O	336-340
provides	O	341-349
interesting	O	350-361
targets	O	362-369
for	O	370-373
therapeutic	O	374-385
intervention	O	386-398
.	O	398-399

Anti	O	400-404
-	O	404-405
microRNA	O	405-413
oligonucleotides	O	414-430
constitute	O	431-441
a	O	442-443
class	O	444-449
of	O	450-452
synthetic	O	453-462
antisense	O	463-472
oligonucleotides	O	473-489
used	O	490-494
to	O	495-497
interfere	O	498-507
with	O	508-512
microRNAs	O	513-522
.	O	522-523

In	O	524-526
this	O	527-531
study	O	532-537
,	O	537-538
we	O	539-541
investigate	O	542-553
the	O	554-557
effects	O	558-565
of	O	566-568
chemical	O	569-577
modifications	O	578-591
and	O	592-595
truncations	O	596-607
on	O	608-610
activity	O	611-619
and	O	620-623
specificity	O	624-635
of	O	636-638
anti	O	639-643
-	O	643-644
microRNA	O	644-652
oligonucleotides	O	653-669
targeting	O	670-679
microRNA	B	680-688
-	I	688-689
21	I	689-691
.	O	691-692

We	O	693-695
observed	O	696-704
an	O	705-707
increased	O	708-717
activity	O	718-726
but	O	727-730
reduced	O	731-738
specificity	O	739-750
when	O	751-755
incorporating	O	756-769
locked	O	770-776
nucleic	O	777-784
acid	O	785-789
monomers	O	790-798
,	O	798-799
whereas	O	800-807
the	O	808-811
opposite	O	812-820
was	O	821-824
observed	O	825-833
when	O	834-838
introducing	O	839-850
unlocked	O	851-859
nucleic	O	860-867
acid	O	868-872
monomers	O	873-881
.	O	881-882

Our	O	883-886
data	O	887-891
suggest	O	892-899
that	O	900-904
phosphorothioate	O	905-921
anti	O	922-926
-	O	926-927
microRNA	O	927-935
oligonucleotides	O	936-952
yield	O	953-958
a	O	959-960
greater	O	961-968
activity	O	969-977
than	O	978-982
their	O	983-988
phosphodiester	O	989-1003
counterparts	O	1004-1016
and	O	1017-1020
that	O	1021-1025
a	O	1026-1027
moderate	O	1028-1036
truncation	O	1037-1047
of	O	1048-1050
the	O	1051-1054
anti	O	1055-1059
-	O	1059-1060
microRNA	O	1060-1068
oligonucleotide	O	1069-1084
improves	O	1085-1093
specificity	O	1094-1105
without	O	1106-1113
significantly	O	1114-1127
losing	O	1128-1134
activity	O	1135-1143
.	O	1143-1144

These	O	1145-1150
results	O	1151-1158
provide	O	1159-1166
useful	O	1167-1173
insights	O	1174-1182
for	O	1183-1186
design	O	1187-1193
of	O	1194-1196
anti	O	1197-1201
-	O	1201-1202
microRNA	O	1202-1210
oligonucleotides	O	1211-1227
to	O	1228-1230
achieve	O	1231-1238
both	O	1239-1243
high	O	1244-1248
activity	O	1249-1257
as	O	1258-1260
well	O	1261-1265
as	O	1266-1268
efficient	O	1269-1278
mismatch	O	1279-1287
discrimination	O	1288-1302
.	O	1302-1303

Lipid	O	0-5
-	O	5-6
based	O	6-11
nanoparticle	O	12-24
delivery	O	25-33
of	O	34-36
Pre	O	37-40
-	O	40-41
miR	B	41-44
-	I	44-45
107	I	45-48
inhibits	O	49-57
the	O	58-61
tumorigenicity	O	62-76
of	O	77-79
head	O	80-84
and	O	85-88
neck	O	89-93
squamous	O	94-102
cell	O	103-107
carcinoma	O	108-117
.	O	117-118

Head	O	119-123
and	O	124-127
neck	O	128-132
squamous	O	133-141
cell	O	142-146
carcinoma	O	147-156
(	O	157-158
HNSCC	O	158-163
)	O	163-164
is	O	165-167
the	O	168-171
sixth	O	172-177
most	O	178-182
prevalent	O	183-192
cancer	O	193-199
worldwide	O	200-209
with	O	210-214
about	O	215-220
600	O	221-224
,	O	224-225
000	O	225-228
new	O	229-232
cases	O	233-238
diagnosed	O	239-248
in	O	249-251
the	O	252-255
last	O	256-260
year	O	261-265
.	O	265-266

Our	O	267-270
laboratory	O	271-281
showed	O	282-288
that	O	289-293
miR	B	294-297
-	I	297-298
107	I	298-301
expression	O	302-312
is	O	313-315
reduced	O	316-323
and	O	324-327
functions	O	328-337
as	O	338-340
a	O	341-342
tumor	O	343-348
suppressor	O	349-359
gene	O	360-364
in	O	365-367
HNSCC	O	368-373
suggesting	O	374-384
the	O	385-388
potential	O	389-398
application	O	399-410
of	O	411-413
miR	B	414-417
-	I	417-418
107	I	418-421
as	O	422-424
a	O	425-426
novel	O	427-432
anticancer	O	433-443
therapeutic	O	444-455
.	O	455-456

In	O	457-459
this	O	460-464
study	O	465-470
,	O	470-471
we	O	472-474
determined	O	475-485
the	O	486-489
efficiency	O	490-500
and	O	501-504
efficacy	O	505-513
of	O	514-516
cationic	O	517-525
lipid	O	526-531
nanoparticles	O	532-545
to	O	546-548
deliver	O	549-556
pre	O	557-560
-	O	560-561
miR	B	561-564
-	I	564-565
107	I	565-568
(	O	569-570
NP	O	570-572
/	O	572-573
pre	O	573-576
-	O	576-577
miR	B	577-580
-	I	580-581
107	I	581-584
)	O	584-585
in	O	586-588
HNSCC	O	589-594
cells	O	595-600
in	O	601-603
vitro	O	604-609
and	O	610-613
in	O	614-616
vivo	O	617-621
.	O	621-622

NP	O	623-625
/	O	625-626
pre	O	626-629
-	O	629-630
miR	B	630-633
-	I	633-634
107	I	634-637
increased	O	638-647
delivery	O	648-656
of	O	657-659
miR	B	660-663
-	I	663-664
107	I	664-667
into	O	668-672
HNSCC	O	673-678
cells	O	679-684
by	O	685-687
greater	O	688-695
than	O	696-700
80	O	701-703
,	O	703-704
000	O	704-707
-	O	707-708
fold	O	708-712
compared	O	713-721
to	O	722-724
free	O	725-729
pre	O	730-733
-	O	733-734
miR	B	734-737
-	I	737-738
107	I	738-741
.	O	741-742

Levels	O	743-749
of	O	750-752
known	O	753-758
miR	B	759-762
-	I	762-763
107	I	763-766
targets	O	767-774
,	O	774-775
protein	O	776-783
kinase	O	784-790
Cepsilon	O	791-799
(	O	800-801
PKCepsilon	O	801-811
)	O	811-812
,	O	812-813
cyclin	O	814-820
-	O	820-821
dependent	O	821-830
kinase	O	831-837
6	O	838-839
(	O	840-841
CDK6	O	841-845
)	O	845-846
,	O	846-847
and	O	848-851
hypoxia	O	852-859
-	O	859-860
inducible	O	860-869
factor	O	870-876
1	O	877-878
-	O	878-879
beta	O	879-883
(	O	884-885
HIF1	O	885-889
-	O	889-890
beta	O	890-894
)	O	894-895
,	O	895-896
decreased	O	897-906
following	O	907-916
NP	O	917-919
/	O	919-920
pre	O	920-923
-	O	923-924
miR	B	924-927
-	I	927-928
107	I	928-931
treatment	O	932-941
.	O	941-942

Clonogenic	O	943-953
survival	O	954-962
,	O	962-963
cell	O	964-968
invasion	O	969-977
,	O	977-978
and	O	979-982
cell	O	983-987
migration	O	988-997
of	O	998-1000
HNSCC	O	1001-1006
cells	O	1007-1012
was	O	1013-1016
inhibited	O	1017-1026
with	O	1027-1031
NP	O	1032-1034
/	O	1034-1035
pre	O	1035-1038
-	O	1038-1039
miR	B	1039-1042
-	I	1042-1043
107	I	1043-1046
.	O	1046-1047

Moreover	O	1048-1056
,	O	1056-1057
NP	O	1058-1060
/	O	1060-1061
pre	O	1061-1064
-	O	1064-1065
miR	B	1065-1068
-	I	1068-1069
107	I	1069-1072
reduced	O	1073-1080
the	O	1081-1084
cancer	O	1085-1091
-	O	1091-1092
initiating	O	1092-1102
cell	O	1103-1107
(	O	1108-1109
CIC	O	1109-1112
)	O	1112-1113
population	O	1114-1124
and	O	1125-1128
dampened	O	1129-1137
the	O	1138-1141
expression	O	1142-1152
of	O	1153-1155
the	O	1156-1159
core	O	1160-1164
embryonic	O	1165-1174
stem	O	1175-1179
cell	O	1180-1184
transcription	O	1185-1198
factors	O	1199-1206
,	O	1206-1207
Nanog	O	1208-1213
,	O	1213-1214
Oct3	O	1215-1219
/	O	1219-1220
4	O	1220-1221
,	O	1221-1222
and	O	1223-1226
Sox2	O	1227-1231
.	O	1231-1232

In	O	1233-1235
a	O	1236-1237
preclinical	O	1238-1249
mouse	O	1250-1255
model	O	1256-1261
of	O	1262-1264
HNSCC	O	1265-1270
,	O	1270-1271
systemic	O	1272-1280
administration	O	1281-1295
of	O	1296-1298
NP	O	1299-1301
/	O	1301-1302
pre	O	1302-1305
-	O	1305-1306
miR	B	1306-1309
-	I	1309-1310
107	I	1310-1313
significantly	O	1314-1327
retarded	O	1328-1336
tumor	O	1337-1342
growth	O	1343-1349
by	O	1350-1352
45	O	1353-1355
.	O	1355-1356
2	O	1356-1357
%	O	1357-1358
compared	O	1359-1367
to	O	1368-1370
NP	O	1371-1373
/	O	1373-1374
pre	O	1374-1377
-	O	1377-1378
miR	O	1378-1381
-	O	1381-1382
control	O	1382-1389
(	O	1390-1391
P	O	1391-1392
<	O	1393-1394
0	O	1395-1396
.	O	1396-1397
005	O	1397-1400
,	O	1400-1401
n	O	1402-1403
=	O	1404-1405
7	O	1406-1407
)	O	1407-1408
.	O	1408-1409

Kaplan	O	1410-1416
-	O	1416-1417
Meier	O	1417-1422
analysis	O	1423-1431
showed	O	1432-1438
a	O	1439-1440
survival	O	1441-1449
advantage	O	1450-1459
for	O	1460-1463
the	O	1464-1467
NP	O	1468-1470
/	O	1470-1471
pre	O	1471-1474
-	O	1474-1475
miR	B	1475-1478
-	I	1478-1479
107	I	1479-1482
treatment	O	1483-1492
group	O	1493-1498
(	O	1499-1500
P	O	1500-1501
=	O	1502-1503
0	O	1504-1505
.	O	1505-1506
017	O	1506-1509
)	O	1509-1510
.	O	1510-1511

Our	O	1512-1515
results	O	1516-1523
demonstrate	O	1524-1535
that	O	1536-1540
cationic	O	1541-1549
lipid	O	1550-1555
nanoparticles	O	1556-1569
are	O	1570-1573
an	O	1574-1576
effective	O	1577-1586
carrier	O	1587-1594
approach	O	1595-1603
to	O	1604-1606
deliver	O	1607-1614
therapeutic	O	1615-1626
miRs	O	1627-1631
to	O	1632-1634
HNSCC	O	1635-1640
.	O	1640-1641

Effect	O	0-6
of	O	7-9
curcumin	O	10-18
on	O	19-21
miRNA	O	22-27
expression	O	28-38
in	O	39-41
human	O	42-47
Y79	O	48-51
retinoblastoma	O	52-66
cells	O	67-72
.	O	72-73

PURPOSE	O	74-81
:	O	81-82
Retinoblastoma	O	83-97
(	O	98-99
RB	O	99-101
)	O	101-102
is	O	103-105
the	O	106-109
most	O	110-114
common	O	115-121
intraocular	O	122-133
malignancy	O	134-144
in	O	145-147
children	O	148-156
.	O	156-157

Deregulation	O	158-170
of	O	171-173
several	O	174-181
miRNAs	O	182-188
has	O	189-192
been	O	193-197
identified	O	198-208
in	O	209-211
RB	O	212-214
,	O	214-215
suggesting	O	216-226
a	O	227-228
potential	O	229-238
role	O	239-243
in	O	244-246
tumorigenesis	O	247-260
.	O	260-261

Recent	O	262-268
evidence	O	269-277
suggests	O	278-286
that	O	287-291
many	O	292-296
dietary	O	297-304
components	O	305-315
like	O	316-320
folate	O	321-327
,	O	327-328
retinoids	O	329-338
and	O	339-342
curcumin	O	343-351
act	O	352-355
as	O	356-358
potential	O	359-368
anticancer	O	369-379
/	O	379-380
antiproliferative	O	380-397
agents	O	398-404
by	O	405-407
regulating	O	408-418
the	O	419-422
expression	O	423-433
of	O	434-436
miRNA	O	437-442
.	O	442-443

In	O	444-446
this	O	447-451
study	O	452-457
,	O	457-458
we	O	459-461
investigated	O	462-474
the	O	475-478
effect	O	479-485
of	O	486-488
phenolic	O	489-497
compound	O	498-506
curcumin	O	507-515
on	O	516-518
miRNA	O	519-524
expression	O	525-535
in	O	536-538
Y79	O	539-542
RB	O	543-545
cells	O	546-551
.	O	551-552

MATERIALS	O	553-562
AND	O	563-566
METHODS	O	567-574
:	O	574-575
We	O	576-578
analyzed	O	579-587
the	O	588-591
expression	O	592-602
profile	O	603-610
of	O	611-613
miRNA	O	614-619
by	O	620-622
microarray	O	623-633
analysis	O	634-642
and	O	643-646
quantitative	O	647-659
real	O	660-664
-	O	664-665
time	O	665-669
polymerase	O	670-680
chain	O	681-686
reaction	O	687-695
(	O	696-697
qRT	O	697-700
-	O	700-701
PCR	O	701-704
)	O	704-705
in	O	706-708
curcumin	O	709-717
-	O	717-718
treated	O	718-725
Y79	O	726-729
RB	O	730-732
cells	O	733-738
.	O	738-739

Transfection	O	740-752
of	O	753-755
miR	B	756-759
-	I	759-760
22	I	760-762
was	O	763-766
performed	O	767-776
using	O	777-782
Lipofectamine	O	783-796
2000	O	797-801
.	O	801-802

Cell	O	803-807
viability	O	808-817
,	O	817-818
in	O	819-821
vitro	O	822-827
scratch	O	828-835
migration	O	836-845
assay	O	846-851
,	O	851-852
prediction	O	853-863
of	O	864-866
miRNA	O	867-872
targets	O	873-880
and	O	881-884
Western	O	885-892
blot	O	893-897
analysis	O	898-906
were	O	907-911
performed	O	912-921
to	O	922-924
determine	O	925-934
the	O	935-938
biological	O	939-949
function	O	950-958
of	O	959-961
miR	B	962-965
-	I	965-966
22	I	966-968
in	O	969-971
Y79	O	972-975
RB	O	976-978
cells	O	979-984
.	O	984-985

RESULTS	O	986-993
:	O	993-994
In	O	995-997
Y79	O	998-1001
RB	O	1002-1004
cells	O	1005-1010
treated	O	1011-1018
with	O	1019-1023
curcumin	O	1024-1032
,	O	1032-1033
5	O	1034-1035
human	O	1036-1041
miRNAs	O	1042-1048
were	O	1049-1053
upregulated	O	1054-1065
and	O	1066-1069
16	O	1070-1072
were	O	1073-1077
downregulated	O	1078-1091
as	O	1092-1094
detected	O	1095-1103
with	O	1104-1108
the	O	1109-1112
miRNA	O	1113-1118
microarray	O	1119-1129
analysis	O	1130-1138
.	O	1138-1139

miR	B	1140-1143
-	I	1143-1144
22	I	1144-1146
,	O	1146-1147
a	O	1148-1149
tumor	O	1150-1155
-	O	1155-1156
suppressor	O	1156-1166
miRNA	O	1167-1172
was	O	1173-1176
one	O	1177-1180
of	O	1181-1183
the	O	1184-1187
miRNA	O	1188-1193
which	O	1194-1199
was	O	1200-1203
upregulated	O	1204-1215
by	O	1216-1218
curcumin	O	1219-1227
.	O	1227-1228

Transfected	O	1229-1240
miR	B	1241-1244
-	I	1244-1245
22	I	1245-1247
Y79	O	1248-1251
cells	O	1252-1257
inhibited	O	1258-1267
the	O	1268-1271
cell	O	1272-1276
proliferation	O	1277-1290
and	O	1291-1294
reduced	O	1295-1302
the	O	1303-1306
migration	O	1307-1316
,	O	1316-1317
and	O	1318-1321
erythoblastic	O	1322-1335
leukemia	O	1336-1344
viral	O	1345-1350
oncogene	O	1351-1359
homolog	O	1360-1367
3	O	1368-1369
(	O	1370-1371
Erbb3	O	1371-1376
)	O	1376-1377
was	O	1378-1381
confirmed	O	1382-1391
to	O	1392-1394
be	O	1395-1397
the	O	1398-1401
target	O	1402-1408
gene	O	1409-1413
of	O	1414-1416
miR	B	1417-1420
-	I	1420-1421
22	I	1421-1423
.	O	1423-1424

CONCLUSION	O	1425-1435
:	O	1435-1436
These	O	1437-1442
observations	O	1443-1455
suggest	O	1456-1463
that	O	1464-1468
curcumin	O	1469-1477
modulate	O	1478-1486
the	O	1487-1490
miRNA	O	1491-1496
expression	O	1497-1507
profile	O	1508-1515
,	O	1515-1516
thereby	O	1517-1524
exerting	O	1525-1533
its	O	1534-1537
anticancer	O	1538-1548
effects	O	1549-1556
on	O	1557-1559
RB	O	1560-1562
cells	O	1563-1568
.	O	1568-1569

Evidence	O	0-8
for	O	9-12
cell	O	13-17
cycle	O	18-23
suppression	O	24-35
and	O	36-39
microRNA	O	40-48
regulation	O	49-59
of	O	60-62
cyclin	O	63-69
D1	O	70-72
during	O	73-79
anoxia	O	80-86
exposure	O	87-95
in	O	96-98
turtles	O	99-106
.	O	106-107

The	O	108-111
red	O	112-115
-	O	115-116
eared	O	116-121
slider	O	122-128
turtle	O	129-135
(	O	136-137
Trachemys	O	137-146
scripta	O	147-154
elegans	O	155-162
)	O	162-163
has	O	164-167
a	O	168-169
well	O	170-174
-	O	174-175
developed	O	175-184
natural	O	185-192
tolerance	O	193-202
for	O	203-206
oxygen	O	207-213
deprivation	O	214-225
that	O	226-230
derives	O	231-238
from	O	239-243
biochemical	O	244-255
adaptations	O	256-267
,	O	267-268
including	O	269-278
anoxia	O	279-285
-	O	285-286
induced	O	286-293
suppression	O	294-305
of	O	306-308
metabolic	O	309-318
rate	O	319-323
.	O	323-324

We	O	325-327
hypothesized	O	328-340
that	O	341-345
mechanisms	O	346-356
that	O	357-361
suppress	O	362-370
ATP	O	371-374
-	O	374-375
expensive	O	375-384
cell	O	385-389
cycle	O	390-395
activity	O	396-404
would	O	405-410
contribute	O	411-421
significantly	O	422-435
to	O	436-438
establishing	O	439-451
the	O	452-455
hypometabolic	O	456-469
state	O	470-475
during	O	476-482
anaerobiosis	O	483-495
.	O	495-496

Cyclin	O	497-503
D1	O	504-506
is	O	507-509
a	O	510-511
critical	O	512-520
regulator	O	521-530
of	O	531-533
the	O	534-537
G	O	538-539
1	O	540-541
phase	O	542-547
of	O	548-550
the	O	551-554
cell	O	555-559
cycle	O	560-565
and	O	566-569
is	O	570-572
regarded	O	573-581
as	O	582-584
key	O	585-588
to	O	589-591
initiating	O	592-602
cell	O	603-607
proliferation	O	608-621
.	O	621-622

The	O	623-626
relative	O	627-635
protein	O	636-643
expression	O	644-654
of	O	655-657
cyclin	O	658-664
D1	O	665-667
was	O	668-671
analyzed	O	672-680
in	O	681-683
both	O	684-688
whole	O	689-694
-	O	694-695
cell	O	695-699
and	O	700-703
nuclear	O	704-711
fractions	O	712-721
of	O	722-724
liver	O	725-730
,	O	730-731
kidney	O	732-738
and	O	739-742
skeletal	O	743-751
muscle	O	752-758
from	O	759-763
turtles	O	764-771
exposed	O	772-779
to	O	780-782
5	O	783-784
or	O	785-787
20	O	788-790
h	O	791-792
of	O	793-795
submergence	O	796-807
anoxia	O	808-814
.	O	814-815

Expression	O	816-826
of	O	827-829
cyclin	O	830-836
D1	O	837-839
in	O	840-842
both	O	843-847
total	O	848-853
and	O	854-857
nuclear	O	858-865
fractions	O	866-875
decreased	O	876-885
significantly	O	886-899
under	O	900-905
anoxia	O	906-912
in	O	913-915
liver	O	916-921
and	O	922-925
kidney	O	926-932
as	O	933-935
compared	O	936-944
with	O	945-949
aerobic	O	950-957
controls	O	958-966
,	O	966-967
but	O	968-971
no	O	972-974
significant	O	975-986
change	O	987-993
occurred	O	994-1002
in	O	1003-1005
muscle	O	1006-1012
.	O	1012-1013

The	O	1014-1017
relative	O	1018-1026
phosphorylation	O	1027-1042
state	O	1043-1048
of	O	1049-1051
cyclin	O	1052-1058
D1	O	1059-1061
(	O	1062-1063
threonine	O	1063-1072
286	O	1073-1076
)	O	1076-1077
was	O	1078-1081
also	O	1082-1086
unchanged	O	1087-1096
during	O	1097-1103
anoxia	O	1104-1110
in	O	1111-1113
all	O	1114-1117
tissues	O	1118-1125
.	O	1125-1126

Since	O	1127-1132
phosphorylation	O	1133-1148
of	O	1149-1151
threonine	O	1152-1161
286	O	1162-1165
is	O	1166-1168
necessary	O	1169-1178
for	O	1179-1182
proteasomal	O	1183-1194
degradation	O	1195-1206
of	O	1207-1209
cyclin	O	1210-1216
D1	O	1217-1219
,	O	1219-1220
this	O	1221-1225
implies	O	1226-1233
that	O	1234-1238
an	O	1239-1241
alternative	O	1242-1253
mechanism	O	1254-1263
is	O	1264-1266
responsible	O	1267-1278
for	O	1279-1282
cyclin	O	1283-1289
D1	O	1290-1292
suppression	O	1293-1304
in	O	1305-1307
anoxia	O	1308-1314
.	O	1314-1315

Levels	O	1316-1322
of	O	1323-1325
cyclin	O	1326-1332
D1	O	1333-1335
mRNA	O	1336-1340
transcripts	O	1341-1352
did	O	1353-1356
not	O	1357-1360
change	O	1361-1367
under	O	1368-1373
anoxia	O	1374-1380
in	O	1381-1383
any	O	1384-1387
tissue	O	1388-1394
,	O	1394-1395
so	O	1396-1398
a	O	1399-1400
post	O	1401-1405
-	O	1405-1406
transcriptional	O	1406-1421
method	O	1422-1428
of	O	1429-1431
regulation	O	1432-1442
was	O	1443-1446
implicated	O	1447-1457
.	O	1457-1458

Analysis	O	1459-1467
of	O	1468-1470
the	O	1471-1474
3	O	1475-1476
'	O	1476-1477
UTR	O	1477-1480
of	O	1481-1483
cyclin	O	1484-1490
D1	O	1491-1493
showed	O	1494-1500
the	O	1501-1504
presence	O	1505-1513
of	O	1514-1516
both	O	1517-1521
an	O	1522-1524
AU	O	1525-1527
-	O	1527-1528
rich	O	1528-1532
region	O	1533-1539
and	O	1540-1543
a	O	1544-1545
conserved	O	1546-1555
binding	O	1556-1563
site	O	1564-1568
for	O	1569-1572
microRNA	B	1573-1581
-	I	1581-1582
16	I	1582-1584
-	I	1584-1585
1	I	1585-1586
and	O	1587-1590
microRNA	B	1591-1599
-	I	1599-1600
15a	I	1600-1603
.	O	1603-1604

Levels	O	1605-1611
of	O	1612-1614
both	O	1615-1619
microRNAs	O	1620-1629
increased	O	1630-1639
in	O	1640-1642
liver	O	1643-1648
and	O	1649-1652
kidney	O	1653-1659
(	O	1660-1661
but	O	1661-1664
not	O	1665-1668
in	O	1669-1671
muscle	O	1672-1678
)	O	1678-1679
under	O	1680-1685
anoxic	O	1686-1692
conditions	O	1693-1703
,	O	1703-1704
implicating	O	1705-1716
microRNA	O	1717-1725
inhibition	O	1726-1736
of	O	1737-1739
mRNA	O	1740-1744
translation	O	1745-1756
as	O	1757-1759
the	O	1760-1763
mechanism	O	1764-1773
underlying	O	1774-1784
the	O	1785-1788
suppression	O	1789-1800
of	O	1801-1803
cyclin	O	1804-1810
D1	O	1811-1813
protein	O	1814-1821
levels	O	1822-1828
in	O	1829-1831
the	O	1832-1835
anoxic	O	1836-1842
turtle	O	1843-1849
.	O	1849-1850

Prognostic	O	0-10
significance	O	11-23
of	O	24-26
miR	B	27-30
-	I	30-31
205	I	31-34
in	O	35-37
endometrial	O	38-49
cancer	O	50-56
.	O	56-57

PURPOSE	O	58-65
:	O	65-66
microRNAs	O	67-76
have	O	77-81
emerged	O	82-89
as	O	90-92
key	O	93-96
regulators	O	97-107
of	O	108-110
gene	O	111-115
expression	O	116-126
,	O	126-127
and	O	128-131
their	O	132-137
altered	O	138-145
expression	O	146-156
has	O	157-160
been	O	161-165
associated	O	166-176
with	O	177-181
tumorigenesis	O	182-195
and	O	196-199
tumor	O	200-205
progression	O	206-217
.	O	217-218

Thus	O	219-223
,	O	223-224
microRNAs	O	225-234
have	O	235-239
potential	O	240-249
as	O	250-252
both	O	253-257
cancer	O	258-264
biomarkers	O	265-275
and	O	276-279
/	O	279-280
or	O	280-282
potential	O	283-292
novel	O	293-298
therapeutic	O	299-310
targets	O	311-318
.	O	318-319

Although	O	320-328
accumulating	O	329-341
evidence	O	342-350
suggests	O	351-359
the	O	360-363
role	O	364-368
of	O	369-371
aberrant	O	372-380
microRNA	O	381-389
expression	O	390-400
in	O	401-403
endometrial	O	404-415
carcinogenesis	O	416-430
,	O	430-431
there	O	432-437
are	O	438-441
still	O	442-447
limited	O	448-455
data	O	456-460
available	O	461-470
about	O	471-476
the	O	477-480
prognostic	O	481-491
significance	O	492-504
of	O	505-507
microRNAs	O	508-517
in	O	518-520
endometrial	O	521-532
cancer	O	533-539
.	O	539-540

The	O	541-544
goal	O	545-549
of	O	550-552
this	O	553-557
study	O	558-563
is	O	564-566
to	O	567-569
investigate	O	570-581
the	O	582-585
prognostic	O	586-596
value	O	597-602
of	O	603-605
selected	O	606-614
key	O	615-618
microRNAs	O	619-628
in	O	629-631
endometrial	O	632-643
cancer	O	644-650
by	O	651-653
the	O	654-657
analysis	O	658-666
of	O	667-669
archival	O	670-678
formalin	O	679-687
-	O	687-688
fixed	O	688-693
paraffin	O	694-702
-	O	702-703
embedded	O	703-711
tissues	O	712-719
.	O	719-720

EXPERIMENTAL	O	721-733
DESIGN	O	734-740
:	O	740-741
Total	O	742-747
RNAs	O	748-752
were	O	753-757
extracted	O	758-767
from	O	768-772
48	O	773-775
paired	O	776-782
normal	O	783-789
and	O	790-793
endometrial	O	794-805
tumor	O	806-811
specimens	O	812-821
using	O	822-827
Trizol	O	828-834
based	O	835-840
approach	O	841-849
.	O	849-850

The	O	851-854
expression	O	855-865
of	O	866-868
miR	B	869-872
-	I	872-873
26a	I	873-876
,	O	876-877
let	O	878-881
-	O	881-882
7g	O	882-884
,	O	884-885
miR	B	886-889
-	I	889-890
21	I	890-892
,	O	892-893
miR	B	894-897
-	I	897-898
181b	I	898-902
,	O	902-903
miR	B	904-907
-	I	907-908
200c	I	908-912
,	O	912-913
miR	B	914-917
-	I	917-918
192	I	918-921
,	O	921-922
miR	B	923-926
-	I	926-927
215	I	927-930
,	O	930-931
miR	B	932-935
-	I	935-936
200c	I	936-940
,	O	940-941
and	O	942-945
miR	B	946-949
-	I	949-950
205	I	950-953
were	O	954-958
quantified	O	959-969
by	O	970-972
real	O	973-977
time	O	978-982
qRT	O	983-986
-	O	986-987
PCR	O	987-990
expression	O	991-1001
analysis	O	1002-1010
.	O	1010-1011

Targets	O	1012-1019
of	O	1020-1022
the	O	1023-1026
differentially	O	1027-1041
expressed	O	1042-1051
miRNAs	O	1052-1058
were	O	1059-1063
quantified	O	1064-1074
using	O	1075-1080
immunohistochemistry	O	1081-1101
.	O	1101-1102

Statistical	O	1103-1114
analysis	O	1115-1123
was	O	1124-1127
performed	O	1128-1137
by	O	1138-1140
GraphPad	O	1141-1149
Prism	O	1150-1155
5	O	1156-1157
.	O	1157-1158
0	O	1158-1159
.	O	1159-1160

RESULTS	O	1161-1168
:	O	1168-1169
The	O	1170-1173
expression	O	1174-1184
levels	O	1185-1191
of	O	1192-1194
miR	B	1195-1198
-	I	1198-1199
200c	I	1199-1203
(	O	1204-1205
P	O	1205-1206
<	O	1206-1207
0	O	1207-1208
.	O	1208-1209
0001	O	1209-1213
)	O	1213-1214
and	O	1215-1218
miR	B	1219-1222
-	I	1222-1223
205	I	1223-1226
(	O	1227-1228
P	O	1228-1229
<	O	1229-1230
0	O	1230-1231
.	O	1231-1232
0001	O	1232-1236
)	O	1236-1237
were	O	1238-1242
significantly	O	1243-1256
increased	O	1257-1266
in	O	1267-1269
endometrial	O	1270-1281
tumors	O	1282-1288
compared	O	1289-1297
to	O	1298-1300
normal	O	1301-1307
tissues	O	1308-1315
.	O	1315-1316

Kaplan	O	1317-1323
-	O	1323-1324
Meier	O	1324-1329
survival	O	1330-1338
analysis	O	1339-1347
revealed	O	1348-1356
that	O	1357-1361
high	O	1362-1366
levels	O	1367-1373
of	O	1374-1376
miR	B	1377-1380
-	I	1380-1381
205	I	1381-1384
expression	O	1385-1395
were	O	1396-1400
associated	O	1401-1411
with	O	1412-1416
poor	O	1417-1421
patient	O	1422-1429
overall	O	1430-1437
survival	O	1438-1446
(	O	1447-1448
hazard	O	1448-1454
ratio	O	1455-1460
,	O	1460-1461
0	O	1462-1463
.	O	1463-1464
377	O	1464-1467
;	O	1467-1468
Logrank	O	1469-1476
test	O	1477-1481
,	O	1481-1482
P	O	1483-1484
=	O	1485-1486
0	O	1487-1488
.	O	1488-1489
028	O	1489-1492
)	O	1492-1493
.	O	1493-1494

Furthermore	O	1495-1506
,	O	1506-1507
decreased	O	1508-1517
expression	O	1518-1528
of	O	1529-1531
a	O	1532-1533
miR	B	1534-1537
-	I	1537-1538
205	I	1538-1541
target	O	1542-1548
PTEN	O	1549-1553
was	O	1554-1557
detected	O	1558-1566
in	O	1567-1569
endometrial	O	1570-1581
cancer	O	1582-1588
tissues	O	1589-1596
compared	O	1597-1605
to	O	1606-1608
normal	O	1609-1615
tissues	O	1616-1623
.	O	1623-1624

CONCLUSION	O	1625-1635
:	O	1635-1636
miR	B	1637-1640
-	I	1640-1641
205	I	1641-1644
holds	O	1645-1650
a	O	1651-1652
unique	O	1653-1659
potential	O	1660-1669
as	O	1670-1672
a	O	1673-1674
prognostic	O	1675-1685
biomarker	O	1686-1695
in	O	1696-1698
endometrial	O	1699-1710
cancer	O	1711-1717
.	O	1717-1718

Small	O	0-5
temporal	O	6-14
RNAs	O	15-19
in	O	20-22
animal	O	23-29
development	O	30-41
.	O	41-42

The	O	43-46
lin	B	47-50
-	I	50-51
4	I	51-52
/	O	52-53
miR	B	53-56
-	I	56-57
125	I	57-60
and	O	61-64
let	B	65-68
-	I	68-69
7	I	69-70
microRNAs	O	71-80
are	O	81-84
at	O	85-87
the	O	88-91
heart	O	92-97
of	O	98-100
the	O	101-104
heterochronic	O	105-118
pathway	O	119-126
,	O	126-127
which	O	128-133
controls	O	134-142
temporal	O	143-151
cell	O	152-156
fate	O	157-161
determination	O	162-175
during	O	176-182
Caenorhabditis	O	183-197
elegans	O	198-205
development	O	206-217
.	O	217-218

These	O	219-224
small	O	225-230
temporal	O	231-239
RNAs	O	240-244
are	O	245-248
clustered	O	249-258
along	O	259-264
with	O	265-269
a	O	270-271
third	O	272-277
microRNA	O	278-286
,	O	286-287
miR	B	288-291
-	I	291-292
100	I	292-295
,	O	295-296
in	O	297-299
the	O	300-303
genomes	O	304-311
of	O	312-314
most	O	315-319
animals	O	320-327
.	O	327-328

Their	O	329-334
conserved	O	335-344
temporal	O	345-353
and	O	354-357
neural	O	358-364
expression	O	365-375
profile	O	376-383
suggests	O	384-392
a	O	393-394
general	O	395-402
role	O	403-407
in	O	408-410
cell	O	411-415
fate	O	416-420
determination	O	421-434
during	O	435-441
nervous	O	442-449
system	O	450-456
differentiation	O	457-472
.	O	472-473

By	O	474-476
triggering	O	477-487
consecutive	O	488-499
differentiation	O	500-515
programs	O	516-524
,	O	524-525
these	O	526-531
microRNAs	O	532-541
probably	O	542-550
help	O	551-555
to	O	556-558
determine	O	559-568
birth	O	569-574
-	O	574-575
order	O	575-580
dependent	O	581-590
temporal	O	591-599
identity	O	600-608
and	O	609-612
thereby	O	613-620
contribute	O	621-631
to	O	632-634
neural	O	635-641
stem	O	642-646
cell	O	647-651
multipotency	O	652-664
.	O	664-665

MicroRNA	B	0-8
-	I	8-9
143	I	9-12
(	O	13-14
miR	B	14-17
-	I	17-18
143	I	18-21
)	O	21-22
regulates	O	23-32
cancer	O	33-39
glycolysis	O	40-50
via	O	51-54
targeting	O	55-64
hexokinase	O	65-75
2	O	76-77
gene	O	78-82
.	O	82-83

High	O	84-88
glycolysis	O	89-99
,	O	99-100
well	O	101-105
known	O	106-111
as	O	112-114
"	O	115-116
Warburg	O	116-123
effect	O	124-130
,	O	130-131
"	O	131-132
is	O	133-135
frequently	O	136-146
observed	O	147-155
in	O	156-158
a	O	159-160
variety	O	161-168
of	O	169-171
cancers	O	172-179
.	O	179-180

Whether	O	181-188
the	O	189-192
deregulation	O	193-205
of	O	206-208
miRNAs	O	209-215
contributes	O	216-227
to	O	228-230
the	O	231-234
Warburg	O	235-242
effect	O	243-249
remains	O	250-257
largely	O	258-265
unknown	O	266-273
.	O	273-274

Because	O	275-282
miRNA	O	283-288
regulates	O	289-298
gene	O	299-303
expression	O	304-314
at	O	315-317
both	O	318-322
mRNA	O	323-327
and	O	328-331
protein	O	332-339
levels	O	340-346
,	O	346-347
we	O	348-350
constructed	O	351-362
a	O	363-364
gene	O	365-369
functional	O	370-380
association	O	381-392
network	O	393-400
,	O	400-401
which	O	402-407
allows	O	408-414
us	O	415-417
to	O	418-420
detect	O	421-427
the	O	428-431
gene	O	432-436
activity	O	437-445
instead	O	446-453
of	O	454-456
gene	O	457-461
expression	O	462-472
,	O	472-473
to	O	474-476
integratively	O	477-490
analyze	O	491-498
the	O	499-502
microarray	O	503-513
data	O	514-518
for	O	519-522
gene	O	523-527
expression	O	528-538
and	O	539-542
miRNA	O	543-548
expression	O	549-559
profiling	O	560-569
and	O	570-573
identify	O	574-582
glycolysis	O	583-593
-	O	593-594
related	O	594-601
gene	O	602-606
-	O	606-607
miRNA	O	607-612
pairs	O	613-618
deregulated	O	619-630
in	O	631-633
cancer	O	634-640
.	O	640-641

Hexokinase	O	642-652
2	O	653-654
(	O	655-656
HK2	O	656-659
)	O	659-660
,	O	660-661
coding	O	662-668
for	O	669-672
the	O	673-676
first	O	677-682
rate	O	683-687
-	O	687-688
limiting	O	688-696
enzyme	O	697-703
of	O	704-706
glycolysis	O	707-717
,	O	717-718
is	O	719-721
among	O	722-727
the	O	728-731
top	O	732-735
list	O	736-740
of	O	741-743
genes	O	744-749
predicted	O	750-759
and	O	760-763
potentially	O	764-775
regulated	O	776-785
by	O	786-788
multiple	O	789-797
miRNAs	O	798-804
including	O	805-814
miR	B	815-818
-	I	818-819
143	I	819-822
.	O	822-823

Interestingly	O	824-837
,	O	837-838
miR	B	839-842
-	I	842-843
143	I	843-846
expression	O	847-857
was	O	858-861
inversely	O	862-871
associated	O	872-882
with	O	883-887
HK2	O	888-891
protein	O	892-899
level	O	900-905
but	O	906-909
not	O	910-913
mRNA	O	914-918
level	O	919-924
in	O	925-927
human	O	928-933
lung	O	934-938
cancer	O	939-945
samples	O	946-953
.	O	953-954

miR	B	955-958
-	I	958-959
143	I	959-962
,	O	962-963
down	O	964-968
-	O	968-969
regulated	O	969-978
by	O	979-981
mammalian	O	982-991
target	O	992-998
of	O	999-1001
rapamycin	O	1002-1011
activation	O	1012-1022
,	O	1022-1023
reduces	O	1024-1031
glucose	O	1032-1039
metabolism	O	1040-1050
and	O	1051-1054
inhibits	O	1055-1063
cancer	O	1064-1070
cell	O	1071-1075
proliferation	O	1076-1089
and	O	1090-1093
tumor	O	1094-1099
formation	O	1100-1109
through	O	1110-1117
targeting	O	1118-1127
HK2	O	1128-1131
.	O	1131-1132

Collectively	O	1133-1145
,	O	1145-1146
we	O	1147-1149
have	O	1150-1154
not	O	1155-1158
only	O	1159-1163
established	O	1164-1175
a	O	1176-1177
novel	O	1178-1183
methodology	O	1184-1195
for	O	1196-1199
gene	O	1200-1204
-	O	1204-1205
miRNA	O	1205-1210
pair	O	1211-1215
prediction	O	1216-1226
but	O	1227-1230
also	O	1231-1235
identified	O	1236-1246
miR	B	1247-1250
-	I	1250-1251
143	I	1251-1254
as	O	1255-1257
an	O	1258-1260
essential	O	1261-1270
regulator	O	1271-1280
of	O	1281-1283
cancer	O	1284-1290
glycolysis	O	1291-1301
via	O	1302-1305
targeting	O	1306-1315
HK2	O	1316-1319
.	O	1319-1320

Characterization	O	0-16
of	O	17-19
skin	O	20-24
ulceration	O	25-35
syndrome	O	36-44
associated	O	45-55
microRNAs	O	56-65
in	O	66-68
sea	O	69-72
cucumber	O	73-81
Apostichopus	O	82-94
japonicus	O	95-104
by	O	105-107
deep	O	108-112
sequencing	O	113-123
.	O	123-124

MicroRNAs	O	125-134
(	O	135-136
miRNAs	O	136-142
)	O	142-143
constitute	O	144-154
a	O	155-156
family	O	157-163
of	O	164-166
small	O	167-172
RNA	O	173-176
species	O	177-184
which	O	185-190
have	O	191-195
been	O	196-200
demonstrated	O	201-213
to	O	214-216
be	O	217-219
one	O	220-223
of	O	224-226
key	O	227-230
effectors	O	231-240
in	O	241-243
mediating	O	244-253
host	O	254-258
-	O	258-259
pathogen	O	259-267
interaction	O	268-279
.	O	279-280

In	O	281-283
this	O	284-288
study	O	289-294
,	O	294-295
two	O	296-299
haemocytes	O	300-310
miRNA	O	311-316
libraries	O	317-326
were	O	327-331
constructed	O	332-343
with	O	344-348
deep	O	349-353
sequenced	O	354-363
by	O	364-366
illumina	O	367-375
Hiseq2000	O	376-385
from	O	386-390
healthy	O	391-398
(	O	399-400
L1	O	400-402
)	O	402-403
and	O	404-407
skin	O	408-412
ulceration	O	413-423
syndrome	O	424-432
Apostichopus	O	433-445
japonicus	O	446-455
(	O	456-457
L2	O	457-459
)	O	459-460
.	O	460-461

The	O	462-465
high	O	466-470
throughput	O	471-481
solexa	O	482-488
sequencing	O	489-499
resulted	O	500-508
in	O	509-511
9	O	512-513
,	O	513-514
579	O	514-517
,	O	517-518
038	O	518-521
and	O	522-525
7	O	526-527
,	O	527-528
742	O	528-531
,	O	531-532
558	O	532-535
clean	O	536-541
data	O	542-546
from	O	547-551
L1	O	552-554
and	O	555-558
L2	O	559-561
,	O	561-562
respectively	O	563-575
.	O	575-576

Sequences	O	577-586
analysis	O	587-595
revealed	O	596-604
that	O	605-609
40	O	610-612
conserved	O	613-622
miRNAs	O	623-629
were	O	630-634
found	O	635-640
in	O	641-643
both	O	644-648
libraries	O	649-658
,	O	658-659
in	O	660-662
which	O	663-668
let	B	669-672
-	I	672-673
7	I	673-674
and	O	675-678
mir	B	679-682
-	I	682-683
125	I	683-686
were	O	687-691
speculated	O	692-702
to	O	703-705
be	O	706-708
clustered	O	709-718
together	O	719-727
and	O	728-731
expressed	O	732-741
accordingly	O	742-753
.	O	753-754

Eighty	O	755-761
-	O	761-762
six	O	762-765
miRNA	O	766-771
candidates	O	772-782
were	O	783-787
also	O	788-792
identified	O	793-803
by	O	804-806
reference	O	807-816
genome	O	817-823
search	O	824-830
and	O	831-834
stem	O	835-839
-	O	839-840
loop	O	840-844
structure	O	845-854
prediction	O	855-865
.	O	865-866

Importantly	O	867-878
,	O	878-879
mir	B	880-883
-	I	883-884
31	I	884-886
and	O	887-890
mir	B	891-894
-	I	894-895
2008	I	895-899
displayed	O	900-909
signi	O	910-915
fi	O	916-918
cant	O	919-923
differential	O	924-936
expression	O	937-947
between	O	948-955
the	O	956-959
two	O	960-963
libraries	O	964-973
according	O	974-983
to	O	984-986
FPKM	O	987-991
model	O	992-997
,	O	997-998
which	O	999-1004
might	O	1005-1010
be	O	1011-1013
considered	O	1014-1024
as	O	1025-1027
promising	O	1028-1037
targets	O	1038-1045
for	O	1046-1049
elucidating	O	1050-1061
the	O	1062-1065
intrinsic	O	1066-1075
mechanism	O	1076-1085
of	O	1086-1088
skin	O	1089-1093
ulceration	O	1094-1104
syndrome	O	1105-1113
outbreak	O	1114-1122
in	O	1123-1125
the	O	1126-1129
species	O	1130-1137
.	O	1137-1138

A	O	0-1
-	O	1-2
to	O	2-4
-	O	4-5
I	O	5-6
editing	O	7-14
of	O	15-17
microRNAs	O	18-27
in	O	28-30
the	O	31-34
mammalian	O	35-44
brain	O	45-50
increases	O	51-60
during	O	61-67
development	O	68-79
.	O	79-80

Adenosine	O	81-90
-	O	90-91
to	O	91-93
-	O	93-94
inosine	O	94-101
(	O	102-103
A	O	103-104
-	O	104-105
to	O	105-107
-	O	107-108
I	O	108-109
)	O	109-110
RNA	O	111-114
editing	O	115-122
targets	O	123-130
double	O	131-137
-	O	137-138
stranded	O	138-146
RNA	O	147-150
stem	O	151-155
-	O	155-156
loop	O	156-160
structures	O	161-171
in	O	172-174
the	O	175-178
mammalian	O	179-188
brain	O	189-194
.	O	194-195

It	O	196-198
has	O	199-202
previously	O	203-213
been	O	214-218
shown	O	219-224
that	O	225-229
miRNAs	O	230-236
are	O	237-240
substrates	O	241-251
for	O	252-255
A	O	256-257
-	O	257-258
to	O	258-260
-	O	260-261
I	O	261-262
editing	O	263-270
.	O	270-271

For	O	272-275
the	O	276-279
first	O	280-285
time	O	286-290
,	O	290-291
we	O	292-294
show	O	295-299
that	O	300-304
for	O	305-308
several	O	309-316
definitions	O	317-328
of	O	329-331
edited	O	332-338
miRNA	O	339-344
,	O	344-345
the	O	346-349
level	O	350-355
of	O	356-358
editing	O	359-366
increases	O	367-376
with	O	377-381
development	O	382-393
,	O	393-394
thereby	O	395-402
indicating	O	403-413
a	O	414-415
regulatory	O	416-426
role	O	427-431
for	O	432-435
editing	O	436-443
during	O	444-450
brain	O	451-456
maturation	O	457-467
.	O	467-468

We	O	469-471
use	O	472-475
high	O	476-480
-	O	480-481
throughput	O	481-491
RNA	O	492-495
sequencing	O	496-506
to	O	507-509
determine	O	510-519
editing	O	520-527
levels	O	528-534
in	O	535-537
mature	O	538-544
miRNA	O	545-550
,	O	550-551
from	O	552-556
the	O	557-560
mouse	O	561-566
transcriptome	O	567-580
,	O	580-581
and	O	582-585
compare	O	586-593
these	O	594-599
with	O	600-604
the	O	605-608
levels	O	609-615
of	O	616-618
editing	O	619-626
in	O	627-629
pri	O	630-633
-	O	633-634
miRNA	O	634-639
.	O	639-640

We	O	641-643
show	O	644-648
that	O	649-653
increased	O	654-663
editing	O	664-671
during	O	672-678
development	O	679-690
gradually	O	691-700
changes	O	701-708
the	O	709-712
proportions	O	713-724
of	O	725-727
the	O	728-731
two	O	732-735
miR	B	736-739
-	I	739-740
376a	I	740-744
isoforms	O	745-753
,	O	753-754
which	O	755-760
previously	O	761-771
have	O	772-776
been	O	777-781
shown	O	782-787
to	O	788-790
have	O	791-795
different	O	796-805
targets	O	806-813
.	O	813-814

Several	O	815-822
other	O	823-828
miRNAs	O	829-835
that	O	836-840
also	O	841-845
are	O	846-849
edited	O	850-856
in	O	857-859
the	O	860-863
seed	O	864-868
sequence	O	869-877
show	O	878-882
an	O	883-885
increased	O	886-895
level	O	896-901
of	O	902-904
editing	O	905-912
through	O	913-920
development	O	921-932
.	O	932-933

By	O	934-936
comparing	O	937-946
editing	O	947-954
of	O	955-957
pri	O	958-961
-	O	961-962
miRNA	O	962-967
with	O	968-972
editing	O	973-980
and	O	981-984
expression	O	985-995
of	O	996-998
the	O	999-1002
corresponding	O	1003-1016
mature	O	1017-1023
miRNA	O	1024-1029
,	O	1029-1030
we	O	1031-1033
also	O	1034-1038
show	O	1039-1043
an	O	1044-1046
editing	O	1047-1054
-	O	1054-1055
induced	O	1055-1062
developmental	O	1063-1076
regulation	O	1077-1087
of	O	1088-1090
miRNA	O	1091-1096
expression	O	1097-1107
.	O	1107-1108

Taken	O	1109-1114
together	O	1115-1123
,	O	1123-1124
our	O	1125-1128
results	O	1129-1136
imply	O	1137-1142
that	O	1143-1147
RNA	O	1148-1151
editing	O	1152-1159
influences	O	1160-1170
the	O	1171-1174
miRNA	O	1175-1180
repertoire	O	1181-1191
during	O	1192-1198
brain	O	1199-1204
maturation	O	1205-1215
.	O	1215-1216

microRNA	B	0-8
-	I	8-9
92a	I	9-12
expression	O	13-23
in	O	24-26
the	O	27-30
sera	O	31-35
and	O	36-39
dermal	O	40-46
fibroblasts	O	47-58
increases	O	59-68
in	O	69-71
patients	O	72-80
with	O	81-85
scleroderma	O	86-97
.	O	97-98

OBJECTIVES	O	99-109
:	O	109-110
microRNAs	O	111-120
(	O	121-122
miRNAs	O	122-128
)	O	128-129
play	O	130-134
a	O	135-136
part	O	137-141
in	O	142-144
various	O	145-152
cellular	O	153-161
activities	O	162-172
.	O	172-173

However	O	174-181
,	O	181-182
the	O	183-186
role	O	187-191
of	O	192-194
miRNA	O	195-200
in	O	201-203
SSc	O	204-207
is	O	208-210
not	O	211-214
fully	O	215-220
understood	O	221-231
.	O	231-232

This	O	233-237
study	O	238-243
investigated	O	244-256
the	O	257-260
expression	O	261-271
and	O	272-275
role	O	276-280
of	O	281-283
miR	B	284-287
-	I	287-288
92a	I	288-291
in	O	292-294
SSc	O	295-298
patients	O	299-307
and	O	308-311
evaluated	O	312-321
the	O	322-325
possibility	O	326-337
that	O	338-342
miR	B	343-346
-	I	346-347
92a	I	347-350
is	O	351-353
involved	O	354-362
in	O	363-365
the	O	366-369
pathogenesis	O	370-382
of	O	383-385
this	O	386-390
disease	O	391-398
.	O	398-399

METHODS	O	400-407
:	O	407-408
Serum	O	409-414
samples	O	415-422
were	O	423-427
obtained	O	428-436
from	O	437-441
61	O	442-444
SSc	O	445-448
patients	O	449-457
.	O	457-458

mRNAs	O	459-464
were	O	465-469
purified	O	470-478
from	O	479-483
serum	O	484-489
and	O	490-493
levels	O	494-500
of	O	501-503
miR	B	504-507
-	I	507-508
92a	I	508-511
and	O	512-515
miR	B	516-519
-	I	519-520
135	I	520-523
were	O	524-528
measured	O	529-537
with	O	538-542
quantitative	O	543-555
real	O	556-560
-	O	560-561
time	O	561-565
PCR	O	566-569
.	O	569-570

miR	B	571-574
-	I	574-575
92a	I	575-578
expression	O	579-589
in	O	590-592
dermal	O	593-599
fibroblasts	O	600-611
was	O	612-615
also	O	616-620
determined	O	621-631
by	O	632-634
quantitative	O	635-647
real	O	648-652
-	O	652-653
time	O	653-657
PCR	O	658-661
.	O	661-662

Immunoblotting	O	663-677
was	O	678-681
performed	O	682-691
to	O	692-694
detect	O	695-701
MMP	O	702-705
-	O	705-706
1	O	706-707
protein	O	708-715
.	O	715-716

RESULTS	O	717-724
:	O	724-725
The	O	726-729
median	O	730-736
serum	O	737-742
levels	O	743-749
of	O	750-752
miR	B	753-756
-	I	756-757
92a	I	757-760
,	O	760-761
not	O	762-765
miR	B	766-769
-	I	769-770
135	I	770-773
,	O	773-774
were	O	775-779
significantly	O	780-793
higher	O	794-800
in	O	801-803
SSc	O	804-807
patients	O	808-816
than	O	817-821
normal	O	822-828
subjects	O	829-837
.	O	837-838

The	O	839-842
constitutive	O	843-855
up	O	856-858
-	O	858-859
regulated	O	859-868
miR	B	869-872
-	I	872-873
92a	I	873-876
expression	O	877-887
was	O	888-891
also	O	892-896
found	O	897-902
in	O	903-905
cultured	O	906-914
dermal	O	915-921
fibroblasts	O	922-933
from	O	934-938
SSc	O	939-942
skin	O	943-947
,	O	947-948
which	O	949-954
was	O	955-958
decreased	O	959-968
by	O	969-971
the	O	972-975
transfection	O	976-988
with	O	989-993
siRNA	O	994-999
of	O	1000-1002
TGF	O	1003-1006
-	O	1006-1007
beta	O	1007-1011
.	O	1011-1012

Furthermore	O	1013-1024
,	O	1024-1025
the	O	1026-1029
forced	O	1030-1036
overexpression	O	1037-1051
of	O	1052-1054
miR	B	1055-1058
-	I	1058-1059
92a	I	1059-1062
in	O	1063-1065
normal	O	1066-1072
dermal	O	1073-1079
fibroblasts	O	1080-1091
using	O	1092-1097
miR	B	1098-1101
-	I	1101-1102
92a	I	1102-1105
mimic	O	1106-1111
resulted	O	1112-1120
in	O	1121-1123
the	O	1124-1127
down	O	1128-1132
-	O	1132-1133
regulation	O	1133-1143
of	O	1144-1146
MMP	O	1147-1150
-	O	1150-1151
1	O	1151-1152
expression	O	1153-1163
.	O	1163-1164

CONCLUSION	O	1165-1175
:	O	1175-1176
The	O	1177-1180
increase	O	1181-1189
of	O	1190-1192
miR	B	1193-1196
-	I	1196-1197
92a	I	1197-1200
in	O	1201-1203
SSc	O	1204-1207
may	O	1208-1211
be	O	1212-1214
due	O	1215-1218
to	O	1219-1221
the	O	1222-1225
stimulation	O	1226-1237
of	O	1238-1240
intrinsic	O	1241-1250
TGF	O	1251-1254
-	O	1254-1255
beta	O	1255-1259
activation	O	1260-1270
seen	O	1271-1275
in	O	1276-1278
this	O	1279-1283
disease	O	1284-1291
.	O	1291-1292

There	O	1293-1298
is	O	1299-1301
also	O	1302-1306
a	O	1307-1308
possibility	O	1309-1320
that	O	1321-1325
MMP	O	1326-1329
-	O	1329-1330
1	O	1330-1331
is	O	1332-1334
the	O	1335-1338
target	O	1339-1345
of	O	1346-1348
miR	B	1349-1352
-	I	1352-1353
92a	I	1353-1356
and	O	1357-1360
that	O	1361-1365
increased	O	1366-1375
miR	B	1376-1379
-	I	1379-1380
92a	I	1380-1383
expression	O	1384-1394
therefore	O	1395-1404
plays	O	1405-1410
a	O	1411-1412
role	O	1413-1417
in	O	1418-1420
excessive	O	1421-1430
collagen	O	1431-1439
accumulation	O	1440-1452
in	O	1453-1455
SSc	O	1456-1459
via	O	1460-1463
the	O	1464-1467
down	O	1468-1472
-	O	1472-1473
regulation	O	1473-1483
of	O	1484-1486
MMP	O	1487-1490
-	O	1490-1491
1	O	1491-1492
.	O	1492-1493

Clarifying	O	1494-1504
the	O	1505-1508
role	O	1509-1513
of	O	1514-1516
miRNAs	O	1517-1523
in	O	1524-1526
SSc	O	1527-1530
may	O	1531-1534
result	O	1535-1541
in	O	1542-1544
a	O	1545-1546
better	O	1547-1553
understanding	O	1554-1567
of	O	1568-1570
this	O	1571-1575
disease	O	1576-1583
and	O	1584-1587
the	O	1588-1591
development	O	1592-1603
of	O	1604-1606
new	O	1607-1610
therapeutic	O	1611-1622
approaches	O	1623-1633
.	O	1633-1634

Downregulation	O	0-14
of	O	15-17
microRNA	B	18-26
99a	I	27-30
in	O	31-33
oral	O	34-38
squamous	O	39-47
cell	O	48-52
carcinomas	O	53-63
contributes	O	64-75
to	O	76-78
the	O	79-82
growth	O	83-89
and	O	90-93
survival	O	94-102
of	O	103-105
oral	O	106-110
cancer	O	111-117
cells	O	118-123
.	O	123-124

MicroRNAs	O	125-134
(	O	135-136
miRNAs	O	136-142
)	O	142-143
are	O	144-147
small	O	148-153
non	O	154-157
-	O	157-158
coding	O	158-164
RNA	O	165-168
molecules	O	169-178
that	O	179-183
regulate	O	184-192
gene	O	193-197
expression	O	198-208
by	O	209-211
either	O	212-218
translational	O	219-232
inhibition	O	233-243
or	O	244-246
mRNA	O	247-251
degradation	O	252-263
.	O	263-264

miRNAs	O	265-271
play	O	272-276
pivotal	O	277-284
roles	O	285-290
in	O	291-293
physiological	O	294-307
functioning	O	308-319
and	O	320-323
pathological	O	324-336
progression	O	337-348
.	O	348-349

The	O	350-353
function	O	354-362
of	O	363-365
microRNA	B	366-374
-	I	374-375
99a	I	375-378
(	O	379-380
miR	B	380-383
-	I	383-384
99a	I	384-387
)	O	387-388
in	O	389-391
oral	O	392-396
squamous	O	397-405
cell	O	406-410
carcinoma	O	411-420
(	O	421-422
OSCC	O	422-426
)	O	426-427
remains	O	428-435
unclear	O	436-443
.	O	443-444

In	O	445-447
the	O	448-451
present	O	452-459
study	O	460-465
,	O	465-466
we	O	467-469
investigated	O	470-482
the	O	483-486
roles	O	487-492
of	O	493-495
miR	B	496-499
-	I	499-500
99a	I	500-503
in	O	504-506
OSCC	O	507-511
development	O	512-523
and	O	524-527
the	O	528-531
underlying	O	532-542
mechanisms	O	543-553
in	O	554-556
25	O	557-559
cases	O	560-565
of	O	566-568
primary	O	569-576
OSCC	O	577-581
tissues	O	582-589
and	O	590-593
Tca	O	594-597
-	O	597-598
8113	O	598-602
cells	O	603-608
.	O	608-609

The	O	610-613
cells	O	614-619
were	O	620-624
analyzed	O	625-633
using	O	634-639
FACS	O	640-644
analysis	O	645-653
and	O	654-657
western	O	658-665
blotting	O	666-674
.	O	674-675

Results	O	676-683
showed	O	684-690
that	O	691-695
the	O	696-699
expression	O	700-710
levels	O	711-717
of	O	718-720
miR	B	721-724
-	I	724-725
99a	I	725-728
were	O	729-733
markedly	O	734-742
decreased	O	743-752
in	O	753-755
OSCC	O	756-760
tissues	O	761-768
compared	O	769-777
with	O	778-782
the	O	783-786
adjacent	O	787-795
non	O	796-799
-	O	799-800
tumor	O	800-805
tissues	O	806-813
(	O	814-815
n	O	815-816
=	O	816-817
25	O	817-819
)	O	819-820
.	O	820-821

The	O	822-825
results	O	826-833
of	O	834-836
in	O	837-839
vitro	O	840-845
experiments	O	846-857
showed	O	858-864
that	O	865-869
miR	B	870-873
-	I	873-874
99a	I	874-877
mimics	O	878-884
significantly	O	885-898
inhibited	O	899-908
the	O	909-912
proliferation	O	913-926
of	O	927-929
Tca	O	930-933
-	O	933-934
8113	O	934-938
cells	O	939-944
,	O	944-945
a	O	946-947
tongue	O	948-954
squamous	O	955-963
carcinoma	O	964-973
cell	O	974-978
line	O	979-983
,	O	983-984
and	O	985-988
that	O	989-993
miR	B	994-997
-	I	997-998
99a	I	998-1001
mimics	O	1002-1008
markedly	O	1009-1017
induced	O	1018-1025
the	O	1026-1029
apoptosis	O	1030-1039
of	O	1040-1042
Tca	O	1043-1046
-	O	1046-1047
8113	O	1047-1051
cells	O	1052-1057
.	O	1057-1058

Furthermore	O	1059-1070
,	O	1070-1071
we	O	1072-1074
demonstrated	O	1075-1087
that	O	1088-1092
mammalian	O	1093-1102
target	O	1103-1109
of	O	1110-1112
rapamycin	O	1113-1122
(	O	1123-1124
mTOR	O	1124-1128
)	O	1128-1129
was	O	1130-1133
directly	O	1134-1142
targeted	O	1143-1151
by	O	1152-1154
miR	B	1155-1158
-	I	1158-1159
99a	I	1159-1162
,	O	1162-1163
as	O	1164-1166
the	O	1167-1170
overexpression	O	1171-1185
of	O	1186-1188
miR	B	1189-1192
-	I	1192-1193
99a	I	1193-1196
in	O	1197-1199
Tca	O	1200-1203
-	O	1203-1204
8113	O	1204-1208
cells	O	1209-1214
downregulated	O	1215-1228
the	O	1229-1232
protein	O	1233-1240
expression	O	1241-1251
level	O	1252-1257
of	O	1258-1260
mTOR	O	1261-1265
.	O	1265-1266

Thus	O	1267-1271
,	O	1271-1272
our	O	1273-1276
findings	O	1277-1285
suggest	O	1286-1293
that	O	1294-1298
the	O	1299-1302
downregulation	O	1303-1317
of	O	1318-1320
miR	B	1321-1324
-	I	1324-1325
99a	I	1325-1328
in	O	1329-1331
OSCC	O	1332-1336
tissues	O	1337-1344
is	O	1345-1347
associated	O	1348-1358
with	O	1359-1363
tumor	O	1364-1369
development	O	1370-1381
.	O	1381-1382

miR	B	1383-1386
-	I	1386-1387
99a	I	1387-1390
regulates	O	1391-1400
the	O	1401-1404
growth	O	1405-1411
and	O	1412-1415
survival	O	1416-1424
of	O	1425-1427
OSCC	O	1428-1432
cells	O	1433-1438
and	O	1439-1442
may	O	1443-1446
be	O	1447-1449
exploited	O	1450-1459
as	O	1460-1462
a	O	1463-1464
biomarker	O	1465-1474
and	O	1475-1478
therapeutic	O	1479-1490
target	O	1491-1497
for	O	1498-1501
patients	O	1502-1510
with	O	1511-1515
OSCC	O	1516-1520
.	O	1520-1521

The	O	0-3
negative	O	4-12
feedback	O	13-21
-	O	21-22
loop	O	22-26
between	O	27-34
the	O	35-38
oncomir	O	39-46
Mir	B	47-50
-	I	50-51
24	I	51-53
-	I	53-54
1	I	54-55
and	O	56-59
menin	O	60-65
modulates	O	66-75
the	O	76-79
Men1	O	80-84
tumorigenesis	O	85-98
by	O	99-101
mimicking	O	102-111
the	O	112-115
"	O	116-117
Knudson	O	117-124
'	O	124-125
s	O	125-126
second	O	127-133
hit	O	134-137
"	O	137-138
.	O	138-139

Multiple	O	140-148
endocrine	O	149-158
neoplasia	O	159-168
type	O	169-173
1	O	174-175
(	O	176-177
MEN1	O	177-181
)	O	181-182
syndrome	O	183-191
is	O	192-194
a	O	195-196
rare	O	197-201
hereditary	O	202-212
cancer	O	213-219
disorder	O	220-228
characterized	O	229-242
by	O	243-245
tumors	O	246-252
of	O	253-255
the	O	256-259
parathyroids	O	260-272
,	O	272-273
of	O	274-276
the	O	277-280
neuroendocrine	O	281-295
cells	O	296-301
,	O	301-302
of	O	303-305
the	O	306-309
gastro	O	310-316
-	O	316-317
entero	O	317-323
-	O	323-324
pancreatic	O	324-334
tract	O	335-340
,	O	340-341
of	O	342-344
the	O	345-348
anterior	O	349-357
pituitary	O	358-367
,	O	367-368
and	O	369-372
by	O	373-375
non	O	376-379
-	O	379-380
endocrine	O	380-389
neoplasms	O	390-399
and	O	400-403
lesions	O	404-411
.	O	411-412

MEN1	O	413-417
gene	O	418-422
,	O	422-423
a	O	424-425
tumor	O	426-431
suppressor	O	432-442
gene	O	443-447
,	O	447-448
encodes	O	449-456
menin	O	457-462
protein	O	463-470
.	O	470-471

Loss	O	472-476
of	O	477-479
heterozygosity	O	480-494
at	O	495-497
11q13	O	498-503
is	O	504-506
typical	O	507-514
of	O	515-517
MEN1	O	518-522
tumors	O	523-529
,	O	529-530
in	O	531-533
agreement	O	534-543
with	O	544-548
the	O	549-552
Knudson	O	553-560
'	O	560-561
s	O	561-562
two	O	563-566
-	O	566-567
hit	O	567-570
hypothesis	O	571-581
.	O	581-582

In	O	583-585
silico	O	586-592
analysis	O	593-601
with	O	602-606
Target	O	607-613
Scan	O	614-618
,	O	618-619
Miranda	O	620-627
and	O	628-631
Pictar	O	632-638
-	O	638-639
Vert	O	639-643
softwares	O	644-653
for	O	654-657
the	O	658-661
prediction	O	662-672
of	O	673-675
miRNA	O	676-681
targets	O	682-689
indicated	O	690-699
miR	B	700-703
-	I	703-704
24	I	704-706
-	I	706-707
1	I	707-708
as	O	709-711
capable	O	712-719
to	O	720-722
bind	O	723-727
to	O	728-730
the	O	731-734
3	O	735-736
'	O	736-737
UTR	O	737-740
of	O	741-743
MEN1	O	744-748
mRNA	O	749-753
.	O	753-754

We	O	755-757
investigated	O	758-770
this	O	771-775
possibility	O	776-787
by	O	788-790
analysis	O	791-799
of	O	800-802
miR	B	803-806
-	I	806-807
24	I	807-809
-	I	809-810
1	I	810-811
expression	O	812-822
profiles	O	823-831
in	O	832-834
parathyroid	O	835-846
adenomatous	O	847-858
tissues	O	859-866
from	O	867-871
MEN1	O	872-876
gene	O	877-881
mutation	O	882-890
carriers	O	891-899
,	O	899-900
in	O	901-903
their	O	904-909
sporadic	O	910-918
non	O	919-922
-	O	922-923
MEN1	O	923-927
counterparts	O	928-940
,	O	940-941
and	O	942-945
in	O	946-948
normal	O	949-955
parathyroid	O	956-967
tissue	O	968-974
.	O	974-975

Interestingly	O	976-989
,	O	989-990
the	O	991-994
MEN1	O	995-999
tumorigenesis	O	1000-1013
seems	O	1014-1019
to	O	1020-1022
be	O	1023-1025
under	O	1026-1031
the	O	1032-1035
control	O	1036-1043
of	O	1044-1046
a	O	1047-1048
"	O	1049-1050
negative	O	1050-1058
feedback	O	1059-1067
loop	O	1068-1072
"	O	1072-1073
between	O	1074-1081
miR	B	1082-1085
-	I	1085-1086
24	I	1086-1088
-	I	1088-1089
1	I	1089-1090
and	O	1091-1094
menin	O	1095-1100
protein	O	1101-1108
,	O	1108-1109
that	O	1110-1114
mimics	O	1115-1121
the	O	1122-1125
second	O	1126-1132
hit	O	1133-1136
of	O	1137-1139
Knudson	O	1140-1147
'	O	1147-1148
s	O	1148-1149
hypothesis	O	1150-1160
and	O	1161-1164
that	O	1165-1169
could	O	1170-1175
buffer	O	1176-1182
the	O	1183-1186
effect	O	1187-1193
of	O	1194-1196
the	O	1197-1200
stochastic	O	1201-1211
factors	O	1212-1219
that	O	1220-1224
contribute	O	1225-1235
to	O	1236-1238
the	O	1239-1242
onset	O	1243-1248
and	O	1249-1252
progression	O	1253-1264
of	O	1265-1267
this	O	1268-1272
disease	O	1273-1280
.	O	1280-1281

Our	O	1282-1285
data	O	1286-1290
show	O	1291-1295
an	O	1296-1298
alternative	O	1299-1310
way	O	1311-1314
to	O	1315-1317
MEN1	O	1318-1322
tumorigenesis	O	1323-1336
and	O	1337-1340
,	O	1340-1341
probably	O	1342-1350
,	O	1350-1351
to	O	1352-1354
the	O	1355-1358
"	O	1359-1360
two	O	1360-1363
-	O	1363-1364
hit	O	1364-1367
dogma	O	1368-1373
"	O	1373-1374
.	O	1374-1375

The	O	1376-1379
functional	O	1380-1390
significance	O	1391-1403
of	O	1404-1406
this	O	1407-1411
regulatory	O	1412-1422
mechanism	O	1423-1432
in	O	1433-1435
MEN1	O	1436-1440
tumorigenesis	O	1441-1454
is	O	1455-1457
also	O	1458-1462
the	O	1463-1466
basis	O	1467-1472
for	O	1473-1476
opening	O	1477-1484
future	O	1485-1491
developments	O	1492-1504
of	O	1505-1507
RNA	O	1508-1511
antagomir	O	1512-1521
(	O	1521-1522
s	O	1522-1523
)	O	1523-1524
-	O	1524-1525
based	O	1525-1530
strategies	O	1531-1541
in	O	1542-1544
the	O	1545-1548
in	O	1549-1551
vivo	O	1552-1556
control	O	1557-1564
of	O	1565-1567
tumorigenesis	O	1568-1581
in	O	1582-1584
MEN1	O	1585-1589
carriers	O	1590-1598
.	O	1598-1599

miR	B	0-3
-	I	3-4
33	I	4-6
controls	O	7-15
the	O	16-19
expression	O	20-30
of	O	31-33
biliary	O	34-41
transporters	O	42-54
,	O	54-55
and	O	56-59
mediates	O	60-68
statin	O	69-75
-	O	75-76
and	O	77-80
diet	O	81-85
-	O	85-86
induced	O	86-93
hepatotoxicity	O	94-108
.	O	108-109

Bile	O	110-114
secretion	O	115-124
is	O	125-127
essential	O	128-137
for	O	138-141
whole	O	142-147
body	O	148-152
sterol	O	153-159
homeostasis	O	160-171
.	O	171-172

Loss	O	173-177
-	O	177-178
of	O	178-180
-	O	180-181
function	O	181-189
mutations	O	190-199
in	O	200-202
specific	O	203-211
canalicular	O	212-223
transporters	O	224-236
in	O	237-239
the	O	240-243
hepatocyte	O	244-254
disrupt	O	255-262
bile	O	263-267
flow	O	268-272
and	O	273-276
result	O	277-283
in	O	284-286
cholestasis	O	287-298
.	O	298-299

We	O	300-302
show	O	303-307
that	O	308-312
two	O	313-316
of	O	317-319
these	O	320-325
transporters	O	326-338
,	O	338-339
ABCB11	O	340-346
and	O	347-350
ATP8B1	O	351-357
,	O	357-358
are	O	359-362
functional	O	363-373
targets	O	374-381
of	O	382-384
miR	B	385-388
-	I	388-389
33	I	389-391
,	O	391-392
a	O	393-394
micro	O	395-400
-	O	400-401
RNA	O	401-404
that	O	405-409
is	O	410-412
expressed	O	413-422
from	O	423-427
within	O	428-434
an	O	435-437
intron	O	438-444
of	O	445-447
SREBP	O	448-453
-	O	453-454
2	O	454-455
.	O	455-456

Consequently	O	457-469
,	O	469-470
manipulation	O	471-483
of	O	484-486
miR	B	487-490
-	I	490-491
33	I	491-493
levels	O	494-500
in	O	501-503
vivo	O	504-508
with	O	509-513
adenovirus	O	514-524
or	O	525-527
with	O	528-532
antisense	O	533-542
oligonucleotides	O	543-559
results	O	560-567
in	O	568-570
changes	O	571-578
in	O	579-581
bile	O	582-586
secretion	O	587-596
and	O	597-600
bile	O	601-605
recovery	O	606-614
from	O	615-619
the	O	620-623
gallbladder	O	624-635
.	O	635-636

Using	O	637-642
radiolabelled	O	643-656
cholesterol	O	657-668
,	O	668-669
we	O	670-672
show	O	673-677
that	O	678-682
systemic	O	683-691
silencing	O	692-701
of	O	702-704
miR	B	705-708
-	I	708-709
33	I	709-711
leads	O	712-717
to	O	718-720
increased	O	721-730
sterols	O	731-738
in	O	739-741
bile	O	742-746
and	O	747-750
enhanced	O	751-759
reverse	O	760-767
cholesterol	O	768-779
transport	O	780-789
in	O	790-792
vivo	O	793-797
.	O	797-798

Finally	O	799-806
,	O	806-807
we	O	808-810
report	O	811-817
that	O	818-822
simvastatin	O	823-834
causes	O	835-841
,	O	841-842
in	O	843-845
a	O	846-847
dose	O	848-852
-	O	852-853
dependent	O	853-862
manner	O	863-869
,	O	869-870
profound	O	871-879
hepatotoxicity	O	880-894
and	O	895-898
lethality	O	899-908
in	O	909-911
mice	O	912-916
fed	O	917-920
a	O	921-922
lithogenic	O	923-933
diet	O	934-938
.	O	938-939

These	O	940-945
latter	O	946-952
results	O	953-960
are	O	961-964
reminiscent	O	965-976
of	O	977-979
the	O	980-983
recurrent	O	984-993
cholestasis	O	994-1005
found	O	1006-1011
in	O	1012-1014
some	O	1015-1019
patients	O	1020-1028
prescribed	O	1029-1039
statins	O	1040-1047
.	O	1047-1048

Importantly	O	1049-1060
,	O	1060-1061
pretreatment	O	1062-1074
of	O	1075-1077
mice	O	1078-1082
with	O	1083-1087
anti	O	1088-1092
-	O	1092-1093
miR	B	1093-1096
-	I	1096-1097
33	I	1097-1099
oligonucleotides	O	1100-1116
rescues	O	1117-1124
the	O	1125-1128
hepatotoxic	O	1129-1140
phenotype	O	1141-1150
.	O	1150-1151

Therefore	O	1152-1161
,	O	1161-1162
we	O	1163-1165
conclude	O	1166-1174
that	O	1175-1179
miR	B	1180-1183
-	I	1183-1184
33	I	1184-1186
mediates	O	1187-1195
some	O	1196-1200
of	O	1201-1203
the	O	1204-1207
undesired	O	1208-1217
,	O	1217-1218
hepatotoxic	O	1219-1230
effects	O	1231-1238
of	O	1239-1241
statins	O	1242-1249
.	O	1249-1250

Deregulated	O	0-11
microRNAs	O	12-21
in	O	22-24
myotonic	O	25-33
dystrophy	O	34-43
type	O	44-48
2	O	49-50
.	O	50-51

Myotonic	O	52-60
Dystrophy	O	61-70
Type	O	71-75
-	O	75-76
2	O	76-77
(	O	78-79
DM2	O	79-82
)	O	82-83
is	O	84-86
an	O	87-89
autosomal	O	90-99
dominant	O	100-108
disease	O	109-116
caused	O	117-123
by	O	124-126
the	O	127-130
expansion	O	131-140
of	O	141-143
a	O	144-145
CCTG	O	146-150
tetraplet	O	151-160
repeat	O	161-167
.	O	167-168

It	O	169-171
is	O	172-174
a	O	175-176
multisystemic	O	177-190
disorder	O	191-199
,	O	199-200
affecting	O	201-210
skeletal	O	211-219
muscles	O	220-227
,	O	227-228
the	O	229-232
heart	O	233-238
,	O	238-239
the	O	240-243
eye	O	244-247
,	O	247-248
the	O	249-252
central	O	253-260
nervous	O	261-268
system	O	269-275
and	O	276-279
the	O	280-283
endocrine	O	284-293
system	O	294-300
.	O	300-301

Since	O	302-307
microRNA	O	308-316
(	O	317-318
miRNA	O	318-323
)	O	323-324
expression	O	325-335
is	O	336-338
disrupted	O	339-348
in	O	349-351
Myotonic	O	352-360
Dystrophy	O	361-370
Type	O	371-375
-	O	375-376
1	O	376-377
and	O	378-381
many	O	382-386
other	O	387-392
myopathies	O	393-403
,	O	403-404
miRNAs	O	405-411
deregulation	O	412-424
was	O	425-428
studied	O	429-436
in	O	437-439
skeletal	O	440-448
muscle	O	449-455
biopsies	O	456-464
of	O	465-467
13	O	468-470
DM2	O	471-474
patients	O	475-483
and	O	484-487
13	O	488-490
controls	O	491-499
.	O	499-500

Eleven	O	501-507
miRNAs	O	508-514
were	O	515-519
deregulated	O	520-531
:	O	531-532
9	O	533-534
displayed	O	535-544
higher	O	545-551
levels	O	552-558
compared	O	559-567
to	O	568-570
controls	O	571-579
(	O	580-581
miR	B	581-584
-	I	584-585
34a	I	585-588
-	I	588-589
5p	I	589-591
,	O	591-592
miR	B	593-596
-	I	596-597
34b	I	597-600
-	I	600-601
3p	I	601-603
,	O	603-604
miR	B	605-608
-	I	608-609
34c	I	609-612
-	I	612-613
5p	I	613-615
,	O	615-616
miR	B	617-620
-	I	620-621
146b	I	621-625
-	I	625-626
5p	I	626-628
,	O	628-629
miR	B	630-633
-	I	633-634
208a	I	634-638
,	O	638-639
miR	B	640-643
-	I	643-644
221	I	644-647
-	I	647-648
3p	I	648-650
and	O	651-654
miR	B	655-658
-	I	658-659
381	I	659-662
)	O	662-663
,	O	663-664
while	O	665-670
4	O	671-672
were	O	673-677
decreased	O	678-687
(	O	688-689
miR	B	689-692
-	I	692-693
125b	I	693-697
-	I	697-698
5p	I	698-700
,	O	700-701
miR	B	702-705
-	I	705-706
193a	I	706-710
-	I	710-711
3p	I	711-713
,	O	713-714
miR	B	715-718
-	I	718-719
193b	I	719-723
-	I	723-724
3p	I	724-726
and	O	727-730
miR	B	731-734
-	I	734-735
378a	I	735-739
-	I	739-740
3p	I	740-742
)	O	742-743
.	O	743-744

To	O	745-747
explore	O	748-755
the	O	756-759
relevance	O	760-769
of	O	770-772
DM2	O	773-776
miRNA	O	777-782
deregulation	O	783-795
,	O	795-796
the	O	797-800
predicted	O	801-810
interactions	O	811-823
between	O	824-831
miRNA	O	832-837
and	O	838-841
mRNA	O	842-846
were	O	847-851
investigated	O	852-864
.	O	864-865

Global	O	866-872
gene	O	873-877
expression	O	878-888
was	O	889-892
analyzed	O	893-901
in	O	902-904
DM2	O	905-908
and	O	909-912
controls	O	913-921
and	O	922-925
bioinformatic	O	926-939
analysis	O	940-948
identified	O	949-959
more	O	960-964
than	O	965-969
1	O	970-971
,	O	971-972
000	O	972-975
miRNA	O	976-981
/	O	981-982
mRNA	O	982-986
interactions	O	987-999
.	O	999-1000

Pathway	O	1001-1008
and	O	1009-1012
function	O	1013-1021
analysis	O	1022-1030
highlighted	O	1031-1042
the	O	1043-1046
involvement	O	1047-1058
of	O	1059-1061
the	O	1062-1065
miRNA	O	1066-1071
-	O	1071-1072
deregulated	O	1072-1083
mRNAs	O	1084-1089
in	O	1090-1092
multiple	O	1093-1101
aspects	O	1102-1109
of	O	1110-1112
DM2	O	1113-1116
pathophysiology	O	1117-1132
.	O	1132-1133

In	O	1134-1136
conclusion	O	1137-1147
,	O	1147-1148
the	O	1149-1152
observed	O	1153-1161
miRNA	O	1162-1167
dysregulations	O	1168-1182
may	O	1183-1186
contribute	O	1187-1197
to	O	1198-1200
DM2	O	1201-1204
pathogenetic	O	1205-1217
mechanisms	O	1218-1228
.	O	1228-1229

MicroRNA	B	0-8
-	I	8-9
21	I	9-11
modulates	O	12-21
the	O	22-25
levels	O	26-32
of	O	33-35
reactive	O	36-44
oxygen	O	45-51
species	O	52-59
by	O	60-62
targeting	O	63-72
SOD3	O	73-77
and	O	78-81
TNFalpha	O	82-90
.	O	90-91

MicroRNA	B	92-100
-	I	100-101
21	I	101-103
(	O	104-105
miR	B	105-108
-	I	108-109
21	I	109-111
)	O	111-112
is	O	113-115
an	O	116-118
oncomir	O	119-126
overexpressed	O	127-140
in	O	141-143
most	O	144-148
human	O	149-154
tumors	O	155-161
in	O	162-164
that	O	165-169
it	O	170-172
promotes	O	173-181
malignant	O	182-191
growth	O	192-198
and	O	199-202
progression	O	203-214
by	O	215-217
acting	O	218-224
on	O	225-227
multiple	O	228-236
targets	O	237-244
.	O	244-245

Here	O	246-250
,	O	250-251
we	O	252-254
broaden	O	255-262
the	O	263-266
impact	O	267-273
of	O	274-276
miR	B	277-280
-	I	280-281
21	I	281-283
in	O	284-286
cancer	O	287-293
by	O	294-296
showing	O	297-304
that	O	305-309
it	O	310-312
regulates	O	313-322
the	O	323-326
formation	O	327-336
of	O	337-339
reactive	O	340-348
oxygen	O	349-355
species	O	356-363
(	O	364-365
ROS	O	365-368
)	O	368-369
that	O	370-374
promote	O	375-382
tumorigenesis	O	383-396
.	O	396-397

Key	O	398-401
targets	O	402-409
of	O	410-412
miR	B	413-416
-	I	416-417
21	I	417-419
in	O	420-422
mediating	O	423-432
this	O	433-437
function	O	438-446
were	O	447-451
SOD3	O	452-456
and	O	457-460
TNFalpha	O	461-469
.	O	469-470

We	O	471-473
found	O	474-479
that	O	480-484
miR	B	485-488
-	I	488-489
21	I	489-491
inhibited	O	492-501
the	O	502-505
metabolism	O	506-516
of	O	517-519
superoxide	O	520-530
to	O	531-533
hydrogen	O	534-542
peroxide	O	543-551
,	O	551-552
produced	O	553-561
either	O	562-568
by	O	569-571
endogenous	O	572-582
basal	O	583-588
activities	O	589-599
or	O	600-602
exposure	O	603-611
to	O	612-614
ionizing	O	615-623
radiation	O	624-633
(	O	634-635
IR	O	635-637
)	O	637-638
,	O	638-639
by	O	640-642
directing	O	643-652
attenuating	O	653-664
SOD3	O	665-669
or	O	670-672
by	O	673-675
an	O	676-678
indirect	O	679-687
mechanism	O	688-697
that	O	698-702
limited	O	703-710
TNFa	O	711-715
production	O	716-726
,	O	726-727
thereby	O	728-735
reducing	O	736-744
SOD2	O	745-749
levels	O	750-756
.	O	756-757

Importantly	O	758-769
,	O	769-770
both	O	771-775
effects	O	776-783
contributed	O	784-795
to	O	796-798
an	O	799-801
elevation	O	802-811
of	O	812-814
IR	O	815-817
-	O	817-818
induced	O	818-825
cell	O	826-830
transformation	O	831-845
.	O	845-846

Our	O	847-850
findings	O	851-859
,	O	859-860
therefore	O	861-870
,	O	870-871
establish	O	872-881
that	O	882-886
miR	B	887-890
-	I	890-891
21	I	891-893
promotes	O	894-902
tumorigenesis	O	903-916
to	O	917-919
a	O	920-921
large	O	922-927
extent	O	928-934
through	O	935-942
its	O	943-946
regulation	O	947-957
of	O	958-960
cellular	O	961-969
ROS	O	970-973
levels	O	974-980
.	O	980-981

Copy	O	0-4
-	O	4-5
number	O	5-11
gains	O	12-17
of	O	18-20
HUWE1	O	21-26
due	O	27-30
to	O	31-33
replication	O	34-45
-	O	45-46
and	O	47-50
recombination	O	51-64
-	O	64-65
based	O	65-70
rearrangements	O	71-85
.	O	85-86

We	O	87-89
previously	O	90-100
reported	O	101-109
on	O	110-112
nonrecurrent	O	113-125
overlapping	O	126-137
duplications	O	138-150
at	O	151-153
Xp11	O	154-158
.	O	158-159
22	O	159-161
in	O	162-164
individuals	O	165-176
with	O	177-181
nonsyndromic	O	182-194
intellectual	O	195-207
disability	O	208-218
(	O	219-220
ID	O	220-222
)	O	222-223
harboring	O	224-233
HSD17B10	O	234-242
,	O	242-243
HUWE1	O	244-249
,	O	249-250
and	O	251-254
the	O	255-258
microRNAs	O	259-268
miR	B	269-272
-	I	272-273
98	I	273-275
and	O	276-279
let	B	280-283
-	I	283-284
7f	I	284-286
-	I	286-287
2	I	287-288
in	O	289-291
the	O	292-295
smallest	O	296-304
region	O	305-311
of	O	312-314
overlap	O	315-322
.	O	322-323

Here	O	324-328
,	O	328-329
we	O	330-332
describe	O	333-341
six	O	342-345
additional	O	346-356
individuals	O	357-368
with	O	369-373
nonsyndromic	O	374-386
ID	O	387-389
and	O	390-393
overlapping	O	394-405
microduplications	O	406-423
that	O	424-428
segregate	O	429-438
in	O	439-441
the	O	442-445
families	O	446-454
.	O	454-455

High	O	456-460
-	O	460-461
resolution	O	461-471
mapping	O	472-479
of	O	480-482
the	O	483-486
12	O	487-489
copy	O	490-494
-	O	494-495
number	O	495-501
gains	O	502-507
reduced	O	508-515
the	O	516-519
minimal	O	520-527
duplicated	O	528-538
region	O	539-545
to	O	546-548
the	O	549-552
HUWE1	O	553-558
locus	O	559-564
only	O	565-569
.	O	569-570

Consequently	O	571-583
,	O	583-584
increased	O	585-594
mRNA	O	595-599
levels	O	600-606
were	O	607-611
detected	O	612-620
for	O	621-624
HUWE1	O	625-630
,	O	630-631
but	O	632-635
not	O	636-639
HSD17B10	O	640-648
.	O	648-649

Marker	O	650-656
and	O	657-660
SNP	O	661-664
analysis	O	665-673
,	O	673-674
together	O	675-683
with	O	684-688
identification	O	689-703
of	O	704-706
two	O	707-710
de	O	711-713
novo	O	714-718
events	O	719-725
,	O	725-726
suggested	O	727-736
a	O	737-738
paternally	O	739-749
derived	O	750-757
intrachromosomal	O	758-774
duplication	O	775-786
event	O	787-792
.	O	792-793

In	O	794-796
four	O	797-801
independent	O	802-813
families	O	814-822
,	O	822-823
we	O	824-826
report	O	827-833
on	O	834-836
a	O	837-838
polymorphic	O	839-850
70	O	851-853
kb	O	854-856
recurrent	O	857-866
copy	O	867-871
-	O	871-872
number	O	872-878
gain	O	879-883
,	O	883-884
which	O	885-890
harbors	O	891-898
part	O	899-903
of	O	904-906
HUWE1	O	907-912
(	O	913-914
exon	O	914-918
28	O	919-921
to	O	922-924
3	O	925-926
'	O	926-927
untranslated	O	928-940
region	O	941-947
)	O	947-948
,	O	948-949
including	O	950-959
miR	B	960-963
-	I	963-964
98	I	964-966
and	O	967-970
let	B	971-974
-	I	974-975
7f	I	975-977
-	I	977-978
2	I	978-979
.	O	979-980

Our	O	981-984
findings	O	985-993
thus	O	994-998
demonstrate	O	999-1010
that	O	1011-1015
HUWE1	O	1016-1021
is	O	1022-1024
the	O	1025-1028
only	O	1029-1033
remaining	O	1034-1043
dosage	O	1044-1050
-	O	1050-1051
sensitive	O	1051-1060
gene	O	1061-1065
associated	O	1066-1076
with	O	1077-1081
the	O	1082-1085
ID	O	1086-1088
phenotype	O	1089-1098
.	O	1098-1099

Junction	O	1100-1108
and	O	1109-1112
in	O	1113-1115
silico	O	1116-1122
analysis	O	1123-1131
of	O	1132-1134
breakpoint	O	1135-1145
regions	O	1146-1153
demonstrated	O	1154-1166
simple	O	1167-1173
microhomology	O	1174-1187
-	O	1187-1188
mediated	O	1188-1196
rearrangements	O	1197-1211
suggestive	O	1212-1222
of	O	1223-1225
replication	O	1226-1237
-	O	1237-1238
based	O	1238-1243
duplication	O	1244-1255
events	O	1256-1262
.	O	1262-1263

Intriguingly	O	1264-1276
,	O	1276-1277
in	O	1278-1280
a	O	1281-1282
single	O	1283-1289
family	O	1290-1296
,	O	1296-1297
the	O	1298-1301
duplication	O	1302-1313
was	O	1314-1317
generated	O	1318-1327
through	O	1328-1335
nonallelic	O	1336-1346
homologous	O	1347-1357
recombination	O	1358-1371
(	O	1372-1373
NAHR	O	1373-1377
)	O	1377-1378
with	O	1379-1383
the	O	1384-1387
use	O	1388-1391
of	O	1392-1394
HUWE1	O	1395-1400
-	O	1400-1401
flanking	O	1401-1409
imperfect	O	1410-1419
low	O	1420-1423
-	O	1423-1424
copy	O	1424-1428
repeats	O	1429-1436
,	O	1436-1437
which	O	1438-1443
drive	O	1444-1449
this	O	1450-1454
infrequent	O	1455-1465
NAHR	O	1466-1470
event	O	1471-1476
.	O	1476-1477

The	O	1478-1481
recurrent	O	1482-1491
partial	O	1492-1499
HUWE1	O	1500-1505
copy	O	1506-1510
-	O	1510-1511
number	O	1511-1517
gain	O	1518-1522
was	O	1523-1526
also	O	1527-1531
generated	O	1532-1541
through	O	1542-1549
NAHR	O	1550-1554
,	O	1554-1555
but	O	1556-1559
here	O	1560-1564
,	O	1564-1565
the	O	1566-1569
homologous	O	1570-1580
sequences	O	1581-1590
used	O	1591-1595
were	O	1596-1600
identified	O	1601-1611
as	O	1612-1614
TcMAR	O	1615-1620
-	O	1620-1621
Tigger	O	1621-1627
DNA	O	1628-1631
elements	O	1632-1640
,	O	1640-1641
a	O	1642-1643
template	O	1644-1652
that	O	1653-1657
has	O	1658-1661
not	O	1662-1665
yet	O	1666-1669
been	O	1670-1674
reported	O	1675-1683
for	O	1684-1687
NAHR	O	1688-1692
.	O	1692-1693

In	O	1694-1696
summary	O	1697-1704
,	O	1704-1705
we	O	1706-1708
showed	O	1709-1715
that	O	1716-1720
an	O	1721-1723
increased	O	1724-1733
dosage	O	1734-1740
of	O	1741-1743
HUWE1	O	1744-1749
causes	O	1750-1756
nonsyndromic	O	1757-1769
ID	O	1770-1772
and	O	1773-1776
demonstrated	O	1777-1789
that	O	1790-1794
the	O	1795-1798
Xp11	O	1799-1803
.	O	1803-1804
22	O	1804-1806
region	O	1807-1813
is	O	1814-1816
prone	O	1817-1822
to	O	1823-1825
recombination	O	1826-1839
-	O	1839-1840
and	O	1841-1844
replication	O	1845-1856
-	O	1856-1857
based	O	1857-1862
rearrangements	O	1863-1877
.	O	1877-1878

Loss	O	0-4
of	O	5-7
miR	B	8-11
-	I	11-12
126	I	12-15
is	O	16-18
crucial	O	19-26
to	O	27-29
pancreatic	O	30-40
cancer	O	41-47
progression	O	48-59
.	O	59-60

The	O	61-64
tumor	O	65-70
-	O	70-71
suppressor	O	71-81
miRNA	B	82-87
126	I	88-91
(	O	92-93
miR	B	93-96
-	I	96-97
126	I	97-100
)	O	100-101
is	O	102-104
downregulated	O	105-118
in	O	119-121
many	O	122-126
tumors	O	127-133
and	O	134-137
has	O	138-141
recently	O	142-150
been	O	151-155
placed	O	156-162
at	O	163-165
the	O	166-169
heart	O	170-175
of	O	176-178
complex	O	179-186
metastatic	O	187-197
pathways	O	198-206
.	O	206-207

Hamada	O	208-214
and	O	215-218
colleagues	O	219-229
have	O	230-234
identified	O	235-245
miR	B	246-249
-	I	249-250
126	I	250-253
as	O	254-256
being	O	257-262
downregulated	O	263-276
in	O	277-279
pancreatic	O	280-290
ductal	O	291-297
adenocarcinoma	O	298-312
(	O	313-314
PDAC	O	314-318
)	O	318-319
patient	O	320-327
samples	O	328-335
and	O	336-339
cell	O	340-344
lines	O	345-350
.	O	350-351

The	O	352-355
protein	O	356-363
ADAM9	O	364-369
has	O	370-373
been	O	374-378
implicated	O	379-389
in	O	390-392
the	O	393-396
progression	O	397-408
of	O	409-411
various	O	412-419
solid	O	420-425
tumors	O	426-432
including	O	433-442
PDAC	O	443-447
.	O	447-448

ADAM9	O	449-454
is	O	455-457
overexpressed	O	458-471
in	O	472-474
PDAC	O	475-479
and	O	480-483
also	O	484-488
a	O	489-490
direct	O	491-497
target	O	498-504
of	O	505-507
miR	B	508-511
-	I	511-512
126	I	512-515
.	O	515-516

The	O	517-520
miR	B	521-524
-	I	524-525
126	I	525-528
/	O	528-529
ADAM9	O	529-534
axis	O	535-539
was	O	540-543
subsequently	O	544-556
established	O	557-568
to	O	569-571
control	O	572-579
migration	O	580-589
and	O	590-593
invasion	O	594-602
in	O	603-605
PDAC	O	606-610
,	O	610-611
as	O	612-614
well	O	615-619
as	O	620-622
reversal	O	623-631
of	O	632-634
epithelial	O	635-645
-	O	645-646
to	O	646-648
-	O	648-649
mesenchymal	O	649-660
transition	O	661-671
.	O	671-672

miR	B	673-676
-	I	676-677
126	I	677-680
is	O	681-683
also	O	684-688
known	O	689-694
to	O	695-697
target	O	698-704
other	O	705-710
crucial	O	711-718
oncogenes	O	719-728
in	O	729-731
PDAC	O	732-736
such	O	737-741
as	O	742-744
KRAS	O	745-749
and	O	750-753
CRK	O	754-757
.	O	757-758

Replacing	O	759-768
miR	B	769-772
-	I	772-773
126	I	773-776
in	O	777-779
PDAC	O	780-784
patients	O	785-793
may	O	794-797
be	O	798-800
a	O	801-802
novel	O	803-808
strategy	O	809-817
for	O	818-821
preventing	O	822-832
progression	O	833-844
and	O	845-848
metastasis	O	849-859
.	O	859-860

Comprehensive	O	0-13
microRNA	O	14-22
profiling	O	23-32
in	O	33-35
B	O	36-37
-	O	37-38
cells	O	38-43
of	O	44-46
human	O	47-52
centenarians	O	53-65
by	O	66-68
massively	O	69-78
parallel	O	79-87
sequencing	O	88-98
.	O	98-99

BACKGROUND	O	100-110
:	O	110-111
MicroRNAs	O	112-121
(	O	122-123
miRNAs	O	123-129
)	O	129-130
are	O	131-134
small	O	135-140
,	O	140-141
non	O	142-145
-	O	145-146
coding	O	146-152
RNAs	O	153-157
that	O	158-162
regulate	O	163-171
gene	O	172-176
expression	O	177-187
and	O	188-191
play	O	192-196
a	O	197-198
critical	O	199-207
role	O	208-212
in	O	213-215
development	O	216-227
,	O	227-228
homeostasis	O	229-240
,	O	240-241
and	O	242-245
disease	O	246-253
.	O	253-254

Despite	O	255-262
their	O	263-268
demonstrated	O	269-281
roles	O	282-287
in	O	288-290
age	O	291-294
-	O	294-295
associated	O	295-305
pathologies	O	306-317
,	O	317-318
little	O	319-325
is	O	326-328
known	O	329-334
about	O	335-340
the	O	341-344
role	O	345-349
of	O	350-352
miRNAs	O	353-359
in	O	360-362
human	O	363-368
aging	O	369-374
and	O	375-378
longevity	O	379-388
.	O	388-389

RESULTS	O	390-397
:	O	397-398
We	O	399-401
employed	O	402-410
massively	O	411-420
parallel	O	421-429
sequencing	O	430-440
technology	O	441-451
to	O	452-454
identify	O	455-463
miRNAs	O	464-470
expressed	O	471-480
in	O	481-483
B	O	484-485
-	O	485-486
cells	O	486-491
from	O	492-496
Ashkenazi	O	497-506
Jewish	O	507-513
centenarians	O	514-526
,	O	526-527
i	O	528-529
.	O	529-530
e	O	530-531
.	O	531-532
,	O	532-533
those	O	534-539
living	O	540-546
to	O	547-549
a	O	550-551
hundred	O	552-559
and	O	560-563
a	O	564-565
human	O	566-571
model	O	572-577
of	O	578-580
exceptional	O	581-592
longevity	O	593-602
,	O	602-603
and	O	604-607
younger	O	608-615
controls	O	616-624
without	O	625-632
a	O	633-634
family	O	635-641
history	O	642-649
of	O	650-652
longevity	O	653-662
.	O	662-663

With	O	664-668
data	O	669-673
from	O	674-678
26	O	679-681
.	O	681-682
7	O	682-683
million	O	684-691
reads	O	692-697
comprising	O	698-708
9	O	709-710
.	O	710-711
4	O	711-712
x	O	713-714
108	O	715-718
bp	O	719-721
from	O	722-726
3	O	727-728
centenarian	O	729-740
and	O	741-744
3	O	745-746
control	O	747-754
individuals	O	755-766
,	O	766-767
we	O	768-770
discovered	O	771-781
a	O	782-783
total	O	784-789
of	O	790-792
276	O	793-796
known	O	797-802
miRNAs	O	803-809
and	O	810-813
8	O	814-815
unknown	O	816-823
miRNAs	O	824-830
ranging	O	831-838
several	O	839-846
orders	O	847-853
of	O	854-856
magnitude	O	857-866
in	O	867-869
expression	O	870-880
levels	O	881-887
,	O	887-888
a	O	889-890
typical	O	891-898
characteristics	O	899-914
of	O	915-917
saturated	O	918-927
miRNA	O	928-933
-	O	933-934
sequencing	O	934-944
.	O	944-945

A	O	946-947
total	O	948-953
of	O	954-956
22	O	957-959
miRNAs	O	960-966
were	O	967-971
found	O	972-977
to	O	978-980
be	O	981-983
significantly	O	984-997
upregulated	O	998-1009
,	O	1009-1010
with	O	1011-1015
only	O	1016-1020
2	O	1021-1022
miRNAs	O	1023-1029
downregulated	O	1030-1043
,	O	1043-1044
in	O	1045-1047
centenarians	O	1048-1060
as	O	1061-1063
compared	O	1064-1072
to	O	1073-1075
controls	O	1076-1084
.	O	1084-1085

Gene	O	1086-1090
Ontology	O	1091-1099
analysis	O	1100-1108
of	O	1109-1111
the	O	1112-1115
predicted	O	1116-1125
and	O	1126-1129
validated	O	1130-1139
targets	O	1140-1147
of	O	1148-1150
the	O	1151-1154
24	O	1155-1157
differentially	O	1158-1172
expressed	O	1173-1182
miRNAs	O	1183-1189
indicated	O	1190-1199
enrichment	O	1200-1210
of	O	1211-1213
functional	O	1214-1224
pathways	O	1225-1233
involved	O	1234-1242
in	O	1243-1245
cell	O	1246-1250
metabolism	O	1251-1261
,	O	1261-1262
cell	O	1263-1267
cycle	O	1268-1273
,	O	1273-1274
cell	O	1275-1279
signaling	O	1280-1289
,	O	1289-1290
and	O	1291-1294
cell	O	1295-1299
differentiation	O	1300-1315
.	O	1315-1316

A	O	1317-1318
cross	O	1319-1324
sectional	O	1325-1334
expression	O	1335-1345
analysis	O	1346-1354
of	O	1355-1357
the	O	1358-1361
differentially	O	1362-1376
expressed	O	1377-1386
miRNAs	O	1387-1393
in	O	1394-1396
B	O	1397-1398
-	O	1398-1399
cells	O	1399-1404
from	O	1405-1409
Ashkenazi	O	1410-1419
Jewish	O	1420-1426
individuals	O	1427-1438
between	O	1439-1446
the	O	1447-1450
50th	O	1451-1455
and	O	1456-1459
100th	O	1460-1465
years	O	1466-1471
of	O	1472-1474
age	O	1475-1478
indicated	O	1479-1488
that	O	1489-1493
expression	O	1494-1504
levels	O	1505-1511
of	O	1512-1514
miR	B	1515-1518
-	I	1518-1519
363	I	1519-1522
*	I	1522-1523
declined	O	1524-1532
significantly	O	1533-1546
with	O	1547-1551
age	O	1552-1555
.	O	1555-1556

Centenarians	O	1557-1569
,	O	1569-1570
however	O	1571-1578
,	O	1578-1579
maintained	O	1580-1590
the	O	1591-1594
youthful	O	1595-1603
expression	O	1604-1614
level	O	1615-1620
.	O	1620-1621

This	O	1622-1626
result	O	1627-1633
suggests	O	1634-1642
that	O	1643-1647
miR	B	1648-1651
-	I	1651-1652
363	I	1652-1655
*	I	1655-1656
may	O	1657-1660
be	O	1661-1663
a	O	1664-1665
candidate	O	1666-1675
longevity	O	1676-1685
-	O	1685-1686
associated	O	1686-1696
miRNA	O	1697-1702
.	O	1702-1703

CONCLUSION	O	1704-1714
:	O	1714-1715
Our	O	1716-1719
comprehensive	O	1720-1733
miRNA	O	1734-1739
data	O	1740-1744
provide	O	1745-1752
a	O	1753-1754
resource	O	1755-1763
for	O	1764-1767
further	O	1768-1775
studies	O	1776-1783
to	O	1784-1786
identify	O	1787-1795
genetic	O	1796-1803
pathways	O	1804-1812
associated	O	1813-1823
with	O	1824-1828
aging	O	1829-1834
and	O	1835-1838
longevity	O	1839-1848
in	O	1849-1851
humans	O	1852-1858
.	O	1858-1859

Regulation	O	0-10
of	O	11-13
cell	O	14-18
cycle	O	19-24
checkpoint	O	25-35
kinase	O	36-42
WEE1	O	43-47
by	O	48-50
miR	B	51-54
-	I	54-55
195	I	55-58
in	O	59-61
malignant	O	62-71
melanoma	O	72-80
.	O	80-81

WEE1	O	82-86
kinase	O	87-93
has	O	94-97
been	O	98-102
described	O	103-112
as	O	113-115
a	O	116-117
major	O	118-123
gate	O	124-128
keeper	O	129-135
at	O	136-138
the	O	139-142
G2	O	143-145
cell	O	146-150
cycle	O	151-156
checkpoint	O	157-167
and	O	168-171
to	O	172-174
be	O	175-177
involved	O	178-186
in	O	187-189
tumour	O	190-196
progression	O	197-208
in	O	209-211
different	O	212-221
malignant	O	222-231
tumours	O	232-239
.	O	239-240

Here	O	241-245
we	O	246-248
analysed	O	249-257
the	O	258-261
expression	O	262-272
levels	O	273-279
of	O	280-282
WEE1	O	283-287
in	O	288-290
a	O	291-292
series	O	293-299
of	O	300-302
melanoma	O	303-311
patient	O	312-319
samples	O	320-327
and	O	328-331
melanoma	O	332-340
cell	O	341-345
lines	O	346-351
using	O	352-357
immunoblotting	O	358-372
,	O	372-373
quantitative	O	374-386
real	O	387-391
-	O	391-392
time	O	392-396
PCR	O	397-400
and	O	401-404
immunohistochemistry	O	405-425
.	O	425-426

WEE1	O	427-431
expression	O	432-442
was	O	443-446
significantly	O	447-460
downregulated	O	461-474
in	O	475-477
patient	O	478-485
samples	O	486-493
of	O	494-496
metastatic	O	497-507
origin	O	508-514
as	O	515-517
compared	O	518-526
with	O	527-531
primary	O	532-539
melanomas	O	540-549
and	O	550-553
in	O	554-556
melanoma	O	557-565
cell	O	566-570
lines	O	571-576
of	O	577-579
high	O	580-584
aggressiveness	O	585-599
as	O	600-602
compared	O	603-611
with	O	612-616
cell	O	617-621
lines	O	622-627
of	O	628-630
low	O	631-634
aggressiveness	O	635-649
.	O	649-650

Moreover	O	651-659
,	O	659-660
there	O	661-666
was	O	667-670
an	O	671-673
inverse	O	674-681
correlation	O	682-693
between	O	694-701
the	O	702-705
expression	O	706-716
of	O	717-719
WEE1	O	720-724
and	O	725-728
WEE1	O	729-733
-	O	733-734
targeting	O	734-743
microRNA	O	744-752
miR	B	753-756
-	I	756-757
195	I	757-760
.	O	760-761

Further	O	762-769
analyses	O	770-778
showed	O	779-785
that	O	786-790
transfection	O	791-803
of	O	804-806
melanoma	O	807-815
cell	O	816-820
lines	O	821-826
with	O	827-831
miR	B	832-835
-	I	835-836
195	I	836-839
indeed	O	840-846
reduced	O	847-854
WEE1	O	855-859
mRNA	O	860-864
and	O	865-868
protein	O	869-876
expression	O	877-887
in	O	888-890
these	O	891-896
cells	O	897-902
.	O	902-903

Reporter	O	904-912
gene	O	913-917
analysis	O	918-926
confirmed	O	927-936
direct	O	937-943
targeting	O	944-953
of	O	954-956
the	O	957-960
WEE1	O	961-965
3	O	966-967
'	O	967-968
untranslated	O	969-981
region	O	982-988
(	O	989-990
3	O	990-991
'	O	991-992
UTR	O	992-995
)	O	995-996
by	O	997-999
miR	B	1000-1003
-	I	1003-1004
195	I	1004-1007
.	O	1007-1008

Overexpression	O	1009-1023
of	O	1024-1026
miR	B	1027-1030
-	I	1030-1031
195	I	1031-1034
in	O	1035-1037
SK	O	1038-1040
-	O	1040-1041
Mel	O	1041-1044
-	O	1044-1045
28	O	1045-1047
melanoma	O	1048-1056
cells	O	1057-1062
was	O	1063-1066
accompanied	O	1067-1078
by	O	1079-1081
WEE1	O	1082-1086
reduction	O	1087-1096
and	O	1097-1100
significantly	O	1101-1114
reduced	O	1115-1122
stress	O	1123-1129
-	O	1129-1130
induced	O	1130-1137
G2	O	1138-1140
-	O	1140-1141
M	O	1141-1142
cell	O	1143-1147
cycle	O	1148-1153
arrest	O	1154-1160
,	O	1160-1161
which	O	1162-1167
could	O	1168-1173
be	O	1174-1176
restored	O	1177-1185
by	O	1186-1188
stable	O	1189-1195
overexpression	O	1196-1210
of	O	1211-1213
WEE1	O	1214-1218
.	O	1218-1219

Moreover	O	1220-1228
,	O	1228-1229
miR	B	1230-1233
-	I	1233-1234
195	I	1234-1237
overexpression	O	1238-1252
and	O	1253-1256
WEE1	O	1257-1261
knockdown	O	1262-1271
,	O	1271-1272
respectively	O	1273-1285
,	O	1285-1286
increased	O	1287-1296
melanoma	O	1297-1305
cell	O	1306-1310
proliferation	O	1311-1324
.	O	1324-1325

miR	B	1326-1329
-	I	1329-1330
195	I	1330-1333
overexpression	O	1334-1348
also	O	1349-1353
enhanced	O	1354-1362
migration	O	1363-1372
and	O	1373-1376
invasiveness	O	1377-1389
of	O	1390-1392
melanoma	O	1393-1401
cells	O	1402-1407
.	O	1407-1408

Taken	O	1409-1414
together	O	1415-1423
,	O	1423-1424
the	O	1425-1428
present	O	1429-1436
study	O	1437-1442
shows	O	1443-1448
that	O	1449-1453
WEE1	O	1454-1458
expression	O	1459-1469
in	O	1470-1472
malignant	O	1473-1482
melanoma	O	1483-1491
is	O	1492-1494
directly	O	1495-1503
regulated	O	1504-1513
by	O	1514-1516
miR	B	1517-1520
-	I	1520-1521
195	I	1521-1524
.	O	1524-1525

miR	B	1526-1529
-	I	1529-1530
195	I	1530-1533
-	O	1533-1534
mediated	O	1534-1542
downregulation	O	1543-1557
of	O	1558-1560
WEE1	O	1561-1565
in	O	1566-1568
metastatic	O	1569-1579
lesions	O	1580-1587
may	O	1588-1591
help	O	1592-1596
to	O	1597-1599
overcome	O	1600-1608
cell	O	1609-1613
cycle	O	1614-1619
arrest	O	1620-1626
under	O	1627-1632
stress	O	1633-1639
conditions	O	1640-1650
in	O	1651-1653
the	O	1654-1657
local	O	1658-1663
tissue	O	1664-1670
microenvironment	O	1671-1687
to	O	1688-1690
allow	O	1691-1696
unrestricted	O	1697-1709
growth	O	1710-1716
of	O	1717-1719
tumour	O	1720-1726
cells	O	1727-1732
.	O	1732-1733

Plasma	O	0-6
microRNA	O	7-15
profiles	O	16-24
for	O	25-28
bladder	O	29-36
cancer	O	37-43
detection	O	44-53
.	O	53-54

BACKGROUND	O	55-65
:	O	65-66
Bladder	O	67-74
cancer	O	75-81
(	O	82-83
BC	O	83-85
)	O	85-86
is	O	87-89
a	O	90-91
burdensome	O	92-102
disease	O	103-110
with	O	111-115
significant	O	116-127
morbidity	O	128-137
,	O	137-138
mortality	O	139-148
,	O	148-149
and	O	150-153
cost	O	154-158
.	O	158-159

The	O	160-163
development	O	164-175
of	O	176-178
novel	O	179-184
plasma	O	185-191
-	O	191-192
based	O	192-197
biomarkers	O	198-208
for	O	209-212
BC	O	213-215
diagnosis	O	216-225
and	O	226-229
surveillance	O	230-242
could	O	243-248
significantly	O	249-262
improve	O	263-270
clinical	O	271-279
outcomes	O	280-288
and	O	289-292
decrease	O	293-301
health	O	302-308
expenditures	O	309-321
.	O	321-322

Plasma	O	323-329
miRNAs	O	330-336
are	O	337-340
promising	O	341-350
biomarkers	O	351-361
that	O	362-366
have	O	367-371
yet	O	372-375
to	O	376-378
be	O	379-381
rigorously	O	382-392
investigated	O	393-405
in	O	406-408
BC	O	409-411
.	O	411-412

OBJECTIVE	O	413-422
:	O	422-423
To	O	424-426
determine	O	427-436
the	O	437-440
feasibility	O	441-452
and	O	453-456
efficacy	O	457-465
of	O	466-468
detecting	O	469-478
BC	O	479-481
with	O	482-486
plasma	O	487-493
miRNA	O	494-499
signatures	O	500-510
.	O	510-511

MATERIALS	O	512-521
AND	O	522-525
METHODS	O	526-533
:	O	533-534
Plasma	O	535-541
miRNA	O	542-547
was	O	548-551
isolated	O	552-560
from	O	561-565
20	O	566-568
patients	O	569-577
with	O	578-582
bladder	O	583-590
cancer	O	591-597
and	O	598-601
18	O	602-604
noncancerous	O	605-617
controls	O	618-626
.	O	626-627

Samples	O	628-635
were	O	636-640
analyzed	O	641-649
with	O	650-654
a	O	655-656
miRNA	O	657-662
array	O	663-668
containing	O	669-679
duplicate	O	680-689
probes	O	690-696
for	O	697-700
each	O	701-705
miRNA	O	706-711
in	O	712-714
the	O	715-718
Sanger	O	719-725
database	O	726-734
.	O	734-735

Logistic	O	736-744
regression	O	745-755
modeling	O	756-764
was	O	765-768
used	O	769-773
to	O	774-776
optimize	O	777-785
diagnostic	O	786-796
miRNA	O	797-802
signatures	O	803-813
to	O	814-816
distinguish	O	817-828
between	O	829-836
muscle	O	837-843
invasive	O	844-852
BC	O	853-855
(	O	856-857
MIBC	O	857-861
)	O	861-862
,	O	862-863
non	O	864-867
-	O	867-868
muscle	O	868-874
-	O	874-875
invasive	O	875-883
BC	O	884-886
(	O	887-888
NMIBC	O	888-893
)	O	893-894
and	O	895-898
noncancerous	O	899-911
controls	O	912-920
.	O	920-921

RESULTS	O	922-929
:	O	929-930
Seventy	O	931-938
-	O	938-939
nine	O	939-943
differentially	O	944-958
expressed	O	959-968
plasma	O	969-975
miRNAs	O	976-982
(	O	983-984
local	O	984-989
false	O	990-995
discovery	O	996-1005
rate	O	1006-1010
[	O	1011-1012
FDR	O	1012-1015
]	O	1015-1016
<	O	1017-1018
0	O	1018-1019
.	O	1019-1020
5	O	1020-1021
)	O	1021-1022
in	O	1023-1025
patients	O	1026-1034
with	O	1035-1039
or	O	1040-1042
without	O	1043-1050
BC	O	1051-1053
were	O	1054-1058
identified	O	1059-1069
.	O	1069-1070

Some	O	1071-1075
diagnostically	O	1076-1090
relevant	O	1091-1099
miRNAs	O	1100-1106
,	O	1106-1107
such	O	1108-1112
as	O	1113-1115
miR	B	1116-1119
-	I	1119-1120
200b	I	1120-1124
,	O	1124-1125
were	O	1126-1130
up	O	1131-1133
-	O	1133-1134
regulated	O	1134-1143
in	O	1144-1146
MIBC	O	1147-1151
patients	O	1152-1160
,	O	1160-1161
whereas	O	1162-1169
others	O	1170-1176
,	O	1176-1177
such	O	1178-1182
as	O	1183-1185
miR	B	1186-1189
-	I	1189-1190
92	I	1190-1192
and	O	1193-1196
miR	B	1197-1200
-	I	1200-1201
33	I	1201-1203
,	O	1203-1204
were	O	1205-1209
inversely	O	1210-1219
correlated	O	1220-1230
with	O	1231-1235
advanced	O	1236-1244
clinical	O	1245-1253
stage	O	1254-1259
,	O	1259-1260
supporting	O	1261-1271
the	O	1272-1275
notion	O	1276-1282
that	O	1283-1287
miRNAs	O	1288-1294
released	O	1295-1303
in	O	1304-1306
the	O	1307-1310
circulation	O	1311-1322
have	O	1323-1327
a	O	1328-1329
variety	O	1330-1337
of	O	1338-1340
cellular	O	1341-1349
origins	O	1350-1357
.	O	1357-1358

Logistic	O	1359-1367
regression	O	1368-1378
modeling	O	1379-1387
was	O	1388-1391
able	O	1392-1396
to	O	1397-1399
predict	O	1400-1407
diagnosis	O	1408-1417
with	O	1418-1422
89	O	1423-1425
%	O	1425-1426
accuracy	O	1427-1435
for	O	1436-1439
detecting	O	1440-1449
the	O	1450-1453
presence	O	1454-1462
or	O	1463-1465
absence	O	1466-1473
of	O	1474-1476
BC	O	1477-1479
,	O	1479-1480
92	O	1481-1483
%	O	1483-1484
accuracy	O	1485-1493
for	O	1494-1497
distinguishing	O	1498-1512
invasive	O	1513-1521
BC	O	1522-1524
from	O	1525-1529
other	O	1530-1535
cases	O	1536-1541
,	O	1541-1542
100	O	1543-1546
%	O	1546-1547
accuracy	O	1548-1556
for	O	1557-1560
distinguishing	O	1561-1575
MIBC	O	1576-1580
from	O	1581-1585
controls	O	1586-1594
,	O	1594-1595
and	O	1596-1599
79	O	1600-1602
%	O	1602-1603
accuracy	O	1604-1612
for	O	1613-1616
three	O	1617-1622
-	O	1622-1623
way	O	1623-1626
classification	O	1627-1641
between	O	1642-1649
MIBC	O	1650-1654
,	O	1654-1655
NIMBC	O	1656-1661
,	O	1661-1662
and	O	1663-1666
controls	O	1667-1675
.	O	1675-1676

CONCLUSIONS	O	1677-1688
:	O	1688-1689
This	O	1690-1694
study	O	1695-1700
provides	O	1701-1709
preliminary	O	1710-1721
data	O	1722-1726
supporting	O	1727-1737
the	O	1738-1741
use	O	1742-1745
of	O	1746-1748
plasma	O	1749-1755
miRNAs	O	1756-1762
as	O	1763-1765
a	O	1766-1767
noninvasive	O	1768-1779
means	O	1780-1785
of	O	1786-1788
BC	O	1789-1791
detection	O	1792-1801
.	O	1801-1802

Future	O	1803-1809
studies	O	1810-1817
will	O	1818-1822
be	O	1823-1825
required	O	1826-1834
to	O	1835-1837
further	O	1838-1845
specify	O	1846-1853
the	O	1854-1857
optimal	O	1858-1865
plasma	O	1866-1872
miRNA	O	1873-1878
signature	O	1879-1888
,	O	1888-1889
and	O	1890-1893
to	O	1894-1896
apply	O	1897-1902
these	O	1903-1908
signatures	O	1909-1919
to	O	1920-1922
clinical	O	1923-1931
scenarios	O	1932-1941
,	O	1941-1942
such	O	1943-1947
as	O	1948-1950
initial	O	1951-1958
BC	O	1959-1961
detection	O	1962-1971
and	O	1972-1975
BC	O	1976-1978
surveillance	O	1979-1991
.	O	1991-1992

MicroRNA	O	0-8
profiling	O	9-18
of	O	19-21
Epstein	O	22-29
-	O	29-30
Barr	O	30-34
virus	O	35-40
-	O	40-41
associated	O	41-51
NK	O	52-54
/	O	54-55
T	O	55-56
-	O	56-57
cell	O	57-61
lymphomas	O	62-71
by	O	72-74
deep	O	75-79
sequencing	O	80-90
.	O	90-91

The	O	92-95
Epstein	O	96-103
-	O	103-104
Barr	O	104-108
virus	O	109-114
(	O	115-116
EBV	O	116-119
)	O	119-120
is	O	121-123
an	O	124-126
oncogenic	O	127-136
human	O	137-142
Herpes	O	143-149
virus	O	150-155
involved	O	156-164
in	O	165-167
the	O	168-171
pathogenesis	O	172-184
of	O	185-187
nasal	O	188-193
NK	O	194-196
/	O	196-197
T	O	197-198
-	O	198-199
cell	O	199-203
lymphoma	O	204-212
.	O	212-213

EBV	O	214-217
encodes	O	218-225
microRNAs	O	226-235
(	O	236-237
miRNAs	O	237-243
)	O	243-244
and	O	245-248
induces	O	249-256
changes	O	257-264
in	O	265-267
the	O	268-271
host	O	272-276
cellular	O	277-285
miRNA	O	286-291
profile	O	292-299
.	O	299-300

MiRNAs	O	301-307
are	O	308-311
short	O	312-317
non	O	318-321
-	O	321-322
coding	O	322-328
RNAs	O	329-333
of	O	334-336
about	O	337-342
19	O	343-345
-	O	345-346
25	O	346-348
nt	O	349-351
length	O	352-358
that	O	359-363
regulate	O	364-372
gene	O	373-377
expression	O	378-388
by	O	389-391
post	O	392-396
-	O	396-397
transcriptional	O	397-412
mechanisms	O	413-423
and	O	424-427
are	O	428-431
frequently	O	432-442
deregulated	O	443-454
in	O	455-457
human	O	458-463
malignancies	O	464-476
including	O	477-486
cancer	O	487-493
.	O	493-494

The	O	495-498
microRNA	O	499-507
profiles	O	508-516
of	O	517-519
EBV	O	520-523
-	O	523-524
positive	O	524-532
NK	O	533-535
/	O	535-536
T	O	536-537
-	O	537-538
cell	O	538-542
lymphoma	O	543-551
,	O	551-552
non	O	553-556
-	O	556-557
infected	O	557-565
T	O	566-567
-	O	567-568
cell	O	568-572
lymphoma	O	573-581
and	O	582-585
normal	O	586-592
thymus	O	593-599
were	O	600-604
established	O	605-616
by	O	617-619
deep	O	620-624
sequencing	O	625-635
of	O	636-638
small	O	639-644
RNA	O	645-648
libraries	O	649-658
.	O	658-659

The	O	660-663
comparison	O	664-674
of	O	675-677
the	O	678-681
EBV	O	682-685
-	O	685-686
positive	O	686-694
NK	O	695-697
/	O	697-698
T	O	698-699
-	O	699-700
cell	O	700-704
vs	O	705-707
.	O	707-708
EBV	O	709-712
-	O	712-713
negative	O	713-721
T	O	722-723
-	O	723-724
cell	O	724-728
lymphoma	O	729-737
revealed	O	738-746
15	O	747-749
up	O	750-752
-	O	752-753
und	O	754-757
16	O	758-760
down	O	761-765
-	O	765-766
regulated	O	766-775
miRNAs	O	776-782
.	O	782-783

In	O	784-786
contrast	O	787-795
,	O	795-796
the	O	797-800
majority	O	801-809
of	O	810-812
miRNAs	O	813-819
was	O	820-823
repressed	O	824-833
in	O	834-836
the	O	837-840
lymphomas	O	841-850
compared	O	851-859
to	O	860-862
normal	O	863-869
tissue	O	870-876
.	O	876-877

We	O	878-880
also	O	881-885
identified	O	886-896
10	O	897-899
novel	O	900-905
miRNAs	O	906-912
from	O	913-917
known	O	918-923
precursors	O	924-934
and	O	935-938
two	O	939-942
so	O	943-945
far	O	946-949
unknown	O	950-957
miRNAs	O	958-964
.	O	964-965

The	O	966-969
sequencing	O	970-980
results	O	981-988
were	O	989-993
confirmed	O	994-1003
for	O	1004-1007
selected	O	1008-1016
miRNAs	O	1017-1023
by	O	1024-1026
quantitative	O	1027-1039
Real	O	1040-1044
-	O	1044-1045
Time	O	1045-1049
PCR	O	1050-1053
(	O	1054-1055
qRT	O	1055-1058
-	O	1058-1059
PCR	O	1059-1062
)	O	1062-1063
.	O	1063-1064

We	O	1065-1067
show	O	1068-1072
that	O	1073-1077
the	O	1078-1081
proinflammatory	O	1082-1097
cytokine	O	1098-1106
interleukin	O	1107-1118
1	O	1119-1120
alpha	O	1121-1126
(	O	1127-1128
IL1A	O	1128-1132
)	O	1132-1133
is	O	1134-1136
a	O	1137-1138
target	O	1139-1145
for	O	1146-1149
miR	B	1150-1153
-	I	1153-1154
142	I	1154-1157
-	I	1157-1158
3p	I	1158-1160
and	O	1161-1164
the	O	1165-1168
oncogenic	O	1169-1178
BCL6	O	1179-1183
for	O	1184-1187
miR	B	1188-1191
-	I	1191-1192
205	I	1192-1195
.	O	1195-1196

MiR	B	1197-1200
-	I	1200-1201
142	I	1201-1204
-	I	1204-1205
3p	I	1205-1207
is	O	1208-1210
down	O	1211-1215
-	O	1215-1216
regulated	O	1216-1225
in	O	1226-1228
the	O	1229-1232
EBV	O	1233-1236
-	O	1236-1237
positive	O	1237-1245
vs	O	1246-1248
.	O	1248-1249
EBV	O	1250-1253
-	O	1253-1254
negative	O	1254-1262
lymphomas	O	1263-1272
.	O	1272-1273

MiR	B	1274-1277
-	I	1277-1278
205	I	1278-1281
was	O	1282-1285
undetectable	O	1286-1298
in	O	1299-1301
EBV	O	1302-1305
-	O	1305-1306
negative	O	1306-1314
lymphoma	O	1315-1323
and	O	1324-1327
strongly	O	1328-1336
down	O	1337-1341
-	O	1341-1342
regulated	O	1342-1351
in	O	1352-1354
EBV	O	1355-1358
-	O	1358-1359
positive	O	1359-1367
NK	O	1368-1370
/	O	1370-1371
T	O	1371-1372
-	O	1372-1373
cell	O	1373-1377
lymphoma	O	1378-1386
as	O	1387-1389
compared	O	1390-1398
to	O	1399-1401
thymus	O	1402-1408
.	O	1408-1409

The	O	1410-1413
targets	O	1414-1421
were	O	1422-1426
confirmed	O	1427-1436
by	O	1437-1439
reporter	O	1440-1448
assays	O	1449-1455
and	O	1456-1459
by	O	1460-1462
down	O	1463-1467
-	O	1467-1468
regulation	O	1468-1478
of	O	1479-1481
the	O	1482-1485
proteins	O	1486-1494
by	O	1495-1497
ectopic	O	1498-1505
expression	O	1506-1516
of	O	1517-1519
the	O	1520-1523
cognate	O	1524-1531
miRNAs	O	1532-1538
.	O	1538-1539

Taken	O	1540-1545
together	O	1546-1554
,	O	1554-1555
our	O	1556-1559
findings	O	1560-1568
demonstrate	O	1569-1580
the	O	1581-1584
relevance	O	1585-1594
of	O	1595-1597
deregulated	O	1598-1609
miRNAs	O	1610-1616
for	O	1617-1620
the	O	1621-1624
post	O	1625-1629
-	O	1629-1630
transcriptional	O	1630-1645
gene	O	1646-1650
regulation	O	1651-1661
in	O	1662-1664
nasal	O	1665-1670
NK	O	1671-1673
/	O	1673-1674
T	O	1674-1675
-	O	1675-1676
cell	O	1676-1680
lymphomas	O	1681-1690
.	O	1690-1691

miRNA	B	0-5
-	I	5-6
146a	I	6-10
expression	O	11-21
positively	O	22-32
regulates	O	33-42
tumor	O	43-48
necrosis	O	49-57
factor	O	58-64
-	O	64-65
alpha	O	65-70
-	O	70-71
induced	O	71-78
interleukin	O	79-90
-	O	90-91
8	O	91-92
production	O	93-103
in	O	104-106
mesenchymal	O	107-118
stem	O	119-123
cells	O	124-129
and	O	130-133
differentiated	O	134-148
lung	O	149-153
epithelial	O	154-164
-	O	164-165
like	O	165-169
cells	O	170-175
.	O	175-176

Bone	O	177-181
marrow	O	182-188
-	O	188-189
derived	O	189-196
mesenchymal	O	197-208
stem	O	209-213
cells	O	214-219
(	O	220-221
BM	O	221-223
-	O	223-224
MSC	O	224-227
)	O	227-228
can	O	229-232
be	O	233-235
differentiated	O	236-250
into	O	251-255
lung	O	256-260
epithelial	O	261-271
-	O	271-272
like	O	272-276
cells	O	277-282
(	O	283-284
MSC	O	284-287
-	O	287-288
EC	O	288-290
)	O	290-291
in	O	292-294
vitro	O	295-300
.	O	300-301

The	O	302-305
response	O	306-314
of	O	315-317
BM	O	318-320
-	O	320-321
MSC	O	321-324
and	O	325-328
MSC	O	329-332
-	O	332-333
EC	O	333-335
to	O	336-338
stimuli	O	339-346
may	O	347-350
vary	O	351-355
because	O	356-363
of	O	364-366
their	O	367-372
character	O	373-382
and	O	383-386
differentiation	O	387-402
.	O	402-403

We	O	404-406
aimed	O	407-412
to	O	413-415
investigate	O	416-427
the	O	428-431
factors	O	432-439
that	O	440-444
may	O	445-448
influence	O	449-458
in	O	459-461
vitro	O	462-467
differentiation	O	468-483
of	O	484-486
BM	O	487-489
-	O	489-490
MSC	O	490-493
to	O	494-496
MSC	O	497-500
-	O	500-501
EC	O	501-503
.	O	503-504

We	O	505-507
determined	O	508-518
the	O	519-522
response	O	523-531
of	O	532-534
BM	O	535-537
-	O	537-538
MSC	O	538-541
,	O	541-542
MSC	O	543-546
-	O	546-547
EC	O	547-549
,	O	549-550
bronchial	O	551-560
epithelial	O	561-571
cells	O	572-577
,	O	577-578
and	O	579-582
alveolar	O	583-591
epithelial	O	592-602
cells	O	603-608
to	O	609-611
tumor	O	612-617
necrosis	O	618-626
factor	O	627-633
(	O	634-635
TNF	O	635-638
)	O	638-639
-	O	639-640
alpha	O	640-645
stimulation	O	646-657
.	O	657-658

We	O	659-661
also	O	662-666
investigated	O	667-679
the	O	680-683
changes	O	684-691
in	O	692-694
micro	B	695-700
(	I	700-701
mi	I	701-703
)	I	703-704
RNA	I	704-707
-	I	707-708
146a	I	708-712
,	O	712-713
miRNA	B	714-719
-	I	719-720
155	I	720-723
,	O	723-724
and	O	725-728
TNF	O	729-732
receptor	O	733-741
1	O	742-743
(	O	744-745
TNFR1	O	745-750
)	O	750-751
expression	O	752-762
after	O	763-768
stimulation	O	769-780
.	O	780-781

Our	O	782-785
results	O	786-793
demonstrate	O	794-805
that	O	806-810
the	O	811-814
addition	O	815-823
of	O	824-826
transforming	O	827-839
growth	O	840-846
factor	O	847-853
-	O	853-854
beta	O	854-858
(	O	858-859
1	O	859-860
)	O	860-861
and	O	862-865
extracellular	O	866-879
matrix	O	880-886
collagen	O	887-895
are	O	896-899
required	O	900-908
to	O	909-911
facilitate	O	912-922
such	O	923-927
differentiation	O	928-943
.	O	943-944

After	O	945-950
3	O	951-952
weeks	O	953-958
of	O	959-961
culture	O	962-969
,	O	969-970
the	O	971-974
morphological	O	975-988
appearance	O	989-999
and	O	1000-1003
expression	O	1004-1014
of	O	1015-1017
airway	O	1018-1024
epithelial	O	1025-1035
markers	O	1036-1043
,	O	1043-1044
cytokeratin	O	1045-1056
and	O	1057-1060
Clara	O	1061-1066
cell	O	1067-1071
secretory	O	1072-1081
protein	O	1082-1089
,	O	1089-1090
in	O	1091-1093
MSC	O	1094-1097
-	O	1097-1098
EC	O	1098-1100
were	O	1101-1105
characteristics	O	1106-1121
of	O	1122-1124
lung	O	1125-1129
epithelial	O	1130-1140
cells	O	1141-1146
.	O	1146-1147

In	O	1148-1150
response	O	1151-1159
to	O	1160-1162
TNF	O	1163-1166
-	O	1166-1167
alpha	O	1167-1172
stimulation	O	1173-1184
,	O	1184-1185
the	O	1186-1189
maximal	O	1190-1197
interleukin	O	1198-1209
(	O	1210-1211
IL	O	1211-1213
)	O	1213-1214
-	O	1214-1215
8	O	1215-1216
production	O	1217-1227
by	O	1228-1230
BM	O	1231-1233
-	O	1233-1234
MSC	O	1234-1237
at	O	1238-1240
the	O	1241-1244
24	O	1245-1247
-	O	1247-1248
h	O	1248-1249
time	O	1250-1254
point	O	1255-1260
was	O	1261-1264
4	O	1265-1266
.	O	1266-1267
8	O	1267-1268
times	O	1269-1274
greater	O	1275-1282
compared	O	1283-1291
with	O	1292-1296
MSC	O	1297-1300
-	O	1300-1301
EC	O	1301-1303
.	O	1303-1304

TNF	O	1305-1308
-	O	1308-1309
alpha	O	1309-1314
induced	O	1315-1322
a	O	1323-1324
significant	O	1325-1336
increase	O	1337-1345
in	O	1346-1348
the	O	1349-1352
expression	O	1353-1363
of	O	1364-1366
miRNA	B	1367-1372
-	I	1372-1373
146a	I	1373-1377
in	O	1378-1380
BM	O	1381-1383
-	O	1383-1384
MSC	O	1384-1387
as	O	1388-1390
compared	O	1391-1399
with	O	1400-1404
MSC	O	1405-1408
-	O	1408-1409
EC	O	1409-1411
.	O	1411-1412

miRNA	B	1413-1418
-	I	1418-1419
155	I	1419-1422
expression	O	1423-1433
remained	O	1434-1442
unchanged	O	1443-1452
after	O	1453-1458
stimulation	O	1459-1470
.	O	1470-1471

TNFR1	O	1472-1477
mRNA	O	1478-1482
also	O	1483-1487
significantly	O	1488-1501
increased	O	1502-1511
in	O	1512-1514
BM	O	1515-1517
-	O	1517-1518
MSC	O	1518-1521
after	O	1522-1527
TNF	O	1528-1531
-	O	1531-1532
alpha	O	1532-1537
stimulation	O	1538-1549
.	O	1549-1550

This	O	1551-1555
was	O	1556-1559
not	O	1560-1563
observed	O	1564-1572
in	O	1573-1575
MSC	O	1576-1579
-	O	1579-1580
EC	O	1580-1582
.	O	1582-1583

Transfection	O	1584-1596
with	O	1597-1601
miRNA	B	1602-1607
-	I	1607-1608
146a	I	1608-1612
mimics	O	1613-1619
resulted	O	1620-1628
in	O	1629-1631
a	O	1632-1633
significant	O	1634-1645
increase	O	1646-1654
of	O	1655-1657
miRNA	B	1658-1663
-	I	1663-1664
146a	I	1664-1668
expression	O	1669-1679
and	O	1680-1683
IL	O	1684-1686
-	O	1686-1687
8	O	1687-1688
production	O	1689-1699
in	O	1700-1702
both	O	1703-1707
types	O	1708-1713
of	O	1714-1716
cells	O	1717-1722
.	O	1722-1723

In	O	1724-1726
contrast	O	1727-1735
,	O	1735-1736
miRNA	B	1737-1742
-	I	1742-1743
146a	I	1743-1747
inhibitors	O	1748-1758
reduced	O	1759-1766
miRNA	B	1767-1772
-	I	1772-1773
146a	I	1773-1777
expression	O	1778-1788
and	O	1789-1792
IL	O	1793-1795
-	O	1795-1796
8	O	1796-1797
production	O	1798-1808
.	O	1808-1809

Overexpression	O	1810-1824
of	O	1825-1827
miRNA	B	1828-1833
-	I	1833-1834
146a	I	1834-1838
,	O	1838-1839
which	O	1840-1845
positively	O	1846-1856
regulates	O	1857-1866
TNF	O	1867-1870
-	O	1870-1871
alpha	O	1871-1876
-	O	1876-1877
induced	O	1877-1884
IL	O	1885-1887
-	O	1887-1888
8	O	1888-1889
release	O	1890-1897
,	O	1897-1898
may	O	1899-1902
enhance	O	1903-1910
the	O	1911-1914
inflammatory	O	1915-1927
response	O	1928-1936
in	O	1937-1939
both	O	1940-1944
BM	O	1945-1947
-	O	1947-1948
MSC	O	1948-1951
and	O	1952-1955
MSC	O	1956-1959
-	O	1959-1960
EC	O	1960-1962
.	O	1962-1963

The	O	1964-1967
expression	O	1968-1978
of	O	1979-1981
miRNA	B	1982-1987
-	I	1987-1988
146a	I	1988-1992
and	O	1993-1996
the	O	1997-2000
response	O	2001-2009
to	O	2010-2012
stimuli	O	2013-2020
may	O	2021-2024
be	O	2025-2027
modulated	O	2028-2037
through	O	2038-2045
mature	O	2046-2052
differentiation	O	2053-2068
of	O	2069-2071
BM	O	2072-2074
-	O	2074-2075
MSC	O	2075-2078
.	O	2078-2079

Identification	O	0-14
of	O	15-17
miR	B	18-21
-	I	21-22
145	I	22-25
as	O	26-28
a	O	29-30
key	O	31-34
regulator	O	35-44
of	O	45-47
the	O	48-51
pigmentary	O	52-62
process	O	63-70
.	O	70-71

The	O	72-75
current	O	76-83
treatments	O	84-94
for	O	95-98
hyperpigmentation	O	99-116
are	O	117-120
often	O	121-126
associated	O	127-137
with	O	138-142
a	O	143-144
lack	O	145-149
of	O	150-152
efficacy	O	153-161
and	O	162-165
adverse	O	166-173
side	O	174-178
effects	O	179-186
.	O	186-187

We	O	188-190
hypothesized	O	191-203
that	O	204-208
microRNA	O	209-217
(	O	218-219
miRNA	O	219-224
)	O	224-225
-	O	225-226
based	O	226-231
treatments	O	232-242
may	O	243-246
offer	O	247-252
an	O	253-255
attractive	O	256-266
alternative	O	267-278
by	O	279-281
specifically	O	282-294
targeting	O	295-304
key	O	305-308
genes	O	309-314
in	O	315-317
melanogenesis	O	318-331
.	O	331-332

The	O	333-336
aim	O	337-340
of	O	341-343
this	O	344-348
study	O	349-354
was	O	355-358
to	O	359-361
identify	O	362-370
miRNAs	O	371-377
interfering	O	378-389
with	O	390-394
the	O	395-398
pigmentary	O	399-409
process	O	410-417
and	O	418-421
to	O	422-424
assess	O	425-431
their	O	432-437
functional	O	438-448
role	O	449-453
.	O	453-454

miRNA	O	455-460
profiling	O	461-470
was	O	471-474
performed	O	475-484
on	O	485-487
mouse	O	488-493
melanocytes	O	494-505
after	O	506-511
three	O	512-517
consecutive	O	518-529
treatments	O	530-540
involving	O	541-550
forskolin	O	551-560
and	O	561-564
solar	O	565-570
-	O	570-571
simulated	O	571-580
UV	O	581-583
(	O	584-585
ssUV	O	585-589
)	O	589-590
irradiation	O	591-602
.	O	602-603

Sixteen	O	604-611
miRNAs	O	612-618
were	O	619-623
identified	O	624-634
as	O	635-637
differentially	O	638-652
expressed	O	653-662
in	O	663-665
treated	O	666-673
melan	O	674-679
-	O	679-680
a	O	680-681
cells	O	682-687
versus	O	688-694
untreated	O	695-704
cells	O	705-710
.	O	710-711

Remarkably	O	712-722
,	O	722-723
a	O	724-725
15	O	726-728
-	O	728-729
fold	O	729-733
downregulation	O	734-748
of	O	749-751
miR	B	752-755
-	I	755-756
145	I	756-759
was	O	760-763
detected	O	764-772
.	O	772-773

Overexpression	O	774-788
or	O	789-791
downregulation	O	792-806
of	O	807-809
miR	B	810-813
-	I	813-814
145	I	814-817
in	O	818-820
melan	O	821-826
-	O	826-827
a	O	827-828
cells	O	829-834
revealed	O	835-843
reduced	O	844-851
or	O	852-854
increased	O	855-864
expression	O	865-875
of	O	876-878
Sox9	O	879-883
,	O	883-884
Mitf	O	885-889
,	O	889-890
Tyr	O	891-894
,	O	894-895
Trp1	O	896-900
,	O	900-901
Myo5a	O	902-907
,	O	907-908
Rab27a	O	909-915
,	O	915-916
and	O	917-920
Fscn1	O	921-926
,	O	926-927
respectively	O	928-940
.	O	940-941

Moreover	O	942-950
,	O	950-951
a	O	952-953
luciferase	O	954-964
reporter	O	965-973
assay	O	974-979
demonstrated	O	980-992
direct	O	993-999
targeting	O	1000-1009
of	O	1010-1012
Myo5a	O	1013-1018
by	O	1019-1021
miR	B	1022-1025
-	I	1025-1026
145	I	1026-1029
in	O	1030-1032
mouse	O	1033-1038
and	O	1039-1042
human	O	1043-1048
melanocytes	O	1049-1060
.	O	1060-1061

Immunofluorescence	O	1062-1080
tagging	O	1081-1088
of	O	1089-1091
melanosomes	O	1092-1103
in	O	1104-1106
miR	B	1107-1110
-	I	1110-1111
145	I	1111-1114
-	O	1114-1115
transfected	O	1115-1126
human	O	1127-1132
melanocytes	O	1133-1144
displayed	O	1145-1154
perinuclear	O	1155-1166
accumulation	O	1167-1179
of	O	1180-1182
melanosomes	O	1183-1194
with	O	1195-1199
additional	O	1200-1210
hypopigmentation	O	1211-1227
of	O	1228-1230
harvested	O	1231-1240
cell	O	1241-1245
pellets	O	1246-1253
.	O	1253-1254

In	O	1255-1257
conclusion	O	1258-1268
,	O	1268-1269
this	O	1270-1274
study	O	1275-1280
has	O	1281-1284
established	O	1285-1296
an	O	1297-1299
miRNA	O	1300-1305
signature	O	1306-1315
associated	O	1316-1326
with	O	1327-1331
forskolin	O	1332-1341
and	O	1342-1345
ssUV	O	1346-1350
treatment	O	1351-1360
.	O	1360-1361

The	O	1362-1365
significant	O	1366-1377
down	O	1378-1382
-	O	1382-1383
or	O	1384-1386
upregulation	O	1387-1399
of	O	1400-1402
major	O	1403-1408
pigmentation	O	1409-1421
genes	O	1422-1427
,	O	1427-1428
after	O	1429-1434
modulating	O	1435-1445
miR	B	1446-1449
-	I	1449-1450
145	I	1450-1453
expression	O	1454-1464
,	O	1464-1465
suggests	O	1466-1474
a	O	1475-1476
key	O	1477-1480
role	O	1481-1485
for	O	1486-1489
miR	B	1490-1493
-	I	1493-1494
145	I	1494-1497
in	O	1498-1500
regulating	O	1501-1511
melanogenesis	O	1512-1525
.	O	1525-1526

CDA	O	0-3
-	O	3-4
2	O	4-5
induces	O	6-13
cell	O	14-18
differentiation	O	19-34
through	O	35-42
suppressing	O	43-54
Twist	O	55-60
/	O	60-61
SLUG	O	61-65
signaling	O	66-75
via	O	76-79
miR	B	80-83
-	I	83-84
124	I	84-87
in	O	88-90
glioma	O	91-97
.	O	97-98

Cell	O	99-103
differentiation	O	104-119
agent	O	120-125
-	O	125-126
2	O	126-127
(	O	128-129
CDA	O	129-132
-	O	132-133
2	O	133-134
)	O	134-135
is	O	136-138
an	O	139-141
extraction	O	142-152
from	O	153-157
healthy	O	158-165
human	O	166-171
urine	O	172-177
consisting	O	178-188
of	O	189-191
primary	O	192-199
organic	O	200-207
acids	O	208-213
and	O	214-217
peptides	O	218-226
,	O	226-227
and	O	228-231
it	O	232-234
has	O	235-238
been	O	239-243
demonstrated	O	244-256
to	O	257-259
inhibit	O	260-267
growth	O	268-274
and	O	275-278
induce	O	279-285
differentiation	O	286-301
in	O	302-304
glioma	O	305-311
and	O	312-315
other	O	316-321
cell	O	322-326
lines	O	327-332
.	O	332-333

But	O	334-337
the	O	338-341
mechanism	O	342-351
of	O	352-354
CDA	O	355-358
-	O	358-359
2	O	359-360
remains	O	361-368
unclear	O	369-376
.	O	376-377

In	O	378-380
this	O	381-385
study	O	386-391
,	O	391-392
we	O	393-395
demonstrated	O	396-408
that	O	409-413
CDA	O	414-417
-	O	417-418
2	O	418-419
inhibited	O	420-429
cell	O	430-434
growth	O	435-441
and	O	442-445
induced	O	446-453
differentiation	O	454-469
of	O	470-472
glioma	O	473-479
cells	O	480-485
,	O	485-486
accompanied	O	487-498
with	O	499-503
decreased	O	504-513
expression	O	514-524
of	O	525-527
SLUG	O	528-532
,	O	532-533
Twist	O	534-539
and	O	540-543
Vimentin	O	544-552
in	O	553-555
both	O	556-560
SWO	O	561-564
-	O	564-565
38	O	565-567
and	O	568-571
U251	O	572-576
cell	O	577-581
lines	O	582-587
.	O	587-588

Overexpression	O	589-603
of	O	604-606
SLUG	O	607-611
or	O	612-614
Twist	O	615-620
greatly	O	621-628
eliminated	O	629-639
the	O	640-643
efficiency	O	644-654
of	O	655-657
CDA	O	658-661
-	O	661-662
2	O	662-663
in	O	664-666
inducing	O	667-675
differentiation	O	676-691
.	O	691-692

Further	O	693-700
study	O	701-706
showed	O	707-713
that	O	714-718
CDA	O	719-722
-	O	722-723
2	O	723-724
treatment	O	725-734
resulted	O	735-743
in	O	744-746
great	O	747-752
changed	O	753-760
microRNAs	O	761-770
(	O	771-772
miRNAs	O	772-778
)	O	778-779
detected	O	780-788
by	O	789-791
quantitative	O	792-804
PCR	O	805-808
,	O	808-809
in	O	810-812
which	O	813-818
miR	B	819-822
-	I	822-823
124	I	823-826
was	O	827-830
one	O	831-834
of	O	835-837
the	O	838-841
most	O	842-846
changed	O	847-854
miRNAs	O	855-861
and	O	862-865
its	O	866-869
level	O	870-875
was	O	876-879
increased	O	880-889
by	O	890-892
fourfold	O	893-901
.	O	901-902

The	O	903-906
result	O	907-913
of	O	914-916
miRNA	O	917-922
target	O	923-929
prediction	O	930-940
showed	O	941-947
that	O	948-952
miR	B	953-956
-	I	956-957
124	I	957-960
could	O	961-966
regulate	O	967-975
hundreds	O	976-984
of	O	985-987
genes	O	988-993
which	O	994-999
were	O	1000-1004
relative	O	1005-1013
to	O	1014-1016
cell	O	1017-1021
differentiation	O	1022-1037
,	O	1037-1038
such	O	1039-1043
as	O	1044-1046
SLUG	O	1047-1051
,	O	1051-1052
Vimentin	O	1053-1061
,	O	1061-1062
actin	O	1063-1068
cytoskeleton	O	1069-1081
,	O	1081-1082
focal	O	1083-1088
adhesion	O	1089-1097
,	O	1097-1098
tight	O	1099-1104
junction	O	1105-1113
.	O	1113-1114

Inhibition	O	1115-1125
of	O	1126-1128
miR	B	1129-1132
-	I	1132-1133
124	I	1133-1136
up	O	1137-1139
-	O	1139-1140
regulated	O	1140-1149
SLUG	O	1150-1154
,	O	1154-1155
Twist	O	1156-1161
and	O	1162-1165
Vimentin	O	1166-1174
proteins	O	1175-1183
,	O	1183-1184
and	O	1185-1188
partly	O	1189-1195
eliminated	O	1196-1206
the	O	1207-1210
function	O	1211-1219
of	O	1220-1222
CDA	O	1223-1226
-	O	1226-1227
2	O	1227-1228
on	O	1229-1231
these	O	1232-1237
mesenchymal	O	1238-1249
markers	O	1250-1257
.	O	1257-1258

Our	O	1259-1262
findings	O	1263-1271
demonstrated	O	1272-1284
for	O	1285-1288
the	O	1289-1292
first	O	1293-1298
time	O	1299-1303
that	O	1304-1308
CDA	O	1309-1312
-	O	1312-1313
2	O	1313-1314
induced	O	1315-1322
cell	O	1323-1327
differentiation	O	1328-1343
through	O	1344-1351
suppressing	O	1352-1363
Twist	O	1364-1369
and	O	1370-1373
SLUG	O	1374-1378
via	O	1379-1382
miR	B	1383-1386
-	I	1386-1387
124	I	1387-1390
in	O	1391-1393
glioma	O	1394-1400
cells	O	1401-1406
.	O	1406-1407

MicroRNA	B	0-8
-	I	8-9
130b	I	9-13
and	O	14-17
microRNA	B	18-26
-	I	26-27
374b	I	27-31
mediate	O	32-39
the	O	40-43
effect	O	44-50
of	O	51-53
maternal	O	54-62
dietary	O	63-70
protein	O	71-78
on	O	79-81
offspring	O	82-91
lipid	O	92-97
metabolism	O	98-108
in	O	109-111
Meishan	O	112-119
pigs	O	120-124
.	O	124-125

To	O	126-128
investigate	O	129-140
whether	O	141-148
the	O	149-152
effect	O	153-159
of	O	160-162
maternal	O	163-171
dietary	O	172-179
protein	O	180-187
on	O	188-190
offspring	O	191-200
lipid	O	201-206
metabolism	O	207-217
is	O	218-220
mediated	O	221-229
by	O	230-232
microRNA	O	233-241
(	O	242-243
miRNA	O	243-248
)	O	248-249
,	O	249-250
fourteen	O	251-259
Meishan	O	260-267
sows	O	268-272
were	O	273-277
fed	O	278-281
either	O	282-288
low	O	289-292
-	O	292-293
protein	O	293-300
(	O	301-302
LP	O	302-304
,	O	304-305
half	O	306-310
of	O	311-313
standard	O	314-322
protein	O	323-330
(	O	331-332
SP	O	332-334
)	O	334-335
level	O	336-341
,	O	341-342
n	O	343-344
7	O	345-346
)	O	346-347
or	O	348-350
SP	O	351-353
(	O	354-355
n	O	355-356
7	O	357-358
)	O	358-359
diets	O	360-365
throughout	O	366-376
gestation	O	377-386
and	O	387-390
lactation	O	391-400
periods	O	401-408
.	O	408-409

PPAR	O	410-414
-	O	414-415
gamma	O	415-420
and	O	421-424
CCAAT	O	425-430
/	O	430-431
enhancer	O	431-439
-	O	439-440
binding	O	440-447
protein	O	448-455
-	O	455-456
beta	O	456-460
(	O	461-462
C	O	462-463
/	O	463-464
EBP	O	464-467
-	O	467-468
beta	O	468-472
)	O	472-473
protein	O	474-481
expression	O	482-492
was	O	493-496
evaluated	O	497-506
.	O	506-507

The	O	508-511
expression	O	512-522
of	O	523-525
miRNA	O	526-531
predicted	O	532-541
to	O	542-544
directly	O	545-553
target	O	554-560
PPAR	O	561-565
-	O	565-566
gamma	O	566-571
and	O	572-575
C	O	576-577
/	O	577-578
EBP	O	578-581
-	O	581-582
beta	O	582-586
in	O	587-589
the	O	590-593
subcutaneous	O	594-606
fat	O	607-610
of	O	611-613
offspring	O	614-623
at	O	624-626
weaning	O	627-634
age	O	635-638
was	O	639-642
determined	O	643-653
,	O	653-654
and	O	655-658
the	O	659-662
functions	O	663-672
of	O	673-675
these	O	676-681
potential	O	682-691
miRNA	O	692-697
were	O	698-702
verified	O	703-711
.	O	711-712

The	O	713-716
results	O	717-724
showed	O	725-731
that	O	732-736
piglet	O	737-743
body	O	744-748
weight	O	749-755
and	O	756-759
back	O	760-764
fat	O	765-768
thickness	O	769-778
were	O	779-783
significantly	O	784-797
decreased	O	798-807
in	O	808-810
the	O	811-814
LP	O	815-817
group	O	818-823
compared	O	824-832
with	O	833-837
the	O	838-841
SP	O	842-844
group	O	845-850
(	O	851-852
P	O	852-853
<	O	853-854
0	O	854-855
.	O	855-856
05	O	856-858
)	O	858-859
.	O	859-860

The	O	861-864
protein	O	865-872
level	O	873-878
of	O	879-881
PPAR	O	882-886
-	O	886-887
gamma	O	887-892
was	O	893-896
significantly	O	897-910
decreased	O	911-920
and	O	921-924
C	O	925-926
/	O	926-927
EBP	O	927-930
-	O	930-931
beta	O	931-935
protein	O	936-943
expression	O	944-954
was	O	955-958
also	O	959-963
decreased	O	964-973
,	O	973-974
though	O	975-981
not	O	982-985
significantly	O	986-999
(	O	1000-1001
P	O	1001-1002
=	O	1002-1003
0	O	1003-1004
.	O	1004-1005
056	O	1005-1008
)	O	1008-1009
,	O	1009-1010
in	O	1011-1013
the	O	1014-1017
subcutaneous	O	1018-1030
fat	O	1031-1034
of	O	1035-1037
the	O	1038-1041
LP	O	1042-1044
group	O	1045-1050
.	O	1050-1051

Furthermore	O	1052-1063
,	O	1063-1064
miRNA	O	1065-1070
expression	O	1071-1081
analysis	O	1082-1090
showed	O	1091-1097
that	O	1098-1102
miR	B	1103-1106
-	I	1106-1107
130b	I	1107-1111
,	O	1111-1112
targeting	O	1113-1122
the	O	1123-1126
PPAR	O	1127-1131
-	O	1131-1132
gamma	O	1132-1137
3	O	1138-1139
'	O	1139-1140
-	O	1140-1141
untranslated	O	1141-1153
region	O	1154-1160
(	O	1161-1162
UTR	O	1162-1165
)	O	1165-1166
,	O	1166-1167
and	O	1168-1171
miR	B	1172-1175
-	I	1175-1176
374b	I	1176-1180
,	O	1180-1181
targeting	O	1182-1191
the	O	1192-1195
C	O	1196-1197
/	O	1197-1198
EBP	O	1198-1201
-	O	1201-1202
beta	O	1202-1206
3	O	1207-1208
'	O	1208-1209
-	O	1209-1210
UTR	O	1210-1213
,	O	1213-1214
were	O	1215-1219
significantly	O	1220-1233
increased	O	1234-1243
in	O	1244-1246
the	O	1247-1250
LP	O	1251-1253
group	O	1254-1259
compared	O	1260-1268
with	O	1269-1273
the	O	1274-1277
SP	O	1278-1280
group	O	1281-1286
;	O	1286-1287
other	O	1288-1293
candidate	O	1294-1303
regulatory	O	1304-1314
miRNA	O	1315-1320
were	O	1321-1325
expressed	O	1326-1335
similarly	O	1336-1345
in	O	1346-1348
both	O	1349-1353
groups	O	1354-1360
.	O	1360-1361

Dual	O	1362-1366
luciferase	O	1367-1377
activity	O	1378-1386
assay	O	1387-1392
results	O	1393-1400
indicated	O	1401-1410
that	O	1411-1415
miR	B	1416-1419
-	I	1419-1420
130b	I	1420-1424
directly	O	1425-1433
recognised	O	1434-1444
and	O	1445-1448
bound	O	1449-1454
to	O	1455-1457
the	O	1458-1461
3	O	1462-1463
'	O	1463-1464
-	O	1464-1465
UTR	O	1465-1468
of	O	1469-1471
PPAR	O	1472-1476
-	O	1476-1477
gamma	O	1477-1482
and	O	1483-1486
thereby	O	1487-1494
suppressed	O	1495-1505
PPAR	O	1506-1510
-	O	1510-1511
gamma	O	1511-1516
gene	O	1517-1521
expression	O	1522-1532
.	O	1532-1533

Similar	O	1534-1541
results	O	1542-1549
were	O	1550-1554
found	O	1555-1560
for	O	1561-1564
miR	B	1565-1568
-	I	1568-1569
374b	I	1569-1573
and	O	1574-1577
the	O	1578-1581
3	O	1582-1583
'	O	1583-1584
-	O	1584-1585
UTR	O	1585-1588
of	O	1589-1591
C	O	1592-1593
/	O	1593-1594
EBP	O	1594-1597
-	O	1597-1598
beta	O	1598-1602
.	O	1602-1603

The	O	1604-1607
present	O	1608-1615
study	O	1616-1621
showed	O	1622-1628
that	O	1629-1633
miR	B	1634-1637
-	I	1637-1638
130b	I	1638-1642
and	O	1643-1646
miR	B	1647-1650
-	I	1650-1651
374b	I	1651-1655
are	O	1656-1659
involved	O	1660-1668
in	O	1669-1671
the	O	1672-1675
effect	O	1676-1682
of	O	1683-1685
maternal	O	1686-1694
dietary	O	1695-1702
protein	O	1703-1710
on	O	1711-1713
offspring	O	1714-1723
lipid	O	1724-1729
metabolism	O	1730-1740
in	O	1741-1743
pigs	O	1744-1748
.	O	1748-1749

These	O	1750-1755
results	O	1756-1763
shed	O	1764-1768
new	O	1769-1772
light	O	1773-1778
on	O	1779-1781
our	O	1782-1785
understanding	O	1786-1799
of	O	1800-1802
the	O	1803-1806
maternal	O	1807-1815
effect	O	1816-1822
on	O	1823-1825
offspring	O	1826-1835
lipid	O	1836-1841
deposition	O	1842-1852
.	O	1852-1853

MicroRNA	O	0-8
-	O	8-9
mediated	O	9-17
regulation	O	18-28
of	O	29-31
pancreatic	O	32-42
cancer	O	43-49
cell	O	50-54
proliferation	O	55-68
.	O	68-69

MicroRNAs	O	70-79
(	O	80-81
miRNAs	O	81-87
)	O	87-88
comprising	O	89-99
19	O	100-102
-	O	102-103
25	O	103-105
nucleotides	O	106-117
are	O	118-121
highly	O	122-128
conserved	O	129-138
small	O	139-144
non	O	145-148
-	O	148-149
coding	O	149-155
RNAs	O	156-160
which	O	161-166
regulate	O	167-175
normal	O	176-182
gene	O	183-187
expression	O	188-198
during	O	199-205
development	O	206-217
,	O	217-218
cell	O	219-223
proliferation	O	224-237
and	O	238-241
apoptosis	O	242-251
by	O	252-254
targeting	O	255-264
mRNAs	O	265-270
of	O	271-273
protein	O	274-281
-	O	281-282
coding	O	282-288
genes	O	289-294
at	O	295-297
the	O	298-301
post	O	302-306
-	O	306-307
transcriptional	O	307-322
level	O	323-328
.	O	328-329

Prevalent	O	330-339
studies	O	340-347
suggest	O	348-355
that	O	356-360
some	O	361-365
human	O	366-371
miRNAs	O	372-378
,	O	378-379
such	O	380-384
as	O	385-387
miRNA	B	388-393
-	I	393-394
16	I	394-396
,	O	396-397
are	O	398-401
deregulated	O	402-413
in	O	414-416
human	O	417-422
cancer	O	423-429
and	O	430-433
behave	O	434-440
as	O	441-443
tumor	O	444-449
suppressors	O	450-461
.	O	461-462

The	O	463-466
overall	O	467-474
objective	O	475-484
of	O	485-487
our	O	488-491
investigation	O	492-505
was	O	506-509
to	O	510-512
assess	O	513-519
whether	O	520-527
miRNA	B	528-533
-	I	533-534
16	I	534-536
(	O	537-538
miR	B	538-541
-	I	541-542
16	I	542-544
)	O	544-545
is	O	546-548
involved	O	549-557
in	O	558-560
the	O	561-564
regulation	O	565-575
of	O	576-578
critical	O	579-587
genes	O	588-593
,	O	593-594
such	O	595-599
as	O	600-602
BCL2	O	603-607
,	O	607-608
that	O	609-613
control	O	614-621
the	O	622-625
sensitivity	O	626-637
of	O	638-640
pancreatic	O	641-651
cancer	O	652-658
cells	O	659-664
to	O	665-667
apoptosis	O	668-677
.	O	677-678

This	O	679-683
study	O	684-689
showed	O	690-696
that	O	697-701
the	O	702-705
ectopic	O	706-713
overexpression	O	714-728
of	O	729-731
miR	B	732-735
-	I	735-736
16	I	736-738
may	O	739-742
be	O	743-745
therapeutically	O	746-761
beneficial	O	762-772
as	O	773-775
is	O	776-778
evidenced	O	779-788
by	O	789-791
impaired	O	792-800
cell	O	801-805
survival	O	806-814
with	O	815-819
concomitant	O	820-831
attenuation	O	832-843
of	O	844-846
anti	O	847-851
-	O	851-852
apoptotic	O	852-861
protein	O	862-869
Bcl	O	870-873
-	O	873-874
2	O	874-875
.	O	875-876

Moreover	O	877-885
,	O	885-886
the	O	887-890
luciferase	O	891-901
reporter	O	902-910
assay	O	911-916
suggested	O	917-926
that	O	927-931
miR	B	932-935
-	I	935-936
16	I	936-938
post	O	939-943
-	O	943-944
transcriptionally	O	944-961
regulates	O	962-971
Bcl	O	972-975
-	O	975-976
2	O	976-977
expression	O	978-988
in	O	989-991
pancreatic	O	992-1002
cancer	O	1003-1009
cells	O	1010-1015
through	O	1016-1023
the	O	1024-1027
target	O	1028-1034
sites	O	1035-1040
of	O	1041-1043
the	O	1044-1047
3	O	1048-1049
'	O	1049-1050
untranslated	O	1051-1063
region	O	1064-1070
of	O	1071-1073
this	O	1074-1078
gene	O	1079-1083
.	O	1083-1084

Alterations	O	0-11
of	O	12-14
microRNA	O	15-23
expression	O	24-34
patterns	O	35-43
in	O	44-46
human	O	47-52
cervical	O	53-61
carcinoma	O	62-71
cells	O	72-77
(	O	78-79
Ca	O	79-81
Ski	O	82-85
)	O	85-86
toward	O	87-93
1	O	94-95
'	O	95-96
S	O	96-97
-	O	97-98
1	O	98-99
'	O	99-100
-	O	100-101
acetoxychavicol	O	101-116
acetate	O	117-124
and	O	125-128
cisplatin	O	129-138
.	O	138-139

The	O	140-143
aims	O	144-148
of	O	149-151
this	O	152-156
study	O	157-162
were	O	163-167
to	O	168-170
investigate	O	171-182
the	O	183-186
combined	O	187-195
effects	O	196-203
of	O	204-206
a	O	207-208
natural	O	209-216
compound	O	217-225
1	O	226-227
'	O	227-228
S	O	228-229
-	O	229-230
1	O	230-231
'	O	231-232
-	O	232-233
acetoxychavicol	O	233-248
acetate	O	249-256
(	O	257-258
ACA	O	258-261
)	O	261-262
with	O	263-267
cisplatin	O	268-277
(	O	278-279
CDDP	O	279-283
)	O	283-284
on	O	285-287
HPV	O	288-291
-	O	291-292
positive	O	292-300
human	O	301-306
cervical	O	307-315
carcinoma	O	316-325
cell	O	326-330
lines	O	331-336
(	O	337-338
Ca	O	338-340
Ski	O	341-344
-	O	344-345
low	O	345-348
cisplatin	O	349-358
sensitivity	O	359-370
and	O	371-374
HeLa	O	375-379
-	O	379-380
high	O	380-384
cisplatin	O	385-394
sensitivity	O	395-406
)	O	406-407
,	O	407-408
and	O	409-412
to	O	413-415
identify	O	416-424
microRNAs	O	425-434
(	O	435-436
miRNAs	O	436-442
)	O	442-443
modulated	O	444-453
in	O	454-456
response	O	457-465
toward	O	466-472
ACA	O	473-476
and	O	477-480
/	O	480-481
or	O	481-483
CDDP	O	484-488
.	O	488-489

It	O	490-492
was	O	493-496
revealed	O	497-505
that	O	506-510
both	O	511-515
ACA	O	516-519
and	O	520-523
CDDP	O	524-528
induced	O	529-536
dose	O	537-541
-	O	541-542
and	O	543-546
time	O	547-551
-	O	551-552
dependent	O	552-561
cytotoxicity	O	562-574
when	O	575-579
used	O	580-584
as	O	585-587
a	O	588-589
stand	O	590-595
-	O	595-596
alone	O	596-601
agent	O	602-607
,	O	607-608
while	O	609-614
synergistic	O	615-626
effects	O	627-634
were	O	635-639
observed	O	640-648
when	O	649-653
used	O	654-658
in	O	659-661
combination	O	662-673
with	O	674-678
a	O	679-680
combination	O	681-692
index	O	693-698
(	O	699-700
CI	O	700-702
)	O	702-703
value	O	704-709
of	O	710-712
0	O	713-714
.	O	714-715
74	O	715-717
+	O	718-719
/	O	719-720
-	O	720-721
0	O	722-723
.	O	723-724
01	O	724-726
and	O	727-730
0	O	731-732
.	O	732-733
85	O	733-735
+	O	736-737
/	O	737-738
-	O	738-739
0	O	740-741
.	O	741-742
01	O	742-744
in	O	745-747
Ca	O	748-750
Ski	O	751-754
and	O	755-758
HeLa	O	759-763
cells	O	764-769
,	O	769-770
respectively	O	771-783
.	O	783-784

A	O	785-786
total	O	787-792
of	O	793-795
25	O	796-798
miRNAs	O	799-805
were	O	806-810
found	O	811-816
to	O	817-819
be	O	820-822
significantly	O	823-836
differentially	O	837-851
expressed	O	852-861
in	O	862-864
response	O	865-873
to	O	874-876
ACA	O	877-880
and	O	881-884
/	O	884-885
or	O	885-887
CDDP	O	888-892
.	O	892-893

These	O	894-899
include	O	900-907
hsa	B	908-911
-	I	911-912
miR	I	912-915
-	I	915-916
138	I	916-919
,	O	919-920
hsa	B	921-924
-	I	924-925
miR	I	925-928
-	I	928-929
210	I	929-932
,	O	932-933
and	O	934-937
hsa	B	938-941
-	I	941-942
miR	I	942-945
-	I	945-946
744	I	946-949
with	O	950-954
predicted	O	955-964
gene	O	965-969
targets	O	970-977
involved	O	978-986
in	O	987-989
signaling	O	990-999
pathways	O	1000-1008
regulating	O	1009-1019
apoptosis	O	1020-1029
and	O	1030-1033
cell	O	1034-1038
cycle	O	1039-1044
progression	O	1045-1056
.	O	1056-1057

In	O	1058-1060
conclusion	O	1061-1071
,	O	1071-1072
ACA	O	1073-1076
acts	O	1077-1081
as	O	1082-1084
a	O	1085-1086
chemosensitizer	O	1087-1102
which	O	1103-1108
synergistically	O	1109-1124
potentiates	O	1125-1136
the	O	1137-1140
cytotoxic	O	1141-1150
effect	O	1151-1157
of	O	1158-1160
CDDP	O	1161-1165
in	O	1166-1168
cervical	O	1169-1177
cancer	O	1178-1184
cells	O	1185-1190
.	O	1190-1191

The	O	1192-1195
altered	O	1196-1203
miRNA	O	1204-1209
expression	O	1210-1220
upon	O	1221-1225
administration	O	1226-1240
of	O	1241-1243
ACA	O	1244-1247
and	O	1248-1251
/	O	1251-1252
or	O	1252-1254
CDDP	O	1255-1259
suggests	O	1260-1268
that	O	1269-1273
miRNAs	O	1274-1280
play	O	1281-1285
an	O	1286-1288
important	O	1289-1298
role	O	1299-1303
in	O	1304-1306
anticancer	O	1307-1317
drug	O	1318-1322
responses	O	1323-1332
,	O	1332-1333
which	O	1334-1339
can	O	1340-1343
be	O	1344-1346
manipulated	O	1347-1358
for	O	1359-1362
therapeutic	O	1363-1374
purposes	O	1375-1383
.	O	1383-1384

Dysregulation	O	0-13
of	O	14-16
miRNA146a	O	17-26
versus	O	27-33
IRAK1	O	34-39
induces	O	40-47
IL	O	48-50
-	O	50-51
17	O	51-53
persistence	O	54-65
in	O	66-68
the	O	69-72
psoriatic	O	73-82
skin	O	83-87
lesions	O	88-95
.	O	95-96

Psoriasis	O	97-106
is	O	107-109
a	O	110-111
common	O	112-118
chronic	O	119-126
inflammatory	O	127-139
skin	O	140-144
disorder	O	145-153
with	O	154-158
dysregulation	O	159-172
of	O	173-175
miRNAs	O	176-182
.	O	182-183

The	O	184-187
expression	O	188-198
pattern	O	199-206
of	O	207-209
miR	B	210-213
-	I	213-214
146a	I	214-218
and	O	219-222
target	O	223-229
gene	O	230-234
IRAK1	O	235-240
in	O	241-243
lesions	O	244-251
and	O	252-255
PBMCs	O	256-261
of	O	262-264
plaque	O	265-271
psoriasis	O	272-281
remains	O	282-289
unclear	O	290-297
.	O	297-298

In	O	299-301
our	O	302-305
study	O	306-311
,	O	311-312
we	O	313-315
found	O	316-321
the	O	322-325
expression	O	326-336
of	O	337-339
miR	B	340-343
-	I	343-344
146a	I	344-348
was	O	349-352
up	O	353-355
-	O	355-356
regulated	O	356-365
both	O	366-370
in	O	371-373
lesions	O	374-381
and	O	382-385
PBMCs	O	386-391
of	O	392-394
psoriatic	O	395-404
patients	O	405-413
,	O	413-414
and	O	415-418
positively	O	419-429
correlated	O	430-440
with	O	441-445
IL	O	446-448
-	O	448-449
17	O	449-451
expression	O	452-462
,	O	462-463
whereas	O	464-471
the	O	472-475
target	O	476-482
gene	O	483-487
IRAK1	O	488-493
expression	O	494-504
was	O	505-508
expressed	O	509-518
differentially	O	519-533
in	O	534-536
lesions	O	537-544
and	O	545-548
peripheral	O	549-559
blood	O	560-565
.	O	565-566

Inability	O	567-576
of	O	577-579
miR	B	580-583
-	I	583-584
146a	I	584-588
inhibiting	O	589-599
target	O	600-606
gene	O	607-611
IRAK1	O	612-617
may	O	618-621
contribute	O	622-632
to	O	633-635
the	O	636-639
persistent	O	640-650
inflammation	O	651-663
in	O	664-666
lesions	O	667-674
of	O	675-677
psoriasis	O	678-687
.	O	687-688

Effect	O	0-6
of	O	7-9
miR	B	10-13
-	I	13-14
451	I	14-17
on	O	18-20
the	O	21-24
biological	O	25-35
behavior	O	36-44
of	O	45-47
the	O	48-51
esophageal	O	52-62
carcinoma	O	63-72
cell	O	73-77
line	O	78-82
EC9706	O	83-89
.	O	89-90

BACKGROUND	O	91-101
:	O	101-102
MicroRNAs	O	103-112
play	O	113-117
important	O	118-127
roles	O	128-133
in	O	134-136
coordinating	O	137-149
a	O	150-151
variety	O	152-159
of	O	160-162
cellular	O	163-171
processes	O	172-181
.	O	181-182

Abnormal	O	183-191
expression	O	192-202
of	O	203-205
miRNAs	O	206-212
has	O	213-216
been	O	217-221
linked	O	222-228
to	O	229-231
several	O	232-239
cancers	O	240-247
.	O	247-248

However	O	249-256
,	O	256-257
the	O	258-261
functional	O	262-272
role	O	273-277
of	O	278-280
miR	B	281-284
-	I	284-285
451	I	285-288
in	O	289-291
esophageal	O	292-302
squamous	O	303-311
cell	O	312-316
carcinoma	O	317-326
remains	O	327-334
unclear	O	335-342
.	O	342-343

AIMS	O	344-348
:	O	348-349
The	O	350-353
present	O	354-361
study	O	362-367
explored	O	368-376
the	O	377-380
effects	O	381-388
of	O	389-391
miR	B	392-395
-	I	395-396
451	I	396-399
on	O	400-402
the	O	403-406
biological	O	407-417
behavior	O	418-426
of	O	427-429
the	O	430-433
esophageal	O	434-444
carcinoma	O	445-454
cell	O	455-459
line	O	460-464
EC9706	O	465-471
.	O	471-472

METHODS	O	473-480
:	O	480-481
Synthetic	O	482-491
miR	B	492-495
-	I	495-496
451	I	496-499
mimics	O	500-506
were	O	507-511
transfected	O	512-523
into	O	524-528
EC9706	O	529-535
cells	O	536-541
using	O	542-547
Lipofectamine	O	548-561
2000	O	562-566
.	O	566-567

The	O	568-571
expression	O	572-582
of	O	583-585
miR	B	586-589
-	I	589-590
451	I	590-593
was	O	594-597
analyzed	O	598-606
by	O	607-609
RT	O	610-612
-	O	612-613
PCR	O	613-616
and	O	617-620
the	O	621-624
expressions	O	625-636
of	O	637-639
Bcl	O	640-643
-	O	643-644
2	O	644-645
,	O	645-646
AKT	O	647-650
and	O	651-654
phosphorylated	O	655-669
AKT	O	670-673
were	O	674-678
analyzed	O	679-687
by	O	688-690
Western	O	691-698
blotting	O	699-707
.	O	707-708

The	O	709-712
MTT	O	713-716
assay	O	717-722
,	O	722-723
soft	O	724-728
agar	O	729-733
colony	O	734-740
formation	O	741-750
assay	O	751-756
,	O	756-757
transwell	O	758-767
assay	O	768-773
and	O	774-777
FACS	O	778-782
were	O	783-787
used	O	788-792
to	O	793-795
assess	O	796-802
the	O	803-806
effect	O	807-813
of	O	814-816
miR	B	817-820
-	I	820-821
451	I	821-824
on	O	825-827
EC9706	O	828-834
cell	O	835-839
proliferation	O	840-853
,	O	853-854
invasion	O	855-863
,	O	863-864
metastasis	O	865-875
and	O	876-879
apoptosis	O	880-889
.	O	889-890

Tumor	O	891-896
growth	O	897-903
was	O	904-907
assessed	O	908-916
by	O	917-919
subcutaneous	O	920-932
inoculation	O	933-944
of	O	945-947
cells	O	948-953
into	O	954-958
BALB	O	959-963
/	O	963-964
c	O	964-965
nude	O	966-970
mice	O	971-975
.	O	975-976

RESULTS	O	977-984
:	O	984-985
In	O	986-988
comparison	O	989-999
to	O	1000-1002
the	O	1003-1006
controls	O	1007-1015
,	O	1015-1016
a	O	1017-1018
significant	O	1019-1030
increase	O	1031-1039
in	O	1040-1042
the	O	1043-1046
expression	O	1047-1057
of	O	1058-1060
miR	B	1061-1064
-	I	1064-1065
451	I	1065-1068
was	O	1069-1072
associated	O	1073-1083
with	O	1084-1088
significantly	O	1089-1102
decreased	O	1103-1112
expressions	O	1113-1124
of	O	1125-1127
Bcl	O	1128-1131
-	O	1131-1132
2	O	1132-1133
,	O	1133-1134
AKT	O	1135-1138
and	O	1139-1142
p	O	1143-1144
-	O	1144-1145
AKT	O	1145-1148
,	O	1148-1149
and	O	1150-1153
a	O	1154-1155
significant	O	1156-1167
increase	O	1168-1176
in	O	1177-1179
the	O	1180-1183
apoptosis	O	1184-1193
rate	O	1194-1198
.	O	1198-1199

The	O	1200-1203
number	O	1204-1210
of	O	1211-1213
cell	O	1214-1218
clones	O	1219-1225
was	O	1226-1229
significantly	O	1230-1243
decreased	O	1244-1253
by	O	1254-1256
miR	B	1257-1260
-	I	1260-1261
451	I	1261-1264
expression	O	1265-1275
,	O	1275-1276
which	O	1277-1282
also	O	1283-1287
caused	O	1288-1294
the	O	1295-1298
inhibition	O	1299-1309
of	O	1310-1312
cell	O	1313-1317
proliferation	O	1318-1331
.	O	1331-1332

The	O	1333-1336
average	O	1337-1344
number	O	1345-1351
of	O	1352-1354
cells	O	1355-1360
penetrating	O	1361-1372
the	O	1373-1376
matrigel	O	1377-1385
was	O	1386-1389
significantly	O	1390-1403
lower	O	1404-1409
than	O	1410-1414
the	O	1415-1418
controls	O	1419-1427
.	O	1427-1428

Injection	O	1429-1438
of	O	1439-1441
miR	B	1442-1445
-	I	1445-1446
451	I	1446-1449
inhibited	O	1450-1459
tumor	O	1460-1465
growth	O	1466-1472
in	O	1473-1475
a	O	1476-1477
xenograft	O	1478-1487
model	O	1488-1493
.	O	1493-1494

CONCLUSIONS	O	1495-1506
:	O	1506-1507
Upregulated	O	1508-1519
expression	O	1520-1530
of	O	1531-1533
miR	B	1534-1537
-	I	1537-1538
451	I	1538-1541
induced	O	1542-1549
apoptosis	O	1550-1559
and	O	1560-1563
suppressed	O	1564-1574
cell	O	1575-1579
proliferation	O	1580-1593
,	O	1593-1594
invasion	O	1595-1603
and	O	1604-1607
metastasis	O	1608-1618
in	O	1619-1621
the	O	1622-1625
esophageal	O	1626-1636
carcinoma	O	1637-1646
cell	O	1647-1651
line	O	1652-1656
EC9706	O	1657-1663
.	O	1663-1664

In	O	1665-1667
addition	O	1668-1676
,	O	1676-1677
injection	O	1678-1687
of	O	1688-1690
miR	B	1691-1694
-	I	1694-1695
451	I	1695-1698
inhibited	O	1699-1708
tumor	O	1709-1714
growth	O	1715-1721
in	O	1722-1724
a	O	1725-1726
xenograft	O	1727-1736
model	O	1737-1742
of	O	1743-1745
esophageal	O	1746-1756
cancer	O	1757-1763
.	O	1763-1764

A	O	0-1
polymorphism	O	2-14
in	O	15-17
the	O	18-21
3	O	22-23
'	O	23-24
-	O	24-25
untranslated	O	25-37
region	O	38-44
of	O	45-47
the	O	48-51
NPM1	O	52-56
gene	O	57-61
causes	O	62-68
illegitimate	O	69-81
regulation	O	82-92
by	O	93-95
microRNA	B	96-104
-	I	104-105
337	I	105-108
-	I	108-109
5p	I	109-111
and	O	112-115
correlates	O	116-126
with	O	127-131
adverse	O	132-139
outcome	O	140-147
in	O	148-150
acute	O	151-156
myeloid	O	157-164
leukemia	O	165-173
.	O	173-174

Nucleophosmin	O	175-188
,	O	188-189
encoded	O	190-197
by	O	198-200
NPM1	O	201-205
,	O	205-206
is	O	207-209
a	O	210-211
haploinsufficient	O	212-229
suppressor	O	230-240
in	O	241-243
hematologic	O	244-255
malignancies	O	256-268
.	O	268-269

NPM1	O	270-274
mutations	O	275-284
are	O	285-288
mostly	O	289-295
found	O	296-301
in	O	302-304
acute	O	305-310
myeloid	O	311-318
leukemia	O	319-327
patients	O	328-336
with	O	337-341
normal	O	342-348
karyotype	O	349-358
and	O	359-362
associated	O	363-373
with	O	374-378
favorable	O	379-388
prognosis	O	389-398
.	O	398-399

A	O	400-401
polymorphic	O	402-413
nucleotide	O	414-424
T	O	425-426
deletion	O	427-435
with	O	436-440
unknown	O	441-448
significance	O	449-461
is	O	462-464
present	O	465-472
in	O	473-475
the	O	476-479
NPM1	O	480-484
3	O	485-486
'	O	486-487
-	O	487-488
untranslated	O	488-500
region	O	501-507
.	O	507-508

Here	O	509-513
,	O	513-514
we	O	515-517
showed	O	518-524
that	O	525-529
the	O	530-533
homozygous	O	534-544
nucleotide	O	545-555
T	O	556-557
deletion	O	558-566
was	O	567-570
associated	O	571-581
with	O	582-586
adverse	O	587-594
outcomes	O	595-603
and	O	604-607
could	O	608-613
independently	O	614-627
predict	O	628-635
shortened	O	636-645
survival	O	646-654
in	O	655-657
patients	O	658-666
with	O	667-671
de	O	672-674
novo	O	675-679
acute	O	680-685
myeloid	O	686-693
leukemia	O	694-702
.	O	702-703

Mechanistically	O	704-719
,	O	719-720
we	O	721-723
demonstrated	O	724-736
that	O	737-741
the	O	742-745
nucleotide	O	746-756
T	O	757-758
deletion	O	759-767
created	O	768-775
an	O	776-778
illegitimate	O	779-791
binding	O	792-799
NPM1	O	800-804
for	O	805-808
miR	B	809-812
-	I	812-813
337	I	813-816
-	I	816-817
5p	I	817-819
,	O	819-820
which	O	821-826
was	O	827-830
widely	O	831-837
expressed	O	838-847
in	O	848-850
different	O	851-860
acute	O	861-866
myeloid	O	867-874
leukemia	O	875-883
subtypes	O	884-892
and	O	893-896
inhibited	O	897-906
NPM1	O	907-911
expression	O	912-922
.	O	922-923

Accordingly	O	924-935
,	O	935-936
NPM1	O	937-941
levels	O	942-948
were	O	949-953
found	O	954-959
to	O	960-962
be	O	963-965
significantly	O	966-979
reduced	O	980-987
and	O	988-991
correlated	O	992-1002
with	O	1003-1007
miR	B	1008-1011
-	I	1011-1012
337	I	1012-1015
-	I	1015-1016
5p	I	1016-1018
levels	O	1019-1025
in	O	1026-1028
patients	O	1029-1037
carrying	O	1038-1046
a	O	1047-1048
homozygous	O	1049-1059
nucleotide	O	1060-1070
T	O	1071-1072
-	O	1072-1073
deletion	O	1073-1081
genotype	O	1082-1090
.	O	1090-1091

Together	O	1092-1100
,	O	1100-1101
our	O	1102-1105
findings	O	1106-1114
uncover	O	1115-1122
a	O	1123-1124
microRNA	O	1125-1133
-	O	1133-1134
mediated	O	1134-1142
control	O	1143-1150
of	O	1151-1153
NPM1	O	1154-1158
expression	O	1159-1169
that	O	1170-1174
contributes	O	1175-1186
to	O	1187-1189
disease	O	1190-1197
heterogeneity	O	1198-1211
and	O	1212-1215
suggest	O	1216-1223
additional	O	1224-1234
prognostic	O	1235-1245
values	O	1246-1252
of	O	1253-1255
NPM1	O	1256-1260
in	O	1261-1263
acute	O	1264-1269
myeloid	O	1270-1277
leukemia	O	1278-1286
.	O	1286-1287

MicroRNAs	O	0-9
and	O	10-13
cardiac	O	14-21
sarcoplasmic	O	22-34
reticulum	O	35-44
calcium	O	45-52
ATPase	O	53-59
-	O	59-60
2	O	60-61
in	O	62-64
human	O	65-70
myocardial	O	71-81
infarction	O	82-92
:	O	92-93
expression	O	94-104
and	O	105-108
bioinformatic	O	109-122
analysis	O	123-131
.	O	131-132

BACKGROUND	O	133-143
:	O	143-144
Cardiac	O	145-152
sarco	O	153-158
(	O	158-159
endo	O	159-163
)	O	163-164
plasmic	O	164-171
reticulum	O	172-181
calcium	O	182-189
ATPase	O	190-196
-	O	196-197
2	O	197-198
(	O	199-200
SERCA2	O	200-206
)	O	206-207
plays	O	208-213
one	O	214-217
of	O	218-220
the	O	221-224
central	O	225-232
roles	O	233-238
in	O	239-241
myocardial	O	242-252
contractility	O	253-266
.	O	266-267

Both	O	268-272
,	O	272-273
SERCA2	O	274-280
mRNA	O	281-285
and	O	286-289
protein	O	290-297
are	O	298-301
reduced	O	302-309
in	O	310-312
myocardial	O	313-323
infarction	O	324-334
(	O	335-336
MI	O	336-338
)	O	338-339
,	O	339-340
but	O	341-344
the	O	345-348
correlation	O	349-360
has	O	361-364
not	O	365-368
been	O	369-373
always	O	374-380
observed	O	381-389
.	O	389-390

MicroRNAs	O	391-400
(	O	401-402
miRNAs	O	402-408
)	O	408-409
act	O	410-413
by	O	414-416
targeting	O	417-426
3	O	427-428
'	O	428-429
-	O	429-430
UTR	O	430-433
mRNA	O	434-438
,	O	438-439
causing	O	440-447
translational	O	448-461
repression	O	462-472
in	O	473-475
physiological	O	476-489
and	O	490-493
pathological	O	494-506
conditions	O	507-517
,	O	517-518
including	O	519-528
cardiovascular	O	529-543
diseases	O	544-552
.	O	552-553

One	O	554-557
of	O	558-560
the	O	561-564
aims	O	565-569
of	O	570-572
our	O	573-576
study	O	577-582
was	O	583-586
to	O	587-589
identify	O	590-598
miRNAs	O	599-605
that	O	606-610
could	O	611-616
influence	O	617-626
SERCA2	O	627-633
expression	O	634-644
in	O	645-647
human	O	648-653
MI	O	654-656
.	O	656-657

RESULTS	O	658-665
:	O	665-666
The	O	667-670
protein	O	671-678
SERCA2	O	679-685
was	O	686-689
decreased	O	690-699
and	O	700-703
43	O	704-706
miRNAs	O	707-713
were	O	714-718
deregulated	O	719-730
in	O	731-733
infarcted	O	734-743
myocardium	O	744-754
compared	O	755-763
to	O	764-766
corresponding	O	767-780
remote	O	781-787
myocardium	O	788-798
,	O	798-799
analyzed	O	800-808
by	O	809-811
western	O	812-819
blot	O	820-824
and	O	825-828
microRNA	O	829-837
microarrays	O	838-849
,	O	849-850
respectively	O	851-863
.	O	863-864

All	O	865-868
the	O	869-872
samples	O	873-880
were	O	881-885
stored	O	886-892
as	O	893-895
FFPE	O	896-900
tissue	O	901-907
and	O	908-911
in	O	912-914
RNAlater	O	915-923
.	O	923-924

miRNAs	O	925-931
binding	O	932-939
prediction	O	940-950
to	O	951-953
SERCA2	O	954-960
including	O	961-970
four	O	971-975
prediction	O	976-986
algorithms	O	987-997
(	O	998-999
TargetScan	O	999-1009
,	O	1009-1010
PicTar	O	1011-1017
,	O	1017-1018
miRanda	O	1019-1026
and	O	1027-1030
mirTarget2	O	1031-1041
)	O	1041-1042
identified	O	1043-1053
213	O	1054-1057
putative	O	1058-1066
miRNAs	O	1067-1073
.	O	1073-1074

TAM	O	1075-1078
and	O	1079-1082
miRNApath	O	1083-1092
annotation	O	1093-1103
of	O	1104-1106
deregulated	O	1107-1118
miRNAs	O	1119-1125
identified	O	1126-1136
18	O	1137-1139
functional	O	1140-1150
and	O	1151-1154
21	O	1155-1157
diseased	O	1158-1166
states	O	1167-1173
related	O	1174-1181
to	O	1182-1184
heart	O	1185-1190
diseases	O	1191-1199
,	O	1199-1200
and	O	1201-1204
association	O	1205-1216
of	O	1217-1219
the	O	1220-1223
half	O	1224-1228
of	O	1229-1231
the	O	1232-1235
deregulated	O	1236-1247
miRNAs	O	1248-1254
to	O	1255-1257
SERCA2	O	1258-1264
.	O	1264-1265

Free	O	1266-1270
-	O	1270-1271
energy	O	1271-1277
of	O	1278-1280
binding	O	1281-1288
and	O	1289-1292
flanking	O	1293-1301
regions	O	1302-1309
(	O	1310-1311
RNA22	O	1311-1316
,	O	1316-1317
RNAfold	O	1318-1325
)	O	1325-1326
was	O	1327-1330
calculated	O	1331-1341
for	O	1342-1345
10	O	1346-1348
up	O	1349-1351
-	O	1351-1352
regulated	O	1352-1361
miRNAs	O	1362-1368
from	O	1369-1373
microarray	O	1374-1384
analysis	O	1385-1393
(	O	1394-1395
miR	B	1395-1398
-	I	1398-1399
122	I	1399-1402
,	O	1402-1403
miR	B	1404-1407
-	I	1407-1408
320a	I	1408-1412
/	O	1412-1413
b	B	1413-1414
/	O	1414-1415
c	B	1415-1416
/	O	1416-1417
d	B	1417-1418
,	O	1418-1419
miR	B	1420-1423
-	I	1423-1424
574	I	1424-1427
-	I	1427-1428
3p	I	1428-1430
/	I	1430-1431
-	I	1431-1432
5p	I	1432-1434
,	O	1434-1435
miR	B	1436-1439
-	I	1439-1440
199a	I	1440-1444
,	O	1444-1445
miR	B	1446-1449
-	I	1449-1450
140	I	1450-1453
,	O	1453-1454
and	O	1455-1458
miR	B	1459-1462
-	I	1462-1463
483	I	1463-1466
)	O	1466-1467
,	O	1467-1468
and	O	1469-1472
nine	O	1473-1477
miRNAs	O	1478-1484
deregulated	O	1485-1496
from	O	1497-1501
microarray	O	1502-1512
analysis	O	1513-1521
were	O	1522-1526
used	O	1527-1531
for	O	1532-1535
validation	O	1536-1546
with	O	1547-1551
qPCR	O	1552-1556
(	O	1557-1558
miR	B	1558-1561
-	I	1561-1562
21	I	1562-1564
,	O	1564-1565
miR	B	1566-1569
-	I	1569-1570
122	I	1570-1573
,	O	1573-1574
miR	B	1575-1578
-	I	1578-1579
126	I	1579-1582
,	O	1582-1583
miR	B	1584-1587
-	I	1587-1588
1	I	1588-1589
,	O	1589-1590
miR	B	1591-1594
-	I	1594-1595
133	I	1595-1598
,	O	1598-1599
miR	B	1600-1603
-	I	1603-1604
125a	I	1604-1608
/	O	1608-1609
b	B	1609-1610
,	O	1610-1611
and	O	1612-1615
miR	B	1616-1619
-	I	1619-1620
98	I	1620-1622
)	O	1622-1623
.	O	1623-1624

Based	O	1625-1630
on	O	1631-1633
qPCR	O	1634-1638
results	O	1639-1646
,	O	1646-1647
the	O	1648-1651
comparison	O	1652-1662
between	O	1663-1670
FFPE	O	1671-1675
and	O	1676-1679
RNAlater	O	1680-1688
stored	O	1689-1695
tissue	O	1696-1702
samples	O	1703-1710
,	O	1710-1711
between	O	1712-1719
Sybr	O	1720-1724
Green	O	1725-1730
and	O	1731-1734
TaqMan	O	1735-1741
approaches	O	1742-1752
,	O	1752-1753
as	O	1754-1756
well	O	1757-1761
as	O	1762-1764
between	O	1765-1772
different	O	1773-1782
reference	O	1783-1792
genes	O	1793-1798
were	O	1799-1803
also	O	1804-1808
performed	O	1809-1818
.	O	1818-1819

CONCLUSION	O	1820-1830
:	O	1830-1831
Combing	O	1832-1839
all	O	1840-1843
the	O	1844-1847
results	O	1848-1855
,	O	1855-1856
we	O	1857-1859
identified	O	1860-1870
certain	O	1871-1878
miRNAs	O	1879-1885
as	O	1886-1888
potential	O	1889-1898
regulators	O	1899-1909
of	O	1910-1912
SERCA2	O	1913-1919
;	O	1919-1920
however	O	1921-1928
,	O	1928-1929
further	O	1930-1937
functional	O	1938-1948
studies	O	1949-1956
are	O	1957-1960
needed	O	1961-1967
for	O	1968-1971
verification	O	1972-1984
.	O	1984-1985

Using	O	1986-1991
qPCR	O	1992-1996
,	O	1996-1997
we	O	1998-2000
confirmed	O	2001-2010
deregulation	O	2011-2023
of	O	2024-2026
nine	O	2027-2031
miRNAs	O	2032-2038
in	O	2039-2041
human	O	2042-2047
MI	O	2048-2050
,	O	2050-2051
and	O	2052-2055
show	O	2056-2060
that	O	2061-2065
qPCR	O	2066-2070
normalization	O	2071-2084
strategy	O	2085-2093
is	O	2094-2096
important	O	2097-2106
for	O	2107-2110
the	O	2111-2114
outcome	O	2115-2122
of	O	2123-2125
miRNA	O	2126-2131
expression	O	2132-2142
analysis	O	2143-2151
in	O	2152-2154
human	O	2155-2160
MI	O	2161-2163
.	O	2163-2164

MiR	B	0-3
-	I	3-4
34a	I	4-7
is	O	8-10
involved	O	11-19
in	O	20-22
Tat	O	23-26
-	O	26-27
induced	O	27-34
HIV	O	35-38
-	O	38-39
1	O	39-40
long	O	41-45
terminal	O	46-54
repeat	O	55-61
(	O	62-63
LTR	O	63-66
)	O	66-67
transactivation	O	68-83
through	O	84-91
the	O	92-95
SIRT1	O	96-101
/	O	101-102
NFkappaB	O	102-110
pathway	O	111-118
.	O	118-119

MicroRNAs	O	120-129
(	O	130-131
miRNAs	O	131-137
)	O	137-138
regulate	O	139-147
gene	O	148-152
expression	O	153-163
and	O	164-167
may	O	168-171
contribute	O	172-182
to	O	183-185
HIV	O	186-189
-	O	189-190
1	O	190-191
infection	O	192-201
.	O	201-202

In	O	203-205
this	O	206-210
study	O	211-216
,	O	216-217
our	O	218-221
goal	O	222-226
was	O	227-230
to	O	231-233
investigate	O	234-245
the	O	246-249
mechanisms	O	250-260
by	O	261-263
which	O	264-269
miR	B	270-273
-	I	273-274
34a	I	274-277
influenced	O	278-288
Tat	O	289-292
-	O	292-293
induced	O	293-300
HIV	O	301-304
-	O	304-305
1	O	305-306
transactivation	O	307-322
through	O	323-330
the	O	331-334
SIRT1	O	335-340
/	O	340-341
NFkappaB	O	341-349
pathway	O	350-357
.	O	357-358

We	O	359-361
showed	O	362-368
that	O	369-373
Tat	O	374-377
induced	O	378-385
up	O	386-388
-	O	388-389
regulation	O	389-399
of	O	400-402
miR	B	403-406
-	I	406-407
34a	I	407-410
expression	O	411-421
in	O	422-424
TZM	O	425-428
-	O	428-429
bl	O	429-431
cells	O	432-437
.	O	437-438

MiR	B	439-442
-	I	442-443
34a	I	443-446
significantly	O	447-460
inhibited	O	461-470
SIRT1	O	471-476
expression	O	477-487
.	O	487-488

Overexpression	O	489-503
of	O	504-506
miR	B	507-510
-	I	510-511
34a	I	511-514
increased	O	515-524
Tat	O	525-528
-	O	528-529
induced	O	529-536
LTR	O	537-540
transactivation	O	541-556
.	O	556-557

Forced	O	558-564
expression	O	565-575
of	O	576-578
miR	B	579-582
-	I	582-583
34a	I	583-586
decreased	O	587-596
SIRT1	O	597-602
protein	O	603-610
expression	O	611-621
and	O	622-625
consequently	O	626-638
diminished	O	639-649
Tat	O	650-653
-	O	653-654
induced	O	654-661
acetylation	O	662-673
of	O	674-676
p65	O	677-680
,	O	680-681
while	O	682-687
treatment	O	688-697
with	O	698-702
a	O	703-704
miR	B	705-708
-	I	708-709
34a	I	709-712
inhibitor	O	713-722
had	O	723-726
the	O	727-730
opposite	O	731-739
effect	O	740-746
.	O	746-747

These	O	748-753
results	O	754-761
suggest	O	762-769
that	O	770-774
regulating	O	775-785
SIRT1	O	786-791
by	O	792-794
down	O	795-799
-	O	799-800
regulation	O	800-810
of	O	811-813
miR	B	814-817
-	I	817-818
34a	I	818-821
levels	O	822-828
may	O	829-832
be	O	833-835
a	O	836-837
therapeutic	O	838-849
strategy	O	850-858
against	O	859-866
HIV	O	867-870
-	O	870-871
1	O	871-872
replication	O	873-884
.	O	884-885

miR	B	0-3
-	I	3-4
15a	I	4-7
and	O	8-11
miR	B	12-15
-	I	15-16
16	I	16-18
affect	O	19-25
the	O	26-29
angiogenesis	O	30-42
of	O	43-45
multiple	O	46-54
myeloma	O	55-62
by	O	63-65
targeting	O	66-75
VEGF	O	76-80
.	O	80-81

Deregulated	O	82-93
microRNAs	O	94-103
(	O	104-105
miRNAs	O	105-111
)	O	111-112
and	O	113-116
their	O	117-122
roles	O	123-128
in	O	129-131
cancer	O	132-138
development	O	139-150
have	O	151-155
attracted	O	156-165
much	O	166-170
attention	O	171-180
.	O	180-181

Two	O	182-185
miRNAs	O	186-192
,	O	192-193
miR	B	194-197
-	I	197-198
15a	I	198-201
and	O	202-205
miR	B	206-209
-	I	209-210
16	I	210-212
,	O	212-213
which	O	214-219
act	O	220-223
as	O	224-226
putative	O	227-235
tumor	O	236-241
suppressor	O	242-252
by	O	253-255
targeting	O	256-265
the	O	266-269
oncogene	O	270-278
BCL2	O	279-283
,	O	283-284
have	O	285-289
been	O	290-294
implicated	O	295-305
in	O	306-308
cell	O	309-313
cycle	O	314-319
,	O	319-320
apoptosis	O	321-330
and	O	331-334
proliferation	O	335-348
.	O	348-349

In	O	350-352
this	O	353-357
study	O	358-363
,	O	363-364
we	O	365-367
investigated	O	368-380
the	O	381-384
possible	O	385-393
role	O	394-398
of	O	399-401
miR	B	402-405
-	I	405-406
15a	I	406-409
/	O	409-410
16	B	410-412
in	O	413-415
the	O	416-419
angiogenesis	O	420-432
of	O	433-435
multiple	O	436-444
myeloma	O	445-452
(	O	453-454
MM	O	454-456
)	O	456-457
.	O	457-458

Using	O	459-464
a	O	465-466
stem	O	467-471
-	O	471-472
loop	O	472-476
quantitative	O	477-489
reverse	O	490-497
transcription	O	498-511
-	O	511-512
PCR	O	512-515
,	O	515-516
we	O	517-519
analyzed	O	520-528
miR	B	529-532
-	I	532-533
15a	I	533-536
/	O	536-537
16	B	537-539
expressions	O	540-551
in	O	552-554
bone	O	555-559
marrow	O	560-566
samples	O	567-574
from	O	575-579
newly	O	580-585
diagnosed	O	586-595
MM	O	596-598
patients	O	599-607
and	O	608-611
a	O	612-613
panel	O	614-619
of	O	620-622
MM	O	623-625
cell	O	626-630
lines	O	631-636
.	O	636-637

miRNA	O	638-643
transfection	O	644-656
,	O	656-657
western	O	658-665
blotting	O	666-674
analysis	O	675-683
and	O	684-687
assay	O	688-693
of	O	694-696
luciferase	O	697-707
activity	O	708-716
were	O	717-721
used	O	722-726
to	O	727-729
examine	O	730-737
whether	O	738-745
vascular	O	746-754
endothelial	O	755-766
growth	O	767-773
factor	O	774-780
(	O	781-782
VEGF	O	782-786
)	O	786-787
is	O	788-790
the	O	791-794
target	O	795-801
of	O	802-804
miR	B	805-808
-	I	808-809
15a	I	809-812
/	O	812-813
16	B	813-815
.	O	815-816

The	O	817-820
functional	O	821-831
roles	O	832-837
of	O	838-840
miR	B	841-844
-	I	844-845
15a	I	845-848
/	O	848-849
16	B	849-851
on	O	852-854
tumorigenesis	O	855-868
and	O	869-872
angiogenesis	O	873-885
were	O	886-890
examined	O	891-899
by	O	900-902
in	O	903-905
vitro	O	906-911
angiogenesis	O	912-924
models	O	925-931
and	O	932-935
in	O	936-938
vivo	O	939-943
tumor	O	944-949
xenograft	O	950-959
model	O	960-965
.	O	965-966

We	O	967-969
showed	O	970-976
that	O	977-981
miR	B	982-985
-	I	985-986
15a	I	986-989
and	O	990-993
miR	B	994-997
-	I	997-998
16	I	998-1000
were	O	1001-1005
significantly	O	1006-1019
underexpressed	O	1020-1034
in	O	1035-1037
primary	O	1038-1045
MM	O	1046-1048
cells	O	1049-1054
as	O	1055-1057
well	O	1058-1062
as	O	1063-1065
in	O	1066-1068
MM	O	1069-1071
cell	O	1072-1076
lines	O	1077-1082
.	O	1082-1083

The	O	1084-1087
aberrant	O	1088-1096
expression	O	1097-1107
of	O	1108-1110
miR	B	1111-1114
-	I	1114-1115
15a	I	1115-1118
/	O	1118-1119
16	B	1119-1121
was	O	1122-1125
detected	O	1126-1134
especially	O	1135-1145
in	O	1146-1148
advanced	O	1149-1157
stage	O	1158-1163
MM	O	1164-1166
.	O	1166-1167

In	O	1168-1170
human	O	1171-1176
MM	O	1177-1179
cell	O	1180-1184
lines	O	1185-1190
and	O	1191-1194
normal	O	1195-1201
plasma	O	1202-1208
cells	O	1209-1214
,	O	1214-1215
expression	O	1216-1226
of	O	1227-1229
miR	B	1230-1233
-	I	1233-1234
15a	I	1234-1237
/	O	1237-1238
16	B	1238-1240
inversely	O	1241-1250
correlated	O	1251-1261
with	O	1262-1266
the	O	1267-1270
expression	O	1271-1281
of	O	1282-1284
VEGF	O	1285-1289
-	O	1289-1290
A	O	1290-1291
.	O	1291-1292

Western	O	1293-1300
blotting	O	1301-1309
combined	O	1310-1318
with	O	1319-1323
the	O	1324-1327
luciferase	O	1328-1338
reporter	O	1339-1347
assay	O	1348-1353
demonstrated	O	1354-1366
that	O	1367-1371
VEGF	O	1372-1376
-	O	1376-1377
A	O	1377-1378
was	O	1379-1382
a	O	1383-1384
direct	O	1385-1391
target	O	1392-1398
of	O	1399-1401
miR	B	1402-1405
-	I	1405-1406
15a	I	1406-1409
/	O	1409-1410
16	B	1410-1412
.	O	1412-1413

Ectopic	O	1414-1421
overexpression	O	1422-1436
of	O	1437-1439
miR	B	1440-1443
-	I	1443-1444
15a	I	1444-1447
/	O	1447-1448
16	B	1448-1450
led	O	1451-1454
to	O	1455-1457
decreased	O	1458-1467
pro	O	1468-1471
-	O	1471-1472
angiogenic	O	1472-1482
activity	O	1483-1491
of	O	1492-1494
MM	O	1495-1497
cells	O	1498-1503
.	O	1503-1504

Finally	O	1505-1512
,	O	1512-1513
infection	O	1514-1523
of	O	1524-1526
lentivirus	B	1527-1537
-	I	1537-1538
miR	I	1538-1541
-	I	1541-1542
15a	I	1542-1545
or	O	1546-1548
lentivirus	B	1549-1559
-	I	1559-1560
miR	I	1560-1563
-	I	1563-1564
16	I	1564-1566
resulted	O	1567-1575
in	O	1576-1578
significant	O	1579-1590
inhibition	O	1591-1601
of	O	1602-1604
tumor	O	1605-1610
growth	O	1611-1617
and	O	1618-1621
angiogenesis	O	1622-1634
in	O	1635-1637
nude	O	1638-1642
mice	O	1643-1647
.	O	1647-1648

This	O	1649-1653
study	O	1654-1659
suggest	O	1660-1667
that	O	1668-1672
miR	B	1673-1676
-	I	1676-1677
15a	I	1677-1680
/	O	1680-1681
16	B	1681-1683
could	O	1684-1689
play	O	1690-1694
a	O	1695-1696
role	O	1697-1701
in	O	1702-1704
the	O	1705-1708
tumorigenesis	O	1709-1722
of	O	1723-1725
MM	O	1726-1728
at	O	1729-1731
least	O	1732-1737
in	O	1738-1740
part	O	1741-1745
by	O	1746-1748
modulation	O	1749-1759
of	O	1760-1762
angiogenesis	O	1763-1775
through	O	1776-1783
targeting	O	1784-1793
VEGF	O	1794-1798
-	O	1798-1799
A	O	1799-1800
.	O	1800-1801

Circulating	O	0-11
microRNAs	O	12-21
identified	O	22-32
in	O	33-35
a	O	36-37
genome	O	38-44
-	O	44-45
wide	O	45-49
serum	O	50-55
microRNA	O	56-64
expression	O	65-75
analysis	O	76-84
as	O	85-87
noninvasive	O	88-99
biomarkers	O	100-110
for	O	111-114
endometriosis	O	115-128
.	O	128-129

CONTEXT	O	130-137
:	O	137-138
There	O	139-144
is	O	145-147
currently	O	148-157
no	O	158-160
reliable	O	161-169
noninvasive	O	170-181
biomarker	O	182-191
for	O	192-195
the	O	196-199
clinical	O	200-208
diagnosis	O	209-218
of	O	219-221
endometriosis	O	222-235
.	O	235-236

Previous	O	237-245
analyses	O	246-254
have	O	255-259
reported	O	260-268
that	O	269-273
circulating	O	274-285
microRNAs	O	286-295
(	O	296-297
miRNAs	O	297-303
)	O	303-304
can	O	305-308
serve	O	309-314
as	O	315-317
biomarkers	O	318-328
for	O	329-332
a	O	333-334
number	O	335-341
of	O	342-344
diseases	O	345-353
.	O	353-354

OBJECTIVE	O	355-364
:	O	364-365
The	O	366-369
study	O	370-375
aims	O	376-380
to	O	381-383
detect	O	384-390
the	O	391-394
serum	O	395-400
miRNAs	O	401-407
that	O	408-412
are	O	413-416
differentially	O	417-431
expressed	O	432-441
between	O	442-449
endometriosis	O	450-463
patients	O	464-472
and	O	473-476
negative	O	477-485
controls	O	486-494
to	O	495-497
evaluate	O	498-506
the	O	507-510
potential	O	511-520
of	O	521-523
these	O	524-529
miRNAs	O	530-536
as	O	537-539
diagnostic	O	540-550
markers	O	551-558
for	O	559-562
endometriosis	O	563-576
.	O	576-577

DESIGN	O	578-584
:	O	584-585
A	O	586-587
total	O	588-593
of	O	594-596
765	O	597-600
serum	O	601-606
miRNAs	O	607-613
were	O	614-618
profiled	O	619-627
using	O	628-633
a	O	634-635
TaqMan	O	636-642
microRNA	O	643-651
array	O	652-657
in	O	658-660
a	O	661-662
pool	O	663-667
of	O	668-670
10	O	671-673
endometriosis	O	674-687
patients	O	688-696
and	O	697-700
a	O	701-702
pool	O	703-707
of	O	708-710
10	O	711-713
negative	O	714-722
controls	O	723-731
,	O	731-732
and	O	733-736
a	O	737-738
set	O	739-742
of	O	743-745
selected	O	746-754
miRNAs	O	755-761
were	O	762-766
further	O	767-774
analyzed	O	775-783
in	O	784-786
a	O	787-788
validation	O	789-799
cohort	O	800-806
consisting	O	807-817
of	O	818-820
sera	O	821-825
from	O	826-830
60	O	831-833
patients	O	834-842
and	O	843-846
25	O	847-849
controls	O	850-858
including	O	859-868
10	O	869-871
samples	O	872-879
used	O	880-884
in	O	885-887
array	O	888-893
profiling	O	894-903
.	O	903-904

RESULTS	O	905-912
:	O	912-913
The	O	914-917
relative	O	918-926
expression	O	927-937
levels	O	938-944
of	O	945-947
miR	B	948-951
-	I	951-952
199a	I	952-956
and	O	957-960
miR	B	961-964
-	I	964-965
122	I	965-968
were	O	969-973
found	O	974-979
to	O	980-982
be	O	983-985
up	O	986-988
-	O	988-989
regulated	O	989-998
in	O	999-1001
endometriosis	O	1002-1015
patient	O	1016-1023
samples	O	1024-1031
compared	O	1032-1040
with	O	1041-1045
control	O	1046-1053
samples	O	1054-1061
,	O	1061-1062
whereas	O	1063-1070
miR	B	1071-1074
-	I	1074-1075
145	I	1075-1078
*	I	1078-1079
,	O	1079-1080
miR	B	1081-1084
-	I	1084-1085
141	I	1085-1088
*	I	1088-1089
,	O	1089-1090
miR	B	1091-1094
-	I	1094-1095
542	I	1095-1098
-	I	1098-1099
3p	I	1099-1101
,	O	1101-1102
and	O	1103-1106
miR	B	1107-1110
-	I	1110-1111
9	I	1111-1112
*	I	1112-1113
were	O	1114-1118
down	O	1119-1123
-	O	1123-1124
regulated	O	1124-1133
in	O	1134-1136
endometriosis	O	1137-1150
patients	O	1151-1159
.	O	1159-1160

Importantly	O	1161-1172
,	O	1172-1173
the	O	1174-1177
relative	O	1178-1186
expression	O	1187-1197
of	O	1198-1200
miR	B	1201-1204
-	I	1204-1205
199a	I	1205-1209
(	O	1210-1211
P	O	1211-1212
<	O	1213-1214
0	O	1215-1216
.	O	1216-1217
05	O	1217-1219
)	O	1219-1220
and	O	1221-1224
miR	B	1225-1228
-	I	1228-1229
122	I	1229-1232
can	O	1233-1236
be	O	1237-1239
used	O	1240-1244
to	O	1245-1247
discriminate	O	1248-1260
between	O	1261-1268
severe	O	1269-1275
and	O	1276-1279
mild	O	1280-1284
endometriosis	O	1285-1298
.	O	1298-1299

We	O	1300-1302
also	O	1303-1307
found	O	1308-1313
that	O	1314-1318
miR	B	1319-1322
-	I	1322-1323
199a	I	1323-1327
is	O	1328-1330
well	O	1331-1335
correlated	O	1336-1346
with	O	1347-1351
pelvic	O	1352-1358
adhesion	O	1359-1367
and	O	1368-1371
lesion	O	1372-1378
distribution	O	1379-1391
(	O	1392-1393
P	O	1393-1394
<	O	1395-1396
0	O	1397-1398
.	O	1398-1399
05	O	1399-1401
)	O	1401-1402
and	O	1403-1406
associated	O	1407-1417
with	O	1418-1422
hormone	O	1423-1430
-	O	1430-1431
mediated	O	1431-1439
signaling	O	1440-1449
pathways	O	1450-1458
.	O	1458-1459

Furthermore	O	1460-1471
,	O	1471-1472
we	O	1473-1475
investigated	O	1476-1488
the	O	1489-1492
diagnostic	O	1493-1503
value	O	1504-1509
of	O	1510-1512
these	O	1513-1518
molecules	O	1519-1528
and	O	1529-1532
confirmed	O	1533-1542
the	O	1543-1546
optimal	O	1547-1554
combination	O	1555-1566
of	O	1567-1569
miR	B	1570-1573
-	I	1573-1574
199a	I	1574-1578
,	O	1578-1579
miR	B	1580-1583
-	I	1583-1584
122	I	1584-1587
,	O	1587-1588
miR	B	1589-1592
-	I	1592-1593
145	I	1593-1596
*	I	1596-1597
,	O	1597-1598
and	O	1599-1602
miR	B	1603-1606
-	I	1606-1607
542	I	1607-1610
-	I	1610-1611
3p	I	1611-1613
with	O	1614-1618
area	O	1619-1623
under	O	1624-1629
the	O	1630-1633
curve	O	1634-1639
of	O	1640-1642
0	O	1643-1644
.	O	1644-1645
994	O	1645-1648
(	O	1649-1650
95	O	1650-1652
%	O	1652-1653
confidence	O	1654-1664
interval	O	1665-1673
=	O	1674-1675
0	O	1676-1677
.	O	1677-1678
984	O	1678-1681
-	O	1681-1682
1	O	1682-1683
.	O	1683-1684
000	O	1684-1687
,	O	1687-1688
P	O	1689-1690
<	O	1691-1692
0	O	1693-1694
.	O	1694-1695
001	O	1695-1698
)	O	1698-1699
and	O	1700-1703
a	O	1704-1705
cutoff	O	1706-1712
point	O	1713-1718
(	O	1719-1720
0	O	1720-1721
.	O	1721-1722
4950	O	1722-1726
)	O	1726-1727
of	O	1728-1730
93	O	1731-1733
.	O	1733-1734
22	O	1734-1736
%	O	1736-1737
sensitivity	O	1738-1749
and	O	1750-1753
96	O	1754-1756
.	O	1756-1757
00	O	1757-1759
%	O	1759-1760
specificity	O	1761-1772
.	O	1772-1773

CONCLUSIONS	O	1774-1785
:	O	1785-1786
Our	O	1787-1790
study	O	1791-1796
demonstrated	O	1797-1809
that	O	1810-1814
the	O	1815-1818
circulating	O	1819-1830
miRNAs	O	1831-1837
miR	B	1838-1841
-	I	1841-1842
199a	I	1842-1846
,	O	1846-1847
miR	B	1848-1851
-	I	1851-1852
122	I	1852-1855
,	O	1855-1856
miR	B	1857-1860
-	I	1860-1861
145	I	1861-1864
*	I	1864-1865
,	O	1865-1866
and	O	1867-1870
miR	B	1871-1874
-	I	1874-1875
542	I	1875-1878
-	I	1878-1879
3p	I	1879-1881
could	O	1882-1887
potentially	O	1888-1899
serve	O	1900-1905
as	O	1906-1908
noninvasive	O	1909-1920
biomarkers	O	1921-1931
for	O	1932-1935
endometriosis	O	1936-1949
.	O	1949-1950

miR	B	1951-1954
-	I	1954-1955
199a	I	1955-1959
may	O	1960-1963
also	O	1964-1968
play	O	1969-1973
an	O	1974-1976
important	O	1977-1986
role	O	1987-1991
in	O	1992-1994
the	O	1995-1998
progression	O	1999-2010
of	O	2011-2013
the	O	2014-2017
disease	O	2018-2025
.	O	2025-2026

This	O	2027-2031
is	O	2032-2034
the	O	2035-2038
first	O	2039-2044
report	O	2045-2051
that	O	2052-2056
circulating	O	2057-2068
miRNAs	O	2069-2075
serve	O	2076-2081
as	O	2082-2084
biomarkers	O	2085-2095
of	O	2096-2098
endometriosis	O	2099-2112
.	O	2112-2113

MicroRNA	B	0-8
-	I	8-9
137	I	9-12
promoter	O	13-21
methylation	O	22-33
in	O	34-36
oral	O	37-41
lichen	O	42-48
planus	O	49-55
and	O	56-59
oral	O	60-64
squamous	O	65-73
cell	O	74-78
carcinoma	O	79-88
.	O	88-89

Oral	O	90-94
lichen	O	95-101
planus	O	102-108
(	O	109-110
OLP	O	110-113
)	O	113-114
is	O	115-117
a	O	118-119
common	O	120-126
oral	O	127-131
mucosal	O	132-139
disease	O	140-147
,	O	147-148
which	O	149-154
is	O	155-157
generally	O	158-167
considered	O	168-178
a	O	179-180
potentially	O	181-192
malignant	O	193-202
lesion	O	203-209
.	O	209-210

To	O	211-213
identify	O	214-222
efficiently	O	223-234
prognostic	O	235-245
biomarker	O	246-255
,	O	255-256
we	O	257-259
investigated	O	260-272
the	O	273-276
microRNA	B	277-285
-	I	285-286
137	I	286-289
(	O	290-291
miR	B	291-294
-	I	294-295
137	I	295-298
)	O	298-299
promoter	O	300-308
methylation	O	309-320
in	O	321-323
OLP	O	324-327
and	O	328-331
compared	O	332-340
with	O	341-345
the	O	346-349
samples	O	350-357
from	O	358-362
healthy	O	363-370
volunteers	O	371-381
and	O	382-385
patients	O	386-394
with	O	395-399
oral	O	400-404
squamous	O	405-413
cell	O	414-418
carcinoma	O	419-428
(	O	429-430
OSCC	O	430-434
)	O	434-435
.	O	435-436

A	O	437-438
total	O	439-444
of	O	445-447
20	O	448-450
OLP	O	451-454
and	O	455-458
12	O	459-461
patients	O	462-470
with	O	471-475
OSCC	O	476-480
as	O	481-483
well	O	484-488
as	O	489-491
10	O	492-494
healthy	O	495-502
subjects	O	503-511
were	O	512-516
subjected	O	517-526
to	O	527-529
miR	B	530-533
-	I	533-534
137	I	534-537
promoter	O	538-546
methylation	O	547-558
analysis	O	559-567
using	O	568-573
methylation	O	574-585
-	O	585-586
specific	O	586-594
PCR	O	595-598
(	O	599-600
MSP	O	600-603
)	O	603-604
.	O	604-605

To	O	606-608
address	O	609-616
the	O	617-620
malignancy	O	621-631
prediction	O	632-642
potential	O	643-652
from	O	653-657
miR	B	658-661
-	I	661-662
137	I	662-665
promoter	O	666-674
methylation	O	675-686
status	O	687-693
,	O	693-694
methylation	O	695-706
of	O	707-709
the	O	710-713
p16	O	714-717
gene	O	718-722
,	O	722-723
a	O	724-725
well	O	726-730
-	O	730-731
known	O	731-736
tumor	O	737-742
suppressor	O	743-753
,	O	753-754
was	O	755-758
investigated	O	759-771
in	O	772-774
the	O	775-778
same	O	779-783
samples	O	784-791
.	O	791-792

The	O	793-796
p16	O	797-800
methylation	O	801-812
and	O	813-816
miR	B	817-820
-	I	820-821
137	I	821-824
promoter	O	825-833
methylation	O	834-845
were	O	846-850
found	O	851-856
to	O	857-859
be	O	860-862
25	O	863-865
%	O	865-866
and	O	867-870
35	O	871-873
%	O	873-874
in	O	875-877
patients	O	878-886
with	O	887-891
OLP	O	892-895
,	O	895-896
50	O	897-899
%	O	899-900
and	O	901-904
58	O	905-907
.	O	907-908
3	O	908-909
%	O	909-910
in	O	911-913
patients	O	914-922
with	O	923-927
OSCC	O	928-932
,	O	932-933
and	O	934-937
0	O	938-939
%	O	939-940
and	O	941-944
0	O	945-946
%	O	946-947
in	O	948-950
healthy	O	951-958
subjects	O	959-967
,	O	967-968
respectively	O	969-981
.	O	981-982

The	O	983-986
differences	O	987-998
between	O	999-1006
miR	B	1007-1010
-	I	1010-1011
137	I	1011-1014
and	O	1015-1018
p16	O	1019-1022
methylation	O	1023-1034
levels	O	1035-1041
were	O	1042-1046
statistically	O	1047-1060
significant	O	1061-1072
between	O	1073-1080
healthy	O	1081-1088
controls	O	1089-1097
and	O	1098-1101
patients	O	1102-1110
.	O	1110-1111

Methylation	O	1112-1123
levels	O	1124-1130
of	O	1131-1133
the	O	1134-1137
two	O	1138-1141
promoters	O	1142-1151
were	O	1152-1156
also	O	1157-1161
influenced	O	1162-1172
by	O	1173-1175
age	O	1176-1179
,	O	1179-1180
gender	O	1181-1187
,	O	1187-1188
and	O	1189-1192
lesion	O	1193-1199
duration	O	1200-1208
.	O	1208-1209

Interestingly	O	1210-1223
,	O	1223-1224
aberrant	O	1225-1233
promoter	O	1234-1242
methylation	O	1243-1254
of	O	1255-1257
the	O	1258-1261
p16	O	1262-1265
and	O	1266-1269
miR	B	1270-1273
-	I	1273-1274
137	I	1274-1277
genes	O	1278-1283
was	O	1284-1287
only	O	1288-1292
found	O	1293-1298
in	O	1299-1301
the	O	1302-1305
epithelium	O	1306-1316
but	O	1317-1320
not	O	1321-1324
in	O	1325-1327
the	O	1328-1331
connective	O	1332-1342
tissue	O	1343-1349
from	O	1350-1354
patients	O	1355-1363
with	O	1364-1368
OLP	O	1369-1372
.	O	1372-1373

This	O	1374-1378
raises	O	1379-1385
the	O	1386-1389
possibility	O	1390-1401
to	O	1402-1404
use	O	1405-1408
miR	B	1409-1412
-	I	1412-1413
137	I	1413-1416
methylation	O	1417-1428
as	O	1429-1431
a	O	1432-1433
biomarker	O	1434-1443
for	O	1444-1447
malignant	O	1448-1457
prediction	O	1458-1468
in	O	1469-1471
patients	O	1472-1480
with	O	1481-1485
OLP	O	1486-1489
.	O	1489-1490

Antiangiogenic	O	0-14
role	O	15-19
of	O	20-22
miR	B	23-26
-	I	26-27
361	I	27-30
in	O	31-33
human	O	34-39
umbilical	O	40-49
vein	O	50-54
endothelial	O	55-66
cells	O	67-72
:	O	72-73
functional	O	74-84
interaction	O	85-96
with	O	97-101
the	O	102-105
peptide	O	106-113
somatostatin	O	114-126
.	O	126-127

Somatostatin	O	128-140
(	O	141-142
SRIF	O	142-146
)	O	146-147
acts	O	148-152
as	O	153-155
antiangiogenic	O	156-170
factor	O	171-177
,	O	177-178
but	O	179-182
its	O	183-186
role	O	187-191
in	O	192-194
the	O	195-198
regulation	O	199-209
of	O	210-212
microRNAs	O	213-222
(	O	223-224
miRNAs	O	224-230
)	O	230-231
targeting	O	232-241
proangiogenic	O	242-255
factors	O	256-263
is	O	264-266
unknown	O	267-274
.	O	274-275

We	O	276-278
used	O	279-283
human	O	284-289
umbilical	O	290-299
vein	O	300-304
endothelial	O	305-316
cells	O	317-322
(	O	323-324
HUVEC	O	324-329
)	O	329-330
to	O	331-333
investigate	O	334-345
whether	O	346-353
(	O	354-355
1	O	355-356
)	O	356-357
miRNAs	O	358-364
targeting	O	365-374
proangiogenic	O	375-388
factors	O	389-396
are	O	397-400
influenced	O	401-411
by	O	412-414
hypoxia	O	415-422
,	O	422-423
(	O	424-425
2	O	425-426
)	O	426-427
their	O	428-433
expression	O	434-444
is	O	445-447
regulated	O	448-457
by	O	458-460
SRIF	O	461-465
,	O	465-466
and	O	467-470
(	O	471-472
3	O	472-473
)	O	473-474
SRIF	O	475-479
-	O	479-480
regulated	O	480-489
miRNAs	O	490-496
affect	O	497-503
HUVEC	O	504-509
angiogenic	O	510-520
phenotype	O	521-530
.	O	530-531

The	O	532-535
involvement	O	536-547
of	O	548-550
signal	O	551-557
transducer	O	558-568
and	O	569-572
activator	O	573-582
of	O	583-585
transcription	O	586-599
(	O	600-601
STAT	O	601-605
)	O	605-606
3	O	607-608
and	O	609-612
hypoxia	O	613-620
inducible	O	621-630
factor	O	631-637
(	O	638-639
HIF	O	639-642
)	O	642-643
-	O	643-644
1	O	644-645
in	O	646-648
miRNA	O	649-654
effects	O	655-662
was	O	663-666
studied	O	667-674
.	O	674-675

Quantitative	O	676-688
real	O	689-693
-	O	693-694
time	O	694-698
PCR	O	699-702
,	O	702-703
Western	O	704-711
blot	O	712-716
,	O	716-717
cell	O	718-722
proliferation	O	723-736
assays	O	737-743
,	O	743-744
and	O	745-748
enzyme	O	749-755
-	O	755-756
linked	O	756-762
immunosorbent	O	763-776
assay	O	777-782
(	O	783-784
ELISA	O	784-789
)	O	789-790
were	O	791-795
used	O	796-800
.	O	800-801

Using	O	802-807
specific	O	808-816
algorithms	O	817-827
,	O	827-828
three	O	829-834
miRNAs	O	835-841
(	O	842-843
miR	B	843-846
-	I	846-847
17	I	847-849
,	O	849-850
miR	B	851-854
-	I	854-855
18b	I	855-858
,	O	858-859
and	O	860-863
miR	B	864-867
-	I	867-868
361	I	868-871
)	O	871-872
were	O	873-877
predicted	O	878-887
to	O	888-890
bind	O	891-895
angiogenesis	O	896-908
-	O	908-909
associated	O	909-919
factors	O	920-927
including	O	928-937
STAT3	O	938-943
,	O	943-944
HIF	O	945-948
-	O	948-949
1alpha	O	949-955
,	O	955-956
and	O	957-960
vascular	O	961-969
endothelial	O	970-981
growth	O	982-988
factor	O	989-995
(	O	996-997
VEGF	O	997-1001
)	O	1001-1002
.	O	1002-1003

Hypoxia	O	1004-1011
downregulates	O	1012-1025
miR	B	1026-1029
-	I	1029-1030
17	I	1030-1032
and	O	1033-1036
miR	B	1037-1040
-	I	1040-1041
361	I	1041-1044
without	O	1045-1052
affecting	O	1053-1062
miR	B	1063-1066
-	I	1066-1067
18b	I	1067-1070
.	O	1070-1071

SRIF	O	1072-1076
restored	O	1077-1085
decreased	O	1086-1095
levels	O	1096-1102
of	O	1103-1105
miR	B	1106-1109
-	I	1109-1110
361	I	1110-1113
acting	O	1114-1120
at	O	1121-1123
the	O	1124-1127
SRIF	O	1128-1132
receptor	O	1133-1141
sst	O	1142-1145
(	O	1145-1146
1	O	1146-1147
)	O	1147-1148
.	O	1148-1149

Downregulated	O	1150-1163
miR	B	1164-1167
-	I	1167-1168
361	I	1168-1171
was	O	1172-1175
also	O	1176-1180
restored	O	1181-1189
by	O	1190-1192
HIF	O	1193-1196
-	O	1196-1197
1alpha	O	1197-1203
inhibition	O	1204-1214
with	O	1215-1219
YC	O	1220-1222
-	O	1222-1223
1	O	1223-1224
.	O	1224-1225

Combined	O	1226-1234
application	O	1235-1246
of	O	1247-1249
SRIF	O	1250-1254
did	O	1255-1258
not	O	1259-1262
influence	O	1263-1272
YC	O	1273-1275
-	O	1275-1276
1	O	1276-1277
-	O	1277-1278
induced	O	1278-1285
miR	B	1286-1289
-	I	1289-1290
361	I	1290-1293
downregulation	O	1294-1308
,	O	1308-1309
suggesting	O	1310-1320
that	O	1321-1325
YC	O	1326-1328
-	O	1328-1329
1	O	1329-1330
and	O	1331-1334
SRIF	O	1335-1339
modulate	O	1340-1348
miR	B	1349-1352
-	I	1352-1353
361	I	1353-1356
through	O	1357-1364
a	O	1365-1366
common	O	1367-1373
mechanism	O	1374-1383
involving	O	1384-1393
HIF	O	1394-1397
-	O	1397-1398
1alpha	O	1398-1404
.	O	1404-1405

This	O	1406-1410
possibility	O	1411-1422
was	O	1423-1426
confirmed	O	1427-1436
by	O	1437-1439
the	O	1440-1443
result	O	1444-1450
that	O	1451-1455
HIF	O	1456-1459
-	O	1459-1460
1alpha	O	1460-1466
activation	O	1467-1477
in	O	1478-1480
normoxia	O	1481-1489
-	O	1489-1490
downregulated	O	1490-1503
miR	B	1504-1507
-	I	1507-1508
361	I	1508-1511
and	O	1512-1515
that	O	1516-1520
this	O	1521-1525
downregulation	O	1526-1540
was	O	1541-1544
prevented	O	1545-1554
by	O	1555-1557
SRIF	O	1558-1562
.	O	1562-1563

miR	B	1564-1567
-	I	1567-1568
361	I	1568-1571
overexpression	O	1572-1586
reduced	O	1587-1594
hypoxia	O	1595-1602
-	O	1602-1603
induced	O	1603-1610
cell	O	1611-1615
proliferation	O	1616-1629
and	O	1630-1633
VEGF	O	1634-1638
release	O	1639-1646
indicating	O	1647-1657
miR	B	1658-1661
-	I	1661-1662
361	I	1662-1665
involvement	O	1666-1677
in	O	1678-1680
the	O	1681-1684
acquisition	O	1685-1696
of	O	1697-1699
an	O	1700-1702
angiogenic	O	1703-1713
phenotype	O	1714-1723
by	O	1724-1726
HUVEC	O	1727-1732
.	O	1732-1733

miR	B	1734-1737
-	I	1737-1738
361	I	1738-1741
effects	O	1742-1749
on	O	1750-1752
VEGF	O	1753-1757
were	O	1758-1762
enhanced	O	1763-1771
by	O	1772-1774
the	O	1775-1778
coadministration	O	1779-1795
of	O	1796-1798
SRIF	O	1799-1803
.	O	1803-1804

Our	O	1805-1808
results	O	1809-1816
suggest	O	1817-1824
that	O	1825-1829
(	O	1830-1831
1	O	1831-1832
)	O	1832-1833
SRIF	O	1834-1838
regulates	O	1839-1848
miR	B	1849-1852
-	I	1852-1853
361	I	1853-1856
expression	O	1857-1867
through	O	1868-1875
a	O	1876-1877
control	O	1878-1885
on	O	1886-1888
HIF	O	1889-1892
-	O	1892-1893
1	O	1893-1894
,	O	1894-1895
(	O	1896-1897
2	O	1897-1898
)	O	1898-1899
miR	B	1900-1903
-	I	1903-1904
361	I	1904-1907
affects	O	1908-1915
HUVEC	O	1916-1921
angiogenic	O	1922-1932
phenotype	O	1933-1942
,	O	1942-1943
and	O	1944-1947
(	O	1948-1949
3	O	1949-1950
)	O	1950-1951
SRIF	O	1952-1956
and	O	1957-1960
miR	B	1961-1964
-	I	1964-1965
361	I	1965-1968
act	O	1969-1972
cooperatively	O	1973-1986
in	O	1987-1989
limiting	O	1990-1998
hypoxia	O	1999-2006
-	O	2006-2007
induced	O	2007-2014
VEGF	O	2015-2019
release	O	2020-2027
.	O	2027-2028

The	O	0-3
role	O	4-8
of	O	9-11
microRNA	O	12-20
in	O	21-23
metastatic	O	24-34
colorectal	O	35-45
cancer	O	46-52
and	O	53-56
its	O	57-60
significance	O	61-73
in	O	74-76
cancer	O	77-83
prognosis	O	84-93
and	O	94-97
treatment	O	98-107
.	O	107-108

microRNAs	O	109-118
(	O	119-120
miRNAs	O	120-126
)	O	126-127
are	O	128-131
small	O	132-137
,	O	137-138
non	O	139-142
-	O	142-143
coding	O	143-149
RNA	O	150-153
molecules	O	154-163
that	O	164-168
regulate	O	169-177
gene	O	178-182
expression	O	183-193
by	O	194-196
targeting	O	197-206
specific	O	207-215
mRNAs	O	216-221
.	O	221-222

microRNAs	O	223-232
play	O	233-237
a	O	238-239
role	O	240-244
in	O	245-247
several	O	248-255
physiological	O	256-269
processes	O	270-279
in	O	280-282
the	O	283-286
cell	O	287-291
,	O	291-292
including	O	293-302
migration	O	303-312
,	O	312-313
proliferation	O	314-327
,	O	327-328
differentiation	O	329-344
and	O	345-348
apoptosis	O	349-358
.	O	358-359

Apart	O	360-365
from	O	366-370
their	O	371-376
role	O	377-381
in	O	382-384
regular	O	385-392
metabolism	O	393-403
,	O	403-404
abnormal	O	405-413
profiles	O	414-422
of	O	423-425
miRNA	O	426-431
expression	O	432-442
accompany	O	443-452
cancer	O	453-459
transformation	O	460-474
,	O	474-475
including	O	476-485
colorectal	O	486-496
cancer	O	497-503
(	O	504-505
CRC	O	505-508
)	O	508-509
metastasis	O	510-520
.	O	520-521

microRNAs	O	522-531
may	O	532-535
play	O	536-540
a	O	541-542
role	O	543-547
in	O	548-550
each	O	551-555
phase	O	556-561
of	O	562-564
CRC	O	565-568
metastasis	O	569-579
including	O	580-589
angiogenesis	O	590-602
,	O	602-603
invasion	O	604-612
,	O	612-613
intravasation	O	614-627
,	O	627-628
circulation	O	629-640
,	O	640-641
extravasation	O	642-655
and	O	656-659
metastatic	O	660-670
colonization	O	671-683
.	O	683-684

microRNA	O	685-693
levels	O	694-700
may	O	701-704
serve	O	705-710
as	O	711-713
a	O	714-715
predictive	O	716-726
CRC	O	727-730
marker	O	731-737
,	O	737-738
which	O	739-744
was	O	745-748
confirmed	O	749-758
by	O	759-761
the	O	762-765
serum	O	766-771
level	O	772-777
of	O	778-780
miR	B	781-784
-	I	784-785
29a	I	785-788
targeting	O	789-798
KLF4	O	799-803
,	O	803-804
a	O	805-806
marker	O	807-813
of	O	814-816
cell	O	817-821
stemness	O	822-830
,	O	830-831
and	O	832-835
the	O	836-839
plasma	O	840-846
level	O	847-852
of	O	853-855
miR	B	856-859
-	I	859-860
221	I	860-863
down	O	864-868
-	O	868-869
regulating	O	869-879
c	O	880-881
-	O	881-882
Kit	O	882-885
,	O	885-886
Stat5A	O	887-893
and	O	894-897
ETS1	O	898-902
,	O	902-903
which	O	904-909
are	O	910-913
signal	O	914-920
transducers	O	921-932
and	O	933-936
transcription	O	937-950
factor	O	951-957
,	O	957-958
respectively	O	959-971
.	O	971-972

In	O	973-975
turn	O	976-980
,	O	980-981
the	O	982-985
level	O	986-991
of	O	992-994
miR	B	995-998
-	I	998-999
143	I	999-1002
in	O	1003-1005
CRC	O	1006-1009
cells	O	1010-1015
decreasing	O	1016-1026
the	O	1027-1030
amount	O	1031-1037
of	O	1038-1040
MACC1	O	1041-1046
(	O	1047-1048
metastasis	O	1048-1058
-	O	1058-1059
associated	O	1059-1069
in	O	1070-1072
colon	O	1073-1078
cancer	O	1079-1085
-	O	1085-1086
1	O	1086-1087
)	O	1087-1088
and	O	1089-1092
oncogenic	O	1093-1102
KRAS	O	1103-1107
protein	O	1108-1115
,	O	1115-1116
may	O	1117-1120
be	O	1121-1123
utilized	O	1124-1132
as	O	1133-1135
a	O	1136-1137
prognostic	O	1138-1148
marker	O	1149-1155
.	O	1155-1156

Also	O	1157-1161
,	O	1161-1162
single	O	1163-1169
nucleotide	O	1170-1180
polymorphisms	O	1181-1194
of	O	1195-1197
genes	O	1198-1203
encoding	O	1204-1212
miRNAs	O	1213-1219
,	O	1219-1220
including	O	1221-1230
miR	B	1231-1234
-	I	1234-1235
423	I	1235-1238
and	O	1239-1242
miR	B	1243-1246
-	I	1246-1247
608	I	1247-1250
,	O	1250-1251
which	O	1252-1257
correlate	O	1258-1267
with	O	1268-1272
tumor	O	1273-1278
recurrence	O	1279-1289
,	O	1289-1290
may	O	1291-1294
be	O	1295-1297
useful	O	1298-1304
as	O	1305-1307
diagnostic	O	1308-1318
,	O	1318-1319
prognostic	O	1320-1330
and	O	1331-1334
predictive	O	1335-1345
indicators	O	1346-1356
in	O	1357-1359
CRC	O	1360-1363
metastasis	O	1364-1374
.	O	1374-1375

Pre	O	1376-1379
-	O	1379-1380
miR	B	1380-1383
-	I	1383-1384
34a	I	1384-1387
and	O	1388-1391
pre	O	1392-1395
-	O	1395-1396
miR	B	1396-1399
-	I	1399-1400
199a	I	1400-1404
decreased	O	1405-1414
the	O	1415-1418
level	O	1419-1424
of	O	1425-1427
Axl	O	1428-1431
,	O	1431-1432
a	O	1433-1434
tyrosine	O	1435-1443
-	O	1443-1444
protein	O	1444-1451
kinase	O	1452-1458
receptor	O	1459-1467
,	O	1467-1468
so	O	1469-1471
they	O	1472-1476
can	O	1477-1480
be	O	1481-1483
considered	O	1484-1494
as	O	1495-1497
drugs	O	1498-1503
in	O	1504-1506
antimetastatic	O	1507-1521
therapy	O	1522-1529
.	O	1529-1530

On	O	1531-1533
the	O	1534-1537
other	O	1538-1543
hand	O	1544-1548
,	O	1548-1549
miR	B	1550-1553
-	I	1553-1554
222	I	1554-1557
targeting	O	1558-1567
ADAM	O	1568-1572
-	O	1572-1573
17	O	1573-1575
,	O	1575-1576
a	O	1577-1578
disintegrin	O	1579-1590
and	O	1591-1594
metalloproteinase	O	1595-1612
,	O	1612-1613
and	O	1614-1617
miR	B	1618-1621
-	I	1621-1622
328	I	1622-1625
interacting	O	1626-1637
with	O	1638-1642
ABCG2	O	1643-1648
,	O	1648-1649
an	O	1650-1652
ABC	O	1653-1656
transporter	O	1657-1668
,	O	1668-1669
may	O	1670-1673
overcome	O	1674-1682
drug	O	1683-1687
resistance	O	1688-1698
of	O	1699-1701
cancer	O	1702-1708
cells	O	1709-1714
.	O	1714-1715

microRNAs	O	1716-1725
may	O	1726-1729
be	O	1730-1732
considered	O	1733-1743
in	O	1744-1746
wide	O	1747-1751
-	O	1751-1752
range	O	1752-1757
application	O	1758-1769
to	O	1770-1772
facilitate	O	1773-1783
CRC	O	1784-1787
metastasis	O	1788-1798
diagnosis	O	1799-1808
,	O	1808-1809
prognosis	O	1810-1819
,	O	1819-1820
prediction	O	1821-1831
and	O	1832-1835
therapy	O	1836-1843
,	O	1843-1844
however	O	1845-1852
,	O	1852-1853
further	O	1854-1861
clinical	O	1862-1870
,	O	1870-1871
epidemiological	O	1872-1887
and	O	1888-1891
in	O	1892-1894
vitro	O	1895-1900
studies	O	1901-1908
should	O	1909-1915
be	O	1916-1918
conducted	O	1919-1928
to	O	1929-1931
verify	O	1932-1938
their	O	1939-1944
utility	O	1945-1952
.	O	1952-1953

BCR	O	0-3
-	O	3-4
ABL	O	4-7
mediated	O	8-16
repression	O	17-27
of	O	28-30
miR	B	31-34
-	I	34-35
223	I	35-38
results	O	39-46
in	O	47-49
the	O	50-53
activation	O	54-64
of	O	65-67
MEF2C	O	68-73
and	O	74-77
PTBP2	O	78-83
in	O	84-86
chronic	O	87-94
myeloid	O	95-102
leukemia	O	103-111
.	O	111-112

Epigenetic	O	0-10
activation	O	11-21
of	O	22-24
the	O	25-28
MiR	B	29-32
-	I	32-33
200	I	33-36
family	O	37-43
contributes	O	44-55
to	O	56-58
H19	O	59-62
-	O	62-63
mediated	O	63-71
metastasis	O	72-82
suppression	O	83-94
in	O	95-97
hepatocellular	O	98-112
carcinoma	O	113-122
.	O	122-123

Although	O	124-132
numerous	O	133-141
long	O	142-146
non	O	147-150
-	O	150-151
coding	O	151-157
RNAs	O	158-162
(	O	163-164
lncRNAs	O	164-171
)	O	171-172
have	O	173-177
been	O	178-182
identified	O	183-193
in	O	194-196
mammals	O	197-204
,	O	204-205
many	O	206-210
of	O	211-213
their	O	214-219
biological	O	220-230
roles	O	231-236
remain	O	237-243
to	O	244-246
be	O	247-249
characterized	O	250-263
.	O	263-264

Early	O	265-270
reports	O	271-278
suggest	O	279-286
that	O	287-291
H19	O	292-295
contributes	O	296-307
to	O	308-310
carcinogenesis	O	311-325
,	O	325-326
including	O	327-336
hepatocellular	O	337-351
carcinoma	O	352-361
(	O	362-363
HCC	O	363-366
)	O	366-367
.	O	367-368

Examination	O	369-380
of	O	381-383
the	O	384-387
Oncomine	O	388-396
resource	O	397-405
showed	O	406-412
that	O	413-417
most	O	418-422
HCC	O	423-426
cases	O	427-432
express	O	433-440
H19	O	441-444
at	O	445-447
a	O	448-449
level	O	450-455
that	O	456-460
is	O	461-463
comparable	O	464-474
with	O	475-479
the	O	480-483
liver	O	484-489
,	O	489-490
with	O	491-495
a	O	496-497
tendency	O	498-506
toward	O	507-513
lower	O	514-519
expression	O	520-530
.	O	530-531

This	O	532-536
is	O	537-539
consistent	O	540-550
with	O	551-555
our	O	556-559
previous	O	560-568
microarray	O	569-579
data	O	580-584
and	O	585-588
indicates	O	589-598
a	O	599-600
more	O	601-605
complicated	O	606-617
role	O	618-622
of	O	623-625
H19	O	626-629
in	O	630-632
HCC	O	633-636
that	O	637-641
needs	O	642-647
to	O	648-650
be	O	651-653
characterized	O	654-667
.	O	667-668

In	O	669-671
this	O	672-676
study	O	677-682
,	O	682-683
the	O	684-687
expression	O	688-698
level	O	699-704
of	O	705-707
H19	O	708-711
was	O	712-715
assessed	O	716-724
in	O	725-727
different	O	728-737
regions	O	738-745
of	O	746-748
HCC	O	749-752
patients	O	753-761
'	O	761-762
liver	O	763-768
samples	O	769-776
.	O	776-777

Loss	O	778-782
-	O	782-783
and	O	784-787
gain	O	788-792
-	O	792-793
of	O	793-795
-	O	795-796
function	O	796-804
studies	O	805-812
on	O	813-815
this	O	816-820
lncRNA	O	821-827
in	O	828-830
the	O	831-834
HCC	O	835-838
cell	O	839-843
lines	O	844-849
,	O	849-850
SMMC7721	O	851-859
and	O	860-863
HCCLM3	O	864-870
,	O	870-871
were	O	872-876
used	O	877-881
to	O	882-884
characterize	O	885-897
its	O	898-901
effects	O	902-909
on	O	910-912
gene	O	913-917
expression	O	918-928
and	O	929-932
to	O	933-935
assess	O	936-942
its	O	943-946
effect	O	947-953
on	O	954-956
HCC	O	957-960
metastasis	O	961-971
both	O	972-976
in	O	977-979
vitro	O	980-985
and	O	986-989
in	O	990-992
vivo	O	993-997
.	O	997-998

In	O	999-1001
this	O	1002-1006
study	O	1007-1012
,	O	1012-1013
we	O	1014-1016
show	O	1017-1021
that	O	1022-1026
H19	O	1027-1030
was	O	1031-1034
underexpressed	O	1035-1049
in	O	1050-1052
intratumoral	O	1053-1065
HCC	O	1066-1069
tissues	O	1070-1077
(	O	1078-1079
T	O	1079-1080
)	O	1080-1081
,	O	1081-1082
as	O	1083-1085
compared	O	1086-1094
with	O	1095-1099
peritumoral	O	1100-1111
tissues	O	1112-1119
(	O	1120-1121
L	O	1121-1122
)	O	1122-1123
.	O	1123-1124

Additionally	O	1125-1137
,	O	1137-1138
low	O	1139-1142
T	O	1143-1144
/	O	1144-1145
L	O	1145-1146
ratio	O	1147-1152
of	O	1153-1155
H19	O	1156-1159
predicted	O	1160-1169
poor	O	1170-1174
prognosis	O	1175-1184
.	O	1184-1185

H19	O	1186-1189
suppressed	O	1190-1200
HCC	O	1201-1204
progression	O	1205-1216
metastasis	O	1217-1227
and	O	1228-1231
the	O	1232-1235
expression	O	1236-1246
of	O	1247-1249
markers	O	1250-1257
of	O	1258-1260
epithelial	O	1261-1271
-	O	1271-1272
to	O	1272-1274
-	O	1274-1275
mesenchymal	O	1275-1286
transition	O	1287-1297
.	O	1297-1298

Furthermore	O	1299-1310
,	O	1310-1311
H19	O	1312-1315
associated	O	1316-1326
with	O	1327-1331
the	O	1332-1335
protein	O	1336-1343
complex	O	1344-1351
hnRNP	O	1352-1357
U	O	1358-1359
/	O	1359-1360
PCAF	O	1360-1364
/	O	1364-1365
RNAPol	O	1365-1371
II	O	1372-1374
,	O	1374-1375
activating	O	1376-1386
miR	B	1387-1390
-	I	1390-1391
200	I	1391-1394
family	O	1395-1401
by	O	1402-1404
increasing	O	1405-1415
histone	O	1416-1423
acetylation	O	1424-1435
.	O	1435-1436

The	O	1437-1440
results	O	1441-1448
demonstrate	O	1449-1460
that	O	1461-1465
H19	O	1466-1469
can	O	1470-1473
alter	O	1474-1479
the	O	1480-1483
miR	B	1484-1487
-	I	1487-1488
200	I	1488-1491
pathway	O	1492-1499
,	O	1499-1500
thus	O	1501-1505
contributing	O	1506-1518
to	O	1519-1521
mesenchymal	O	1522-1533
-	O	1533-1534
to	O	1534-1536
-	O	1536-1537
epithelial	O	1537-1547
transition	O	1548-1558
and	O	1559-1562
to	O	1563-1565
the	O	1566-1569
suppression	O	1570-1581
of	O	1582-1584
tumor	O	1585-1590
metastasis	O	1591-1601
.	O	1601-1602

These	O	1603-1608
data	O	1609-1613
provide	O	1614-1621
an	O	1622-1624
explanation	O	1625-1636
for	O	1637-1640
the	O	1641-1644
hitherto	O	1645-1653
puzzling	O	1654-1662
literature	O	1663-1673
on	O	1674-1676
the	O	1677-1680
relationship	O	1681-1693
between	O	1694-1701
H19	O	1702-1705
and	O	1706-1709
cancer	O	1710-1716
,	O	1716-1717
and	O	1718-1721
could	O	1722-1727
suggest	O	1728-1735
the	O	1736-1739
development	O	1740-1751
of	O	1752-1754
combination	O	1755-1766
therapies	O	1767-1776
that	O	1777-1781
target	O	1782-1788
H19	O	1789-1792
and	O	1793-1796
the	O	1797-1800
miR	B	1801-1804
-	I	1804-1805
200	I	1805-1808
family	O	1809-1815
.	O	1815-1816

A	O	0-1
MicroRNA196a2	B	2-15
*	I	15-16
and	O	17-20
TP63	O	21-25
circuit	O	26-33
regulated	O	34-43
by	O	44-46
estrogen	O	47-55
receptor	O	56-64
-	O	64-65
alpha	O	65-70
and	O	71-74
ERK2	O	75-79
that	O	80-84
controls	O	85-93
breast	O	94-100
cancer	O	101-107
proliferation	O	108-121
and	O	122-125
invasiveness	O	126-138
properties	O	139-149
.	O	149-150

Estrogen	O	151-159
receptor	O	160-168
alpha	O	169-174
(	O	175-176
ERalpha	O	176-183
)	O	183-184
is	O	185-187
present	O	188-195
in	O	196-198
about	O	199-204
70	O	205-207
%	O	208-209
of	O	210-212
human	O	213-218
breast	O	219-225
cancers	O	226-233
and	O	234-237
,	O	237-238
working	O	239-246
in	O	247-249
conjunction	O	250-261
with	O	262-266
extracellular	O	267-280
signal	O	281-287
-	O	287-288
regulated	O	288-297
kinase	O	298-304
2	O	305-306
(	O	307-308
ERK2	O	308-312
)	O	312-313
,	O	313-314
this	O	315-319
nuclear	O	320-327
hormone	O	328-335
receptor	O	336-344
regulates	O	345-354
the	O	355-358
expression	O	359-369
of	O	370-372
many	O	373-377
protein	O	378-385
-	O	385-386
encoding	O	386-394
genes	O	395-400
.	O	400-401

Given	O	402-407
the	O	408-411
crucial	O	412-419
roles	O	420-425
of	O	426-428
miRNAs	O	429-435
in	O	436-438
cancer	O	439-445
biology	O	446-453
,	O	453-454
we	O	455-457
investigated	O	458-470
the	O	471-474
regulation	O	475-485
of	O	486-488
miRNAs	O	489-495
by	O	496-498
estradiol	O	499-508
(	O	509-510
E2	O	510-512
)	O	512-513
through	O	514-521
ERalpha	O	522-529
and	O	530-533
ERK2	O	534-538
,	O	538-539
and	O	540-543
their	O	544-549
impact	O	550-556
on	O	557-559
target	O	560-566
gene	O	567-571
expression	O	572-582
and	O	583-586
phenotypic	O	587-597
properties	O	598-608
of	O	609-611
breast	O	612-618
cancer	O	619-625
cells	O	626-631
.	O	631-632

We	O	633-635
identified	O	636-646
miRNA	O	647-652
-	O	652-653
encoding	O	653-661
genes	O	662-667
harboring	O	668-677
overlapping	O	678-689
ERalpha	O	690-697
and	O	698-701
ERK	O	702-705
chromatin	O	706-715
binding	O	716-723
sites	O	724-729
in	O	730-732
ERalpha	O	733-740
-	O	740-741
positive	O	741-749
MCF	O	750-753
-	O	753-754
7	O	754-755
cells	O	756-761
and	O	762-765
showed	O	766-772
ERalpha	O	773-780
and	O	781-784
ERK2	O	785-789
to	O	790-792
bind	O	793-797
to	O	798-800
these	O	801-806
sites	O	807-812
and	O	813-816
to	O	817-819
be	O	820-822
required	O	823-831
for	O	832-835
transcriptional	O	836-851
induction	O	852-861
of	O	862-864
these	O	865-870
miRNAs	O	871-877
by	O	878-880
E2	O	881-883
.	O	883-884

Hsa	B	885-888
-	I	888-889
miR	I	889-892
-	I	892-893
196a2	I	893-898
*	I	898-899
,	O	899-900
the	O	901-904
most	O	905-909
highly	O	910-916
estrogen	O	917-925
up	O	926-928
-	O	928-929
regulated	O	929-938
miRNA	O	939-944
,	O	944-945
markedly	O	946-954
down	O	955-959
-	O	959-960
regulated	O	960-969
tumor	O	970-975
protein	O	976-983
p63	O	984-987
(	O	988-989
TP63	O	989-993
)	O	993-994
,	O	994-995
a	O	996-997
member	O	998-1004
of	O	1005-1007
the	O	1008-1011
p53	O	1012-1015
family	O	1016-1022
.	O	1022-1023

In	O	1024-1026
ERalpha	O	1027-1034
-	O	1034-1035
positive	O	1035-1043
and	O	1044-1047
ERalpha	O	1048-1055
-	O	1055-1056
negative	O	1056-1064
breast	O	1065-1071
cancer	O	1072-1078
cells	O	1079-1084
,	O	1084-1085
proliferative	O	1086-1099
and	O	1100-1103
invasiveness	O	1104-1116
properties	O	1117-1127
were	O	1128-1132
suppressed	O	1133-1143
by	O	1144-1146
hsa	B	1147-1150
-	I	1150-1151
miR	I	1151-1154
-	I	1154-1155
196a2	I	1155-1160
*	I	1160-1161
expression	O	1162-1172
and	O	1173-1176
enhanced	O	1177-1185
by	O	1186-1188
hsa	B	1189-1192
-	I	1192-1193
miR	I	1193-1196
-	I	1196-1197
196a2	I	1197-1202
*	I	1202-1203
antagonism	O	1204-1214
or	O	1215-1217
TP63	O	1218-1222
target	O	1223-1229
protector	O	1230-1239
oligonucleotides	O	1240-1256
.	O	1256-1257

Hsa	B	1258-1261
-	I	1261-1262
miR	I	1262-1265
-	I	1265-1266
196a2	I	1266-1271
*	I	1271-1272
and	O	1273-1276
TP63	O	1277-1281
were	O	1282-1286
inversely	O	1287-1296
correlated	O	1297-1307
in	O	1308-1310
breast	O	1311-1317
cancer	O	1318-1324
cell	O	1325-1329
lines	O	1330-1335
and	O	1336-1339
in	O	1340-1342
a	O	1343-1344
large	O	1345-1350
cohort	O	1351-1357
of	O	1358-1360
human	O	1361-1366
breast	O	1367-1373
tumors	O	1374-1380
,	O	1380-1381
implying	O	1382-1390
clinical	O	1391-1399
relevance	O	1400-1409
.	O	1409-1410

The	O	1411-1414
findings	O	1415-1423
reveal	O	1424-1430
a	O	1431-1432
tumor	O	1433-1438
suppressive	O	1439-1450
role	O	1451-1455
of	O	1456-1458
hsa	O	1459-1462
-	O	1462-1463
miR	O	1463-1466
-	O	1466-1467
196a2	O	1467-1472
*	O	1472-1473
through	O	1474-1481
regulation	O	1482-1492
of	O	1493-1495
TP63	O	1496-1500
by	O	1501-1503
ERalpha	O	1504-1511
and	O	1512-1515
/	O	1515-1516
or	O	1516-1518
ERK2	O	1519-1523
signaling	O	1524-1533
.	O	1533-1534

Manipulating	O	1535-1547
the	O	1548-1551
hsa	B	1552-1555
-	I	1555-1556
miR	I	1556-1559
-	I	1559-1560
196a2	I	1560-1565
*	I	1565-1566
-	O	1566-1567
TP63	O	1567-1571
axis	O	1572-1576
might	O	1577-1582
provide	O	1583-1590
a	O	1591-1592
potential	O	1593-1602
tumor	O	1603-1608
-	O	1608-1609
suppressive	O	1609-1620
strategy	O	1621-1629
to	O	1630-1632
alleviate	O	1633-1642
the	O	1643-1646
aggressive	O	1647-1657
behavior	O	1658-1666
and	O	1667-1670
poor	O	1671-1675
prognosis	O	1676-1685
of	O	1686-1688
some	O	1689-1693
ERalpha	O	1694-1701
-	O	1701-1702
positive	O	1702-1710
as	O	1711-1713
well	O	1714-1718
as	O	1719-1721
many	O	1722-1726
ERalpha	O	1727-1734
-	O	1734-1735
negative	O	1735-1743
breast	O	1744-1750
cancers	O	1751-1758
.	O	1758-1759

MiR	B	0-3
-	I	3-4
124	I	4-7
targets	O	8-15
Slug	O	16-20
to	O	21-23
regulate	O	24-32
epithelial	O	33-43
-	O	43-44
mesenchymal	O	44-55
transition	O	56-66
and	O	67-70
metastasis	O	71-81
of	O	82-84
breast	O	85-91
cancer	O	92-98
.	O	98-99

MicroRNAs	O	100-109
(	O	110-111
miRNAs	O	111-117
or	O	118-120
miR	O	121-124
)	O	124-125
have	O	126-130
been	O	131-135
integrated	O	136-146
into	O	147-151
tumorigenic	O	152-163
programs	O	164-172
as	O	173-175
either	O	176-182
oncogenes	O	183-192
or	O	193-195
tumor	O	196-201
suppressor	O	202-212
genes	O	213-218
.	O	218-219

The	O	220-223
miR	B	224-227
-	I	227-228
124	I	228-231
was	O	232-235
reported	O	236-244
to	O	245-247
be	O	248-250
attenuated	O	251-261
in	O	262-264
several	O	265-272
tumors	O	273-279
,	O	279-280
such	O	281-285
as	O	286-288
glioma	O	289-295
,	O	295-296
medulloblastoma	O	297-312
and	O	313-316
hepatocellular	O	317-331
carcinoma	O	332-341
.	O	341-342

However	O	343-350
,	O	350-351
its	O	352-355
role	O	356-360
in	O	361-363
cancer	O	364-370
remains	O	371-378
greatly	O	379-386
elusive	O	387-394
.	O	394-395

In	O	396-398
this	O	399-403
study	O	404-409
,	O	409-410
we	O	411-413
show	O	414-418
that	O	419-423
the	O	424-427
miR	B	428-431
-	I	431-432
124	I	432-435
expression	O	436-446
is	O	447-449
significantly	O	450-463
suppressed	O	464-474
in	O	475-477
human	O	478-483
breast	O	484-490
cancer	O	491-497
specimens	O	498-507
,	O	507-508
which	O	509-514
is	O	515-517
reversely	O	518-527
correlated	O	528-538
to	O	539-541
histological	O	542-554
grade	O	555-560
of	O	561-563
the	O	564-567
cancer	O	568-574
.	O	574-575

More	O	576-580
intriguingly	O	581-593
,	O	593-594
ectopic	O	595-602
expression	O	603-613
of	O	614-616
miR	B	617-620
-	I	620-621
124	I	621-624
in	O	625-627
aggressive	O	628-638
breast	O	639-645
cancer	O	646-652
cell	O	653-657
lines	O	658-663
MDA	O	664-667
-	O	667-668
MB	O	668-670
-	O	670-671
231	O	671-674
and	O	675-678
BT	O	679-681
-	O	681-682
549	O	682-685
strongly	O	686-694
inhibits	O	695-703
cell	O	704-708
motility	O	709-717
and	O	718-721
invasive	O	722-730
capacity	O	731-739
,	O	739-740
as	O	741-743
well	O	744-748
as	O	749-751
the	O	752-755
epithelial	O	756-766
-	O	766-767
mesenchymal	O	767-778
transition	O	779-789
process	O	790-797
.	O	797-798

Also	O	799-803
,	O	803-804
lentivirus	O	805-815
-	O	815-816
delivered	O	816-825
miR	B	826-829
-	I	829-830
124	I	830-833
endows	O	834-840
MDA	O	841-844
-	O	844-845
MB	O	845-847
-	O	847-848
231	O	848-851
cells	O	852-857
with	O	858-862
the	O	863-866
ability	O	867-874
to	O	875-877
suppress	O	878-886
cell	O	887-891
colony	O	892-898
formation	O	899-908
in	O	909-911
vitro	O	912-917
and	O	918-921
pulmonary	O	922-931
metastasis	O	932-942
in	O	943-945
vivo	O	946-950
.	O	950-951

Further	O	952-959
studies	O	960-967
have	O	968-972
identified	O	973-983
the	O	984-987
E	O	988-989
-	O	989-990
cadherin	O	990-998
transcription	O	999-1012
repressor	O	1013-1022
Slug	O	1023-1027
as	O	1028-1030
a	O	1031-1032
direct	O	1033-1039
target	O	1040-1046
gene	O	1047-1051
of	O	1052-1054
miR	B	1055-1058
-	I	1058-1059
124	I	1059-1062
;	O	1062-1063
its	O	1064-1067
downregulation	O	1068-1082
by	O	1083-1085
miR	B	1086-1089
-	I	1089-1090
124	I	1090-1093
increases	O	1094-1103
the	O	1104-1107
expression	O	1108-1118
of	O	1119-1121
E	O	1122-1123
-	O	1123-1124
cadherin	O	1124-1132
,	O	1132-1133
a	O	1134-1135
hallmark	O	1136-1144
of	O	1145-1147
epithelial	O	1148-1158
cells	O	1159-1164
and	O	1165-1168
a	O	1169-1170
repressor	O	1171-1180
of	O	1181-1183
cell	O	1184-1188
invasion	O	1189-1197
and	O	1198-1201
metastasis	O	1202-1212
.	O	1212-1213

Moreover	O	1214-1222
,	O	1222-1223
knockdown	O	1224-1233
of	O	1234-1236
Slug	O	1237-1241
notably	O	1242-1249
impairs	O	1250-1257
the	O	1258-1261
motility	O	1262-1270
of	O	1271-1273
MDA	O	1274-1277
-	O	1277-1278
MB	O	1278-1280
-	O	1280-1281
231	O	1281-1284
cells	O	1285-1290
,	O	1290-1291
whereas	O	1292-1299
re	O	1300-1302
-	O	1302-1303
expression	O	1303-1313
of	O	1314-1316
Slug	O	1317-1321
abrogates	O	1322-1331
the	O	1332-1335
reduction	O	1336-1345
of	O	1346-1348
motility	O	1349-1357
and	O	1358-1361
invasion	O	1362-1370
ability	O	1371-1378
induced	O	1379-1386
by	O	1387-1389
miR	B	1390-1393
-	I	1393-1394
124	I	1394-1397
in	O	1398-1400
MDA	O	1401-1404
-	O	1404-1405
MB	O	1405-1407
-	O	1407-1408
231	O	1408-1411
cells	O	1412-1417
.	O	1417-1418

These	O	1419-1424
findings	O	1425-1433
highlight	O	1434-1443
an	O	1444-1446
important	O	1447-1456
role	O	1457-1461
for	O	1462-1465
miR	B	1466-1469
-	I	1469-1470
124	I	1470-1473
in	O	1474-1476
the	O	1477-1480
regulation	O	1481-1491
of	O	1492-1494
invasive	O	1495-1503
and	O	1504-1507
metastatic	O	1508-1518
potential	O	1519-1528
of	O	1529-1531
breast	O	1532-1538
cancer	O	1539-1545
and	O	1546-1549
suggest	O	1550-1557
a	O	1558-1559
potential	O	1560-1569
application	O	1570-1581
of	O	1582-1584
miR	B	1585-1588
-	I	1588-1589
124	I	1589-1592
in	O	1593-1595
cancer	O	1596-1602
treatment	O	1603-1612
.	O	1612-1613

SOX4	O	0-4
transcriptionally	O	5-22
regulates	O	23-32
multiple	O	33-41
SEMA3	O	42-47
/	O	47-48
plexin	O	48-54
family	O	55-61
members	O	62-69
and	O	70-73
promotes	O	74-82
tumor	O	83-88
growth	O	89-95
in	O	96-98
pancreatic	O	99-109
cancer	O	110-116
.	O	116-117

Semaphorin	O	118-128
signaling	O	129-138
through	O	139-146
Plexin	O	147-153
frequently	O	154-164
participates	O	165-177
in	O	178-180
tumorigenesis	O	181-194
and	O	195-198
malignant	O	199-208
progression	O	209-220
in	O	221-223
various	O	224-231
types	O	232-237
of	O	238-240
cancer	O	241-247
.	O	247-248

In	O	249-251
particular	O	252-262
,	O	262-263
the	O	264-267
role	O	268-272
of	O	273-275
semaphorin	O	276-286
signaling	O	287-296
in	O	297-299
pancreatic	O	300-310
ductal	O	311-317
adenocarcinoma	O	318-332
(	O	333-334
PDAC	O	334-338
)	O	338-339
remains	O	340-347
unexplored	O	348-358
,	O	358-359
despite	O	360-367
a	O	368-369
high	O	370-374
likelihood	O	375-385
of	O	386-388
metastasis	O	389-399
and	O	400-403
mortality	O	404-413
.	O	413-414

Unlike	O	415-421
other	O	422-427
epithelial	O	428-438
malignancies	O	439-451
that	O	452-456
often	O	457-462
express	O	463-470
a	O	471-472
small	O	473-478
number	O	479-485
of	O	486-488
specific	O	489-497
genes	O	498-503
in	O	504-506
the	O	507-510
Semaphorin	O	511-521
/	O	521-522
Plexin	O	522-528
family	O	529-535
,	O	535-536
five	O	537-541
or	O	542-544
more	O	545-549
are	O	550-553
often	O	554-559
expressed	O	560-569
in	O	570-572
human	O	573-578
PDAC	O	579-583
.	O	583-584

Such	O	585-589
concomitant	O	590-601
expression	O	602-612
of	O	613-615
these	O	616-621
SEMA3	O	622-627
/	O	627-628
Plexin	O	628-634
family	O	635-641
members	O	642-649
is	O	650-652
not	O	653-656
a	O	657-658
result	O	659-665
of	O	666-668
gene	O	669-673
amplification	O	674-687
,	O	687-688
but	O	689-692
(	O	693-694
at	O	694-696
least	O	697-702
partially	O	703-712
)	O	712-713
from	O	714-718
increased	O	719-728
gene	O	729-733
transcription	O	734-747
activated	O	748-757
by	O	758-760
SOX4	O	761-765
de	O	766-768
novo	O	769-773
expressed	O	774-783
in	O	784-786
PDAC	O	787-791
.	O	791-792

Via	O	793-796
chromatin	O	797-806
-	O	806-807
immunoprecipitation	O	807-826
,	O	826-827
luciferase	O	828-838
promoter	O	839-847
activity	O	848-856
assay	O	857-862
and	O	863-866
electrophoresis	O	867-882
mobility	O	883-891
shift	O	892-897
assay	O	898-903
,	O	903-904
SOX4	O	905-909
is	O	910-912
demonstrated	O	913-925
to	O	926-928
bind	O	929-933
to	O	934-936
the	O	937-940
consensus	O	941-950
site	O	951-955
at	O	956-958
the	O	959-962
promoter	O	963-971
of	O	972-974
each	O	975-979
SEMA3	O	980-985
and	O	986-989
Plexin	O	990-996
gene	O	997-1001
to	O	1002-1004
enhance	O	1005-1012
transcription	O	1013-1026
activity	O	1027-1035
.	O	1035-1036

Conversely	O	1037-1047
,	O	1047-1048
RNAi	O	1049-1053
-	O	1053-1054
knockdown	O	1054-1063
of	O	1064-1066
SOX4	O	1067-1071
in	O	1072-1074
PDAC	O	1075-1079
cell	O	1080-1084
lines	O	1085-1090
results	O	1091-1098
in	O	1099-1101
decreased	O	1102-1111
expression	O	1112-1122
of	O	1123-1125
SEMA3	O	1126-1131
/	O	1131-1132
Plexin	O	1132-1138
family	O	1139-1145
members	O	1146-1153
and	O	1154-1157
is	O	1158-1160
associated	O	1161-1171
with	O	1172-1176
restricted	O	1177-1187
tumor	O	1188-1193
growth	O	1194-1200
both	O	1201-1205
in	O	1206-1208
vitro	O	1209-1214
and	O	1215-1218
in	O	1219-1221
SCID	O	1222-1226
mice	O	1227-1231
.	O	1231-1232

We	O	1233-1235
further	O	1236-1243
demonstrate	O	1244-1255
that	O	1256-1260
SOX4	O	1261-1265
levels	O	1266-1272
parallel	O	1273-1281
with	O	1282-1286
the	O	1287-1290
summed	O	1291-1297
expression	O	1298-1308
of	O	1309-1311
SEMA3	O	1312-1317
/	O	1317-1318
Plexin	O	1318-1324
family	O	1325-1331
members	O	1332-1339
(	O	1340-1341
P	O	1341-1342
=	O	1343-1344
0	O	1345-1346
.	O	1346-1347
033	O	1347-1350
,	O	1350-1351
NPar	O	1352-1356
Kruskal	O	1357-1364
-	O	1364-1365
Wallis	O	1365-1371
one	O	1372-1375
-	O	1375-1376
way	O	1376-1379
analysis	O	1380-1388
)	O	1388-1389
,	O	1389-1390
which	O	1391-1396
also	O	1397-1401
correlates	O	1402-1412
with	O	1413-1417
poor	O	1418-1422
survival	O	1423-1431
in	O	1432-1434
human	O	1435-1440
PDAC	O	1441-1445
(	O	1446-1447
P	O	1447-1448
=	O	1449-1450
0	O	1451-1452
.	O	1452-1453
0409	O	1453-1457
,	O	1457-1458
Kaplan	O	1459-1465
-	O	1465-1466
Meier	O	1466-1471
analysis	O	1472-1480
)	O	1480-1481
.	O	1481-1482

Intriguingly	O	1483-1495
,	O	1495-1496
miR	B	1497-1500
-	I	1500-1501
129	I	1501-1504
-	I	1504-1505
2	I	1505-1506
and	O	1507-1510
miR	B	1511-1514
-	I	1514-1515
335	I	1515-1518
,	O	1518-1519
both	O	1520-1524
of	O	1525-1527
which	O	1528-1533
target	O	1534-1540
SOX4	O	1541-1545
for	O	1546-1549
degradation	O	1550-1561
,	O	1561-1562
are	O	1563-1566
co	O	1567-1569
-	O	1569-1570
repressed	O	1570-1579
in	O	1580-1582
human	O	1583-1588
PDAC	O	1589-1593
cases	O	1594-1599
associated	O	1600-1610
with	O	1611-1615
up	O	1616-1618
-	O	1618-1619
regulated	O	1619-1628
SOX4	O	1629-1633
in	O	1634-1636
a	O	1637-1638
statistically	O	1639-1652
significant	O	1653-1664
way	O	1665-1668
.	O	1668-1669

In	O	1670-1672
conclusion	O	1673-1683
,	O	1683-1684
we	O	1685-1687
disclose	O	1688-1696
a	O	1697-1698
miR	B	1699-1702
-	I	1702-1703
129	I	1703-1706
-	I	1706-1707
2	I	1707-1708
(	O	1708-1709
miR	B	1709-1712
-	I	1712-1713
335	I	1713-1716
)	O	1716-1717
/	O	1717-1718
SOX4	O	1718-1722
/	O	1722-1723
Semaphorin	O	1723-1733
-	O	1733-1734
Plexin	O	1734-1740
regulatory	O	1741-1751
axis	O	1752-1756
in	O	1757-1759
the	O	1760-1763
tumorigenesis	O	1764-1777
of	O	1778-1780
pancreatic	O	1781-1791
cancer	O	1792-1798
.	O	1798-1799

miR	B	0-3
-	I	3-4
17	I	4-6
-	I	6-7
5p	I	7-9
regulates	O	10-19
endocytic	O	20-29
trafficking	O	30-41
through	O	42-49
targeting	O	50-59
TBC1D2	O	60-66
/	O	66-67
Armus	O	67-72
.	O	72-73

miRNA	O	74-79
cluster	O	80-87
miR	B	88-91
-	I	91-92
17	I	92-94
-	I	94-95
92	I	95-97
is	O	98-100
known	O	101-106
as	O	107-109
oncomir	O	110-117
-	O	117-118
1	O	118-119
due	O	120-123
to	O	124-126
its	O	127-130
potent	O	131-137
oncogenic	O	138-147
function	O	148-156
.	O	156-157

miR	B	158-161
-	I	161-162
17	I	162-164
-	I	164-165
92	I	165-167
is	O	168-170
a	O	171-172
polycistronic	O	173-186
cluster	O	187-194
that	O	195-199
encodes	O	200-207
6	O	208-209
miRNAs	O	210-216
,	O	216-217
and	O	218-221
can	O	222-225
both	O	226-230
facilitate	O	231-241
and	O	242-245
inhibit	O	246-253
cell	O	254-258
proliferation	O	259-272
.	O	272-273

Known	O	274-279
targets	O	280-287
of	O	288-290
miRNAs	O	291-297
encoded	O	298-305
by	O	306-308
this	O	309-313
cluster	O	314-321
are	O	322-325
largely	O	326-333
regulators	O	334-344
of	O	345-347
cell	O	348-352
cycle	O	353-358
progression	O	359-370
and	O	371-374
apoptosis	O	375-384
.	O	384-385

Here	O	386-390
,	O	390-391
we	O	392-394
show	O	395-399
that	O	400-404
miRNAs	O	405-411
encoded	O	412-419
by	O	420-422
this	O	423-427
cluster	O	428-435
and	O	436-439
sharing	O	440-447
the	O	448-451
seed	O	452-456
sequence	O	457-465
of	O	466-468
miR	B	469-472
-	I	472-473
17	I	473-475
exert	O	476-481
their	O	482-487
influence	O	488-497
on	O	498-500
one	O	501-504
of	O	505-507
the	O	508-511
most	O	512-516
essential	O	517-526
cellular	O	527-535
processes	O	536-545
-	O	546-547
endocytic	O	548-557
trafficking	O	558-569
.	O	569-570

By	O	571-573
mRNA	O	574-578
expression	O	579-589
analysis	O	590-598
we	O	599-601
identified	O	602-612
that	O	613-617
regulation	O	618-628
of	O	629-631
endocytic	O	632-641
trafficking	O	642-653
by	O	654-656
miR	B	657-660
-	I	660-661
17	I	661-663
can	O	664-667
potentially	O	668-679
be	O	680-682
achieved	O	683-691
by	O	692-694
targeting	O	695-704
of	O	705-707
a	O	708-709
number	O	710-716
of	O	717-719
trafficking	O	720-731
regulators	O	732-742
.	O	742-743

We	O	744-746
have	O	747-751
thoroughly	O	752-762
validated	O	763-772
TBC1D2	O	773-779
/	O	779-780
Armus	O	780-785
,	O	785-786
a	O	787-788
GAP	O	789-792
of	O	793-795
Rab7	O	796-800
GTPase	O	801-807
,	O	807-808
as	O	809-811
a	O	812-813
novel	O	814-819
target	O	820-826
of	O	827-829
miR	B	830-833
-	I	833-834
17	I	834-836
.	O	836-837

Our	O	838-841
study	O	842-847
reveals	O	848-855
regulation	O	856-866
of	O	867-869
endocytic	O	870-879
trafficking	O	880-891
as	O	892-894
a	O	895-896
novel	O	897-902
function	O	903-911
of	O	912-914
miR	B	915-918
-	I	918-919
17	I	919-921
,	O	921-922
which	O	923-928
might	O	929-934
act	O	935-938
cooperatively	O	939-952
with	O	953-957
other	O	958-963
functions	O	964-973
of	O	974-976
miR	B	977-980
-	I	980-981
17	I	981-983
and	O	984-987
related	O	988-995
miRNAs	O	996-1002
in	O	1003-1005
health	O	1006-1012
and	O	1013-1016
disease	O	1017-1024
.	O	1024-1025

miR	B	0-3
-	I	3-4
124	I	4-7
-	O	7-8
regulated	O	8-17
RhoG	O	18-22
:	O	22-23
A	O	24-25
conductor	O	26-35
of	O	36-38
neuronal	O	39-47
process	O	48-55
complexity	O	56-66
.	O	66-67

RhoG	O	68-72
is	O	73-75
a	O	76-77
member	O	78-84
of	O	85-87
the	O	88-91
Rho	O	92-95
family	O	96-102
of	O	103-105
small	O	106-111
GTPases	O	112-119
sharing	O	120-127
highest	O	128-135
sequence	O	136-144
similarity	O	145-155
with	O	156-160
Rac	O	161-164
and	O	165-168
Cdc42	O	169-174
.	O	174-175

Mig	O	176-179
-	O	179-180
2	O	180-181
and	O	182-185
Mtl	O	186-189
represent	O	190-199
the	O	200-203
functional	O	204-214
equivalents	O	215-226
of	O	227-229
RhoG	O	230-234
in	O	235-237
Caenorhabditis	O	238-252
elegans	O	253-260
and	O	261-264
Drosophila	O	265-275
,	O	275-276
respectively	O	277-289
.	O	289-290

RhoG	O	291-295
has	O	296-299
attracted	O	300-309
great	O	310-315
interest	O	316-324
because	O	325-332
it	O	333-335
plays	O	336-341
a	O	342-343
central	O	344-351
role	O	352-356
in	O	357-359
the	O	360-363
regulation	O	364-374
of	O	375-377
cytoskeletal	O	378-390
reorganization	O	391-405
in	O	406-408
various	O	409-416
physiological	O	417-430
and	O	431-434
pathophysiological	O	435-453
situations	O	454-464
.	O	464-465

For	O	466-469
example	O	470-477
,	O	477-478
it	O	479-481
is	O	482-484
fundamental	O	485-496
to	O	497-499
phagocytotic	O	500-512
processes	O	513-522
,	O	522-523
is	O	524-526
able	O	527-531
to	O	532-534
regulate	O	535-543
gene	O	544-548
expression	O	549-559
,	O	559-560
cell	O	561-565
survival	O	566-574
and	O	575-578
proliferation	O	579-592
,	O	592-593
and	O	594-597
is	O	598-600
involved	O	601-609
in	O	610-612
cell	O	613-617
migration	O	618-627
and	O	628-631
in	O	632-634
the	O	635-638
invasion	O	639-647
of	O	648-650
pathogenic	O	651-661
bacteria	O	662-670
.	O	670-671

The	O	672-675
activation	O	676-686
of	O	687-689
Rac1	O	690-694
via	O	695-698
an	O	699-701
ELMO	O	702-706
/	O	706-707
Dock180	O	707-714
module	O	715-721
has	O	722-725
been	O	726-730
elaborated	O	731-741
to	O	742-744
be	O	745-747
important	O	748-757
for	O	758-761
RhoG	O	762-766
signaling	O	767-776
.	O	776-777

Although	O	778-786
a	O	787-788
stimulatory	O	789-800
role	O	801-805
for	O	806-809
neurite	O	810-817
outgrowth	O	818-827
in	O	828-830
the	O	831-834
pheochromocytoma	O	835-851
PC12	O	852-856
cell	O	857-861
line	O	862-866
has	O	867-870
been	O	871-875
assigned	O	876-884
to	O	885-887
RhoG	O	888-892
,	O	892-893
the	O	894-897
exact	O	898-903
function	O	904-912
of	O	913-915
this	O	916-920
GTPase	O	921-927
for	O	928-931
the	O	932-935
development	O	936-947
of	O	948-950
the	O	951-954
processes	O	955-964
of	O	965-967
primary	O	968-975
neurons	O	976-983
remains	O	984-991
to	O	992-994
be	O	995-997
clarified	O	998-1007
.	O	1007-1008

In	O	1009-1011
this	O	1012-1016
view	O	1017-1021
,	O	1021-1022
we	O	1023-1025
discuss	O	1026-1033
the	O	1034-1037
impact	O	1038-1044
of	O	1045-1047
RhoG	O	1048-1052
on	O	1053-1055
axonal	O	1056-1062
and	O	1063-1066
dendritic	O	1067-1076
differentiation	O	1077-1092
,	O	1092-1093
its	O	1094-1097
role	O	1098-1102
as	O	1103-1105
a	O	1106-1107
conductor	O	1108-1117
of	O	1118-1120
Rac1	O	1121-1125
and	O	1126-1129
Cdc42	O	1130-1135
activity	O	1136-1144
and	O	1145-1148
the	O	1149-1152
functional	O	1153-1163
regulation	O	1164-1174
of	O	1175-1177
RhoG	O	1178-1182
expression	O	1183-1193
by	O	1194-1196
the	O	1197-1200
microRNA	O	1201-1209
miR	B	1210-1213
-	I	1213-1214
124	I	1214-1217
.	O	1217-1218

Focal	O	0-5
DNA	O	6-9
copy	O	10-14
number	O	15-21
changes	O	22-29
in	O	30-32
neuroblastoma	O	33-46
target	O	47-53
MYCN	O	54-58
regulated	O	59-68
genes	O	69-74
.	O	74-75

Neuroblastoma	O	76-89
is	O	90-92
an	O	93-95
embryonic	O	96-105
tumor	O	106-111
arising	O	112-119
from	O	120-124
immature	O	125-133
sympathetic	O	134-145
nervous	O	146-153
system	O	154-160
cells	O	161-166
.	O	166-167

Recurrent	O	168-177
genomic	O	178-185
alterations	O	186-197
include	O	198-205
MYCN	O	206-210
and	O	211-214
ALK	O	215-218
amplification	O	219-232
as	O	233-235
well	O	236-240
as	O	241-243
recurrent	O	244-253
patterns	O	254-262
of	O	263-265
gains	O	266-271
and	O	272-275
losses	O	276-282
of	O	283-285
whole	O	286-291
or	O	292-294
large	O	295-300
partial	O	301-308
chromosome	O	309-319
segments	O	320-328
.	O	328-329

A	O	330-331
recent	O	332-338
whole	O	339-344
genome	O	345-351
sequencing	O	352-362
effort	O	363-369
yielded	O	370-377
no	O	378-380
frequently	O	381-391
recurring	O	392-401
mutations	O	402-411
in	O	412-414
genes	O	415-420
other	O	421-426
than	O	427-431
those	O	432-437
affecting	O	438-447
ALK	O	448-451
.	O	451-452

However	O	453-460
,	O	460-461
the	O	462-465
study	O	466-471
further	O	472-479
stresses	O	480-488
the	O	489-492
importance	O	493-503
of	O	504-506
DNA	O	507-510
copy	O	511-515
number	O	516-522
alterations	O	523-534
in	O	535-537
this	O	538-542
disease	O	543-550
,	O	550-551
in	O	552-554
particular	O	555-565
for	O	566-569
genes	O	570-575
implicated	O	576-586
in	O	587-589
neuritogenesis	O	590-604
.	O	604-605

Here	O	606-610
we	O	611-613
provide	O	614-621
additional	O	622-632
evidence	O	633-641
for	O	642-645
the	O	646-649
importance	O	650-660
of	O	661-663
focal	O	664-669
DNA	O	670-673
copy	O	674-678
number	O	679-685
gains	O	686-691
and	O	692-695
losses	O	696-702
,	O	702-703
which	O	704-709
are	O	710-713
predominantly	O	714-727
observed	O	728-736
in	O	737-739
MYCN	O	740-744
amplified	O	745-754
tumors	O	755-761
.	O	761-762

A	O	763-764
focal	O	765-770
5	O	771-772
kb	O	773-775
gain	O	776-780
encompassing	O	781-793
the	O	794-797
MYCN	O	798-802
regulated	O	803-812
miR	B	813-816
-	I	816-817
17	I	817-819
~	I	819-820
92	I	820-822
cluster	O	823-830
as	O	831-833
sole	O	834-838
gene	O	839-843
was	O	844-847
detected	O	848-856
in	O	857-859
a	O	860-861
neuroblastoma	O	862-875
cell	O	876-880
line	O	881-885
and	O	886-889
further	O	890-897
analyses	O	898-906
of	O	907-909
the	O	910-913
array	O	914-919
CGH	O	920-923
data	O	924-928
set	O	929-932
demonstrated	O	933-945
enrichment	O	946-956
for	O	957-960
other	O	961-966
MYCN	O	967-971
target	O	972-978
genes	O	979-984
in	O	985-987
focal	O	988-993
gains	O	994-999
and	O	1000-1003
amplifications	O	1004-1018
.	O	1018-1019

Next	O	1020-1024
we	O	1025-1027
applied	O	1028-1035
an	O	1036-1038
integrated	O	1039-1049
genomics	O	1050-1058
analysis	O	1059-1067
to	O	1068-1070
prioritize	O	1071-1081
MYCN	O	1082-1086
down	O	1087-1091
regulated	O	1092-1101
genes	O	1102-1107
mediated	O	1108-1116
by	O	1117-1119
MYCN	O	1120-1124
driven	O	1125-1131
miRNAs	O	1132-1138
within	O	1139-1145
regions	O	1146-1153
of	O	1154-1156
focal	O	1157-1162
heterozygous	O	1163-1175
or	O	1176-1178
homozygous	O	1179-1189
deletion	O	1190-1198
.	O	1198-1199

We	O	1200-1202
identified	O	1203-1213
RGS5	O	1214-1218
,	O	1218-1219
a	O	1220-1221
negative	O	1222-1230
regulator	O	1231-1240
of	O	1241-1243
G	O	1244-1245
-	O	1245-1246
protein	O	1246-1253
signaling	O	1254-1263
implicated	O	1264-1274
in	O	1275-1277
vascular	O	1278-1286
normalization	O	1287-1300
,	O	1300-1301
invasion	O	1302-1310
and	O	1311-1314
metastasis	O	1315-1325
,	O	1325-1326
targeted	O	1327-1335
by	O	1336-1338
a	O	1339-1340
focal	O	1341-1346
homozygous	O	1347-1357
deletion	O	1358-1366
,	O	1366-1367
as	O	1368-1370
a	O	1371-1372
new	O	1373-1376
MYCN	O	1377-1381
target	O	1382-1388
gene	O	1389-1393
,	O	1393-1394
down	O	1395-1399
regulated	O	1400-1409
through	O	1410-1417
MYCN	O	1418-1422
activated	O	1423-1432
miRNAs	O	1433-1439
.	O	1439-1440

In	O	1441-1443
addition	O	1444-1452
,	O	1452-1453
we	O	1454-1456
expand	O	1457-1463
the	O	1464-1467
miR	B	1468-1471
-	I	1471-1472
17	I	1472-1474
~	I	1474-1475
92	I	1475-1477
regulatory	O	1478-1488
network	O	1489-1496
controlling	O	1497-1508
TGFss	O	1509-1514
signaling	O	1515-1524
in	O	1525-1527
neuroblastoma	O	1528-1541
with	O	1542-1546
the	O	1547-1550
ring	O	1551-1555
finger	O	1556-1562
protein	O	1563-1570
11	O	1571-1573
encoding	O	1574-1582
gene	O	1583-1587
RNF11	O	1588-1593
,	O	1593-1594
which	O	1595-1600
was	O	1601-1604
previously	O	1605-1615
shown	O	1616-1621
to	O	1622-1624
be	O	1625-1627
targeted	O	1628-1636
by	O	1637-1639
the	O	1640-1643
miR	B	1644-1647
-	I	1647-1648
17	I	1648-1650
~	I	1650-1651
92	I	1651-1653
member	O	1654-1660
miR	B	1661-1664
-	I	1664-1665
19b	I	1665-1668
.	O	1668-1669

Taken	O	1670-1675
together	O	1676-1684
,	O	1684-1685
our	O	1686-1689
data	O	1690-1694
indicate	O	1695-1703
that	O	1704-1708
focal	O	1709-1714
DNA	O	1715-1718
copy	O	1719-1723
number	O	1724-1730
imbalances	O	1731-1741
in	O	1742-1744
neuroblastoma	O	1745-1758
(	O	1759-1760
1	O	1760-1761
)	O	1761-1762
target	O	1763-1769
genes	O	1770-1775
that	O	1776-1780
are	O	1781-1784
implicated	O	1785-1795
in	O	1796-1798
MYCN	O	1799-1803
signaling	O	1804-1813
,	O	1813-1814
possibly	O	1815-1823
selected	O	1824-1832
to	O	1833-1835
reinforce	O	1836-1845
MYCN	O	1846-1850
oncogene	O	1851-1859
addiction	O	1860-1869
and	O	1870-1873
(	O	1874-1875
2	O	1875-1876
)	O	1876-1877
serve	O	1878-1883
as	O	1884-1886
a	O	1887-1888
resource	O	1889-1897
for	O	1898-1901
identifying	O	1902-1913
new	O	1914-1917
molecular	O	1918-1927
targets	O	1928-1935
for	O	1936-1939
treatment	O	1940-1949
.	O	1949-1950

MicroRNA	B	0-8
-	I	8-9
31	I	9-11
activates	O	12-21
the	O	22-25
RAS	O	26-29
pathway	O	30-37
and	O	38-41
functions	O	42-51
as	O	52-54
an	O	55-57
oncogenic	O	58-67
MicroRNA	O	68-76
in	O	77-79
human	O	80-85
colorectal	O	86-96
cancer	O	97-103
by	O	104-106
repressing	O	107-117
RAS	O	118-121
p21	O	122-125
GTPase	O	126-132
activating	O	133-143
protein	O	144-151
1	O	152-153
(	O	154-155
RASA1	O	155-160
)	O	160-161
.	O	161-162

MicroRNAs	O	163-172
(	O	173-174
miRNAs	O	174-180
)	O	180-181
are	O	182-185
known	O	186-191
to	O	192-194
play	O	195-199
a	O	200-201
vital	O	202-207
role	O	208-212
in	O	213-215
colorectal	O	216-226
cancer	O	227-233
.	O	233-234

We	O	235-237
found	O	238-243
a	O	244-245
widespread	O	246-256
disruption	O	257-267
in	O	268-270
miRNA	O	271-276
expression	O	277-287
during	O	288-294
colorectal	O	295-305
tumorigenesis	O	306-319
using	O	320-325
microarray	O	326-336
and	O	337-340
quantitative	O	341-353
RT	O	354-356
-	O	356-357
PCR	O	357-360
analysis	O	361-369
;	O	369-370
of	O	371-373
the	O	374-377
161	O	378-381
miRNAs	O	382-388
altered	O	389-396
in	O	397-399
colorectal	O	400-410
cancer	O	411-417
compared	O	418-426
with	O	427-431
normal	O	432-438
adjacent	O	439-447
tissue	O	448-454
samples	O	455-462
,	O	462-463
miR	B	464-467
-	I	467-468
31	I	468-470
was	O	471-474
the	O	475-478
most	O	479-483
significantly	O	484-497
dysregulated	O	498-510
.	O	510-511

We	O	512-514
identified	O	515-525
candidate	O	526-535
targets	O	536-543
of	O	544-546
miR	B	547-550
-	I	550-551
31	I	551-553
using	O	554-559
bioinformatics	O	560-574
approaches	O	575-585
and	O	586-589
validated	O	590-599
RAS	O	600-603
p21	O	604-607
GTPase	O	608-614
activating	O	615-625
protein	O	626-633
1	O	634-635
(	O	636-637
RASA1	O	637-642
)	O	642-643
as	O	644-646
a	O	647-648
direct	O	649-655
target	O	656-662
.	O	662-663

First	O	664-669
,	O	669-670
we	O	671-673
found	O	674-679
an	O	680-682
inverse	O	683-690
correlation	O	691-702
between	O	703-710
miR	B	711-714
-	I	714-715
31	I	715-717
and	O	718-721
RASA1	O	722-727
protein	O	728-735
levels	O	736-742
in	O	743-745
vivo	O	746-750
.	O	750-751

Second	O	752-758
,	O	758-759
in	O	760-762
vitro	O	763-768
evidence	O	769-777
demonstrated	O	778-790
that	O	791-795
RASA1	O	796-801
expression	O	802-812
was	O	813-816
significantly	O	817-830
decreased	O	831-840
by	O	841-843
treatment	O	844-853
with	O	854-858
pre	O	859-862
-	O	862-863
miR	B	863-866
-	I	866-867
31	I	867-869
-	O	869-870
LV	O	870-872
,	O	872-873
whereas	O	874-881
anti	O	882-886
-	O	886-887
miR	B	887-890
-	I	890-891
31	I	891-893
-	O	893-894
LV	O	894-896
treatment	O	897-906
increased	O	907-916
RASA1	O	917-922
protein	O	923-930
levels	O	931-937
.	O	937-938

Third	O	939-944
,	O	944-945
a	O	946-947
luciferase	O	948-958
reporter	O	959-967
assay	O	968-973
confirmed	O	974-983
that	O	984-988
miR	B	989-992
-	I	992-993
31	I	993-995
directly	O	996-1004
recognizes	O	1005-1015
a	O	1016-1017
specific	O	1018-1026
location	O	1027-1035
within	O	1036-1042
the	O	1043-1046
3	O	1047-1048
'	O	1048-1049
-	O	1049-1050
untranslated	O	1050-1062
region	O	1063-1069
of	O	1070-1072
RASA1	O	1073-1078
transcripts	O	1079-1090
.	O	1090-1091

Furthermore	O	1092-1103
,	O	1103-1104
the	O	1105-1108
biological	O	1109-1119
consequences	O	1120-1132
of	O	1133-1135
miR	B	1136-1139
-	I	1139-1140
31	I	1140-1142
targeting	O	1143-1152
RASA1	O	1153-1158
were	O	1159-1163
examined	O	1164-1172
by	O	1173-1175
the	O	1176-1179
cell	O	1180-1184
proliferation	O	1185-1198
assay	O	1199-1204
in	O	1205-1207
vitro	O	1208-1213
and	O	1214-1217
by	O	1218-1220
the	O	1221-1224
immunodeficient	O	1225-1240
mouse	O	1241-1246
xenograft	O	1247-1256
tumor	O	1257-1262
model	O	1263-1268
in	O	1269-1271
vivo	O	1272-1276
.	O	1276-1277

Taken	O	1278-1283
together	O	1284-1292
,	O	1292-1293
our	O	1294-1297
results	O	1298-1305
demonstrate	O	1306-1317
for	O	1318-1321
the	O	1322-1325
first	O	1326-1331
time	O	1332-1336
that	O	1337-1341
miR	B	1342-1345
-	I	1345-1346
31	I	1346-1348
plays	O	1349-1354
a	O	1355-1356
significant	O	1357-1368
role	O	1369-1373
in	O	1374-1376
activating	O	1377-1387
the	O	1388-1391
RAS	O	1392-1395
signaling	O	1396-1405
pathway	O	1406-1413
through	O	1414-1421
the	O	1422-1425
inhibition	O	1426-1436
of	O	1437-1439
RASA1	O	1440-1445
translation	O	1446-1457
,	O	1457-1458
thereby	O	1459-1466
improving	O	1467-1476
colorectal	O	1477-1487
cancer	O	1488-1494
cell	O	1495-1499
growth	O	1500-1506
and	O	1507-1510
stimulating	O	1511-1522
tumorigenesis	O	1523-1536
.	O	1536-1537

Two	O	0-3
panels	O	4-10
of	O	11-13
plasma	O	14-20
microRNAs	O	21-30
as	O	31-33
non	O	34-37
-	O	37-38
invasive	O	38-46
biomarkers	O	47-57
for	O	58-61
prediction	O	62-72
of	O	73-75
recurrence	O	76-86
in	O	87-89
resectable	O	90-100
NSCLC	O	101-106
.	O	106-107

The	O	108-111
diagnosis	O	112-121
of	O	122-124
non	O	125-128
-	O	128-129
small	O	129-134
cell	O	135-139
lung	O	140-144
carcinoma	O	145-154
(	O	155-156
NSCLC	O	156-161
)	O	161-162
at	O	163-165
an	O	166-168
early	O	169-174
stage	O	175-180
,	O	180-181
as	O	182-184
well	O	185-189
as	O	190-192
better	O	193-199
prediction	O	200-210
of	O	211-213
outcome	O	214-221
remains	O	222-229
clinically	O	230-240
challenging	O	241-252
due	O	253-256
to	O	257-259
the	O	260-263
lack	O	264-268
of	O	269-271
specific	O	272-280
and	O	281-284
robust	O	285-291
non	O	292-295
-	O	295-296
invasive	O	296-304
markers	O	305-312
.	O	312-313

The	O	314-317
discovery	O	318-327
of	O	328-330
microRNAs	O	331-340
(	O	341-342
miRNAs	O	342-348
)	O	348-349
,	O	349-350
particularly	O	351-363
those	O	364-369
found	O	370-375
in	O	376-378
the	O	379-382
bloodstream	O	383-394
,	O	394-395
has	O	396-399
opened	O	400-406
up	O	407-409
new	O	410-413
perspectives	O	414-426
for	O	427-430
tumor	O	431-436
diagnosis	O	437-446
and	O	447-450
prognosis	O	451-460
.	O	460-461

The	O	462-465
aim	O	466-469
of	O	470-472
our	O	473-476
study	O	477-482
was	O	483-486
to	O	487-489
determine	O	490-499
whether	O	500-507
expression	O	508-518
profiles	O	519-527
of	O	528-530
specific	O	531-539
miRNAs	O	540-546
in	O	547-549
plasma	O	550-556
could	O	557-562
accurately	O	563-573
discriminate	O	574-586
between	O	587-594
NSCLC	O	595-600
patients	O	601-609
and	O	610-613
controls	O	614-622
,	O	622-623
and	O	624-627
whether	O	628-635
they	O	636-640
are	O	641-644
able	O	645-649
to	O	650-652
predict	O	653-660
the	O	661-664
prognosis	O	665-674
of	O	675-677
resectable	O	678-688
NSCLC	O	689-694
patients	O	695-703
.	O	703-704

We	O	705-707
therefore	O	708-717
evaluated	O	718-727
a	O	728-729
series	O	730-736
of	O	737-739
seventeen	O	740-749
NSCLC	O	750-755
-	O	755-756
related	O	756-763
miRNAs	O	764-770
by	O	771-773
quantitative	O	774-786
real	O	787-791
-	O	791-792
time	O	792-796
(	O	797-798
qRT	O	798-801
)	O	801-802
-	O	802-803
PCR	O	803-806
in	O	807-809
plasma	O	810-816
from	O	817-821
52	O	822-824
patients	O	825-833
with	O	834-838
I	O	839-840
-	O	840-841
IIIA	O	841-845
stages	O	846-852
NSCLC	O	853-858
,	O	858-859
10	O	860-862
patients	O	863-871
with	O	872-876
chronic	O	877-884
obstructive	O	885-896
pulmonary	O	897-906
disease	O	907-914
(	O	915-916
COPD	O	916-920
)	O	920-921
and	O	922-925
20	O	926-928
-	O	928-929
age	O	929-932
,	O	932-933
sex	O	934-937
and	O	938-941
smoking	O	942-949
status	O	950-956
-	O	956-957
matched	O	957-964
healthy	O	965-972
individuals	O	973-984
.	O	984-985

We	O	986-988
identified	O	989-999
an	O	1000-1002
eleven	O	1003-1009
-	O	1009-1010
plasma	O	1010-1016
miRNA	O	1017-1022
panel	O	1023-1028
that	O	1029-1033
could	O	1034-1039
distinguish	O	1040-1051
NSCLC	O	1052-1057
patients	O	1058-1066
from	O	1067-1071
healthy	O	1072-1079
subjects	O	1080-1088
(	O	1089-1090
AUC	O	1090-1093
=	O	1094-1095
0	O	1096-1097
.	O	1097-1098
879	O	1098-1101
)	O	1101-1102
.	O	1102-1103

A	O	1104-1105
six	O	1106-1109
-	O	1109-1110
plasma	O	1110-1116
miRNA	O	1117-1122
panel	O	1123-1128
was	O	1129-1132
able	O	1133-1137
to	O	1138-1140
discriminate	O	1141-1153
between	O	1154-1161
NSCLC	O	1162-1167
patients	O	1168-1176
and	O	1177-1180
COPD	O	1181-1185
patients	O	1186-1194
(	O	1195-1196
AUC	O	1196-1199
=	O	1200-1201
0	O	1202-1203
.	O	1203-1204
944	O	1204-1207
)	O	1207-1208
.	O	1208-1209

Furthermore	O	1210-1221
,	O	1221-1222
we	O	1223-1225
identified	O	1226-1236
a	O	1237-1238
three	O	1239-1244
-	O	1244-1245
miRNA	O	1245-1250
plasma	O	1251-1257
signature	O	1258-1267
(	O	1268-1269
high	O	1269-1273
miR	B	1274-1277
-	I	1277-1278
155	I	1278-1281
-	I	1281-1282
5p	I	1282-1284
,	O	1284-1285
high	O	1286-1290
miR	B	1291-1294
-	I	1294-1295
223	I	1295-1298
-	I	1298-1299
3p	I	1299-1301
,	O	1301-1302
and	O	1303-1306
low	O	1307-1310
miR	B	1311-1314
-	I	1314-1315
126	I	1315-1318
-	I	1318-1319
3p	I	1319-1321
)	O	1321-1322
that	O	1323-1327
significantly	O	1328-1341
associated	O	1342-1352
with	O	1353-1357
a	O	1358-1359
higher	O	1360-1366
risk	O	1367-1371
for	O	1372-1375
progression	O	1376-1387
in	O	1388-1390
adenocarcinoma	O	1391-1405
patients	O	1406-1414
.	O	1414-1415

In	O	1416-1418
addition	O	1419-1427
,	O	1427-1428
a	O	1429-1430
three	O	1431-1436
-	O	1436-1437
miRNA	O	1437-1442
plasma	O	1443-1449
panel	O	1450-1455
(	O	1456-1457
high	O	1457-1461
miR	B	1462-1465
-	I	1465-1466
20a	I	1466-1469
-	I	1469-1470
5p	I	1470-1472
,	O	1472-1473
low	O	1474-1477
miR	B	1478-1481
-	I	1481-1482
152	I	1482-1485
-	I	1485-1486
3p	I	1486-1488
,	O	1488-1489
and	O	1490-1493
low	O	1494-1497
miR	B	1498-1501
-	I	1501-1502
199a	I	1502-1506
-	I	1506-1507
5p	I	1507-1509
)	O	1509-1510
significantly	O	1511-1524
predicted	O	1525-1534
survival	O	1535-1543
of	O	1544-1546
squamous	O	1547-1555
cell	O	1556-1560
carcinoma	O	1561-1570
patients	O	1571-1579
.	O	1579-1580

In	O	1581-1583
conclusion	O	1584-1594
,	O	1594-1595
we	O	1596-1598
identified	O	1599-1609
two	O	1610-1613
plasma	O	1614-1620
miRNA	O	1621-1626
expression	O	1627-1637
profiles	O	1638-1646
that	O	1647-1651
may	O	1652-1655
be	O	1656-1658
useful	O	1659-1665
for	O	1666-1669
predicting	O	1670-1680
the	O	1681-1684
outcome	O	1685-1692
of	O	1693-1695
patients	O	1696-1704
with	O	1705-1709
resectable	O	1710-1720
NSCLC	O	1721-1726
.	O	1726-1727

Differential	O	0-12
expression	O	13-23
of	O	24-26
miRNAs	O	27-33
in	O	34-36
the	O	37-40
serum	O	41-46
of	O	47-49
patients	O	50-58
with	O	59-63
high	O	64-68
-	O	68-69
risk	O	69-73
oral	O	74-78
lesions	O	79-86
.	O	86-87

Oral	O	88-92
cancer	O	93-99
is	O	100-102
one	O	103-106
of	O	107-109
the	O	110-113
most	O	114-118
commonly	O	119-127
diagnosed	O	128-137
cancers	O	138-145
worldwide	O	146-155
.	O	155-156

Disease	O	157-164
is	O	165-167
often	O	168-173
diagnosed	O	174-183
at	O	184-186
later	O	187-192
stages	O	193-199
,	O	199-200
which	O	201-206
is	O	207-209
associated	O	210-220
with	O	221-225
a	O	226-227
poor	O	228-232
5	O	233-234
-	O	234-235
year	O	235-239
survival	O	240-248
rate	O	249-253
and	O	254-257
a	O	258-259
high	O	260-264
rate	O	265-269
of	O	270-272
local	O	273-278
recurrence	O	279-289
.	O	289-290

MicroRNAs	O	291-300
(	O	301-302
miRNAs	O	302-308
)	O	308-309
,	O	309-310
a	O	311-312
group	O	313-318
of	O	319-321
small	O	322-327
,	O	327-328
noncoding	O	329-338
RNAs	O	339-343
,	O	343-344
can	O	345-348
be	O	349-351
isolated	O	352-360
from	O	361-365
blood	O	366-371
serum	O	372-377
samples	O	378-385
and	O	386-389
have	O	390-394
demonstrated	O	395-407
utility	O	408-415
as	O	416-418
biomarkers	O	419-429
in	O	430-432
multiple	O	433-441
cancer	O	442-448
types	O	449-454
.	O	454-455

The	O	456-459
aim	O	460-463
of	O	464-466
this	O	467-471
study	O	472-477
was	O	478-481
to	O	482-484
examine	O	485-492
the	O	493-496
expression	O	497-507
profiles	O	508-516
of	O	517-519
circulating	O	520-531
miRNAs	O	532-538
in	O	539-541
the	O	542-545
serum	O	546-551
of	O	552-554
patients	O	555-563
with	O	564-568
high	O	569-573
-	O	573-574
risk	O	574-578
oral	O	579-583
lesions	O	584-591
(	O	592-593
HRLs	O	593-597
;	O	597-598
oral	O	599-603
cancer	O	604-610
or	O	611-613
carcinoma	O	614-623
in	O	624-626
situ	O	627-631
)	O	631-632
and	O	633-636
to	O	637-639
explore	O	640-647
their	O	648-653
utility	O	654-661
as	O	662-664
potential	O	665-674
oral	O	675-679
cancer	O	680-686
biomarkers	O	687-697
.	O	697-698

Global	O	699-705
serum	O	706-711
miRNA	O	712-717
profiles	O	718-726
were	O	727-731
generated	O	732-741
using	O	742-747
quantitative	O	748-760
PCR	O	761-764
method	O	765-771
from	O	772-776
1	O	777-778
)	O	778-779
patients	O	780-788
diagnosed	O	789-798
with	O	799-803
HRLs	O	804-808
and	O	809-812
undergoing	O	813-823
intent	O	824-830
-	O	830-831
to	O	831-833
-	O	833-834
cure	O	834-838
surgical	O	839-847
treatment	O	848-857
(	O	858-859
N	O	859-860
=	O	861-862
30	O	863-865
)	O	865-866
and	O	867-870
2	O	871-872
)	O	872-873
a	O	874-875
demographically	O	876-891
matched	O	892-899
,	O	899-900
noncancer	O	901-910
control	O	911-918
group	O	919-924
(	O	925-926
N	O	926-927
=	O	928-929
26	O	930-932
)	O	932-933
.	O	933-934

We	O	935-937
next	O	938-942
honed	O	943-948
our	O	949-952
list	O	953-957
of	O	958-960
serum	O	961-966
miRNAs	O	967-973
associated	O	974-984
with	O	985-989
disease	O	990-997
by	O	998-1000
reducing	O	1001-1009
the	O	1010-1013
effects	O	1014-1021
of	O	1022-1024
interpatient	O	1025-1037
variability	O	1038-1049
;	O	1049-1050
we	O	1051-1053
compared	O	1054-1062
serum	O	1063-1068
miRNA	O	1069-1074
profiles	O	1075-1083
from	O	1084-1088
samples	O	1089-1096
taken	O	1097-1102
both	O	1103-1107
before	O	1108-1114
and	O	1115-1118
after	O	1119-1124
tumor	O	1125-1130
resections	O	1131-1141
(	O	1142-1143
N	O	1143-1144
=	O	1145-1146
10	O	1147-1149
)	O	1149-1150
.	O	1150-1151

Based	O	1152-1157
on	O	1158-1160
these	O	1161-1166
analyses	O	1167-1175
,	O	1175-1176
fifteen	O	1177-1184
miRNAs	O	1185-1191
were	O	1192-1196
significantly	O	1197-1210
upregulated	O	1211-1222
and	O	1223-1226
five	O	1227-1231
were	O	1232-1236
significantly	O	1237-1250
downregulated	O	1251-1264
based	O	1265-1270
on	O	1271-1273
presence	O	1274-1282
of	O	1283-1285
disease	O	1286-1293
(	O	1294-1295
minimum	O	1295-1302
fold	O	1303-1307
-	O	1307-1308
change	O	1308-1314
>	O	1315-1316
2	O	1316-1317
in	O	1318-1320
at	O	1321-1323
least	O	1324-1329
50	O	1330-1332
%	O	1332-1333
of	O	1334-1336
samples	O	1337-1344
,	O	1344-1345
P	O	1346-1347
<	O	1348-1349
0	O	1350-1351
.	O	1351-1352
05	O	1352-1354
,	O	1354-1355
permutation	O	1356-1367
)	O	1367-1368
.	O	1368-1369

Five	O	1370-1374
of	O	1375-1377
these	O	1378-1383
miRNAs	O	1384-1390
(	O	1391-1392
miR	B	1392-1395
-	I	1395-1396
16	I	1396-1398
,	O	1398-1399
let	B	1400-1403
-	I	1403-1404
7b	I	1404-1406
,	O	1406-1407
miR	B	1408-1411
-	I	1411-1412
338	I	1412-1415
-	I	1415-1416
3p	I	1416-1418
,	O	1418-1419
miR	B	1420-1423
-	I	1423-1424
223	I	1424-1427
,	O	1427-1428
and	O	1429-1432
miR	B	1433-1436
-	I	1436-1437
29a	I	1437-1440
)	O	1440-1441
yielded	O	1442-1449
an	O	1450-1452
area	O	1453-1457
under	O	1458-1463
the	O	1464-1467
ROC	O	1468-1471
curve	O	1472-1477
(	O	1478-1479
AUC	O	1479-1482
)	O	1482-1483
>	O	1484-1485
0	O	1485-1486
.	O	1486-1487
8	O	1487-1488
,	O	1488-1489
suggesting	O	1490-1500
utility	O	1501-1508
as	O	1509-1511
noninvasive	O	1512-1523
biomarkers	O	1524-1534
for	O	1535-1538
detection	O	1539-1548
of	O	1549-1551
oral	O	1552-1556
cancer	O	1557-1563
or	O	1564-1566
high	O	1567-1571
-	O	1571-1572
grade	O	1572-1577
lesions	O	1578-1585
.	O	1585-1586

Combining	O	1587-1596
these	O	1597-1602
serum	O	1603-1608
miRNA	O	1609-1614
profiles	O	1615-1623
with	O	1624-1628
other	O	1629-1634
screening	O	1635-1644
techniques	O	1645-1655
could	O	1656-1661
greatly	O	1662-1669
improve	O	1670-1677
the	O	1678-1681
sensitivity	O	1682-1693
in	O	1694-1696
oral	O	1697-1701
cancer	O	1702-1708
detection	O	1709-1718
.	O	1718-1719

Pharmaco	O	0-8
-	O	8-9
miR	O	9-12
:	O	12-13
linking	O	14-21
microRNAs	O	22-31
and	O	32-35
drug	O	36-40
effects	O	41-48
.	O	48-49

MicroRNAs	O	50-59
(	O	60-61
miRNAs	O	61-67
)	O	67-68
are	O	69-72
short	O	73-78
regulatory	O	79-89
RNAs	O	90-94
that	O	95-99
down	O	100-104
-	O	104-105
regulate	O	105-113
gene	O	114-118
expression	O	119-129
.	O	129-130

They	O	131-135
are	O	136-139
essential	O	140-149
for	O	150-153
cell	O	154-158
homeostasis	O	159-170
and	O	171-174
active	O	175-181
in	O	182-184
many	O	185-189
disease	O	190-197
states	O	198-204
.	O	204-205

A	O	206-207
major	O	208-213
discovery	O	214-223
is	O	224-226
the	O	227-230
ability	O	231-238
of	O	239-241
miRNAs	O	242-248
to	O	249-251
determine	O	252-261
the	O	262-265
efficacy	O	266-274
of	O	275-277
drugs	O	278-283
,	O	283-284
which	O	285-290
has	O	291-294
given	O	295-300
rise	O	301-305
to	O	306-308
the	O	309-312
field	O	313-318
of	O	319-321
'	O	322-323
miRNA	O	323-328
pharmacogenomics	O	329-345
'	O	345-346
through	O	347-354
'	O	355-356
Pharmaco	O	356-364
-	O	364-365
miRs	O	365-369
'	O	369-370
.	O	370-371

miRNAs	O	372-378
play	O	379-383
a	O	384-385
significant	O	386-397
role	O	398-402
in	O	403-405
pharmacogenomics	O	406-422
by	O	423-425
down	O	426-430
-	O	430-431
regulating	O	431-441
genes	O	442-447
that	O	448-452
are	O	453-456
important	O	457-466
for	O	467-470
drug	O	471-475
function	O	476-484
.	O	484-485

These	O	486-491
interactions	O	492-504
can	O	505-508
be	O	509-511
described	O	512-521
as	O	522-524
triplet	O	525-532
sets	O	533-537
consisting	O	538-548
of	O	549-551
a	O	552-553
miRNA	O	554-559
,	O	559-560
a	O	561-562
target	O	563-569
gene	O	570-574
and	O	575-578
a	O	579-580
drug	O	581-585
associated	O	586-596
with	O	597-601
the	O	602-605
gene	O	606-610
.	O	610-611

We	O	612-614
have	O	615-619
developed	O	620-629
a	O	630-631
web	O	632-635
server	O	636-642
which	O	643-648
links	O	649-654
miRNA	O	655-660
expression	O	661-671
and	O	672-675
drug	O	676-680
function	O	681-689
by	O	690-692
combining	O	693-702
data	O	703-707
on	O	708-710
miRNA	O	711-716
targeting	O	717-726
and	O	727-730
protein	O	731-738
-	O	738-739
drug	O	739-743
interactions	O	744-756
.	O	756-757

miRNA	O	758-763
targeting	O	764-773
information	O	774-785
derive	O	786-792
from	O	793-797
both	O	798-802
experimental	O	803-815
data	O	816-820
and	O	821-824
computational	O	825-838
predictions	O	839-850
,	O	850-851
and	O	852-855
protein	O	856-863
-	O	863-864
drug	O	864-868
interactions	O	869-881
are	O	882-885
annotated	O	886-895
by	O	896-898
the	O	899-902
Pharmacogenomics	O	903-919
Knowledge	O	920-929
base	O	930-934
(	O	935-936
PharmGKB	O	936-944
)	O	944-945
.	O	945-946

Pharmaco	O	947-955
-	O	955-956
miR	O	956-959
'	O	959-960
s	O	960-961
input	O	962-967
consists	O	968-976
of	O	977-979
miRNAs	O	980-986
,	O	986-987
genes	O	988-993
and	O	994-997
/	O	997-998
or	O	998-1000
drug	O	1001-1005
names	O	1006-1011
and	O	1012-1015
the	O	1016-1019
output	O	1020-1026
consists	O	1027-1035
of	O	1036-1038
miRNA	O	1039-1044
pharmacogenomic	O	1045-1060
sets	O	1061-1065
or	O	1066-1068
a	O	1069-1070
list	O	1071-1075
of	O	1076-1078
unique	O	1079-1085
associated	O	1086-1096
miRNAs	O	1097-1103
,	O	1103-1104
genes	O	1105-1110
and	O	1111-1114
drugs	O	1115-1120
.	O	1120-1121

We	O	1122-1124
have	O	1125-1129
furthermore	O	1130-1141
built	O	1142-1147
a	O	1148-1149
database	O	1150-1158
,	O	1158-1159
named	O	1160-1165
Pharmaco	O	1166-1174
-	O	1174-1175
miR	O	1175-1178
Verified	O	1179-1187
Sets	O	1188-1192
(	O	1193-1194
VerSe	O	1194-1199
)	O	1199-1200
,	O	1200-1201
which	O	1202-1207
contains	O	1208-1216
miRNA	O	1217-1222
pharmacogenomic	O	1223-1238
data	O	1239-1243
manually	O	1244-1252
curated	O	1253-1260
from	O	1261-1265
the	O	1266-1269
literature	O	1270-1280
,	O	1280-1281
can	O	1282-1285
be	O	1286-1288
searched	O	1289-1297
and	O	1298-1301
downloaded	O	1302-1312
via	O	1313-1316
Pharmaco	O	1317-1325
-	O	1325-1326
miR	O	1326-1329
and	O	1330-1333
informs	O	1334-1341
on	O	1342-1344
trends	O	1345-1351
and	O	1352-1355
generalities	O	1356-1368
published	O	1369-1378
in	O	1379-1381
the	O	1382-1385
field	O	1386-1391
.	O	1391-1392

Overall	O	1393-1400
,	O	1400-1401
we	O	1402-1404
present	O	1405-1412
examples	O	1413-1421
of	O	1422-1424
how	O	1425-1428
Pharmaco	O	1429-1437
-	O	1437-1438
miR	O	1438-1441
provides	O	1442-1450
possible	O	1451-1459
explanations	O	1460-1472
for	O	1473-1476
previously	O	1477-1487
published	O	1488-1497
observations	O	1498-1510
,	O	1510-1511
including	O	1512-1521
how	O	1522-1525
the	O	1526-1529
cisplatin	O	1530-1539
and	O	1540-1543
5	O	1544-1545
-	O	1545-1546
fluorouracil	O	1546-1558
resistance	O	1559-1569
induced	O	1570-1577
by	O	1578-1580
miR	B	1581-1584
-	I	1584-1585
148a	I	1585-1589
may	O	1590-1593
be	O	1594-1596
caused	O	1597-1603
by	O	1604-1606
miR	B	1607-1610
-	I	1610-1611
148a	I	1611-1615
targeting	O	1616-1625
of	O	1626-1628
the	O	1629-1632
gene	O	1633-1637
KIT	O	1638-1641
.	O	1641-1642

The	O	1643-1646
information	O	1647-1658
is	O	1659-1661
available	O	1662-1671
at	O	1672-1674
www	O	1675-1678
.	O	1678-1679
Pharmaco	O	1679-1687
-	O	1687-1688
miR	O	1688-1691
.	O	1691-1692
org	O	1692-1695
.	O	1695-1696

Deep	O	0-4
sequencing	O	5-15
of	O	16-18
small	O	19-24
RNA	O	25-28
transcriptome	O	29-42
reveals	O	43-50
novel	O	51-56
non	O	57-60
-	O	60-61
coding	O	61-67
RNAs	O	68-72
in	O	73-75
hepatocellular	O	76-90
carcinoma	O	91-100
.	O	100-101

BACKGROUND	O	102-112
&	O	113-114
AIMS	O	115-119
:	O	119-120
Small	O	121-126
non	O	127-130
-	O	130-131
coding	O	131-137
RNAs	O	138-142
(	O	143-144
ncRNA	O	144-149
)	O	149-150
are	O	151-154
increasingly	O	155-167
recognized	O	168-178
to	O	179-181
play	O	182-186
important	O	187-196
roles	O	197-202
in	O	203-205
tumorigenesis	O	206-219
.	O	219-220

With	O	221-225
the	O	226-229
advent	O	230-236
of	O	237-239
deep	O	240-244
sequencing	O	245-255
,	O	255-256
efforts	O	257-264
have	O	265-269
been	O	270-274
put	O	275-278
forth	O	279-284
to	O	285-287
profile	O	288-295
the	O	296-299
miRNome	O	300-307
in	O	308-310
a	O	311-312
number	O	313-319
of	O	320-322
human	O	323-328
malignancies	O	329-341
.	O	341-342

However	O	343-350
,	O	350-351
information	O	352-363
on	O	364-366
ncRNA	O	367-372
in	O	373-375
hepatocellular	O	376-390
carcinoma	O	391-400
(	O	401-402
HCC	O	402-405
)	O	405-406
,	O	406-407
especially	O	408-418
the	O	419-422
non	O	423-426
-	O	426-427
microRNA	O	427-435
transcripts	O	436-447
,	O	447-448
is	O	449-451
still	O	452-457
lacking	O	458-465
.	O	465-466

METHODS	O	467-474
:	O	474-475
Small	O	476-481
RNA	O	482-485
transcriptomes	O	486-500
of	O	501-503
two	O	504-507
HCC	O	508-511
cell	O	512-516
lines	O	517-522
(	O	523-524
HKCI	O	524-528
-	O	528-529
4	O	529-530
and	O	531-534
HKCI	O	535-539
-	O	539-540
8	O	540-541
)	O	541-542
and	O	543-546
an	O	547-549
immortalized	O	550-562
hepatocyte	O	563-573
line	O	574-578
(	O	579-580
MIHA	O	580-584
)	O	584-585
were	O	586-590
examined	O	591-599
using	O	600-605
Illumina	O	606-614
massively	O	615-624
parallel	O	625-633
sequencing	O	634-644
.	O	644-645

Dysregulated	O	646-658
ncRNAs	O	659-665
were	O	666-670
verified	O	671-679
in	O	680-682
paired	O	683-689
HCC	O	690-693
tumors	O	694-700
and	O	701-704
non	O	705-708
-	O	708-709
tumoral	O	709-716
livers	O	717-723
(	O	724-725
n	O	725-726
=	O	726-727
73	O	727-729
)	O	729-730
by	O	731-733
quantitative	O	734-746
reverse	O	747-754
transcription	O	755-768
-	O	768-769
polymerase	O	769-779
chain	O	780-785
reaction	O	786-794
.	O	794-795

Clinicopathologic	O	796-813
correlations	O	814-826
and	O	827-830
in	O	831-833
vitro	O	834-839
functional	O	840-850
investigations	O	851-865
were	O	866-870
further	O	871-878
carried	O	879-886
out	O	887-890
.	O	890-891

RESULTS	O	892-899
:	O	899-900
The	O	901-904
combined	O	905-913
bioinformatic	O	914-927
and	O	928-931
biological	O	932-942
analyses	O	943-951
showed	O	952-958
the	O	959-962
presence	O	963-971
of	O	972-974
ncRNAs	O	975-981
and	O	982-985
the	O	986-989
involvement	O	990-1001
of	O	1002-1004
a	O	1005-1006
new	O	1007-1010
PIWI	O	1011-1015
-	O	1015-1016
interacting	O	1016-1027
RNA	O	1028-1031
(	O	1032-1033
piRNA	O	1033-1038
)	O	1038-1039
,	O	1039-1040
piR	O	1041-1044
-	O	1044-1045
Hep1	O	1045-1049
,	O	1049-1050
in	O	1051-1053
liver	O	1054-1059
tumorigenesis	O	1060-1073
.	O	1073-1074

piR	O	1075-1078
-	O	1078-1079
Hep1	O	1079-1083
was	O	1084-1087
found	O	1088-1093
to	O	1094-1096
be	O	1097-1099
upregulated	O	1100-1111
in	O	1112-1114
46	O	1115-1117
.	O	1117-1118
6	O	1118-1119
%	O	1119-1120
of	O	1121-1123
HCC	O	1124-1127
tumors	O	1128-1134
compared	O	1135-1143
to	O	1144-1146
the	O	1147-1150
corresponding	O	1151-1164
adjacent	O	1165-1173
non	O	1174-1177
-	O	1177-1178
tumoral	O	1178-1185
liver	O	1186-1191
.	O	1191-1192

Silencing	O	1193-1202
of	O	1203-1205
piR	O	1206-1209
-	O	1209-1210
Hep1	O	1210-1214
inhibited	O	1215-1224
cell	O	1225-1229
viability	O	1230-1239
,	O	1239-1240
motility	O	1241-1249
,	O	1249-1250
and	O	1251-1254
invasiveness	O	1255-1267
,	O	1267-1268
with	O	1269-1273
a	O	1274-1275
concomitant	O	1276-1287
reduction	O	1288-1297
in	O	1298-1300
the	O	1301-1304
level	O	1305-1310
of	O	1311-1313
active	O	1314-1320
AKT	O	1321-1324
phosphorylation	O	1325-1340
.	O	1340-1341

In	O	1342-1344
the	O	1345-1348
analysis	O	1349-1357
of	O	1358-1360
miRNA	O	1361-1366
,	O	1366-1367
we	O	1368-1370
showed	O	1371-1377
for	O	1378-1381
the	O	1382-1385
first	O	1386-1391
time	O	1392-1396
,	O	1396-1397
the	O	1398-1401
abundant	O	1402-1410
expression	O	1411-1421
of	O	1422-1424
miR	B	1425-1428
-	I	1428-1429
1323	I	1429-1433
in	O	1434-1436
HCC	O	1437-1440
and	O	1441-1444
its	O	1445-1448
distinct	O	1449-1457
association	O	1458-1469
in	O	1470-1472
tumors	O	1473-1479
arising	O	1480-1487
from	O	1488-1492
a	O	1493-1494
cirrhotic	O	1495-1504
background	O	1505-1515
.	O	1515-1516

Furthermore	O	1517-1528
,	O	1528-1529
miR	B	1530-1533
-	I	1533-1534
1323	I	1534-1538
overexpression	O	1539-1553
in	O	1554-1556
cirrhotic	O	1557-1566
HCC	O	1567-1570
correlated	O	1571-1581
with	O	1582-1586
poorer	O	1587-1593
disease	O	1594-1601
-	O	1601-1602
free	O	1602-1606
and	O	1607-1610
overall	O	1611-1618
survivals	O	1619-1628
of	O	1629-1631
patients	O	1632-1640
(	O	1641-1642
p	O	1642-1643
<	O	1643-1644
0	O	1644-1645
.	O	1645-1646
009	O	1646-1649
)	O	1649-1650
.	O	1650-1651

CONCLUSIONS	O	1652-1663
:	O	1663-1664
Our	O	1665-1668
study	O	1669-1674
demonstrated	O	1675-1687
the	O	1688-1691
value	O	1692-1697
of	O	1698-1700
next	O	1701-1705
-	O	1705-1706
generation	O	1706-1716
sequencing	O	1717-1727
in	O	1728-1730
dissecting	O	1731-1741
the	O	1742-1745
ncRNome	O	1746-1753
in	O	1754-1756
cancer	O	1757-1763
.	O	1763-1764

The	O	1765-1768
comprehensive	O	1769-1782
definition	O	1783-1793
of	O	1794-1796
transcriptome	O	1797-1810
unveils	O	1811-1818
virtually	O	1819-1828
all	O	1829-1832
types	O	1833-1838
of	O	1839-1841
ncRNAs	O	1842-1848
and	O	1849-1852
provides	O	1853-1861
new	O	1862-1865
insight	O	1866-1873
into	O	1874-1878
liver	O	1879-1884
carcinogenetic	O	1885-1899
events	O	1900-1906
.	O	1906-1907

Tat	O	0-3
-	O	3-4
activating	O	4-14
regulatory	O	15-25
DNA	O	26-29
-	O	29-30
binding	O	30-37
protein	O	38-45
regulates	O	46-55
glycolysis	O	56-66
in	O	67-69
hepatocellular	O	70-84
carcinoma	O	85-94
by	O	95-97
regulating	O	98-108
the	O	109-112
platelet	O	113-121
isoform	O	122-129
of	O	130-132
phosphofructokinase	O	133-152
through	O	153-160
microRNA	B	161-169
520	I	170-173
.	O	173-174

Metabolic	O	175-184
changes	O	185-192
are	O	193-196
common	O	197-203
features	O	204-212
of	O	213-215
many	O	216-220
cancer	O	221-227
cells	O	228-233
and	O	234-237
are	O	238-241
frequently	O	242-252
associated	O	253-263
with	O	264-268
the	O	269-272
clinical	O	273-281
outcome	O	282-289
of	O	290-292
patients	O	293-301
with	O	302-306
various	O	307-314
cancers	O	315-322
,	O	322-323
including	O	324-333
hepatocellular	O	334-348
carcinoma	O	349-358
(	O	359-360
HCC	O	360-363
)	O	363-364
.	O	364-365

Thus	O	366-370
,	O	370-371
aberrant	O	372-380
metabolic	O	381-390
pathways	O	391-399
in	O	400-402
cancer	O	403-409
cells	O	410-415
are	O	416-419
attractive	O	420-430
targets	O	431-438
for	O	439-442
cancer	O	443-449
therapy	O	450-457
.	O	457-458

However	O	459-466
,	O	466-467
our	O	468-471
understanding	O	472-485
of	O	486-488
cancer	O	489-495
-	O	495-496
specific	O	496-504
regulatory	O	505-515
mechanisms	O	516-526
of	O	527-529
cell	O	530-534
metabolism	O	535-545
is	O	546-548
still	O	549-554
very	O	555-559
limited	O	560-567
.	O	567-568

We	O	569-571
found	O	572-577
that	O	578-582
Tat	O	583-586
-	O	586-587
activating	O	587-597
regulatory	O	598-608
DNA	O	609-612
-	O	612-613
binding	O	613-620
protein	O	621-628
(	O	629-630
TARDBP	O	630-636
)	O	636-637
is	O	638-640
a	O	641-642
novel	O	643-648
regulator	O	649-658
of	O	659-661
glycolysis	O	662-672
in	O	673-675
HCC	O	676-679
cells	O	680-685
.	O	685-686

TARDBP	O	687-693
regulates	O	694-703
expression	O	704-714
of	O	715-717
the	O	718-721
platelet	O	722-730
isoform	O	731-738
of	O	739-741
phosphofructokinase	O	742-761
(	O	762-763
PFKP	O	763-767
)	O	767-768
,	O	768-769
the	O	770-773
rate	O	774-778
-	O	778-779
limiting	O	779-787
enzyme	O	788-794
of	O	795-797
glycolysis	O	798-808
that	O	809-813
catalyzes	O	814-823
the	O	824-827
irreversible	O	828-840
conversion	O	841-851
of	O	852-854
fructose	O	855-863
-	O	863-864
6	O	864-865
-	O	865-866
phosphate	O	866-875
to	O	876-878
fructose	O	879-887
-	O	887-888
1	O	888-889
,	O	889-890
6	O	890-891
-	O	891-892
bisphosphate	O	892-904
.	O	904-905

Silencing	O	906-915
of	O	916-918
TARDBP	O	919-925
expression	O	926-936
in	O	937-939
multiple	O	940-948
HCC	O	949-952
cell	O	953-957
lines	O	958-963
leads	O	964-969
to	O	970-972
impaired	O	973-981
glucose	O	982-989
metabolism	O	990-1000
and	O	1001-1004
inhibition	O	1005-1015
of	O	1016-1018
in	O	1019-1021
vitro	O	1022-1027
and	O	1028-1031
in	O	1032-1034
vivo	O	1035-1039
growth	O	1040-1046
of	O	1047-1049
HCC	O	1050-1053
cells	O	1054-1059
.	O	1059-1060

Notably	O	1061-1068
,	O	1068-1069
the	O	1070-1073
microRNA	O	1074-1082
520	O	1083-1086
(	O	1087-1088
miR	B	1088-1091
-	I	1091-1092
520	I	1092-1095
)	O	1095-1096
family	O	1097-1103
is	O	1104-1106
an	O	1107-1109
intermediate	O	1110-1122
regulator	O	1123-1132
of	O	1133-1135
TARDBP	O	1136-1142
-	O	1142-1143
mediated	O	1143-1151
regulation	O	1152-1162
of	O	1163-1165
glycolysis	O	1166-1176
.	O	1176-1177

Mechanistically	O	1178-1193
,	O	1193-1194
TARDBP	O	1195-1201
suppressed	O	1202-1212
expression	O	1213-1223
of	O	1224-1226
the	O	1227-1230
miR	B	1231-1234
-	I	1234-1235
520	I	1235-1238
family	O	1239-1245
,	O	1245-1246
which	O	1247-1252
,	O	1252-1253
in	O	1254-1256
turn	O	1257-1261
,	O	1261-1262
inhibited	O	1263-1272
expression	O	1273-1283
of	O	1284-1286
PFKP	O	1287-1291
.	O	1291-1292

We	O	1293-1295
further	O	1296-1303
showed	O	1304-1310
that	O	1311-1315
expression	O	1316-1326
of	O	1327-1329
TARDBP	O	1330-1336
is	O	1337-1339
significantly	O	1340-1353
associated	O	1354-1364
with	O	1365-1369
the	O	1370-1373
overall	O	1374-1381
survival	O	1382-1390
of	O	1391-1393
patients	O	1394-1402
with	O	1403-1407
HCC	O	1408-1411
.	O	1411-1412

CONCLUSION	O	1413-1423
:	O	1423-1424
Our	O	1425-1428
study	O	1429-1434
provides	O	1435-1443
new	O	1444-1447
mechanistic	O	1448-1459
insights	O	1460-1468
into	O	1469-1473
the	O	1474-1477
regulation	O	1478-1488
of	O	1489-1491
glycolysis	O	1492-1502
in	O	1503-1505
HCC	O	1506-1509
cells	O	1510-1515
and	O	1516-1519
reveals	O	1520-1527
TARDBP	O	1528-1534
as	O	1535-1537
a	O	1538-1539
potential	O	1540-1549
therapeutic	O	1550-1561
target	O	1562-1568
for	O	1569-1572
HCC	O	1573-1576
.	O	1576-1577

Overexpression	O	0-14
of	O	15-17
YWHAZ	O	18-23
relates	O	24-31
to	O	32-34
tumor	O	35-40
cell	O	41-45
proliferation	O	46-59
and	O	60-63
malignant	O	64-73
outcome	O	74-81
of	O	82-84
gastric	O	85-92
carcinoma	O	93-102
.	O	102-103

BACKGROUND	O	104-114
:	O	114-115
Several	O	116-123
studies	O	124-131
have	O	132-136
demonstrated	O	137-149
that	O	150-154
YWHAZ	O	155-160
(	O	161-162
14	O	162-164
-	O	164-165
3	O	165-166
-	O	166-167
3zeta	O	167-172
)	O	172-173
,	O	173-174
included	O	175-183
in	O	184-186
the	O	187-190
14	O	191-193
-	O	193-194
3	O	194-195
-	O	195-196
3	O	196-197
family	O	198-204
of	O	205-207
proteins	O	208-216
,	O	216-217
has	O	218-221
been	O	222-226
implicated	O	227-237
in	O	238-240
the	O	241-244
initiation	O	245-255
and	O	256-259
progression	O	260-271
of	O	272-274
cancers	O	275-282
.	O	282-283

We	O	284-286
tested	O	287-293
whether	O	294-301
YWHAZ	O	302-307
acted	O	308-313
as	O	314-316
a	O	317-318
cancer	O	319-325
-	O	325-326
promoting	O	326-335
gene	O	336-340
through	O	341-348
its	O	349-352
activation	O	353-363
/	O	363-364
overexpression	O	364-378
in	O	379-381
gastric	O	382-389
cancer	O	390-396
(	O	397-398
GC	O	398-400
)	O	400-401
.	O	401-402

METHODS	O	403-410
:	O	410-411
We	O	412-414
analysed	O	415-423
7	O	424-425
GC	O	426-428
cell	O	429-433
lines	O	434-439
and	O	440-443
141	O	444-447
primary	O	448-455
tumours	O	456-463
,	O	463-464
which	O	465-470
were	O	471-475
curatively	O	476-486
resected	O	487-495
in	O	496-498
our	O	499-502
hospital	O	503-511
between	O	512-519
2001	O	520-524
and	O	525-528
2003	O	529-533
.	O	533-534

RESULTS	O	535-542
:	O	542-543
Overexpression	O	544-558
of	O	559-561
the	O	562-565
YWHAZ	O	566-571
protein	O	572-579
was	O	580-583
frequently	O	584-594
detected	O	595-603
in	O	604-606
GC	O	607-609
cell	O	610-614
lines	O	615-620
(	O	621-622
six	O	622-625
out	O	626-629
of	O	630-632
seven	O	633-638
lines	O	639-644
,	O	644-645
85	O	646-648
.	O	648-649
7	O	649-650
%	O	650-651
)	O	651-652
and	O	653-656
primary	O	657-664
tumour	O	665-671
samples	O	672-679
of	O	680-682
GC	O	683-685
(	O	686-687
72	O	687-689
out	O	690-693
of	O	694-696
141	O	697-700
cases	O	701-706
,	O	706-707
51	O	708-710
%	O	710-711
)	O	711-712
,	O	712-713
and	O	714-717
significantly	O	718-731
correlated	O	732-742
with	O	743-747
larger	O	748-754
tumour	O	755-761
size	O	762-766
,	O	766-767
venous	O	768-774
and	O	775-778
lymphatic	O	779-788
invasion	O	789-797
,	O	797-798
deeper	O	799-805
tumour	O	806-812
depth	O	813-818
,	O	818-819
and	O	820-823
higher	O	824-830
pathological	O	831-843
stage	O	844-849
and	O	850-853
recurrence	O	854-864
rate	O	865-869
.	O	869-870

Patients	O	871-879
with	O	880-884
YWHAZ	O	885-890
-	O	890-891
overexpressing	O	891-905
tumours	O	906-913
had	O	914-917
worse	O	918-923
overall	O	924-931
survival	O	932-940
rates	O	941-946
than	O	947-951
those	O	952-957
with	O	958-962
non	O	963-966
-	O	966-967
expressing	O	967-977
tumours	O	978-985
in	O	986-988
both	O	989-993
intensity	O	994-1003
and	O	1004-1007
proportion	O	1008-1018
expression	O	1019-1029
-	O	1029-1030
dependent	O	1030-1039
manner	O	1040-1046
.	O	1046-1047

YWHAZ	O	1048-1053
positivity	O	1054-1064
was	O	1065-1068
independently	O	1069-1082
associated	O	1083-1093
with	O	1094-1098
a	O	1099-1100
worse	O	1101-1106
outcome	O	1107-1114
in	O	1115-1117
multivariate	O	1118-1130
analysis	O	1131-1139
(	O	1140-1141
P	O	1141-1142
=	O	1142-1143
0	O	1143-1144
.	O	1144-1145
0491	O	1145-1149
,	O	1149-1150
hazard	O	1151-1157
ratio	O	1158-1163
2	O	1164-1165
.	O	1165-1166
3	O	1166-1167
(	O	1168-1169
1	O	1169-1170
.	O	1170-1171
003	O	1171-1174
-	O	1174-1175
5	O	1175-1176
.	O	1176-1177
304	O	1177-1180
)	O	1180-1181
)	O	1181-1182
.	O	1182-1183

Knockdown	O	1184-1193
of	O	1194-1196
YWHAZ	O	1197-1202
expression	O	1203-1213
using	O	1214-1219
several	O	1220-1227
specific	O	1228-1236
siRNAs	O	1237-1243
inhibited	O	1244-1253
the	O	1254-1257
proliferation	O	1258-1271
,	O	1271-1272
migration	O	1273-1282
,	O	1282-1283
and	O	1284-1287
invasion	O	1288-1296
of	O	1297-1299
YWHAZ	O	1300-1305
-	O	1305-1306
overexpressing	O	1306-1320
GC	O	1321-1323
cells	O	1324-1329
.	O	1329-1330

Higher	O	1331-1337
expression	O	1338-1348
of	O	1349-1351
the	O	1352-1355
YWHAZ	O	1356-1361
protein	O	1362-1369
was	O	1370-1373
significantly	O	1374-1387
associated	O	1388-1398
with	O	1399-1403
the	O	1404-1407
lower	O	1408-1413
expression	O	1414-1424
of	O	1425-1427
miR	B	1428-1431
-	I	1431-1432
375	I	1432-1435
in	O	1436-1438
primary	O	1439-1446
GC	O	1447-1449
tissues	O	1450-1457
(	O	1458-1459
P	O	1459-1460
=	O	1460-1461
0	O	1461-1462
.	O	1462-1463
0047	O	1463-1467
)	O	1467-1468
.	O	1468-1469

CONCLUSION	O	1470-1480
:	O	1480-1481
These	O	1482-1487
findings	O	1488-1496
suggest	O	1497-1504
that	O	1505-1509
YWHAZ	O	1510-1515
has	O	1516-1519
a	O	1520-1521
pivotal	O	1522-1529
role	O	1530-1534
in	O	1535-1537
tumour	O	1538-1544
cell	O	1545-1549
proliferation	O	1550-1563
through	O	1564-1571
its	O	1572-1575
overexpression	O	1576-1590
,	O	1590-1591
and	O	1592-1595
highlight	O	1596-1605
its	O	1606-1609
usefulness	O	1610-1620
as	O	1621-1623
a	O	1624-1625
prognostic	O	1626-1636
factor	O	1637-1643
and	O	1644-1647
potential	O	1648-1657
therapeutic	O	1658-1669
target	O	1670-1676
in	O	1677-1679
GC	O	1680-1682
.	O	1682-1683

Hypoxia	O	0-7
-	O	7-8
responsive	O	8-18
miRNAs	O	19-25
target	O	26-32
argonaute	O	33-42
1	O	43-44
to	O	45-47
promote	O	48-55
angiogenesis	O	56-68
.	O	68-69

Despite	O	70-77
a	O	78-79
general	O	80-87
repression	O	88-98
of	O	99-101
translation	O	102-113
under	O	114-119
hypoxia	O	120-127
,	O	127-128
cells	O	129-134
selectively	O	135-146
upregulate	O	147-157
a	O	158-159
set	O	160-163
of	O	164-166
hypoxia	O	167-174
-	O	174-175
inducible	O	175-184
genes	O	185-190
.	O	190-191

Results	O	192-199
from	O	200-204
deep	O	205-209
sequencing	O	210-220
revealed	O	221-229
that	O	230-234
Let	B	235-238
-	I	238-239
7	I	239-240
and	O	241-244
miR	B	245-248
-	I	248-249
103	I	249-252
/	O	252-253
107	B	253-256
are	O	257-260
hypoxia	O	261-268
-	O	268-269
responsive	O	269-279
microRNAs	O	280-289
(	O	290-291
HRMs	O	291-295
)	O	295-296
that	O	297-301
are	O	302-305
strongly	O	306-314
induced	O	315-322
in	O	323-325
vascular	O	326-334
endothelial	O	335-346
cells	O	347-352
.	O	352-353

In	O	354-356
silico	O	357-363
bioinformatics	O	364-378
and	O	379-382
in	O	383-385
vitro	O	386-391
validation	O	392-402
showed	O	403-409
that	O	410-414
these	O	415-420
HRMs	O	421-425
are	O	426-429
induced	O	430-437
by	O	438-440
HIF1alpha	O	441-450
and	O	451-454
target	O	455-461
argonaute	O	462-471
1	O	472-473
(	O	474-475
AGO1	O	475-479
)	O	479-480
,	O	480-481
which	O	482-487
anchors	O	488-495
the	O	496-499
microRNA	O	500-508
-	O	508-509
induced	O	509-516
silencing	O	517-526
complex	O	527-534
(	O	535-536
miRISC	O	536-542
)	O	542-543
.	O	543-544

HRM	O	545-548
targeting	O	549-558
of	O	559-561
AGO1	O	562-566
resulted	O	567-575
in	O	576-578
the	O	579-582
translational	O	583-596
desuppression	O	597-610
of	O	611-613
VEGF	O	614-618
mRNA	O	619-623
.	O	623-624

Inhibition	O	625-635
of	O	636-638
HRM	O	639-642
or	O	643-645
overexpression	O	646-660
of	O	661-663
AGO1	O	664-668
without	O	669-676
the	O	677-680
3	O	681-682
'	O	682-683
untranslated	O	684-696
region	O	697-703
decreased	O	704-713
hypoxia	O	714-721
-	O	721-722
induced	O	722-729
angiogenesis	O	730-742
.	O	742-743

Conversely	O	744-754
,	O	754-755
AGO1	O	756-760
knockdown	O	761-770
increased	O	771-780
angiogenesis	O	781-793
under	O	794-799
normoxia	O	800-808
in	O	809-811
vivo	O	812-816
.	O	816-817

In	O	818-820
addition	O	821-829
,	O	829-830
data	O	831-835
from	O	836-840
tumor	O	841-846
xenografts	O	847-857
and	O	858-861
human	O	862-867
cancer	O	868-874
specimens	O	875-884
indicate	O	885-893
that	O	894-898
AGO1	O	899-903
-	O	903-904
mediated	O	904-912
translational	O	913-926
desuppression	O	927-940
of	O	941-943
VEGF	O	944-948
may	O	949-952
be	O	953-955
associated	O	956-966
with	O	967-971
tumor	O	972-977
angiogenesis	O	978-990
and	O	991-994
poor	O	995-999
prognosis	O	1000-1009
.	O	1009-1010

These	O	1011-1016
findings	O	1017-1025
provide	O	1026-1033
evidence	O	1034-1042
for	O	1043-1046
an	O	1047-1049
angiogenic	O	1050-1060
pathway	O	1061-1068
involving	O	1069-1078
HRMs	O	1079-1083
that	O	1084-1088
target	O	1089-1095
AGO1	O	1096-1100
and	O	1101-1104
suggest	O	1105-1112
that	O	1113-1117
this	O	1118-1122
pathway	O	1123-1130
may	O	1131-1134
be	O	1135-1137
a	O	1138-1139
suitable	O	1140-1148
target	O	1149-1155
for	O	1156-1159
anti	O	1160-1164
-	O	1164-1165
or	O	1166-1168
proangiogenesis	O	1169-1184
strategies	O	1185-1195
.	O	1195-1196

Identification	O	0-14
of	O	15-17
serum	O	18-23
microRNAs	O	24-33
in	O	34-36
genome	O	37-43
-	O	43-44
wide	O	44-48
serum	O	49-54
microRNA	O	55-63
expression	O	64-74
profiles	O	75-83
as	O	84-86
novel	O	87-92
noninvasive	O	93-104
biomarkers	O	105-115
for	O	116-119
malignant	O	120-129
peripheral	O	130-140
nerve	O	141-146
sheath	O	147-153
tumor	O	154-159
diagnosis	O	160-169
.	O	169-170

Recent	O	171-177
studies	O	178-185
found	O	186-191
that	O	192-196
serum	O	197-202
microRNAs	O	203-212
(	O	213-214
miRNAs	O	214-220
)	O	220-221
could	O	222-227
serve	O	228-233
as	O	234-236
stable	O	237-243
and	O	244-247
noninvasive	O	248-259
biomarkers	O	260-270
for	O	271-274
disease	O	275-282
diagnosis	O	283-292
.	O	292-293

We	O	294-296
used	O	297-301
genome	O	302-308
-	O	308-309
wide	O	309-313
serum	O	314-319
miRNA	O	320-325
expression	O	326-336
analysis	O	337-345
to	O	346-348
investigate	O	349-360
the	O	361-364
role	O	365-369
of	O	370-372
serum	O	373-378
miRNAs	O	379-385
in	O	386-388
distinguishing	O	389-403
malignant	O	404-413
peripheral	O	414-424
nerve	O	425-430
sheath	O	431-437
tumor	O	438-443
(	O	444-445
MPNST	O	445-450
)	O	450-451
patients	O	452-460
with	O	461-465
and	O	466-469
without	O	470-477
neurofibromatosis	O	478-495
type	O	496-500
1	O	501-502
(	O	503-504
NF1	O	504-507
)	O	507-508
from	O	509-513
NF1	O	514-517
patients	O	518-526
.	O	526-527

A	O	528-529
total	O	530-535
of	O	536-538
100	O	539-542
patients	O	543-551
with	O	552-556
NF1	O	557-560
,	O	560-561
93	O	562-564
sporadic	O	565-573
MPNST	O	574-579
patients	O	580-588
,	O	588-589
and	O	590-593
71	O	594-596
NF1	O	597-600
MPNST	O	601-606
patients	O	607-615
were	O	616-620
enrolled	O	621-629
in	O	630-632
this	O	633-637
two	O	638-641
-	O	641-642
stage	O	642-647
,	O	647-648
case	O	649-653
-	O	653-654
control	O	654-661
study	O	662-667
.	O	667-668

Solexa	O	669-675
sequencing	O	676-686
was	O	687-690
used	O	691-695
to	O	696-698
screen	O	699-705
for	O	706-709
miRNAs	O	710-716
that	O	717-721
expressed	O	722-731
differentially	O	732-746
in	O	747-749
three	O	750-755
pooled	O	756-762
serum	O	763-768
samples	O	769-776
from	O	777-781
10	O	782-784
NF1	O	785-788
patients	O	789-797
,	O	797-798
10	O	799-801
sporadic	O	802-810
MPNST	O	811-816
patients	O	817-825
,	O	825-826
and	O	827-830
10	O	831-833
NF1	O	834-837
MPNST	O	838-843
patients	O	844-852
.	O	852-853

The	O	854-857
detected	O	858-866
serum	O	867-872
miRNAs	O	873-879
then	O	880-884
were	O	885-889
validated	O	890-899
in	O	900-902
90	O	903-905
patients	O	906-914
with	O	915-919
NF1	O	920-923
,	O	923-924
83	O	925-927
patients	O	928-936
with	O	937-941
sporadic	O	942-950
MPNST	O	951-956
,	O	956-957
and	O	958-961
61	O	962-964
NF1	O	965-968
MPNST	O	969-974
patients	O	975-983
by	O	984-986
individual	O	987-997
quantitative	O	998-1010
reverse	O	1011-1018
transcriptase	O	1019-1032
polymerase	O	1033-1043
chain	O	1044-1049
reaction	O	1050-1058
assays	O	1059-1065
.	O	1065-1066

Eight	O	1067-1072
serum	O	1073-1078
miRNAs	O	1079-1085
altered	O	1086-1093
more	O	1094-1098
than	O	1099-1103
fivefold	O	1104-1112
by	O	1113-1115
Solexa	O	1116-1122
sequencing	O	1123-1133
between	O	1134-1141
MPNST	O	1142-1147
patients	O	1148-1156
(	O	1157-1158
with	O	1158-1162
and	O	1163-1166
without	O	1167-1174
NF1	O	1175-1178
)	O	1178-1179
and	O	1180-1183
NF1	O	1184-1187
patients	O	1188-1196
.	O	1196-1197

MiR	B	1198-1201
-	I	1201-1202
801	I	1202-1205
and	O	1206-1209
miR	B	1210-1213
-	I	1213-1214
214	I	1214-1217
increased	O	1218-1227
both	O	1228-1232
in	O	1233-1235
sporadic	O	1236-1244
MPNST	O	1245-1250
patients	O	1251-1259
and	O	1260-1263
NF1	O	1264-1267
MPNST	O	1268-1273
patients	O	1274-1282
when	O	1283-1287
compared	O	1288-1296
with	O	1297-1301
NF1	O	1302-1305
patients	O	1306-1314
.	O	1314-1315

The	O	1316-1319
sensitivity	O	1320-1331
and	O	1332-1335
the	O	1336-1339
specificity	O	1340-1351
of	O	1352-1354
sporadic	O	1355-1363
MPNST	O	1364-1369
detection	O	1370-1379
by	O	1380-1382
the	O	1383-1386
two	O	1387-1390
-	O	1390-1391
miRNA	O	1391-1396
signature	O	1397-1406
were	O	1407-1411
0	O	1412-1413
.	O	1413-1414
747	O	1414-1417
and	O	1418-1421
0	O	1422-1423
.	O	1423-1424
856	O	1424-1427
,	O	1427-1428
respectively	O	1429-1441
.	O	1441-1442

MiR	B	1443-1446
-	I	1446-1447
24	I	1447-1449
was	O	1450-1453
only	O	1454-1458
significantly	O	1459-1472
up	O	1473-1475
-	O	1475-1476
regulated	O	1476-1485
in	O	1486-1488
NF1	O	1489-1492
MPNST	O	1493-1498
patients	O	1499-1507
.	O	1507-1508

The	O	1509-1512
combination	O	1513-1524
of	O	1525-1527
the	O	1528-1531
three	O	1532-1537
miRNAs	O	1538-1544
(	O	1545-1546
MiR	B	1546-1549
-	I	1549-1550
801	I	1550-1553
,	O	1553-1554
miR	B	1555-1558
-	I	1558-1559
214	I	1559-1562
,	O	1562-1563
and	O	1564-1567
miR	B	1568-1571
-	I	1571-1572
24	I	1572-1574
)	O	1574-1575
could	O	1576-1581
distinguish	O	1582-1593
NF1	O	1594-1597
MPNST	O	1598-1603
patients	O	1604-1612
from	O	1613-1617
NF1	O	1618-1621
patients	O	1622-1630
with	O	1631-1635
a	O	1636-1637
sensitivity	O	1638-1649
of	O	1650-1652
0	O	1653-1654
.	O	1654-1655
820	O	1655-1658
and	O	1659-1662
a	O	1663-1664
specificity	O	1665-1676
of	O	1677-1679
0	O	1680-1681
.	O	1681-1682
844	O	1682-1685
.	O	1685-1686

The	O	1687-1690
serum	O	1691-1696
-	O	1696-1697
based	O	1697-1702
miRNA	O	1703-1708
expression	O	1709-1719
profiles	O	1720-1728
could	O	1729-1734
serve	O	1735-1740
as	O	1741-1743
novel	O	1744-1749
noninvasive	O	1750-1761
biomarkers	O	1762-1772
in	O	1773-1775
sporadic	O	1776-1784
MPNST	O	1785-1790
and	O	1791-1794
NF1	O	1795-1798
MPNST	O	1799-1804
detection	O	1805-1814
.	O	1814-1815

Control	O	0-7
of	O	8-10
cholesterol	O	11-22
metabolism	O	23-33
and	O	34-37
plasma	O	38-44
high	O	45-49
-	O	49-50
density	O	50-57
lipoprotein	O	58-69
levels	O	70-76
by	O	77-79
microRNA	B	80-88
-	I	88-89
144	I	89-92
.	O	92-93

RATIONALE	O	94-103
:	O	103-104
Foam	O	105-109
cell	O	110-114
formation	O	115-124
because	O	125-132
of	O	133-135
excessive	O	136-145
accumulation	O	146-158
of	O	159-161
cholesterol	O	162-173
by	O	174-176
macrophages	O	177-188
is	O	189-191
a	O	192-193
pathological	O	194-206
hallmark	O	207-215
of	O	216-218
atherosclerosis	O	219-234
,	O	234-235
the	O	236-239
major	O	240-245
cause	O	246-251
of	O	252-254
morbidity	O	255-264
and	O	265-268
mortality	O	269-278
in	O	279-281
Western	O	282-289
societies	O	290-299
.	O	299-300

Liver	O	301-306
X	O	307-308
nuclear	O	309-316
receptors	O	317-326
(	O	327-328
LXRs	O	328-332
)	O	332-333
regulate	O	334-342
the	O	343-346
expression	O	347-357
of	O	358-360
the	O	361-364
adenosine	O	365-374
triphosphate	O	375-387
-	O	387-388
binding	O	388-395
cassette	O	396-404
(	O	405-406
ABC	O	406-409
)	O	409-410
transporters	O	411-423
,	O	423-424
including	O	425-434
adenosine	O	435-444
triphosphate	O	445-457
-	O	457-458
binding	O	458-465
cassette	O	466-474
transporter	O	475-486
A1	O	487-489
(	O	490-491
ABCA1	O	491-496
)	O	496-497
and	O	498-501
adenosine	O	502-511
triphosphate	O	512-524
-	O	524-525
binding	O	525-532
cassette	O	533-541
transporter	O	542-553
G1	O	554-556
(	O	557-558
ABCG1	O	558-563
)	O	563-564
.	O	564-565

ABCA1	O	566-571
and	O	572-575
ABCG1	O	576-581
facilitate	O	582-592
the	O	593-596
efflux	O	597-603
of	O	604-606
cholesterol	O	607-618
from	O	619-623
macrophages	O	624-635
and	O	636-639
regulate	O	640-648
high	O	649-653
-	O	653-654
density	O	654-661
lipoprotein	O	662-673
(	O	674-675
HDL	O	675-678
)	O	678-679
biogenesis	O	680-690
.	O	690-691

Increasing	O	692-702
evidence	O	703-711
supports	O	712-720
the	O	721-724
role	O	725-729
of	O	730-732
microRNA	O	733-741
(	O	742-743
miRNAs	O	743-749
)	O	749-750
in	O	751-753
regulating	O	754-764
cholesterol	O	765-776
metabolism	O	777-787
through	O	788-795
ABC	O	796-799
transporters	O	800-812
.	O	812-813

OBJECTIVE	O	814-823
:	O	823-824
We	O	825-827
aimed	O	828-833
to	O	834-836
identify	O	837-845
novel	O	846-851
miRNAs	O	852-858
that	O	859-863
regulate	O	864-872
cholesterol	O	873-884
metabolism	O	885-895
in	O	896-898
macrophages	O	899-910
stimulated	O	911-921
with	O	922-926
LXR	O	927-930
agonists	O	931-939
.	O	939-940

METHODS	O	941-948
AND	O	949-952
RESULTS	O	953-960
:	O	960-961
To	O	962-964
map	O	965-968
the	O	969-972
miRNA	O	973-978
expression	O	979-989
signature	O	990-999
of	O	1000-1002
macrophages	O	1003-1014
stimulated	O	1015-1025
with	O	1026-1030
LXR	O	1031-1034
agonists	O	1035-1043
,	O	1043-1044
we	O	1045-1047
performed	O	1048-1057
an	O	1058-1060
miRNA	O	1061-1066
profiling	O	1067-1076
microarray	O	1077-1087
analysis	O	1088-1096
in	O	1097-1099
primary	O	1100-1107
mouse	O	1108-1113
peritoneal	O	1114-1124
macrophages	O	1125-1136
stimulated	O	1137-1147
with	O	1148-1152
LXR	O	1153-1156
ligands	O	1157-1164
.	O	1164-1165

We	O	1166-1168
report	O	1169-1175
that	O	1176-1180
LXR	O	1181-1184
ligands	O	1185-1192
increase	O	1193-1201
miR	B	1202-1205
-	I	1205-1206
144	I	1206-1209
expression	O	1210-1220
in	O	1221-1223
macrophages	O	1224-1235
and	O	1236-1239
mouse	O	1240-1245
livers	O	1246-1252
.	O	1252-1253

Overexpression	O	1254-1268
of	O	1269-1271
miR	B	1272-1275
-	I	1275-1276
144	I	1276-1279
reduces	O	1280-1287
ABCA1	O	1288-1293
expression	O	1294-1304
and	O	1305-1308
attenuates	O	1309-1319
cholesterol	O	1320-1331
efflux	O	1332-1338
to	O	1339-1341
apolipoproteinA1	O	1342-1358
in	O	1359-1361
macrophages	O	1362-1373
.	O	1373-1374

Delivery	O	1375-1383
of	O	1384-1386
miR	B	1387-1390
-	I	1390-1391
144	I	1391-1394
oligonucleotides	O	1395-1411
to	O	1412-1414
mice	O	1415-1419
attenuates	O	1420-1430
ABCA1	O	1431-1436
expression	O	1437-1447
in	O	1448-1450
the	O	1451-1454
liver	O	1455-1460
,	O	1460-1461
reducing	O	1462-1470
HDL	O	1471-1474
levels	O	1475-1481
.	O	1481-1482

Conversely	O	1483-1493
,	O	1493-1494
silencing	O	1495-1504
of	O	1505-1507
miR	B	1508-1511
-	I	1511-1512
144	I	1512-1515
in	O	1516-1518
mice	O	1519-1523
increases	O	1524-1533
the	O	1534-1537
expression	O	1538-1548
of	O	1549-1551
ABCA1	O	1552-1557
and	O	1558-1561
plasma	O	1562-1568
HDL	O	1569-1572
levels	O	1573-1579
.	O	1579-1580

Thus	O	1581-1585
,	O	1585-1586
miR	B	1587-1590
-	I	1590-1591
144	I	1591-1594
seems	O	1595-1600
to	O	1601-1603
regulate	O	1604-1612
both	O	1613-1617
macrophage	O	1618-1628
cholesterol	O	1629-1640
efflux	O	1641-1647
and	O	1648-1651
HDL	O	1652-1655
biogenesis	O	1656-1666
in	O	1667-1669
the	O	1670-1673
liver	O	1674-1679
.	O	1679-1680

CONCLUSIONS	O	1681-1692
:	O	1692-1693
miR	B	1694-1697
-	I	1697-1698
144	I	1698-1701
regulates	O	1702-1711
cholesterol	O	1712-1723
metabolism	O	1724-1734
via	O	1735-1738
suppressing	O	1739-1750
ABCA1	O	1751-1756
expression	O	1757-1767
and	O	1768-1771
modulation	O	1772-1782
of	O	1783-1785
miRNAs	O	1786-1792
may	O	1793-1796
represent	O	1797-1806
a	O	1807-1808
potential	O	1809-1818
therapeutical	O	1819-1832
intervention	O	1833-1845
for	O	1846-1849
treating	O	1850-1858
dyslipidemia	O	1859-1871
and	O	1872-1875
atherosclerotic	O	1876-1891
vascular	O	1892-1900
disease	O	1901-1908
.	O	1908-1909

Effects	O	0-7
of	O	8-10
vitamin	O	11-18
E	O	19-20
on	O	21-23
expressions	O	24-35
of	O	36-38
eight	O	39-44
microRNAs	O	45-54
in	O	55-57
the	O	58-61
liver	O	62-67
of	O	68-70
Nile	O	71-75
tilapia	O	76-83
(	O	84-85
Oreochromis	O	85-96
niloticus	O	97-106
)	O	106-107
.	O	107-108

Currently	O	109-118
,	O	118-119
microRNAs	O	120-129
(	O	130-131
miRNAs	O	131-137
)	O	137-138
are	O	139-142
known	O	143-148
to	O	149-151
regulate	O	152-160
cellular	O	161-169
processes	O	170-179
such	O	180-184
as	O	185-187
apoptosis	O	188-197
,	O	197-198
differentiation	O	199-214
,	O	214-215
cell	O	216-220
cycle	O	221-226
,	O	226-227
and	O	228-231
immune	O	232-238
functions	O	239-248
,	O	248-249
and	O	250-253
their	O	254-259
expression	O	260-270
can	O	271-274
be	O	275-277
altered	O	278-285
by	O	286-288
distinct	O	289-297
stress	O	298-304
conditions	O	305-315
,	O	315-316
such	O	317-321
as	O	322-324
oxidative	O	325-334
stress	O	335-341
.	O	341-342

In	O	343-345
immune	O	346-352
systems	O	353-360
of	O	361-363
fish	O	364-368
,	O	368-369
vitamin	O	370-377
E	O	378-379
(	O	380-381
VE	O	381-383
)	O	383-384
has	O	385-388
a	O	389-390
defined	O	391-398
role	O	399-403
as	O	404-406
an	O	407-409
antioxidant	O	410-421
.	O	421-422

In	O	423-425
order	O	426-431
to	O	432-434
understand	O	435-445
the	O	446-449
molecular	O	450-459
mechanism	O	460-469
of	O	470-472
vitamin	O	473-480
E	O	481-482
defending	O	483-492
from	O	493-497
oxidative	O	498-507
stress	O	508-514
,	O	514-515
three	O	516-521
groups	O	522-528
of	O	529-531
juvenile	O	532-540
Nile	O	541-545
tilapia	O	546-553
(	O	554-555
Oreochromis	O	555-566
niloticus	O	567-576
)	O	576-577
(	O	578-579
initial	O	579-586
weight	O	587-593
3	O	594-595
.	O	595-596
25	O	596-598
+	O	599-600
/	O	600-601
-	O	601-602
0	O	603-604
.	O	604-605
02	O	605-607
g	O	608-609
)	O	609-610
were	O	611-615
fed	O	616-619
to	O	620-622
satiation	O	623-632
with	O	633-637
3	O	638-639
semi	O	640-644
-	O	644-645
purified	O	645-653
diets	O	654-659
containing	O	660-670
VE	O	671-673
(	O	674-675
DL	O	675-677
-	O	677-678
alpha	O	678-683
-	O	683-684
tocopherol	O	684-694
acetate	O	695-702
)	O	702-703
of	O	704-706
0	O	707-708
,	O	708-709
50	O	710-712
,	O	712-713
and	O	714-717
2500	O	718-722
mg	O	723-725
/	O	725-726
kg	O	726-728
supplementation	O	729-744
,	O	744-745
respectively	O	746-758
,	O	758-759
with	O	760-764
the	O	765-768
expressions	O	769-780
of	O	781-783
eight	O	784-789
miRNAs	O	790-796
(	O	797-798
miR	B	798-801
-	I	801-802
21	I	802-804
,	O	804-805
miR	B	806-809
-	I	809-810
223	I	810-813
,	O	813-814
miR	B	815-818
-	I	818-819
146a	I	819-823
,	O	823-824
miR	B	825-828
-	I	828-829
125b	I	829-833
,	O	833-834
miR	B	835-838
-	I	838-839
181a	I	839-843
,	O	843-844
miR	B	845-848
-	I	848-849
16	I	849-851
,	O	851-852
miR	B	853-856
-	I	856-857
155	I	857-860
and	O	861-864
miR	B	865-868
-	I	868-869
122	I	869-872
)	O	872-873
in	O	874-876
the	O	877-880
liver	O	881-886
of	O	887-889
tilapia	O	890-897
subsequently	O	898-910
detected	O	911-919
after	O	920-925
8	O	926-927
-	O	927-928
week	O	928-932
growth	O	933-939
experiment	O	940-950
.	O	950-951

Results	O	952-959
showed	O	960-966
that	O	967-971
VE	O	972-974
-	O	974-975
deficient	O	975-984
(	O	985-986
0	O	986-987
mg	O	988-990
/	O	990-991
kg	O	991-993
supplementation	O	994-1009
)	O	1009-1010
decreased	O	1011-1020
the	O	1021-1024
activity	O	1025-1033
of	O	1034-1036
superoxide	O	1037-1047
dismutase	O	1048-1057
(	O	1058-1059
SOD	O	1059-1062
)	O	1062-1063
,	O	1063-1064
and	O	1065-1068
decreased	O	1069-1078
the	O	1079-1082
expressions	O	1083-1094
of	O	1095-1097
miR	B	1098-1101
-	I	1101-1102
223	I	1102-1105
,	O	1105-1106
miR	B	1107-1110
-	I	1110-1111
146a	I	1111-1115
,	O	1115-1116
miR	B	1117-1120
-	I	1120-1121
16	I	1121-1123
and	O	1124-1127
miR	B	1128-1131
-	I	1131-1132
122	I	1132-1135
,	O	1135-1136
while	O	1137-1142
excessive	O	1143-1152
supplementation	O	1153-1168
of	O	1169-1171
VE	O	1172-1174
(	O	1175-1176
2500	O	1176-1180
mg	O	1181-1183
/	O	1183-1184
kg	O	1184-1186
)	O	1186-1187
decreased	O	1188-1197
SOD	O	1198-1201
activity	O	1202-1210
and	O	1211-1214
increased	O	1215-1224
the	O	1225-1228
expressions	O	1229-1240
of	O	1241-1243
all	O	1244-1247
the	O	1248-1251
eight	O	1252-1257
miRNAs	O	1258-1264
.	O	1264-1265

The	O	1266-1269
targets	O	1270-1277
of	O	1278-1280
the	O	1281-1284
eight	O	1285-1290
miRNAs	O	1291-1297
were	O	1298-1302
further	O	1303-1310
predicated	O	1311-1321
with	O	1322-1326
bioinformatic	O	1327-1340
approach	O	1341-1349
and	O	1350-1353
the	O	1354-1357
possible	O	1358-1366
regulating	O	1367-1377
mechanisms	O	1378-1388
of	O	1389-1391
VE	O	1392-1394
via	O	1395-1398
miRNAs	O	1399-1405
were	O	1406-1410
analyzed	O	1411-1419
.	O	1419-1420

The	O	1421-1424
present	O	1425-1432
study	O	1433-1438
confirmed	O	1439-1448
that	O	1449-1453
the	O	1454-1457
differences	O	1458-1469
in	O	1470-1472
dietary	O	1473-1480
VE	O	1481-1483
affected	O	1484-1492
expression	O	1493-1503
of	O	1504-1506
hepatic	O	1507-1514
miRNAs	O	1515-1521
which	O	1522-1527
may	O	1528-1531
partly	O	1532-1538
demonstrate	O	1539-1550
the	O	1551-1554
molecular	O	1555-1564
mechanism	O	1565-1574
of	O	1575-1577
VE	O	1578-1580
,	O	1580-1581
and	O	1582-1585
the	O	1586-1589
new	O	1590-1593
idea	O	1594-1598
of	O	1599-1601
introducing	O	1602-1613
miRNAs	O	1614-1620
into	O	1621-1625
research	O	1626-1634
will	O	1635-1639
provide	O	1640-1647
the	O	1648-1651
basic	O	1652-1657
data	O	1658-1662
for	O	1663-1666
researches	O	1667-1677
of	O	1678-1680
molecular	O	1681-1690
nutrition	O	1691-1700
.	O	1700-1701

miR	B	0-3
-	I	3-4
155	I	4-7
:	O	7-8
an	O	9-11
ancient	O	12-19
regulator	O	20-29
of	O	30-32
the	O	33-36
immune	O	37-43
system	O	44-50
.	O	50-51

MicroRNAs	O	52-61
(	O	62-63
miRNAs	O	63-69
)	O	69-70
are	O	71-74
a	O	75-76
newly	O	77-82
recognized	O	83-93
class	O	94-99
of	O	100-102
regulatory	O	103-113
genes	O	114-119
which	O	120-125
repress	O	126-133
the	O	134-137
expression	O	138-148
of	O	149-151
protein	O	152-159
-	O	159-160
coding	O	160-166
genes	O	167-172
.	O	172-173

Numerous	O	174-182
studies	O	183-190
have	O	191-195
uncovered	O	196-205
a	O	206-207
complex	O	208-215
role	O	216-220
for	O	221-224
miRNAs	O	225-231
regulating	O	232-242
many	O	243-247
aspects	O	248-255
of	O	256-258
a	O	259-260
variety	O	261-268
of	O	269-271
cellular	O	272-280
processes	O	281-290
including	O	291-300
cell	O	301-305
growth	O	306-312
,	O	312-313
differentiation	O	314-329
,	O	329-330
and	O	331-334
lineage	O	335-342
commitment	O	343-353
.	O	353-354

In	O	355-357
the	O	358-361
immune	O	362-368
system	O	369-375
,	O	375-376
miR	B	377-380
-	I	380-381
155	I	381-384
is	O	385-387
unique	O	388-394
in	O	395-397
its	O	398-401
ability	O	402-409
to	O	410-412
shape	O	413-418
the	O	419-422
transcriptome	O	423-436
of	O	437-439
activated	O	440-449
myeloid	O	450-457
and	O	458-461
lymphoid	O	462-470
cells	O	471-476
controlling	O	477-488
diverse	O	489-496
biological	O	497-507
functions	O	508-517
ranging	O	518-525
from	O	526-530
inflammation	O	531-543
to	O	544-546
immunological	O	547-560
memory	O	561-567
.	O	567-568

Not	O	569-572
surprisingly	O	573-585
,	O	585-586
a	O	587-588
tight	O	589-594
control	O	595-602
of	O	603-605
miR	B	606-609
-	I	609-610
155	I	610-613
expression	O	614-624
is	O	625-627
required	O	628-636
to	O	637-639
avoid	O	640-645
malignant	O	646-655
transformation	O	656-670
,	O	670-671
as	O	672-674
evidenced	O	675-684
by	O	685-687
miR	B	688-691
-	I	691-692
155	I	692-695
overexpression	O	696-710
in	O	711-713
many	O	714-718
cancers	O	719-726
of	O	727-729
B	O	730-731
-	O	731-732
cell	O	732-736
origin	O	737-743
.	O	743-744

In	O	745-747
this	O	748-752
review	O	753-759
,	O	759-760
we	O	761-763
discuss	O	764-771
the	O	772-775
potential	O	776-785
of	O	786-788
miR	B	789-792
-	I	792-793
155	I	793-796
as	O	797-799
a	O	800-801
molecular	O	802-811
target	O	812-818
for	O	819-822
therapeutic	O	823-834
intervention	O	835-847
and	O	848-851
discuss	O	852-859
the	O	860-863
function	O	864-872
of	O	873-875
miR	B	876-879
-	I	879-880
155	I	880-883
in	O	884-886
the	O	887-890
context	O	891-898
of	O	899-901
protective	O	902-912
immunity	O	913-921
.	O	921-922

We	O	923-925
first	O	926-931
look	O	932-936
back	O	937-941
into	O	942-946
the	O	947-950
emergence	O	951-960
of	O	961-963
miR	B	964-967
-	I	967-968
155	I	968-971
in	O	972-974
evolution	O	975-984
,	O	984-985
which	O	986-991
is	O	992-994
coincidental	O	995-1007
with	O	1008-1012
the	O	1013-1016
emergence	O	1017-1026
of	O	1027-1029
the	O	1030-1033
ancestors	O	1034-1043
of	O	1044-1046
the	O	1047-1050
antigen	O	1051-1058
receptors	O	1059-1068
.	O	1068-1069

We	O	1070-1072
then	O	1073-1077
summarize	O	1078-1087
what	O	1088-1092
we	O	1093-1095
have	O	1096-1100
learned	O	1101-1108
about	O	1109-1114
the	O	1115-1118
role	O	1119-1123
of	O	1124-1126
miR	B	1127-1130
-	I	1130-1131
155	I	1131-1134
in	O	1135-1137
the	O	1138-1141
regulation	O	1142-1152
of	O	1153-1155
lymphoid	O	1156-1164
subsets	O	1165-1172
at	O	1173-1175
the	O	1176-1179
cellular	O	1180-1188
and	O	1189-1192
molecular	O	1193-1202
level	O	1203-1208
in	O	1209-1211
the	O	1212-1215
context	O	1216-1223
of	O	1224-1226
recent	O	1227-1233
progress	O	1234-1242
in	O	1243-1245
this	O	1246-1250
field	O	1251-1256
.	O	1256-1257

Expression	O	0-10
of	O	11-13
miR	B	14-17
-	I	17-18
142	I	18-21
-	I	21-22
5p	I	22-24
in	O	25-27
peripheral	O	28-38
blood	O	39-44
mononuclear	O	45-56
cells	O	57-62
from	O	63-67
renal	O	68-73
transplant	O	74-84
patients	O	85-93
with	O	94-98
chronic	O	99-106
antibody	O	107-115
-	O	115-116
mediated	O	116-124
rejection	O	125-134
.	O	134-135

In	O	136-138
renal	O	139-144
transplantation	O	145-160
,	O	160-161
the	O	162-165
unresponsiveness	O	166-182
of	O	183-185
patients	O	186-194
undergoing	O	195-205
chronic	O	206-213
antibody	O	214-222
mediated	O	223-231
rejection	O	232-241
(	O	242-243
CAMR	O	243-247
)	O	247-248
to	O	249-251
classical	O	252-261
treatment	O	262-271
stress	O	272-278
on	O	279-281
the	O	282-285
need	O	286-290
for	O	291-294
accurate	O	295-303
biomarkers	O	304-314
to	O	315-317
improve	O	318-325
its	O	326-329
diagnosis	O	330-339
.	O	339-340

We	O	341-343
aim	O	344-347
to	O	348-350
determine	O	351-360
whether	O	361-368
microRNA	O	369-377
expression	O	378-388
patterns	O	389-397
may	O	398-401
be	O	402-404
associated	O	405-415
with	O	416-420
a	O	421-422
diagnosis	O	423-432
of	O	433-435
CAMR	O	436-440
.	O	440-441

We	O	442-444
performed	O	445-454
expression	O	455-465
profiling	O	466-475
of	O	476-478
miRNAs	O	479-485
in	O	486-488
peripheral	O	489-499
blood	O	500-505
mononuclear	O	506-517
cells	O	518-523
(	O	524-525
PBMC	O	525-529
)	O	529-530
of	O	531-533
kidney	O	534-540
transplant	O	541-551
recipients	O	552-562
with	O	563-567
CAMR	O	568-572
or	O	573-575
stable	O	576-582
graft	O	583-588
function	O	589-597
.	O	597-598

Among	O	599-604
257	O	605-608
expressed	O	609-618
miRNAs	O	619-625
,	O	625-626
10	O	627-629
miRNAs	O	630-636
associated	O	637-647
with	O	648-652
CAMR	O	653-657
were	O	658-662
selected	O	663-671
.	O	671-672

Among	O	673-678
them	O	679-683
,	O	683-684
miR	B	685-688
-	I	688-689
142	I	689-692
-	I	692-693
5p	I	693-695
was	O	696-699
increased	O	700-709
in	O	710-712
PBMC	O	713-717
and	O	718-721
biopsies	O	722-730
of	O	731-733
patients	O	734-742
with	O	743-747
CAMR	O	748-752
as	O	753-755
well	O	756-760
as	O	761-763
in	O	764-766
a	O	767-768
rodent	O	769-775
model	O	776-781
of	O	782-784
CAMR	O	785-789
.	O	789-790

The	O	791-794
lack	O	795-799
of	O	800-802
modulation	O	803-813
of	O	814-816
miR	B	817-820
-	I	820-821
142	I	821-824
-	I	824-825
5p	I	825-827
in	O	828-830
PBMC	O	831-835
of	O	836-838
patients	O	839-847
with	O	848-852
renal	O	853-858
failure	O	859-866
,	O	866-867
suggests	O	868-876
that	O	877-881
its	O	882-885
over	O	886-890
-	O	890-891
expression	O	891-901
in	O	902-904
CAMR	O	905-909
was	O	910-913
associated	O	914-924
with	O	925-929
immunological	O	930-943
disorders	O	944-953
rather	O	954-960
than	O	961-965
renal	O	966-971
dysfunction	O	972-983
.	O	983-984

A	O	985-986
ROC	O	987-990
curve	O	991-996
analysis	O	997-1005
performed	O	1006-1015
on	O	1016-1018
independent	O	1019-1030
samples	O	1031-1038
showed	O	1039-1045
that	O	1046-1050
miR	B	1051-1054
-	I	1054-1055
142	I	1055-1058
-	I	1058-1059
5p	I	1059-1061
is	O	1062-1064
a	O	1065-1066
potential	O	1067-1076
biomarker	O	1077-1086
of	O	1087-1089
CAMR	O	1090-1094
allowing	O	1095-1103
a	O	1104-1105
very	O	1106-1110
good	O	1111-1115
discrimination	O	1116-1130
of	O	1131-1133
the	O	1134-1137
patients	O	1138-1146
with	O	1147-1151
CAMR	O	1152-1156
(	O	1157-1158
AUC	O	1158-1161
=	O	1162-1163
0	O	1164-1165
.	O	1165-1166
74	O	1166-1168
;	O	1168-1169
p	O	1170-1171
=	O	1172-1173
0	O	1174-1175
.	O	1175-1176
0056	O	1176-1180
)	O	1180-1181
.	O	1181-1182

Moreover	O	1183-1191
,	O	1191-1192
its	O	1193-1196
expression	O	1197-1207
was	O	1208-1211
decreased	O	1212-1221
in	O	1222-1224
PHA	O	1225-1228
-	O	1228-1229
activated	O	1229-1238
blood	O	1239-1244
cells	O	1245-1250
and	O	1251-1254
was	O	1255-1258
not	O	1259-1262
modulated	O	1263-1272
in	O	1273-1275
PBMC	O	1276-1280
from	O	1281-1285
patients	O	1286-1294
with	O	1295-1299
acute	O	1300-1305
rejection	O	1306-1315
,	O	1315-1316
excluding	O	1317-1326
a	O	1327-1328
non	O	1329-1332
-	O	1332-1333
specific	O	1333-1341
T	O	1342-1343
cell	O	1344-1348
activation	O	1349-1359
expression	O	1360-1370
.	O	1370-1371

The	O	1372-1375
absence	O	1376-1383
of	O	1384-1386
modulation	O	1387-1397
of	O	1398-1400
this	O	1401-1405
miRNA	O	1406-1411
in	O	1412-1414
immunosuppressed	O	1415-1431
patients	O	1432-1440
suggests	O	1441-1449
that	O	1450-1454
its	O	1455-1458
expression	O	1459-1469
was	O	1470-1473
not	O	1474-1477
influenced	O	1478-1488
by	O	1489-1491
treatment	O	1492-1501
.	O	1501-1502

Finally	O	1503-1510
,	O	1510-1511
the	O	1512-1515
analysis	O	1516-1524
of	O	1525-1527
miR	B	1528-1531
-	I	1531-1532
142	I	1532-1535
-	I	1535-1536
5p	I	1536-1538
predicted	O	1539-1548
targets	O	1549-1556
under	O	1557-1562
-	O	1562-1563
expressed	O	1563-1572
in	O	1573-1575
CAMR	O	1576-1580
PBMC	O	1581-1585
in	O	1586-1588
a	O	1589-1590
published	O	1591-1600
microarray	O	1601-1611
dataset	O	1612-1619
revealed	O	1620-1628
an	O	1629-1631
enrichment	O	1632-1642
of	O	1643-1645
immune	O	1646-1652
-	O	1652-1653
related	O	1653-1660
genes	O	1661-1666
.	O	1666-1667

Altogether	O	1668-1678
,	O	1678-1679
these	O	1680-1685
data	O	1686-1690
suggest	O	1691-1698
that	O	1699-1703
miR	B	1704-1707
-	I	1707-1708
142	I	1708-1711
-	I	1711-1712
5p	I	1712-1714
could	O	1715-1720
be	O	1721-1723
used	O	1724-1728
as	O	1729-1731
a	O	1732-1733
biomarker	O	1734-1743
in	O	1744-1746
CAMR	O	1747-1751
and	O	1752-1755
these	O	1756-1761
finding	O	1762-1769
may	O	1770-1773
improve	O	1774-1781
our	O	1782-1785
understanding	O	1786-1799
of	O	1800-1802
chronic	O	1803-1810
rejection	O	1811-1820
mechanisms	O	1821-1831
.	O	1831-1832

MicroRNA	B	0-8
-	I	8-9
376c	I	9-13
inhibits	O	14-22
cell	O	23-27
proliferation	O	28-41
and	O	42-45
invasion	O	46-54
in	O	55-57
osteosarcoma	O	58-70
by	O	71-73
targeting	O	74-83
to	O	84-86
transforming	O	87-99
growth	O	100-106
factor	O	107-113
-	O	113-114
alpha	O	114-119
.	O	119-120

MicroRNAs	O	121-130
are	O	131-134
a	O	135-136
class	O	137-142
of	O	143-145
small	O	146-151
noncoding	O	152-161
RNAs	O	162-166
that	O	167-171
function	O	172-180
as	O	181-183
critical	O	184-192
gene	O	193-197
regulators	O	198-208
through	O	209-216
targeting	O	217-226
mRNAs	O	227-232
for	O	233-236
translational	O	237-250
repression	O	251-261
or	O	262-264
degradation	O	265-276
.	O	276-277

In	O	278-280
this	O	281-285
study	O	286-291
,	O	291-292
we	O	293-295
showed	O	296-302
that	O	303-307
miR	B	308-311
-	I	311-312
376c	I	312-316
expression	O	317-327
level	O	328-333
was	O	334-337
decreased	O	338-347
while	O	348-353
transforming	O	354-366
growth	O	367-373
factor	O	374-380
-	O	380-381
alpha	O	381-386
(	O	387-388
TGFA	O	388-392
)	O	392-393
mRNA	O	394-398
expression	O	399-409
levels	O	410-416
were	O	417-421
increased	O	422-431
in	O	432-434
osteosarcoma	O	435-447
tissues	O	448-455
and	O	456-459
cell	O	460-464
lines	O	465-470
,	O	470-471
and	O	472-475
we	O	476-478
identified	O	479-489
TGFA	O	490-494
as	O	495-497
a	O	498-499
novel	O	500-505
direct	O	506-512
target	O	513-519
of	O	520-522
miR	B	523-526
-	I	526-527
376c	I	527-531
.	O	531-532

Overexpression	O	533-547
of	O	548-550
miR	B	551-554
-	I	554-555
376c	I	555-559
suppressed	O	560-570
TGFA	O	571-575
expression	O	576-586
and	O	587-590
the	O	591-594
expression	O	595-605
of	O	606-608
its	O	609-612
downstream	O	613-623
signaling	O	624-633
molecule	O	634-642
such	O	643-647
as	O	648-650
epidermal	O	651-660
growth	O	661-667
factor	O	668-674
receptor	O	675-683
,	O	683-684
and	O	685-688
attenuated	O	689-699
cell	O	700-704
proliferation	O	705-718
and	O	719-722
invasion	O	723-731
.	O	731-732

Forced	O	733-739
expression	O	740-750
of	O	751-753
TGFA	O	754-758
could	O	759-764
partly	O	765-771
rescue	O	772-778
the	O	779-782
inhibitory	O	783-793
effect	O	794-800
of	O	801-803
miR	B	804-807
-	I	807-808
376c	I	808-812
in	O	813-815
the	O	816-819
cells	O	820-825
.	O	825-826

Taken	O	827-832
together	O	833-841
,	O	841-842
these	O	843-848
findings	O	849-857
will	O	858-862
shed	O	863-867
light	O	868-873
on	O	874-876
the	O	877-880
role	O	881-885
and	O	886-889
mechanism	O	890-899
of	O	900-902
miR	B	903-906
-	I	906-907
376c	I	907-911
in	O	912-914
regulating	O	915-925
osteosarcoma	O	926-938
cell	O	939-943
growth	O	944-950
via	O	951-954
miR	B	955-958
-	I	958-959
376c	I	959-963
/	O	963-964
TGFA	O	964-968
axis	O	969-973
,	O	973-974
and	O	975-978
miR	B	979-982
-	I	982-983
376c	I	983-987
may	O	988-991
serve	O	992-997
as	O	998-1000
a	O	1001-1002
potential	O	1003-1012
therapeutic	O	1013-1024
target	O	1025-1031
in	O	1032-1034
osteosarcoma	O	1035-1047
in	O	1048-1050
the	O	1051-1054
future	O	1055-1061
.	O	1061-1062

MicroRNAs	O	0-9
as	O	10-12
tumour	O	13-19
suppressors	O	20-31
in	O	32-34
canine	O	35-41
and	O	42-45
human	O	46-51
melanoma	O	52-60
cells	O	61-66
and	O	67-70
as	O	71-73
a	O	74-75
prognostic	O	76-86
factor	O	87-93
in	O	94-96
canine	O	97-103
melanomas	O	104-113
.	O	113-114

Malignant	O	115-124
melanoma	O	125-133
(	O	134-135
MM	O	135-137
)	O	137-138
is	O	139-141
one	O	142-145
of	O	146-148
the	O	149-152
most	O	153-157
aggressive	O	158-168
cancers	O	169-176
in	O	177-179
dogs	O	180-184
and	O	185-188
in	O	189-191
humans	O	192-198
.	O	198-199

However	O	200-207
,	O	207-208
the	O	209-212
molecular	O	213-222
mechanisms	O	223-233
of	O	234-236
its	O	237-240
development	O	241-252
and	O	253-256
progression	O	257-268
remain	O	269-275
unclear	O	276-283
.	O	283-284

Presently	O	285-294
,	O	294-295
we	O	296-298
examined	O	299-307
the	O	308-311
expression	O	312-322
profile	O	323-330
of	O	331-333
microRNAs	O	334-343
(	O	344-345
miRs	O	345-349
)	O	349-350
in	O	351-353
canine	O	354-360
oral	O	361-365
MM	O	366-368
tissues	O	369-376
and	O	377-380
paired	O	381-387
normal	O	388-394
oral	O	395-399
mucosa	O	400-406
tissues	O	407-414
by	O	415-417
using	O	418-423
the	O	424-427
microRNA	O	428-436
-	O	436-437
microarray	O	437-447
assay	O	448-453
and	O	454-457
quantitative	O	458-470
RT	O	471-473
-	O	473-474
PCR	O	474-477
.	O	477-478

Importantly	O	479-490
,	O	490-491
a	O	492-493
decreased	O	494-503
expression	O	504-514
of	O	515-517
miR	B	518-521
-	I	521-522
203	I	522-525
was	O	526-529
significantly	O	530-543
associated	O	544-554
with	O	555-559
a	O	560-561
shorter	O	562-569
survival	O	570-578
time	O	579-583
.	O	583-584

Also	O	585-589
,	O	589-590
miR	B	591-594
-	I	594-595
203	I	595-598
and	O	599-602
-	B	603-604
205	I	604-607
were	O	608-612
markedly	O	613-621
down	O	622-626
-	O	626-627
regulated	O	627-636
in	O	637-639
canine	O	640-646
and	O	647-650
human	O	651-656
MM	O	657-659
cell	O	660-664
lines	O	665-670
tested	O	671-677
.	O	677-678

Furthermore	O	679-690
,	O	690-691
the	O	692-695
ectopic	O	696-703
expression	O	704-714
of	O	715-717
miR	B	718-721
-	I	721-722
205	I	722-725
had	O	726-729
a	O	730-731
significant	O	732-743
inhibitory	O	744-754
effect	O	755-761
on	O	762-764
the	O	765-768
cell	O	769-773
growth	O	774-780
of	O	781-783
canine	O	784-790
and	O	791-794
human	O	795-800
melanoma	O	801-809
cells	O	810-815
tested	O	816-822
by	O	823-825
targeting	O	826-835
erbb3	O	836-841
.	O	841-842

Our	O	843-846
data	O	847-851
suggest	O	852-859
that	O	860-864
miR	B	865-868
-	I	868-869
203	I	869-872
is	O	873-875
a	O	876-877
new	O	878-881
prognostic	O	882-892
factor	O	893-899
in	O	900-902
canine	O	903-909
oral	O	910-914
MMs	O	915-918
and	O	919-922
that	O	923-927
miR	B	928-931
-	I	931-932
205	I	932-935
functions	O	936-945
as	O	946-948
a	O	949-950
tumour	O	951-957
suppressor	O	958-968
by	O	969-971
targeting	O	972-981
erbb3	O	982-987
in	O	988-990
both	O	991-995
canine	O	996-1002
and	O	1003-1006
human	O	1007-1012
MM	O	1013-1015
cells	O	1016-1021
.	O	1021-1022

Let	B	0-3
-	I	3-4
7b	I	4-6
and	O	7-10
miR	B	11-14
-	I	14-15
495	I	15-18
stimulate	O	19-28
differentiation	O	29-44
and	O	45-48
prevent	O	49-56
metaplasia	O	57-67
of	O	68-70
pancreatic	O	71-81
acinar	O	82-88
cells	O	89-94
by	O	95-97
repressing	O	98-108
HNF6	O	109-113
.	O	113-114

BACKGROUND	O	115-125
&	O	126-127
AIMS	O	128-132
:	O	132-133
Diseases	O	134-142
of	O	143-145
the	O	146-149
exocrine	O	150-158
pancreas	O	159-167
are	O	168-171
often	O	172-177
associated	O	178-188
with	O	189-193
perturbed	O	194-203
differentiation	O	204-219
of	O	220-222
acinar	O	223-229
cells	O	230-235
.	O	235-236

MicroRNAs	O	237-246
(	O	247-248
miRNAs	O	248-254
)	O	254-255
regulate	O	256-264
pancreas	O	265-273
development	O	274-285
,	O	285-286
yet	O	287-290
little	O	291-297
is	O	298-300
known	O	301-306
about	O	307-312
their	O	313-318
contribution	O	319-331
to	O	332-334
acinar	O	335-341
cell	O	342-346
differentiation	O	347-362
.	O	362-363

We	O	364-366
aimed	O	367-372
to	O	373-375
identify	O	376-384
miRNAs	O	385-391
that	O	392-396
promote	O	397-404
and	O	405-408
control	O	409-416
the	O	417-420
maintenance	O	421-432
of	O	433-435
acinar	O	436-442
differentiation	O	443-458
.	O	458-459

METHODS	O	460-467
:	O	467-468
We	O	469-471
studied	O	472-479
mice	O	480-484
with	O	485-489
pancreas	O	490-498
-	O	498-499
or	O	500-502
acinar	O	503-509
-	O	509-510
specific	O	510-518
inactivation	O	519-531
of	O	532-534
Dicer	O	535-540
(	O	541-542
Foxa3	O	542-547
-	O	547-548
Cre	O	548-551
/	O	551-552
Dicer	O	552-557
(	O	557-558
loxP	O	558-562
/	O	562-563
-	O	563-564
)	O	564-565
mice	O	566-570
)	O	570-571
,	O	571-572
combined	O	573-581
(	O	582-583
or	O	583-585
not	O	586-589
)	O	589-590
with	O	591-595
inactivation	O	596-608
of	O	609-611
hepatocyte	O	612-622
nuclear	O	623-630
factor	O	631-637
(	O	638-639
HNF	O	639-642
)	O	642-643
6	O	644-645
(	O	646-647
Foxa3	O	647-652
-	O	652-653
Cre	O	653-656
/	O	656-657
Dicer	O	657-662
(	O	662-663
loxP	O	663-667
/	O	667-668
-	O	668-669
)	O	669-670
/	O	670-671
Hnf6	O	671-675
-	O	675-676
/	O	676-677
-	O	677-678
mice	O	679-683
)	O	683-684
.	O	684-685

The	O	686-689
role	O	690-694
of	O	695-697
specific	O	698-706
miRNAs	O	707-713
in	O	714-716
acinar	O	717-723
differentiation	O	724-739
was	O	740-743
investigated	O	744-756
by	O	757-759
transfecting	O	760-772
cultured	O	773-781
cells	O	782-787
with	O	788-792
miRNA	O	793-798
mimics	O	799-805
or	O	806-808
inhibitors	O	809-819
.	O	819-820

Pancreatitis	O	821-833
-	O	833-834
induced	O	834-841
metaplasia	O	842-852
was	O	853-856
investigated	O	857-869
in	O	870-872
mice	O	873-877
after	O	878-883
administration	O	884-898
of	O	899-901
cerulein	O	902-910
.	O	910-911

RESULTS	O	912-919
:	O	919-920
Inhibition	O	921-931
of	O	932-934
miRNA	O	935-940
synthesis	O	941-950
in	O	951-953
acini	O	954-959
by	O	960-962
inactivation	O	963-975
of	O	976-978
Dicer	O	979-984
and	O	985-988
pancreatitis	O	989-1001
-	O	1001-1002
induced	O	1002-1009
metaplasia	O	1010-1020
were	O	1021-1025
associated	O	1026-1036
with	O	1037-1041
repression	O	1042-1052
of	O	1053-1055
acinar	O	1056-1062
differentiation	O	1063-1078
and	O	1079-1082
with	O	1083-1087
induction	O	1088-1097
of	O	1098-1100
HNF6	O	1101-1105
and	O	1106-1109
hepatic	O	1110-1117
genes	O	1118-1123
.	O	1123-1124

The	O	1125-1128
phenotype	O	1129-1138
of	O	1139-1141
Dicer	O	1142-1147
-	O	1147-1148
deficient	O	1148-1157
acini	O	1158-1163
depends	O	1164-1171
on	O	1172-1174
the	O	1175-1178
induction	O	1179-1188
of	O	1189-1191
HNF6	O	1192-1196
;	O	1196-1197
overexpression	O	1198-1212
of	O	1213-1215
this	O	1216-1220
factor	O	1221-1227
in	O	1228-1230
developing	O	1231-1241
acinar	O	1242-1248
cells	O	1249-1254
is	O	1255-1257
sufficient	O	1258-1268
to	O	1269-1271
repress	O	1272-1279
acinar	O	1280-1286
differentiation	O	1287-1302
and	O	1303-1306
to	O	1307-1309
induce	O	1310-1316
hepatic	O	1317-1324
genes	O	1325-1330
.	O	1330-1331

Let	B	1332-1335
-	I	1335-1336
7b	I	1336-1338
and	O	1339-1342
miR	B	1343-1346
-	I	1346-1347
495	I	1347-1350
repress	O	1351-1358
HNF6	O	1359-1363
and	O	1364-1367
are	O	1368-1371
expressed	O	1372-1381
in	O	1382-1384
developing	O	1385-1395
acini	O	1396-1401
.	O	1401-1402

Their	O	1403-1408
expression	O	1409-1419
is	O	1420-1422
inhibited	O	1423-1432
in	O	1433-1435
Dicer	O	1436-1441
-	O	1441-1442
deficient	O	1442-1451
acini	O	1452-1457
,	O	1457-1458
as	O	1459-1461
well	O	1462-1466
as	O	1467-1469
in	O	1470-1472
pancreatitis	O	1473-1485
-	O	1485-1486
induced	O	1486-1493
metaplasia	O	1494-1504
.	O	1504-1505

In	O	1506-1508
addition	O	1509-1517
,	O	1517-1518
inhibiting	O	1519-1529
let	B	1530-1533
-	I	1533-1534
7b	I	1534-1536
and	O	1537-1540
miR	B	1541-1544
-	I	1544-1545
495	I	1545-1548
in	O	1549-1551
acinar	O	1552-1558
cells	O	1559-1564
results	O	1565-1572
in	O	1573-1575
similar	O	1576-1583
effects	O	1584-1591
to	O	1592-1594
those	O	1595-1600
found	O	1601-1606
in	O	1607-1609
Dicer	O	1610-1615
-	O	1615-1616
deficient	O	1616-1625
acini	O	1626-1631
and	O	1632-1635
metaplastic	O	1636-1647
cells	O	1648-1653
,	O	1653-1654
namely	O	1655-1661
induction	O	1662-1671
of	O	1672-1674
HNF6	O	1675-1679
and	O	1680-1683
hepatic	O	1684-1691
genes	O	1692-1697
and	O	1698-1701
repression	O	1702-1712
of	O	1713-1715
acinar	O	1716-1722
differentiation	O	1723-1738
.	O	1738-1739

CONCLUSIONS	O	1740-1751
:	O	1751-1752
Let	B	1753-1756
-	I	1756-1757
7b	I	1757-1759
,	O	1759-1760
miR	B	1761-1764
-	I	1764-1765
495	I	1765-1768
,	O	1768-1769
and	O	1770-1773
their	O	1774-1779
targets	O	1780-1787
constitute	O	1788-1798
a	O	1799-1800
gene	O	1801-1805
network	O	1806-1813
that	O	1814-1818
is	O	1819-1821
required	O	1822-1830
to	O	1831-1833
establish	O	1834-1843
and	O	1844-1847
maintain	O	1848-1856
pancreatic	O	1857-1867
acinar	O	1868-1874
cell	O	1875-1879
differentiation	O	1880-1895
.	O	1895-1896

Additional	O	1897-1907
studies	O	1908-1915
of	O	1916-1918
this	O	1919-1923
network	O	1924-1931
will	O	1932-1936
increase	O	1937-1945
our	O	1946-1949
understanding	O	1950-1963
of	O	1964-1966
pancreatic	O	1967-1977
diseases	O	1978-1986
.	O	1986-1987

Mir	B	0-3
-	I	3-4
375	I	4-7
enhances	O	8-16
ruthenium	O	17-26
-	O	26-27
derived	O	27-34
compound	O	35-43
Rawq01	O	44-50
induced	O	51-58
cell	O	59-63
death	O	64-69
in	O	70-72
human	O	73-78
ovarian	O	79-86
cancer	O	87-93
.	O	93-94

Ovarian	O	95-102
cancer	O	103-109
is	O	110-112
one	O	113-116
of	O	117-119
the	O	120-123
most	O	124-128
common	O	129-135
gynecological	O	136-149
malignancies	O	150-162
.	O	162-163

Limited	O	164-171
efficacy	O	172-180
of	O	181-183
cytotoxic	O	184-193
chemotherapy	O	194-206
is	O	207-209
a	O	210-211
key	O	212-215
obstacle	O	216-224
in	O	225-227
the	O	228-231
treatment	O	232-241
of	O	242-244
advanced	O	245-253
ovarian	O	254-261
cancer	O	262-268
.	O	268-269

This	O	270-274
study	O	275-280
aimed	O	281-286
to	O	287-289
investigate	O	290-301
whether	O	302-309
Mir	B	310-313
-	I	313-314
375	I	314-317
enhances	O	318-326
Rawq01	O	327-333
(	O	334-335
a	O	335-336
ruthenium	O	337-346
derived	O	347-354
compound	O	355-363
)	O	363-364
induced	O	365-372
cell	O	373-377
death	O	378-383
in	O	384-386
ovarian	O	387-394
cancer	O	395-401
.	O	401-402

METHODS	O	403-410
:	O	410-411
Three	O	412-417
human	O	418-423
ovarian	O	424-431
cancer	O	432-438
cell	O	439-443
lines	O	444-449
were	O	450-454
selected	O	455-463
,	O	463-464
and	O	465-468
independently	O	469-482
treated	O	483-490
with	O	491-495
Rawq01	O	496-502
+	O	502-503
mir	B	503-506
-	I	506-507
375	I	507-510
and	O	511-514
Rawq01	O	515-521
+	O	521-522
control	O	522-529
.	O	529-530

MTT	O	531-534
assay	O	535-540
and	O	541-544
flow	O	545-549
cytometry	O	550-559
were	O	560-564
performed	O	565-574
to	O	575-577
detect	O	578-584
the	O	585-588
growth	O	589-595
of	O	596-598
ovarian	O	599-606
cancer	O	607-613
cells	O	614-619
.	O	619-620

Western	O	621-628
blot	O	629-633
was	O	634-637
carried	O	638-645
out	O	646-649
to	O	650-652
determine	O	653-662
the	O	663-666
expression	O	667-677
of	O	678-680
apoptotic	O	681-690
associated	O	691-701
proteins	O	702-710
.	O	710-711

In	O	712-714
addition	O	715-723
,	O	723-724
ovarian	O	725-732
cancer	O	733-739
xenografts	O	740-750
were	O	751-755
established	O	756-767
to	O	768-770
explore	O	771-778
whether	O	779-786
mir	B	787-790
-	I	790-791
375	I	791-794
increased	O	795-804
the	O	805-808
in	O	809-811
vivo	O	812-816
chemosensitivity	O	817-833
of	O	834-836
ovarian	O	837-844
cancer	O	845-851
cells	O	852-857
to	O	858-860
RAWQ01	O	861-867
.	O	867-868

RESULTS	O	869-876
:	O	876-877
Over	O	878-882
-	O	882-883
expression	O	883-893
of	O	894-896
mir	B	897-900
-	I	900-901
375	I	901-904
sensitized	O	905-915
the	O	916-919
ovarian	O	920-927
cancer	O	928-934
cells	O	935-940
to	O	941-943
RAWQ01	O	944-950
.	O	950-951

Mir	B	952-955
-	I	955-956
375	I	956-959
enhanced	O	960-968
the	O	969-972
in	O	973-975
vitro	O	976-981
sensitivity	O	982-993
of	O	994-996
ovarian	O	997-1004
cancer	O	1005-1011
cells	O	1012-1017
to	O	1018-1020
RAWQ01	O	1021-1027
by	O	1028-1030
inducing	O	1031-1039
apoptosis	O	1040-1049
.	O	1049-1050

Mir	B	1051-1054
-	I	1054-1055
375	I	1055-1058
also	O	1059-1063
increased	O	1064-1073
the	O	1074-1077
in	O	1078-1080
vivo	O	1081-1085
chemosensitivity	O	1086-1102
of	O	1103-1105
ovarian	O	1106-1113
cancer	O	1114-1120
cells	O	1121-1126
to	O	1127-1129
RAWQ01	O	1130-1136
.	O	1136-1137

CONCLUSION	O	1138-1148
:	O	1148-1149
Mir	B	1150-1153
-	I	1153-1154
375	I	1154-1157
can	O	1158-1161
enhance	O	1162-1169
Rawq01	O	1170-1176
induced	O	1177-1184
cell	O	1185-1189
death	O	1190-1195
in	O	1196-1198
human	O	1199-1204
ovarian	O	1205-1212
cancer	O	1213-1219
both	O	1220-1224
in	O	1225-1227
vitro	O	1228-1233
and	O	1234-1237
in	O	1238-1240
vivo	O	1241-1245
.	O	1245-1246

MicroRNAs	O	0-9
and	O	10-13
Drug	O	14-18
Addiction	O	19-28
.	O	28-29

Drug	O	30-34
addiction	O	35-44
is	O	45-47
considered	O	48-58
a	O	59-60
disorder	O	61-69
of	O	70-72
neuroplasticity	O	73-88
in	O	89-91
brain	O	92-97
reward	O	98-104
and	O	105-108
cognition	O	109-118
systems	O	119-126
resulting	O	127-136
from	O	137-141
aberrant	O	142-150
activation	O	151-161
of	O	162-164
gene	O	165-169
expression	O	170-180
programs	O	181-189
in	O	190-192
response	O	193-201
to	O	202-204
prolonged	O	205-214
drug	O	215-219
consumption	O	220-231
.	O	231-232

Non	O	233-236
-	O	236-237
coding	O	237-243
RNAs	O	244-248
(	O	249-250
ncRNAs	O	250-256
)	O	256-257
are	O	258-261
key	O	262-265
regulators	O	266-276
of	O	277-279
almost	O	280-286
all	O	287-290
aspects	O	291-298
of	O	299-301
cellular	O	302-310
physiology	O	311-321
.	O	321-322

MicroRNAs	O	323-332
(	O	333-334
miRNAs	O	334-340
)	O	340-341
are	O	342-345
small	O	346-351
(	O	352-353
approximately	O	354-367
21	O	368-370
-	O	370-371
23	O	371-373
nucleotides	O	374-385
)	O	385-386
ncRNAs	O	387-393
transcripts	O	394-405
that	O	406-410
regulate	O	411-419
gene	O	420-424
expression	O	425-435
at	O	436-438
the	O	439-442
post	O	443-447
-	O	447-448
transcriptional	O	448-463
level	O	464-469
.	O	469-470

Recently	O	471-479
,	O	479-480
miRNAs	O	481-487
were	O	488-492
shown	O	493-498
to	O	499-501
play	O	502-506
key	O	507-510
roles	O	511-516
in	O	517-519
the	O	520-523
drug	O	524-528
-	O	528-529
induced	O	529-536
remodeling	O	537-547
of	O	548-550
brain	O	551-556
reward	O	557-563
systems	O	564-571
that	O	572-576
likely	O	577-583
drives	O	584-590
the	O	591-594
emergence	O	595-604
of	O	605-607
addiction	O	608-617
.	O	617-618

Here	O	619-623
,	O	623-624
we	O	625-627
review	O	628-634
evidence	O	635-643
suggesting	O	644-654
that	O	655-659
one	O	660-663
particular	O	664-674
miRNA	O	675-680
,	O	680-681
miR	B	682-685
-	I	685-686
212	I	686-689
,	O	689-690
plays	O	691-696
a	O	697-698
particularly	O	699-711
prominent	O	712-721
role	O	722-726
in	O	727-729
vulnerability	O	730-743
to	O	744-746
cocaine	O	747-754
addiction	O	755-764
.	O	764-765

We	O	766-768
review	O	769-775
evidence	O	776-784
showing	O	785-792
that	O	793-797
miR	B	798-801
-	I	801-802
212	I	802-805
expression	O	806-816
is	O	817-819
increased	O	820-829
in	O	830-832
the	O	833-836
dorsal	O	837-843
striatum	O	844-852
of	O	853-855
rats	O	856-860
that	O	861-865
show	O	866-870
compulsive	O	871-881
-	O	881-882
like	O	882-886
cocaine	O	887-894
-	O	894-895
taking	O	895-901
behaviors	O	902-911
.	O	911-912

Increases	O	913-922
in	O	923-925
miR	B	926-929
-	I	929-930
212	I	930-933
expression	O	934-944
appear	O	945-951
to	O	952-954
protect	O	955-962
against	O	963-970
cocaine	O	971-978
addiction	O	979-988
,	O	988-989
as	O	990-992
virus	O	993-998
-	O	998-999
mediated	O	999-1007
striatal	O	1008-1016
miR	B	1017-1020
-	I	1020-1021
212	I	1021-1024
overexpression	O	1025-1039
decreases	O	1040-1049
cocaine	O	1050-1057
consumption	O	1058-1069
in	O	1070-1072
rats	O	1073-1077
.	O	1077-1078

Conversely	O	1079-1089
,	O	1089-1090
disruption	O	1091-1101
of	O	1102-1104
striatal	O	1105-1113
miR	B	1114-1117
-	I	1117-1118
212	I	1118-1121
signaling	O	1122-1131
using	O	1132-1137
an	O	1138-1140
antisense	O	1141-1150
oligonucleotide	O	1151-1166
increases	O	1167-1176
cocaine	O	1177-1184
intake	O	1185-1191
.	O	1191-1192

We	O	1193-1195
also	O	1196-1200
review	O	1201-1207
data	O	1208-1212
that	O	1213-1217
identify	O	1218-1226
two	O	1227-1230
mechanisms	O	1231-1241
by	O	1242-1244
which	O	1245-1250
miR	B	1251-1254
-	I	1254-1255
212	I	1255-1258
may	O	1259-1262
regulate	O	1263-1271
cocaine	O	1272-1279
intake	O	1280-1286
.	O	1286-1287

First	O	1288-1293
,	O	1293-1294
miR	B	1295-1298
-	I	1298-1299
212	I	1299-1302
has	O	1303-1306
been	O	1307-1311
shown	O	1312-1317
to	O	1318-1320
amplify	O	1321-1328
striatal	O	1329-1337
cAMP	O	1338-1342
response	O	1343-1351
element	O	1352-1359
binding	O	1360-1367
protein	O	1368-1375
(	O	1376-1377
CREB	O	1377-1381
)	O	1381-1382
signaling	O	1383-1392
through	O	1393-1400
a	O	1401-1402
mechanism	O	1403-1412
involving	O	1413-1422
activation	O	1423-1433
of	O	1434-1436
Raf1	O	1437-1441
kinase	O	1442-1448
.	O	1448-1449

Second	O	1450-1456
,	O	1456-1457
miR	B	1458-1461
-	I	1461-1462
212	I	1462-1465
was	O	1466-1469
also	O	1470-1474
shown	O	1475-1480
to	O	1481-1483
regulate	O	1484-1492
cocaine	O	1493-1500
intake	O	1501-1507
by	O	1508-1510
repressing	O	1511-1521
striatal	O	1522-1530
expression	O	1531-1541
of	O	1542-1544
methyl	O	1545-1551
CpG	O	1552-1555
binding	O	1556-1563
protein	O	1564-1571
2	O	1572-1573
(	O	1574-1575
MeCP2	O	1575-1580
)	O	1580-1581
,	O	1581-1582
consequently	O	1583-1595
decreasing	O	1596-1606
protein	O	1607-1614
levels	O	1615-1621
of	O	1622-1624
brain	O	1625-1630
-	O	1630-1631
derived	O	1631-1638
neurotrophic	O	1639-1651
factor	O	1652-1658
(	O	1659-1660
BDNF	O	1660-1664
)	O	1664-1665
.	O	1665-1666

The	O	1667-1670
concerted	O	1671-1680
actions	O	1681-1688
of	O	1689-1691
miR	B	1692-1695
-	I	1695-1696
212	I	1696-1699
on	O	1700-1702
striatal	O	1703-1711
CREB	O	1712-1716
and	O	1717-1720
MeCP2	O	1721-1726
/	O	1726-1727
BDNF	O	1727-1731
activity	O	1732-1740
greatly	O	1741-1748
attenuate	O	1749-1758
the	O	1759-1762
motivational	O	1763-1775
effects	O	1776-1783
of	O	1784-1786
cocaine	O	1787-1794
.	O	1794-1795

These	O	1796-1801
findings	O	1802-1810
highlight	O	1811-1820
the	O	1821-1824
unique	O	1825-1831
role	O	1832-1836
for	O	1837-1840
miRNAs	O	1841-1847
in	O	1848-1850
simultaneously	O	1851-1865
controlling	O	1866-1877
multiple	O	1878-1886
signaling	O	1887-1896
cascades	O	1897-1905
implicated	O	1906-1916
in	O	1917-1919
addiction	O	1920-1929
.	O	1929-1930

Multicolor	O	0-10
microRNA	O	11-19
FISH	O	20-24
effectively	O	25-36
differentiates	O	37-51
tumor	O	52-57
types	O	58-63
.	O	63-64

MicroRNAs	O	65-74
(	O	75-76
miRNAs	O	76-82
)	O	82-83
are	O	84-87
excellent	O	88-97
tumor	O	98-103
biomarkers	O	104-114
because	O	115-122
of	O	123-125
their	O	126-131
cell	O	132-136
-	O	136-137
type	O	137-141
specificity	O	142-153
and	O	154-157
abundance	O	158-167
.	O	167-168

However	O	169-176
,	O	176-177
many	O	178-182
miRNA	O	183-188
detection	O	189-198
methods	O	199-206
,	O	206-207
such	O	208-212
as	O	213-215
real	O	216-220
-	O	220-221
time	O	221-225
PCR	O	226-229
,	O	229-230
obliterate	O	231-241
valuable	O	242-250
visuospatial	O	251-263
information	O	264-275
in	O	276-278
tissue	O	279-285
samples	O	286-293
.	O	293-294

To	O	295-297
enable	O	298-304
miRNA	O	305-310
visualization	O	311-324
in	O	325-327
formalin	O	328-336
-	O	336-337
fixed	O	337-342
paraffin	O	343-351
-	O	351-352
embedded	O	352-360
(	O	361-362
FFPE	O	362-366
)	O	366-367
tissues	O	368-375
,	O	375-376
we	O	377-379
developed	O	380-389
multicolor	O	390-400
miRNA	O	401-406
FISH	O	407-411
.	O	411-412

As	O	413-415
a	O	416-417
proof	O	418-423
of	O	424-426
concept	O	427-434
,	O	434-435
we	O	436-438
used	O	439-443
this	O	444-448
method	O	449-455
to	O	456-458
differentiate	O	459-472
two	O	473-476
skin	O	477-481
tumors	O	482-488
,	O	488-489
basal	O	490-495
cell	O	496-500
carcinoma	O	501-510
(	O	511-512
BCC	O	512-515
)	O	515-516
and	O	517-520
Merkel	O	521-527
cell	O	528-532
carcinoma	O	533-542
(	O	543-544
MCC	O	544-547
)	O	547-548
,	O	548-549
with	O	550-554
overlapping	O	555-566
histologic	O	567-577
features	O	578-586
but	O	587-590
distinct	O	591-599
cellular	O	600-608
origins	O	609-616
.	O	616-617

Using	O	618-623
sequencing	O	624-634
-	O	634-635
based	O	635-640
miRNA	O	641-646
profiling	O	647-656
and	O	657-660
discriminant	O	661-673
analysis	O	674-682
,	O	682-683
we	O	684-686
identified	O	687-697
the	O	698-701
tumor	O	702-707
-	O	707-708
specific	O	708-716
miRNAs	O	717-723
miR	B	724-727
-	I	727-728
205	I	728-731
and	O	732-735
miR	B	736-739
-	I	739-740
375	I	740-743
in	O	744-746
BCC	O	747-750
and	O	751-754
MCC	O	755-758
,	O	758-759
respectively	O	760-772
.	O	772-773

We	O	774-776
addressed	O	777-786
three	O	787-792
major	O	793-798
shortcomings	O	799-811
in	O	812-814
miRNA	O	815-820
FISH	O	821-825
,	O	825-826
identifying	O	827-838
optimal	O	839-846
conditions	O	847-857
for	O	858-861
miRNA	O	862-867
fixation	O	868-876
and	O	877-880
ribosomal	O	881-890
RNA	O	891-894
(	O	895-896
rRNA	O	896-900
)	O	900-901
retention	O	902-911
using	O	912-917
model	O	918-923
compounds	O	924-933
and	O	934-937
high	O	938-942
-	O	942-943
pressure	O	943-951
liquid	O	952-958
chromatography	O	959-973
(	O	974-975
HPLC	O	975-979
)	O	979-980
analyses	O	981-989
,	O	989-990
enhancing	O	991-1000
signal	O	1001-1007
amplification	O	1008-1021
and	O	1022-1025
detection	O	1026-1035
by	O	1036-1038
increasing	O	1039-1049
probe	O	1050-1055
-	O	1055-1056
hapten	O	1056-1062
linker	O	1063-1069
lengths	O	1070-1077
,	O	1077-1078
and	O	1079-1082
improving	O	1083-1092
probe	O	1093-1098
specificity	O	1099-1110
using	O	1111-1116
shortened	O	1117-1126
probes	O	1127-1133
with	O	1134-1138
minimal	O	1139-1146
rRNA	O	1147-1151
sequence	O	1152-1160
complementarity	O	1161-1176
.	O	1176-1177

We	O	1178-1180
validated	O	1181-1190
our	O	1191-1194
method	O	1195-1201
on	O	1202-1204
4	O	1205-1206
BCC	O	1207-1210
and	O	1211-1214
12	O	1215-1217
MCC	O	1218-1221
tumors	O	1222-1228
.	O	1228-1229

Amplified	O	1230-1239
miR	B	1240-1243
-	I	1243-1244
205	I	1244-1247
and	O	1248-1251
miR	B	1252-1255
-	I	1255-1256
375	I	1256-1259
signals	O	1260-1267
were	O	1268-1272
normalized	O	1273-1283
against	O	1284-1291
directly	O	1292-1300
detectable	O	1301-1311
reference	O	1312-1321
rRNA	O	1322-1326
signals	O	1327-1334
.	O	1334-1335

Tumors	O	1336-1342
were	O	1343-1347
classified	O	1348-1358
using	O	1359-1364
predefined	O	1365-1375
cutoff	O	1376-1382
values	O	1383-1389
,	O	1389-1390
and	O	1391-1394
all	O	1395-1398
were	O	1399-1403
correctly	O	1404-1413
identified	O	1414-1424
in	O	1425-1427
blinded	O	1428-1435
analysis	O	1436-1444
.	O	1444-1445

Our	O	1446-1449
study	O	1450-1455
establishes	O	1456-1467
a	O	1468-1469
reliable	O	1470-1478
miRNA	O	1479-1484
FISH	O	1485-1489
technique	O	1490-1499
for	O	1500-1503
parallel	O	1504-1512
visualization	O	1513-1526
of	O	1527-1529
differentially	O	1530-1544
expressed	O	1545-1554
miRNAs	O	1555-1561
in	O	1562-1564
FFPE	O	1565-1569
tumor	O	1570-1575
tissues	O	1576-1583
.	O	1583-1584

Insulin	O	0-7
promotes	O	8-16
glucose	O	17-24
consumption	O	25-36
via	O	37-40
regulation	O	41-51
of	O	52-54
miR	B	55-58
-	I	58-59
99a	I	59-62
/	O	62-63
mTOR	O	63-67
/	O	67-68
PKM2	O	68-72
pathway	O	73-80
.	O	80-81

Insulin	O	82-89
is	O	90-92
known	O	93-98
to	O	99-101
regulate	O	102-110
multiple	O	111-119
cellular	O	120-128
functions	O	129-138
and	O	139-142
is	O	143-145
used	O	146-150
for	O	151-154
the	O	155-158
treatment	O	159-168
of	O	169-171
diabetes	O	172-180
.	O	180-181

MicroRNAs	O	182-191
have	O	192-196
been	O	197-201
demonstrated	O	202-214
to	O	215-217
be	O	218-220
involved	O	221-229
in	O	230-232
many	O	233-237
human	O	238-243
diseases	O	244-252
,	O	252-253
including	O	254-263
Type	O	264-268
2	O	269-270
diabetes	O	271-279
.	O	279-280

In	O	281-283
this	O	284-288
study	O	289-294
,	O	294-295
we	O	296-298
showed	O	299-305
that	O	306-310
insulin	O	311-318
decreased	O	319-328
miR	B	329-332
-	I	332-333
99a	I	333-336
expression	O	337-347
levels	O	348-354
,	O	354-355
but	O	356-359
induced	O	360-367
glucose	O	368-375
consumption	O	376-387
and	O	388-391
lactate	O	392-399
production	O	400-410
,	O	410-411
and	O	412-415
increased	O	416-425
the	O	426-429
expression	O	430-440
of	O	441-443
mTOR	O	444-448
,	O	448-449
HIF	O	450-453
-	O	453-454
1alpha	O	454-460
and	O	461-464
PKM2	O	465-469
in	O	470-472
HepG2	O	473-478
and	O	479-482
HL7702	O	483-489
cells	O	490-495
.	O	495-496

Forced	O	497-503
expression	O	504-514
of	O	515-517
miR	B	518-521
-	I	521-522
99a	I	522-525
or	O	526-528
rapamycin	O	529-538
treatment	O	539-548
blocked	O	549-556
insulin	O	557-564
-	O	564-565
induced	O	565-572
PKM2	O	573-577
and	O	578-581
HIF	O	582-585
-	O	585-586
1alpha	O	586-592
expression	O	593-603
,	O	603-604
and	O	605-608
glucose	O	609-616
consumption	O	617-628
and	O	629-632
lactate	O	633-640
production	O	641-651
.	O	651-652

Meanwhile	O	653-662
,	O	662-663
knockdown	O	664-673
of	O	674-676
HIF	O	677-680
-	O	680-681
1alpha	O	681-687
inhibited	O	688-697
PKM2	O	698-702
expression	O	703-713
and	O	714-717
insulin	O	718-725
-	O	725-726
induced	O	726-733
glucose	O	734-741
consumption	O	742-753
.	O	753-754

Taken	O	755-760
together	O	761-769
,	O	769-770
these	O	771-776
findings	O	777-785
will	O	786-790
reveal	O	791-797
the	O	798-801
role	O	802-806
and	O	807-810
mechanism	O	811-820
of	O	821-823
insulin	O	824-831
in	O	832-834
regulating	O	835-845
glycolytic	O	846-856
activities	O	857-867
via	O	868-871
miR	B	872-875
-	I	875-876
99a	I	876-879
/	O	879-880
mTOR	O	880-884
.	O	884-885

MicroRNA	B	0-8
-	I	8-9
199a	I	9-13
is	O	14-16
induced	O	17-24
in	O	25-27
dystrophic	O	28-38
muscle	O	39-45
and	O	46-49
affects	O	50-57
WNT	O	58-61
signaling	O	62-71
,	O	71-72
cell	O	73-77
proliferation	O	78-91
,	O	91-92
and	O	93-96
myogenic	O	97-105
differentiation	O	106-121
.	O	121-122

In	O	123-125
patients	O	126-134
with	O	135-139
Duchenne	O	140-148
muscular	O	149-157
dystrophy	O	158-167
(	O	168-169
DMD	O	169-172
)	O	172-173
,	O	173-174
the	O	175-178
absence	O	179-186
of	O	187-189
a	O	190-191
functional	O	192-202
dystrophin	O	203-213
protein	O	214-221
results	O	222-229
in	O	230-232
sarcolemmal	O	233-244
instability	O	245-256
,	O	256-257
abnormal	O	258-266
calcium	O	267-274
signaling	O	275-284
,	O	284-285
cardiomyopathy	O	286-300
,	O	300-301
and	O	302-305
skeletal	O	306-314
muscle	O	315-321
degeneration	O	322-334
.	O	334-335

Using	O	336-341
the	O	342-345
dystrophin	O	346-356
-	O	356-357
deficient	O	357-366
sapje	O	367-372
zebrafish	O	373-382
model	O	383-388
,	O	388-389
we	O	390-392
have	O	393-397
identified	O	398-408
microRNAs	O	409-418
(	O	419-420
miRNAs	O	420-426
)	O	426-427
that	O	428-432
,	O	432-433
in	O	434-436
comparison	O	437-447
to	O	448-450
our	O	451-454
previous	O	455-463
findings	O	464-472
in	O	473-475
human	O	476-481
DMD	O	482-485
muscle	O	486-492
biopsies	O	493-501
,	O	501-502
are	O	503-506
uniquely	O	507-515
dysregulated	O	516-528
in	O	529-531
dystrophic	O	532-542
muscle	O	543-549
across	O	550-556
vertebrate	O	557-567
species	O	568-575
.	O	575-576

MiR	B	577-580
-	I	580-581
199a	I	581-585
-	I	585-586
5p	I	586-588
is	O	589-591
dysregulated	O	592-604
in	O	605-607
dystrophin	O	608-618
-	O	618-619
deficient	O	619-628
zebrafish	O	629-638
,	O	638-639
mdx	O	640-643
(	O	643-644
5cv	O	644-647
)	O	647-648
mice	O	649-653
,	O	653-654
and	O	655-658
human	O	659-664
muscle	O	665-671
biopsies	O	672-680
.	O	680-681

MiR	B	682-685
-	I	685-686
199a	I	686-690
-	I	690-691
5p	I	691-693
mature	O	694-700
miRNA	O	701-706
sequences	O	707-716
are	O	717-720
transcribed	O	721-732
from	O	733-737
stem	O	738-742
loop	O	743-747
precursor	O	748-757
miRNAs	O	758-764
that	O	765-769
are	O	770-773
found	O	774-779
within	O	780-786
the	O	787-790
introns	O	791-798
of	O	799-801
the	O	802-805
dynamin	O	806-813
-	O	813-814
2	O	814-815
and	O	816-819
dynamin	O	820-827
-	O	827-828
3	O	828-829
loci	O	830-834
.	O	834-835

The	O	836-839
miR	B	840-843
-	I	843-844
199a	I	844-848
-	I	848-849
2	I	849-850
stem	O	851-855
loop	O	856-860
precursor	O	861-870
transcript	O	871-881
that	O	882-886
gives	O	887-892
rise	O	893-897
to	O	898-900
the	O	901-904
miR	B	905-908
-	I	908-909
199a	I	909-913
-	I	913-914
5p	I	914-916
mature	O	917-923
transcript	O	924-934
was	O	935-938
found	O	939-944
to	O	945-947
be	O	948-950
elevated	O	951-959
in	O	960-962
human	O	963-968
dystrophic	O	969-979
muscle	O	980-986
.	O	986-987

The	O	988-991
levels	O	992-998
of	O	999-1001
expression	O	1002-1012
of	O	1013-1015
miR	B	1016-1019
-	I	1019-1020
199a	I	1020-1024
-	I	1024-1025
5p	I	1025-1027
are	O	1028-1031
regulated	O	1032-1041
in	O	1042-1044
a	O	1045-1046
serum	O	1047-1052
response	O	1053-1061
factor	O	1062-1068
(	O	1069-1070
SRF	O	1070-1073
)	O	1073-1074
-	O	1074-1075
dependent	O	1075-1084
manner	O	1085-1091
along	O	1092-1097
with	O	1098-1102
myocardin	O	1103-1112
-	O	1112-1113
related	O	1113-1120
transcription	O	1121-1134
factors	O	1135-1142
.	O	1142-1143

Inhibition	O	1144-1154
of	O	1155-1157
SRF	O	1158-1161
-	O	1161-1162
signaling	O	1162-1171
reduces	O	1172-1179
miR	B	1180-1183
-	I	1183-1184
199a	I	1184-1188
-	I	1188-1189
5p	I	1189-1191
transcript	O	1192-1202
levels	O	1203-1209
during	O	1210-1216
myogenic	O	1217-1225
differentiation	O	1226-1241
.	O	1241-1242

Manipulation	O	1243-1255
of	O	1256-1258
miR	B	1259-1262
-	I	1262-1263
199a	I	1263-1267
-	I	1267-1268
5p	I	1268-1270
expression	O	1271-1281
in	O	1282-1284
human	O	1285-1290
primary	O	1291-1298
myoblasts	O	1299-1308
and	O	1309-1312
myotubes	O	1313-1321
resulted	O	1322-1330
in	O	1331-1333
dramatic	O	1334-1342
changes	O	1343-1350
in	O	1351-1353
cellular	O	1354-1362
size	O	1363-1367
,	O	1367-1368
proliferation	O	1369-1382
,	O	1382-1383
and	O	1384-1387
differentiation	O	1388-1403
.	O	1403-1404

MiR	B	1405-1408
-	I	1408-1409
199a	I	1409-1413
-	I	1413-1414
5p	I	1414-1416
targets	O	1417-1424
several	O	1425-1432
myogenic	O	1433-1441
cell	O	1442-1446
proliferation	O	1447-1460
and	O	1461-1464
differentiation	O	1465-1480
regulatory	O	1481-1491
factors	O	1492-1499
within	O	1500-1506
the	O	1507-1510
WNT	O	1511-1514
signaling	O	1515-1524
pathway	O	1525-1532
,	O	1532-1533
including	O	1534-1543
FZD4	O	1544-1548
,	O	1548-1549
JAG1	O	1550-1554
,	O	1554-1555
and	O	1556-1559
WNT2	O	1560-1564
.	O	1564-1565

Overexpression	O	1566-1580
of	O	1581-1583
miR	B	1584-1587
-	I	1587-1588
199a	I	1588-1592
-	I	1592-1593
5p	I	1593-1595
in	O	1596-1598
the	O	1599-1602
muscles	O	1603-1610
of	O	1611-1613
transgenic	O	1614-1624
zebrafish	O	1625-1634
resulted	O	1635-1643
in	O	1644-1646
abnormal	O	1647-1655
myofiber	O	1656-1664
disruption	O	1665-1675
and	O	1676-1679
sarcolemmal	O	1680-1691
membrane	O	1692-1700
detachment	O	1701-1711
,	O	1711-1712
pericardial	O	1713-1724
edema	O	1725-1730
,	O	1730-1731
and	O	1732-1735
lethality	O	1736-1745
.	O	1745-1746

Together	O	1747-1755
,	O	1755-1756
these	O	1757-1762
studies	O	1763-1770
identify	O	1771-1779
miR	B	1780-1783
-	I	1783-1784
199a	I	1784-1788
-	I	1788-1789
5p	I	1789-1791
as	O	1792-1794
a	O	1795-1796
potential	O	1797-1806
regulator	O	1807-1816
of	O	1817-1819
myogenesis	O	1820-1830
through	O	1831-1838
suppression	O	1839-1850
of	O	1851-1853
WNT	O	1854-1857
-	O	1857-1858
signaling	O	1858-1867
factors	O	1868-1875
that	O	1876-1880
act	O	1881-1884
to	O	1885-1887
balance	O	1888-1895
myogenic	O	1896-1904
cell	O	1905-1909
proliferation	O	1910-1923
and	O	1924-1927
differentiation	O	1928-1943
.	O	1943-1944

Local	O	0-5
inhibition	O	6-16
of	O	17-19
microRNA	B	20-28
-	I	28-29
24	I	29-31
improves	O	32-40
reparative	O	41-51
angiogenesis	O	52-64
and	O	65-68
left	O	69-73
ventricle	O	74-83
remodeling	O	84-94
and	O	95-98
function	O	99-107
in	O	108-110
mice	O	111-115
with	O	116-120
myocardial	O	121-131
infarction	O	132-142
.	O	142-143

Myocardial	O	144-154
infarction	O	155-165
(	O	166-167
MI	O	167-169
)	O	169-170
is	O	171-173
the	O	174-177
leading	O	178-185
cause	O	186-191
of	O	192-194
death	O	195-200
worldwide	O	201-210
.	O	210-211

MicroRNAs	O	212-221
regulate	O	222-230
the	O	231-234
expression	O	235-245
of	O	246-248
their	O	249-254
target	O	255-261
genes	O	262-267
,	O	267-268
thus	O	269-273
mediating	O	274-283
a	O	284-285
plethora	O	286-294
of	O	295-297
pathophysiological	O	298-316
functions	O	317-326
.	O	326-327

Recently	O	328-336
,	O	336-337
miRNA	B	338-343
-	I	343-344
24	I	344-346
emerged	O	347-354
as	O	355-357
an	O	358-360
important	O	361-370
but	O	371-374
controversial	O	375-388
miRNA	O	389-394
involved	O	395-403
in	O	404-406
post	O	407-411
-	O	411-412
MI	O	412-414
responses	O	415-424
.	O	424-425

Here	O	426-430
,	O	430-431
we	O	432-434
aimed	O	435-440
at	O	441-443
clarifying	O	444-454
the	O	455-458
effect	O	459-465
of	O	466-468
adenovirus	O	469-479
-	O	479-480
mediate	O	480-487
intra	O	488-493
-	O	493-494
myocardial	O	494-504
delivery	O	505-513
of	O	514-516
a	O	517-518
decoy	O	519-524
for	O	525-528
miRNA	B	529-534
-	I	534-535
24	I	535-537
in	O	538-540
a	O	541-542
mouse	O	543-548
MI	O	549-551
model	O	552-557
and	O	558-561
to	O	562-564
investigate	O	565-576
the	O	577-580
impact	O	581-587
of	O	588-590
miRNA	B	591-596
-	I	596-597
24	I	597-599
inhibition	O	600-610
on	O	611-613
angiogenesis	O	614-626
and	O	627-630
cardiovascular	O	631-645
apoptosis	O	646-655
.	O	655-656

After	O	657-662
MI	O	663-665
induction	O	666-675
,	O	675-676
miRNA	B	677-682
-	I	682-683
24	I	683-685
expression	O	686-696
was	O	697-700
lower	O	701-706
in	O	707-709
the	O	710-713
peri	O	714-718
-	O	718-719
infarct	O	719-726
tissue	O	727-733
and	O	734-737
its	O	738-741
resident	O	742-750
cardiomyocytes	O	751-765
and	O	766-769
fibroblasts	O	770-781
;	O	781-782
while	O	783-788
it	O	789-791
increased	O	792-801
in	O	802-804
endothelial	O	805-816
cells	O	817-822
(	O	823-824
ECs	O	824-827
)	O	827-828
.	O	828-829

Local	O	830-835
adenovirus	O	836-846
-	O	846-847
mediated	O	847-855
miRNA	B	856-861
-	I	861-862
24	I	862-864
decoy	O	865-870
delivery	O	871-879
increased	O	880-889
angiogenesis	O	890-902
and	O	903-906
blood	O	907-912
perfusion	O	913-922
in	O	923-925
the	O	926-929
peri	O	930-934
-	O	934-935
infarct	O	935-942
myocardium	O	943-953
,	O	953-954
reduced	O	955-962
infarct	O	963-970
size	O	971-975
,	O	975-976
induced	O	977-984
fibroblast	O	985-995
apopotosis	O	996-1006
and	O	1007-1010
overall	O	1011-1018
improved	O	1019-1027
cardiac	O	1028-1035
function	O	1036-1044
.	O	1044-1045

Notwithstanding	O	1046-1061
these	O	1062-1067
beneficial	O	1068-1078
effects	O	1079-1086
,	O	1086-1087
miRNA	B	1088-1093
-	I	1093-1094
24	I	1094-1096
decoy	O	1097-1102
increased	O	1103-1112
cardiomyocytes	O	1113-1127
apoptosis	O	1128-1137
.	O	1137-1138

In	O	1139-1141
vitro	O	1142-1147
,	O	1147-1148
miRNA	B	1149-1154
-	I	1154-1155
24	I	1155-1157
inhibition	O	1158-1168
enhanced	O	1169-1177
ECs	O	1178-1181
survival	O	1182-1190
,	O	1190-1191
proliferation	O	1192-1205
and	O	1206-1209
networking	O	1210-1220
in	O	1221-1223
capillary	O	1224-1233
-	O	1233-1234
like	O	1234-1238
tubes	O	1239-1244
and	O	1245-1248
induced	O	1249-1256
cardiomyocyte	O	1257-1270
and	O	1271-1274
fibroblast	O	1275-1285
apoptosis	O	1286-1295
.	O	1295-1296

Finally	O	1297-1304
,	O	1304-1305
we	O	1306-1308
identified	O	1309-1319
eNOS	O	1320-1324
as	O	1325-1327
a	O	1328-1329
novel	O	1330-1335
direct	O	1336-1342
target	O	1343-1349
of	O	1350-1352
miR	B	1353-1356
-	I	1356-1357
24	I	1357-1359
in	O	1360-1362
human	O	1363-1368
cultured	O	1369-1377
ECs	O	1378-1381
and	O	1382-1385
in	O	1386-1388
vivo	O	1389-1393
.	O	1393-1394

Our	O	1395-1398
findings	O	1399-1407
suggest	O	1408-1415
that	O	1416-1420
miRNA	B	1421-1426
-	I	1426-1427
24	I	1427-1429
inhibition	O	1430-1440
exerts	O	1441-1447
distinct	O	1448-1456
biological	O	1457-1467
effects	O	1468-1475
on	O	1476-1478
ECs	O	1479-1482
,	O	1482-1483
cardiomyocytes	O	1484-1498
and	O	1499-1502
fibroblasts	O	1503-1514
.	O	1514-1515

The	O	1516-1519
overall	O	1520-1527
result	O	1528-1534
of	O	1535-1537
post	O	1538-1542
-	O	1542-1543
infarction	O	1543-1553
local	O	1554-1559
miRNA	B	1560-1565
-	I	1565-1566
24	I	1566-1568
inhibition	O	1569-1579
appears	O	1580-1587
to	O	1588-1590
be	O	1591-1593
therapeutic	O	1594-1605
.	O	1605-1606

Circulating	O	0-11
miRNAs	O	12-18
reflect	O	19-26
early	O	27-32
myocardial	O	33-43
injury	O	44-50
and	O	51-54
recovery	O	55-63
after	O	64-69
heart	O	70-75
transplantation	O	76-91
.	O	91-92

BACKGROUND	O	93-103
:	O	103-104
MicroRNAs	O	105-114
(	O	115-116
miRNAs	O	116-122
)	O	122-123
are	O	124-127
short	O	128-133
,	O	133-134
single	O	135-141
-	O	141-142
stranded	O	142-150
and	O	151-154
non	O	155-158
-	O	158-159
coding	O	159-165
RNAs	O	166-170
,	O	170-171
freely	O	172-178
circulating	O	179-190
in	O	191-193
human	O	194-199
plasma	O	200-206
and	O	207-210
correlating	O	211-222
with	O	223-227
vary	O	228-232
pathologies	O	233-244
.	O	244-245

In	O	246-248
this	O	249-253
study	O	254-259
,	O	259-260
we	O	261-263
monitored	O	264-273
early	O	274-279
myocardial	O	280-290
injury	O	291-297
and	O	298-301
recovery	O	302-310
after	O	311-316
heart	O	317-322
transplantation	O	323-338
by	O	339-341
detecting	O	342-351
levels	O	352-358
of	O	359-361
circulating	O	362-373
muscle	O	374-380
-	O	380-381
specific	O	381-389
miR	B	390-393
-	I	393-394
133a	I	394-398
,	O	398-399
miR	B	400-403
-	I	403-404
133b	I	404-408
and	O	409-412
miR	B	413-416
-	I	416-417
208a	I	417-421
.	O	421-422

METHODS	O	423-430
:	O	430-431
7	O	432-433
consecutive	O	434-445
patients	O	446-454
underwent	O	455-464
heart	O	465-470
transplantation	O	471-486
in	O	487-489
Fuwai	O	490-495
hospital	O	496-504
and	O	505-508
14	O	509-511
healthy	O	512-519
controls	O	520-528
were	O	529-533
included	O	534-542
in	O	543-545
our	O	546-549
study	O	550-555
.	O	555-556

Peripheral	O	557-567
vein	O	568-572
blood	O	573-578
was	O	579-582
drawn	O	583-588
from	O	589-593
patients	O	594-602
on	O	603-605
the	O	606-609
day	O	610-613
just	O	614-618
after	O	619-624
transplantation	O	625-640
(	O	641-642
day	O	642-645
0	O	646-647
)	O	647-648
,	O	648-649
the	O	650-653
1st	O	654-657
,	O	657-658
2nd	O	659-662
,	O	662-663
3rd	O	664-667
,	O	667-668
7th	O	669-672
and	O	673-676
14th	O	677-681
day	O	682-685
after	O	686-691
transplantation	O	692-707
respectively	O	708-720
.	O	720-721

Serum	O	722-727
from	O	728-732
peripheral	O	733-743
blood	O	744-749
was	O	750-753
obtained	O	754-762
for	O	763-766
cardiac	O	767-774
troponin	O	775-783
I	O	784-785
(	O	786-787
cTnI	O	787-791
)	O	791-792
measurement	O	793-804
.	O	804-805

Plasma	O	806-812
was	O	813-816
centrifuged	O	817-828
from	O	829-833
peripheral	O	834-844
blood	O	845-850
for	O	851-854
measuring	O	855-864
miR	B	865-868
-	I	868-869
133a	I	869-873
,	O	873-874
miR	B	875-878
-	I	878-879
133b	I	879-883
and	O	884-887
miR	B	888-891
-	I	891-892
208a	I	892-896
by	O	897-899
quantitative	O	900-912
reverse	O	913-920
transcription	O	921-934
polymerase	O	935-945
chain	O	946-951
reaction	O	952-960
(	O	961-962
qRT	O	962-965
-	O	965-966
PCR	O	966-969
)	O	969-970
.	O	970-971

The	O	972-975
plasma	O	976-982
concentration	O	983-996
of	O	997-999
miRNAs	O	1000-1006
were	O	1007-1011
calculated	O	1012-1022
by	O	1023-1025
absolute	O	1026-1034
quantification	O	1035-1049
method	O	1050-1056
.	O	1056-1057

The	O	1058-1061
sensitivity	O	1062-1073
and	O	1074-1077
specificity	O	1078-1089
of	O	1090-1092
circulating	O	1093-1104
miRNAs	O	1105-1111
were	O	1112-1116
revealed	O	1117-1125
by	O	1126-1128
receiver	O	1129-1137
operating	O	1138-1147
characteristic	O	1148-1162
curve	O	1163-1168
(	O	1169-1170
ROC	O	1170-1173
)	O	1173-1174
analysis	O	1175-1183
.	O	1183-1184

Correlations	O	1185-1197
between	O	1198-1205
miRNAs	O	1206-1212
and	O	1213-1216
cTnI	O	1217-1221
/	O	1222-1223
perioperative	O	1224-1237
parameters	O	1238-1248
were	O	1249-1253
analyzed	O	1254-1262
.	O	1262-1263

RESULTS	O	1264-1271
:	O	1271-1272
Similar	O	1273-1280
to	O	1281-1283
cTnI	O	1284-1288
,	O	1288-1289
miR	B	1290-1293
-	I	1293-1294
133a	I	1294-1298
,	O	1298-1299
miR	B	1300-1303
-	I	1303-1304
133b	I	1304-1308
and	O	1309-1312
miR	B	1313-1316
-	I	1316-1317
208a	I	1317-1321
all	O	1322-1325
showed	O	1326-1332
dynamic	O	1333-1340
changes	O	1341-1348
from	O	1349-1353
high	O	1354-1358
to	O	1359-1361
low	O	1362-1365
levels	O	1366-1372
early	O	1373-1378
after	O	1379-1384
operation	O	1385-1394
.	O	1394-1395

The	O	1396-1399
Sensitivity	O	1400-1411
and	O	1412-1415
specificity	O	1416-1427
of	O	1428-1430
miRNAs	O	1431-1437
were	O	1438-1442
:	O	1442-1443
miR	B	1444-1447
-	I	1447-1448
133a	I	1448-1452
(	O	1453-1454
85	O	1454-1456
.	O	1456-1457
7	O	1457-1458
%	O	1458-1459
,	O	1459-1460
100	O	1460-1463
%	O	1463-1464
)	O	1464-1465
,	O	1465-1466
miR	B	1467-1470
-	I	1470-1471
208a	I	1471-1475
(	O	1476-1477
100	O	1477-1480
%	O	1480-1481
,	O	1481-1482
100	O	1482-1485
%	O	1485-1486
)	O	1486-1487
,	O	1487-1488
and	O	1489-1492
miR	B	1493-1496
-	I	1496-1497
133b	I	1497-1501
(	O	1502-1503
90	O	1503-1505
%	O	1505-1506
,	O	1506-1507
100	O	1507-1510
%	O	1510-1511
)	O	1511-1512
.	O	1512-1513

Correlations	O	1514-1526
between	O	1527-1534
miRNAs	O	1535-1541
and	O	1542-1545
cTnI	O	1546-1550
were	O	1551-1555
statistically	O	1556-1569
significant	O	1570-1581
(	O	1582-1583
p	O	1583-1584
<	O	1585-1586
0	O	1587-1588
.	O	1588-1589
05	O	1589-1591
)	O	1591-1592
,	O	1592-1593
especially	O	1594-1604
for	O	1605-1608
miR	B	1609-1612
-	I	1612-1613
133b	I	1613-1617
(	O	1618-1619
R2	O	1619-1621
=	O	1622-1623
0	O	1624-1625
.	O	1625-1626
813	O	1626-1629
,	O	1629-1630
p	O	1631-1632
<	O	1633-1634
0	O	1635-1636
.	O	1636-1637
001	O	1637-1640
)	O	1640-1641
.	O	1641-1642

MiR	B	1643-1646
-	I	1646-1647
133b	I	1647-1651
from	O	1652-1656
Day	O	1657-1660
0	O	1661-1662
-	O	1662-1663
Day	O	1663-1666
2	O	1667-1668
(	O	1669-1670
r	O	1670-1671
>	O	1672-1673
0	O	1674-1675
.	O	1675-1676
98	O	1676-1678
,	O	1678-1679
p	O	1680-1681
<	O	1682-1683
0	O	1684-1685
.	O	1685-1686
01	O	1686-1688
)	O	1688-1689
,	O	1689-1690
and	O	1691-1694
cTnI	O	1695-1699
from	O	1700-1704
Day	O	1705-1708
1	O	1709-1710
-	O	1710-1711
Day	O	1712-1715
3	O	1716-1717
(	O	1718-1719
r	O	1719-1720
>	O	1721-1722
0	O	1723-1724
.	O	1724-1725
86	O	1725-1727
,	O	1727-1728
p	O	1729-1730
<	O	1731-1732
0	O	1733-1734
.	O	1734-1735
05	O	1735-1737
)	O	1737-1738
had	O	1739-1742
strong	O	1743-1749
correlations	O	1750-1762
with	O	1763-1767
bypass	O	1768-1774
time	O	1775-1779
,	O	1779-1780
particularly	O	1781-1793
parallel	O	1794-1802
bypass	O	1803-1809
time	O	1810-1814
.	O	1814-1815

Obviously	O	1816-1825
,	O	1825-1826
miR	B	1827-1830
-	I	1830-1831
133b	I	1831-1835
had	O	1836-1839
a	O	1840-1841
better	O	1842-1848
correlation	O	1849-1860
than	O	1861-1865
cTnI	O	1866-1870
.	O	1870-1871

Circulating	O	1872-1883
miR	B	1884-1887
-	I	1887-1888
133b	I	1888-1892
correlated	O	1893-1903
well	O	1904-1908
with	O	1909-1913
parameters	O	1914-1924
of	O	1925-1927
heart	O	1928-1933
function	O	1934-1942
such	O	1943-1947
as	O	1948-1950
central	O	1951-1958
venous	O	1959-1965
pressure	O	1966-1974
(	O	1975-1976
CVP	O	1976-1979
)	O	1979-1980
,	O	1980-1981
pulmonary	O	1982-1991
capillary	O	1992-2001
wedge	O	2002-2007
pressure	O	2008-2016
(	O	2017-2018
PCWP	O	2018-2022
)	O	2022-2023
,	O	2023-2024
cardiac	O	2025-2032
output	O	2033-2039
(	O	2040-2041
CO	O	2041-2043
)	O	2043-2044
and	O	2045-2048
inotrope	O	2049-2057
support	O	2058-2065
,	O	2065-2066
while	O	2067-2072
cTnI	O	2073-2077
only	O	2078-2082
correlated	O	2083-2093
with	O	2094-2098
3	O	2099-2100
of	O	2101-2103
the	O	2104-2107
4	O	2108-2109
parameters	O	2110-2120
mentioned	O	2121-2130
above	O	2131-2136
.	O	2136-2137

MiR	B	2138-2141
-	I	2141-2142
133b	I	2142-2146
also	O	2147-2151
had	O	2152-2155
strong	O	2156-2162
correlations	O	2163-2175
with	O	2176-2180
ventilation	O	2181-2192
time	O	2193-2197
(	O	2198-2199
r	O	2199-2200
>	O	2201-2202
0	O	2203-2204
.	O	2204-2205
99	O	2205-2207
,	O	2207-2208
p	O	2209-2210
<	O	2211-2212
0	O	2213-2214
.	O	2214-2215
001	O	2215-2218
)	O	2218-2219
and	O	2220-2223
length	O	2224-2230
of	O	2231-2233
ICU	O	2234-2237
stay	O	2238-2242
(	O	2243-2244
r	O	2244-2245
>	O	2246-2247
0	O	2248-2249
.	O	2249-2250
92	O	2250-2252
,	O	2252-2253
p	O	2254-2255
<	O	2256-2257
0	O	2258-2259
.	O	2259-2260
05	O	2260-2262
)	O	2262-2263
,	O	2263-2264
both	O	2265-2269
of	O	2270-2272
which	O	2273-2278
reflected	O	2279-2288
the	O	2289-2292
recovery	O	2293-2301
after	O	2302-2307
operation	O	2308-2317
.	O	2317-2318

The	O	2319-2322
correlation	O	2323-2334
coefficients	O	2335-2347
of	O	2348-2350
miR	B	2351-2354
-	I	2354-2355
133b	I	2355-2359
were	O	2360-2364
also	O	2365-2369
higher	O	2370-2376
than	O	2377-2381
that	O	2382-2386
of	O	2387-2389
cTnI	O	2390-2394
.	O	2394-2395

CONCLUSIONS	O	2396-2407
:	O	2407-2408
The	O	2409-2412
dynamic	O	2413-2420
change	O	2421-2427
in	O	2428-2430
circulating	O	2431-2442
muscle	O	2443-2449
-	O	2449-2450
specific	O	2450-2458
miRNAs	O	2459-2465
,	O	2465-2466
especially	O	2467-2477
miR	B	2478-2481
-	I	2481-2482
133b	I	2482-2486
can	O	2487-2490
reflect	O	2491-2498
early	O	2499-2504
myocardial	O	2505-2515
injury	O	2516-2522
after	O	2523-2528
heart	O	2529-2534
transplantation	O	2535-2550
.	O	2550-2551

And	O	2552-2555
miR	B	2556-2559
-	I	2559-2560
133b	I	2560-2564
may	O	2565-2568
have	O	2569-2573
advantages	O	2574-2584
over	O	2585-2589
cTnI	O	2590-2594
in	O	2595-2597
forecasting	O	2598-2609
graft	O	2610-2615
dysfunction	O	2616-2627
and	O	2628-2631
recovery	O	2632-2640
of	O	2641-2643
patients	O	2644-2652
after	O	2653-2658
operation	O	2659-2668
.	O	2668-2669

MicroRNA	B	0-8
-	I	8-9
155	I	9-12
in	O	13-15
the	O	16-19
pathogenesis	O	20-32
of	O	33-35
atherosclerosis	O	36-51
:	O	51-52
a	O	53-54
conflicting	O	55-66
role	O	67-71
?	O	71-72

Atherosclerosis	O	73-88
is	O	89-91
widely	O	92-98
appreciated	O	99-110
to	O	111-113
involve	O	114-121
a	O	122-123
chronic	O	124-131
lipid	O	132-137
-	O	137-138
induced	O	138-145
inflammatory	O	146-158
reaction	O	159-167
of	O	168-170
the	O	171-174
arterial	O	175-183
wall	O	184-188
in	O	189-191
response	O	192-200
to	O	201-203
haemodynamic	O	204-216
stress	O	217-223
and	O	224-227
dyslipidaemia	O	228-241
.	O	241-242

The	O	243-246
dysfunction	O	247-258
of	O	259-261
resident	O	262-270
vascular	O	271-279
cells	O	280-285
and	O	286-289
recruitment	O	290-301
of	O	302-304
infiltrating	O	305-317
leukocyte	O	318-327
cells	O	328-333
orchestrate	O	334-345
a	O	346-347
complex	O	348-355
interplay	O	356-365
in	O	366-368
the	O	369-372
initiation	O	373-383
and	O	384-387
development	O	388-399
of	O	400-402
atherosclerosis	O	403-418
.	O	418-419

Despite	O	420-427
a	O	428-429
great	O	430-435
many	O	436-440
advances	O	441-449
in	O	450-452
recent	O	453-459
years	O	460-465
,	O	465-466
the	O	467-470
detailed	O	471-479
mechanisms	O	480-490
modulating	O	491-501
the	O	502-505
inflammation	O	506-518
in	O	519-521
atherosclerosis	O	522-537
have	O	538-542
not	O	543-546
been	O	547-551
fully	O	552-557
elucidated	O	558-568
.	O	568-569

MicroRNAs	O	570-579
(	O	580-581
miRNAs	O	581-587
)	O	587-588
are	O	589-592
small	O	593-598
non	O	599-602
-	O	602-603
coding	O	603-609
RNA	O	610-613
(	O	614-615
ncRNA	O	615-620
)	O	620-621
molecules	O	622-631
that	O	632-636
regulate	O	637-645
gene	O	646-650
expression	O	651-661
post	O	662-666
-	O	666-667
transcriptionally	O	667-684
by	O	685-687
degradation	O	688-699
and	O	700-703
translational	O	704-717
repression	O	718-728
of	O	729-731
target	O	732-738
messenger	O	739-748
RNAs	O	749-753
(	O	754-755
mRNAs	O	755-760
)	O	760-761
.	O	761-762

Substantial	O	763-774
evidence	O	775-783
demonstrates	O	784-796
that	O	797-801
miRNAs	O	802-808
play	O	809-813
a	O	814-815
vital	O	816-821
role	O	822-826
in	O	827-829
the	O	830-833
physiological	O	834-847
control	O	848-855
of	O	856-858
gene	O	859-863
expression	O	864-874
and	O	875-878
in	O	879-881
the	O	882-885
pathogenesis	O	886-898
of	O	899-901
malignant	O	902-911
,	O	911-912
infectious	O	913-923
,	O	923-924
and	O	925-928
cardiovascular	O	929-943
disorders	O	944-953
.	O	953-954

MiR	B	955-958
-	I	958-959
155	I	959-962
,	O	962-963
a	O	964-965
typical	O	966-973
multi	O	974-979
-	O	979-980
functional	O	980-990
miRNA	O	991-996
,	O	996-997
has	O	998-1001
recently	O	1002-1010
emerged	O	1011-1018
as	O	1019-1021
a	O	1022-1023
novel	O	1024-1029
component	O	1030-1039
of	O	1040-1042
inflammatory	O	1043-1055
signal	O	1056-1062
transduction	O	1063-1075
in	O	1076-1078
the	O	1079-1082
pathogenesis	O	1083-1095
of	O	1096-1098
atherosclerosis	O	1099-1114
.	O	1114-1115

MiR	B	1116-1119
-	I	1119-1120
155	I	1120-1123
-	O	1123-1124
mediated	O	1124-1132
regulation	O	1133-1143
is	O	1144-1146
extensively	O	1147-1158
involved	O	1159-1167
in	O	1168-1170
endothelial	O	1171-1182
cells	O	1183-1188
(	O	1189-1190
ECs	O	1190-1193
)	O	1193-1194
,	O	1194-1195
macrophages	O	1196-1207
,	O	1207-1208
dendritic	O	1209-1218
cell	O	1219-1223
(	O	1224-1225
DCs	O	1225-1228
)	O	1228-1229
,	O	1229-1230
vascular	O	1231-1239
smooth	O	1240-1246
muscle	O	1247-1253
cells	O	1254-1259
(	O	1260-1261
VSMCs	O	1261-1266
)	O	1266-1267
and	O	1268-1271
differentiation	O	1272-1287
of	O	1288-1290
leukocyte	O	1291-1300
subsets	O	1301-1308
.	O	1308-1309

MiR	B	1310-1313
-	I	1313-1314
155	I	1314-1317
can	O	1318-1321
modulate	O	1322-1330
the	O	1331-1334
expression	O	1335-1345
of	O	1346-1348
genes	O	1349-1354
correlated	O	1355-1365
with	O	1366-1370
inflammation	O	1371-1383
in	O	1384-1386
different	O	1387-1396
cell	O	1397-1401
types	O	1402-1407
in	O	1408-1410
vitro	O	1411-1416
and	O	1417-1420
also	O	1421-1425
affect	O	1426-1432
the	O	1433-1436
atherogenesis	O	1437-1450
in	O	1451-1453
vivo	O	1454-1458
.	O	1458-1459

However	O	1460-1467
,	O	1467-1468
miR	B	1469-1472
-	I	1472-1473
155	I	1473-1476
appears	O	1477-1484
to	O	1485-1487
play	O	1488-1492
a	O	1493-1494
conflicting	O	1495-1506
role	O	1507-1511
in	O	1512-1514
the	O	1515-1518
disease	O	1519-1526
pathogenesis	O	1527-1539
.	O	1539-1540

Besides	O	1541-1548
,	O	1548-1549
miR	B	1550-1553
-	I	1553-1554
155	I	1554-1557
is	O	1558-1560
potentially	O	1561-1572
applied	O	1573-1580
as	O	1581-1583
a	O	1584-1585
novel	O	1586-1591
disease	O	1592-1599
biomarker	O	1600-1609
and	O	1610-1613
therapeutic	O	1614-1625
target	O	1626-1632
in	O	1633-1635
diagnosing	O	1636-1646
and	O	1647-1650
treating	O	1651-1659
atherosclerosis	O	1660-1675
.	O	1675-1676

This	O	1677-1681
article	O	1682-1689
reviews	O	1690-1697
the	O	1698-1701
pertinent	O	1702-1711
literature	O	1712-1722
and	O	1723-1726
mechanisms	O	1727-1737
of	O	1738-1740
action	O	1741-1747
of	O	1748-1750
miR	B	1751-1754
-	I	1754-1755
155	I	1755-1758
that	O	1759-1763
have	O	1764-1768
thus	O	1769-1773
far	O	1774-1777
been	O	1778-1782
associated	O	1783-1793
with	O	1794-1798
atherosclerosis	O	1799-1814
.	O	1814-1815

Here	O	1816-1820
we	O	1821-1823
first	O	1824-1829
introduce	O	1830-1839
in	O	1840-1842
brief	O	1843-1848
the	O	1849-1852
basic	O	1853-1858
knowledge	O	1859-1868
of	O	1869-1871
the	O	1872-1875
miRNA	O	1876-1881
regulation	O	1882-1892
and	O	1893-1896
later	O	1897-1902
discuss	O	1903-1910
with	O	1911-1915
emphasis	O	1916-1924
the	O	1925-1928
regulatory	O	1929-1939
role	O	1940-1944
of	O	1945-1947
miR	B	1948-1951
-	I	1951-1952
155	I	1952-1955
in	O	1956-1958
various	O	1959-1966
cell	O	1967-1971
types	O	1972-1977
involved	O	1978-1986
in	O	1987-1989
atherosclerosis	O	1990-2005
.	O	2005-2006

The	O	0-3
miRNA	O	4-9
pathway	O	10-17
controls	O	18-26
rapid	O	27-32
changes	O	33-40
in	O	41-43
activity	O	44-52
-	O	52-53
dependent	O	53-62
synaptic	O	63-71
structure	O	72-81
at	O	82-84
the	O	85-88
Drosophila	O	89-99
melanogaster	O	100-112
neuromuscular	O	113-126
junction	O	127-135
.	O	135-136

It	O	137-139
is	O	140-142
widely	O	143-149
accepted	O	150-158
that	O	159-163
long	O	164-168
-	O	168-169
term	O	169-173
changes	O	174-181
in	O	182-184
synapse	O	185-192
structure	O	193-202
and	O	203-206
function	O	207-215
are	O	216-219
mediated	O	220-228
by	O	229-231
rapid	O	232-237
activity	O	238-246
-	O	246-247
dependent	O	247-256
gene	O	257-261
transcription	O	262-275
and	O	276-279
new	O	280-283
protein	O	284-291
synthesis	O	292-301
.	O	301-302

A	O	303-304
growing	O	305-312
amount	O	313-319
of	O	320-322
evidence	O	323-331
suggests	O	332-340
that	O	341-345
the	O	346-349
microRNA	O	350-358
(	O	359-360
miRNA	O	360-365
)	O	365-366
pathway	O	367-374
plays	O	375-380
an	O	381-383
important	O	384-393
role	O	394-398
in	O	399-401
coordinating	O	402-414
these	O	415-420
processes	O	421-430
.	O	430-431

Despite	O	432-439
recent	O	440-446
advances	O	447-455
in	O	456-458
this	O	459-463
field	O	464-469
,	O	469-470
there	O	471-476
remains	O	477-484
a	O	485-486
critical	O	487-495
need	O	496-500
to	O	501-503
identify	O	504-512
specific	O	513-521
activity	O	522-530
-	O	530-531
regulated	O	531-540
miRNAs	O	541-547
as	O	548-550
well	O	551-555
as	O	556-558
their	O	559-564
key	O	565-568
messenger	O	569-578
RNA	O	579-582
(	O	583-584
mRNA	O	584-588
)	O	588-589
targets	O	590-597
.	O	597-598

To	O	599-601
address	O	602-609
these	O	610-615
questions	O	616-625
,	O	625-626
we	O	627-629
used	O	630-634
the	O	635-638
larval	O	639-645
Drosophila	O	646-656
melanogaster	O	657-669
neuromuscular	O	670-683
junction	O	684-692
(	O	693-694
NMJ	O	694-697
)	O	697-698
as	O	699-701
a	O	702-703
model	O	704-709
synapse	O	710-717
in	O	718-720
which	O	721-726
to	O	727-729
identify	O	730-738
novel	O	739-744
miRNA	O	745-750
-	O	750-751
mediated	O	751-759
mechanisms	O	760-770
that	O	771-775
control	O	776-783
activity	O	784-792
-	O	792-793
dependent	O	793-802
synaptic	O	803-811
growth	O	812-818
.	O	818-819

First	O	820-825
,	O	825-826
we	O	827-829
developed	O	830-839
a	O	840-841
screen	O	842-848
to	O	849-851
identify	O	852-860
miRNAs	O	861-867
differentially	O	868-882
regulated	O	883-892
in	O	893-895
the	O	896-899
larval	O	900-906
CNS	O	907-910
following	O	911-920
spaced	O	921-927
synaptic	O	928-936
stimulation	O	937-948
.	O	948-949

Surprisingly	O	950-962
,	O	962-963
we	O	964-966
identified	O	967-977
five	O	978-982
miRNAs	O	983-989
(	O	990-991
miRs	B	991-995
-	I	995-996
1	I	996-997
,	O	997-998
-	B	999-1000
8	I	1000-1001
,	O	1001-1002
-	B	1003-1004
289	I	1004-1007
,	O	1007-1008
-	B	1009-1010
314	I	1010-1013
,	O	1013-1014
and	O	1015-1018
-	B	1019-1020
958	I	1020-1023
)	O	1023-1024
that	O	1025-1029
were	O	1030-1034
significantly	O	1035-1048
downregulated	O	1049-1062
by	O	1063-1065
activity	O	1066-1074
.	O	1074-1075

Neuronal	O	1076-1084
misexpression	O	1085-1098
of	O	1099-1101
three	O	1102-1107
miRNAs	O	1108-1114
(	O	1115-1116
miRs	B	1116-1120
-	I	1120-1121
8	I	1121-1122
,	O	1122-1123
-	B	1124-1125
289	I	1125-1128
,	O	1128-1129
and	O	1130-1133
-	B	1134-1135
958	I	1135-1138
)	O	1138-1139
suppressed	O	1140-1150
activity	O	1151-1159
-	O	1159-1160
dependent	O	1160-1169
synaptic	O	1170-1178
growth	O	1179-1185
suggesting	O	1186-1196
that	O	1197-1201
these	O	1202-1207
miRNAs	O	1208-1214
control	O	1215-1222
the	O	1223-1226
translation	O	1227-1238
of	O	1239-1241
biologically	O	1242-1254
relevant	O	1255-1263
target	O	1264-1270
mRNAs	O	1271-1276
.	O	1276-1277

Functional	O	1278-1288
annotation	O	1289-1299
cluster	O	1300-1307
analysis	O	1308-1316
revealed	O	1317-1325
that	O	1326-1330
putative	O	1331-1339
targets	O	1340-1347
of	O	1348-1350
miRs	B	1351-1355
-	I	1355-1356
8	I	1356-1357
and	O	1358-1361
-	B	1362-1363
289	I	1363-1366
are	O	1367-1370
significantly	O	1371-1384
enriched	O	1385-1393
in	O	1394-1396
clusters	O	1397-1405
involved	O	1406-1414
in	O	1415-1417
the	O	1418-1421
control	O	1422-1429
of	O	1430-1432
neuronal	O	1433-1441
processes	O	1442-1451
including	O	1452-1461
axon	O	1462-1466
development	O	1467-1478
,	O	1478-1479
pathfinding	O	1480-1491
,	O	1491-1492
and	O	1493-1496
growth	O	1497-1503
.	O	1503-1504

In	O	1505-1507
support	O	1508-1515
of	O	1516-1518
this	O	1519-1523
,	O	1523-1524
miR	B	1525-1528
-	I	1528-1529
8	I	1529-1530
regulated	O	1531-1540
the	O	1541-1544
expression	O	1545-1555
of	O	1556-1558
a	O	1559-1560
wingless	O	1561-1569
3	O	1570-1571
'	O	1571-1572
UTR	O	1572-1575
(	O	1576-1577
wg	O	1577-1579
3	O	1580-1581
'	O	1581-1582
untranslated	O	1583-1595
region	O	1596-1602
)	O	1602-1603
reporter	O	1604-1612
in	O	1613-1615
vitro	O	1616-1621
.	O	1621-1622

Wg	O	1623-1625
is	O	1626-1628
an	O	1629-1631
important	O	1632-1641
presynaptic	O	1642-1653
regulatory	O	1654-1664
protein	O	1665-1672
required	O	1673-1681
for	O	1682-1685
activity	O	1686-1694
-	O	1694-1695
dependent	O	1695-1704
axon	O	1705-1709
terminal	O	1710-1718
growth	O	1719-1725
at	O	1726-1728
the	O	1729-1732
fly	O	1733-1736
NMJ	O	1737-1740
.	O	1740-1741

In	O	1742-1744
conclusion	O	1745-1755
,	O	1755-1756
our	O	1757-1760
results	O	1761-1768
are	O	1769-1772
consistent	O	1773-1783
with	O	1784-1788
a	O	1789-1790
model	O	1791-1796
where	O	1797-1802
key	O	1803-1806
activity	O	1807-1815
-	O	1815-1816
regulated	O	1816-1825
miRNAs	O	1826-1832
are	O	1833-1836
required	O	1837-1845
to	O	1846-1848
coordinate	O	1849-1859
the	O	1860-1863
expression	O	1864-1874
of	O	1875-1877
genes	O	1878-1883
involved	O	1884-1892
in	O	1893-1895
activity	O	1896-1904
-	O	1904-1905
dependent	O	1905-1914
synaptogenesis	O	1915-1929
.	O	1929-1930

Viability	O	0-9
,	O	9-10
longevity	O	11-20
,	O	20-21
and	O	22-25
egg	O	26-29
production	O	30-40
of	O	41-43
Drosophila	O	44-54
melanogaster	O	55-67
are	O	68-71
regulated	O	72-81
by	O	82-84
the	O	85-88
miR	B	89-92
-	I	92-93
282	I	93-96
microRNA	O	97-105
.	O	105-106

The	O	107-110
first	O	111-116
microRNAs	O	117-126
were	O	127-131
discovered	O	132-142
some	O	143-147
20	O	148-150
years	O	151-156
ago	O	157-160
,	O	160-161
but	O	162-165
only	O	166-170
a	O	171-172
small	O	173-178
fraction	O	179-187
of	O	188-190
the	O	191-194
microRNA	O	195-203
-	O	203-204
encoding	O	204-212
genes	O	213-218
have	O	219-223
been	O	224-228
described	O	229-238
in	O	239-241
detail	O	242-248
yet	O	249-252
.	O	252-253

Here	O	254-258
we	O	259-261
report	O	262-268
the	O	269-272
molecular	O	273-282
analysis	O	283-291
of	O	292-294
a	O	295-296
computationally	O	297-312
predicted	O	313-322
Drosophila	O	323-333
melanogaster	O	334-346
microRNA	O	347-355
gene	O	356-360
,	O	360-361
mir	B	362-365
-	I	365-366
282	I	366-369
.	O	369-370

We	O	371-373
show	O	374-378
that	O	379-383
the	O	384-387
mir	B	388-391
-	I	391-392
282	I	392-395
gene	O	396-400
is	O	401-403
the	O	404-407
source	O	408-414
of	O	415-417
a	O	418-419
4	O	420-421
.	O	421-422
9	O	422-423
-	O	423-424
kb	O	424-426
-	O	426-427
long	O	427-431
primary	O	432-439
transcript	O	440-450
with	O	451-455
a	O	456-457
5	O	458-459
'	O	459-460
cap	O	461-464
and	O	465-468
a	O	469-470
3	O	471-472
'	O	472-473
-	O	473-474
poly	O	474-478
(	O	478-479
A	O	479-480
)	O	480-481
sequence	O	482-490
and	O	491-494
a	O	495-496
mature	O	497-503
microRNA	O	504-512
of	O	513-515
approximately	O	516-529
25	O	530-532
bp	O	533-535
.	O	535-536

Our	O	537-540
data	O	541-545
strongly	O	546-554
suggest	O	555-562
the	O	563-566
existence	O	567-576
of	O	577-579
an	O	580-582
independent	O	583-594
mir	B	595-598
-	I	598-599
282	I	599-602
gene	O	603-607
conserved	O	608-617
in	O	618-620
holometabolic	O	621-634
insects	O	635-642
.	O	642-643

We	O	644-646
give	O	647-651
evidence	O	652-660
that	O	661-665
the	O	666-669
mir	B	670-673
-	I	673-674
282	I	674-677
locus	O	678-683
encodes	O	684-691
a	O	692-693
functional	O	694-704
transcript	O	705-715
that	O	716-720
influences	O	721-731
viability	O	732-741
,	O	741-742
longevity	O	743-752
,	O	752-753
and	O	754-757
egg	O	758-761
production	O	762-772
in	O	773-775
Drosophila	O	776-786
.	O	786-787

We	O	788-790
identify	O	791-799
the	O	800-803
nervous	O	804-811
system	O	812-818
-	O	818-819
specific	O	819-827
adenylate	O	828-837
cyclase	O	838-845
(	O	846-847
rutabaga	O	847-855
)	O	855-856
as	O	857-859
a	O	860-861
target	O	862-868
of	O	869-871
miR	B	872-875
-	I	875-876
282	I	876-879
and	O	880-883
assume	O	884-890
that	O	891-895
one	O	896-899
of	O	900-902
the	O	903-906
main	O	907-911
functions	O	912-921
of	O	922-924
mir	B	925-928
-	I	928-929
282	I	929-932
is	O	933-935
the	O	936-939
regulation	O	940-950
of	O	951-953
adenylate	O	954-963
cyclase	O	964-971
activity	O	972-980
in	O	981-983
the	O	984-987
nervous	O	988-995
system	O	996-1002
during	O	1003-1009
metamorphosis	O	1010-1023
.	O	1023-1024

MicroRNAs	O	0-9
in	O	10-12
cerebral	O	13-21
ischemia	O	22-30
-	O	30-31
induced	O	31-38
neurogenesis	O	39-51
.	O	51-52

Cerebral	O	53-61
ischemia	O	62-70
induces	O	71-78
neurogenesis	O	79-91
,	O	91-92
including	O	93-102
proliferation	O	103-116
and	O	117-120
differentiation	O	121-136
of	O	137-139
neural	O	140-146
progenitor	O	147-157
cells	O	158-163
and	O	164-167
migration	O	168-177
of	O	178-180
newly	O	181-186
generated	O	187-196
neuroblasts	O	197-208
.	O	208-209

MicroRNAs	O	210-219
(	O	220-221
miRNAs	O	221-227
)	O	227-228
are	O	229-232
small	O	233-238
noncoding	O	239-248
RNAs	O	249-253
that	O	254-258
decrease	O	259-267
gene	O	268-272
expression	O	273-283
through	O	284-291
mRNA	O	292-296
destabilization	O	297-312
and	O	313-316
/	O	316-317
or	O	317-319
translational	O	320-333
repression	O	334-344
.	O	344-345

Emerging	O	346-354
data	O	355-359
indicate	O	360-368
that	O	369-373
miRNAs	O	374-380
have	O	381-385
a	O	386-387
role	O	388-392
in	O	393-395
mediating	O	396-405
processes	O	406-415
of	O	416-418
proliferation	O	419-432
and	O	433-436
differentiation	O	437-452
of	O	453-455
adult	O	456-461
neural	O	462-468
progenitor	O	469-479
cells	O	480-485
.	O	485-486

This	O	487-491
article	O	492-499
reviews	O	500-507
recent	O	508-514
findings	O	515-523
on	O	524-526
miRNA	O	527-532
profile	O	533-540
changes	O	541-548
in	O	549-551
neural	O	552-558
progenitor	O	559-569
cells	O	570-575
after	O	576-581
cerebral	O	582-590
infarction	O	591-601
and	O	602-605
the	O	606-609
contributions	O	610-623
of	O	624-626
miRNAs	O	627-633
to	O	634-636
their	O	637-642
ischemia	O	643-651
-	O	651-652
induced	O	652-659
proliferation	O	660-673
and	O	674-677
differentiation	O	678-693
.	O	693-694

We	O	695-697
highlight	O	698-707
interactions	O	708-720
between	O	721-728
the	O	729-732
miR	B	733-736
-	I	736-737
124	I	737-740
and	O	741-744
the	O	745-748
miR17	B	749-754
-	I	754-755
92	I	755-757
cluster	O	758-765
and	O	766-769
the	O	770-773
Notch	O	774-779
and	O	780-783
Sonic	O	784-789
hedgehog	O	790-798
signaling	O	799-808
pathways	O	809-817
in	O	818-820
mediating	O	821-830
stroke	O	831-837
-	O	837-838
induced	O	838-845
neurogenesis	O	846-858
.	O	858-859

Decreased	O	0-9
expression	O	10-20
of	O	21-23
microRNA	B	24-32
-	I	32-33
625	I	33-36
is	O	37-39
associated	O	40-50
with	O	51-55
tumor	O	56-61
metastasis	O	62-72
and	O	73-76
poor	O	77-81
prognosis	O	82-91
in	O	92-94
patients	O	95-103
with	O	104-108
colorectal	O	109-119
cancer	O	120-126
.	O	126-127

BACKGROUND	O	128-138
:	O	138-139
MicroRNAs	O	140-149
(	O	150-151
miRNAs	O	151-157
)	O	157-158
play	O	159-163
an	O	164-166
essential	O	167-176
role	O	177-181
in	O	182-184
colorectal	O	185-195
cancer	O	196-202
(	O	203-204
CRC	O	204-207
)	O	207-208
development	O	209-220
and	O	221-224
progression	O	225-236
.	O	236-237

Aberrant	O	238-246
miR	B	247-250
-	I	250-251
625	I	251-254
expression	O	255-265
has	O	266-269
been	O	270-274
reported	O	275-283
in	O	284-286
several	O	287-294
cancers	O	295-302
.	O	302-303

However	O	304-311
,	O	311-312
the	O	313-316
clinical	O	317-325
significance	O	326-338
of	O	339-341
miR	B	342-345
-	I	345-346
625	I	346-349
in	O	350-352
human	O	353-358
CRC	O	359-362
has	O	363-366
not	O	367-370
been	O	371-375
addressed	O	376-385
.	O	385-386

METHODS	O	387-394
:	O	394-395
miR	B	396-399
-	I	399-400
625	I	400-403
expression	O	404-414
was	O	415-418
determined	O	419-429
in	O	430-432
96	O	433-435
pairs	O	436-441
of	O	442-444
primary	O	445-452
CRC	O	453-456
and	O	457-460
their	O	461-466
corresponding	O	467-480
adjacent	O	481-489
nontumor	O	490-498
tissues	O	499-506
by	O	507-509
quantitative	O	510-522
reverse	O	523-530
transcriptase	O	531-544
-	O	544-545
polymerase	O	545-555
chain	O	556-561
reaction	O	562-570
.	O	570-571

Associations	O	572-584
of	O	585-587
miR	B	588-591
-	I	591-592
625	I	592-595
expression	O	596-606
with	O	607-611
demographic	O	612-623
and	O	624-627
clinicopathologic	O	628-645
features	O	646-654
were	O	655-659
determined	O	660-670
.	O	670-671

Additionally	O	672-684
,	O	684-685
the	O	686-689
effects	O	690-697
of	O	698-700
ectopic	O	701-708
expression	O	709-719
of	O	720-722
miR	B	723-726
-	I	726-727
625	I	727-730
on	O	731-733
cell	O	734-738
migration	O	739-748
and	O	749-752
invasion	O	753-761
were	O	762-766
investigated	O	767-779
in	O	780-782
vitro	O	783-788
and	O	789-792
in	O	793-795
vivo	O	796-800
.	O	800-801

RESULTS	O	802-809
:	O	809-810
miR	B	811-814
-	I	814-815
625	I	815-818
was	O	819-822
significantly	O	823-836
downregulated	O	837-850
in	O	851-853
CRC	O	854-857
tissues	O	858-865
and	O	866-869
cell	O	870-874
lines	O	875-880
.	O	880-881

In	O	882-884
addition	O	885-893
,	O	893-894
the	O	895-898
decreased	O	899-908
expression	O	909-919
of	O	920-922
miR	B	923-926
-	I	926-927
625	I	927-930
was	O	931-934
positively	O	935-945
associated	O	946-956
with	O	957-961
advanced	O	962-970
lymph	O	971-976
node	O	977-981
metastasis	O	982-992
(	O	993-994
P	O	994-995
=	O	996-997
0	O	998-999
.	O	999-1000
038	O	1000-1003
)	O	1003-1004
,	O	1004-1005
liver	O	1006-1011
metastasis	O	1012-1022
(	O	1023-1024
P	O	1024-1025
=	O	1026-1027
0	O	1028-1029
.	O	1029-1030
031	O	1030-1033
)	O	1033-1034
,	O	1034-1035
poor	O	1036-1040
overall	O	1041-1048
survival	O	1049-1057
(	O	1058-1059
P	O	1059-1060
=	O	1061-1062
0	O	1063-1064
.	O	1064-1065
002	O	1065-1068
)	O	1068-1069
,	O	1069-1070
and	O	1071-1074
an	O	1075-1077
unfavorable	O	1078-1089
prognosis	O	1090-1099
for	O	1100-1103
CRC	O	1104-1107
patients	O	1108-1116
,	O	1116-1117
as	O	1118-1120
determined	O	1121-1131
through	O	1132-1139
a	O	1140-1141
multivariate	O	1142-1154
analysis	O	1155-1163
(	O	1164-1165
P	O	1165-1166
=	O	1167-1168
0	O	1169-1170
.	O	1170-1171
034	O	1171-1174
)	O	1174-1175
.	O	1175-1176

Moreover	O	1177-1185
,	O	1185-1186
functional	O	1187-1197
assays	O	1198-1204
demonstrated	O	1205-1217
that	O	1218-1222
ectopic	O	1223-1230
miR	B	1231-1234
-	I	1234-1235
625	I	1235-1238
expression	O	1239-1249
inhibits	O	1250-1258
the	O	1259-1262
invasion	O	1263-1271
and	O	1272-1275
migration	O	1276-1285
of	O	1286-1288
HCT116	O	1289-1295
CRC	O	1296-1299
cells	O	1300-1305
both	O	1306-1310
in	O	1311-1313
vitro	O	1314-1319
and	O	1320-1323
in	O	1324-1326
vivo	O	1327-1331
.	O	1331-1332

CONCLUSIONS	O	1333-1344
:	O	1344-1345
Our	O	1346-1349
results	O	1350-1357
suggest	O	1358-1365
that	O	1366-1370
miR	B	1371-1374
-	I	1374-1375
625	I	1375-1378
may	O	1379-1382
serve	O	1383-1388
as	O	1389-1391
an	O	1392-1394
efficient	O	1395-1404
clinical	O	1405-1413
biomarker	O	1414-1423
and	O	1424-1427
a	O	1428-1429
therapeutic	O	1430-1441
tool	O	1442-1446
for	O	1447-1450
the	O	1451-1454
inhibition	O	1455-1465
of	O	1466-1468
metastasis	O	1469-1479
in	O	1480-1482
CRC	O	1483-1486
.	O	1486-1487

miR	B	0-3
-	I	3-4
26a	I	4-7
and	O	8-11
its	O	12-15
target	O	16-22
CKS2	O	23-27
modulate	O	28-36
cell	O	37-41
growth	O	42-48
and	O	49-52
tumorigenesis	O	53-66
of	O	67-69
papillary	O	70-79
thyroid	O	80-87
carcinoma	O	88-97
.	O	97-98

BACKGROUND	O	99-109
:	O	109-110
While	O	111-116
many	O	117-121
studies	O	122-129
have	O	130-134
shown	O	135-140
that	O	141-145
levels	O	146-152
of	O	153-155
miR	B	156-159
-	I	159-160
26a	I	160-163
are	O	164-167
lower	O	168-173
in	O	174-176
papillary	O	177-186
thyroid	O	187-194
carcinoma	O	195-204
(	O	205-206
PTC	O	206-209
)	O	209-210
,	O	210-211
the	O	212-215
role	O	216-220
and	O	221-224
mechanism	O	225-234
of	O	235-237
miR	B	238-241
-	I	241-242
26a	I	242-245
in	O	246-248
PTC	O	249-252
are	O	253-256
unclear	O	257-264
.	O	264-265

METHOD	O	266-272
:	O	272-273
We	O	274-276
used	O	277-281
database	O	282-290
searches	O	291-299
to	O	300-302
select	O	303-309
potential	O	310-319
mRNA	O	320-324
targets	O	325-332
of	O	333-335
miR	B	336-339
-	I	339-340
26a	I	340-343
.	O	343-344

Anti	O	345-349
-	O	349-350
miR	B	350-353
-	I	353-354
26a	I	354-357
,	O	357-358
miR	B	359-362
-	I	362-363
26a	I	363-366
mimic	O	367-372
,	O	372-373
siRNA	O	374-379
for	O	380-383
CKS2	O	384-388
and	O	389-392
their	O	393-398
effects	O	399-406
on	O	407-409
cell	O	410-414
growth	O	415-421
,	O	421-422
cell	O	423-427
-	O	427-428
cycle	O	428-433
distribution	O	434-446
and	O	447-450
colony	O	451-457
formation	O	458-467
were	O	468-472
evaluated	O	473-482
.	O	482-483

We	O	484-486
also	O	487-491
evaluate	O	492-500
the	O	501-504
over	O	505-509
-	O	509-510
expressed	O	510-519
miR	B	520-523
-	I	523-524
26a	I	524-527
in	O	528-530
TPC	O	531-534
-	O	534-535
1	O	535-536
cells	O	537-542
in	O	543-545
severe	O	546-552
combined	O	553-561
immune	O	562-568
-	O	568-569
deficient	O	569-578
mice	O	579-583
.	O	583-584

We	O	585-587
used	O	588-592
luciferase	O	593-603
reporter	O	604-612
assays	O	613-619
,	O	619-620
real	O	621-625
-	O	625-626
time	O	626-630
PCR	O	631-634
and	O	635-638
western	O	639-646
blot	O	647-651
analysis	O	652-660
to	O	661-663
measure	O	664-671
the	O	672-675
expression	O	676-686
and	O	687-690
activity	O	691-699
of	O	700-702
miR	B	703-706
-	I	706-707
26a	I	707-710
,	O	710-711
CKS2	O	712-716
,	O	716-717
and	O	718-721
related	O	722-729
factors	O	730-737
such	O	738-742
as	O	743-745
cyclin	O	746-752
B1	O	753-755
,	O	755-756
cyclin	O	757-763
A	O	764-765
,	O	765-766
cdk1	O	767-771
,	O	771-772
bcl	O	773-776
-	O	776-777
xl	O	777-779
and	O	780-783
Akt	O	784-787
.	O	787-788

Finally	O	789-796
,	O	796-797
we	O	798-800
measured	O	801-809
the	O	810-813
relationship	O	814-826
between	O	827-834
the	O	835-838
levels	O	839-845
of	O	846-848
miR	B	849-852
-	I	852-853
26a	I	853-856
and	O	857-860
CKS2	O	861-865
in	O	866-868
PTC	O	869-872
and	O	873-876
normal	O	877-883
thyroid	O	884-891
tissues	O	892-899
.	O	899-900

RESULTS	O	901-908
:	O	908-909
Relative	O	910-918
to	O	919-921
normal	O	922-928
thyroid	O	929-936
tissues	O	937-944
,	O	944-945
miR	B	946-949
-	I	949-950
26a	I	950-953
is	O	954-956
consistently	O	957-969
down	O	970-974
-	O	974-975
regulated	O	975-984
in	O	985-987
TPC	O	988-991
specimens	O	992-1001
,	O	1001-1002
and	O	1003-1006
CKS2	O	1007-1011
was	O	1012-1015
identified	O	1016-1026
as	O	1027-1029
a	O	1030-1031
potential	O	1032-1041
target	O	1042-1048
.	O	1048-1049

Up	O	1050-1052
-	O	1052-1053
regulated	O	1053-1062
miR	B	1063-1066
-	I	1066-1067
26a	I	1067-1070
expression	O	1071-1081
or	O	1082-1084
down	O	1085-1089
-	O	1089-1090
regulated	O	1090-1099
CKS2	O	1100-1104
expression	O	1105-1115
in	O	1116-1118
TPC	O	1119-1122
-	O	1122-1123
1	O	1123-1124
and	O	1125-1128
CGTH	O	1129-1133
W3	O	1134-1136
cells	O	1137-1142
lines	O	1143-1148
caused	O	1149-1155
G2	O	1156-1158
phase	O	1159-1164
-	O	1164-1165
arrest	O	1165-1171
.	O	1171-1172

Decreased	O	1173-1182
miR	B	1183-1186
-	I	1186-1187
26a	I	1187-1190
expression	O	1191-1201
or	O	1202-1204
increased	O	1205-1214
CKS2	O	1215-1219
expression	O	1220-1230
could	O	1231-1236
have	O	1237-1241
inverse	O	1242-1249
function	O	1250-1258
on	O	1259-1261
PTC	O	1262-1265
cell	O	1266-1270
lines	O	1271-1276
.	O	1276-1277

CyclinB1	O	1278-1286
,	O	1286-1287
cyclinA	O	1288-1295
,	O	1295-1296
bcl	O	1297-1300
-	O	1300-1301
xl	O	1301-1303
and	O	1304-1307
AKt	O	1308-1311
are	O	1312-1315
indirectly	O	1316-1326
regulated	O	1327-1336
by	O	1337-1339
miR	B	1340-1343
-	I	1343-1344
26a	I	1344-1347
in	O	1348-1350
a	O	1351-1352
CKS2	O	1353-1357
-	O	1357-1358
dependent	O	1358-1367
manner	O	1368-1374
.	O	1374-1375

Finally	O	1376-1383
,	O	1383-1384
CKS2	O	1385-1389
is	O	1390-1392
overexpressed	O	1393-1406
in	O	1407-1409
PTC	O	1410-1413
specimens	O	1414-1423
relative	O	1424-1432
to	O	1433-1435
normal	O	1436-1442
thyroid	O	1443-1450
tissue	O	1451-1457
,	O	1457-1458
and	O	1459-1462
a	O	1463-1464
significant	O	1465-1476
inverse	O	1477-1484
correlation	O	1485-1496
exists	O	1497-1503
between	O	1504-1511
miR	B	1512-1515
-	I	1515-1516
26a	I	1516-1519
and	O	1520-1523
CKS2	O	1524-1528
expression	O	1529-1539
in	O	1540-1542
clinical	O	1543-1551
PTC	O	1552-1555
specimens	O	1556-1565
.	O	1565-1566

CONCLUSION	O	1567-1577
:	O	1577-1578
Our	O	1579-1582
data	O	1583-1587
indicate	O	1588-1596
that	O	1597-1601
miR	B	1602-1605
-	I	1605-1606
26a	I	1606-1609
functions	O	1610-1619
as	O	1620-1622
a	O	1623-1624
growth	O	1625-1631
-	O	1631-1632
suppressive	O	1632-1643
miRNA	O	1644-1649
in	O	1650-1652
PTC	O	1653-1656
,	O	1656-1657
and	O	1658-1661
that	O	1662-1666
its	O	1667-1670
suppressive	O	1671-1682
effects	O	1683-1690
are	O	1691-1694
mediated	O	1695-1703
mainly	O	1704-1710
by	O	1711-1713
repressing	O	1714-1724
CKS2	O	1725-1729
expression	O	1730-1740
.	O	1740-1741

MicroRNA	B	0-8
-	I	8-9
24	I	9-11
suppression	O	12-23
of	O	24-26
N	O	27-28
-	O	28-29
deacetylase	O	29-40
/	O	40-41
N	O	41-42
-	O	42-43
sulfotransferase	O	43-59
-	O	59-60
1	O	60-61
(	O	62-63
NDST1	O	63-68
)	O	68-69
reduces	O	70-77
endothelial	O	78-89
cell	O	90-94
responsiveness	O	95-109
to	O	110-112
vascular	O	113-121
endothelial	O	122-133
growth	O	134-140
factor	O	141-147
A	O	148-149
(	O	150-151
VEGFA	O	151-156
)	O	156-157
.	O	157-158

Heparan	O	159-166
sulfate	O	167-174
(	O	175-176
HS	O	176-178
)	O	178-179
proteoglycans	O	180-193
,	O	193-194
present	O	195-202
at	O	203-205
the	O	206-209
plasma	O	210-216
membrane	O	217-225
of	O	226-228
vascular	O	229-237
endothelial	O	238-249
cells	O	250-255
,	O	255-256
bind	O	257-261
to	O	262-264
the	O	265-268
angiogenic	O	269-279
growth	O	280-286
factor	O	287-293
VEGFA	O	294-299
to	O	300-302
modulate	O	303-311
its	O	312-315
signaling	O	316-325
through	O	326-333
VEGFR2	O	334-340
.	O	340-341

The	O	342-345
interactions	O	346-358
between	O	359-366
VEGFA	O	367-372
and	O	373-376
proteoglycan	O	377-389
co	O	390-392
-	O	392-393
receptors	O	393-402
require	O	403-410
sulfated	O	411-419
domains	O	420-427
in	O	428-430
the	O	431-434
HS	O	435-437
chains	O	438-444
.	O	444-445

To	O	446-448
date	O	449-453
,	O	453-454
it	O	455-457
is	O	458-460
essentially	O	461-472
unknown	O	473-480
how	O	481-484
the	O	485-488
formation	O	489-498
of	O	499-501
sulfated	O	502-510
protein	O	511-518
-	O	518-519
binding	O	519-526
domains	O	527-534
in	O	535-537
HS	O	538-540
can	O	541-544
be	O	545-547
regulated	O	548-557
by	O	558-560
microRNAs	O	561-570
.	O	570-571

In	O	572-574
the	O	575-578
present	O	579-586
study	O	587-592
,	O	592-593
we	O	594-596
show	O	597-601
that	O	602-606
microRNA	B	607-615
-	I	615-616
24	I	616-618
(	O	619-620
miR	B	620-623
-	I	623-624
24	I	624-626
)	O	626-627
targets	O	628-635
NDST1	O	636-641
to	O	642-644
reduce	O	645-651
HS	O	652-654
sulfation	O	655-664
and	O	665-668
thereby	O	669-676
the	O	677-680
binding	O	681-688
affinity	O	689-697
of	O	698-700
HS	O	701-703
for	O	704-707
VEGFA	O	708-713
.	O	713-714

Elevated	O	715-723
levels	O	724-730
of	O	731-733
miR	B	734-737
-	I	737-738
24	I	738-740
also	O	741-745
resulted	O	746-754
in	O	755-757
reduced	O	758-765
levels	O	766-772
of	O	773-775
VEGFR2	O	776-782
and	O	783-786
blunted	O	787-794
VEGFA	O	795-800
signaling	O	801-810
.	O	810-811

Similarly	O	812-821
,	O	821-822
suppression	O	823-834
of	O	835-837
NDST1	O	838-843
using	O	844-849
siRNA	O	850-855
led	O	856-859
to	O	860-862
a	O	863-864
reduction	O	865-874
in	O	875-877
VEGFR2	O	878-884
expression	O	885-895
.	O	895-896

Consequently	O	897-909
,	O	909-910
not	O	911-914
only	O	915-919
VEGFA	O	920-925
binding	O	926-933
,	O	933-934
but	O	935-938
also	O	939-943
VEGFR2	O	944-950
protein	O	951-958
expression	O	959-969
is	O	970-972
dependent	O	973-982
on	O	983-985
NDST1	O	986-991
function	O	992-1000
.	O	1000-1001

Furthermore	O	1002-1013
,	O	1013-1014
overexpression	O	1015-1029
of	O	1030-1032
miR	B	1033-1036
-	I	1036-1037
24	I	1037-1039
,	O	1039-1040
or	O	1041-1043
siRNA	O	1044-1049
-	O	1049-1050
mediated	O	1050-1058
reduction	O	1059-1068
of	O	1069-1071
NDST1	O	1072-1077
,	O	1077-1078
reduced	O	1079-1086
endothelial	O	1087-1098
cell	O	1099-1103
chemotaxis	O	1104-1114
in	O	1115-1117
response	O	1118-1126
to	O	1127-1129
VEGFA	O	1130-1135
.	O	1135-1136

These	O	1137-1142
findings	O	1143-1151
establish	O	1152-1161
NDST1	O	1162-1167
as	O	1168-1170
a	O	1171-1172
target	O	1173-1179
of	O	1180-1182
miR	B	1183-1186
-	I	1186-1187
24	I	1187-1189
and	O	1190-1193
demonstrate	O	1194-1205
how	O	1206-1209
such	O	1210-1214
NDST1	O	1215-1220
suppression	O	1221-1232
in	O	1233-1235
endothelial	O	1236-1247
cells	O	1248-1253
results	O	1254-1261
in	O	1262-1264
reduced	O	1265-1272
responsiveness	O	1273-1287
to	O	1288-1290
VEGFA	O	1291-1296
.	O	1296-1297

Identification	O	0-14
of	O	15-17
four	O	18-22
serum	O	23-28
microRNAs	O	29-38
from	O	39-43
a	O	44-45
genome	O	46-52
-	O	52-53
wide	O	53-57
serum	O	58-63
microRNA	O	64-72
expression	O	73-83
profile	O	84-91
as	O	92-94
potential	O	95-104
non	O	105-108
-	O	108-109
invasive	O	109-117
biomarkers	O	118-128
for	O	129-132
endometrioid	O	133-145
endometrial	O	146-157
cancer	O	158-164
.	O	164-165

Serum	O	166-171
microRNAs	O	172-181
(	O	182-183
miRNAs	O	183-189
)	O	189-190
,	O	190-191
with	O	192-196
their	O	197-202
remarkable	O	203-213
stability	O	214-223
and	O	224-227
unique	O	228-234
concentration	O	235-248
profiles	O	249-257
in	O	258-260
patients	O	261-269
with	O	270-274
various	O	275-282
diseases	O	283-291
,	O	291-292
are	O	293-296
promising	O	297-306
non	O	307-310
-	O	310-311
invasive	O	311-319
biomarkers	O	320-330
for	O	331-334
tumor	O	335-340
detection	O	341-350
.	O	350-351

The	O	352-355
present	O	356-363
study	O	364-369
investigated	O	370-382
the	O	383-386
altered	O	387-394
profiles	O	395-403
of	O	404-406
serum	O	407-412
microRNAs	O	413-422
in	O	423-425
patients	O	426-434
with	O	435-439
endometrioid	O	440-452
endometrial	O	453-464
cancer	O	465-471
(	O	472-473
EEC	O	473-476
)	O	476-477
in	O	478-480
order	O	481-486
to	O	487-489
predict	O	490-497
the	O	498-501
malignancy	O	502-512
of	O	513-515
the	O	516-519
disease	O	520-527
at	O	528-530
a	O	531-532
relatively	O	533-543
early	O	544-549
stage	O	550-555
.	O	555-556

TaqMan	O	557-563
(	O	563-564
R	O	564-565
)	O	565-566
low	O	567-570
-	O	570-571
density	O	571-578
arrays	O	579-585
(	O	586-587
TDLAs	O	587-592
)	O	592-593
were	O	594-598
used	O	599-603
to	O	604-606
perform	O	607-614
an	O	615-617
analysis	O	618-626
in	O	627-629
the	O	630-633
initial	O	634-641
screening	O	642-651
phase	O	652-657
using	O	658-663
serum	O	664-669
samples	O	670-677
pooled	O	678-684
from	O	685-689
seven	O	690-695
EEC	O	696-699
patients	O	700-708
and	O	709-712
20	O	713-715
controls	O	716-724
.	O	724-725

The	O	726-729
differential	O	730-742
expression	O	743-753
was	O	754-757
validated	O	758-767
using	O	768-773
a	O	774-775
hydrolysis	O	776-786
probe	O	787-792
-	O	792-793
based	O	793-798
stem	O	799-803
-	O	803-804
loop	O	804-808
quantitative	O	809-821
reverse	O	822-829
transcription	O	830-843
polymerase	O	844-854
chain	O	855-860
reaction	O	861-869
(	O	870-871
qRT	O	871-874
-	O	874-875
PCR	O	875-878
)	O	878-879
in	O	880-882
samples	O	883-890
taken	O	891-896
from	O	897-901
26	O	902-904
EEC	O	905-908
patients	O	909-917
and	O	918-921
22	O	922-924
age	O	925-928
-	O	928-929
and	O	930-933
gender	O	934-940
-	O	940-941
matched	O	941-948
healthy	O	949-956
controls	O	957-965
.	O	965-966

The	O	967-970
data	O	971-975
obtained	O	976-984
from	O	985-989
the	O	990-993
TLDAs	O	994-999
demonstrated	O	1000-1012
that	O	1013-1017
22	O	1018-1020
serum	O	1021-1026
miRNAs	O	1027-1033
were	O	1034-1038
markedly	O	1039-1047
upregulated	O	1048-1059
in	O	1060-1062
the	O	1063-1066
EEC	O	1067-1070
patients	O	1071-1079
compared	O	1080-1088
with	O	1089-1093
the	O	1094-1097
controls	O	1098-1106
.	O	1106-1107

The	O	1108-1111
qRT	O	1112-1115
-	O	1115-1116
PCR	O	1116-1119
analysis	O	1120-1128
further	O	1129-1136
identified	O	1137-1147
a	O	1148-1149
profile	O	1150-1157
of	O	1158-1160
four	O	1161-1165
serum	O	1166-1171
miRNAs	O	1172-1178
(	O	1179-1180
miR	B	1180-1183
-	I	1183-1184
222	I	1184-1187
,	O	1187-1188
miR	B	1189-1192
-	I	1192-1193
223	I	1193-1196
,	O	1196-1197
miR	B	1198-1201
-	I	1201-1202
186	I	1202-1205
and	O	1206-1209
miR	B	1210-1213
-	I	1213-1214
204	I	1214-1217
)	O	1217-1218
as	O	1219-1221
a	O	1222-1223
fingerprint	O	1224-1235
for	O	1236-1239
EEC	O	1240-1243
detection	O	1244-1253
.	O	1253-1254

The	O	1255-1258
area	O	1259-1263
under	O	1264-1269
the	O	1270-1273
receiver	O	1274-1282
operating	O	1283-1292
characteristic	O	1293-1307
(	O	1308-1309
ROC	O	1309-1312
)	O	1312-1313
curve	O	1314-1319
of	O	1320-1322
this	O	1323-1327
four	O	1328-1332
-	O	1332-1333
serum	O	1333-1338
miRNA	O	1339-1344
signature	O	1345-1354
was	O	1355-1358
0	O	1359-1360
.	O	1360-1361
927	O	1361-1364
,	O	1364-1365
which	O	1366-1371
was	O	1372-1375
markedly	O	1376-1384
higher	O	1385-1391
than	O	1392-1396
that	O	1397-1401
of	O	1402-1404
carbohydrate	O	1405-1417
antigen	O	1418-1425
125	O	1426-1429
(	O	1430-1431
CA	O	1431-1433
-	O	1433-1434
125	O	1434-1437
;	O	1437-1438
0	O	1439-1440
.	O	1440-1441
673	O	1441-1444
)	O	1444-1445
.	O	1445-1446

The	O	1447-1450
four	O	1451-1455
-	O	1455-1456
miRNA	O	1456-1461
signature	O	1462-1471
identified	O	1472-1482
by	O	1483-1485
genome	O	1486-1492
-	O	1492-1493
wide	O	1493-1497
serum	O	1498-1503
miRNA	O	1504-1509
expression	O	1510-1520
profiling	O	1521-1530
analysis	O	1531-1539
provides	O	1540-1548
a	O	1549-1550
novel	O	1551-1556
,	O	1556-1557
non	O	1558-1561
-	O	1561-1562
invasive	O	1562-1570
approach	O	1571-1579
for	O	1580-1583
EEC	O	1584-1587
diagnosis	O	1588-1597
.	O	1597-1598

[	O	0-1
Screening	O	1-10
of	O	11-13
specific	O	14-22
microRNA	O	23-31
in	O	32-34
hippocampus	O	35-46
of	O	47-49
depression	O	50-60
model	O	61-66
rats	O	67-71
and	O	72-75
intervention	O	76-88
effect	O	89-95
of	O	96-98
Chaihu	O	99-105
Shugan	O	106-112
San	O	113-116
]	O	116-117
.	O	117-118

OBJECTIVE	O	119-128
:	O	128-129
To	O	130-132
screen	O	133-139
microRNAs	O	140-149
with	O	150-154
specific	O	155-163
expression	O	164-174
of	O	175-177
in	O	178-180
hippocampus	O	181-192
of	O	193-195
rats	O	196-200
with	O	201-205
chronic	O	206-213
stress	O	214-220
induced	O	221-228
depression	O	229-239
model	O	240-245
,	O	245-246
and	O	247-250
observe	O	251-258
the	O	259-262
effect	O	263-269
of	O	270-272
traditional	O	273-284
Chinese	O	285-292
medicine	O	293-301
Chaihu	O	302-308
Shugan	O	309-315
San	O	316-319
on	O	320-322
the	O	323-326
expression	O	327-337
of	O	338-340
microRNA	O	341-349
in	O	350-352
hippocampus	O	353-364
.	O	364-365

METHOD	O	366-372
:	O	372-373
SD	O	374-376
rats	O	377-381
were	O	382-386
randomly	O	387-395
divided	O	396-403
into	O	404-408
3	O	409-410
groups	O	411-417
:	O	417-418
the	O	419-422
normal	O	423-429
control	O	430-437
group	O	438-443
,	O	443-444
the	O	445-448
model	O	449-454
control	O	455-462
group	O	463-468
and	O	469-472
the	O	473-476
Chaihu	O	477-483
Shugan	O	484-490
San	O	491-494
group	O	495-500
.	O	500-501

The	O	502-505
depression	O	506-516
model	O	517-522
was	O	523-526
replicated	O	527-537
by	O	538-540
unpredictable	O	541-554
chronic	O	555-562
mild	O	563-567
stress	O	568-574
combined	O	575-583
with	O	584-588
separation	O	589-599
.	O	599-600

Behavioral	O	601-611
changes	O	612-619
of	O	620-622
the	O	623-626
rats	O	627-631
were	O	632-636
observed	O	637-645
by	O	646-648
Open	O	649-653
-	O	653-654
field	O	654-659
test	O	660-664
and	O	665-668
sucrose	O	669-676
solution	O	677-685
consumption	O	686-697
test	O	698-702
,	O	702-703
and	O	704-707
the	O	708-711
expression	O	712-722
of	O	723-725
microRNAs	O	726-735
in	O	736-738
hippocampus	O	739-750
was	O	751-754
assayed	O	755-762
by	O	763-765
microRNA	O	766-774
micro	O	775-780
-	O	780-781
array	O	781-786
.	O	786-787

RESULT	O	788-794
:	O	794-795
Compared	O	796-804
with	O	805-809
the	O	810-813
normal	O	814-820
control	O	821-828
group	O	829-834
,	O	834-835
there	O	836-841
were	O	842-846
13	O	847-849
specific	O	850-858
miRNAs	O	859-865
in	O	866-868
hippocampus	O	869-880
in	O	881-883
the	O	884-887
model	O	888-893
control	O	894-901
group	O	902-907
with	O	908-912
the	O	913-916
expression	O	917-927
difference	O	928-938
of	O	939-941
more	O	942-946
than	O	947-951
2	O	952-953
times	O	954-959
.	O	959-960

Among	O	961-966
them	O	967-971
,	O	971-972
down	O	973-977
-	O	977-978
regulating	O	978-988
miRNAs	O	989-995
included	O	996-1004
miR298	O	1005-1011
,	O	1011-1012
miR	B	1013-1016
-	I	1016-1017
130b	I	1017-1021
,	O	1021-1022
miR	B	1023-1026
-	I	1026-1027
135a	I	1027-1031
,	O	1031-1032
miR	B	1033-1036
-	I	1036-1037
323	I	1037-1040
,	O	1040-1041
miR	B	1042-1045
-	I	1045-1046
503	I	1046-1049
,	O	1049-1050
miR	B	1051-1054
-	I	1054-1055
15b	I	1055-1058
,	O	1058-1059
miR	B	1060-1063
-	I	1063-1064
532	I	1064-1067
,	O	1067-1068
and	O	1069-1072
miR	B	1073-1076
-	I	1076-1077
125a	I	1077-1081
,	O	1081-1082
and	O	1083-1086
the	O	1087-1090
up	O	1091-1093
-	O	1093-1094
regulation	O	1094-1104
miRNAs	O	1105-1111
included	O	1112-1120
miR7a	B	1121-1126
,	O	1126-1127
miR	B	1128-1131
-	I	1131-1132
212	I	1132-1135
,	O	1135-1136
miR	B	1137-1140
-	I	1140-1141
124	I	1141-1144
,	O	1144-1145
miR	B	1146-1149
-	I	1149-1150
139	I	1150-1153
,	O	1153-1154
and	O	1155-1158
miR	B	1159-1162
-	I	1162-1163
182	I	1163-1166
.	O	1166-1167

Among	O	1168-1173
the	O	1174-1177
13	O	1178-1180
specific	O	1181-1189
miRNAs	O	1190-1196
,	O	1196-1197
miR	B	1198-1201
-	I	1201-1202
125a	I	1202-1206
and	O	1207-1210
miR	B	1211-1214
-	I	1214-1215
182	I	1215-1218
recovered	O	1219-1228
to	O	1229-1231
normal	O	1232-1238
after	O	1239-1244
intervention	O	1245-1257
with	O	1258-1262
Chaihu	O	1263-1269
Shugan	O	1270-1276
San	O	1277-1280
in	O	1281-1283
the	O	1284-1287
Chaihu	O	1288-1294
Shugan	O	1295-1301
San	O	1302-1305
group	O	1306-1311
.	O	1311-1312

CONCLUSION	O	1313-1323
:	O	1323-1324
This	O	1325-1329
study	O	1330-1335
preliminarily	O	1336-1349
found	O	1350-1355
that	O	1356-1360
13	O	1361-1363
specific	O	1364-1372
miRNAs	O	1373-1379
in	O	1380-1382
hippocampus	O	1383-1394
are	O	1395-1398
related	O	1399-1406
to	O	1407-1409
depression	O	1410-1420
.	O	1420-1421

Among	O	1422-1427
them	O	1428-1432
,	O	1432-1433
miR	B	1434-1437
-	I	1437-1438
125a	I	1438-1442
and	O	1443-1446
miR	B	1447-1450
-	I	1450-1451
182	I	1451-1454
recover	O	1455-1462
to	O	1463-1465
normal	O	1466-1472
after	O	1473-1478
intervention	O	1479-1491
with	O	1492-1496
Chaihu	O	1497-1503
Shugan	O	1504-1510
San	O	1511-1514
,	O	1514-1515
which	O	1516-1521
may	O	1522-1525
be	O	1526-1528
the	O	1529-1532
target	O	1533-1539
points	O	1540-1546
of	O	1547-1549
the	O	1550-1553
antidepressant	O	1554-1568
effect	O	1569-1575
of	O	1576-1578
Chaihu	O	1579-1585
Shugan	O	1586-1592
San	O	1593-1596
.	O	1596-1597

We	O	1598-1600
shall	O	1601-1606
further	O	1607-1614
analyze	O	1615-1622
the	O	1623-1626
target	O	1627-1633
genes	O	1634-1639
and	O	1640-1643
their	O	1644-1649
mechanisms	O	1650-1660
.	O	1660-1661

MicroRNA	B	0-8
-	I	8-9
106b	I	9-13
induces	O	14-21
mitochondrial	O	22-35
dysfunction	O	36-47
and	O	48-51
insulin	O	52-59
resistance	O	60-70
in	O	71-73
C2C12	O	74-79
myotubes	O	80-88
by	O	89-91
targeting	O	92-101
mitofusin	O	102-111
-	O	111-112
2	O	112-113
.	O	113-114

MicroRNA	B	115-123
-	I	123-124
106b	I	124-128
(	O	129-130
miR	B	130-133
-	I	133-134
106b	I	134-138
)	O	138-139
is	O	140-142
reported	O	143-151
to	O	152-154
correlate	O	155-164
closely	O	165-172
with	O	173-177
skeletal	O	178-186
muscle	O	187-193
insulin	O	194-201
resistance	O	202-212
and	O	213-216
type	O	217-221
2	O	222-223
diabetes	O	224-232
.	O	232-233

The	O	234-237
aim	O	238-241
of	O	242-244
this	O	245-249
study	O	250-255
was	O	256-259
to	O	260-262
identify	O	263-271
an	O	272-274
mRNA	O	275-279
targeted	O	280-288
by	O	289-291
miR	B	292-295
-	I	295-296
106b	I	296-300
which	O	301-306
regulates	O	307-316
skeletal	O	317-325
muscle	O	326-332
insulin	O	333-340
sensitivity	O	341-352
.	O	352-353

MiR	B	354-357
-	I	357-358
106b	I	358-362
was	O	363-366
found	O	367-372
to	O	373-375
target	O	376-382
the	O	383-386
3	O	387-388
'	O	388-389
untranslated	O	390-402
region	O	403-409
(	O	410-411
3	O	411-412
'	O	412-413
UTR	O	414-417
)	O	417-418
of	O	419-421
mitofusin	O	422-431
-	O	431-432
2	O	432-433
(	O	434-435
Mfn2	O	435-439
)	O	439-440
through	O	441-448
miR	B	449-452
-	I	452-453
106b	I	453-457
binding	O	458-465
sites	O	466-471
and	O	472-475
to	O	476-478
downregulate	O	479-491
Mfn2	O	492-496
protein	O	497-504
abundance	O	505-514
at	O	515-517
the	O	518-521
post	O	522-526
-	O	526-527
transcriptional	O	527-542
level	O	543-548
by	O	549-551
luciferase	O	552-562
activity	O	563-571
assay	O	572-577
combined	O	578-586
with	O	587-591
mutational	O	592-602
analysis	O	603-611
and	O	612-615
immunoblotting	O	616-630
.	O	630-631

Overexpression	O	632-646
of	O	647-649
miR	B	650-653
-	I	653-654
106b	I	654-658
resulted	O	659-667
in	O	668-670
mitochondrial	O	671-684
dysfunction	O	685-696
and	O	697-700
insulin	O	701-708
resistance	O	709-719
in	O	720-722
C2C12	O	723-728
myotubes	O	729-737
.	O	737-738

MiR	B	739-742
-	I	742-743
106b	I	743-747
was	O	748-751
increased	O	752-761
in	O	762-764
insulin	O	765-772
-	O	772-773
resistant	O	773-782
cultured	O	783-791
C2C12	O	792-797
myotubes	O	798-806
induced	O	807-814
by	O	815-817
TNF	O	818-821
-	O	821-822
alpha	O	822-827
,	O	827-828
and	O	829-832
accompanied	O	833-844
by	O	845-847
increasing	O	848-858
Mfn2	O	859-863
level	O	864-869
,	O	869-870
miR	B	871-874
-	I	874-875
106b	I	875-879
loss	O	880-884
of	O	885-887
function	O	888-896
improved	O	897-905
mitochondrial	O	906-919
function	O	920-928
and	O	929-932
insulin	O	933-940
sensitivity	O	941-952
impaired	O	953-961
by	O	962-964
TNF	O	965-968
-	O	968-969
alpha	O	969-974
in	O	975-977
C2C12	O	978-983
myotubes	O	984-992
.	O	992-993

In	O	994-996
addition	O	997-1005
,	O	1005-1006
both	O	1007-1011
overexpression	O	1012-1026
and	O	1027-1030
downregulation	O	1031-1045
of	O	1046-1048
miR	B	1049-1052
-	I	1052-1053
106b	I	1053-1057
upregulated	O	1058-1069
peroxisome	O	1070-1080
proliferator	O	1081-1093
-	O	1093-1094
activated	O	1094-1103
receptor	O	1104-1112
gamma	O	1113-1118
coactivator	O	1119-1130
(	O	1131-1132
PGC	O	1132-1135
)	O	1135-1136
-	O	1136-1137
1alpha	O	1137-1143
and	O	1144-1147
estrogen	O	1148-1156
-	O	1156-1157
related	O	1157-1164
receptor	O	1165-1173
(	O	1174-1175
ERR	O	1175-1178
)	O	1178-1179
-	O	1179-1180
alpha	O	1180-1185
expression	O	1186-1196
.	O	1196-1197

MiR	B	1198-1201
-	I	1201-1202
106b	I	1202-1206
targeted	O	1207-1215
Mfn2	O	1216-1220
and	O	1221-1224
regulated	O	1225-1234
skeletal	O	1235-1243
muscle	O	1244-1250
mitochondrial	O	1251-1264
function	O	1265-1273
and	O	1274-1277
insulin	O	1278-1285
sensitivity	O	1286-1297
.	O	1297-1298

Therefor	O	1299-1307
,	O	1307-1308
Inhibition	O	1309-1319
of	O	1320-1322
miR	B	1323-1326
-	I	1326-1327
106b	I	1327-1331
may	O	1332-1335
be	O	1336-1338
a	O	1339-1340
potential	O	1341-1350
new	O	1351-1354
strategy	O	1355-1363
for	O	1364-1367
treating	O	1368-1376
insulin	O	1377-1384
resistance	O	1385-1395
and	O	1396-1399
type	O	1400-1404
2	O	1405-1406
diabetes	O	1407-1415
.	O	1415-1416

Coordinated	O	0-11
targeting	O	12-21
of	O	22-24
the	O	25-28
EGFR	O	29-33
signaling	O	34-43
axis	O	44-48
by	O	49-51
microRNA	B	52-60
-	I	60-61
27a	I	61-64
*	I	64-65
.	O	65-66

Epidermal	O	67-76
growth	O	77-83
factor	O	84-90
receptor	O	91-99
(	O	100-101
EGFR	O	101-105
)	O	105-106
has	O	107-110
been	O	111-115
characterized	O	116-129
as	O	130-132
a	O	133-134
critical	O	135-143
factor	O	144-150
in	O	151-153
the	O	154-157
development	O	158-169
and	O	170-173
progression	O	174-185
of	O	186-188
multiple	O	189-197
solid	O	198-203
tumors	O	204-210
,	O	210-211
including	O	212-221
head	O	222-226
and	O	227-230
neck	O	231-235
squamous	O	236-244
cell	O	245-249
carcinoma	O	250-259
(	O	260-261
HNSCC	O	261-266
)	O	266-267
.	O	267-268

However	O	269-276
,	O	276-277
monotherapy	O	278-289
with	O	290-294
EGFR	O	295-299
-	O	299-300
specific	O	300-308
agents	O	309-315
has	O	316-319
not	O	320-323
been	O	324-328
as	O	329-331
dramatic	O	332-340
as	O	341-343
preclinical	O	344-355
studies	O	356-363
have	O	364-368
suggested	O	369-378
.	O	378-379

Since	O	380-385
complex	O	386-393
regulation	O	394-404
of	O	405-407
the	O	408-411
EGFR	O	412-416
signaling	O	417-426
axis	O	427-431
might	O	432-437
confound	O	438-446
current	O	447-454
attempts	O	455-463
to	O	464-466
inhibit	O	467-474
EGFR	O	475-479
directly	O	480-488
,	O	488-489
we	O	490-492
searched	O	493-501
for	O	502-505
microRNAs	O	506-515
(	O	516-517
miRNAs	O	517-523
)	O	523-524
that	O	525-529
may	O	530-533
target	O	534-540
the	O	541-544
EGFR	O	545-549
signaling	O	550-559
axis	O	560-564
.	O	564-565

We	O	566-568
identified	O	569-579
miR	B	580-583
-	I	583-584
27a	I	584-587
(	O	588-589
miR	B	589-592
-	I	592-593
27a	I	593-596
-	I	596-597
3p	I	597-599
)	O	599-600
and	O	601-604
its	O	605-608
complementary	O	609-622
or	O	623-625
star	O	626-630
(	O	631-632
*	O	632-633
)	O	633-634
strand	O	635-641
,	O	641-642
miR	B	643-646
-	I	646-647
27a	I	647-650
*	I	650-651
(	O	652-653
miR	B	653-656
-	I	656-657
27a	I	657-660
-	I	660-661
5p	I	661-663
)	O	663-664
,	O	664-665
as	O	666-668
novel	O	669-674
miRNAs	O	675-681
targeting	O	682-691
EGFR	O	692-696
,	O	696-697
which	O	698-703
were	O	704-708
significantly	O	709-722
downregulated	O	723-736
in	O	737-739
multiple	O	740-748
HNSCC	O	749-754
cell	O	755-759
lines	O	760-765
.	O	765-766

Analysis	O	767-775
of	O	776-778
human	O	779-784
specimens	O	785-794
demonstrated	O	795-807
that	O	808-812
miR	B	813-816
-	I	816-817
27a	I	817-820
*	I	820-821
is	O	822-824
significantly	O	825-838
underexpressed	O	839-853
in	O	854-856
HNSCC	O	857-862
as	O	863-865
compared	O	866-874
to	O	875-877
normal	O	878-884
mucosa	O	885-891
.	O	891-892

Increased	O	893-902
expression	O	903-913
of	O	914-916
miR	B	917-920
-	I	920-921
27a	I	921-924
*	I	924-925
in	O	926-928
HNSCC	O	929-934
produced	O	935-943
a	O	944-945
profound	O	946-954
cytotoxic	O	955-964
effect	O	965-971
not	O	972-975
seen	O	976-980
with	O	981-985
miR	B	986-989
-	I	989-990
27a	I	990-993
.	O	993-994

Analysis	O	995-1003
for	O	1004-1007
potential	O	1008-1017
targets	O	1018-1025
of	O	1026-1028
miR	B	1029-1032
-	I	1032-1033
27a	I	1033-1036
*	I	1036-1037
led	O	1038-1041
to	O	1042-1044
the	O	1045-1048
identification	O	1049-1063
of	O	1064-1066
AKT1	O	1067-1071
(	O	1072-1073
protein	O	1073-1080
kinase	O	1081-1087
B	O	1088-1089
)	O	1089-1090
and	O	1091-1094
mTOR	O	1095-1099
(	O	1100-1101
mammalian	O	1101-1110
target	O	1111-1117
of	O	1118-1120
rapamycin	O	1121-1130
)	O	1130-1131
within	O	1132-1138
the	O	1139-1142
EGFR	O	1143-1147
signaling	O	1148-1157
axis	O	1158-1162
.	O	1162-1163

Treatment	O	1164-1173
with	O	1174-1178
miR	B	1179-1182
-	I	1182-1183
27a	I	1183-1186
*	I	1186-1187
led	O	1188-1191
to	O	1192-1194
coordinated	O	1195-1206
downregulation	O	1207-1221
of	O	1222-1224
EGFR	O	1225-1229
,	O	1229-1230
AKT1	O	1231-1235
and	O	1236-1239
mTOR	O	1240-1244
.	O	1244-1245

Overexpression	O	1246-1260
of	O	1261-1263
EGFR	O	1264-1268
signaling	O	1269-1278
pathway	O	1279-1286
components	O	1287-1297
decreased	O	1298-1307
the	O	1308-1311
overall	O	1312-1319
effect	O	1320-1326
of	O	1327-1329
miR	B	1330-1333
-	I	1333-1334
27a	I	1334-1337
*	I	1337-1338
on	O	1339-1341
HNSCC	O	1342-1347
cell	O	1348-1352
viability	O	1353-1362
.	O	1362-1363

Constitutive	O	1364-1376
and	O	1377-1380
inducible	O	1381-1390
expression	O	1391-1401
of	O	1402-1404
miR	B	1405-1408
-	I	1408-1409
27a	I	1409-1412
*	I	1412-1413
in	O	1414-1416
a	O	1417-1418
murine	O	1419-1425
orthotopic	O	1426-1436
xenograft	O	1437-1446
model	O	1447-1452
of	O	1453-1455
oral	O	1456-1460
cavity	O	1461-1467
cancer	O	1468-1474
led	O	1475-1478
to	O	1479-1481
decreased	O	1482-1491
tumor	O	1492-1497
growth	O	1498-1504
.	O	1504-1505

Direct	O	1506-1512
intratumoral	O	1513-1525
injection	O	1526-1535
of	O	1536-1538
miR	B	1539-1542
-	I	1542-1543
27a	I	1543-1546
*	I	1546-1547
inhibited	O	1548-1557
tumor	O	1558-1563
growth	O	1564-1570
in	O	1571-1573
vivo	O	1574-1578
.	O	1578-1579

These	O	1580-1585
findings	O	1586-1594
identify	O	1595-1603
miR	B	1604-1607
-	I	1607-1608
27a	I	1608-1611
*	I	1611-1612
as	O	1613-1615
a	O	1616-1617
functional	O	1618-1628
star	O	1629-1633
sequence	O	1634-1642
that	O	1643-1647
exhibits	O	1648-1656
novel	O	1657-1662
coordinated	O	1663-1674
regulation	O	1675-1685
of	O	1686-1688
the	O	1689-1692
EGFR	O	1693-1697
pathway	O	1698-1705
in	O	1706-1708
solid	O	1709-1714
tumors	O	1715-1721
and	O	1722-1725
potentially	O	1726-1737
represents	O	1738-1748
a	O	1749-1750
novel	O	1751-1756
therapeutic	O	1757-1768
option	O	1769-1775
.	O	1775-1776

MicroRNA	B	0-8
-	I	8-9
30b	I	9-12
is	O	13-15
a	O	16-17
multifunctional	O	18-33
regulator	O	34-43
of	O	44-46
aortic	O	47-53
valve	O	54-59
interstitial	O	60-72
cells	O	73-78
.	O	78-79

OBJECTIVE	O	80-89
:	O	89-90
Calcific	O	91-99
aortic	O	100-106
valve	O	107-112
disease	O	113-120
is	O	121-123
an	O	124-126
active	O	127-133
process	O	134-141
involving	O	142-151
a	O	152-153
wide	O	154-158
range	O	159-164
of	O	165-167
pathologic	O	168-178
changes	O	179-186
.	O	186-187

Valve	O	188-193
interstitial	O	194-206
cells	O	207-212
are	O	213-216
the	O	217-220
most	O	221-225
prevalent	O	226-235
cells	O	236-241
in	O	242-244
the	O	245-248
heart	O	249-254
valve	O	255-260
and	O	261-264
maintain	O	265-273
normal	O	274-280
valve	O	281-286
structure	O	287-296
and	O	297-300
function	O	301-309
.	O	309-310

MicroRNAs	O	311-320
(	O	321-322
miRNAs	O	322-328
)	O	328-329
are	O	330-333
essential	O	334-343
posttranscriptional	O	344-363
modulators	O	364-374
of	O	375-377
gene	O	378-382
expression	O	383-393
,	O	393-394
and	O	395-398
miRNA	B	399-404
-	I	404-405
30b	I	405-408
is	O	409-411
a	O	412-413
known	O	414-419
repressor	O	420-429
of	O	430-432
bone	O	433-437
morphogenetic	O	438-451
protein	O	452-459
2	O	460-461
-	O	461-462
mediated	O	462-470
osteogenesis	O	471-483
.	O	483-484

We	O	485-487
hypothesized	O	488-500
that	O	501-505
miRNA	B	506-511
-	I	511-512
30b	I	512-515
is	O	516-518
a	O	519-520
multifunctional	O	521-536
regulator	O	537-546
of	O	547-549
aortic	O	550-556
valve	O	557-562
interstitial	O	563-575
cells	O	576-581
during	O	582-588
calcification	O	589-602
.	O	602-603

METHODS	O	604-611
:	O	611-612
To	O	613-615
determine	O	616-625
the	O	626-629
role	O	630-634
of	O	635-637
miRNA	B	638-643
-	I	643-644
30b	I	644-647
in	O	648-650
calcific	O	651-659
aortic	O	660-666
valve	O	667-672
disease	O	673-680
,	O	680-681
we	O	682-684
evaluated	O	685-694
miRNA	O	695-700
expression	O	701-711
in	O	712-714
human	O	715-720
calcific	O	721-729
aortic	O	730-736
valve	O	737-742
leaflets	O	743-751
obtained	O	752-760
intraoperatively	O	761-777
.	O	777-778

Furthermore	O	779-790
,	O	790-791
human	O	792-797
valve	O	798-803
interstitial	O	804-816
cells	O	817-822
were	O	823-827
evaluated	O	828-837
with	O	838-842
regard	O	843-849
to	O	850-852
miRNA	B	853-858
-	I	858-859
30b	I	859-862
expression	O	863-873
and	O	874-877
osteogenesis	O	878-890
by	O	891-893
quantitative	O	894-906
real	O	907-911
-	O	911-912
time	O	912-916
polymerase	O	917-927
chain	O	928-933
reaction	O	934-942
,	O	942-943
Western	O	944-951
blotting	O	952-960
,	O	960-961
flow	O	962-966
cytometry	O	967-976
,	O	976-977
and	O	978-981
alkaline	O	982-990
phosphatase	O	991-1002
assays	O	1003-1009
.	O	1009-1010

RESULTS	O	1011-1018
:	O	1018-1019
In	O	1020-1022
this	O	1023-1027
study	O	1028-1033
,	O	1033-1034
we	O	1035-1037
demonstrated	O	1038-1050
that	O	1051-1055
miRNA	B	1056-1061
-	I	1061-1062
30b	I	1062-1065
attenuates	O	1066-1076
bone	O	1077-1081
morphogenetic	O	1082-1095
protein	O	1096-1103
2	O	1104-1105
-	O	1105-1106
induced	O	1106-1113
osteoblast	O	1114-1124
differentiation	O	1125-1140
by	O	1141-1143
targeting	O	1144-1153
Runx2	O	1154-1159
,	O	1159-1160
Smad1	O	1161-1166
,	O	1166-1167
and	O	1168-1171
caspase	O	1172-1179
-	O	1179-1180
3	O	1180-1181
.	O	1181-1182

Transfection	O	1183-1195
of	O	1196-1198
a	O	1199-1200
mimic	O	1201-1206
of	O	1207-1209
miRNA	B	1210-1215
-	I	1215-1216
30b	I	1216-1219
led	O	1220-1223
to	O	1224-1226
decreases	O	1227-1236
in	O	1237-1239
alkaline	O	1240-1248
phosphatase	O	1249-1260
activity	O	1261-1269
and	O	1270-1273
expressions	O	1274-1285
of	O	1286-1288
Runx2	O	1289-1294
,	O	1294-1295
Smad1	O	1296-1301
,	O	1301-1302
and	O	1303-1306
caspase	O	1307-1314
-	O	1314-1315
3	O	1315-1316
.	O	1316-1317

Furthermore	O	1318-1329
,	O	1329-1330
dual	O	1331-1335
luciferase	O	1336-1346
reporter	O	1347-1355
assays	O	1356-1362
confirmed	O	1363-1372
that	O	1373-1377
Runx2	O	1378-1383
,	O	1383-1384
Smad1	O	1385-1390
,	O	1390-1391
and	O	1392-1395
caspase	O	1396-1403
-	O	1403-1404
3	O	1404-1405
are	O	1406-1409
direct	O	1410-1416
targets	O	1417-1424
of	O	1425-1427
miRNA	B	1428-1433
-	I	1433-1434
30b	I	1434-1437
.	O	1437-1438

CONCLUSIONS	O	1439-1450
:	O	1450-1451
We	O	1452-1454
demonstrated	O	1455-1467
a	O	1468-1469
remarkable	O	1470-1480
role	O	1481-1485
of	O	1486-1488
miRNA	B	1489-1494
-	I	1494-1495
30b	I	1495-1498
in	O	1499-1501
calcific	O	1502-1510
aortic	O	1511-1517
valve	O	1518-1523
disease	O	1524-1531
as	O	1532-1534
a	O	1535-1536
regulator	O	1537-1546
of	O	1547-1549
human	O	1550-1555
aortic	O	1556-1562
valvular	O	1563-1571
calcification	O	1572-1585
and	O	1586-1589
apoptosis	O	1590-1599
through	O	1600-1607
direct	O	1608-1614
targeting	O	1615-1624
of	O	1625-1627
Runx2	O	1628-1633
,	O	1633-1634
Smad1	O	1635-1640
,	O	1640-1641
and	O	1642-1645
caspase	O	1646-1653
-	O	1653-1654
3	O	1654-1655
.	O	1655-1656

Targeting	O	1657-1666
of	O	1667-1669
miRNA	B	1670-1675
-	I	1675-1676
30b	I	1676-1679
could	O	1680-1685
serve	O	1686-1691
as	O	1692-1694
a	O	1695-1696
novel	O	1697-1702
therapeutic	O	1703-1714
strategy	O	1715-1723
to	O	1724-1726
limit	O	1727-1732
progressive	O	1733-1744
calcification	O	1745-1758
in	O	1759-1761
aortic	O	1762-1768
stenosis	O	1769-1777
.	O	1777-1778

Molecular	O	0-9
strategy	O	10-18
to	O	19-21
reduce	O	22-28
in	O	29-31
vivo	O	32-36
collagen	O	37-45
barrier	O	46-53
promotes	O	54-62
entry	O	63-68
of	O	69-71
NCX1	O	72-76
positive	O	77-85
inducible	O	86-95
pluripotent	O	96-107
stem	O	108-112
cells	O	113-118
(	O	119-120
iPSC	O	120-124
(	O	124-125
NCX	O	125-128
(	O	128-129
1	O	129-130
)	O	130-131
(	O	131-132
+	O	132-133
)	O	133-134
)	O	134-135
)	O	135-136
into	O	137-141
ischemic	O	142-150
(	O	151-152
or	O	152-154
injured	O	155-162
)	O	162-163
myocardium	O	164-174
.	O	174-175

OBJECTIVE	O	176-185
:	O	185-186
The	O	187-190
purpose	O	191-198
of	O	199-201
this	O	202-206
study	O	207-212
was	O	213-216
to	O	217-219
assess	O	220-226
the	O	227-230
effect	O	231-237
of	O	238-240
collagen	O	241-249
composition	O	250-261
on	O	262-264
engraftment	O	265-276
of	O	277-279
progenitor	O	280-290
cells	O	291-296
within	O	297-303
infarcted	O	304-313
myocardium	O	314-324
.	O	324-325

BACKGROUND	O	326-336
:	O	336-337
We	O	338-340
previously	O	341-351
reported	O	352-360
that	O	361-365
intramyocardial	O	366-381
penetration	O	382-393
of	O	394-396
stem	O	397-401
/	O	401-402
progenitor	O	402-412
cells	O	413-418
in	O	419-421
epicardial	O	422-432
patches	O	433-440
was	O	441-444
enhanced	O	445-453
when	O	454-458
collagen	O	459-467
was	O	468-471
reduced	O	472-479
in	O	480-482
hearts	O	483-489
overexpressing	O	490-504
adenylyl	O	505-513
cyclase	O	514-521
-	O	521-522
6	O	522-523
(	O	524-525
AC6	O	525-528
)	O	528-529
.	O	529-530

In	O	531-533
this	O	534-538
study	O	539-544
we	O	545-547
hypothesized	O	548-560
an	O	561-563
alternative	O	564-575
strategy	O	576-584
wherein	O	585-592
overexpression	O	593-607
of	O	608-610
microRNA	B	611-619
-	I	619-620
29b	I	620-623
(	O	624-625
miR	B	625-628
-	I	628-629
29b	I	629-632
)	O	632-633
,	O	633-634
inhibiting	O	635-645
mRNAs	O	646-651
that	O	652-656
encode	O	657-663
cardiac	O	664-671
fibroblast	O	672-682
proteins	O	683-691
involved	O	692-700
in	O	701-703
fibrosis	O	704-712
,	O	712-713
would	O	714-719
similarly	O	720-729
facilitate	O	730-740
progenitor	O	741-751
cell	O	752-756
migration	O	757-766
into	O	767-771
infarcted	O	772-781
rat	O	782-785
myocardium	O	786-796
.	O	796-797

METHODS	O	798-805
:	O	805-806
In	O	807-809
vitro	O	810-815
:	O	815-816
A	O	817-818
tri	O	819-822
-	O	822-823
cell	O	823-827
patch	O	828-833
(	O	834-835
Tri	O	835-838
-	O	838-839
P	O	839-840
)	O	840-841
consisting	O	842-852
of	O	853-855
cardiac	O	856-863
sodium	O	864-870
-	O	870-871
calcium	O	871-878
exchanger	O	879-888
-	O	888-889
1	O	889-890
(	O	891-892
NCX1	O	892-896
)	O	896-897
positive	O	898-906
iPSC	O	907-911
(	O	912-913
iPSC	O	913-917
(	O	917-918
NCX1	O	918-922
+	O	922-923
)	O	923-924
)	O	924-925
,	O	925-926
endothelial	O	927-938
cells	O	939-944
(	O	945-946
EC	O	946-948
)	O	948-949
,	O	949-950
and	O	951-954
mouse	O	955-960
embryonic	O	961-970
fibroblasts	O	971-982
(	O	983-984
MEF	O	984-987
)	O	987-988
was	O	989-992
created	O	993-1000
,	O	1000-1001
co	O	1002-1004
-	O	1004-1005
cultured	O	1005-1013
,	O	1013-1014
and	O	1015-1018
seeded	O	1019-1025
on	O	1026-1028
isolated	O	1029-1037
peritoneum	O	1038-1048
.	O	1048-1049

The	O	1050-1053
expression	O	1054-1064
of	O	1065-1067
fibrosis	O	1068-1076
-	O	1076-1077
related	O	1077-1084
genes	O	1085-1090
was	O	1091-1094
analyzed	O	1095-1103
in	O	1104-1106
cardiac	O	1107-1114
fibroblasts	O	1115-1126
(	O	1127-1128
CFb	O	1128-1131
)	O	1131-1132
by	O	1133-1135
qPCR	O	1136-1140
and	O	1141-1144
Western	O	1145-1152
blot	O	1153-1157
.	O	1157-1158

In	O	1159-1161
vivo	O	1162-1166
:	O	1166-1167
Nude	O	1168-1172
rat	O	1173-1176
hearts	O	1177-1183
were	O	1184-1188
administered	O	1189-1201
mimic	O	1202-1207
miRNA	B	1208-1213
-	I	1213-1214
29b	I	1214-1217
(	O	1218-1219
miR	B	1219-1222
-	I	1222-1223
29b	I	1223-1226
)	O	1226-1227
,	O	1227-1228
miRNA	B	1229-1234
-	I	1234-1235
29b	I	1235-1238
inhibitor	O	1239-1248
(	O	1249-1250
Anti	O	1250-1254
-	O	1254-1255
29b	O	1255-1258
)	O	1258-1259
,	O	1259-1260
or	O	1261-1263
negative	O	1264-1272
mimic	O	1273-1278
(	O	1279-1280
Ctrl	O	1280-1284
)	O	1284-1285
before	O	1286-1292
creation	O	1293-1301
of	O	1302-1304
an	O	1305-1307
ischemically	O	1308-1320
induced	O	1321-1328
regional	O	1329-1337
myocardial	O	1338-1348
infarction	O	1349-1359
(	O	1360-1361
MI	O	1361-1363
)	O	1363-1364
.	O	1364-1365

The	O	1366-1369
Tri	O	1370-1373
-	O	1373-1374
P	O	1374-1375
was	O	1376-1379
placed	O	1380-1386
over	O	1387-1391
the	O	1392-1395
infarcted	O	1396-1405
region	O	1406-1412
7	O	1413-1414
days	O	1415-1419
later	O	1420-1425
.	O	1425-1426

Angiomyogenesis	O	1427-1442
was	O	1443-1446
analyzed	O	1447-1455
by	O	1456-1458
micro	O	1459-1464
-	O	1464-1465
CT	O	1465-1467
imaging	O	1468-1475
and	O	1476-1479
immunofluorescent	O	1480-1497
staining	O	1498-1506
.	O	1506-1507

Echocardiography	O	1508-1524
was	O	1525-1528
performed	O	1529-1538
weekly	O	1539-1545
.	O	1545-1546

RESULTS	O	1547-1554
:	O	1554-1555
The	O	1556-1559
number	O	1560-1566
of	O	1567-1569
green	O	1570-1575
fluorescent	O	1576-1587
protein	O	1588-1595
positive	O	1596-1604
(	O	1605-1606
GFP	O	1606-1609
(	O	1609-1610
+	O	1610-1611
)	O	1611-1612
)	O	1612-1613
cells	O	1614-1619
,	O	1619-1620
capillary	O	1621-1630
density	O	1631-1638
,	O	1638-1639
and	O	1640-1643
heart	O	1644-1649
function	O	1650-1658
were	O	1659-1663
significantly	O	1664-1677
increased	O	1678-1687
in	O	1688-1690
hearts	O	1691-1697
overexpressing	O	1698-1712
miR	B	1713-1716
-	I	1716-1717
29b	I	1717-1720
as	O	1721-1723
compared	O	1724-1732
with	O	1733-1737
Ctrl	O	1738-1742
and	O	1743-1746
Anti	O	1747-1751
-	O	1751-1752
29b	O	1752-1755
groups	O	1756-1762
.	O	1762-1763

Conversely	O	1764-1774
,	O	1774-1775
down	O	1776-1780
-	O	1780-1781
regulation	O	1781-1791
of	O	1792-1794
miR	B	1795-1798
-	I	1798-1799
29b	I	1799-1802
with	O	1803-1807
anti	O	1808-1812
-	O	1812-1813
29b	O	1813-1816
in	O	1817-1819
vitro	O	1820-1825
and	O	1826-1829
in	O	1830-1832
vivo	O	1833-1837
induced	O	1838-1845
interstitial	O	1846-1858
fibrosis	O	1859-1867
and	O	1868-1871
cardiac	O	1872-1879
remodeling	O	1880-1890
.	O	1890-1891

CONCLUSION	O	1892-1902
:	O	1902-1903
Overexpression	O	1904-1918
of	O	1919-1921
miR	B	1922-1925
-	I	1925-1926
29b	I	1926-1929
significantly	O	1930-1943
reduced	O	1944-1951
scar	O	1952-1956
formation	O	1957-1966
after	O	1967-1972
MI	O	1973-1975
and	O	1976-1979
facilitated	O	1980-1991
iPSC	O	1992-1996
(	O	1996-1997
NCX1	O	1997-2001
+	O	2001-2002
)	O	2002-2003
penetration	O	2004-2015
from	O	2016-2020
the	O	2021-2024
cell	O	2025-2029
patch	O	2030-2035
into	O	2036-2040
the	O	2041-2044
infarcted	O	2045-2054
area	O	2055-2059
,	O	2059-2060
resulting	O	2061-2070
in	O	2071-2073
restoration	O	2074-2085
of	O	2086-2088
heart	O	2089-2094
function	O	2095-2103
after	O	2104-2109
MI	O	2110-2112
.	O	2112-2113

Alteration	O	0-10
of	O	11-13
the	O	14-17
microRNA	O	18-26
network	O	27-34
during	O	35-41
the	O	42-45
progression	O	46-57
of	O	58-60
Alzheimer	O	61-70
'	O	70-71
s	O	71-72
disease	O	73-80
.	O	80-81

An	O	82-84
overview	O	85-93
of	O	94-96
miRNAs	O	97-103
altered	O	104-111
in	O	112-114
Alzheimer	O	115-124
'	O	124-125
s	O	125-126
disease	O	127-134
(	O	135-136
AD	O	136-138
)	O	138-139
was	O	140-143
established	O	144-155
by	O	156-158
profiling	O	159-168
the	O	169-172
hippocampus	O	173-184
of	O	185-187
a	O	188-189
cohort	O	190-196
of	O	197-199
41	O	200-202
late	O	203-207
-	O	207-208
onset	O	208-213
AD	O	214-216
(	O	217-218
LOAD	O	218-222
)	O	222-223
patients	O	224-232
and	O	233-236
23	O	237-239
controls	O	240-248
,	O	248-249
showing	O	250-257
deregulation	O	258-270
of	O	271-273
35	O	274-276
miRNAs	O	277-283
.	O	283-284

Profiling	O	285-294
of	O	295-297
miRNAs	O	298-304
in	O	305-307
the	O	308-311
prefrontal	O	312-322
cortex	O	323-329
of	O	330-332
a	O	333-334
second	O	335-341
independent	O	342-353
cohort	O	354-360
of	O	361-363
49	O	364-366
patients	O	367-375
grouped	O	376-383
by	O	384-386
Braak	O	387-392
stages	O	393-399
revealed	O	400-408
41	O	409-411
deregulated	O	412-423
miRNAs	O	424-430
.	O	430-431

We	O	432-434
focused	O	435-442
on	O	443-445
miR	B	446-449
-	I	449-450
132	I	450-453
-	I	453-454
3p	I	454-456
which	O	457-462
is	O	463-465
strongly	O	466-474
altered	O	475-482
in	O	483-485
both	O	486-490
brain	O	491-496
areas	O	497-502
.	O	502-503

Downregulation	O	504-518
of	O	519-521
this	O	522-526
miRNA	O	527-532
occurs	O	533-539
already	O	540-547
at	O	548-550
Braak	O	551-556
stages	O	557-563
III	O	564-567
and	O	568-571
IV	O	572-574
,	O	574-575
before	O	576-582
loss	O	583-587
of	O	588-590
neuron	O	591-597
-	O	597-598
specific	O	598-606
miRNAs	O	607-613
.	O	613-614

Next	O	615-619
-	O	619-620
generation	O	620-630
sequencing	O	631-641
confirmed	O	642-651
a	O	652-653
strong	O	654-660
decrease	O	661-669
of	O	670-672
miR	B	673-676
-	I	676-677
132	I	677-680
-	I	680-681
3p	I	681-683
and	O	684-687
of	O	688-690
three	O	691-696
family	O	697-703
-	O	703-704
related	O	704-711
miRNAs	O	712-718
encoded	O	719-726
by	O	727-729
the	O	730-733
same	O	734-738
miRNA	O	739-744
cluster	O	745-752
on	O	753-755
chromosome	O	756-766
17	O	767-769
.	O	769-770

Deregulation	O	771-783
of	O	784-786
miR	B	787-790
-	I	790-791
132	I	791-794
-	I	794-795
3p	I	795-797
in	O	798-800
AD	O	801-803
brain	O	804-809
appears	O	810-817
to	O	818-820
occur	O	821-826
mainly	O	827-833
in	O	834-836
neurons	O	837-844
displaying	O	845-855
Tau	O	856-859
hyper	O	860-865
-	O	865-866
phosphorylation	O	866-881
.	O	881-882

We	O	883-885
provide	O	886-893
evidence	O	894-902
that	O	903-907
miR	B	908-911
-	I	911-912
132	I	912-915
-	I	915-916
3p	I	916-918
may	O	919-922
contribute	O	923-933
to	O	934-936
disease	O	937-944
progression	O	945-956
through	O	957-964
aberrant	O	965-973
regulation	O	974-984
of	O	985-987
mRNA	O	988-992
targets	O	993-1000
in	O	1001-1003
the	O	1004-1007
Tau	O	1008-1011
network	O	1012-1019
.	O	1019-1020

The	O	1021-1024
transcription	O	1025-1038
factor	O	1039-1045
(	O	1046-1047
TF	O	1047-1049
)	O	1049-1050
FOXO1a	O	1051-1057
appears	O	1058-1065
to	O	1066-1068
be	O	1069-1071
a	O	1072-1073
key	O	1074-1077
target	O	1078-1084
of	O	1085-1087
miR	B	1088-1091
-	I	1091-1092
132	I	1092-1095
-	I	1095-1096
3p	I	1096-1098
in	O	1099-1101
this	O	1102-1106
pathway	O	1107-1114
.	O	1114-1115

microR	B	0-6
-	I	6-7
142	I	7-10
-	I	10-11
3p	I	11-13
down	O	14-18
-	O	18-19
regulates	O	19-28
IRAK	O	29-33
-	O	33-34
1	O	34-35
in	O	36-38
response	O	39-47
to	O	48-50
Mycobacterium	O	51-64
bovis	O	65-70
BCG	O	71-74
infection	O	75-84
in	O	85-87
macrophages	O	88-99
.	O	99-100

MicroRNAs	O	101-110
(	O	111-112
miRNAs	O	112-118
)	O	118-119
have	O	120-124
been	O	125-129
demonstrated	O	130-142
to	O	143-145
play	O	146-150
a	O	151-152
pivotal	O	153-160
role	O	161-165
in	O	166-168
the	O	169-172
regulation	O	173-183
of	O	184-186
target	O	187-193
gene	O	194-198
expression	O	199-209
at	O	210-212
the	O	213-216
post	O	217-221
-	O	221-222
transcriptional	O	222-237
level	O	238-243
.	O	243-244

In	O	245-247
order	O	248-253
to	O	254-256
better	O	257-263
understand	O	264-274
the	O	275-278
role	O	279-283
of	O	284-286
miRNA	O	287-292
in	O	293-295
the	O	296-299
immunological	O	300-313
regulation	O	314-324
of	O	325-327
macrophages	O	328-339
against	O	340-347
Mycobacterium	O	348-361
bovis	O	362-367
BCG	O	368-371
infection	O	372-381
,	O	381-382
we	O	383-385
explored	O	386-394
the	O	395-398
alteration	O	399-409
of	O	410-412
immune	O	413-419
-	O	419-420
related	O	420-427
miRNA	O	428-433
profile	O	434-441
in	O	442-444
macrophage	O	445-455
RAW264	O	456-462
.	O	462-463
7	O	463-464
cells	O	465-470
in	O	471-473
response	O	474-482
to	O	483-485
BCG	O	486-489
infection	O	490-499
in	O	500-502
this	O	503-507
study	O	508-513
.	O	513-514

Our	O	515-518
results	O	519-526
demonstrated	O	527-539
that	O	540-544
miR	B	545-548
-	I	548-549
142	I	549-552
-	I	552-553
3p	I	553-555
was	O	556-559
a	O	560-561
potential	O	562-571
to	O	572-574
negatively	O	575-585
regulate	O	586-594
the	O	595-598
production	O	599-609
of	O	610-612
pro	O	613-616
-	O	616-617
inflammatory	O	617-629
mediators	O	630-639
NF	O	640-642
-	O	642-643
kappaB	O	643-649
(	O	650-651
NF	O	651-653
-	O	653-654
kappaB1	O	654-661
)	O	661-662
,	O	662-663
TNF	O	664-667
-	O	667-668
alpha	O	668-673
and	O	674-677
IL	O	678-680
-	O	680-681
6	O	681-682
in	O	683-685
the	O	686-689
macrophages	O	690-701
in	O	702-704
part	O	705-709
through	O	710-717
a	O	718-719
mechanism	O	720-729
of	O	730-732
targeting	O	733-742
IRAK	O	743-747
-	O	747-748
1	O	748-749
gene	O	750-754
and	O	755-758
post	O	759-763
-	O	763-764
transcriptionally	O	764-781
down	O	782-786
-	O	786-787
regulating	O	787-797
IRAK	O	798-802
-	O	802-803
1	O	803-804
protein	O	805-812
expression	O	813-823
.	O	823-824

Control	O	0-7
of	O	8-10
the	O	11-14
rescue	O	15-21
and	O	22-25
replication	O	26-37
of	O	38-40
Semliki	O	41-48
Forest	O	49-55
virus	O	56-61
recombinants	O	62-74
by	O	75-77
the	O	78-81
insertion	O	82-91
of	O	92-94
miRNA	O	95-100
target	O	101-107
sequences	O	108-117
.	O	117-118

Due	O	119-122
to	O	123-125
their	O	126-131
broad	O	132-137
cell	O	138-142
-	O	142-143
and	O	144-147
tissue	O	148-154
-	O	154-155
tropism	O	155-162
,	O	162-163
alphavirus	O	164-174
-	O	174-175
based	O	175-180
replication	O	181-192
-	O	192-193
competent	O	193-202
vectors	O	203-210
are	O	211-214
of	O	215-217
particular	O	218-228
interest	O	229-237
for	O	238-241
anti	O	242-246
-	O	246-247
cancer	O	247-253
therapy	O	254-261
.	O	261-262

These	O	263-268
properties	O	269-279
may	O	280-283
,	O	283-284
however	O	285-292
,	O	292-293
be	O	294-296
potentially	O	297-308
hazardous	O	309-318
unless	O	319-325
the	O	326-329
virus	O	330-335
infection	O	336-345
is	O	346-348
controlled	O	349-359
.	O	359-360

While	O	361-366
the	O	367-370
RNA	O	371-374
genome	O	375-381
of	O	382-384
alphaviruses	O	385-397
precludes	O	398-407
the	O	408-411
standard	O	412-420
control	O	421-428
techniques	O	429-439
,	O	439-440
host	O	441-445
miRNAs	O	446-452
can	O	453-456
be	O	457-459
used	O	460-464
to	O	465-467
down	O	468-472
-	O	472-473
regulate	O	473-481
viral	O	482-487
replication	O	488-499
.	O	499-500

In	O	501-503
this	O	504-508
study	O	509-514
,	O	514-515
target	O	516-522
sites	O	523-528
from	O	529-533
ubiquitous	O	534-544
miRNAs	O	545-551
and	O	552-555
those	O	556-561
of	O	562-564
miRNAs	O	565-571
under	O	572-577
-	O	577-578
represented	O	578-589
in	O	590-592
cervical	O	593-601
cancer	O	602-608
cells	O	609-614
were	O	615-619
inserted	O	620-628
into	O	629-633
replication	O	634-645
-	O	645-646
competent	O	646-655
DNA	O	656-659
/	O	659-660
RNA	O	660-663
layered	O	664-671
vectors	O	672-679
of	O	680-682
Semliki	O	683-690
Forest	O	691-697
virus	O	698-703
.	O	703-704

It	O	705-707
was	O	708-711
found	O	712-717
that	O	718-722
in	O	723-725
order	O	726-731
to	O	732-734
achieve	O	735-742
the	O	743-746
most	O	747-751
efficient	O	752-761
suppression	O	762-773
of	O	774-776
recombinant	O	777-788
virus	O	789-794
rescue	O	795-801
,	O	801-802
the	O	803-806
introduced	O	807-817
target	O	818-824
sequences	O	825-834
must	O	835-839
be	O	840-842
fully	O	843-848
complementary	O	849-862
to	O	863-865
those	O	866-871
of	O	872-874
the	O	875-878
corresponding	O	879-892
miRNAs	O	893-899
.	O	899-900

Target	O	901-907
sites	O	908-913
of	O	914-916
ubiquitous	O	917-927
miRNAs	O	928-934
,	O	934-935
introduced	O	936-946
into	O	947-951
the	O	952-955
3	O	956-957
'	O	957-958
untranslated	O	959-971
region	O	972-978
of	O	979-981
the	O	982-985
viral	O	986-991
vector	O	992-998
,	O	998-999
profoundly	O	1000-1010
reduced	O	1011-1018
the	O	1019-1022
rescue	O	1023-1029
of	O	1030-1032
recombinant	O	1033-1044
viruses	O	1045-1052
.	O	1052-1053

Insertion	O	1054-1063
of	O	1064-1066
the	O	1067-1070
same	O	1071-1075
miRNA	O	1076-1081
targets	O	1082-1089
into	O	1090-1094
coding	O	1095-1101
region	O	1102-1108
of	O	1109-1111
the	O	1112-1115
viral	O	1116-1121
vector	O	1122-1128
was	O	1129-1132
approximately	O	1133-1146
300	O	1147-1150
-	O	1150-1151
fold	O	1151-1155
less	O	1156-1160
effective	O	1161-1170
.	O	1170-1171

Viruses	O	1172-1179
carrying	O	1180-1188
these	O	1189-1194
miRNAs	O	1195-1201
were	O	1202-1206
genetically	O	1207-1218
unstable	O	1219-1227
and	O	1228-1231
rapidly	O	1232-1239
lost	O	1240-1244
the	O	1245-1248
target	O	1249-1255
sequences	O	1256-1265
.	O	1265-1266

This	O	1267-1271
process	O	1272-1279
was	O	1280-1283
delayed	O	1284-1291
,	O	1291-1292
but	O	1293-1296
not	O	1297-1300
completely	O	1301-1311
prevented	O	1312-1321
,	O	1321-1322
by	O	1323-1325
miRNA	O	1326-1331
inhibitors	O	1332-1342
.	O	1342-1343

Target	O	1344-1350
sites	O	1351-1356
of	O	1357-1359
miRNA	O	1360-1365
under	O	1366-1371
-	O	1371-1372
represented	O	1372-1383
in	O	1384-1386
cervical	O	1387-1395
cancer	O	1396-1402
cells	O	1403-1408
had	O	1409-1412
much	O	1413-1417
smaller	O	1418-1425
but	O	1426-1429
still	O	1430-1435
significant	O	1436-1447
effects	O	1448-1455
on	O	1456-1458
recombinant	O	1459-1470
virus	O	1471-1476
rescue	O	1477-1483
in	O	1484-1486
cervical	O	1487-1495
cancer	O	1496-1502
-	O	1502-1503
derived	O	1503-1510
HeLa	O	1511-1515
cells	O	1516-1521
.	O	1521-1522

Over	O	1523-1527
-	O	1527-1528
expression	O	1528-1538
of	O	1539-1541
miR	B	1542-1545
-	I	1545-1546
214	I	1546-1549
,	O	1549-1550
one	O	1551-1554
of	O	1555-1557
these	O	1558-1563
miRNAs	O	1564-1570
,	O	1570-1571
reduced	O	1572-1579
replication	O	1580-1591
of	O	1592-1594
the	O	1595-1598
targeted	O	1599-1607
virus	O	1608-1613
.	O	1613-1614

Though	O	1615-1621
the	O	1622-1625
majority	O	1626-1634
of	O	1635-1637
rescued	O	1638-1645
viruses	O	1646-1653
maintained	O	1654-1664
the	O	1665-1668
introduced	O	1669-1679
miRNA	O	1680-1685
target	O	1686-1692
sequences	O	1693-1702
,	O	1702-1703
genomes	O	1704-1711
with	O	1712-1716
deletions	O	1717-1726
of	O	1727-1729
these	O	1730-1735
sequences	O	1736-1745
were	O	1746-1750
also	O	1751-1755
detected	O	1756-1764
.	O	1764-1765

Thus	O	1766-1770
,	O	1770-1771
the	O	1772-1775
low	O	1776-1779
-	O	1779-1780
level	O	1780-1785
repression	O	1786-1796
of	O	1797-1799
rescue	O	1800-1806
and	O	1807-1810
replication	O	1811-1822
of	O	1823-1825
targeted	O	1826-1834
virus	O	1835-1840
in	O	1841-1843
HeLa	O	1844-1848
cells	O	1849-1854
was	O	1855-1858
still	O	1859-1864
sufficient	O	1865-1875
to	O	1876-1878
cause	O	1879-1884
genetic	O	1885-1892
instability	O	1893-1904
.	O	1904-1905

MicroRNA	B	0-8
-	I	8-9
31	I	9-11
inhibits	O	12-20
cisplatin	O	21-30
-	O	30-31
induced	O	31-38
apoptosis	O	39-48
in	O	49-51
non	O	52-55
-	O	55-56
small	O	56-61
cell	O	62-66
lung	O	67-71
cancer	O	72-78
cells	O	79-84
by	O	85-87
regulating	O	88-98
the	O	99-102
drug	O	103-107
transporter	O	108-119
ABCB9	O	120-125
.	O	125-126

Alterations	O	127-138
in	O	139-141
microRNA	O	142-150
(	O	151-152
miRNA	O	152-157
)	O	157-158
expression	O	159-169
have	O	170-174
been	O	175-179
found	O	180-185
to	O	186-188
be	O	189-191
involved	O	192-200
in	O	201-203
tumor	O	204-209
growth	O	210-216
and	O	217-220
response	O	221-229
to	O	230-232
chemotherapy	O	233-245
.	O	245-246

However	O	247-254
,	O	254-255
the	O	256-259
possible	O	260-268
role	O	269-273
of	O	274-276
miR	B	277-280
-	I	280-281
31	I	281-283
in	O	284-286
cisplatin	O	287-296
(	O	297-298
DDP	O	298-301
)	O	301-302
resistance	O	303-313
in	O	314-316
non	O	317-320
-	O	320-321
small	O	321-326
cell	O	327-331
lung	O	332-336
cancer	O	337-343
(	O	344-345
NSCLC	O	345-350
)	O	350-351
remains	O	352-359
unclear	O	360-367
.	O	367-368

In	O	369-371
this	O	372-376
study	O	377-382
,	O	382-383
we	O	384-386
identified	O	387-397
a	O	398-399
DDP	O	400-403
-	O	403-404
sensitive	O	404-413
and	O	414-417
a	O	418-419
DDP	O	420-423
-	O	423-424
resistant	O	424-433
cell	O	434-438
line	O	439-443
from	O	444-448
four	O	449-453
candidate	O	454-463
human	O	464-469
NSCLC	O	470-475
cell	O	476-480
lines	O	481-486
.	O	486-487

Notably	O	488-495
,	O	495-496
we	O	497-499
found	O	500-505
that	O	506-510
miR	B	511-514
-	I	514-515
31	I	515-517
was	O	518-521
significantly	O	522-535
upregulated	O	536-547
in	O	548-550
the	O	551-554
DDP	O	555-558
-	O	558-559
resistant	O	559-568
cell	O	569-573
line	O	574-578
compared	O	579-587
with	O	588-592
its	O	593-596
level	O	597-602
in	O	603-605
the	O	606-609
DDP	O	610-613
-	O	613-614
sensitive	O	614-623
cell	O	624-628
line	O	629-633
.	O	633-634

As	O	635-637
a	O	638-639
result	O	640-646
,	O	646-647
miR	B	648-651
-	I	651-652
31	I	652-654
overexpression	O	655-669
induced	O	670-677
DDP	O	678-681
resistance	O	682-692
in	O	693-695
the	O	696-699
DDP	O	700-703
-	O	703-704
sensitive	O	704-713
cell	O	714-718
line	O	719-723
,	O	723-724
and	O	725-728
miR	B	729-732
-	I	732-733
31	I	733-735
knockdown	O	736-745
rescued	O	746-753
DDP	O	754-757
sensitivity	O	758-769
in	O	770-772
the	O	773-776
DDP	O	777-780
-	O	780-781
resistant	O	781-790
cell	O	791-795
line	O	796-800
.	O	800-801

Interestingly	O	802-815
,	O	815-816
miR	B	817-820
-	I	820-821
31	I	821-823
was	O	824-827
inversely	O	828-837
correlated	O	838-848
with	O	849-853
the	O	854-857
expression	O	858-868
of	O	869-871
the	O	872-875
drug	O	876-880
resistance	O	881-891
gene	O	892-896
ABCB9	O	897-902
.	O	902-903

The	O	904-907
luciferase	O	908-918
activity	O	919-927
assay	O	928-933
showed	O	934-940
that	O	941-945
miR	B	946-949
-	I	949-950
31	I	950-952
directly	O	953-961
targets	O	962-969
the	O	970-973
3	O	974-975
'	O	975-976
UTR	O	976-979
of	O	980-982
ABCB9	O	983-988
,	O	988-989
which	O	990-995
is	O	996-998
known	O	999-1004
to	O	1005-1007
play	O	1008-1012
a	O	1013-1014
crucial	O	1015-1022
role	O	1023-1027
in	O	1028-1030
drug	O	1031-1035
resistance	O	1036-1046
.	O	1046-1047

Mechanistically	O	1048-1063
,	O	1063-1064
we	O	1065-1067
showed	O	1068-1074
that	O	1075-1079
miR	B	1080-1083
-	I	1083-1084
31	I	1084-1086
confers	O	1087-1094
DDP	O	1095-1098
-	O	1098-1099
induced	O	1099-1106
apoptosis	O	1107-1116
and	O	1117-1120
that	O	1121-1125
inhibition	O	1126-1136
of	O	1137-1139
ABCB9	O	1140-1145
is	O	1146-1148
required	O	1149-1157
for	O	1158-1161
DDP	O	1162-1165
resistance	O	1166-1176
.	O	1176-1177

The	O	1178-1181
data	O	1182-1186
demonstrate	O	1187-1198
that	O	1199-1203
miR	B	1204-1207
-	I	1207-1208
31	I	1208-1210
exerts	O	1211-1217
an	O	1218-1220
anti	O	1221-1225
-	O	1225-1226
apoptotic	O	1226-1235
effect	O	1236-1242
most	O	1243-1247
likely	O	1248-1254
through	O	1255-1262
the	O	1263-1266
inhibition	O	1267-1277
of	O	1278-1280
ABCB9	O	1281-1286
and	O	1287-1290
thus	O	1291-1295
provide	O	1296-1303
a	O	1304-1305
novel	O	1306-1311
strategy	O	1312-1320
involving	O	1321-1330
the	O	1331-1334
use	O	1335-1338
of	O	1339-1341
miR	B	1342-1345
-	I	1345-1346
31	I	1346-1348
as	O	1349-1351
a	O	1352-1353
potential	O	1354-1363
target	O	1364-1370
in	O	1371-1373
NSCLC	O	1374-1379
chemotherapy	O	1380-1392
.	O	1392-1393

Meta	O	0-4
-	O	4-5
analysis	O	5-13
of	O	14-16
the	O	17-20
association	O	21-32
between	O	33-40
a	O	41-42
polymorphism	O	43-55
in	O	56-58
microRNA	B	59-67
-	I	67-68
196a2	I	68-73
and	O	74-77
susceptibility	O	78-92
to	O	93-95
colorectal	O	96-106
cancer	O	107-113
.	O	113-114

BACKGROUND	O	115-125
/	O	125-126
AIMS	O	126-130
:	O	130-131
To	O	132-134
accurately	O	135-145
evaluate	O	146-154
the	O	155-158
impact	O	159-165
of	O	166-168
the	O	169-172
C	O	173-174
/	O	174-175
T	O	175-176
polymorphism	O	177-189
in	O	190-192
microRNA	O	193-201
(	B	202-203
miRNA	I	203-208
)	I	208-209
-	I	209-210
196a2	I	210-215
on	O	216-218
the	O	219-222
colorectal	O	223-233
cancer	O	234-240
(	O	241-242
CRC	O	242-245
)	O	245-246
risk	O	247-251
,	O	251-252
by	O	253-255
meta	O	256-260
-	O	260-261
analysis	O	261-269
.	O	269-270

METHODS	O	271-278
:	O	278-279
An	O	280-282
electronic	O	283-293
search	O	294-300
for	O	301-304
articles	O	305-313
was	O	314-317
conducted	O	318-327
in	O	328-330
PubMed	O	331-337
,	O	337-338
EMBASE	O	339-345
,	O	345-346
ISI	O	347-350
Web	O	351-354
of	O	355-357
Science	O	358-365
,	O	365-366
and	O	367-370
the	O	371-374
Cochrane	O	375-383
Library	O	384-391
.	O	391-392

The	O	393-396
pooled	O	397-403
odds	O	404-408
ratio	O	409-414
(	O	415-416
OR	O	416-418
)	O	418-419
and	O	420-423
its	O	424-427
95	O	428-430
%	O	430-431
confidence	O	432-442
interval	O	443-451
(	O	452-453
CI	O	453-455
)	O	455-456
were	O	457-461
used	O	462-466
to	O	467-469
assess	O	470-476
the	O	477-480
association	O	481-492
through	O	493-500
meta	O	501-505
-	O	505-506
analysis	O	506-514
.	O	514-515

RESULTS	O	516-523
:	O	523-524
5	O	525-526
studies	O	527-534
were	O	535-539
used	O	540-544
for	O	545-548
analysis	O	549-557
.	O	557-558

The	O	559-562
results	O	563-570
showed	O	571-577
a	O	578-579
significant	O	580-591
association	O	592-603
between	O	604-611
the	O	612-615
miRNA	B	616-621
-	I	621-622
196a2	I	622-627
C	O	628-629
/	O	629-630
T	O	630-631
polymorphism	O	632-644
and	O	645-648
CRC	O	649-652
risk	O	653-657
in	O	658-660
the	O	661-664
genetic	O	665-672
models	O	673-679
(	O	680-681
C	O	681-682
vs	O	683-685
.	O	685-686
T	O	687-688
:	O	688-689
OR	O	690-692
=	O	693-694
1	O	695-696
.	O	696-697
168	O	697-700
,	O	700-701
95	O	702-704
%	O	704-705
CI	O	706-708
=	O	709-710
1	O	711-712
.	O	712-713
106	O	713-716
-	O	716-717
1	O	717-718
.	O	718-719
282	O	719-722
,	O	722-723
p	O	724-725
=	O	726-727
0	O	728-729
.	O	729-730
001	O	730-733
;	O	733-734
CC	O	735-737
vs	O	738-740
.	O	740-741
TT	O	742-744
:	O	744-745
OR	O	746-748
=	O	749-750
1	O	751-752
.	O	752-753
368	O	753-756
,	O	756-757
95	O	758-760
%	O	760-761
CI	O	762-764
=	O	765-766
1	O	767-768
.	O	768-769
132	O	769-772
-	O	772-773
1	O	773-774
.	O	774-775
654	O	775-778
,	O	778-779
p	O	780-781
=	O	782-783
0	O	784-785
.	O	785-786
001	O	786-789
;	O	789-790
TC	O	791-793
/	O	793-794
CC	O	794-796
vs	O	797-799
.	O	799-800
TT	O	801-803
:	O	803-804
OR	O	805-807
=	O	808-809
1	O	810-811
.	O	811-812
206	O	812-815
,	O	815-816
95	O	817-819
%	O	819-820
=	O	821-822
CI	O	823-825
1	O	826-827
.	O	827-828
035	O	828-831
-	O	831-832
1	O	832-833
.	O	833-834
405	O	834-837
,	O	837-838
p	O	839-840
=	O	841-842
0	O	843-844
.	O	844-845
016	O	845-848
;	O	848-849
CC	O	850-852
vs	O	853-855
.	O	855-856
TC	O	857-859
/	O	859-860
TT	O	860-862
:	O	862-863
OR	O	864-866
=	O	867-868
1	O	869-870
.	O	870-871
254	O	871-874
,	O	874-875
95	O	876-878
%	O	878-879
CI	O	880-882
=	O	883-884
1	O	885-886
.	O	886-887
077	O	887-890
-	O	890-891
1	O	891-892
.	O	892-893
461	O	893-896
,	O	896-897
p	O	898-899
=	O	900-901
0	O	902-903
.	O	903-904
004	O	904-907
)	O	907-908
,	O	908-909
with	O	910-914
the	O	915-918
exception	O	919-928
of	O	929-931
the	O	932-935
TC	O	936-938
-	O	938-939
versus	O	939-945
-	O	945-946
TT	O	946-948
model	O	949-954
(	O	955-956
TC	O	956-958
vs	O	959-961
.	O	961-962
TT	O	963-965
:	O	965-966
OR	O	967-969
=	O	970-971
1	O	972-973
.	O	973-974
130	O	974-977
,	O	977-978
95	O	979-981
%	O	981-982
CI	O	983-985
=	O	986-987
0	O	988-989
.	O	989-990
961	O	990-993
-	O	993-994
1	O	994-995
.	O	995-996
329	O	996-999
,	O	999-1000
p	O	1001-1002
=	O	1003-1004
0	O	1005-1006
.	O	1006-1007
138	O	1007-1010
)	O	1010-1011
.	O	1011-1012

In	O	1013-1015
a	O	1016-1017
subgroup	O	1018-1026
analysis	O	1027-1035
based	O	1036-1041
on	O	1042-1044
ethnicity	O	1045-1054
,	O	1054-1055
we	O	1056-1058
identified	O	1059-1069
a	O	1070-1071
significant	O	1072-1083
overrepresentation	O	1084-1102
of	O	1103-1105
the	O	1106-1109
polymorphism	O	1110-1122
in	O	1123-1125
individuals	O	1126-1137
of	O	1138-1140
Asian	O	1141-1146
ethnicity	O	1147-1156
.	O	1156-1157

CONCLUSION	O	1158-1168
:	O	1168-1169
This	O	1170-1174
meta	O	1175-1179
-	O	1179-1180
analysis	O	1180-1188
indicates	O	1189-1198
a	O	1199-1200
significant	O	1201-1212
association	O	1213-1224
between	O	1225-1232
the	O	1233-1236
miRNA	B	1237-1242
-	I	1242-1243
196a2	I	1243-1248
polymorphism	O	1249-1261
and	O	1262-1265
CRC	O	1266-1269
risk	O	1270-1274
.	O	1274-1275

A	O	0-1
component	O	2-11
of	O	12-14
the	O	15-18
mir	B	19-22
-	I	22-23
17	I	23-25
-	I	25-26
92	I	26-28
polycistronic	O	29-42
oncomir	O	43-50
promotes	O	51-59
oncogene	O	60-68
-	O	68-69
dependent	O	69-78
apoptosis	O	79-88
.	O	88-89

mir	B	90-93
-	I	93-94
17	I	94-96
-	I	96-97
92	I	97-99
,	O	99-100
a	O	101-102
potent	O	103-109
polycistronic	O	110-123
oncomir	O	124-131
,	O	131-132
encodes	O	133-140
six	O	141-144
mature	O	145-151
miRNAs	O	152-158
with	O	159-163
complex	O	164-171
modes	O	172-177
of	O	178-180
interactions	O	181-193
.	O	193-194

In	O	195-197
the	O	198-201
Emu	O	202-205
-	O	205-206
myc	O	206-209
Burkitt	O	210-217
'	O	217-218
s	O	218-219
lymphoma	O	220-228
model	O	229-234
,	O	234-235
mir	B	236-239
-	I	239-240
17	I	240-242
-	I	242-243
92	I	243-245
exhibits	O	246-254
potent	O	255-261
oncogenic	O	262-271
activity	O	272-280
by	O	281-283
repressing	O	284-294
c	O	295-296
-	O	296-297
Myc	O	297-300
-	O	300-301
induced	O	301-308
apoptosis	O	309-318
,	O	318-319
primarily	O	320-329
through	O	330-337
its	O	338-341
miR	B	342-345
-	I	345-346
19	I	346-348
components	O	349-359
.	O	359-360

Surprisingly	O	361-373
,	O	373-374
mir	B	375-378
-	I	378-379
17	I	379-381
-	I	381-382
92	I	382-384
also	O	385-389
encodes	O	390-397
the	O	398-401
miR	B	402-405
-	I	405-406
92	I	406-408
component	O	409-418
that	O	419-423
negatively	O	424-434
regulates	O	435-444
its	O	445-448
oncogenic	O	449-458
cooperation	O	459-470
with	O	471-475
c	O	476-477
-	O	477-478
Myc	O	478-481
.	O	481-482

This	O	483-487
miR	B	488-491
-	I	491-492
92	I	492-494
effect	O	495-501
is	O	502-504
,	O	504-505
at	O	506-508
least	O	509-514
in	O	515-517
part	O	518-522
,	O	522-523
mediated	O	524-532
by	O	533-535
its	O	536-539
direct	O	540-546
repression	O	547-557
of	O	558-560
Fbw7	O	561-565
,	O	565-566
which	O	567-572
promotes	O	573-581
the	O	582-585
proteosomal	O	586-597
degradation	O	598-609
of	O	610-612
c	O	613-614
-	O	614-615
Myc	O	615-618
.	O	618-619

Thus	O	620-624
,	O	624-625
overexpressing	O	626-640
miR	B	641-644
-	I	644-645
92	I	645-647
leads	O	648-653
to	O	654-656
aberrant	O	657-665
c	O	666-667
-	O	667-668
Myc	O	668-671
increase	O	672-680
,	O	680-681
imposing	O	682-690
a	O	691-692
strong	O	693-699
coupling	O	700-708
between	O	709-716
excessive	O	717-726
proliferation	O	727-740
and	O	741-744
p53	O	745-748
-	O	748-749
dependent	O	749-758
apoptosis	O	759-768
.	O	768-769

Interestingly	O	770-783
,	O	783-784
miR	B	785-788
-	I	788-789
92	I	789-791
antagonizes	O	792-803
the	O	804-807
oncogenic	O	808-817
miR	B	818-821
-	I	821-822
19	I	822-824
miRNAs	O	825-831
;	O	831-832
and	O	833-836
such	O	837-841
functional	O	842-852
interaction	O	853-864
coordinates	O	865-876
proliferation	O	877-890
and	O	891-894
apoptosis	O	895-904
during	O	905-911
c	O	912-913
-	O	913-914
Myc	O	914-917
-	O	917-918
induced	O	918-925
oncogenesis	O	926-937
.	O	937-938

This	O	939-943
miR	B	944-947
-	I	947-948
19	I	948-950
:	O	950-951
miR	B	951-954
-	I	954-955
92	I	955-957
antagonism	O	958-968
is	O	969-971
disrupted	O	972-981
in	O	982-984
B	O	985-986
-	O	986-987
lymphoma	O	987-995
cells	O	996-1001
that	O	1002-1006
favor	O	1007-1012
a	O	1013-1014
greater	O	1015-1022
increase	O	1023-1031
of	O	1032-1034
miR	B	1035-1038
-	I	1038-1039
19	I	1039-1041
over	O	1042-1046
miR	B	1047-1050
-	I	1050-1051
92	I	1051-1053
.	O	1053-1054

Altogether	O	1055-1065
,	O	1065-1066
we	O	1067-1069
suggest	O	1070-1077
a	O	1078-1079
new	O	1080-1083
paradigm	O	1084-1092
whereby	O	1093-1100
the	O	1101-1104
unique	O	1105-1111
gene	O	1112-1116
structure	O	1117-1126
of	O	1127-1129
a	O	1130-1131
polycistronic	O	1132-1145
oncomir	O	1146-1153
confers	O	1154-1161
an	O	1162-1164
intricate	O	1165-1174
balance	O	1175-1182
between	O	1183-1190
oncogene	O	1191-1199
and	O	1200-1203
tumor	O	1204-1209
suppressor	O	1210-1220
crosstalk	O	1221-1230
.	O	1230-1231

DOI	O	1232-1235
:	O	1235-1236
http	O	1236-1240
:	O	1240-1241
/	O	1241-1242
/	O	1242-1243
dx	O	1243-1245
.	O	1245-1246
doi	O	1246-1249
.	O	1249-1250
org	O	1250-1253
/	O	1253-1254
10	O	1254-1256
.	O	1256-1257
7554	O	1257-1261
/	O	1261-1262
eLife	O	1262-1267
.	O	1267-1268
00822	O	1268-1273
.	O	1273-1274
001	O	1274-1277
.	O	1277-1278

miRNA	B	0-5
-	I	5-6
95	I	6-8
mediates	O	9-17
radioresistance	O	18-33
in	O	34-36
tumors	O	37-43
by	O	44-46
targeting	O	47-56
the	O	57-60
sphingolipid	O	61-73
phosphatase	O	74-85
SGPP1	O	86-91
.	O	91-92

Radiation	O	93-102
resistance	O	103-113
poses	O	114-119
a	O	120-121
major	O	122-127
clinical	O	128-136
challenge	O	137-146
in	O	147-149
cancer	O	150-156
treatment	O	157-166
,	O	166-167
but	O	168-171
little	O	172-178
is	O	179-181
known	O	182-187
about	O	188-193
how	O	194-197
microRNA	O	198-206
(	O	207-208
miR	O	208-211
)	O	211-212
may	O	213-216
regulate	O	217-225
this	O	226-230
phenomenon	O	231-241
.	O	241-242

In	O	243-245
this	O	246-250
study	O	251-256
,	O	256-257
we	O	258-260
used	O	261-265
next	O	266-270
-	O	270-271
generation	O	271-281
sequencing	O	282-292
to	O	293-295
perform	O	296-303
an	O	304-306
unbiased	O	307-315
comparison	O	316-326
of	O	327-329
miR	O	330-333
expression	O	334-344
in	O	345-347
PC3	O	348-351
prostate	O	352-360
cancer	O	361-367
cells	O	368-373
rendered	O	374-382
resistant	O	383-392
to	O	393-395
fractionated	O	396-408
radiation	O	409-418
treatment	O	419-428
.	O	428-429

One	O	430-433
miR	O	434-437
candidate	O	438-447
found	O	448-453
to	O	454-456
be	O	457-459
upregulated	O	460-471
by	O	472-474
ionizing	O	475-483
radiation	O	484-493
was	O	494-497
miR	B	498-501
-	I	501-502
95	I	502-504
,	O	504-505
the	O	506-509
enforced	O	510-518
expression	O	519-529
of	O	530-532
which	O	533-538
promoted	O	539-547
radiation	O	548-557
resistance	O	558-568
in	O	569-571
a	O	572-573
variety	O	574-581
of	O	582-584
cancer	O	585-591
cells	O	592-597
.	O	597-598

miR	B	599-602
-	I	602-603
95	I	603-605
overexpression	O	606-620
recapitulated	O	621-634
an	O	635-637
aggressive	O	638-648
phenotype	O	649-658
including	O	659-668
increased	O	669-678
cellular	O	679-687
proliferation	O	688-701
,	O	701-702
deregulated	O	703-714
G2	O	715-717
-	O	717-718
M	O	718-719
checkpoint	O	720-730
following	O	731-740
ionizing	O	741-749
radiation	O	750-759
,	O	759-760
and	O	761-764
increased	O	765-774
invasive	O	775-783
potential	O	784-793
.	O	793-794

Using	O	795-800
combined	O	801-809
in	O	810-812
silico	O	813-819
prediction	O	820-830
and	O	831-834
microarray	O	835-845
expression	O	846-856
analyses	O	857-865
,	O	865-866
we	O	867-869
identified	O	870-880
and	O	881-884
validated	O	885-894
the	O	895-898
sphingolipid	O	899-911
phosphatase	O	912-923
SGPP1	O	924-929
,	O	929-930
an	O	931-933
antagonist	O	934-944
of	O	945-947
sphingosine	O	948-959
-	O	959-960
1	O	960-961
-	O	961-962
phosphate	O	962-971
signaling	O	972-981
,	O	981-982
as	O	983-985
a	O	986-987
target	O	988-994
of	O	995-997
miR	B	998-1001
-	I	1001-1002
95	I	1002-1004
that	O	1005-1009
promotes	O	1010-1018
radiation	O	1019-1028
resistance	O	1029-1039
.	O	1039-1040

Consistent	O	1041-1051
with	O	1052-1056
this	O	1057-1061
finding	O	1062-1069
,	O	1069-1070
cell	O	1071-1075
treatment	O	1076-1085
with	O	1086-1090
FTY720	O	1091-1097
,	O	1097-1098
a	O	1099-1100
clinically	O	1101-1111
approved	O	1112-1120
small	O	1121-1126
molecule	O	1127-1135
inhibitor	O	1136-1145
of	O	1146-1148
S1P	O	1149-1152
signaling	O	1153-1162
,	O	1162-1163
sensitized	O	1164-1174
miR	B	1175-1178
-	I	1178-1179
95	I	1179-1181
overexpressing	O	1182-1196
cells	O	1197-1202
to	O	1203-1205
radiation	O	1206-1215
treatment	O	1216-1225
.	O	1225-1226

In	O	1227-1229
vivo	O	1230-1234
assays	O	1235-1241
extended	O	1242-1250
the	O	1251-1254
significance	O	1255-1267
of	O	1268-1270
these	O	1271-1276
results	O	1277-1284
,	O	1284-1285
showing	O	1286-1293
that	O	1294-1298
miR	B	1299-1302
-	I	1302-1303
95	I	1303-1305
overexpression	O	1306-1320
increased	O	1321-1330
tumor	O	1331-1336
growth	O	1337-1343
and	O	1344-1347
resistance	O	1348-1358
to	O	1359-1361
radiation	O	1362-1371
treatment	O	1372-1381
in	O	1382-1384
tumor	O	1385-1390
xenografts	O	1391-1401
.	O	1401-1402

Furthermore	O	1403-1414
,	O	1414-1415
reduced	O	1416-1423
tumor	O	1424-1429
necrosis	O	1430-1438
and	O	1439-1442
increased	O	1443-1452
cellular	O	1453-1461
proliferation	O	1462-1475
were	O	1476-1480
seen	O	1481-1485
after	O	1486-1491
radiation	O	1492-1501
treatment	O	1502-1511
of	O	1512-1514
miR	B	1515-1518
-	I	1518-1519
95	I	1519-1521
overexpressing	O	1522-1536
tumors	O	1537-1543
compared	O	1544-1552
with	O	1553-1557
control	O	1558-1565
tumors	O	1566-1572
.	O	1572-1573

Finally	O	1574-1581
,	O	1581-1582
miR	B	1583-1586
-	I	1586-1587
95	I	1587-1589
expression	O	1590-1600
was	O	1601-1604
increased	O	1605-1614
in	O	1615-1617
human	O	1618-1623
prostate	O	1624-1632
and	O	1633-1636
breast	O	1637-1643
cancer	O	1644-1650
specimens	O	1651-1660
compared	O	1661-1669
with	O	1670-1674
normal	O	1675-1681
tissue	O	1682-1688
.	O	1688-1689

Together	O	1690-1698
,	O	1698-1699
our	O	1700-1703
work	O	1704-1708
reveals	O	1709-1716
miR	B	1717-1720
-	I	1720-1721
95	I	1721-1723
expression	O	1724-1734
as	O	1735-1737
a	O	1738-1739
critical	O	1740-1748
determinant	O	1749-1760
of	O	1761-1763
radiation	O	1764-1773
resistance	O	1774-1784
in	O	1785-1787
cancer	O	1788-1794
cells	O	1795-1800
.	O	1800-1801

The	O	0-3
role	O	4-8
of	O	9-11
microRNAs	O	12-21
in	O	22-24
hepatitis	O	25-34
C	O	35-36
virus	O	37-42
RNA	O	43-46
replication	O	47-58
.	O	58-59

Replication	O	60-71
of	O	72-74
hepatitis	O	75-84
C	O	85-86
virus	O	87-92
(	O	93-94
HCV	O	94-97
)	O	97-98
RNA	O	99-102
is	O	103-105
influenced	O	106-116
by	O	117-119
a	O	120-121
variety	O	122-129
of	O	130-132
microRNAs	O	133-142
,	O	142-143
with	O	144-148
the	O	149-152
main	O	153-157
player	O	158-164
being	O	165-170
the	O	171-174
liver	O	175-180
-	O	180-181
specific	O	181-189
microRNA	B	190-198
-	I	198-199
122	I	199-202
(	O	203-204
miR	B	204-207
-	I	207-208
122	I	208-211
)	O	211-212
.	O	212-213

Binding	O	214-221
of	O	222-224
miR	B	225-228
-	I	228-229
122	I	229-232
to	O	233-235
two	O	236-239
binding	O	240-247
sites	O	248-253
near	O	254-258
the	O	259-262
5	O	263-264
'	O	264-265
end	O	266-269
of	O	270-272
the	O	273-276
5	O	277-278
'	O	278-279
untranslated	O	280-292
region	O	293-299
(	O	300-301
UTR	O	301-304
)	O	304-305
of	O	306-308
the	O	309-312
HCV	O	313-316
genomic	O	317-324
RNA	O	325-328
results	O	329-336
in	O	337-339
at	O	340-342
least	O	343-348
two	O	349-352
different	O	353-362
effects	O	363-370
.	O	370-371

On	O	372-374
the	O	375-378
one	O	379-382
hand	O	383-387
,	O	387-388
binding	O	389-396
of	O	397-399
miR	B	400-403
-	I	403-404
122	I	404-407
and	O	408-411
the	O	412-415
resulting	O	416-425
recruitment	O	426-437
of	O	438-440
protein	O	441-448
complexes	O	449-458
containing	O	459-469
Argonaute	O	470-479
(	O	480-481
Ago	O	481-484
)	O	484-485
proteins	O	486-494
appears	O	495-502
to	O	503-505
mask	O	506-510
the	O	511-514
viral	O	515-520
RNA	O	521-524
'	O	524-525
s	O	525-526
5	O	527-528
'	O	528-529
end	O	530-533
and	O	534-537
stabilizes	O	538-548
the	O	549-552
viral	O	553-558
RNA	O	559-562
against	O	563-570
nucleolytic	O	571-582
degradation	O	583-594
.	O	594-595

On	O	596-598
the	O	599-602
other	O	603-608
hand	O	609-613
,	O	613-614
this	O	615-619
interaction	O	620-631
of	O	632-634
miR	B	635-638
-	I	638-639
122	I	639-642
with	O	643-647
the	O	648-651
5	O	652-653
'	O	653-654
-	O	654-655
UTR	O	655-658
also	O	659-663
stimulates	O	664-674
HCV	O	675-678
RNA	O	679-682
translation	O	683-694
directed	O	695-703
by	O	704-706
the	O	707-710
internal	O	711-719
ribosome	O	720-728
entry	O	729-734
site	O	735-739
(	O	740-741
IRES	O	741-745
)	O	745-746
located	O	747-754
downstream	O	755-765
of	O	766-768
the	O	769-772
miR	B	773-776
-	I	776-777
122	I	777-780
binding	O	781-788
sites	O	789-794
.	O	794-795

However	O	796-803
,	O	803-804
it	O	805-807
is	O	808-810
suspected	O	811-820
that	O	821-825
additional	O	826-836
,	O	836-837
yet	O	838-841
undefined	O	842-851
roles	O	852-857
of	O	858-860
miR	B	861-864
-	I	864-865
122	I	865-868
in	O	869-871
HCV	O	872-875
replication	O	876-887
may	O	888-891
also	O	892-896
contribute	O	897-907
to	O	908-910
HCV	O	911-914
propagation	O	915-926
.	O	926-927

Accordingly	O	928-939
,	O	939-940
miR	B	941-944
-	I	944-945
122	I	945-948
is	O	949-951
considered	O	952-962
to	O	963-965
contribute	O	966-976
to	O	977-979
the	O	980-983
liver	O	984-989
tropism	O	990-997
of	O	998-1000
the	O	1001-1004
virus	O	1005-1010
.	O	1010-1011

Besides	O	1012-1019
miR	B	1020-1023
-	I	1023-1024
122	I	1024-1027
,	O	1027-1028
let	B	1029-1032
-	I	1032-1033
7b	I	1033-1035
,	O	1035-1036
miR	B	1037-1040
-	I	1040-1041
196	I	1041-1044
,	O	1044-1045
miR	B	1046-1049
-	I	1049-1050
199a	I	1050-1054
*	I	1054-1055
and	O	1056-1059
miR	B	1060-1063
-	I	1063-1064
448	I	1064-1067
have	O	1068-1072
also	O	1073-1077
been	O	1078-1082
reported	O	1083-1091
to	O	1092-1094
interact	O	1095-1103
directly	O	1104-1112
with	O	1113-1117
the	O	1118-1121
HCV	O	1122-1125
RNA	O	1126-1129
.	O	1129-1130

However	O	1131-1138
,	O	1138-1139
the	O	1140-1143
latter	O	1144-1150
microRNAs	O	1151-1160
inhibit	O	1161-1168
HCV	O	1169-1172
replication	O	1173-1184
,	O	1184-1185
and	O	1186-1189
it	O	1190-1192
has	O	1193-1196
been	O	1197-1201
speculated	O	1202-1212
that	O	1213-1217
miR	B	1218-1221
-	I	1221-1222
199a	I	1222-1226
*	I	1226-1227
contributes	O	1228-1239
indirectly	O	1240-1250
to	O	1251-1253
HCV	O	1254-1257
tissue	O	1258-1264
tropism	O	1265-1272
,	O	1272-1273
since	O	1274-1279
it	O	1280-1282
is	O	1283-1285
mostly	O	1286-1292
expressed	O	1293-1302
in	O	1303-1305
cells	O	1306-1311
other	O	1312-1317
than	O	1318-1322
hepatocytes	O	1323-1334
.	O	1334-1335

Other	O	1336-1341
microRNAs	O	1342-1351
influence	O	1352-1361
HCV	O	1362-1365
replication	O	1366-1377
indirectly	O	1378-1388
.	O	1388-1389

Some	O	1390-1394
of	O	1395-1397
those	O	1398-1403
are	O	1404-1407
advantageous	O	1408-1420
for	O	1421-1424
HCV	O	1425-1428
propagation	O	1429-1440
,	O	1440-1441
while	O	1442-1447
others	O	1448-1454
suppress	O	1455-1463
HCV	O	1464-1467
replication	O	1468-1479
.	O	1479-1480

Consequently	O	1481-1493
,	O	1493-1494
HCV	O	1495-1498
up	O	1499-1501
-	O	1501-1502
regulates	O	1502-1511
or	O	1512-1514
down	O	1515-1519
-	O	1519-1520
regulates	O	1520-1529
,	O	1529-1530
respectively	O	1531-1543
,	O	1543-1544
the	O	1545-1548
expression	O	1549-1559
of	O	1560-1562
most	O	1563-1567
of	O	1568-1570
these	O	1571-1576
miRNAs	O	1577-1583
.	O	1583-1584

Genetic	O	0-7
polymorphisms	O	8-21
in	O	22-24
pre	O	25-28
-	O	28-29
microRNAs	O	29-38
and	O	39-42
risk	O	43-47
of	O	48-50
ischemic	O	51-59
stroke	O	60-66
in	O	67-69
a	O	70-71
Chinese	O	72-79
population	O	80-90
.	O	90-91

Ischemic	O	92-100
stroke	O	101-107
is	O	108-110
considered	O	111-121
to	O	122-124
be	O	125-127
a	O	128-129
complex	O	130-137
disease	O	138-145
consisting	O	146-156
of	O	157-159
a	O	160-161
group	O	162-167
of	O	168-170
heterogeneous	O	171-184
disorders	O	185-194
with	O	195-199
multiple	O	200-208
genetic	O	209-216
and	O	217-220
environmental	O	221-234
risk	O	235-239
factors	O	240-247
.	O	247-248

MicroRNAs	O	249-258
participated	O	259-271
in	O	272-274
various	O	275-282
physiopathological	O	283-301
processes	O	302-311
;	O	311-312
common	O	313-319
single	O	320-326
-	O	326-327
nucleotide	O	327-337
polymorphisms	O	338-351
(	O	352-353
SNPs	O	353-357
)	O	357-358
in	O	359-361
pre	O	362-365
-	O	365-366
miRNAs	O	366-372
have	O	373-377
been	O	378-382
shown	O	383-388
to	O	389-391
be	O	392-394
associated	O	395-405
with	O	406-410
susceptibility	O	411-425
to	O	426-428
several	O	429-436
human	O	437-442
diseases	O	443-451
.	O	451-452

We	O	453-455
evaluated	O	456-465
the	O	466-469
associations	O	470-482
of	O	483-485
the	O	486-489
hsa	B	490-493
-	I	493-494
mir	I	494-497
-	I	497-498
196	I	498-501
-	I	501-502
a2	I	502-504
/	O	504-505
rs11614913	O	505-515
T	O	516-517
/	O	517-518
C	O	518-519
,	O	519-520
hsa	B	521-524
-	I	524-525
mir	I	525-528
-	I	528-529
146a	I	529-533
/	O	533-534
rs2910164	O	534-543
C	O	544-545
/	O	545-546
G	O	546-547
,	O	547-548
and	O	549-552
hsa	B	553-556
-	I	556-557
mir	I	557-560
-	I	560-561
499	I	561-564
/	O	564-565
rs3746444	O	565-574
A	O	575-576
/	O	576-577
G	O	577-578
polymorphisms	O	579-592
in	O	593-595
pre	O	596-599
-	O	599-600
miRNAs	O	600-606
with	O	607-611
the	O	612-615
risk	O	616-620
of	O	621-623
ischemic	O	624-632
stroke	O	633-639
in	O	640-642
a	O	643-644
Chinese	O	645-652
population	O	653-663
.	O	663-664

The	O	665-668
three	O	669-674
polymorphisms	O	675-688
were	O	689-693
identified	O	694-704
in	O	705-707
296	O	708-711
ischemic	O	712-720
stroke	O	721-727
patients	O	728-736
and	O	737-740
391	O	741-744
healthy	O	745-752
controls	O	753-761
using	O	762-767
polymerase	O	768-778
chain	O	779-784
reaction	O	785-793
-	O	793-794
restriction	O	794-805
fragment	O	806-814
length	O	815-821
polymorphism	O	822-834
.	O	834-835

The	O	836-839
frequency	O	840-849
of	O	850-852
the	O	853-856
allele	O	857-863
G	O	864-865
of	O	866-868
hsa	B	869-872
-	I	872-873
mir	I	873-876
-	I	876-877
499	I	877-880
/	O	880-881
rs3746444	O	881-890
A	O	891-892
/	O	892-893
G	O	893-894
showed	O	895-901
significant	O	902-913
association	O	914-925
with	O	926-930
ischemic	O	931-939
stroke	O	940-946
when	O	947-951
compared	O	952-960
with	O	961-965
controls	O	966-974
(	O	975-976
OR	O	976-978
=	O	979-980
1	O	981-982
.	O	982-983
509	O	983-986
,	O	986-987
95	O	988-990
%	O	990-991
CI	O	991-993
=	O	994-995
1	O	996-997
.	O	997-998
151	O	998-1001
-	O	1001-1002
1	O	1002-1003
.	O	1003-1004
978	O	1004-1007
,	O	1007-1008
P	O	1009-1010
=	O	1011-1012
0	O	1013-1014
.	O	1014-1015
003	O	1015-1018
)	O	1018-1019
.	O	1019-1020

Increased	O	1021-1030
ischemic	O	1031-1039
stroke	O	1040-1046
risks	O	1047-1052
were	O	1053-1057
associated	O	1058-1068
with	O	1069-1073
rs3746444	O	1074-1083
A	O	1084-1085
/	O	1085-1086
G	O	1086-1087
genotypes	O	1088-1097
in	O	1098-1100
different	O	1101-1110
genetic	O	1111-1118
model	O	1119-1124
(	O	1125-1126
homozygote	O	1126-1136
comparison	O	1137-1147
:	O	1147-1148
P	O	1149-1150
=	O	1151-1152
0	O	1153-1154
.	O	1154-1155
045	O	1155-1158
,	O	1158-1159
OR	O	1160-1162
=	O	1163-1164
2	O	1165-1166
.	O	1166-1167
084	O	1167-1170
,	O	1170-1171
95	O	1172-1174
%	O	1174-1175
CI	O	1175-1177
=	O	1178-1179
1	O	1180-1181
.	O	1181-1182
019	O	1182-1185
-	O	1185-1186
4	O	1186-1187
.	O	1187-1188
262	O	1188-1191
;	O	1191-1192
heterozygote	O	1193-1205
comparison	O	1206-1216
:	O	1216-1217
P	O	1218-1219
=	O	1220-1221
0	O	1222-1223
.	O	1223-1224
024	O	1224-1227
,	O	1227-1228
OR	O	1229-1231
=	O	1232-1233
1	O	1234-1235
.	O	1235-1236
489	O	1236-1239
,	O	1239-1240
95	O	1241-1243
%	O	1243-1244
CI	O	1244-1246
=	O	1247-1248
1	O	1249-1250
.	O	1250-1251
063	O	1251-1254
-	O	1254-1255
2	O	1255-1256
.	O	1256-1257
087	O	1257-1260
;	O	1260-1261
dominant	O	1262-1270
genetic	O	1271-1278
model	O	1279-1284
:	O	1284-1285
P	O	1286-1287
=	O	1288-1289
0	O	1290-1291
.	O	1291-1292
007	O	1292-1295
,	O	1295-1296
OR	O	1297-1299
=	O	1300-1301
1	O	1302-1303
.	O	1303-1304
563	O	1304-1307
,	O	1307-1308
95	O	1309-1311
%	O	1311-1312
CI	O	1312-1314
=	O	1315-1316
1	O	1317-1318
.	O	1318-1319
135	O	1319-1322
-	O	1322-1323
2	O	1323-1324
.	O	1324-1325
153	O	1325-1328
)	O	1328-1329
.	O	1329-1330

Similar	O	1331-1338
results	O	1339-1346
were	O	1347-1351
obtained	O	1352-1360
by	O	1361-1363
adjusted	O	1364-1372
fully	O	1373-1378
risk	O	1379-1383
factors	O	1384-1391
.	O	1391-1392

However	O	1393-1400
,	O	1400-1401
we	O	1402-1404
failed	O	1405-1411
to	O	1412-1414
find	O	1415-1419
any	O	1420-1423
association	O	1424-1435
between	O	1436-1443
the	O	1444-1447
alleles	O	1448-1455
and	O	1456-1459
genotypes	O	1460-1469
of	O	1470-1472
rs2910164	O	1473-1482
C	O	1483-1484
/	O	1484-1485
G	O	1485-1486
and	O	1487-1490
rs11614913	O	1491-1501
T	O	1502-1503
/	O	1503-1504
C	O	1504-1505
SNPs	O	1506-1510
and	O	1511-1514
ischemic	O	1515-1523
stroke	O	1524-1530
,	O	1530-1531
respectively	O	1532-1544
(	O	1545-1546
p	O	1546-1547
>	O	1548-1549
0	O	1550-1551
.	O	1551-1552
05	O	1552-1554
)	O	1554-1555
.	O	1555-1556

The	O	1557-1560
present	O	1561-1568
study	O	1569-1574
provided	O	1575-1583
evidence	O	1584-1592
that	O	1593-1597
hsa	B	1598-1601
-	I	1601-1602
mir	I	1602-1605
-	I	1605-1606
499	I	1606-1609
/	O	1609-1610
rs3746444	O	1610-1619
A	O	1620-1621
/	O	1621-1622
G	O	1622-1623
polymorphism	O	1624-1636
might	O	1637-1642
be	O	1643-1645
associated	O	1646-1656
with	O	1657-1661
a	O	1662-1663
significantly	O	1664-1677
increased	O	1678-1687
risk	O	1688-1692
of	O	1693-1695
ischemic	O	1696-1704
stroke	O	1705-1711
in	O	1712-1714
a	O	1715-1716
Chinese	O	1717-1724
population	O	1725-1735
,	O	1735-1736
indicating	O	1737-1747
that	O	1748-1752
the	O	1753-1756
common	O	1757-1763
genetic	O	1764-1771
polymorphism	O	1772-1784
in	O	1785-1787
pre	O	1788-1791
-	O	1791-1792
microRNAs	O	1792-1801
contributed	O	1802-1813
to	O	1814-1816
the	O	1817-1820
pathogenesis	O	1821-1833
of	O	1834-1836
ischemic	O	1837-1845
stroke	O	1846-1852
.	O	1852-1853

MicroRNA	B	0-8
-	I	8-9
26a	I	9-12
inhibits	O	13-21
angiogenesis	O	22-34
by	O	35-37
down	O	38-42
-	O	42-43
regulating	O	43-53
VEGFA	O	54-59
through	O	60-67
the	O	68-71
PIK3C2alpha	O	72-83
/	O	83-84
Akt	O	84-87
/	O	87-88
HIF	O	88-91
-	O	91-92
1alpha	O	92-98
pathway	O	99-106
in	O	107-109
hepatocellular	O	110-124
carcinoma	O	125-134
.	O	134-135

BACKGROUND	O	136-146
&	O	147-148
AIMS	O	149-153
:	O	153-154
microRNAs	O	155-164
(	O	165-166
miRNAs	O	166-172
)	O	172-173
have	O	174-178
been	O	179-183
reported	O	184-192
to	O	193-195
regulate	O	196-204
angiogenesis	O	205-217
by	O	218-220
down	O	221-225
-	O	225-226
regulating	O	226-236
the	O	237-240
expression	O	241-251
of	O	252-254
pro	O	255-258
-	O	258-259
angiogenic	O	259-269
or	O	270-272
anti	O	273-277
-	O	277-278
angiogenic	O	278-288
factors	O	289-296
.	O	296-297

The	O	298-301
aims	O	302-306
of	O	307-309
this	O	310-314
study	O	315-320
were	O	321-325
to	O	326-328
investigate	O	329-340
whether	O	341-348
miR	B	349-352
-	I	352-353
26a	I	353-356
inhibited	O	357-366
angiogenesis	O	367-379
by	O	380-382
down	O	383-387
-	O	387-388
regulating	O	388-398
vascular	O	399-407
endothelial	O	408-419
growth	O	420-426
factor	O	427-433
A	O	434-435
(	O	436-437
VEGFA	O	437-442
)	O	442-443
and	O	444-447
its	O	448-451
clinical	O	452-460
relevance	O	461-470
in	O	471-473
hepatocellular	O	474-488
carcinoma	O	489-498
(	O	499-500
HCC	O	500-503
)	O	503-504
.	O	504-505

METHODS	O	506-513
:	O	513-514
The	O	515-518
expression	O	519-529
of	O	530-532
miR	B	533-536
-	I	536-537
26a	I	537-540
was	O	541-544
modified	O	545-553
in	O	554-556
HepG2	O	557-562
and	O	563-566
HCCLM3	O	567-573
cell	O	574-578
lines	O	579-584
respectively	O	585-597
,	O	597-598
and	O	599-602
a	O	603-604
panel	O	605-610
of	O	611-613
angiogenic	O	614-624
factors	O	625-632
was	O	633-636
measured	O	637-645
by	O	646-648
real	O	649-653
-	O	653-654
time	O	654-658
PCR	O	659-662
in	O	663-665
the	O	666-669
cells	O	670-675
.	O	675-676

A	O	677-678
luciferase	O	679-689
reporter	O	690-698
assay	O	699-704
was	O	705-708
used	O	709-713
to	O	714-716
validate	O	717-725
the	O	726-729
target	O	730-736
gene	O	737-741
of	O	742-744
miR	B	745-748
-	I	748-749
26a	I	749-752
.	O	752-753

Specific	O	754-762
inhibitors	O	763-773
of	O	774-776
signal	O	777-783
transduction	O	784-796
pathway	O	797-804
and	O	805-808
siRNA	O	809-814
approaches	O	815-825
were	O	826-830
used	O	831-835
to	O	836-838
explore	O	839-846
the	O	847-850
regulatory	O	851-861
mechanism	O	862-871
of	O	872-874
miR	B	875-878
-	I	878-879
26a	I	879-882
.	O	882-883

Migration	O	884-893
and	O	894-897
tube	O	898-902
forming	O	903-910
assays	O	911-917
were	O	918-922
conducted	O	923-932
to	O	933-935
show	O	936-940
the	O	941-944
changes	O	945-952
of	O	953-955
angiogenesis	O	956-968
induced	O	969-976
by	O	977-979
miR	B	980-983
-	I	983-984
26a	I	984-987
and	O	988-991
its	O	992-995
target	O	996-1002
genes	O	1003-1008
.	O	1008-1009

Finally	O	1010-1017
animal	O	1018-1024
studies	O	1025-1032
were	O	1033-1037
used	O	1038-1042
to	O	1043-1045
further	O	1046-1053
validate	O	1054-1062
those	O	1063-1068
findings	O	1069-1077
.	O	1077-1078

RESULTS	O	1079-1086
:	O	1086-1087
Ectopic	O	1088-1095
expression	O	1096-1106
of	O	1107-1109
miR	B	1110-1113
-	I	1113-1114
26a	I	1114-1117
exhibited	O	1118-1127
decreased	O	1128-1137
levels	O	1138-1144
of	O	1145-1147
VEGFA	O	1148-1153
in	O	1154-1156
HepG2	O	1157-1162
cells	O	1163-1168
.	O	1168-1169

Migration	O	1170-1179
and	O	1180-1183
tube	O	1184-1188
forming	O	1189-1196
of	O	1197-1199
human	O	1200-1205
umbilical	O	1206-1215
vein	O	1216-1220
endothelial	O	1221-1232
cells	O	1233-1238
(	O	1239-1240
HUVECs	O	1240-1246
)	O	1246-1247
were	O	1248-1252
decreased	O	1253-1262
in	O	1263-1265
the	O	1266-1269
conditioned	O	1270-1281
medium	O	1282-1288
from	O	1289-1293
ectopic	O	1294-1301
expression	O	1302-1312
of	O	1313-1315
miR	B	1316-1319
-	I	1319-1320
26a	I	1320-1323
in	O	1324-1326
HepG2	O	1327-1332
cells	O	1333-1338
compared	O	1339-1347
to	O	1348-1350
control	O	1351-1358
HepG2	O	1359-1364
cells	O	1365-1370
.	O	1370-1371

The	O	1372-1375
pro	O	1376-1379
-	O	1379-1380
angiogenic	O	1380-1390
effects	O	1391-1398
of	O	1399-1401
the	O	1402-1405
conditioned	O	1406-1417
medium	O	1418-1424
of	O	1425-1427
HepG2	O	1428-1433
cells	O	1434-1439
on	O	1440-1442
HUVECs	O	1443-1449
were	O	1450-1454
specifically	O	1455-1467
decreased	O	1468-1477
by	O	1478-1480
LY294002	O	1481-1489
,	O	1489-1490
YC	O	1491-1493
-	O	1493-1494
1	O	1494-1495
,	O	1495-1496
and	O	1497-1500
bevacizumab	O	1501-1512
.	O	1512-1513

Integrated	O	1514-1524
analysis	O	1525-1533
disclosed	O	1534-1543
PIK3C2alpha	O	1544-1555
as	O	1556-1558
a	O	1559-1560
downstream	O	1561-1571
target	O	1572-1578
gene	O	1579-1583
of	O	1584-1586
miR	B	1587-1590
-	I	1590-1591
26a	I	1591-1594
.	O	1594-1595

Ectopic	O	1596-1603
expression	O	1604-1614
of	O	1615-1617
miR	B	1618-1621
-	I	1621-1622
26a	I	1622-1625
suppressed	O	1626-1636
ectopic	O	1637-1644
and	O	1645-1648
orthotopic	O	1649-1659
tumor	O	1660-1665
growth	O	1666-1672
and	O	1673-1676
vascularity	O	1677-1688
in	O	1689-1691
nude	O	1692-1696
mice	O	1697-1701
.	O	1701-1702

The	O	1703-1706
results	O	1707-1714
in	O	1715-1717
HCCLM3	O	1718-1724
were	O	1725-1729
consistent	O	1730-1740
with	O	1741-1745
those	O	1746-1751
in	O	1752-1754
HepG2	O	1755-1760
.	O	1760-1761

miR	B	1762-1765
-	I	1765-1766
26a	I	1766-1769
expression	O	1770-1780
was	O	1781-1784
inversely	O	1785-1794
correlated	O	1795-1805
with	O	1806-1810
VEGFA	O	1811-1816
expression	O	1817-1827
in	O	1828-1830
HCC	O	1831-1834
patients	O	1835-1843
.	O	1843-1844

CONCLUSIONS	O	1845-1856
:	O	1856-1857
miR	B	1858-1861
-	I	1861-1862
26a	I	1862-1865
modulated	O	1866-1875
angiogenesis	O	1876-1888
of	O	1889-1891
HCC	O	1892-1895
through	O	1896-1903
the	O	1904-1907
PIK3C2alpha	O	1908-1919
/	O	1919-1920
Akt	O	1920-1923
/	O	1923-1924
HIF	O	1924-1927
-	O	1927-1928
1alpha	O	1928-1934
/	O	1934-1935
VEGFA	O	1935-1940
pathway	O	1941-1948
.	O	1948-1949

The	O	1950-1953
expression	O	1954-1964
of	O	1965-1967
VEGFA	O	1968-1973
was	O	1974-1977
inversely	O	1978-1987
correlated	O	1988-1998
with	O	1999-2003
miR	B	2004-2007
-	I	2007-2008
26a	I	2008-2011
expression	O	2012-2022
in	O	2023-2025
HCC	O	2026-2029
tumors	O	2030-2036
.	O	2036-2037

MicroRNA	B	0-8
-	I	8-9
150	I	9-12
inhibits	O	13-21
expression	O	22-32
of	O	33-35
adiponectin	O	36-47
receptor	O	48-56
2	O	57-58
and	O	59-62
is	O	63-65
a	O	66-67
potential	O	68-77
therapeutic	O	78-89
target	O	90-96
in	O	97-99
patients	O	100-108
with	O	109-113
chronic	O	114-121
heart	O	122-127
failure	O	128-135
.	O	135-136

BACKGROUND	O	137-147
:	O	147-148
Adiponectin	O	149-160
is	O	161-163
an	O	164-166
anti	O	167-171
-	O	171-172
inflammatory	O	172-184
adipocytokine	O	185-198
believed	O	199-207
to	O	208-210
be	O	211-213
involved	O	214-222
in	O	223-225
the	O	226-229
pathogenesis	O	230-242
of	O	243-245
chronic	O	246-253
heart	O	254-259
failure	O	260-267
(	O	268-269
CHF	O	269-272
)	O	272-273
.	O	273-274

We	O	275-277
aimed	O	278-283
to	O	284-286
characterize	O	287-299
the	O	300-303
expression	O	304-314
of	O	315-317
adiponectin	O	318-329
and	O	330-333
its	O	334-337
receptors	O	338-347
in	O	348-350
CHF	O	351-354
and	O	355-358
to	O	359-361
assess	O	362-368
the	O	369-372
impact	O	373-379
of	O	380-382
microRNAs	O	383-392
on	O	393-395
the	O	396-399
cardiac	O	400-407
adiponectin	O	408-419
system	O	420-426
.	O	426-427

METHODS	O	428-435
:	O	435-436
Expression	O	437-447
of	O	448-450
adiponectin	O	451-462
and	O	463-466
adiponectin	O	467-478
receptors	O	479-488
(	O	489-490
ADIPOR1	O	490-497
and	O	498-501
ADIPOR2	O	502-509
)	O	509-510
was	O	511-514
studied	O	515-522
by	O	523-525
qPCR	O	526-530
and	O	531-534
immunohistochemistry	O	535-555
in	O	556-558
myocardial	O	559-569
tissues	O	570-577
of	O	578-580
patients	O	581-589
with	O	590-594
end	O	595-598
-	O	598-599
stage	O	599-604
CHF	O	605-608
and	O	609-612
control	O	613-620
subjects	O	621-629
.	O	629-630

MicroRNA	O	631-639
binding	O	640-647
was	O	648-651
evaluated	O	652-661
by	O	662-664
cloning	O	665-672
of	O	673-675
an	O	676-678
ADIPOR2	O	679-686
3	O	687-688
-	O	689-690
untranslated	O	690-702
-	O	702-703
region	O	703-709
reporter	O	710-718
construct	O	719-728
and	O	729-732
subsequent	O	733-743
transfection	O	744-756
experiments	O	757-768
.	O	768-769

Effects	O	770-777
of	O	778-780
miRNA	O	781-786
transfection	O	787-799
were	O	800-804
analyzed	O	805-813
in	O	814-816
cardiomyocyte	O	817-830
cell	O	831-835
cultures	O	836-844
by	O	845-847
qPCR	O	848-852
and	O	853-856
Western	O	857-864
blotting	O	865-873
.	O	873-874

Gene	O	875-879
silencing	O	880-889
of	O	890-892
ADIPOR2	O	893-900
was	O	901-904
performed	O	905-914
by	O	915-917
siRNA	O	918-923
transfection	O	924-936
,	O	936-937
and	O	938-941
the	O	942-945
effects	O	946-953
of	O	954-956
hypoxia	O	957-964
/	O	964-965
serum	O	965-970
starvation	O	971-981
were	O	982-986
analyzed	O	987-995
by	O	996-998
flow	O	999-1003
cytometry	O	1004-1013
.	O	1013-1014

RESULTS	O	1015-1022
:	O	1022-1023
Although	O	1024-1032
CHF	O	1033-1036
patients	O	1037-1045
displayed	O	1046-1055
elevated	O	1056-1064
plasma	O	1065-1071
adiponectin	O	1072-1083
levels	O	1084-1090
,	O	1090-1091
myocardial	O	1092-1102
adiponectin	O	1103-1114
expression	O	1115-1125
generally	O	1126-1135
was	O	1136-1139
very	O	1140-1144
low	O	1145-1148
.	O	1148-1149

In	O	1150-1152
CHF	O	1153-1156
,	O	1156-1157
cardiac	O	1158-1165
ADIPOR1	O	1166-1173
expression	O	1174-1184
increased	O	1185-1194
by	O	1195-1197
>	O	1198-1199
4	O	1199-1200
-	O	1200-1201
fold	O	1201-1205
,	O	1205-1206
whereas	O	1207-1214
the	O	1215-1218
increase	O	1219-1227
in	O	1228-1230
ADIPOR2	O	1231-1238
was	O	1239-1242
less	O	1243-1247
than	O	1248-1252
2	O	1253-1254
-	O	1254-1255
fold	O	1255-1259
.	O	1259-1260

Reporter	O	1261-1269
gene	O	1270-1274
assays	O	1275-1281
on	O	1282-1284
constructs	O	1285-1295
containing	O	1296-1306
the	O	1307-1310
ADIPOR2	O	1311-1318
-	O	1318-1319
3	O	1319-1320
'	O	1320-1321
-	O	1321-1322
untranslated	O	1322-1334
region	O	1335-1341
suggest	O	1342-1349
that	O	1350-1354
microRNA	B	1355-1363
-	I	1363-1364
150	I	1364-1367
specifically	O	1368-1380
repressed	O	1381-1390
ADIPOR2	O	1391-1398
expression	O	1399-1409
.	O	1409-1410

Transfection	O	1411-1423
of	O	1424-1426
cardiomyocytes	O	1427-1441
with	O	1442-1446
premiR	B	1447-1453
-	I	1453-1454
150	I	1454-1457
precursor	O	1458-1467
molecules	O	1468-1477
resulted	O	1478-1486
in	O	1487-1489
60	O	1490-1492
%	O	1492-1493
down	O	1494-1498
-	O	1498-1499
regulation	O	1499-1509
of	O	1510-1512
ADIPOR2	O	1513-1520
mRNA	O	1521-1525
and	O	1526-1529
a	O	1530-1531
significant	O	1532-1543
reduction	O	1544-1553
of	O	1554-1556
ADIPOR2	O	1557-1564
protein	O	1565-1572
expression	O	1573-1583
.	O	1583-1584

MicroRNA	B	1585-1593
-	I	1593-1594
150	I	1594-1597
was	O	1598-1601
substantially	O	1602-1615
expressed	O	1616-1625
in	O	1626-1628
both	O	1629-1633
normal	O	1634-1640
and	O	1641-1644
CHF	O	1645-1648
myocardium	O	1649-1659
,	O	1659-1660
with	O	1661-1665
a	O	1666-1667
1	O	1668-1669
.	O	1669-1670
7	O	1670-1671
-	O	1671-1672
fold	O	1672-1676
higher	O	1677-1683
expression	O	1684-1694
in	O	1695-1697
CHF	O	1698-1701
.	O	1701-1702

Finally	O	1703-1710
,	O	1710-1711
knock	O	1712-1717
-	O	1717-1718
down	O	1718-1722
experiments	O	1723-1734
elucidated	O	1735-1745
a	O	1746-1747
stress	O	1748-1754
-	O	1754-1755
protective	O	1755-1765
role	O	1766-1770
of	O	1771-1773
ADIPOR2	O	1774-1781
in	O	1782-1784
cardiomyocytes	O	1785-1799
.	O	1799-1800

CONCLUSIONS	O	1801-1812
:	O	1812-1813
MicroRNA	B	1814-1822
-	I	1822-1823
150	I	1823-1826
counteracts	O	1827-1838
ADIPOR2	O	1839-1846
up	O	1847-1849
-	O	1849-1850
regulation	O	1850-1860
in	O	1861-1863
CHF	O	1864-1867
and	O	1868-1871
thus	O	1872-1876
may	O	1877-1880
contribute	O	1881-1891
to	O	1892-1894
adiponectin	O	1895-1906
resistance	O	1907-1917
.	O	1917-1918

Targeting	O	1919-1928
microRNA	B	1929-1937
-	I	1937-1938
150	I	1938-1941
may	O	1942-1945
be	O	1946-1948
a	O	1949-1950
future	O	1951-1957
strategy	O	1958-1966
to	O	1967-1969
restore	O	1970-1977
cardioprotective	O	1978-1994
adiponectin	O	1995-2006
effects	O	2007-2014
.	O	2014-2015

Ambient	O	0-7
particulate	O	8-19
air	O	20-23
pollution	O	24-33
and	O	34-37
microRNAs	O	38-47
in	O	48-50
elderly	O	51-58
men	O	59-62
.	O	62-63

BACKGROUND	O	64-74
:	O	74-75
Ambient	O	76-83
particulate	O	84-95
matter	O	96-102
(	O	103-104
PM	O	104-106
)	O	106-107
has	O	108-111
been	O	112-116
associated	O	117-127
with	O	128-132
mortality	O	133-142
and	O	143-146
morbidity	O	147-156
for	O	157-160
cardiovascular	O	161-175
disease	O	176-183
.	O	183-184

MicroRNAs	O	185-194
control	O	195-202
gene	O	203-207
expression	O	208-218
at	O	219-221
a	O	222-223
posttranscriptional	O	224-243
level	O	244-249
.	O	249-250

Altered	O	251-258
microRNA	O	259-267
expression	O	268-278
has	O	279-282
been	O	283-287
reported	O	288-296
in	O	297-299
processes	O	300-309
related	O	310-317
to	O	318-320
cardiovascular	O	321-335
disease	O	336-343
and	O	344-347
PM	O	348-350
exposure	O	351-359
,	O	359-360
such	O	361-365
as	O	366-368
systemic	O	369-377
inflammation	O	378-390
,	O	390-391
endothelial	O	392-403
dysfunction	O	404-415
,	O	415-416
and	O	417-420
atherosclerosis	O	421-436
.	O	436-437

Polymorphisms	O	438-451
in	O	452-454
microRNA	O	455-463
-	O	463-464
related	O	464-471
genes	O	472-477
could	O	478-483
influence	O	484-493
response	O	494-502
to	O	503-505
PM	O	506-508
.	O	508-509

METHODS	O	510-517
:	O	517-518
We	O	519-521
investigated	O	522-534
the	O	535-538
association	O	539-550
of	O	551-553
exposure	O	554-562
to	O	563-565
ambient	O	566-573
particles	O	574-583
in	O	584-586
several	O	587-594
time	O	595-599
windows	O	600-607
(	O	608-609
4	O	609-610
-	O	610-611
hour	O	611-615
to	O	616-618
28	O	619-621
-	O	621-622
day	O	622-625
moving	O	626-632
averages	O	633-641
)	O	641-642
and	O	643-646
blood	O	647-652
leukocyte	O	653-662
expression	O	663-673
changes	O	674-681
in	O	682-684
14	O	685-687
candidate	O	688-697
microRNAs	O	698-707
in	O	708-710
153	O	711-714
elderly	O	715-722
males	O	723-728
from	O	729-733
the	O	734-737
Normative	O	738-747
Aging	O	748-753
Study	O	754-759
(	O	760-761
examined	O	761-769
2005	O	770-774
-	O	774-775
2009	O	775-779
)	O	779-780
.	O	780-781

Potential	O	782-791
effect	O	792-798
modification	O	799-811
by	O	812-814
six	O	815-818
single	O	819-825
nucleotide	O	826-836
polymorphisms	O	837-850
(	O	851-852
SNPs	O	852-856
)	O	856-857
in	O	858-860
three	O	861-866
microRNA	O	867-875
-	O	875-876
related	O	876-883
genes	O	884-889
was	O	890-893
investigated	O	894-906
.	O	906-907

Fine	O	908-912
PM	O	913-915
(	O	916-917
PM2	O	917-920
.	O	920-921
5	O	921-922
)	O	922-923
,	O	923-924
black	O	925-930
carbon	O	931-937
,	O	937-938
organic	O	939-946
carbon	O	947-953
,	O	953-954
and	O	955-958
sulfates	O	959-967
were	O	968-972
measured	O	973-981
at	O	982-984
a	O	985-986
stationary	O	987-997
ambient	O	998-1005
monitoring	O	1006-1016
site	O	1017-1021
.	O	1021-1022

Linear	O	1023-1029
regression	O	1030-1040
models	O	1041-1047
,	O	1047-1048
adjusted	O	1049-1057
for	O	1058-1061
potential	O	1062-1071
confounders	O	1072-1083
,	O	1083-1084
were	O	1085-1089
used	O	1090-1094
to	O	1095-1097
assess	O	1098-1104
effects	O	1105-1112
of	O	1113-1115
particles	O	1116-1125
and	O	1126-1129
SNP	O	1130-1133
-	O	1133-1134
by	O	1134-1136
-	O	1136-1137
pollutant	O	1137-1146
interaction	O	1147-1158
.	O	1158-1159

An	O	1160-1162
in	O	1163-1165
silico	O	1166-1172
pathway	O	1173-1180
analysis	O	1181-1189
was	O	1190-1193
performed	O	1194-1203
on	O	1204-1206
target	O	1207-1213
genes	O	1214-1219
of	O	1220-1222
microRNAs	O	1223-1232
associated	O	1233-1243
with	O	1244-1248
the	O	1249-1252
pollutants	O	1253-1263
.	O	1263-1264

RESULTS	O	1265-1272
:	O	1272-1273
We	O	1274-1276
found	O	1277-1282
a	O	1283-1284
negative	O	1285-1293
association	O	1294-1305
for	O	1306-1309
pollutants	O	1310-1320
in	O	1321-1323
all	O	1324-1327
moving	O	1328-1334
averages	O	1335-1343
and	O	1344-1347
miR	B	1348-1351
-	I	1351-1352
1	I	1352-1353
,	O	1353-1354
-	B	1355-1356
126	I	1356-1359
,	O	1359-1360
-	B	1361-1362
135a	I	1362-1366
,	O	1366-1367
-	B	1368-1369
146a	I	1369-1373
,	O	1373-1374
-	B	1375-1376
155	I	1376-1379
,	O	1379-1380
-	B	1381-1382
21	I	1382-1384
,	O	1384-1385
-	B	1386-1387
222	I	1387-1390
,	O	1390-1391
and	O	1392-1395
-	B	1396-1397
9	I	1397-1398
.	O	1398-1399

The	O	1400-1403
strongest	O	1404-1413
associations	O	1414-1426
were	O	1427-1431
observed	O	1432-1440
with	O	1441-1445
the	O	1446-1449
7	O	1450-1451
-	O	1451-1452
day	O	1452-1455
moving	O	1456-1462
averages	O	1463-1471
for	O	1472-1475
PM2	O	1476-1479
.	O	1479-1480
5	O	1480-1481
and	O	1482-1485
black	O	1486-1491
carbon	O	1492-1498
and	O	1499-1502
with	O	1503-1507
the	O	1508-1511
48	O	1512-1514
-	O	1514-1515
hour	O	1515-1519
moving	O	1520-1526
averages	O	1527-1535
for	O	1536-1539
organic	O	1540-1547
carbon	O	1548-1554
.	O	1554-1555

The	O	1556-1559
association	O	1560-1571
with	O	1572-1576
sulfates	O	1577-1585
was	O	1586-1589
stable	O	1590-1596
across	O	1597-1603
the	O	1604-1607
moving	O	1608-1614
averages	O	1615-1623
.	O	1623-1624

The	O	1625-1628
in	O	1629-1631
silico	O	1632-1638
pathway	O	1639-1646
analysis	O	1647-1655
identified	O	1656-1666
18	O	1667-1669
pathways	O	1670-1678
related	O	1679-1686
to	O	1687-1689
immune	O	1690-1696
response	O	1697-1705
shared	O	1706-1712
by	O	1713-1715
at	O	1716-1718
least	O	1719-1724
two	O	1725-1728
microRNAs	O	1729-1738
;	O	1738-1739
in	O	1740-1742
particular	O	1743-1753
,	O	1753-1754
the	O	1755-1758
"	O	1759-1760
high	O	1760-1764
-	O	1764-1765
mobility	O	1765-1773
group	O	1774-1779
protein	O	1780-1787
B1	O	1788-1790
/	O	1790-1791
advanced	O	1791-1799
glycosylation	O	1800-1813
end	O	1814-1817
product	O	1818-1825
-	O	1825-1826
specific	O	1826-1834
receptor	O	1835-1843
signaling	O	1844-1853
pathway	O	1854-1861
"	O	1861-1862
was	O	1863-1866
shared	O	1867-1873
by	O	1874-1876
miR	B	1877-1880
-	I	1880-1881
126	I	1881-1884
,	O	1884-1885
-	B	1886-1887
146a	I	1887-1891
,	O	1891-1892
-	B	1893-1894
155	I	1894-1897
,	O	1897-1898
-	B	1899-1900
21	I	1900-1902
,	O	1902-1903
and	O	1904-1907
-	B	1908-1909
222	I	1909-1912
.	O	1912-1913

No	O	1914-1916
important	O	1917-1926
associations	O	1927-1939
were	O	1940-1944
observed	O	1945-1953
for	O	1954-1957
miR	B	1958-1961
-	I	1961-1962
125a	I	1962-1966
-	I	1966-1967
5p	I	1967-1969
,	O	1969-1970
-	B	1971-1972
125b	I	1972-1976
,	O	1976-1977
-	B	1978-1979
128	I	1979-1982
,	O	1982-1983
-	B	1984-1985
147	I	1985-1988
,	O	1988-1989
-	B	1990-1991
218	I	1991-1994
,	O	1994-1995
and	O	1996-1999
-	B	2000-2001
96	I	2001-2003
.	O	2003-2004

We	O	2005-2007
found	O	2008-2013
significant	O	2014-2025
SNP	O	2026-2029
-	O	2029-2030
by	O	2030-2032
-	O	2032-2033
pollutant	O	2033-2042
interactions	O	2043-2055
for	O	2056-2059
rs7813	O	2060-2066
,	O	2066-2067
rs910925	O	2068-2076
,	O	2076-2077
and	O	2078-2081
rs1062923	O	2082-2091
in	O	2092-2094
GEMIN4	O	2095-2101
and	O	2102-2105
black	O	2106-2111
carbon	O	2112-2118
and	O	2119-2122
PM2	O	2123-2126
.	O	2126-2127
5	O	2127-2128
for	O	2129-2132
miR	B	2133-2136
-	I	2136-2137
1	I	2137-2138
,	O	2138-2139
-	B	2140-2141
126	I	2141-2144
,	O	2144-2145
-	B	2146-2147
146a	I	2147-2151
,	O	2151-2152
-	B	2153-2154
222	I	2154-2157
,	O	2157-2158
and	O	2159-2162
-	B	2163-2164
9	I	2164-2165
,	O	2165-2166
and	O	2167-2170
for	O	2171-2174
rs1640299	O	2175-2184
in	O	2185-2187
DGCR8	O	2188-2193
and	O	2194-2197
SO4	O	2198-2201
for	O	2202-2205
miR	B	2206-2209
-	I	2209-2210
1	I	2210-2211
and	O	2212-2215
-	B	2216-2217
135a	I	2217-2221
.	O	2221-2222

CONCLUSIONS	O	2223-2234
:	O	2234-2235
Exposure	O	2236-2244
to	O	2245-2247
ambient	O	2248-2255
particles	O	2256-2265
could	O	2266-2271
cause	O	2272-2277
a	O	2278-2279
downregulation	O	2280-2294
of	O	2295-2297
microRNAs	O	2298-2307
involved	O	2308-2316
in	O	2317-2319
processes	O	2320-2329
related	O	2330-2337
to	O	2338-2340
PM	O	2341-2343
exposure	O	2344-2352
.	O	2352-2353

Polymorphisms	O	2354-2367
in	O	2368-2370
GEMIN4	O	2371-2377
and	O	2378-2381
DGCR8	O	2382-2387
could	O	2388-2393
modify	O	2394-2400
these	O	2401-2406
associations	O	2407-2419
.	O	2419-2420

MiRNA	B	0-5
-	I	5-6
296	I	6-9
-	I	9-10
3p	I	10-12
-	O	12-13
ICAM	O	13-17
-	O	17-18
1	O	18-19
axis	O	20-24
promotes	O	25-33
metastasis	O	34-44
of	O	45-47
prostate	O	48-56
cancer	O	57-63
by	O	64-66
possible	O	67-75
enhancing	O	76-85
survival	O	86-94
of	O	95-97
natural	O	98-105
killer	O	106-112
cell	O	113-117
-	O	117-118
resistant	O	118-127
circulating	O	128-139
tumour	O	140-146
cells	O	147-152
.	O	152-153

Natural	O	154-161
killer	O	162-168
(	O	169-170
NK	O	170-172
)	O	172-173
cells	O	174-179
are	O	180-183
important	O	184-193
in	O	194-196
host	O	197-201
to	O	202-204
eliminate	O	205-214
circulating	O	215-226
tumour	O	227-233
cells	O	234-239
(	O	240-241
CTCs	O	241-245
)	O	245-246
in	O	247-249
turn	O	250-254
preventing	O	255-265
the	O	266-269
development	O	270-281
of	O	282-284
tumour	O	285-291
cells	O	292-297
into	O	298-302
metastasis	O	303-313
but	O	314-317
the	O	318-321
mechanisms	O	322-332
are	O	333-336
very	O	337-341
poorly	O	342-348
defined	O	349-356
.	O	356-357

Here	O	358-362
we	O	363-365
find	O	366-370
that	O	371-375
the	O	376-379
expression	O	380-390
level	O	391-396
of	O	397-399
miR	B	400-403
-	I	403-404
296	I	404-407
-	I	407-408
3p	I	408-410
is	O	411-413
much	O	414-418
lower	O	419-424
in	O	425-427
the	O	428-431
non	O	432-435
-	O	435-436
metastatic	O	436-446
human	O	447-452
prostate	O	453-461
cancer	O	462-468
(	O	469-470
PCa	O	470-473
)	O	473-474
cell	O	475-479
line	O	480-484
P69	O	485-488
than	O	489-493
that	O	494-498
in	O	499-501
the	O	502-505
highly	O	506-512
metastatic	O	513-523
cell	O	524-528
line	O	529-533
M12	O	534-537
,	O	537-538
which	O	539-544
is	O	545-547
derived	O	548-555
from	O	556-560
P69	O	561-564
.	O	564-565

We	O	566-568
demonstrate	O	569-580
that	O	581-585
miR	B	586-589
-	I	589-590
296	I	590-593
-	I	593-594
3p	I	594-596
directly	O	597-605
targets	O	606-613
and	O	614-617
inhibits	O	618-626
the	O	627-630
expression	O	631-641
of	O	642-644
intercellular	O	645-658
adhesion	O	659-667
molecule	O	668-676
1	O	677-678
(	O	679-680
ICAM	O	680-684
-	O	684-685
1	O	685-686
)	O	686-687
in	O	688-690
the	O	691-694
malignant	O	695-704
M12	O	705-708
.	O	708-709

The	O	710-713
data	O	714-718
from	O	719-723
clinical	O	724-732
tissue	O	733-739
microarrays	O	740-751
also	O	752-756
show	O	757-761
that	O	762-766
miR	B	767-770
-	I	770-771
296	I	771-774
-	I	774-775
3p	I	775-777
is	O	778-780
frequently	O	781-791
upregulated	O	792-803
and	O	804-807
ICAM	O	808-812
-	O	812-813
1	O	813-814
is	O	815-817
reversely	O	818-827
downregulated	O	828-841
in	O	842-844
PCa	O	845-848
.	O	848-849

Interestingly	O	850-863
,	O	863-864
ectopic	O	865-872
expression	O	873-883
of	O	884-886
miR	B	887-890
-	I	890-891
296	I	891-894
-	I	894-895
3p	I	895-897
in	O	898-900
P69	O	901-904
increases	O	905-914
the	O	915-918
tolerance	O	919-928
to	O	929-931
NK	O	932-934
cells	O	935-940
whereas	O	941-948
knockdown	O	949-958
of	O	959-961
miR	B	962-965
-	I	965-966
296	I	966-969
-	I	969-970
3p	I	970-972
in	O	973-975
M12	O	976-979
reduces	O	980-987
the	O	988-991
resistance	O	992-1002
to	O	1003-1005
NK	O	1006-1008
cells	O	1009-1014
,	O	1014-1015
which	O	1016-1021
both	O	1022-1026
phenotypes	O	1027-1037
can	O	1038-1041
be	O	1042-1044
rescued	O	1045-1052
by	O	1053-1055
re	O	1056-1058
-	O	1058-1059
expression	O	1059-1069
or	O	1070-1072
silencing	O	1073-1082
of	O	1083-1085
ICAM	O	1086-1090
-	O	1090-1091
1	O	1091-1092
in	O	1093-1095
P69	O	1096-1099
and	O	1100-1103
M12	O	1104-1107
,	O	1107-1108
respectively	O	1109-1121
.	O	1121-1122

These	O	1123-1128
results	O	1129-1136
are	O	1137-1140
also	O	1141-1145
manifested	O	1146-1156
in	O	1157-1159
vivo	O	1160-1164
by	O	1165-1167
the	O	1168-1171
decrease	O	1172-1180
in	O	1181-1183
the	O	1184-1187
incidence	O	1188-1197
of	O	1198-1200
pulmonary	O	1201-1210
tumour	O	1211-1217
metastasis	O	1218-1228
exhibited	O	1229-1238
by	O	1239-1241
knockdown	O	1242-1251
of	O	1252-1254
miR	B	1255-1258
-	I	1258-1259
296	I	1259-1262
-	I	1262-1263
3p	I	1263-1265
in	O	1266-1268
M12	O	1269-1272
when	O	1273-1277
injected	O	1278-1286
into	O	1287-1291
athymic	O	1292-1299
nude	O	1300-1304
mice	O	1305-1309
via	O	1310-1313
tail	O	1314-1318
vein	O	1319-1323
,	O	1323-1324
and	O	1325-1328
consistently	O	1329-1341
down	O	1342-1346
-	O	1346-1347
expression	O	1347-1357
of	O	1358-1360
ICAM	O	1361-1365
-	O	1365-1366
1	O	1366-1367
reverses	O	1368-1376
this	O	1377-1381
to	O	1382-1384
increase	O	1385-1393
extravasation	O	1394-1407
of	O	1408-1410
CTCs	O	1411-1415
into	O	1416-1420
lungs	O	1421-1426
.	O	1426-1427

Above	O	1428-1433
results	O	1434-1441
suggest	O	1442-1449
that	O	1450-1454
this	O	1455-1459
newly	O	1460-1465
identified	O	1466-1476
miR	B	1477-1480
-	I	1480-1481
296	I	1481-1484
-	I	1484-1485
3p	I	1485-1487
-	O	1487-1488
ICAM	O	1488-1492
-	O	1492-1493
1	O	1493-1494
axis	O	1495-1499
has	O	1500-1503
a	O	1504-1505
pivotal	O	1506-1513
role	O	1514-1518
in	O	1519-1521
mediating	O	1522-1531
PCa	O	1532-1535
metastasis	O	1536-1546
by	O	1547-1549
possible	O	1550-1558
enhancing	O	1559-1568
survival	O	1569-1577
of	O	1578-1580
NK	O	1581-1583
cell	O	1584-1588
-	O	1588-1589
resistant	O	1589-1598
CTC	O	1599-1602
.	O	1602-1603

Our	O	1604-1607
findings	O	1608-1616
provide	O	1617-1624
novel	O	1625-1630
potential	O	1631-1640
targets	O	1641-1648
for	O	1649-1652
PCa	O	1653-1656
therapy	O	1657-1664
and	O	1665-1668
prognosis	O	1669-1678
.	O	1678-1679

MicroRNA	B	0-8
-	I	8-9
30b	I	9-12
functions	O	13-22
as	O	23-25
a	O	26-27
tumour	O	28-34
suppressor	O	35-45
in	O	46-48
human	O	49-54
colorectal	O	55-65
cancer	O	66-72
by	O	73-75
targeting	O	76-85
KRAS	O	86-90
,	O	90-91
PIK3CD	O	92-98
and	O	99-102
BCL2	O	103-107
.	O	107-108

Colorectal	O	109-119
cancer	O	120-126
(	O	127-128
CRC	O	128-131
)	O	131-132
is	O	133-135
the	O	136-139
third	O	140-145
most	O	146-150
common	O	151-157
cancer	O	158-164
in	O	165-167
the	O	168-171
USA	O	172-175
.	O	175-176

MicroRNAs	O	177-186
play	O	187-191
important	O	192-201
roles	O	202-207
in	O	208-210
the	O	211-214
pathogenesis	O	215-227
of	O	228-230
CRC	O	231-234
.	O	234-235

In	O	236-238
this	O	239-243
study	O	244-249
,	O	249-250
we	O	251-253
investigated	O	254-266
the	O	267-270
role	O	271-275
of	O	276-278
miR	B	279-282
-	I	282-283
30b	I	283-286
in	O	287-289
CRC	O	290-293
and	O	294-297
found	O	298-303
that	O	304-308
its	O	309-312
expression	O	313-323
was	O	324-327
significantly	O	328-341
lower	O	342-347
in	O	348-350
CRC	O	351-354
tissues	O	355-362
than	O	363-367
that	O	368-372
in	O	373-375
normal	O	376-382
tissues	O	383-390
.	O	390-391

We	O	392-394
showed	O	395-401
that	O	402-406
a	O	407-408
low	O	409-412
expression	O	413-423
level	O	424-429
of	O	430-432
miR	B	433-436
-	I	436-437
30b	I	437-440
was	O	441-444
closely	O	445-452
related	O	453-460
to	O	461-463
poor	O	464-468
differentiation	O	469-484
,	O	484-485
advanced	O	486-494
TNM	O	495-498
stage	O	499-504
and	O	505-508
poor	O	509-513
prognosis	O	514-523
of	O	524-526
CRC	O	527-530
.	O	530-531

Further	O	532-539
experiments	O	540-551
showed	O	552-558
that	O	559-563
over	O	564-568
-	O	568-569
expression	O	569-579
of	O	580-582
miR	B	583-586
-	I	586-587
30b	I	587-590
suppressed	O	591-601
CRC	O	602-605
cell	O	606-610
proliferation	O	611-624
in	O	625-627
vitro	O	628-633
and	O	634-637
tumour	O	638-644
growth	O	645-651
in	O	652-654
vivo	O	655-659
.	O	659-660

Specifically	O	661-673
,	O	673-674
miR	B	675-678
-	I	678-679
30b	I	679-682
promoted	O	683-691
G1	O	692-694
arrest	O	695-701
and	O	702-705
induced	O	706-713
apoptosis	O	714-723
.	O	723-724

Moreover	O	725-733
,	O	733-734
KRAS	O	735-739
,	O	739-740
PIK3CD	O	741-747
and	O	748-751
BCL2	O	752-756
were	O	757-761
identified	O	762-772
as	O	773-775
direct	O	776-782
and	O	783-786
functional	O	787-797
targets	O	798-805
of	O	806-808
miR	B	809-812
-	I	812-813
30b	I	813-816
.	O	816-817

MiR	B	818-821
-	I	821-822
30b	I	822-825
directly	O	826-834
targeted	O	835-843
the	O	844-847
3	O	848-849
'	O	849-850
-	O	850-851
untranslated	O	851-863
regions	O	864-871
of	O	872-874
their	O	875-880
mRNAs	O	881-886
and	O	887-890
repressed	O	891-900
their	O	901-906
expression	O	907-917
.	O	917-918

This	O	919-923
study	O	924-929
revealed	O	930-938
functional	O	939-949
and	O	950-953
mechanistic	O	954-965
links	O	966-971
between	O	972-979
miRNA	B	980-985
-	I	985-986
30b	I	986-989
and	O	990-993
oncogene	O	994-1002
KRAS	O	1003-1007
,	O	1007-1008
PIK3CD	O	1009-1015
and	O	1016-1019
BCL2	O	1020-1024
in	O	1025-1027
the	O	1028-1031
pathogenesis	O	1032-1044
of	O	1045-1047
CRC	O	1048-1051
.	O	1051-1052

MiR	B	1053-1056
-	I	1056-1057
30b	I	1057-1060
not	O	1061-1064
only	O	1065-1069
plays	O	1070-1075
important	O	1076-1085
roles	O	1086-1091
in	O	1092-1094
the	O	1095-1098
regulation	O	1099-1109
of	O	1110-1112
cell	O	1113-1117
proliferation	O	1118-1131
and	O	1132-1135
tumour	O	1136-1142
growth	O	1143-1149
in	O	1150-1152
CRC	O	1153-1156
,	O	1156-1157
but	O	1158-1161
is	O	1162-1164
also	O	1165-1169
a	O	1170-1171
potential	O	1172-1181
prognostic	O	1182-1192
marker	O	1193-1199
or	O	1200-1202
therapeutic	O	1203-1214
target	O	1215-1221
for	O	1222-1225
CRC	O	1226-1229
.	O	1229-1230

Restoration	O	1231-1242
of	O	1243-1245
miR	B	1246-1249
-	I	1249-1250
30b	I	1250-1253
expression	O	1254-1264
may	O	1265-1268
represent	O	1269-1278
a	O	1279-1280
promising	O	1281-1290
therapeutic	O	1291-1302
approach	O	1303-1311
for	O	1312-1315
targeting	O	1316-1325
malignant	O	1326-1335
CRC	O	1336-1339
.	O	1339-1340

Clusterin	O	0-9
is	O	10-12
a	O	13-14
gene	O	15-19
-	O	19-20
specific	O	20-28
target	O	29-35
of	O	36-38
microRNA	B	39-47
-	I	47-48
21	I	48-50
in	O	51-53
head	O	54-58
and	O	59-62
neck	O	63-67
squamous	O	68-76
cell	O	77-81
carcinoma	O	82-91
.	O	91-92

PURPOSE	O	93-100
:	O	100-101
MicroRNA	B	102-110
-	I	110-111
21	I	111-113
(	O	114-115
miRNA	B	115-120
-	I	120-121
21	I	121-123
)	O	123-124
has	O	125-128
proto	O	129-134
-	O	134-135
oncogenic	O	135-144
properties	O	145-155
,	O	155-156
although	O	157-165
no	O	166-168
miRNA	B	169-174
-	I	174-175
21	I	175-177
-	O	177-178
specific	O	178-186
targets	O	187-194
have	O	195-199
been	O	200-204
found	O	205-210
in	O	211-213
head	O	214-218
and	O	219-222
neck	O	223-227
squamous	O	228-236
cell	O	237-241
carcinoma	O	242-251
(	O	252-253
HNSCC	O	253-258
)	O	258-259
.	O	259-260

Further	O	261-268
study	O	269-274
of	O	275-277
miRNA	B	278-283
-	I	283-284
21	I	284-286
and	O	287-290
its	O	291-294
specific	O	295-303
targets	O	304-311
is	O	312-314
essential	O	315-324
to	O	325-327
understanding	O	328-341
HNSCC	O	342-347
biology	O	348-355
.	O	355-356

EXPERIMENTAL	O	357-369
DESIGN	O	370-376
:	O	376-377
miRNA	O	378-383
expression	O	384-394
profiles	O	395-403
of	O	404-406
10	O	407-409
HNSCCs	O	410-416
and	O	417-420
10	O	421-423
normal	O	424-430
mucosa	O	431-437
samples	O	438-445
were	O	446-450
investigated	O	451-463
using	O	464-469
a	O	470-471
custom	O	472-478
miRNA	O	479-484
microarray	O	485-495
.	O	495-496

Thirteen	O	497-505
HNSCCs	O	506-512
and	O	513-516
five	O	517-521
normal	O	522-528
mucosa	O	529-535
primary	O	536-543
tissue	O	544-550
specimens	O	551-560
underwent	O	561-570
mRNA	O	571-575
expression	O	576-586
microarray	O	587-597
analysis	O	598-606
.	O	606-607

To	O	608-610
identify	O	611-619
miRNA	B	620-625
-	I	625-626
21	I	626-628
downstream	O	629-639
targets	O	640-647
,	O	647-648
oral	O	649-653
keratinocyte	O	654-666
cells	O	667-672
were	O	673-677
subjected	O	678-687
to	O	688-690
microarray	O	691-701
analysis	O	702-710
after	O	711-716
miRNA	B	717-722
-	I	722-723
21	I	723-725
transient	O	726-735
transfection	O	736-748
.	O	748-749

miRNA	O	750-755
and	O	756-759
mRNA	O	760-764
expression	O	765-775
were	O	776-780
validated	O	781-790
by	O	791-793
reverse	O	794-801
transcription	O	802-815
quantitative	O	816-828
polymerase	O	829-839
chain	O	840-845
reaction	O	846-854
(	O	855-856
RT	O	856-858
-	O	858-859
qPCR	O	859-863
)	O	863-864
in	O	865-867
a	O	868-869
separate	O	870-878
cohort	O	879-885
of	O	886-888
16	O	889-891
HNSCCs	O	892-898
and	O	899-902
15	O	903-905
normal	O	906-912
mucosal	O	913-920
samples	O	921-928
.	O	928-929

Microarray	O	930-940
and	O	941-944
bioinformatics	O	945-959
analyses	O	960-968
were	O	969-973
integrated	O	974-984
to	O	985-987
identify	O	988-996
potential	O	997-1006
gene	O	1007-1011
targets	O	1012-1019
.	O	1019-1020

In	O	1021-1023
vitro	O	1024-1029
assays	O	1030-1036
looked	O	1037-1043
at	O	1044-1046
the	O	1047-1050
function	O	1051-1059
and	O	1060-1063
interaction	O	1064-1075
of	O	1076-1078
miRNA	B	1079-1084
-	I	1084-1085
21	I	1085-1087
and	O	1088-1091
its	O	1092-1095
specific	O	1096-1104
gene	O	1105-1109
targets	O	1110-1117
.	O	1117-1118

RESULTS	O	1119-1126
:	O	1126-1127
miRNA	B	1128-1133
-	I	1133-1134
21	I	1134-1136
was	O	1137-1140
upregulated	O	1141-1152
in	O	1153-1155
HNSCCs	O	1156-1162
and	O	1163-1166
stimulated	O	1167-1177
cell	O	1178-1182
growth	O	1183-1189
.	O	1189-1190

Integrated	O	1191-1201
analyses	O	1202-1210
identified	O	1211-1221
Clusterin	O	1222-1231
(	O	1232-1233
CLU	O	1233-1236
)	O	1236-1237
as	O	1238-1240
a	O	1241-1242
potential	O	1243-1252
miRNA	B	1253-1258
-	I	1258-1259
21	I	1259-1261
gene	O	1262-1266
target	O	1267-1273
.	O	1273-1274

CLU	O	1275-1278
was	O	1279-1282
downregulated	O	1283-1296
after	O	1297-1302
forced	O	1303-1309
expression	O	1310-1320
of	O	1321-1323
miRNA	B	1324-1329
-	I	1329-1330
21	I	1330-1332
in	O	1333-1335
normal	O	1336-1342
and	O	1343-1346
HNSCC	O	1347-1352
cell	O	1353-1357
lines	O	1358-1363
.	O	1363-1364

The	O	1365-1368
activity	O	1369-1377
of	O	1378-1380
a	O	1381-1382
luciferase	O	1383-1393
construct	O	1394-1403
containing	O	1404-1414
the	O	1415-1418
3	O	1419-1420
'	O	1420-1421
-	O	1421-1422
untranslated	O	1422-1434
region	O	1435-1441
(	O	1442-1443
UTR	O	1443-1446
)	O	1446-1447
of	O	1448-1450
CLU	O	1451-1454
was	O	1455-1458
repressed	O	1459-1468
by	O	1469-1471
the	O	1472-1475
ectopic	O	1476-1483
expression	O	1484-1494
of	O	1495-1497
miRNA	B	1498-1503
-	I	1503-1504
21	I	1504-1506
.	O	1506-1507

CLU	O	1508-1511
was	O	1512-1515
also	O	1516-1520
downregulated	O	1521-1534
in	O	1535-1537
primary	O	1538-1545
HNSCCs	O	1546-1552
and	O	1553-1556
correlated	O	1557-1567
with	O	1568-1572
miRNA	B	1573-1578
-	I	1578-1579
21	I	1579-1581
overexpression	O	1582-1596
.	O	1596-1597

CLU	O	1598-1601
variant	O	1602-1609
1	O	1610-1611
(	O	1612-1613
CLU	O	1613-1616
-	O	1616-1617
1	O	1617-1618
)	O	1618-1619
was	O	1620-1623
the	O	1624-1627
predominant	O	1628-1639
splice	O	1640-1646
variant	O	1647-1654
in	O	1655-1657
HNSCCs	O	1658-1664
and	O	1665-1668
showed	O	1669-1675
growth	O	1676-1682
suppression	O	1683-1694
function	O	1695-1703
that	O	1704-1708
was	O	1709-1712
reversed	O	1713-1721
by	O	1722-1724
miRNA	B	1725-1730
-	I	1730-1731
21	I	1731-1733
overexpression	O	1734-1748
.	O	1748-1749

CONCLUSIONS	O	1750-1761
:	O	1761-1762
CLU	O	1763-1766
is	O	1767-1769
a	O	1770-1771
specific	O	1772-1780
,	O	1780-1781
functional	O	1782-1792
target	O	1793-1799
of	O	1800-1802
oncogenic	O	1803-1812
miRNA	B	1813-1818
-	I	1818-1819
21	I	1819-1821
in	O	1822-1824
HNSCCs	O	1825-1831
.	O	1831-1832

CLU	O	1833-1836
-	O	1836-1837
1	O	1837-1838
isoform	O	1839-1846
is	O	1847-1849
the	O	1850-1853
predominant	O	1854-1865
growth	O	1866-1872
-	O	1872-1873
suppressive	O	1873-1884
variant	O	1885-1892
targeted	O	1893-1901
by	O	1902-1904
miRNA	B	1905-1910
-	I	1910-1911
21	I	1911-1913
.	O	1913-1914

Functions	O	0-9
of	O	10-12
microRNA	O	13-21
in	O	22-24
response	O	25-33
to	O	34-36
cocaine	O	37-44
stimulation	O	45-56
.	O	56-57

MicroRNAs	O	58-67
(	O	68-69
miRNAs	O	69-75
)	O	75-76
are	O	77-80
a	O	81-82
type	O	83-87
of	O	88-90
non	O	91-94
-	O	94-95
protein	O	95-102
-	O	102-103
coding	O	103-109
single	O	110-116
-	O	116-117
stranded	O	117-125
RNA	O	126-129
,	O	129-130
which	O	131-136
are	O	137-140
typically	O	141-150
20	O	151-153
-	O	153-154
25	O	154-156
nt	O	157-159
in	O	160-162
length	O	163-169
.	O	169-170

miRNAs	O	171-177
play	O	178-182
important	O	183-192
roles	O	193-198
in	O	199-201
various	O	202-209
biological	O	210-220
processes	O	221-230
,	O	230-231
including	O	232-241
development	O	242-253
,	O	253-254
cell	O	255-259
proliferation	O	260-273
,	O	273-274
differentiation	O	275-290
,	O	290-291
and	O	292-295
apoptosis	O	296-305
.	O	305-306

We	O	307-309
aimed	O	310-315
to	O	316-318
detect	O	319-325
the	O	326-329
miRNA	O	330-335
response	O	336-344
to	O	345-347
cocaine	O	348-355
stimulations	O	356-368
and	O	369-372
their	O	373-378
target	O	379-385
genes	O	386-391
.	O	391-392

Using	O	393-398
the	O	399-402
miRNA	O	403-408
expression	O	409-419
data	O	420-424
GSE21901	O	425-433
downloaded	O	434-444
from	O	445-449
the	O	450-453
Gene	O	454-458
Expression	O	459-469
Omnibus	O	470-477
database	O	478-486
,	O	486-487
we	O	488-490
screened	O	491-499
out	O	500-503
the	O	504-507
differentially	O	508-522
expressed	O	523-532
miRNA	O	533-538
after	O	539-544
short	O	545-550
-	O	550-551
term	O	551-555
(	O	556-557
1	O	557-558
h	O	559-560
)	O	560-561
and	O	562-565
longer	O	566-572
-	O	572-573
term	O	573-577
(	O	578-579
6	O	579-580
h	O	581-582
)	O	582-583
cocaine	O	584-591
stimulations	O	592-604
based	O	605-610
on	O	611-613
the	O	614-617
fold	O	618-622
change	O	623-629
>	O	630-631
1	O	631-632
.	O	632-633
2	O	633-634
.	O	634-635

Target	O	636-642
genes	O	643-648
of	O	649-651
differentially	O	652-666
expressed	O	667-676
miRNAs	O	677-683
were	O	684-688
retrieved	O	689-698
from	O	699-703
TargetScan	O	704-714
database	O	715-723
with	O	724-728
the	O	729-732
context	O	733-740
score	O	741-746
-	O	747-748
0	O	748-749
.	O	749-750
3	O	750-751
.	O	751-752

Functional	O	753-763
annotation	O	764-774
enrichment	O	775-785
analysis	O	786-794
was	O	795-798
performed	O	799-808
for	O	809-812
all	O	813-816
the	O	817-820
target	O	821-827
genes	O	828-833
with	O	834-838
DAVID	O	839-844
.	O	844-845

A	O	846-847
total	O	848-853
of	O	854-856
121	O	857-860
differentially	O	861-875
expressed	O	876-885
miRNAs	O	886-892
between	O	893-900
the	O	901-904
1	O	905-906
-	O	906-907
h	O	907-908
treatment	O	909-918
and	O	919-922
the	O	923-926
control	O	927-934
samples	O	935-942
,	O	942-943
58	O	944-946
between	O	947-954
the	O	955-958
6	O	959-960
-	O	960-961
h	O	961-962
treatment	O	963-972
and	O	973-976
the	O	977-980
control	O	981-988
samples	O	989-996
,	O	996-997
and	O	998-1001
69	O	1002-1004
between	O	1005-1012
the	O	1013-1016
1	O	1017-1018
-	O	1018-1019
h	O	1019-1020
and	O	1021-1024
the	O	1025-1028
6	O	1029-1030
-	O	1030-1031
h	O	1031-1032
treatment	O	1033-1042
samples	O	1043-1050
.	O	1050-1051

Among	O	1052-1057
them	O	1058-1062
,	O	1062-1063
miR	B	1064-1067
-	I	1067-1068
212	I	1068-1071
results	O	1072-1079
of	O	1080-1082
particular	O	1083-1093
interest	O	1094-1102
,	O	1102-1103
since	O	1104-1109
its	O	1110-1113
expression	O	1114-1124
level	O	1125-1130
was	O	1131-1134
constantly	O	1135-1145
elevated	O	1146-1154
responding	O	1155-1165
to	O	1166-1168
cocaine	O	1169-1176
treatment	O	1177-1186
.	O	1186-1187

After	O	1188-1193
functional	O	1194-1204
and	O	1205-1208
pathway	O	1209-1216
annotations	O	1217-1228
of	O	1229-1231
target	O	1232-1238
genes	O	1239-1244
,	O	1244-1245
we	O	1246-1248
proved	O	1249-1255
that	O	1256-1260
miR	B	1261-1264
-	I	1264-1265
212	I	1265-1268
was	O	1269-1272
a	O	1273-1274
critical	O	1275-1283
element	O	1284-1291
in	O	1292-1294
cocaine	O	1295-1302
-	O	1302-1303
addiction	O	1303-1312
,	O	1312-1313
because	O	1314-1321
of	O	1322-1324
its	O	1325-1328
involvement	O	1329-1340
in	O	1341-1343
regulating	O	1344-1354
several	O	1355-1362
important	O	1363-1372
cell	O	1373-1377
cycle	O	1378-1383
events	O	1384-1390
.	O	1390-1391

The	O	1392-1395
results	O	1396-1403
may	O	1404-1407
pave	O	1408-1412
the	O	1413-1416
way	O	1417-1420
for	O	1421-1424
further	O	1425-1432
understanding	O	1433-1446
the	O	1447-1450
regulatory	O	1451-1461
mechanisms	O	1462-1472
of	O	1473-1475
cocaine	O	1476-1483
-	O	1483-1484
response	O	1484-1492
in	O	1493-1495
human	O	1496-1501
bodies	O	1502-1508
.	O	1508-1509

BMPR1B	O	0-6
up	O	7-9
-	O	9-10
regulation	O	10-20
via	O	21-24
a	O	25-26
miRNA	O	27-32
binding	O	33-40
site	O	41-45
variation	O	46-55
defines	O	56-63
endometriosis	O	64-77
susceptibility	O	78-92
and	O	93-96
CA125	O	97-102
levels	O	103-109
.	O	109-110

BACKGROUND	O	111-121
:	O	121-122
Bone	O	123-127
morphogenetic	O	128-141
protein	O	142-149
receptor	O	150-158
I	O	159-160
B	O	161-162
(	O	163-164
BMPR1B	O	164-170
)	O	170-171
is	O	172-174
a	O	175-176
transmembrane	O	177-190
receptor	O	191-199
mediating	O	200-209
TGF	O	210-213
-	O	213-214
beta	O	214-218
signal	O	219-225
transduction	O	226-238
.	O	238-239

Recent	O	240-246
studies	O	247-254
indicate	O	255-263
a	O	264-265
tumor	O	266-271
suppressor	O	272-282
role	O	283-287
for	O	288-291
BMPR1B	O	292-298
in	O	299-301
ovarian	O	302-309
cancer	O	310-316
.	O	316-317

Polymorphism	O	318-330
at	O	331-333
BMPR1B	O	334-340
3	O	341-342
'	O	342-343
UTR	O	343-346
within	O	347-353
the	O	354-357
miR	B	358-361
-	I	361-362
125b	I	362-366
binding	O	367-374
site	O	375-379
alters	O	380-386
its	O	387-390
binding	O	391-398
affinity	O	399-407
toward	O	408-414
the	O	415-418
miRNA	O	419-424
,	O	424-425
which	O	426-431
may	O	432-435
result	O	436-442
in	O	443-445
insufficient	O	446-458
post	O	459-463
-	O	463-464
transcriptional	O	464-479
repression	O	480-490
.	O	490-491

METHODS	O	492-499
:	O	499-500
Single	O	501-507
-	O	507-508
nucleotide	O	508-518
polymorphisms	O	519-532
rs1970801	O	533-542
,	O	542-543
rs1434536	O	544-553
,	O	553-554
and	O	555-558
rs11097457	O	559-569
near	O	570-574
the	O	575-578
miR	B	579-582
-	I	582-583
125b	I	583-587
binding	O	588-595
site	O	596-600
in	O	601-603
BMPR1B	O	604-610
were	O	611-615
genotyped	O	616-625
by	O	626-628
Taqman	O	629-635
assay	O	636-641
on	O	642-644
193	O	645-648
endometriosis	O	649-662
patients	O	663-671
and	O	672-675
202	O	676-679
healthy	O	680-687
controls	O	688-696
.	O	696-697

BMPR1B	O	698-704
and	O	705-708
CA125	O	709-714
levels	O	715-721
in	O	722-724
ectopic	O	725-732
endometrial	O	733-744
tissues	O	745-752
were	O	753-757
evaluated	O	758-767
by	O	768-770
quantitative	O	771-783
PCR	O	784-787
and	O	788-791
immunohistochemistry	O	792-812
.	O	812-813

Luciferase	O	814-824
reporter	O	825-833
assay	O	834-839
was	O	840-843
utilized	O	844-852
to	O	853-855
verify	O	856-862
regulatory	O	863-873
roles	O	874-879
of	O	880-882
BMPR1B	O	883-889
3	O	890-891
'	O	891-892
UTR	O	892-895
with	O	896-900
allelic	O	901-908
variants	O	909-917
of	O	918-920
rs1434536	O	921-930
in	O	931-933
a	O	934-935
cell	O	936-940
line	O	941-945
model	O	946-951
.	O	951-952

Cell	O	953-957
proliferation	O	958-971
and	O	972-975
migration	O	976-985
were	O	986-990
recorded	O	991-999
,	O	999-1000
while	O	1001-1006
expression	O	1007-1017
of	O	1018-1020
BMPR1B	O	1021-1027
,	O	1027-1028
CA125	O	1029-1034
,	O	1034-1035
glucocorticoid	O	1036-1050
receptor	O	1051-1059
(	O	1060-1061
GCCR	O	1061-1065
)	O	1065-1066
and	O	1067-1070
IL	O	1071-1073
-	O	1073-1074
1beta	O	1074-1079
were	O	1080-1084
measured	O	1085-1093
by	O	1094-1096
quantitative	O	1097-1109
PCR	O	1110-1113
in	O	1114-1116
endometrial	O	1117-1128
cells	O	1129-1134
transfected	O	1135-1146
with	O	1147-1151
wild	O	1152-1156
-	O	1156-1157
type	O	1157-1161
or	O	1162-1164
mutated	O	1165-1172
miR	B	1173-1176
-	I	1176-1177
125b	I	1177-1181
.	O	1181-1182

RESULTS	O	1183-1190
:	O	1190-1191
This	O	1192-1196
study	O	1197-1202
found	O	1203-1208
two	O	1209-1212
endometriosis	O	1213-1226
-	O	1226-1227
associated	O	1227-1237
SNPs	O	1238-1242
,	O	1242-1243
rs1434536	O	1244-1253
(	O	1254-1255
P	O	1255-1256
=	O	1257-1258
0	O	1259-1260
.	O	1260-1261
010	O	1261-1264
)	O	1264-1265
and	O	1266-1269
rs1970801	O	1270-1279
(	O	1280-1281
P	O	1281-1282
=	O	1283-1284
0	O	1285-1286
.	O	1286-1287
0087	O	1287-1291
)	O	1291-1292
,	O	1292-1293
located	O	1294-1301
within	O	1302-1308
and	O	1309-1312
next	O	1313-1317
to	O	1318-1320
a	O	1321-1322
miR	B	1323-1326
-	I	1326-1327
125b	I	1327-1331
binding	O	1332-1339
site	O	1340-1344
on	O	1345-1347
BMPR1B	O	1348-1354
.	O	1354-1355

Interestingly	O	1356-1369
,	O	1369-1370
patients	O	1371-1379
with	O	1380-1384
homozygous	O	1385-1395
variant	O	1396-1403
alleles	O	1404-1411
at	O	1412-1414
rs1434536	O	1415-1424
showed	O	1425-1431
significantly	O	1432-1445
lower	O	1446-1451
serum	O	1452-1457
CA125	O	1458-1463
levels	O	1464-1470
.	O	1470-1471

Immunohistochemistry	O	1472-1492
staining	O	1493-1501
further	O	1502-1509
confirmed	O	1510-1519
inverse	O	1520-1527
correlation	O	1528-1539
between	O	1540-1547
BMPR1B	O	1548-1554
and	O	1555-1558
CA125	O	1559-1564
levels	O	1565-1571
in	O	1572-1574
three	O	1575-1580
rs1434536	O	1581-1590
genotypes	O	1591-1600
.	O	1600-1601

Cell	O	1602-1606
assays	O	1607-1613
demonstrated	O	1614-1626
the	O	1627-1630
variant	O	1631-1638
allele	O	1639-1645
of	O	1646-1648
rs1434536	O	1649-1658
up	O	1659-1661
-	O	1661-1662
regulating	O	1662-1672
BMPR1B	O	1673-1679
at	O	1680-1682
both	O	1683-1687
mRNA	O	1688-1692
and	O	1693-1696
protein	O	1697-1704
levels	O	1705-1711
,	O	1711-1712
which	O	1713-1718
negatively	O	1719-1729
correlated	O	1730-1740
with	O	1741-1745
CA125	O	1746-1751
and	O	1752-1755
IL	O	1756-1758
-	O	1758-1759
1beta	O	1759-1764
levels	O	1765-1771
.	O	1771-1772

Disruption	O	1773-1783
of	O	1784-1786
the	O	1787-1790
binding	O	1791-1798
between	O	1799-1806
miR	B	1807-1810
-	I	1810-1811
125b	I	1811-1815
and	O	1816-1819
BMPR1B	O	1820-1826
hampered	O	1827-1835
abnormal	O	1836-1844
cell	O	1845-1849
proliferation	O	1850-1863
.	O	1863-1864

CONCLUSIONS	O	1865-1876
:	O	1876-1877
SNPs	O	1878-1882
of	O	1883-1885
BMPR1B	O	1886-1892
within	O	1893-1899
and	O	1900-1903
next	O	1904-1908
to	O	1909-1911
the	O	1912-1915
miR	B	1916-1919
-	I	1919-1920
125b	I	1920-1924
binding	O	1925-1932
site	O	1933-1937
manifested	O	1938-1948
strong	O	1949-1955
correlation	O	1956-1967
with	O	1968-1972
endometriosis	O	1973-1986
development	O	1987-1998
in	O	1999-2001
a	O	2002-2003
Taiwanese	O	2004-2013
cohort	O	2014-2020
.	O	2020-2021

Disrupting	O	2022-2032
the	O	2033-2036
binding	O	2037-2044
of	O	2045-2047
miR	B	2048-2051
-	I	2051-2052
125b	I	2052-2056
toward	O	2057-2063
BMPR1B	O	2064-2070
would	O	2071-2076
increase	O	2077-2085
protein	O	2086-2093
expression	O	2094-2104
,	O	2104-2105
diminishing	O	2106-2117
abnormal	O	2118-2126
cell	O	2127-2131
proliferation	O	2132-2145
as	O	2146-2148
well	O	2149-2153
as	O	2154-2156
serum	O	2157-2162
and	O	2163-2166
cellular	O	2167-2175
CA125	O	2176-2181
levels	O	2182-2188
.	O	2188-2189

Genetic	O	2190-2197
variation	O	2198-2207
at	O	2208-2210
the	O	2211-2214
miR	B	2215-2218
-	I	2218-2219
125b	I	2219-2223
binding	O	2224-2231
site	O	2232-2236
may	O	2237-2240
play	O	2241-2245
functional	O	2246-2256
roles	O	2257-2262
to	O	2263-2265
protect	O	2266-2273
against	O	2274-2281
endometriosis	O	2282-2295
progression	O	2296-2307
.	O	2307-2308

Targeting	O	0-9
the	O	10-13
production	O	14-24
of	O	25-27
oncogenic	O	28-37
microRNAs	O	38-47
with	O	48-52
multimodal	O	53-63
synthetic	O	64-73
small	O	74-79
molecules	O	80-89
.	O	89-90

MicroRNAs	O	91-100
(	O	101-102
miRNAs	O	102-108
)	O	108-109
are	O	110-113
a	O	114-115
recently	O	116-124
discovered	O	125-135
category	O	136-144
of	O	145-147
small	O	148-153
RNA	O	154-157
molecules	O	158-167
that	O	168-172
regulate	O	173-181
gene	O	182-186
expression	O	187-197
at	O	198-200
the	O	201-204
post	O	205-209
-	O	209-210
transcriptional	O	210-225
level	O	226-231
.	O	231-232

Accumulating	O	233-245
evidence	O	246-254
indicates	O	255-264
that	O	265-269
miRNAs	O	270-276
are	O	277-280
aberrantly	O	281-291
expressed	O	292-301
in	O	302-304
a	O	305-306
variety	O	307-314
of	O	315-317
human	O	318-323
cancers	O	324-331
and	O	332-335
revealed	O	336-344
to	O	345-347
be	O	348-350
oncogenic	O	351-360
and	O	361-364
to	O	365-367
play	O	368-372
a	O	373-374
pivotal	O	375-382
role	O	383-387
in	O	388-390
initiation	O	391-401
and	O	402-405
progression	O	406-417
of	O	418-420
these	O	421-426
pathologies	O	427-438
.	O	438-439

It	O	440-442
is	O	443-445
now	O	446-449
clear	O	450-455
that	O	456-460
the	O	461-464
inhibition	O	465-475
of	O	476-478
oncogenic	O	479-488
miRNAs	O	489-495
,	O	495-496
defined	O	497-504
as	O	505-507
blocking	O	508-516
their	O	517-522
biosynthesis	O	523-535
or	O	536-538
their	O	539-544
function	O	545-553
,	O	553-554
could	O	555-560
find	O	561-565
an	O	566-568
application	O	569-580
in	O	581-583
the	O	584-587
therapy	O	588-595
of	O	596-598
different	O	599-608
types	O	609-614
of	O	615-617
cancer	O	618-624
in	O	625-627
which	O	628-633
these	O	634-639
miRNAs	O	640-646
are	O	647-650
implicated	O	651-661
.	O	661-662

Here	O	663-667
we	O	668-670
report	O	671-677
the	O	678-681
design	O	682-688
,	O	688-689
synthesis	O	690-699
,	O	699-700
and	O	701-704
biological	O	705-715
evaluation	O	716-726
of	O	727-729
new	O	730-733
small	O	734-739
-	O	739-740
molecule	O	740-748
RNA	O	749-752
ligands	O	753-760
targeting	O	761-770
the	O	771-774
production	O	775-785
of	O	786-788
oncogenic	O	789-798
microRNAs	O	799-808
.	O	808-809

In	O	810-812
this	O	813-817
work	O	818-822
we	O	823-825
focused	O	826-833
our	O	834-837
attention	O	838-847
on	O	848-850
miR	B	851-854
-	I	854-855
372	I	855-858
and	O	859-862
miR	B	863-866
-	I	866-867
373	I	867-870
that	O	871-875
are	O	876-879
implicated	O	880-890
in	O	891-893
the	O	894-897
tumorigenesis	O	898-911
of	O	912-914
different	O	915-924
types	O	925-930
of	O	931-933
cancer	O	934-940
such	O	941-945
as	O	946-948
gastric	O	949-956
cancer	O	957-963
.	O	963-964

These	O	965-970
two	O	971-974
oncogenic	O	975-984
miRNAs	O	985-991
are	O	992-995
overexpressed	O	996-1009
in	O	1010-1012
gastric	O	1013-1020
cancer	O	1021-1027
cells	O	1028-1033
starting	O	1034-1042
from	O	1043-1047
their	O	1048-1053
precursors	O	1054-1064
pre	O	1065-1068
-	O	1068-1069
miR	B	1069-1072
-	I	1072-1073
372	I	1073-1076
and	O	1077-1080
pre	O	1081-1084
-	O	1084-1085
miR	B	1085-1088
-	I	1088-1089
373	I	1089-1092
,	O	1092-1093
two	O	1094-1097
stem	O	1098-1102
-	O	1102-1103
loop	O	1103-1107
structured	O	1108-1118
RNAs	O	1119-1123
that	O	1124-1128
lead	O	1129-1133
to	O	1134-1136
mature	O	1137-1143
miRNAs	O	1144-1150
after	O	1151-1156
cleavage	O	1157-1165
by	O	1166-1168
the	O	1169-1172
enzyme	O	1173-1179
Dicer	O	1180-1185
.	O	1185-1186

The	O	1187-1190
small	O	1191-1196
molecules	O	1197-1206
described	O	1207-1216
herein	O	1217-1223
consist	O	1224-1231
of	O	1232-1234
the	O	1235-1238
conjugation	O	1239-1250
of	O	1251-1253
two	O	1254-1257
RNA	O	1258-1261
binding	O	1262-1269
motives	O	1270-1277
,	O	1277-1278
i	O	1279-1280
.	O	1280-1281
e	O	1281-1282
.	O	1282-1283
,	O	1283-1284
the	O	1285-1288
aminoglycoside	O	1289-1303
neomycin	O	1304-1312
and	O	1313-1316
different	O	1317-1326
natural	O	1327-1334
and	O	1335-1338
artificial	O	1339-1349
nucleobases	O	1350-1361
,	O	1361-1362
in	O	1363-1365
order	O	1366-1371
to	O	1372-1374
obtain	O	1375-1381
RNA	O	1382-1385
ligands	O	1386-1393
with	O	1394-1398
increased	O	1399-1408
affinity	O	1409-1417
and	O	1418-1421
selectivity	O	1422-1433
compared	O	1434-1442
to	O	1443-1445
that	O	1446-1450
of	O	1451-1453
parent	O	1454-1460
compounds	O	1461-1470
.	O	1470-1471

After	O	1472-1477
the	O	1478-1481
synthesis	O	1482-1491
of	O	1492-1494
this	O	1495-1499
new	O	1500-1503
series	O	1504-1510
of	O	1511-1513
RNA	O	1514-1517
ligands	O	1518-1525
,	O	1525-1526
we	O	1527-1529
demonstrated	O	1530-1542
that	O	1543-1547
they	O	1548-1552
are	O	1553-1556
able	O	1557-1561
to	O	1562-1564
inhibit	O	1565-1572
the	O	1573-1576
production	O	1577-1587
of	O	1588-1590
the	O	1591-1594
oncogenic	O	1595-1604
miRNA	B	1605-1610
-	I	1610-1611
372	I	1611-1614
and	O	1615-1618
-	B	1619-1620
373	I	1620-1623
by	O	1624-1626
binding	O	1627-1634
their	O	1635-1640
pre	O	1641-1644
-	O	1644-1645
miRNAs	O	1645-1651
and	O	1652-1655
inhibiting	O	1656-1666
the	O	1667-1670
processing	O	1671-1681
by	O	1682-1684
Dicer	O	1685-1690
.	O	1690-1691

Moreover	O	1692-1700
,	O	1700-1701
we	O	1702-1704
proved	O	1705-1711
that	O	1712-1716
some	O	1717-1721
of	O	1722-1724
these	O	1725-1730
compounds	O	1731-1740
bear	O	1741-1745
anti	O	1746-1750
-	O	1750-1751
proliferative	O	1751-1764
activity	O	1765-1773
toward	O	1774-1780
gastric	O	1781-1788
cancer	O	1789-1795
cells	O	1796-1801
and	O	1802-1805
that	O	1806-1810
this	O	1811-1815
activity	O	1816-1824
is	O	1825-1827
likely	O	1828-1834
linked	O	1835-1841
to	O	1842-1844
a	O	1845-1846
decrease	O	1847-1855
in	O	1856-1858
the	O	1859-1862
production	O	1863-1873
of	O	1874-1876
targeted	O	1877-1885
miRNAs	O	1886-1892
.	O	1892-1893

To	O	1894-1896
date	O	1897-1901
,	O	1901-1902
only	O	1903-1907
few	O	1908-1911
examples	O	1912-1920
of	O	1921-1923
small	O	1924-1929
molecules	O	1930-1939
targeting	O	1940-1949
oncogenic	O	1950-1959
miRNAs	O	1960-1966
have	O	1967-1971
been	O	1972-1976
reported	O	1977-1985
,	O	1985-1986
and	O	1987-1990
such	O	1991-1995
inhibitors	O	1996-2006
could	O	2007-2012
be	O	2013-2015
extremely	O	2016-2025
useful	O	2026-2032
for	O	2033-2036
the	O	2037-2040
development	O	2041-2052
of	O	2053-2055
new	O	2056-2059
anticancer	O	2060-2070
therapeutic	O	2071-2082
strategies	O	2083-2093
as	O	2094-2096
well	O	2097-2101
as	O	2102-2104
useful	O	2105-2111
biochemical	O	2112-2123
tools	O	2124-2129
for	O	2130-2133
the	O	2134-2137
study	O	2138-2143
of	O	2144-2146
miRNAs	O	2147-2153
'	O	2153-2154
pathways	O	2155-2163
and	O	2164-2167
mechanisms	O	2168-2178
.	O	2178-2179

Furthermore	O	2180-2191
,	O	2191-2192
this	O	2193-2197
is	O	2198-2200
the	O	2201-2204
first	O	2205-2210
time	O	2211-2215
that	O	2216-2220
a	O	2221-2222
design	O	2223-2229
based	O	2230-2235
on	O	2236-2238
current	O	2239-2246
knowledge	O	2247-2256
about	O	2257-2262
RNA	O	2263-2266
targeting	O	2267-2276
is	O	2277-2279
proposed	O	2280-2288
in	O	2289-2291
order	O	2292-2297
to	O	2298-2300
target	O	2301-2307
miRNAs	O	2308-2314
'	O	2314-2315
production	O	2316-2326
with	O	2327-2331
small	O	2332-2337
molecules	O	2338-2347
.	O	2347-2348

MicroRNA	B	0-8
-	I	8-9
155	I	9-12
promotes	O	13-21
glioma	O	22-28
cell	O	29-33
proliferation	O	34-47
via	O	48-51
the	O	52-55
regulation	O	56-66
of	O	67-69
MXI1	O	70-74
.	O	74-75

Gliomas	O	76-83
are	O	84-87
the	O	88-91
most	O	92-96
common	O	97-103
and	O	104-107
aggressive	O	108-118
primary	O	119-126
tumors	O	127-133
in	O	134-136
the	O	137-140
central	O	141-148
nervous	O	149-156
system	O	157-163
.	O	163-164

Recently	O	165-173
,	O	173-174
Max	O	175-178
interactor	O	179-189
-	O	189-190
1	O	190-191
(	O	192-193
MXI1	O	193-197
)	O	197-198
,	O	198-199
an	O	200-202
antagonist	O	203-213
of	O	214-216
c	O	217-218
-	O	218-219
Myc	O	219-222
that	O	223-227
is	O	228-230
involved	O	231-239
in	O	240-242
brain	O	243-248
tumor	O	249-254
progression	O	255-266
,	O	266-267
has	O	268-271
been	O	272-276
reported	O	277-285
to	O	286-288
be	O	289-291
deregulated	O	292-303
in	O	304-306
a	O	307-308
variety	O	309-316
of	O	317-319
tumors	O	320-326
including	O	327-336
glioma	O	337-343
.	O	343-344

However	O	345-352
,	O	352-353
the	O	354-357
mechanism	O	358-367
of	O	368-370
MXI1	O	371-375
deregulation	O	376-388
in	O	389-391
gliomas	O	392-399
remains	O	400-407
unclear	O	408-415
.	O	415-416

In	O	417-419
this	O	420-424
study	O	425-430
,	O	430-431
we	O	432-434
show	O	435-439
that	O	440-444
the	O	445-448
relative	O	449-457
expression	O	458-468
level	O	469-474
of	O	475-477
MXI1	O	478-482
is	O	483-485
markedly	O	486-494
down	O	495-499
-	O	499-500
regulated	O	500-509
in	O	510-512
glioma	O	513-519
cell	O	520-524
lines	O	525-530
.	O	530-531

Using	O	532-537
integrated	O	538-548
bioinformatic	O	549-562
analysis	O	563-571
and	O	572-575
experimental	O	576-588
confirmation	O	589-601
,	O	601-602
we	O	603-605
identified	O	606-616
several	O	617-624
miRNAs	O	625-631
by	O	632-634
screening	O	635-644
a	O	645-646
panel	O	647-652
of	O	653-655
predicted	O	656-665
miRNAs	O	666-672
that	O	673-677
may	O	678-681
regulate	O	682-690
the	O	691-694
MXI1	O	695-699
3	O	700-701
'	O	701-702
UTR	O	702-705
.	O	705-706

The	O	707-710
strongest	O	711-720
inhibitory	O	721-731
miRNA	O	732-737
,	O	737-738
miR	B	739-742
-	I	742-743
155	I	743-746
,	O	746-747
can	O	748-751
attenuate	O	752-761
the	O	762-765
activity	O	766-774
of	O	775-777
a	O	778-779
luciferase	O	780-790
reporter	O	791-799
gene	O	800-804
that	O	805-809
is	O	810-812
fused	O	813-818
with	O	819-823
the	O	824-827
MXI1	O	828-832
3	O	833-834
'	O	834-835
UTR	O	835-838
and	O	839-842
decrease	O	843-851
the	O	852-855
expression	O	856-866
levels	O	867-873
of	O	874-876
MXI1	O	877-881
mRNA	O	882-886
and	O	887-890
protein	O	891-898
in	O	899-901
U87	O	902-905
glioma	O	906-912
cells	O	913-918
.	O	918-919

The	O	920-923
potential	O	924-933
role	O	934-938
of	O	939-941
miR	B	942-945
-	I	945-946
155	I	946-949
in	O	950-952
promoting	O	953-962
glioma	O	963-969
cell	O	970-974
proliferation	O	975-988
by	O	989-991
targeting	O	992-1001
MXI1	O	1002-1006
was	O	1007-1010
confirmed	O	1011-1020
in	O	1021-1023
various	O	1024-1031
glioma	O	1032-1038
cell	O	1039-1043
lines	O	1044-1049
by	O	1050-1052
rescue	O	1053-1059
experiments	O	1060-1071
using	O	1072-1077
MTT	O	1078-1081
assays	O	1082-1088
,	O	1088-1089
EdU	O	1090-1093
incorporation	O	1094-1107
assay	O	1108-1113
,	O	1113-1114
and	O	1115-1118
cell	O	1119-1123
counting	O	1124-1132
experiments	O	1133-1144
.	O	1144-1145

In	O	1146-1148
addition	O	1149-1157
,	O	1157-1158
we	O	1159-1161
determined	O	1162-1172
that	O	1173-1177
the	O	1178-1181
level	O	1182-1187
of	O	1188-1190
MXI1	O	1191-1195
mRNA	O	1196-1200
was	O	1201-1204
inversely	O	1205-1214
correlated	O	1215-1225
with	O	1226-1230
the	O	1231-1234
expression	O	1235-1245
of	O	1246-1248
miR	B	1249-1252
-	I	1252-1253
155	I	1253-1256
in	O	1257-1259
18	O	1260-1262
sets	O	1263-1267
of	O	1268-1270
glioblastoma	O	1271-1283
multiforme	O	1284-1294
specimens	O	1295-1304
.	O	1304-1305

These	O	1306-1311
findings	O	1312-1320
reveal	O	1321-1327
for	O	1328-1331
the	O	1332-1335
first	O	1336-1341
time	O	1342-1346
that	O	1347-1351
the	O	1352-1355
targeting	O	1356-1365
of	O	1366-1368
MXI1	O	1369-1373
by	O	1374-1376
miR	B	1377-1380
-	I	1380-1381
155	I	1381-1384
may	O	1385-1388
result	O	1389-1395
in	O	1396-1398
a	O	1399-1400
reduction	O	1401-1410
in	O	1411-1413
MXI1	O	1414-1418
expression	O	1419-1429
and	O	1430-1433
promote	O	1434-1441
glioma	O	1442-1448
cell	O	1449-1453
proliferation	O	1454-1467
;	O	1467-1468
this	O	1469-1473
result	O	1474-1480
suggests	O	1481-1489
a	O	1490-1491
novel	O	1492-1497
function	O	1498-1506
of	O	1507-1509
miR	B	1510-1513
-	I	1513-1514
155	I	1514-1517
in	O	1518-1520
targeting	O	1521-1530
MXI1	O	1531-1535
in	O	1536-1538
glioma	O	1539-1545
-	O	1545-1546
genesis	O	1546-1553
.	O	1553-1554

